--
-- PostgreSQL database dump
--

-- Dumped from database version 14.11
-- Dumped by pg_dump version 14.12 (Ubuntu 14.12-1.pgdg20.04+1)

SET statement_timeout = 0;
SET lock_timeout = 0;
SET idle_in_transaction_session_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SELECT pg_catalog.set_config('search_path', '', false);
SET check_function_bodies = false;
SET xmloption = content;
SET client_min_messages = warning;
SET row_security = off;

--
-- Data for Name: roles; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.roles (id, name, permissions, created_at, updated_at) FROM stdin;
e28b16f3-25e2-422a-9531-dd5165e386d5	system_user	{"create": true, "update": true, "delete": false}	2024-05-23 21:17:24.725815+00	2024-05-23 21:17:24.725815+00
f84970fd-5f91-4bca-820f-38ff72fa7cdf	app_user	{"create": true, "update": true, "delete": false}	2024-05-23 21:17:24.725815+00	2024-05-23 21:17:24.725815+00
\.


--
-- Data for Name: users; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.users (id, first_name, last_name, image_url, role_id, active, created_at, updated_at, credentials) FROM stdin;
\.


--
-- Data for Name: audit_log; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.audit_log (id, user_id, action_log, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: comment_categories; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.comment_categories (id, name, created_at, updated_at) FROM stdin;
1	Corrected	2024-05-23 21:17:25.383822+00	2024-05-23 21:17:25.383822+00
2	Amended	2024-05-23 21:17:25.383822+00	2024-05-23 21:17:25.383822+00
3	Report Note	2024-05-23 21:17:25.383822+00	2024-05-23 21:17:25.383822+00
4	Result	2024-05-23 21:17:25.383822+00	2024-05-23 21:17:25.383822+00
5	Failed Reads	2024-05-23 21:17:25.383822+00	2024-05-23 21:17:25.383822+00
6	General	2024-05-23 21:17:25.383822+00	2024-05-23 21:17:25.383822+00
\.


--
-- Data for Name: mapping_status; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.mapping_status (id, name, created_at, updated_at) FROM stdin;
0	Deterministic	2024-05-23 21:17:24.731086+00	2024-05-23 21:17:24.731086+00
1	Unreportable_alleles	2024-05-23 21:17:24.731086+00	2024-05-23 21:17:24.731086+00
2	Unexpected_heterozygous	2024-05-23 21:17:24.731086+00	2024-05-23 21:17:24.731086+00
3	Discordant	2024-05-23 21:17:24.731086+00	2024-05-23 21:17:24.731086+00
4	Indeterministic	2024-05-23 21:17:24.731086+00	2024-05-23 21:17:24.731086+00
\.


--
-- Data for Name: master_versions; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.master_versions (id, version, active, created_at, updated_at) FROM stdin;
e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1.0.0	f	2024-05-23 21:17:25.389104+00	2024-05-23 21:19:49.674629+00
cd112fe5-0c94-42f4-b221-78aa67a88c28	2.1.1	f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:49.674629+00
33ba105b-d0a6-4667-b6e9-927859eb4481	3.1.2	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
\.


--
-- Data for Name: patients; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.patients (id, mrn, first_name, middle_name, last_name, dob, gender, active, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: procedures; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.procedures (id, code, name, created_at, updated_at) FROM stdin;
3979e189-aa25-4087-8c21-df777bb264bd	LBOR0140	CYP2C19 SINGLE PGX TEST	2024-05-23 21:17:24.73613+00	2024-05-23 21:17:24.73613+00
a6000906-9b4a-4670-91c6-50a8e828a293	LBOR0149	DPYD SINGLE PGX TEST	2024-05-23 21:17:24.73613+00	2024-05-23 21:17:24.73613+00
4aed92f8-9c4f-45e2-ac49-47b8790fcb19	LBOR0154	CYP3A5 SINGLE PGX TEST	2024-05-23 21:17:24.73613+00	2024-05-23 21:17:24.73613+00
7091e051-8cfe-46e8-967e-b734ea9d5230	LBOR0202	CYP2C9 SINGLE PGX TEST	2024-05-23 21:17:24.73613+00	2024-05-23 21:17:24.73613+00
6eefc3e8-f2f6-4037-a074-2bf293ca7e90	LBOR0228	THIOPURINE PHARMACOGENETICS PANEL	2024-05-23 21:17:24.73613+00	2024-05-23 21:17:24.73613+00
ed2db461-efa1-4da5-90e0-9988d07222c5	LBOR0229	COMPREHENSIVE PHARMACOGENETICS PANEL	2024-05-23 21:17:24.73613+00	2024-05-23 21:17:24.73613+00
8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	LBOR0230	PHARMACOGENETICS PANEL	2024-05-23 21:17:24.73613+00	2024-05-23 21:17:24.73613+00
\.


--
-- Data for Name: status; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.status (id, name, created_at, updated_at) FROM stdin;
0	Received	2024-05-23 21:17:24.728825+00	2024-05-23 21:17:24.728825+00
1	Impeded	2024-05-23 21:17:24.728825+00	2024-05-23 21:17:24.728825+00
2	Analyzed	2024-05-23 21:17:24.728825+00	2024-05-23 21:17:24.728825+00
3	Claimed	2024-05-23 21:17:24.728825+00	2024-05-23 21:17:24.728825+00
4	On hold	2024-05-23 21:17:24.728825+00	2024-05-23 21:17:24.728825+00
5	Signed out	2024-05-23 21:17:24.728825+00	2024-05-23 21:17:24.728825+00
\.


--
-- Data for Name: orders; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.orders (id, number, plate, patient_id, status, procedure_id, specimen, date_collected, provider, specimen_type, source_id, submitter, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: vcfs; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.vcfs (id, order_id, vcf_url, version, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: results; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.results (id, order_id, vcf_id, result, mapping_status, active, created_by, master_version_id, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: comments; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.comments (id, comment, in_report, category_id, order_id, result_id, user_id, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: drug_categories; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.drug_categories (id, name, created_at, updated_at) FROM stdin;
9ff73e6e-04b8-4723-a417-f038ab4ad9f1	Anti-infective	2024-05-23 21:17:24.877814+00	2024-05-23 21:17:24.877814+00
d7a96599-6afb-4f06-af52-55a726f88825	Anticoagulant	2024-05-23 21:17:24.877814+00	2024-05-23 21:17:24.877814+00
8872bc8f-2721-46ea-aff6-43cc7cceacdb	Antiplatelet	2024-05-23 21:17:24.877814+00	2024-05-23 21:17:24.877814+00
8256a540-e14d-4aaf-ba30-d9e74fe760c7	Cardiovascular	2024-05-23 21:17:24.877814+00	2024-05-23 21:17:24.877814+00
f5494c53-4f75-4641-bf61-e5b25d73687a	Cholesterol	2024-05-23 21:17:24.877814+00	2024-05-23 21:17:24.877814+00
bc2bb773-0df8-4daf-b457-d3c22786521f	Gastrointestinal	2024-05-23 21:17:24.877814+00	2024-05-23 21:17:24.877814+00
efd53084-bd12-4d7d-a158-5a6e14fc7223	Mental health	2024-05-23 21:17:24.877814+00	2024-05-23 21:17:24.877814+00
40e79ade-a29b-4963-bed6-d44ed6ef6a82	Miscellaneous	2024-05-23 21:17:24.877814+00	2024-05-23 21:17:24.877814+00
d2e7eb03-e9c3-43c9-bf2d-fccc35ab9b0e	Neurological	2024-05-23 21:17:24.877814+00	2024-05-23 21:17:24.877814+00
e13ec386-a0fd-4956-9ed3-37f6a708f4c5	Oncology	2024-05-23 21:17:24.877814+00	2024-05-23 21:17:24.877814+00
ded60fea-39ba-4ffc-8411-458f72a7b579	Pain	2024-05-23 21:17:24.877814+00	2024-05-23 21:17:24.877814+00
31562e91-f969-4a4e-8415-92c73a4f3bd9	Transplant	2024-05-23 21:17:24.877814+00	2024-05-23 21:17:24.877814+00
\.


--
-- Data for Name: drugs; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.drugs (id, name, brand_name, drug_category_id, created_at, updated_at) FROM stdin;
e37ac069-3d30-4599-b6ea-2bd2698fb83e	Metoprolol	Lopressor; Toprol XL	8256a540-e14d-4aaf-ba30-d9e74fe760c7	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
d3dddc1d-8bc5-4714-b254-50dec124bbaf	Clopidogrel	Plavix	8872bc8f-2721-46ea-aff6-43cc7cceacdb	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
ccab952d-1055-4d11-8de5-db50dd24f9b1	Omeprazole	Prilosec	bc2bb773-0df8-4daf-b457-d3c22786521f	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
bbb98d14-f488-4791-894c-4107ed94eba6	Lansoprazole	Prevacid	bc2bb773-0df8-4daf-b457-d3c22786521f	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
e7a7c1bc-8557-49f0-9b21-32b50749a4df	Pantoprazole	Protonix	bc2bb773-0df8-4daf-b457-d3c22786521f	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
a688ed6b-9656-47e2-baf1-0809d34b6878	Dexlansoprazole	Dexilant	bc2bb773-0df8-4daf-b457-d3c22786521f	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
45477af2-958f-42d0-853a-8b9f9c7ce998	Amitriptyline	Elavil	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
6d583253-b4f1-4c41-a7b5-aa0e27d4335f	Clomipramine	Anafranil	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
ee2adcd3-4012-4ca7-b689-0c34f879cff0	Imipramine	Tofranil	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
7f4e2cf7-21f6-4730-9934-d9d9b3523481	Trimipramine	Surmontil	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
0657dff9-1f56-42ed-af15-32d062f546db	Nortriptyline	Pamelor	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
b86504f1-f2ff-4550-ba67-d164b88a33a8	Desipramine	Norpramin	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
8eea746d-0da5-4cd2-b726-b6bdc02022fc	Citalopram	Celexa	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
e5d6cd1f-e2cb-4aba-9cf2-98163c4df828	Escitalopram	Lexapro	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
6451a255-0983-473a-9fe4-6c24451820c3	Sertraline	Zoloft	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
9c6424db-aaf9-4e74-83b6-a7d7ac769720	Paroxetine	Paxil; Paxil CR	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
b2601f06-506a-4651-838f-572e6d1c7387	Fluvoxamine	Luvox	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
bb526458-a0a7-42be-b95d-69eed3cf71b7	Venlafaxine	Effexor; Effexor XR	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
f7ee2591-da6d-4636-b5fe-1048587b608a	Vortioxetine	Trintellix	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
390fc57c-6ae0-47bc-9512-cb4bdde98e97	Voriconazole	Vfend	9ff73e6e-04b8-4723-a417-f038ab4ad9f1	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
201ced5d-ae85-40f4-b9fa-3087689af5b4	Clobazam	Onfi; Sympazan	40e79ade-a29b-4963-bed6-d44ed6ef6a82	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
6969532a-6460-4419-b7c5-bbd455af3a11	Efavirenz	Sustiva; Atripla	9ff73e6e-04b8-4723-a417-f038ab4ad9f1	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
2cf72f48-6286-45df-b741-31bdd3ec6c00	Capecitabine	Xeloda	e13ec386-a0fd-4956-9ed3-37f6a708f4c5	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
e8d4c4d1-7661-46ec-8922-99b775dd6ede	Fluorouracil	Adrucil; Efudex; Tolak; Carac	e13ec386-a0fd-4956-9ed3-37f6a708f4c5	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
0d36fae9-d172-4bed-ab68-125ee9d62392	Tacrolimus	Prograf	31562e91-f969-4a4e-8415-92c73a4f3bd9	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
211b33bf-72c3-4545-a4b2-ea558809d086	Celecoxib	Celebrex	ded60fea-39ba-4ffc-8411-458f72a7b579	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
a62bce88-9533-414c-9d39-1f7ac350aeb0	Flurbiprofen	Ansaid	ded60fea-39ba-4ffc-8411-458f72a7b579	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
a98b7a68-c681-46fb-adba-f1541299fe59	Ibuprofen	Advil; Motrin	ded60fea-39ba-4ffc-8411-458f72a7b579	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
5d66d6a8-1c96-4bbd-99fd-0eca947dace6	Meloxicam	Mobic	ded60fea-39ba-4ffc-8411-458f72a7b579	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
c6f6e292-35f2-49be-b0f5-b4a27f0616ec	Piroxicam	Feldene	ded60fea-39ba-4ffc-8411-458f72a7b579	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
c204f810-40e0-4211-990d-c60df4443ab2	Phenytoin	Dilantin	d2e7eb03-e9c3-43c9-bf2d-fccc35ab9b0e	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
496a2efb-e3a0-4c9a-9084-f8a922ed54f7	Fosphenytoin	Cerebyx	d2e7eb03-e9c3-43c9-bf2d-fccc35ab9b0e	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
41d89592-9cb5-42b0-bce0-025ad44d2d7c	Siponimod	Mayzent	d2e7eb03-e9c3-43c9-bf2d-fccc35ab9b0e	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
dc29bc5a-25d6-41cc-afa4-f65a8c29db88	Atorvastatin	Lipitor	f5494c53-4f75-4641-bf61-e5b25d73687a	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
5994c882-0bbe-46da-bf00-c347377368c4	Lovastatin	Mevacor	f5494c53-4f75-4641-bf61-e5b25d73687a	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
d4638249-99fa-435e-b8ba-90e5b99b0748	Pitavastatin	Livalo	f5494c53-4f75-4641-bf61-e5b25d73687a	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
b5e19041-7ec3-492b-9746-1d79e3e937a0	Pravastatin	Pravachol	f5494c53-4f75-4641-bf61-e5b25d73687a	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
90fc5fe6-2bc4-4696-bac1-6bd791233b21	Simvastatin	Zocor	f5494c53-4f75-4641-bf61-e5b25d73687a	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	Fluvastatin	Lescol XL	f5494c53-4f75-4641-bf61-e5b25d73687a	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
8b219877-2b13-4014-b662-403e37354242	Rosuvastatin	Crestor	f5494c53-4f75-4641-bf61-e5b25d73687a	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
61c19ced-3a01-4312-ab9b-ec591541e877	Belinostat	Beleodaq	e13ec386-a0fd-4956-9ed3-37f6a708f4c5	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
9205ea26-5624-454e-8d1f-8bab4c2866a2	Atazanavir	Reyataz	9ff73e6e-04b8-4723-a417-f038ab4ad9f1	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
739f1e73-352a-42d9-9fd8-99f9cc80a0e5	Dapsone	Aczone	9ff73e6e-04b8-4723-a417-f038ab4ad9f1	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
0aa49471-3558-4909-bb35-acbf6817ac45	Methylene Blue	ProvayBlue	40e79ade-a29b-4963-bed6-d44ed6ef6a82	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
89341edd-8cb2-4bdf-9087-185c6b1591a6	Pegloticase	Krystexxa	40e79ade-a29b-4963-bed6-d44ed6ef6a82	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
093eb220-d638-4e4c-96cb-c191c947c13e	Rasburicase	Elitek	e13ec386-a0fd-4956-9ed3-37f6a708f4c5	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
4a935869-581c-46f9-9952-20e811affd82	Tafenoquine	Arakoda; Krintafel	9ff73e6e-04b8-4723-a417-f038ab4ad9f1	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
7018114d-d8e8-48a7-9219-70b585abec26	Primaquine	Primaquine	9ff73e6e-04b8-4723-a417-f038ab4ad9f1	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
79018e4d-e218-4e8f-971d-af3b1f95fbc0	Nitrofurantoin	Macrobid; Macrodantin	9ff73e6e-04b8-4723-a417-f038ab4ad9f1	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
e0acdb40-24e1-4e84-b477-352a1a69922f	Azathioprine	Azasan; Imuran	e13ec386-a0fd-4956-9ed3-37f6a708f4c5	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	Mercaptopurine	Purixan	e13ec386-a0fd-4956-9ed3-37f6a708f4c5	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
129be50f-5d81-4be5-b75d-ce000c6a7250	Thioguanine	Tabloid	e13ec386-a0fd-4956-9ed3-37f6a708f4c5	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
420ab93f-1333-468a-959e-72aa4485e402	Valbenazine	Ingrezza	40e79ade-a29b-4963-bed6-d44ed6ef6a82	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
ab467f62-bb04-4815-90e2-5fc7578cbb66	Tetrabenazine	Xenazine	40e79ade-a29b-4963-bed6-d44ed6ef6a82	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
8d963751-ff27-411b-8d4a-026d53335a9e	Deutetrabenazine	Austedo; Austedo XR	40e79ade-a29b-4963-bed6-d44ed6ef6a82	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
025c0b65-bce6-4a78-9dca-54acad450ea2	Pitolisant	Wakix	40e79ade-a29b-4963-bed6-d44ed6ef6a82	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
5369d927-542a-4b5c-9578-a3d0d6192064	Eliglustat	Cerdelga	40e79ade-a29b-4963-bed6-d44ed6ef6a82	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
70fff4d0-4f7e-4e04-a677-64876a71e24d	Pimozide	Orap	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
b01d12bf-0ae0-4f32-b29d-2ad679892f0b	Iloperidone	Fanapt	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
6a12dbea-1145-4203-911b-e536dbdd2f2b	Brexpiprazole	Rexulti	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
1e6e3bf7-bfb4-40bc-b820-94e181a26f75	Metoclopramide	Reglan	bc2bb773-0df8-4daf-b457-d3c22786521f	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
dc92f451-05c1-43e6-8bf1-8ff5e6de317a	Aripiprazole	Abilify; Abilify Maintena; Aristada	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
752f1592-e6ce-48be-b907-f191400bf24c	Codeine	Tylenol with Codeine	ded60fea-39ba-4ffc-8411-458f72a7b579	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
17e1be64-4c39-48c8-a13b-5d3cd0357c4f	Tramadol	Ultram	ded60fea-39ba-4ffc-8411-458f72a7b579	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
b42d7cb5-1fbb-4800-853c-56ed56c71801	Atomoxetine	Strattera	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
7c52c9c1-1c96-440d-95fe-82088a2ac2f0	Ondansetron	Zofran	bc2bb773-0df8-4daf-b457-d3c22786521f	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
bd146e3e-bfdc-4cbd-a552-b20b6aa25ef3	Abacavir	Ziagen	9ff73e6e-04b8-4723-a417-f038ab4ad9f1	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
38f4957e-e9ac-409f-8507-61aaa2d7b47d	Warfarin	Coumadin; Jantoven	d7a96599-6afb-4f06-af52-55a726f88825	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
09a32385-64b1-47b5-89c8-ead4799165a4	Doxepin	Sinequan	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:17:24.881458+00	2024-05-23 21:17:24.881458+00
26a9b4b1-b8a0-4fc1-a724-6b279761a97e	Irinotecan	Camptosar	e13ec386-a0fd-4956-9ed3-37f6a708f4c5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1784e3b7-771f-4c37-bc3b-1f17c9d6ad8f	Irinotecan liposomal	Onivyde	e13ec386-a0fd-4956-9ed3-37f6a708f4c5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
740a203d-6433-433a-862b-2d426f744d73	Thioridazine	Mellaril	efd53084-bd12-4d7d-a158-5a6e14fc7223	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b3ddb5f2-79af-45de-b3d9-5de0529fa09b	Abrocitinib	Cibinqo	40e79ade-a29b-4963-bed6-d44ed6ef6a82	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
\.


--
-- Data for Name: gene_properties; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.gene_properties (id, name, created_at, updated_at) FROM stdin;
aaea2f54-350c-4b2b-bbe7-26b1ee754e11	Diplotype	2024-05-23 21:17:24.886789+00	2024-05-23 21:17:24.886789+00
e42a990d-eaa3-4b4b-8c95-55d0854cb290	Phenotype	2024-05-23 21:17:24.886789+00	2024-05-23 21:17:24.886789+00
ae88964e-da53-4fcc-9c4e-171828f2445b	ActivityScore	2024-05-23 21:17:24.886789+00	2024-05-23 21:17:24.886789+00
\.


--
-- Data for Name: genes; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.genes (id, name, created_at, updated_at) FROM stdin;
39f5387b-4a50-4696-99ae-6c9062e70c52	ABCG2	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
01b74a5e-f95b-4086-a5b7-899a8de1f228	CYP2B6	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	CYP2C	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
e8d718e4-4831-496c-8448-16ad044c2e9d	CYP2C9	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
32638f99-ec66-41e9-87db-40b5f6c8d7d6	CYP2C19	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
aba94ef2-e507-4963-84dd-24dc2d4f7ffc	CYP2D6	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
cd3bc960-aea4-40fb-a1ad-f54c10b7228b	CYP3A5	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
93d511ec-e5fc-4832-9581-813842b25860	CYP4F2	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
0f0237e6-0568-4790-ae5b-03b0cd6e6d20	DPYD	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
9be7b66e-d066-4d98-bc30-ec1511489398	G6PD	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
daa86f03-86c6-4a8d-abab-476fcd043c9c	NUDT15	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
22fb682a-e57d-4ad2-8dc5-8159f28a9862	SLCO1B1	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
9ca2999f-1b56-4ee8-a254-2da4415cbb72	TPMT	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
58f41405-4198-4822-b10e-eb43cd77bc27	UGT1A1	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
c0f1136b-6463-4304-a473-cae1f384fc8e	VKORC1	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
b31967bd-f6da-49d9-ba4e-cafdd7786116	HLA-B	2024-05-23 21:17:24.733383+00	2024-05-23 21:17:24.733383+00
\.


--
-- Data for Name: genotypes; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.genotypes (id, gene_id, info, status, active, created_at, updated_at) FROM stdin;
d0fa7698-424c-4983-8dc2-83d5be472016	39f5387b-4a50-4696-99ae-6c9062e70c52	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "ABCG2",\n  "orientation": null,\n  "chromosome": "chr4",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000004.11",\n  "variants": [\n    {\n      "chromosome": "chr4",\n      "position": 89052323,\n      "cpicPosition": 89052323,\n      "rsid": "rs2231142",\n      "chromosomeHgvsName": "g.89052323G>T",\n      "cpicAlleles": ["G", "T"],\n      "cpicToVcfAlleleMap": { "T": "T", "G": "G" },\n      "ref": "G",\n      "alts": ["T"]\n    }\n  ],\n  "namedAlleles": []\n}	5	t	2024-05-23 21:17:24.751374+00	2024-05-23 21:17:24.751374+00
047c6dd3-30b8-4d56-a63e-cc9bbdbfa2f6	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	{\n    "formatVersion": "2",\n    "source": "CPIC",\n    "version": "v1.0",\n    "modificationDate": "May 09, 2023, 3:02:09 PM",\n    "gene": "CYP2C",\n    "orientation": null,\n    "chromosome": "chr10",\n    "genomeBuild": "GRCh37.p13",\n    "refSeqChromosomeId": "NC_000010.10",\n    "variants": [{\n        "chromosome": "chr10",\n        "position": 96405502,\n        "cpicPosition": 96405502,\n        "rsid": "rs12777823",\n        "chromosomeHgvsName": "g.96405502G>A",\n        "cpicAlleles": [\n            "A",\n            "G"\n        ],\n        "cpicToVcfAlleleMap": {\n            "A": "A",\n            "G": "G"\n        },\n        "ref": "G",\n        "alts": [\n            "A"\n        ]\n    }],\n    "namedAlleles": []\n}	5	t	2024-05-23 21:17:24.758718+00	2024-05-23 21:17:24.758718+00
6dfe83a9-c07a-4a03-b054-914f6aa13973	e8d718e4-4831-496c-8448-16ad044c2e9d	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "CYP2C9",\n  "orientation": null,\n  "chromosome": "chr10",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000010.10",\n  "variants": [\n    {\n      "chromosome": "chr10",\n      "position": 96701715,\n      "cpicPosition": 96701715,\n      "rsid": "rs72558187",\n      "chromosomeHgvsName": "g.96701715T>C",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "T",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96702047,\n      "cpicPosition": 96702047,\n      "rsid": "rs1799853",\n      "chromosomeHgvsName": "g.96702047C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96702066,\n      "cpicPosition": 96702066,\n      "rsid": "rs7900194",\n      "chromosomeHgvsName": "g.96702066G>A; g.96702066G>T",\n      "cpicAlleles": ["A", "G", "T"],\n      "cpicToVcfAlleleMap": { "A": "A", "T": "T", "G": "G" },\n      "ref": "G",\n      "alts": ["A", "T"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96707539,\n      "cpicPosition": 96707539,\n      "rsid": "rs72558190",\n      "chromosomeHgvsName": "g.96707539C>A",\n      "cpicAlleles": ["A", "C"],\n      "cpicToVcfAlleleMap": { "A": "A", "C": "C" },\n      "ref": "C",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96709040,\n      "cpicPosition": 96709040,\n      "rsid": "rs9332131",\n      "chromosomeHgvsName": "g.96709040del",\n      "cpicAlleles": ["A", "delA"],\n      "cpicToVcfAlleleMap": { "A": "GA", "delA": "G" },\n      "ref": "GA",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96731936,\n      "cpicPosition": 96731936,\n      "rsid": "rs72558192",\n      "chromosomeHgvsName": "g.96731936A>G",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "A",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96740981,\n      "cpicPosition": 96740981,\n      "rsid": "rs28371685",\n      "chromosomeHgvsName": "g.96740981C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96741053,\n      "cpicPosition": 96741053,\n      "rsid": "rs1057910",\n      "chromosomeHgvsName": "g.96741053A>C",\n      "cpicAlleles": ["A", "C"],\n      "cpicToVcfAlleleMap": { "A": "A", "C": "C" },\n      "ref": "A",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96741054,\n      "cpicPosition": 96741054,\n      "rsid": "rs56165452",\n      "chromosomeHgvsName": "g.96741054T>C",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "T",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96741058,\n      "cpicPosition": 96741058,\n      "rsid": "rs28371686",\n      "chromosomeHgvsName": "g.96741058C>G",\n      "cpicAlleles": ["C", "G"],\n      "cpicToVcfAlleleMap": { "C": "C", "G": "G" },\n      "ref": "C",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96748777,\n      "cpicPosition": 96748777,\n      "rsid": "rs9332239",\n      "chromosomeHgvsName": "g.96748777C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "*1",\n      "id": "777668",\n      "alleles": ["T", "C", "G", "C", "GA", "A", "C", "A", "T", "C", "C"],\n      "cpicAlleles": ["T", "C", "G", "C", "A", "A", "C", "A", "T", "C", "C"],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*2",\n      "id": "777670",\n      "alleles": [\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*3",\n      "id": "777672",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*4",\n      "id": "777674",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*5",\n      "id": "777676",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "G",\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "G",\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*6",\n      "id": "777678",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        "delA",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*8",\n      "id": "777682",\n      "alleles": [\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*11",\n      "id": "777688",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*12",\n      "id": "777690",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T"\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T"\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*13",\n      "id": "777692",\n      "alleles": [\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*15",\n      "id": "777696",\n      "alleles": [\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*16",\n      "id": "777698",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}	5	t	2024-05-23 21:17:24.761607+00	2024-05-23 21:17:24.761607+00
c7a83c00-ca7a-436f-94ea-c0128ee0e292	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "CYP2D6",\n  "orientation": null,\n  "chromosome": "chr22",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000022.10",\n  "variants": [\n    {\n      "chromosome": "chr22",\n      "position": 42522613,\n      "cpicPosition": 42522613,\n      "rsid": "rs1135840",\n      "chromosomeHgvsName": "g.42522613G>C",\n      "cpicAlleles": ["C", "G", "S"],\n      "cpicToVcfAlleleMap": { "C": "C", "G": "G" },\n      "ref": "G",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42523943,\n      "cpicPosition": 42523943,\n      "rsid": "rs16947",\n      "chromosomeHgvsName": "g.42523943A>G",\n      "cpicAlleles": ["A", "G", "R"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "A",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42525772,\n      "cpicPosition": 42525772,\n      "rsid": "rs28371706",\n      "chromosomeHgvsName": "g.42525772G>T; g.42525772G>A",\n      "cpicAlleles": ["A", "G", "T"],\n      "cpicToVcfAlleleMap": { "A": "A", "T": "T", "G": "G" },\n      "ref": "G",\n      "alts": ["A", "T"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": "42523534_42523535",\n      "cpicPosition": "42523534_42523535",\n      "rsid": "rs72549346",\n      "chromosomeHgvsName": "g.42523534_42523535dup",\n      "cpicAlleles": ["del", "insCA"],\n      "cpicToVcfAlleleMap": { "del": "G", "insAC": "GCA" },\n      "ref": "G",\n      "alts": ["GCA"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42523592,\n      "cpicPosition": 42523592,\n      "rsid": "rs72549347",\n      "chromosomeHgvsName": "g.42523592G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42523610,\n      "cpicPosition": 42523610,\n      "rsid": "rs59421388",\n      "chromosomeHgvsName": "g.42523610C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42523805,\n      "cpicPosition": 42523805,\n      "rsid": "rs28371725",\n      "chromosomeHgvsName": "g.42523805C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42523854,\n      "cpicPosition": 42523854,\n      "rsid": "rs79292917",\n      "chromosomeHgvsName": "g.42523854C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42523858,\n      "cpicPosition": 42523858,\n      "rsid": "rs5030867",\n      "chromosomeHgvsName": "g.42523858T>G",\n      "cpicAlleles": ["G", "T"],\n      "cpicToVcfAlleleMap": { "T": "T", "G": "G" },\n      "ref": "T",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42524178,\n      "cpicPosition": 42524178,\n      "rsid": "rs5030656",\n      "chromosomeHgvsName": "g.42524178_42524180del",\n      "cpicAlleles": ["TCT", "delTCT"],\n      "cpicToVcfAlleleMap": { "TCT": "CCTT", "delTCT": "C" },\n      "ref": "CCTT",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42524220,\n      "cpicPosition": 42524220,\n      "rsid": "rs72549352",\n      "chromosomeHgvsName": "g.42524220dup",\n      "cpicAlleles": ["G", "GG"],\n      "cpicToVcfAlleleMap": { "GG": "CG", "G": "C" },\n      "ref": "C",\n      "alts": ["CG"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42524244,\n      "cpicPosition": 42524244,\n      "rsid": "rs35742686",\n      "chromosomeHgvsName": "g.42524244del",\n      "cpicAlleles": ["T", "delT"],\n      "cpicToVcfAlleleMap": { "T": "CT", "delT": "C" },\n      "ref": "CT",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42524947,\n      "cpicPosition": 42524947,\n      "rsid": "rs3892097",\n      "chromosomeHgvsName": "g.42524947C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42525035,\n      "cpicPosition": 42525035,\n      "rsid": "rs5030865",\n      "chromosomeHgvsName": "g.42525035C>T; g.42525035C>A",\n      "cpicAlleles": ["A", "C", "T"],\n      "cpicToVcfAlleleMap": { "A": "A", "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["A", "T"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42525086,\n      "cpicPosition": 42525086,\n      "rsid": "rs5030655",\n      "chromosomeHgvsName": "g.42525086del",\n      "cpicAlleles": ["A", "delA"],\n      "cpicToVcfAlleleMap": { "A": "CA", "delA": "C" },\n      "ref": "CA",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42525134,\n      "cpicPosition": 42525134,\n      "rsid": "rs61736512",\n      "chromosomeHgvsName": "g.42525134C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42525182,\n      "cpicPosition": 42525182,\n      "rsid": "rs1135822",\n      "chromosomeHgvsName": "g.42525182A>T",\n      "cpicAlleles": ["A", "T", "W"],\n      "cpicToVcfAlleleMap": { "A": "A", "T": "T" },\n      "ref": "A",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42526657,\n      "cpicPosition": 42526657,\n      "rsid": "rs774671100",\n      "chromosomeHgvsName": "g.42526657dup",\n      "cpicAlleles": ["A", "AA"],\n      "cpicToVcfAlleleMap": { "AA": "CA", "A": "C" },\n      "ref": "C",\n      "alts": ["CA"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42526670,\n      "cpicPosition": 42526670,\n      "rsid": "rs5030862",\n      "chromosomeHgvsName": "g.42526670C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr22",\n      "position": 42526694,\n      "cpicPosition": 42526694,\n      "rsid": "rs1065852",\n      "chromosomeHgvsName": "g.42526694G>A",\n      "cpicAlleles": ["A", "G", "R"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "*1",\n      "id": "777936",\n      "alleles": [\n        "C",\n        "G",\n        "G",\n        "G",\n        "G",\n        "C",\n        "C",\n        "C",\n        "T",\n        "CCTT",\n        "C",\n        "CT",\n        "C",\n        "C",\n        "CA",\n        "C",\n        "A",\n        "C",\n        "C",\n        "G"\n      ],\n      "cpicAlleles": [\n        "C",\n        "G",\n        "G",\n        "del",\n        "G",\n        "C",\n        "C",\n        "C",\n        "T",\n        "TCT",\n        "G",\n        "T",\n        "C",\n        "C",\n        "A",\n        "C",\n        "A",\n        "A",\n        "C",\n        "G"\n      ],\n      "populationFrequency": 0.28500712,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*2",\n      "id": "777938",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.18536054,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*3",\n      "id": "777940",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "delT",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.015922716,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*4",\n      "id": "777942",\n      "alleles": [\n        "C",\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "G"\n      ],\n      "cpicAlleles": [\n        "C",\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "G"\n      ],\n      "populationFrequency": 0.1848476,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*4",\n      "id": "777942",\n      "alleles": [\n        "C",\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A"\n      ],\n      "cpicAlleles": [\n        "C",\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A"\n      ],\n      "populationFrequency": 0.1848476,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n     {\n      "name": "*4",\n      "id": "777942",\n      "alleles": [\n        "G",\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A"\n      ],\n      "cpicAlleles": [\n        "G",\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A"\n      ],\n      "populationFrequency": 0.1848476,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*6",\n      "id": "777946",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "delA",\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.011197059,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*7",\n      "id": "777948",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.0005116425,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*8",\n      "id": "777950",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.00022450546,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*9",\n      "id": "777952",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "delTCT",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.02754178,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*10",\n      "id": "777954",\n      "alleles": [\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A"\n      ],\n      "cpicAlleles": [\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A"\n      ],\n      "populationFrequency": 0.01571283,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*12",\n      "id": "777958",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null\n      ],\n      "populationFrequency": 0.00013778963,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*14",\n      "id": "777962",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.0,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*15",\n      "id": "777964",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "CA",\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "AA",\n        null,\n        null\n      ],\n      "populationFrequency": 0.0004858789,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*17",\n      "id": "777966",\n      "alleles": [\n        "G",\n        "A",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.0039216722,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*21",\n      "id": "777974",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "CG",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "GG",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.0,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*29",\n      "id": "777990",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.0010464214,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*39",\n      "id": "778010",\n      "alleles": [\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.014010031,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*41",\n      "id": "778014",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.09237511,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*42",\n      "id": "778016",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        "GCA",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        "insAC",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.0,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*49",\n      "id": "778030",\n      "alleles": [\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        "A"\n      ],\n      "cpicAlleles": [\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        "A"\n      ],\n      "populationFrequency": 0.0,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*56",\n      "id": "778044",\n      "alleles": [\n        "G",\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A"\n      ],\n      "cpicAlleles": [\n        "G",\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A"\n      ],\n      "populationFrequency": 0.0008093927,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*56",\n      "id": "778044",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.0008093927,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*59",\n      "id": "778050",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": 0.003719603,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*114",\n      "id": "778146",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A"\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A"\n      ],\n      "populationFrequency": 0,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}	5	t	2024-05-23 21:17:24.769602+00	2024-05-23 21:17:24.769602+00
609fec3e-ecb4-448c-aa3c-5241c1ab2c56	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "CYP3A5",\n  "orientation": null,\n  "chromosome": "chr7",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000007.13",\n  "variants": [\n    {\n      "chromosome": "chr7",\n      "position": 99250394,\n      "cpicPosition": 99250394,\n      "rsid": "rs41303343",\n      "chromosomeHgvsName": "g.99250394dup",\n      "cpicAlleles": ["A", "AA"],\n      "cpicToVcfAlleleMap": { "AA": "TA", "A": "T" },\n      "ref": "T",\n      "alts": ["TA"]\n    },\n    {\n      "chromosome": "chr7",\n      "position": 99270539,\n      "cpicPosition": 99270539,\n      "rsid": "rs776746",\n      "chromosomeHgvsName": "g.99270539C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr7",\n      "position": 99262835,\n      "cpicPosition": 99262835,\n      "rsid": "rs10264272",\n      "chromosomeHgvsName": "g.99262835C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "*1",\n      "id": "778218",\n      "alleles": ["T", "T", "C"],\n      "cpicAlleles": ["A", "T", "C"],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*3",\n      "id": "778222",\n      "alleles": [null, "C", null],\n      "cpicAlleles": [null, "C", null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*6",\n      "id": "778228",\n      "alleles": [null, null, "T"],\n      "cpicAlleles": [null, null, "T"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*7",\n      "id": "778230",\n      "alleles": ["TA", null, null],\n      "cpicAlleles": ["AA", null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}	5	t	2024-05-23 21:17:24.773198+00	2024-05-23 21:17:24.773198+00
d54113e5-04dc-4821-81d7-b94a960a5814	93d511ec-e5fc-4832-9581-813842b25860	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "CYP4F2",\n  "orientation": null,\n  "chromosome": "chr19",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000019.9",\n  "variants": [\n    {\n      "chromosome": "chr19",\n      "position": 15990431,\n      "cpicPosition": 15990431,\n      "rsid": "rs2108622",\n      "chromosomeHgvsName": "g.15990431C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "*1",\n      "id": "778238",\n      "alleles": ["C"],\n      "cpicAlleles": ["C"],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*3",\n      "id": "778242",\n      "alleles": ["T"],\n      "cpicAlleles": ["T"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}\n	5	t	2024-05-23 21:17:24.775421+00	2024-05-23 21:17:24.775421+00
81df6754-9b1d-4edc-8b07-ed1a8a116750	01b74a5e-f95b-4086-a5b7-899a8de1f228	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "CYP2B6",\n  "orientation": null,\n  "chromosome": "chr19",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000019.9",\n  "variants": [\n    {\n      "chromosome": "chr19",\n      "position": 41512841,\n      "cpicPosition": 41512841,\n      "rsid": "rs3745274",\n      "chromosomeHgvsName": "g.41512841G>T",\n      "cpicAlleles": ["G", "T"],\n      "cpicToVcfAlleleMap": { "T": "T", "G": "G" },\n      "ref": "G",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr19",\n      "position": 41497129,\n      "cpicPosition": 41497129,\n      "rsid": "rs34223104",\n      "chromosomeHgvsName": "g.41497129T>C",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "T",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr19",\n      "position": 41518221,\n      "cpicPosition": 41518221,\n      "rsid": "rs28399499",\n      "chromosomeHgvsName": "g.41518221T>C",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "T",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr19",\n      "position": 41522715,\n      "cpicPosition": 41522715,\n      "rsid": "rs3211371",\n      "chromosomeHgvsName": "g.41522715C>A; g.41522715C>T",\n      "cpicAlleles": ["A", "C", "T"],\n      "cpicToVcfAlleleMap": { "A": "A", "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["A", "T"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "*1",\n      "id": "777422",\n      "alleles": ["G", "T", "T", "C"],\n      "cpicAlleles": ["G", "T", "T", "C"],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*5",\n      "id": "777430",\n      "alleles": [null, null, null, "T"],\n      "cpicAlleles": [null, null, null, "T"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*6",\n      "id": "777432",\n      "alleles": ["T", null, null, null],\n      "cpicAlleles": ["T", null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*7",\n      "id": "777434",\n      "alleles": ["T", null, null, "T"],\n      "cpicAlleles": ["T", null, null, "T"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*18",\n      "id": "777454",\n      "alleles": [null, null, "C", null],\n      "cpicAlleles": [null, null, "C", null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*22",\n      "id": "777462",\n      "alleles": [null, "C", null, null],\n      "cpicAlleles": [null, "C", null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}	5	f	2024-05-23 21:17:24.754818+00	2024-05-23 21:19:49.674629+00
f249d96c-196c-4432-b1fc-2a2ddc6e4b18	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "DPYD",\n  "orientation": null,\n  "chromosome": "chr1",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000001.10",\n  "variants": [\n    {\n      "chromosome": "chr1",\n      "position": 97544627,\n      "cpicPosition": 97544627,\n      "rsid": "rs1801268",\n      "chromosomeHgvsName": "g.97544627C>A",\n      "cpicAlleles": ["A", "C"],\n      "cpicToVcfAlleleMap": { "A": "A", "C": "C" },\n      "ref": "C",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr1",\n      "position": 97547947,\n      "cpicPosition": 97547947,\n      "rsid": "rs67376798",\n      "chromosomeHgvsName": "g.97547947T>A",\n      "cpicAlleles": ["A", "T"],\n      "cpicToVcfAlleleMap": { "A": "A", "T": "T" },\n      "ref": "T",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr1",\n      "position": 97915614,\n      "cpicPosition": 97915614,\n      "rsid": "rs3918290",\n      "chromosomeHgvsName": "g.97915614C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr1",\n      "position": 97915622,\n      "cpicPosition": 97915623,\n      "rsid": "rs72549303",\n      "chromosomeHgvsName": "g.97915623del",\n      "cpicAlleles": ["G", "delG"],\n      "cpicToVcfAlleleMap": { "delG": "T", "G": "TG" },\n      "ref": "TG",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr1",\n      "position": 97981343,\n      "cpicPosition": 97981343,\n      "rsid": "rs55886062",\n      "chromosomeHgvsName": "g.97981343A>C",\n      "cpicAlleles": ["A", "C"],\n      "cpicToVcfAlleleMap": { "A": "A", "C": "C" },\n      "ref": "A",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr1",\n      "position": 98039419,\n      "cpicPosition": 98039419,\n      "rsid": "rs56038477",\n      "chromosomeHgvsName": "g.98039419C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr1",\n      "position": 98039499,\n      "cpicPosition": 98039499,\n      "rsid": "rs78060119",\n      "chromosomeHgvsName": "g.98039499C>A",\n      "cpicAlleles": ["A", "C"],\n      "cpicToVcfAlleleMap": { "A": "A", "C": "C" },\n      "ref": "C",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr1",\n      "position": 98045449,\n      "cpicPosition": 98045449,\n      "rsid": "rs75017182",\n      "chromosomeHgvsName": "g.98045449G>C",\n      "cpicAlleles": ["C", "G"],\n      "cpicToVcfAlleleMap": { "C": "C", "G": "G" },\n      "ref": "G",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr1",\n      "position": 98157332,\n      "cpicPosition": 98157332,\n      "rsid": "rs1801266",\n      "chromosomeHgvsName": "g.98157332G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr1",\n      "position": 98165030,\n      "cpicPosition": 98165030,\n      "rsid": "rs115232898",\n      "chromosomeHgvsName": "g.98165030T>C",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "T",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr1",\n      "position": 98205966,\n      "cpicPosition": 98205967,\n      "rsid": "rs72549309",\n      "chromosomeHgvsName": "g.98205967ATGA[1]",\n      "cpicAlleles": ["ATGA(1)", "ATGA(2)"],\n      "cpicToVcfAlleleMap": { "ATGA(2)": "AATGA", "ATGA(1)": "A" },\n      "ref": "AATGA",\n      "alts": ["A"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "No Variants Detected",\n      "id": "778327",\n      "alleles": ["C", "T", "C", "TG", "A", "C", "C", "G", "G", "T", "AATGA"],\n      "cpicAlleles": [\n        "C",\n        "T",\n        "C",\n        "G",\n        "A",\n        "C",\n        "C",\n        "G",\n        "G",\n        "T",\n        "ATGA(2)"\n      ],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "c.295_298del",\n      "id": "778337",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A"\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "ATGA(1)"\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "c.557A>G (p.Y186C)",\n      "id": "778351",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "c.703C>T (p.R235W)",\n      "id": "778357",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "c.1129-5923C>G, c.1236G>A",\n      "id": "778377",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        "C",\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        "C",\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "c.1156G>T (p.E386X)",\n      "id": "778379",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "c.1679T>G (p.I560S)",\n      "id": "778419",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "c.1898del (p.P633Qfs)",\n      "id": "778433",\n      "alleles": [\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        "delG",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "c.1905+1G>A",\n      "id": "778437",\n      "alleles": [\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "c.2846A>T (p.D949V)",\n      "id": "778471",\n      "alleles": [\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "c.2983G>T (p.V995F)",\n      "id": "778485",\n      "alleles": [\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}	5	t	2024-05-23 21:17:24.779093+00	2024-05-23 21:17:24.779093+00
5e861df5-0d58-4064-8266-7b2788119fdd	9be7b66e-d066-4d98-bc30-ec1511489398	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "G6PD",\n  "orientation": null,\n  "chromosome": "chrX",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000023.10",\n  "variants": [\n    {\n      "chromosome": "chrX",\n      "position": 153763492,\n      "cpicPosition": 153763492,\n      "rsid": "rs1050829",\n      "chromosomeHgvsName": "g.153763492T>C",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "T",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chrX",\n      "position": 153764217,\n      "cpicPosition": 153764217,\n      "rsid": "rs1050828",\n      "chromosomeHgvsName": "g.153764217C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chrX",\n      "position": 153760472,\n      "cpicPosition": 153760472,\n      "rsid": "rs72554664",\n      "chromosomeHgvsName": "g.153760472C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chrX",\n      "position": 153760484,\n      "cpicPosition": 153760484,\n      "rsid": "rs72554665",\n      "chromosomeHgvsName": "g.153760484C>A;g.153760484C>G",\n      "cpicAlleles": ["A", "C", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "C": "C", "G": "G" },\n      "ref": "C",\n      "alts": ["A", "G"]\n    },\n    {\n      "chromosome": "chrX",\n      "position": 153761205,\n      "cpicPosition": 153761205,\n      "rsid": "rs5030869",\n      "chromosomeHgvsName": "g.153761205C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chrX",\n      "position": 153761240,\n      "cpicPosition": 153761240,\n      "rsid": "rs76723693",\n      "chromosomeHgvsName": "g.153761240A>G",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "A",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chrX",\n      "position": 153762605,\n      "cpicPosition": 153762605,\n      "rsid": "rs137852330",\n      "chromosomeHgvsName": "g.153762605G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chrX",\n      "position": 153762634,\n      "cpicPosition": 153762634,\n      "rsid": "rs5030868",\n      "chromosomeHgvsName": "g.153762634G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chrX",\n      "position": 153762653,\n      "cpicPosition": 153762653,\n      "rsid": "rs267606836",\n      "chromosomeHgvsName": "g.153762653G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chrX",\n      "position": 153763551,\n      "cpicPosition": 153763551,\n      "rsid": "rs267606835",\n      "chromosomeHgvsName": "g.153763551G>C",\n      "cpicAlleles": ["C", "G"],\n      "cpicToVcfAlleleMap": { "C": "C", "G": "G" },\n      "ref": "G",\n      "alts": ["C"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "B",\n      "id": "778666",\n      "alleles": ["T", "C", "C", "C", "C", "A", "G", "G", "G", "G"],\n      "cpicAlleles": ["T", "C", "C", "C", "C", "A", "G", "G", "G", "G"],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "A",\n      "id": "778752",\n      "alleles": ["C", null, null, null, null, null, null, null, null, null],\n      "cpicAlleles": [\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "A- 202A_376G",\n      "id": "778712",\n      "alleles": ["C", "T", null, null, null, null, null, null, null, null],\n      "cpicAlleles": ["C", "T", null, null, null, null, null, null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "A- 968C_376G",\n      "id": "778750",\n      "alleles": ["C", null, null, null, null, "G", null, null, null, null],\n      "cpicAlleles": ["C", null, null, null, null, "G", null, null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "Asahi",\n      "id": "778708",\n      "alleles": [null, "T", null, null, null, null, null, null, null, null],\n      "cpicAlleles": [\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "Canton",\n      "id": "779012",\n      "alleles": [null, null, null, "A", null, null, null, null, null, null],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "Chatham",\n      "id": "778894",\n      "alleles": [null, null, null, null, "T", null, null, null, null, null],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "Coimbra Shunde",\n      "id": "778804",\n      "alleles": [null, null, null, null, null, null, "A", null, null, null],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "Cosenza",\n      "id": "779010",\n      "alleles": [null, null, null, "G", null, null, null, null, null, null],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "Kaiping",\n      "id": "779022",\n      "alleles": [null, null, "T", null, null, null, null, null, null, null],\n      "cpicAlleles": [\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "Mediterranean",\n      "id": "778800",\n      "alleles": [null, null, null, null, null, null, null, "A", null, null],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "Vancouver",\n      "id": "778732",\n      "alleles": [null, null, null, null, null, null, "A", null, "A", "C"],\n      "cpicAlleles": [null, null, null, null, null, null, "A", null, "A", "C"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}	5	t	2024-05-23 21:17:24.782371+00	2024-05-23 21:17:24.782371+00
1b84feb7-236b-49a9-bd21-ec37fd384593	daa86f03-86c6-4a8d-abab-476fcd043c9c	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "NUDT15",\n  "orientation": null,\n  "chromosome": "chr13",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000013.10",\n  "variants": [\n    {\n      "chromosome": "chr13",\n      "position": 48619855,\n      "cpicPosition": 48619855,\n      "rsid": "rs116855232",\n      "chromosomeHgvsName": "g.48619855C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr13",\n      "position": 48619856,\n      "cpicPosition": 48619856,\n      "rsid": "rs147390019",\n      "chromosomeHgvsName": "g.48619856G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr13",\n      "position": 48611934,\n      "cpicPosition": 48611934,\n      "rsid": "rs186364861",\n      "chromosomeHgvsName": "g.48611934G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr13",\n      "position": 48611920,\n      "cpicPosition": 48611920,\n      "rsid": "rs746071566",\n      "chromosomeHgvsName": "g.48611920GAGTCG[2]; g.48611920GAGTCG[4]",\n      "cpicAlleles": ["GAGTCG(2)", "GAGTCG(3)", "GAGTCG(4)", "GAGTCG(5)"],\n      "cpicToVcfAlleleMap": {\n        "GAGTCG(3)": "AGGAGTC",\n        "GAGTCG(4)": "AGGAGTCGGAGTC",\n        "GAGTCG(2)": "A",\n        "GAGTCG(5)": "CGGAGTC"\n      },\n      "ref": "AGGAGTC",\n      "alts": ["A", "AGGAGTCGGAGTC","C"]\n    },\n    {\n      "chromosome": "chr13",\n      "position": 48611983,\n      "cpicPosition": 48611983,\n      "rsid": "rs766023281",\n      "chromosomeHgvsName": "g.48611983G>C",\n      "cpicAlleles": ["C", "G"],\n      "cpicToVcfAlleleMap": { "C": "C", "G": "G" },\n      "ref": "G",\n      "alts": ["C"]\n    },\n    {\n        "chromosome": "chr13",\n        "position": 48611985,\n        "cpicPosition": 48611985,\n        "rsid": "g.48611985A>G",\n        "chromosomeHgvsName": "g.48611985A>G",\n        "cpicAlleles": [\n          "A",\n          "G"\n        ],\n        "cpicToVcfAlleleMap": {\n          "A": "A",\n          "G": "G"\n        },\n        "ref": "A",\n        "alts": [\n          "G"\n        ]\n      }\n  ],\n  "namedAlleles": [\n    {\n      "name": "*1",\n      "id": "779064",\n      "alleles": ["C", "G", "G", "AGGAGTC", "G", "A"],\n      "cpicAlleles": ["C", "G", "G", "GAGTCG(3)", "G", "A"],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*1",\n      "id": "779064",\n      "alleles": ["C", "G", "G", "CGGAGTC", "G", "A"],\n      "cpicAlleles": ["C", "G", "G", "GAGTCG(5)", "G", "A"],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*2",\n      "id": "779066",\n      "alleles": [ "T", null, null, "AGGAGTCGGAGTC", null, null],\n      "cpicAlleles": ["T", null, null, "GAGTCG(4)", null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*3",\n      "id": "779068",\n      "alleles": ["T", null, null, null, null, null],\n      "cpicAlleles": ["T", null, null, null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*4",\n      "id": "779070",\n      "alleles": [null, "A", null, null, null, null],\n      "cpicAlleles": [null, "A", null, null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*5",\n      "id": "779072",\n      "alleles": [null, null, "A", null, null, null],\n      "cpicAlleles": [null, null, "A", null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*6",\n      "id": "779074",\n      "alleles": [null, null, null, "AGGAGTCGGAGTC", null, null],\n      "cpicAlleles": [null, null, null, "GAGTCG(4)", null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*7",\n      "id": "779076",\n      "alleles": [null, null, null, null, "C", null],\n      "cpicAlleles": [null, null, null, null, "C", null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*8",\n      "id": "779078",\n      "alleles": [null, null, null, null, null, "G"],\n      "cpicAlleles": [null, null, null, null, null, "G"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*9",\n      "id": "779080",\n      "alleles": [null, null, null, "A", null, null],\n      "cpicAlleles": [ null, null, null, "GAGTCG(2)", null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}\n	5	t	2024-05-23 21:17:24.785221+00	2024-05-23 21:17:24.785221+00
9053dee5-7022-4f5a-b8e0-6178d75b9d4c	22fb682a-e57d-4ad2-8dc5-8159f28a9862	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "SLCO1B1",\n  "orientation": null,\n  "chromosome": "chr12",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000012.11",\n  "variants": [\n    {\n      "chromosome": "chr12",\n      "position": 21329738,\n      "cpicPosition": 21329738,\n      "rsid": "rs2306283",\n      "chromosomeHgvsName": "g.21329738A>G",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "A",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chr12",\n      "position": 21329813,\n      "cpicPosition": 21329813,\n      "rsid": "rs11045819",\n      "chromosomeHgvsName": "g.21329813C>A",\n      "cpicAlleles": ["A", "C"],\n      "cpicToVcfAlleleMap": { "A": "A", "C": "C" },\n      "ref": "C",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr12",\n      "position": 21331549,\n      "cpicPosition": 21331549,\n      "rsid": "rs4149056",\n      "chromosomeHgvsName": "g.21331549T>C",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "T",\n      "alts": ["C"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "*1",\n      "id": "1002623",\n      "alleles": ["A", "C", "T"],\n      "cpicAlleles": ["A", "C", "T"],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*5",\n      "id": "779285",\n      "alleles": [null, null, "C"],\n      "cpicAlleles": [null, null, "C"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*14",\n      "id": "779303",\n      "alleles": ["G", "A", null],\n      "cpicAlleles": ["G", "A", null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*15",\n      "id": "779305",\n      "alleles": ["G", null, "C"],\n      "cpicAlleles": ["G", null, "C"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*37",\n      "id": "1002685",\n      "alleles": ["G", null, null],\n      "cpicAlleles": ["G", null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}	5	t	2024-05-23 21:17:24.787648+00	2024-05-23 21:17:24.787648+00
2fcf4270-e019-481b-9037-e35f904172ba	9ca2999f-1b56-4ee8-a254-2da4415cbb72	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "TPMT",\n  "orientation": null,\n  "chromosome": "chr6",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000006.11",\n  "variants": [\n    {\n      "chromosome": "chr6",\n      "position": 18130918,\n      "cpicPosition": 18130918,\n      "rsid": "rs1142345",\n      "chromosomeHgvsName": "g.18130918T>C; g.18130918T>G",\n      "cpicAlleles": ["C", "G", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T", "G": "G" },\n      "ref": "T",\n      "alts": ["C", "G"]\n    },\n    {\n      "chromosome": "chr6",\n      "position": 18131012,\n      "cpicPosition": 18131012,\n      "rsid": "rs1800584",\n      "chromosomeHgvsName": "g.18131012C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr6",\n      "position": 18134115,\n      "cpicPosition": 18134115,\n      "rsid": "rs74423290",\n      "chromosomeHgvsName": "g.18134115G>C",\n      "cpicAlleles": ["C", "G"],\n      "cpicToVcfAlleleMap": { "C": "C", "G": "G" },\n      "ref": "G",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr6",\n      "position": 18134121,\n      "cpicPosition": 18134121,\n      "rsid": "rs9333570",\n      "chromosomeHgvsName": "g.18134121C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr6",\n      "position": 18139228,\n      "cpicPosition": 18139228,\n      "rsid": "rs1800460",\n      "chromosomeHgvsName": "g.18139228C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr6",\n      "position": 18139920,\n      "cpicPosition": 18139920,\n      "rsid": "rs72552738",\n      "chromosomeHgvsName": "g.18139920C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr6",\n      "position": 18143955,\n      "cpicPosition": 18143955,\n      "rsid": "rs1800462",\n      "chromosomeHgvsName": "g.18143955C>G",\n      "cpicAlleles": ["C", "G"],\n      "cpicToVcfAlleleMap": { "C": "C", "G": "G" },\n      "ref": "C",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chr6",\n      "position": 18149357,\n      "cpicPosition": 18149357,\n      "rsid": "rs267607275",\n      "chromosomeHgvsName": "g.18149357A>G",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "A",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chr6",\n      "position": 18149358,\n      "cpicPosition": 18149358,\n      "rsid": "rs9333569",\n      "chromosomeHgvsName": "g.18149358T>C",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "T",\n      "alts": ["C"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "*1",\n      "id": "779392",\n      "alleles": ["T", "C", "G", "C", "C", "C", "C", "A", "T"],\n      "cpicAlleles": ["T", "C", "G", "C", "C", "C", "C", "A", "T"],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*2",\n      "id": "779394",\n      "alleles": [null, null, null, null, null, null, "G", null, null],\n      "cpicAlleles": [null, null, null, null, null, null, "G", null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*3A",\n      "id": "779396",\n      "alleles": ["C", null, null, null, "T", null, null, null, null],\n      "cpicAlleles": ["C", null, null, null, "T", null, null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*3B",\n      "id": "779398",\n      "alleles": [null, null, null, null, "T", null, null, null, null],\n      "cpicAlleles": [null, null, null, null, "T", null, null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*3C",\n      "id": "779400",\n      "alleles": ["C", null, null, null, null, null, null, null, null],\n      "cpicAlleles": ["C", null, null, null, null, null, null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*4",\n      "id": "779402",\n      "alleles": [null, "T", null, null, null, null, null, null, null],\n      "cpicAlleles": [null, "T", null, null, null, null, null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*11",\n      "id": "779416",\n      "alleles": [null, null, null, null, null, "T", null, null, null],\n      "cpicAlleles": [null, null, null, null, null, "T", null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*14",\n      "id": "779422",\n      "alleles": [null, null, null, null, null, null, null, null, "C"],\n      "cpicAlleles": [null, null, null, null, null, null, null, null, "C"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*15",\n      "id": "779424",\n      "alleles": [null, null, null, "T", null, null, null, null, null],\n      "cpicAlleles": [null, null, null, "T", null, null, null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*23",\n      "id": "779440",\n      "alleles": [null, null, "C", null, null, null, null, null, null],\n      "cpicAlleles": [null, null, "C", null, null, null, null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*29",\n      "id": "779452",\n      "alleles": [null, null, null, null, null, null, null, "G", null],\n      "cpicAlleles": [null, null, null, null, null, null, null, "G", null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*41",\n      "id": "779476",\n      "alleles": ["G", null, null, null, null, null, null, null, null],\n      "cpicAlleles": ["G", null, null, null, null, null, null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}	5	t	2024-05-23 21:17:24.79064+00	2024-05-23 21:17:24.79064+00
14e68bfd-c9fe-491b-9fe9-dc68d0fd06b4	58f41405-4198-4822-b10e-eb43cd77bc27	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "UGT1A1",\n  "orientation": null,\n  "chromosome": "chr2",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000002.11",\n  "variants": [\n    {\n      "chromosome": "chr2",\n      "position": 234668879,\n      "cpicPosition": 234668881,\n      "rsid": "rs3064744",\n      "chromosomeHgvsName": "g.234668881TA[6]; g.234668881TA[7]; g.234668881TA[8]; g.234668881TA[9]",\n      "cpicAlleles": ["TA(6)", "TA(7)", "TA(8)", "TA(9)"],\n      "cpicToVcfAlleleMap": {\n        "TA(7)": "CAT",\n        "TA(8)": "CATAT",\n        "TA(6)": "C",\n        "TA(9)": "CATATAT"\n      },\n      "ref": "CAT",\n      "alts": ["C", "CATAT", "CATATAT"]\n    },\n    {\n      "chromosome": "chr2",\n      "position": 234669144,\n      "cpicPosition": 234669144,\n      "rsid": "rs4148323",\n      "chromosomeHgvsName": "g.234669144G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr2",\n      "position": 234669619,\n      "cpicPosition": 234669619,\n      "rsid": "rs35350960",\n      "chromosomeHgvsName": "g.234669619C>A",\n      "cpicAlleles": ["A", "C"],\n      "cpicToVcfAlleleMap": { "A": "A", "C": "C" },\n      "ref": "C",\n      "alts": ["A"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "*1",\n      "id": "779488",\n      "alleles": ["CAT", "G", "C"],\n      "cpicAlleles": ["TA(7)", "G", "C"],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*6",\n      "id": "779490",\n      "alleles": [null, "A", null],\n      "cpicAlleles": [null, "A", null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*27",\n      "id": "779492",\n      "alleles": [null, null, "A"],\n      "cpicAlleles": [null, null, "A"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*28",\n      "id": "779494",\n      "alleles": ["CATAT", null, null],\n      "cpicAlleles": ["TA(8)", null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*36",\n      "id": "779496",\n      "alleles": ["C", null, null],\n      "cpicAlleles": ["TA(6)", null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*37",\n      "id": "779498",\n      "alleles": ["CATATAT", null, null],\n      "cpicAlleles": ["TA(9)", null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}	5	t	2024-05-23 21:17:24.793139+00	2024-05-23 21:17:24.793139+00
96c1f48f-14c4-4bcb-bf4f-c06e4a3fce5a	c0f1136b-6463-4304-a473-cae1f384fc8e	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "VKORC1",\n  "orientation": null,\n  "chromosome": "chr16",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000016.9",\n  "variants": [\n    {\n      "chromosome": "chr16",\n      "position": 31107689,\n      "cpicPosition": 31107689,\n      "rsid": "rs9923231",\n      "chromosomeHgvsName": "g.31107689C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    }\n  ],\n  "namedAlleles": []\n}	5	t	2024-05-23 21:17:24.795346+00	2024-05-23 21:17:24.795346+00
240f6e2a-52ea-4c82-b63b-0893b7653857	b31967bd-f6da-49d9-ba4e-cafdd7786116	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "Sep 05, 2023, 3:32:09 PM",\n  "gene": "HLA-B",\n  "orientation": null,\n  "chromosome": "chr6",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000006.11",\n  "variants": [\n    {\n      "chromosome": "chr6",\n      "position": 31431780,\n      "cpicPosition": 31431780,\n      "rsid": "rs2395029",\n      "chromosomeHgvsName": "g.31431780T>G",\n      "cpicAlleles": ["G", "T"],\n      "cpicToVcfAlleleMap": { "T": "T", "G": "G" },\n      "ref": "T",\n      "alts": ["G"]\n    }\n  ],\n  "namedAlleles": []\n}	5	t	2024-05-23 21:17:24.797484+00	2024-05-23 21:17:24.797484+00
ca3bf6a4-0963-43dc-9fa2-9a98a41d662a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "CYP2C19",\n  "orientation": null,\n  "chromosome": "chr10",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000010.10",\n  "variants": [\n    {\n      "chromosome": "chr10",\n      "position": 96535124,\n      "cpicPosition": 96535124,\n      "rsid": "rs12769205",\n      "chromosomeHgvsName": "g.96535124A>G",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "A",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96541616,\n      "cpicPosition": 96541616,\n      "rsid": "rs4244285",\n      "chromosomeHgvsName": "g.96541616G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96521657,\n      "cpicPosition": 96521657,\n      "rsid": "rs12248560",\n      "chromosomeHgvsName": "g.96521657C>T",\n      "cpicAlleles": ["C", "T", "Y"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96522463,\n      "cpicPosition": 96522463,\n      "rsid": "rs28399504",\n      "chromosomeHgvsName": "g.96522463A>G",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "A",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96535173,\n      "cpicPosition": 96535173,\n      "rsid": "rs41291556",\n      "chromosomeHgvsName": "g.96535173T>C",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "T",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96535210,\n      "cpicPosition": 96535210,\n      "rsid": "rs72552267",\n      "chromosomeHgvsName": "g.96535210G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96535246,\n      "cpicPosition": 96535246,\n      "rsid": "rs17884712",\n      "chromosomeHgvsName": "g.96535246G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96540331,\n      "cpicPosition": 96540331,\n      "rsid": "rs140278421",\n      "chromosomeHgvsName": "g.96540331G>C",\n      "cpicAlleles": ["C", "G"],\n      "cpicToVcfAlleleMap": { "C": "C", "G": "G" },\n      "ref": "G",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96540410,\n      "cpicPosition": 96540410,\n      "rsid": "rs4986893",\n      "chromosomeHgvsName": "g.96540410G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96541615,\n      "cpicPosition": 96541615,\n      "rsid": "rs6413438",\n      "chromosomeHgvsName": "g.96541615C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96541701,\n      "cpicPosition": 96541701,\n      "rsid": "rs375781227",\n      "chromosomeHgvsName": "g.96541701G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96541756,\n      "cpicPosition": 96541756,\n      "rsid": "rs72558186",\n      "chromosomeHgvsName": "g.96541756T>A",\n      "cpicAlleles": ["A", "T"],\n      "cpicToVcfAlleleMap": { "A": "A", "T": "T" },\n      "ref": "T",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96602636,\n      "cpicPosition": 96602636,\n      "rsid": "rs118203757",\n      "chromosomeHgvsName": "g.96602636G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96612495,\n      "cpicPosition": 96612495,\n      "rsid": "rs56337013",\n      "chromosomeHgvsName": "g.96612495C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96612522,\n      "cpicPosition": 96612522,\n      "rsid": "rs192154563",\n      "chromosomeHgvsName": "g.96612522C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96612542,\n      "cpicPosition": 96612542,\n      "rsid": "rs118203759",\n      "chromosomeHgvsName": "g.96612542C>G",\n      "cpicAlleles": ["C", "G"],\n      "cpicToVcfAlleleMap": { "C": "C", "G": "G" },\n      "ref": "C",\n      "alts": ["G"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "*1",\n      "id": "777532",\n      "alleles": [\n        "A",\n        "G",\n        "C",\n        "A",\n        "T",\n        "G",\n        "G",\n        "G",\n        "G",\n        "C",\n        "G",\n        "T",\n        "G",\n        "C",\n        "C",\n        "C"\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*2",\n      "id": "777534",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*3",\n      "id": "777536",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*4",\n      "id": "777538",\n      "alleles": [\n        null,\n        null,\n        null,\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*5",\n      "id": "777540",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*6",\n      "id": "777542",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*7",\n      "id": "777544",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*8",\n      "id": "777546",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*9",\n      "id": "777548",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*10",\n      "id": "777550",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*16",\n      "id": "777562",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*17",\n      "id": "777564",\n      "alleles": [\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*22",\n      "id": "777570",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*24",\n      "id": "777574",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*25",\n      "id": "777576",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "G"\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "G"\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*26",\n      "id": "777578",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*35",\n      "id": "777594",\n      "alleles": [\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}\n	5	f	2024-05-23 21:17:24.765232+00	2024-05-23 21:19:14.49248+00
6b170236-0a67-43d9-b41c-0f6fedd86271	32638f99-ec66-41e9-87db-40b5f6c8d7d6	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "CYP2C19",\n  "orientation": null,\n  "chromosome": "chr10",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000010.10",\n  "variants": [\n    {\n      "chromosome": "chr10",\n      "position": 96535124,\n      "cpicPosition": 96535124,\n      "rsid": "rs12769205",\n      "chromosomeHgvsName": "g.96535124A>G",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "A",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96541616,\n      "cpicPosition": 96541616,\n      "rsid": "rs4244285",\n      "chromosomeHgvsName": "g.96541616G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96521657,\n      "cpicPosition": 96521657,\n      "rsid": "rs12248560",\n      "chromosomeHgvsName": "g.96521657C>T",\n      "cpicAlleles": ["C", "T", "Y"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96522463,\n      "cpicPosition": 96522463,\n      "rsid": "rs28399504",\n      "chromosomeHgvsName": "g.96522463A>G",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "A",\n      "alts": ["G"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96535173,\n      "cpicPosition": 96535173,\n      "rsid": "rs41291556",\n      "chromosomeHgvsName": "g.96535173T>C",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "T",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96535210,\n      "cpicPosition": 96535210,\n      "rsid": "rs72552267",\n      "chromosomeHgvsName": "g.96535210G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96535246,\n      "cpicPosition": 96535246,\n      "rsid": "rs17884712",\n      "chromosomeHgvsName": "g.96535246G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96540331,\n      "cpicPosition": 96540331,\n      "rsid": "rs140278421",\n      "chromosomeHgvsName": "g.96540331G>C",\n      "cpicAlleles": ["C", "G"],\n      "cpicToVcfAlleleMap": { "C": "C", "G": "G" },\n      "ref": "G",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96540410,\n      "cpicPosition": 96540410,\n      "rsid": "rs4986893",\n      "chromosomeHgvsName": "g.96540410G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96541615,\n      "cpicPosition": 96541615,\n      "rsid": "rs6413438",\n      "chromosomeHgvsName": "g.96541615C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96541701,\n      "cpicPosition": 96541701,\n      "rsid": "rs375781227",\n      "chromosomeHgvsName": "g.96541701G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96541756,\n      "cpicPosition": 96541756,\n      "rsid": "rs72558186",\n      "chromosomeHgvsName": "g.96541756T>A",\n      "cpicAlleles": ["A", "T"],\n      "cpicToVcfAlleleMap": { "A": "A", "T": "T" },\n      "ref": "T",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96602636,\n      "cpicPosition": 96602636,\n      "rsid": "rs118203757",\n      "chromosomeHgvsName": "g.96602636G>A",\n      "cpicAlleles": ["A", "G"],\n      "cpicToVcfAlleleMap": { "A": "A", "G": "G" },\n      "ref": "G",\n      "alts": ["A"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96612495,\n      "cpicPosition": 96612495,\n      "rsid": "rs56337013",\n      "chromosomeHgvsName": "g.96612495C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96612522,\n      "cpicPosition": 96612522,\n      "rsid": "rs192154563",\n      "chromosomeHgvsName": "g.96612522C>T",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr10",\n      "position": 96612542,\n      "cpicPosition": 96612542,\n      "rsid": "rs118203759",\n      "chromosomeHgvsName": "g.96612542C>G",\n      "cpicAlleles": ["C", "G"],\n      "cpicToVcfAlleleMap": { "C": "C", "G": "G" },\n      "ref": "C",\n      "alts": ["G"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "*1",\n      "id": "777532",\n      "alleles": [\n        "A",\n        "G",\n        "C",\n        "A",\n        "T",\n        "G",\n        "G",\n        "G",\n        "G",\n        "C",\n        "G",\n        "T",\n        "G",\n        "C",\n        "C",\n        "C"\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*2",\n      "id": "777534",\n      "alleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*3",\n      "id": "777536",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*4",\n      "id": "777538",\n      "alleles": [\n        null,\n        null,\n        null,\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*4",\n      "id": "777539",\n      "alleles": [\n        null,\n        null,\n        "T",\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        "T",\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*5",\n      "id": "777540",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*6",\n      "id": "777542",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*7",\n      "id": "777544",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*8",\n      "id": "777546",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*9",\n      "id": "777548",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*10",\n      "id": "777550",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*16",\n      "id": "777562",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "T",\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*17",\n      "id": "777564",\n      "alleles": [\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        "T",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*22",\n      "id": "777570",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "C",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*24",\n      "id": "777574",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*25",\n      "id": "777576",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "G"\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "G"\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*26",\n      "id": "777578",\n      "alleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        "A",\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*35",\n      "id": "777594",\n      "alleles": [\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "cpicAlleles": [\n        "G",\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null,\n        null\n      ],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}\n	5	t	2024-05-23 21:19:14.49248+00	2024-05-23 21:19:14.49248+00
be83b899-55f2-49ac-9bed-b2d2c1686778	01b74a5e-f95b-4086-a5b7-899a8de1f228	{\n  "formatVersion": "2",\n  "source": "CPIC",\n  "version": "v1.0",\n  "modificationDate": "May 09, 2023, 3:02:09 PM",\n  "gene": "CYP2B6",\n  "orientation": null,\n  "chromosome": "chr19",\n  "genomeBuild": "GRCh37.p13",\n  "refSeqChromosomeId": "NC_000019.9",\n  "variants": [\n    {\n      "chromosome": "chr19",\n      "position": 41512841,\n      "cpicPosition": 41512841,\n      "rsid": "rs3745274",\n      "chromosomeHgvsName": "g.41512841G>T",\n      "cpicAlleles": ["G", "T"],\n      "cpicToVcfAlleleMap": { "T": "T", "G": "G" },\n      "ref": "G",\n      "alts": ["T"]\n    },\n    {\n      "chromosome": "chr19",\n      "position": 41497129,\n      "cpicPosition": 41497129,\n      "rsid": "rs34223104",\n      "chromosomeHgvsName": "g.41497129T>C",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "T",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr19",\n      "position": 41518221,\n      "cpicPosition": 41518221,\n      "rsid": "rs28399499",\n      "chromosomeHgvsName": "g.41518221T>C",\n      "cpicAlleles": ["C", "T"],\n      "cpicToVcfAlleleMap": { "C": "C", "T": "T" },\n      "ref": "T",\n      "alts": ["C"]\n    },\n    {\n      "chromosome": "chr19",\n      "position": 41522715,\n      "cpicPosition": 41522715,\n      "rsid": "rs3211371",\n      "chromosomeHgvsName": "g.41522715C>A; g.41522715C>T",\n      "cpicAlleles": ["A", "C", "T"],\n      "cpicToVcfAlleleMap": { "A": "A", "C": "C", "T": "T" },\n      "ref": "C",\n      "alts": ["T", "A"]\n    }\n  ],\n  "namedAlleles": [\n    {\n      "name": "*1",\n      "id": "777422",\n      "alleles": ["G", "T", "T", "C"],\n      "cpicAlleles": ["G", "T", "T", "C"],\n      "populationFrequency": null,\n      "reference": true,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*1",\n      "id": "777423",\n      "alleles": ["G", "T", "T", "A"],\n      "cpicAlleles": ["G", "T", "T", "A"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*5",\n      "id": "777430",\n      "alleles": [null, null, null, "T"],\n      "cpicAlleles": [null, null, null, "T"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*6",\n      "id": "777432",\n      "alleles": ["T", null, null, null],\n      "cpicAlleles": ["T", null, null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*7",\n      "id": "777434",\n      "alleles": ["T", null, null, "T"],\n      "cpicAlleles": ["T", null, null, "T"],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*18",\n      "id": "777454",\n      "alleles": [null, null, "C", null],\n      "cpicAlleles": [null, null, "C", null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    },\n    {\n      "name": "*22",\n      "id": "777462",\n      "alleles": [null, "C", null, null],\n      "cpicAlleles": [null, "C", null, null],\n      "populationFrequency": null,\n      "reference": false,\n      "numCombinations": 0,\n      "numPartials": 0\n    }\n  ]\n}	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
\.


--
-- Data for Name: haplotypes; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.haplotypes (id, gene_id, haplotype, score, population_frequency, function, status, active, created_at, updated_at) FROM stdin;
f7b79e33-683f-4dbe-a9de-f85b11a86d7b	39f5387b-4a50-4696-99ae-6c9062e70c52	G	\N	0.8964	Normal Function	5	t	2024-05-23 21:17:24.800109+00	2024-05-23 21:17:24.800109+00
ed3934dd-2168-4345-bba3-5f6a0e158ec0	39f5387b-4a50-4696-99ae-6c9062e70c52	T	\N	0.1036	Decreased Function	5	t	2024-05-23 21:17:24.800109+00	2024-05-23 21:17:24.800109+00
721c3aac-5d68-4853-94de-c82abea3ca09	01b74a5e-f95b-4086-a5b7-899a8de1f228	*1	\N	0.49070138	Normal Function	5	t	2024-05-23 21:17:24.8027+00	2024-05-23 21:17:24.8027+00
3d49dcf7-6674-4d6f-8925-6b8d20ace487	01b74a5e-f95b-4086-a5b7-899a8de1f228	*5	\N	0.11547839	Normal Function	5	t	2024-05-23 21:17:24.8027+00	2024-05-23 21:17:24.8027+00
b64f99b8-39b4-4a9b-ba99-29f88e7dcd09	01b74a5e-f95b-4086-a5b7-899a8de1f228	*6	\N	0.23297834	Decreased Function	5	t	2024-05-23 21:17:24.8027+00	2024-05-23 21:17:24.8027+00
b45d5d5e-3ab0-4b25-968e-feec018d523f	01b74a5e-f95b-4086-a5b7-899a8de1f228	*7	\N	0.024807692	Decreased Function	5	t	2024-05-23 21:17:24.8027+00	2024-05-23 21:17:24.8027+00
8c754871-b2ea-4aae-810c-712852326602	01b74a5e-f95b-4086-a5b7-899a8de1f228	*18	\N	0.0	No Function	5	t	2024-05-23 21:17:24.8027+00	2024-05-23 21:17:24.8027+00
1c297820-d0f4-4007-a68f-0b4e04c3b86f	01b74a5e-f95b-4086-a5b7-899a8de1f228	*22	\N	0.014	Increased Function	5	t	2024-05-23 21:17:24.8027+00	2024-05-23 21:17:24.8027+00
8b19b7b4-0d72-4b01-869b-8a3acb2c53be	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	G	\N	\N	Normal Function	5	t	2024-05-23 21:17:24.805689+00	2024-05-23 21:17:24.805689+00
56ef68eb-af96-4c0e-965e-629e302e2481	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	A	\N	\N	Decreased Function	5	t	2024-05-23 21:17:24.805689+00	2024-05-23 21:17:24.805689+00
f72bfcc4-7ff1-4f9e-89df-10d4112cc55b	e8d718e4-4831-496c-8448-16ad044c2e9d	*1	1.00	0.79275	Normal Function	5	t	2024-05-23 21:17:24.807788+00	2024-05-23 21:17:24.807788+00
f520b52a-47ad-4238-8611-3433f61a6b05	e8d718e4-4831-496c-8448-16ad044c2e9d	*2	0.50	0.1273007	Decreased Function	5	t	2024-05-23 21:17:24.807788+00	2024-05-23 21:17:24.807788+00
8eddb00b-2b5b-47b3-ada3-33b4ef48bdad	e8d718e4-4831-496c-8448-16ad044c2e9d	*3	0.00	0.07554484	No Function	5	t	2024-05-23 21:17:24.807788+00	2024-05-23 21:17:24.807788+00
cff92809-f5a6-457f-a341-a91d1f82a83a	e8d718e4-4831-496c-8448-16ad044c2e9d	*4	0.50	0.0	Decreased Function	5	t	2024-05-23 21:17:24.807788+00	2024-05-23 21:17:24.807788+00
95996d13-95a6-4244-be81-70a4e554ac6c	e8d718e4-4831-496c-8448-16ad044c2e9d	*5	0.50	0.00017448276	Decreased Function	5	t	2024-05-23 21:17:24.807788+00	2024-05-23 21:17:24.807788+00
776e8ea5-5869-4535-9329-3ef68ecfe2a3	e8d718e4-4831-496c-8448-16ad044c2e9d	*6	0.00	0.00028025627	No Function	5	t	2024-05-23 21:17:24.807788+00	2024-05-23 21:17:24.807788+00
a53bb49c-baa0-4fdb-987d-ccd5fb3d2654	e8d718e4-4831-496c-8448-16ad044c2e9d	*8	0.50	0.0018053303	Decreased Function	5	t	2024-05-23 21:17:24.807788+00	2024-05-23 21:17:24.807788+00
169cbf3c-6271-4b8b-9337-611b71e3e527	e8d718e4-4831-496c-8448-16ad044c2e9d	*11	0.50	0.0016443896	Decreased Function	5	t	2024-05-23 21:17:24.807788+00	2024-05-23 21:17:24.807788+00
abf7ecbe-fcda-456e-9442-8d40a872b178	e8d718e4-4831-496c-8448-16ad044c2e9d	*12	0.50	0.0	Decreased Function	5	t	2024-05-23 21:17:24.807788+00	2024-05-23 21:17:24.807788+00
d31af913-00cb-4f5a-bdff-6c979ced0e50	e8d718e4-4831-496c-8448-16ad044c2e9d	*13	0.00	0.0	No Function	5	t	2024-05-23 21:17:24.807788+00	2024-05-23 21:17:24.807788+00
09bbaaf7-85f7-44cb-b90d-de2f184a2e8b	e8d718e4-4831-496c-8448-16ad044c2e9d	*15	0.00	0.0	No Function	5	t	2024-05-23 21:17:24.807788+00	2024-05-23 21:17:24.807788+00
65117db3-5fda-476b-a6b5-f155f74cace1	e8d718e4-4831-496c-8448-16ad044c2e9d	*16	0.50	0.0	Decreased Function	5	t	2024-05-23 21:17:24.807788+00	2024-05-23 21:17:24.807788+00
877896af-dced-4232-8617-69b7cc5808c8	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*1	\N	0.62514144	Normal Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
a16c8803-ff6c-4d5b-a472-1eb42eab6286	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*2	\N	0.14685704	No Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
f58654a8-70f4-4d59-a386-0803fdfd6e91	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*3	\N	0.0016180738	No Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
59c017a3-3214-4f79-927a-c165551c63b5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*4	\N	0.002359747	No Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
0e01cb82-5f8d-4d9f-84bb-2d48f61cb9dd	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*5	\N	0.000028767667	No Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
da638ee4-1cbc-49b0-ae4f-a57c03bfabf5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*6	\N	0.00030023712	No Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
80bb05d4-2d3b-4e3a-9d19-c5e0fe33ea22	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*7	\N	0.0	No Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
3193cda8-5eed-49d8-aa7e-ad0c4c97a636	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*8	\N	0.0033593778	No Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
d7a620a0-5fbf-4f04-8d38-664532512db1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*9	\N	0.0006602626	Decreased Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
538a028e-3cb3-4a11-95d3-1b71531e9e59	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*10	\N	0.0	Decreased Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
6bdc71f3-07d4-492b-a93b-b1295c7aeedf	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*16	\N	0.0	Decreased Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
8bd69081-afa8-498d-aec8-e5be89b43cc3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*17	\N	0.2154386	Increased Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
2caa18a8-6c4d-4dfb-8e70-b80e8e600721	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*22	\N	0.0	No Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
f786c3b6-6406-4d57-937b-40c9dcf3e356	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*24	\N	0.0	No Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
6f367e68-b796-4234-b210-d97fd947a9b7	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*25	\N	0.0	Decreased Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
c5f00c32-c96a-47cf-a7f9-93fc39a71674	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*26	\N	0.0	Decreased Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
a78f2894-e1fb-403c-97e7-cf75f80796a5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	*35	\N	0.0	No Function	5	t	2024-05-23 21:17:24.81008+00	2024-05-23 21:17:24.81008+00
6dcf628a-dc1b-449a-9728-7ac67c733bf2	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*1	1.00	0.28500712	Normal Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
62fced1e-eb3e-4b86-8b29-30b64d97165e	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*2	1.00	0.18536054	Normal Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
c0429ac0-e0a3-4107-b7b3-ea5e3670f23c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*3	0.00	0.015922716	No Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
2dc7d586-33f2-4d7f-9e8b-48746a754d6a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*4	0.00	0.1848476	No Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
16be242a-3f77-41a0-bdfc-32c853821d02	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*5	0.00	0.029482473	No Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
caae4a66-3d85-489d-b797-e0290f219006	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*6	0.00	0.011197059	No Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
ba3ed4bc-5eb7-4fa7-ac58-3e4e63d4e672	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*7	0.00	0.0005116425	No Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
16504c0f-5ba1-4a0b-9aa7-9983c86bd521	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*8	0.00	0.00022450546	No Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
9e303fc8-5621-4d84-b724-3ebcc0a516b0	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*9	0.25	0.02754178	Decreased Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
90ae287a-7e1b-45f3-9a0a-8d9a1f3f9e55	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*10	0.25	0.01571283	Decreased Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
74399023-f560-4bf1-8f42-e1ea78f38107	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*12	0.00	0.00013778963	No Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
2ebb3b21-3757-4941-ba83-4cf1301bc76f	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*14	0.50	0.0	Decreased Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
9dc67fb2-9f0d-4362-8f87-f481cd890791	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*15	0.00	0.0004858789	No Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
33de1141-3175-4b7c-8ded-b12260d5edbc	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*17	0.50	0.0039216722	Decreased Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
c649f95d-3372-42a8-bf65-3baa4769cffc	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*21	0.00	0.0	No Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
6d934cf7-354c-4409-9648-f6020c124f9c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*29	0.50	0.0010464214	Decreased Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
7efdeb2d-01f7-4c06-8a79-8b3b27f3e27b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*39	1.00	0.014010031	Normal Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
a72a0e17-4b69-4003-9eba-2a38a4daeccc	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*41	0.25	0.09237511	Decreased Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
e5aa9432-e392-45a3-86ae-fbe6f5b6437b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*42	0.00	0.0	No Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
c967d08e-c47b-4479-9824-4d62aa4f9fba	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*49	0.50	0.0	Decreased Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
5aef4e1a-8ff6-49be-afac-1c48c0d0f5f2	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*56	0.00	0.0008093927	No Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
f8789321-4f34-4bcf-b5dd-cc3a216c2cd4	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*59	0.50	0.003719603	Decreased Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
e0ab5d4c-49f1-42b5-9f72-c8d675601b5d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	*114	0.00	0.0	No Function	5	t	2024-05-23 21:17:24.813014+00	2024-05-23 21:17:24.813014+00
8fa7d147-6c53-4bc3-a4ae-1902081d74d1	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	*1	\N	0.07410407	Normal Function	5	t	2024-05-23 21:17:24.815743+00	2024-05-23 21:17:24.815743+00
66be0f17-0004-4472-b74a-abda41ea617b	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	*3	\N	0.9243815	No Function	5	t	2024-05-23 21:17:24.815743+00	2024-05-23 21:17:24.815743+00
e541a003-9b58-461c-843b-b4d585ec3515	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	*6	\N	0.0015144596	No Function	5	t	2024-05-23 21:17:24.815743+00	2024-05-23 21:17:24.815743+00
7a61bc8c-51fb-4ad1-b421-6279f74ae448	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	*7	\N	0.0	No Function	5	t	2024-05-23 21:17:24.815743+00	2024-05-23 21:17:24.815743+00
9bb9aee1-2bf4-4df2-9f4b-28a33f9a9668	93d511ec-e5fc-4832-9581-813842b25860	*1	\N	0.56578875	Normal Function	5	t	2024-05-23 21:17:24.818042+00	2024-05-23 21:17:24.818042+00
b4d366ff-1e42-4156-b915-1ee81efffff4	93d511ec-e5fc-4832-9581-813842b25860	*3	\N	0.27461374	Possibly Decreased Function	5	t	2024-05-23 21:17:24.818042+00	2024-05-23 21:17:24.818042+00
93e08fbb-4f1a-40aa-9fe1-3b6373cc50bf	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	No Variants Detected	1.00	0.000013740047	Normal Function	5	t	2024-05-23 21:17:24.820072+00	2024-05-23 21:17:24.820072+00
17ef3a3f-ff17-4da3-88f8-6bb9bbd55c83	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	c.295_298del	0.00	0.00018195312	No Function	5	t	2024-05-23 21:17:24.820072+00	2024-05-23 21:17:24.820072+00
9cc32b94-4411-4058-a76e-d2435863401d	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	c.557A>G (p.Y186C)	0.50	0.00008854784	Decreased Function	5	t	2024-05-23 21:17:24.820072+00	2024-05-23 21:17:24.820072+00
143838f1-2c57-463f-b08f-83726d7e393b	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	c.703C>T (p.R235W)	0.00	0.00009098349	No Function	5	t	2024-05-23 21:17:24.820072+00	2024-05-23 21:17:24.820072+00
4085f94c-e7af-46b0-9550-9f9723489e4b	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	c.1129-5923C>G, c.1236G>A	0.50	0.023735587	Decreased Function	5	t	2024-05-23 21:17:24.820072+00	2024-05-23 21:17:24.820072+00
1ba0dc0e-33ba-47c7-9f6d-c418d5d9e0a2	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	c.1156G>T (p.E386X)	0.00	0.0	No Function	5	t	2024-05-23 21:17:24.820072+00	2024-05-23 21:17:24.820072+00
50b9c969-9728-4303-ae2a-005d1cecf4ee	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	c.1679T>G (p.I560S)	0.00	0.00055783015	No Function	5	t	2024-05-23 21:17:24.820072+00	2024-05-23 21:17:24.820072+00
17bfb27c-8cca-45ff-8ebb-1973bfc2f07a	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	c.1898del (p.P633Qfs)	0.00	0.0	No Function	5	t	2024-05-23 21:17:24.820072+00	2024-05-23 21:17:24.820072+00
a211a911-2a1b-42a4-827d-1dc4d4f60170	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	c.1905+1G>A	0.00	0.007917321	No Function	5	t	2024-05-23 21:17:24.820072+00	2024-05-23 21:17:24.820072+00
d25383e3-8123-45d0-b355-6cf499292ad6	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	c.2846A>T (p.D949V)	0.50	0.0037400308	Decreased Function	5	t	2024-05-23 21:17:24.820072+00	2024-05-23 21:17:24.820072+00
7cecdd78-09e7-4f82-9665-8cbe8d1d696c	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	c.2983G>T (p.V995F)	0.00	0.0	No Function	5	t	2024-05-23 21:17:24.820072+00	2024-05-23 21:17:24.820072+00
cce1f48a-dec5-4b80-ad48-4047c478d916	9be7b66e-d066-4d98-bc30-ec1511489398	B	\N	0.99463695	Normal Function	5	t	2024-05-23 21:17:24.822635+00	2024-05-23 21:17:24.822635+00
70fc6ba9-c15e-4e56-a35d-fc7715f399e2	9be7b66e-d066-4d98-bc30-ec1511489398	A	\N	0.00054859073	Normal Function	5	t	2024-05-23 21:17:24.822635+00	2024-05-23 21:17:24.822635+00
b09755dd-1b36-4a7d-884e-340595abbc51	9be7b66e-d066-4d98-bc30-ec1511489398	Asahi	\N	0.00016199434	Decreased Function	5	t	2024-05-23 21:17:24.822635+00	2024-05-23 21:17:24.822635+00
ad4c1625-9bd3-438c-a3ee-d1f6642e92eb	9be7b66e-d066-4d98-bc30-ec1511489398	Canton	\N	0.0	Decreased Function	5	t	2024-05-23 21:17:24.822635+00	2024-05-23 21:17:24.822635+00
02417dd0-088a-40ae-b1df-20b377276958	9be7b66e-d066-4d98-bc30-ec1511489398	Chatham	\N	0.00006178815	Decreased Function	5	t	2024-05-23 21:17:24.822635+00	2024-05-23 21:17:24.822635+00
c7989ae3-626d-4978-a4b7-9be0ead046ab	9be7b66e-d066-4d98-bc30-ec1511489398	Cosenza	\N	0.000010319598	Decreased Function	5	t	2024-05-23 21:17:24.822635+00	2024-05-23 21:17:24.822635+00
e691b0a9-1700-485d-870c-1be5f26dfe87	9be7b66e-d066-4d98-bc30-ec1511489398	Mediterranean	\N	0.0005865103	Decreased Function	5	t	2024-05-23 21:17:24.822635+00	2024-05-23 21:17:24.822635+00
bfe45e3d-ab2d-471f-addb-f651c750db5b	9be7b66e-d066-4d98-bc30-ec1511489398	Coimbra Shunde	\N	0.000010230493	Decreased Function	5	t	2024-05-23 21:17:24.822635+00	2024-05-23 21:17:24.822635+00
9b7fdcc4-4a4f-4280-9285-d127bb15d236	9be7b66e-d066-4d98-bc30-ec1511489398	Vancouver	\N	0.0	Poor Function	5	t	2024-05-23 21:17:24.822635+00	2024-05-23 21:17:24.822635+00
a42a572f-62b3-4109-b08e-b2b299901f89	9be7b66e-d066-4d98-bc30-ec1511489398	Kaiping	\N	0.0	Decreased Function	5	t	2024-05-23 21:17:24.822635+00	2024-05-23 21:17:24.822635+00
1402e4f3-e2b9-4b95-8c6d-9f84cde6a8d2	9be7b66e-d066-4d98-bc30-ec1511489398	A- 202A_376G	\N	0.0	Decreased Function	5	t	2024-05-23 21:17:24.822635+00	2024-05-23 21:17:24.822635+00
6f2ce70c-ac7a-4718-aff2-4983cb5bfdcb	9be7b66e-d066-4d98-bc30-ec1511489398	A- 968C_376G	\N	0.0	Decreased Function	5	t	2024-05-23 21:17:24.822635+00	2024-05-23 21:17:24.822635+00
0b466c96-8f53-4324-bc1a-30b6a7e4e096	daa86f03-86c6-4a8d-abab-476fcd043c9c	*1	\N	0.9931303	Normal Function	5	t	2024-05-23 21:17:24.824896+00	2024-05-23 21:17:24.824896+00
2fdea443-fefd-4efe-aa32-6c270ce16c66	daa86f03-86c6-4a8d-abab-476fcd043c9c	*2	\N	0.0	No Function	5	t	2024-05-23 21:17:24.824896+00	2024-05-23 21:17:24.824896+00
c01b1fad-d58b-42c7-8c25-05f03eea24b4	daa86f03-86c6-4a8d-abab-476fcd043c9c	*3	\N	0.002	No Function	5	t	2024-05-23 21:17:24.824896+00	2024-05-23 21:17:24.824896+00
05a11507-3926-43b2-805a-ebae1d0f8cca	daa86f03-86c6-4a8d-abab-476fcd043c9c	*4	\N	0.00003285361	Strongly Decreased Function	5	t	2024-05-23 21:17:24.824896+00	2024-05-23 21:17:24.824896+00
bb46be5a-ca94-4ecf-ade5-1e57560e2556	daa86f03-86c6-4a8d-abab-476fcd043c9c	*5	\N	0.000007794928	Strongly Decreased Function	5	t	2024-05-23 21:17:24.824896+00	2024-05-23 21:17:24.824896+00
5d47c135-506b-4368-a383-69f213935bac	daa86f03-86c6-4a8d-abab-476fcd043c9c	*6	\N	0.003	Strongly Decreased Function	5	t	2024-05-23 21:17:24.824896+00	2024-05-23 21:17:24.824896+00
ae1ba01a-2587-4424-8a96-b745a28e68a7	daa86f03-86c6-4a8d-abab-476fcd043c9c	*7	\N	0.0	Strongly Decreased Function	5	t	2024-05-23 21:17:24.824896+00	2024-05-23 21:17:24.824896+00
e0df7f49-5fe1-4198-95eb-032168baa536	daa86f03-86c6-4a8d-abab-476fcd043c9c	*8	\N	0.0	Decreased Function	5	t	2024-05-23 21:17:24.824896+00	2024-05-23 21:17:24.824896+00
c9ab71ca-a401-4940-8235-f6a0d553b0d2	daa86f03-86c6-4a8d-abab-476fcd043c9c	*9	\N	0.0018290388	No Function	5	t	2024-05-23 21:17:24.824896+00	2024-05-23 21:17:24.824896+00
d0f96c89-4517-4158-84ad-b71ce7be3364	22fb682a-e57d-4ad2-8dc5-8159f28a9862	*1	\N	0.4027496	Normal Function	5	t	2024-05-23 21:17:24.827237+00	2024-05-23 21:17:24.827237+00
c20661f5-e173-4c22-8753-f9ef6033c16b	22fb682a-e57d-4ad2-8dc5-8159f28a9862	*5	\N	0.02040433	No Function	5	t	2024-05-23 21:17:24.827237+00	2024-05-23 21:17:24.827237+00
c033aee5-9862-4b4b-b4af-275de7508b7e	22fb682a-e57d-4ad2-8dc5-8159f28a9862	*14	\N	0.135571	Increased Function	5	t	2024-05-23 21:17:24.827237+00	2024-05-23 21:17:24.827237+00
356127df-0319-4689-9c8a-d1524d102144	22fb682a-e57d-4ad2-8dc5-8159f28a9862	*15	\N	0.15017298	No Function	5	t	2024-05-23 21:17:24.827237+00	2024-05-23 21:17:24.827237+00
a77fe6c0-d872-459f-a6af-7733145e314d	22fb682a-e57d-4ad2-8dc5-8159f28a9862	*37	\N	0.25273752	Normal Function	5	t	2024-05-23 21:17:24.827237+00	2024-05-23 21:17:24.827237+00
d3bfe5a5-d0f2-44ea-b098-4df6f8613815	9ca2999f-1b56-4ee8-a254-2da4415cbb72	*1	\N	0.9534313	Normal Function	5	t	2024-05-23 21:17:24.82974+00	2024-05-23 21:17:24.82974+00
8b7bbc46-6476-4677-8123-1b9523aff408	9ca2999f-1b56-4ee8-a254-2da4415cbb72	*2	\N	0.0020584913	No Function	5	t	2024-05-23 21:17:24.82974+00	2024-05-23 21:17:24.82974+00
f68b608e-0518-4ae9-88c2-364b3a6e4b77	9ca2999f-1b56-4ee8-a254-2da4415cbb72	*3A	\N	0.033840433	No Function	5	t	2024-05-23 21:17:24.82974+00	2024-05-23 21:17:24.82974+00
d97cbaf2-20af-41eb-99fa-4148d159e97c	9ca2999f-1b56-4ee8-a254-2da4415cbb72	*3B	\N	0.0028341785	No Function	5	t	2024-05-23 21:17:24.82974+00	2024-05-23 21:17:24.82974+00
2e525182-45cb-4738-a898-55b428fb3c9b	9ca2999f-1b56-4ee8-a254-2da4415cbb72	*3C	\N	0.0049218307	No Function	5	t	2024-05-23 21:17:24.82974+00	2024-05-23 21:17:24.82974+00
1029b42c-e410-46a1-bffc-3f8797b0f366	9ca2999f-1b56-4ee8-a254-2da4415cbb72	*4	\N	0.000058889815	No Function	5	t	2024-05-23 21:17:24.82974+00	2024-05-23 21:17:24.82974+00
fb7aac21-100a-4694-a9d2-abb437f80c97	9ca2999f-1b56-4ee8-a254-2da4415cbb72	*11	\N	0.00024325753	No Function	5	t	2024-05-23 21:17:24.82974+00	2024-05-23 21:17:24.82974+00
0cea2f3b-25ca-4a41-879e-c6e544a3230b	9ca2999f-1b56-4ee8-a254-2da4415cbb72	*14	\N	0.0	No Function	5	t	2024-05-23 21:17:24.82974+00	2024-05-23 21:17:24.82974+00
672f94e6-adc0-45fb-b8aa-a78432c5e195	9ca2999f-1b56-4ee8-a254-2da4415cbb72	*15	\N	0.000045666697	No Function	5	t	2024-05-23 21:17:24.82974+00	2024-05-23 21:17:24.82974+00
88d85a38-2041-489f-9b7d-c7245dd873a6	9ca2999f-1b56-4ee8-a254-2da4415cbb72	*23	\N	0.000026239319	No Function	5	t	2024-05-23 21:17:24.82974+00	2024-05-23 21:17:24.82974+00
e22be5f0-9d4e-46a4-aafe-4ff0de5ca448	9ca2999f-1b56-4ee8-a254-2da4415cbb72	*29	\N	0.0	No Function	5	t	2024-05-23 21:17:24.82974+00	2024-05-23 21:17:24.82974+00
00a37083-5244-422b-826f-d55da90c5d70	9ca2999f-1b56-4ee8-a254-2da4415cbb72	*41	\N	0.0	No Function	5	t	2024-05-23 21:17:24.82974+00	2024-05-23 21:17:24.82974+00
548068fd-a938-4214-8630-8fb354dc2aab	58f41405-4198-4822-b10e-eb43cd77bc27	*1	\N	0.36072147	Normal Function	5	t	2024-05-23 21:17:24.832083+00	2024-05-23 21:17:24.832083+00
6f37805f-6ab9-4e12-94f4-ffd7c22e9243	58f41405-4198-4822-b10e-eb43cd77bc27	*6	\N	0.007872763	Decreased Function	5	t	2024-05-23 21:17:24.832083+00	2024-05-23 21:17:24.832083+00
26e8f90b-85ff-4f5b-92fc-a8e7e904f37f	58f41405-4198-4822-b10e-eb43cd77bc27	*27	\N	0.0	Decreased Function	5	t	2024-05-23 21:17:24.832083+00	2024-05-23 21:17:24.832083+00
9db7cc26-8de2-49d4-8b67-ae1659ac23fe	58f41405-4198-4822-b10e-eb43cd77bc27	*28	\N	0.31647462	Decreased Function	5	t	2024-05-23 21:17:24.832083+00	2024-05-23 21:17:24.832083+00
6a3444f1-e78a-4012-bd43-f0bc032fc6ea	58f41405-4198-4822-b10e-eb43cd77bc27	*36	\N	0.0	Increased Function	5	t	2024-05-23 21:17:24.832083+00	2024-05-23 21:17:24.832083+00
5f4ca73a-f9fd-4eb2-a061-2442ecea2636	58f41405-4198-4822-b10e-eb43cd77bc27	*37	\N	0.00068587105	Decreased Function	5	t	2024-05-23 21:17:24.832083+00	2024-05-23 21:17:24.832083+00
0496b591-852e-4446-96f9-f547c088d6b2	c0f1136b-6463-4304-a473-cae1f384fc8e	C	\N	\N	Normal Function	5	t	2024-05-23 21:17:24.834635+00	2024-05-23 21:17:24.834635+00
4344b047-0643-49d1-aa5b-0556d39da7ea	c0f1136b-6463-4304-a473-cae1f384fc8e	T	\N	\N	Decreased Function	5	t	2024-05-23 21:17:24.834635+00	2024-05-23 21:17:24.834635+00
b6652629-f529-4de3-a344-2665697f023a	b31967bd-f6da-49d9-ba4e-cafdd7786116	G	\N	\N	High Risk	5	t	2024-05-23 21:17:24.837217+00	2024-05-23 21:17:24.837217+00
cec31a8e-b07c-4399-b6e0-8d11513a65bd	b31967bd-f6da-49d9-ba4e-cafdd7786116	T	\N	\N	Low Risk	5	t	2024-05-23 21:17:24.837217+00	2024-05-23 21:17:24.837217+00
\.


--
-- Data for Name: master_version_genotypes; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.master_version_genotypes (id, master_version_id, genotype_id, created_at, updated_at) FROM stdin;
98c6c629-96cf-473d-b64c-bd4b58e6c344	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d0fa7698-424c-4983-8dc2-83d5be472016	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7729f1c0-ef53-446b-9ba1-5e3cbed577eb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	81df6754-9b1d-4edc-8b07-ed1a8a116750	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7f18bebd-7094-4799-868d-b75d8a09db65	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	047c6dd3-30b8-4d56-a63e-cc9bbdbfa2f6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f654a04e-dfd8-4c88-84a2-6111c4911833	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6dfe83a9-c07a-4a03-b054-914f6aa13973	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
08690e55-77ed-464c-9469-6eca9c797ec8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ca3bf6a4-0963-43dc-9fa2-9a98a41d662a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cdc3a467-79c2-4430-9ea6-8a8b42780292	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c7a83c00-ca7a-436f-94ea-c0128ee0e292	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
427b85c4-14e3-4e82-932e-f0145170169f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	609fec3e-ecb4-448c-aa3c-5241c1ab2c56	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f638e1f2-7e5e-4737-8254-9c8ccce72f82	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d54113e5-04dc-4821-81d7-b94a960a5814	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f043950b-83b0-4a2f-96b6-913dee72daa1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f249d96c-196c-4432-b1fc-2a2ddc6e4b18	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
23bd3467-c132-44e4-ab99-5cef08ccba94	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5e861df5-0d58-4064-8266-7b2788119fdd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
94ed6c03-7f1d-4067-823f-2bed4de437c7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1b84feb7-236b-49a9-bd21-ec37fd384593	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
23638b92-8b53-4796-b626-c3828b669976	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9053dee5-7022-4f5a-b8e0-6178d75b9d4c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
86f3a9f1-7ea5-4192-a59d-5744f3232dd1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2fcf4270-e019-481b-9037-e35f904172ba	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
43833770-c35e-4605-9b16-53701a925fdd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	14e68bfd-c9fe-491b-9fe9-dc68d0fd06b4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
58cdf658-0743-4f91-b4de-f48da7916838	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	96c1f48f-14c4-4bcb-bf4f-c06e4a3fce5a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7c74b749-332a-4cc1-8247-259377d9394f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	240f6e2a-52ea-4c82-b63b-0893b7653857	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a7820d21-b09d-4461-9ca3-86e7e63fc580	cd112fe5-0c94-42f4-b221-78aa67a88c28	d0fa7698-424c-4983-8dc2-83d5be472016	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c61d20d9-e1a8-40d9-9ab5-0d20abff166c	cd112fe5-0c94-42f4-b221-78aa67a88c28	81df6754-9b1d-4edc-8b07-ed1a8a116750	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c0421b83-d786-4035-aee1-545505fc77ed	cd112fe5-0c94-42f4-b221-78aa67a88c28	047c6dd3-30b8-4d56-a63e-cc9bbdbfa2f6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
89aa2b3c-72ad-427d-a744-be00e88d4ccc	cd112fe5-0c94-42f4-b221-78aa67a88c28	6dfe83a9-c07a-4a03-b054-914f6aa13973	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a58b64fb-06a4-47af-9b7e-65f57a1a3fb0	cd112fe5-0c94-42f4-b221-78aa67a88c28	c7a83c00-ca7a-436f-94ea-c0128ee0e292	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ab510ee2-6c7e-4c6f-b009-fb89240a1572	cd112fe5-0c94-42f4-b221-78aa67a88c28	609fec3e-ecb4-448c-aa3c-5241c1ab2c56	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a0ed6b6e-e336-418f-b625-99e48f6b73aa	cd112fe5-0c94-42f4-b221-78aa67a88c28	d54113e5-04dc-4821-81d7-b94a960a5814	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8fd44b2e-71f9-4a62-aa88-3ee1abbf2e20	cd112fe5-0c94-42f4-b221-78aa67a88c28	f249d96c-196c-4432-b1fc-2a2ddc6e4b18	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b4bf5e64-3a2e-40ac-861b-031e709a9f5f	cd112fe5-0c94-42f4-b221-78aa67a88c28	5e861df5-0d58-4064-8266-7b2788119fdd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ef759719-8abf-441b-9d29-18d1a5eb70f2	cd112fe5-0c94-42f4-b221-78aa67a88c28	1b84feb7-236b-49a9-bd21-ec37fd384593	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
63dd894f-a0cf-4748-bf75-f8611ab0566a	cd112fe5-0c94-42f4-b221-78aa67a88c28	9053dee5-7022-4f5a-b8e0-6178d75b9d4c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8d4785be-32dd-45df-a80b-637ac68add66	cd112fe5-0c94-42f4-b221-78aa67a88c28	2fcf4270-e019-481b-9037-e35f904172ba	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5676aee6-8a3d-4370-8ab5-226906d0b546	cd112fe5-0c94-42f4-b221-78aa67a88c28	14e68bfd-c9fe-491b-9fe9-dc68d0fd06b4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ab73c32b-2d60-4a09-8b0e-a4f8d1c1aa04	cd112fe5-0c94-42f4-b221-78aa67a88c28	96c1f48f-14c4-4bcb-bf4f-c06e4a3fce5a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b3504ae8-daf9-473f-ba17-15709002b9e9	cd112fe5-0c94-42f4-b221-78aa67a88c28	240f6e2a-52ea-4c82-b63b-0893b7653857	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b1e5da12-3e54-4245-9dc8-07b34ff0bb87	cd112fe5-0c94-42f4-b221-78aa67a88c28	6b170236-0a67-43d9-b41c-0f6fedd86271	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
53f19a32-9ef4-4b62-95af-ad80d5b994ef	33ba105b-d0a6-4667-b6e9-927859eb4481	d0fa7698-424c-4983-8dc2-83d5be472016	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f054ed4d-b8ab-476a-98e5-92da88b5b158	33ba105b-d0a6-4667-b6e9-927859eb4481	047c6dd3-30b8-4d56-a63e-cc9bbdbfa2f6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
007ffd91-e3f0-4261-84f5-946509106723	33ba105b-d0a6-4667-b6e9-927859eb4481	6dfe83a9-c07a-4a03-b054-914f6aa13973	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8b7d1169-1f1b-45bd-8918-e1b0835ceb29	33ba105b-d0a6-4667-b6e9-927859eb4481	c7a83c00-ca7a-436f-94ea-c0128ee0e292	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f9378e2e-b8ef-4c82-b11e-f8f236939671	33ba105b-d0a6-4667-b6e9-927859eb4481	609fec3e-ecb4-448c-aa3c-5241c1ab2c56	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
13c59bb0-6f63-4060-b16d-d8b5e49e666c	33ba105b-d0a6-4667-b6e9-927859eb4481	d54113e5-04dc-4821-81d7-b94a960a5814	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
caefd58b-2e65-4945-aeaf-eb8507ed9a85	33ba105b-d0a6-4667-b6e9-927859eb4481	f249d96c-196c-4432-b1fc-2a2ddc6e4b18	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4449817c-a729-438d-b053-901694bb30e2	33ba105b-d0a6-4667-b6e9-927859eb4481	5e861df5-0d58-4064-8266-7b2788119fdd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
cf9b074e-6001-4ce3-8e34-e8e43b6db891	33ba105b-d0a6-4667-b6e9-927859eb4481	1b84feb7-236b-49a9-bd21-ec37fd384593	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0e801498-3463-4bc6-b8d5-fe17710528d2	33ba105b-d0a6-4667-b6e9-927859eb4481	9053dee5-7022-4f5a-b8e0-6178d75b9d4c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8074eabb-5aa2-4022-b0cb-51e54d7fd41b	33ba105b-d0a6-4667-b6e9-927859eb4481	2fcf4270-e019-481b-9037-e35f904172ba	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b986a483-92e1-47db-b72a-5d437a66bc67	33ba105b-d0a6-4667-b6e9-927859eb4481	14e68bfd-c9fe-491b-9fe9-dc68d0fd06b4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
cd47c6d3-90cb-43f4-b2a3-16737083cb43	33ba105b-d0a6-4667-b6e9-927859eb4481	96c1f48f-14c4-4bcb-bf4f-c06e4a3fce5a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
476f9e6d-53c1-46a9-ac25-0ebdaca9e7c7	33ba105b-d0a6-4667-b6e9-927859eb4481	240f6e2a-52ea-4c82-b63b-0893b7653857	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ee0cadcf-875b-4e9c-ae40-4662c1e4b0ab	33ba105b-d0a6-4667-b6e9-927859eb4481	6b170236-0a67-43d9-b41c-0f6fedd86271	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3da98cc6-a626-40fa-aef7-99673b01c9a3	33ba105b-d0a6-4667-b6e9-927859eb4481	be83b899-55f2-49ac-9bed-b2d2c1686778	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
\.


--
-- Data for Name: master_version_haplotypes; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.master_version_haplotypes (id, master_version_id, haplotype_id, created_at, updated_at) FROM stdin;
2e78ff7d-77e2-47c6-8ebe-5b065bfc9a9f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f7b79e33-683f-4dbe-a9de-f85b11a86d7b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
825dcac1-5195-4c97-a49d-0478a4f05c49	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ed3934dd-2168-4345-bba3-5f6a0e158ec0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8fb102e9-319f-4f6b-8e71-64899fea1756	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	721c3aac-5d68-4853-94de-c82abea3ca09	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0b2cfb4c-3bd5-4620-9de7-07ea9f17d8a0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3d49dcf7-6674-4d6f-8925-6b8d20ace487	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5453a96c-d09d-48f0-ba0e-c7c09510e4e8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b64f99b8-39b4-4a9b-ba99-29f88e7dcd09	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d7f3c221-fbca-41ff-9ba0-b3a06d6df835	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b45d5d5e-3ab0-4b25-968e-feec018d523f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bb245d1c-9214-4aaa-a42d-80a56413bab7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8c754871-b2ea-4aae-810c-712852326602	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0f60875b-1336-4891-a3f2-9daf47606987	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1c297820-d0f4-4007-a68f-0b4e04c3b86f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9b53fc2b-1066-42f3-b58b-5b0465fa7b56	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8b19b7b4-0d72-4b01-869b-8a3acb2c53be	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7a64f539-7141-4ce9-9172-4de2f3b316c0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	56ef68eb-af96-4c0e-965e-629e302e2481	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d9a6ee93-b11d-4fe6-a3ec-03ad85cb4d06	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f72bfcc4-7ff1-4f9e-89df-10d4112cc55b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fe27dfaf-f9f8-4a38-9374-6ced3796af10	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f520b52a-47ad-4238-8611-3433f61a6b05	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
37577c00-fc54-4d3a-b4ea-de50ba43c77c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8eddb00b-2b5b-47b3-ada3-33b4ef48bdad	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
66e91256-345b-45c0-a741-f878490fa5b3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cff92809-f5a6-457f-a341-a91d1f82a83a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0a2c4b9c-23fa-4ff3-bbcc-5e195de5fd85	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	95996d13-95a6-4244-be81-70a4e554ac6c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3f8a3785-d79f-4e5d-91b2-104d83752dad	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	776e8ea5-5869-4535-9329-3ef68ecfe2a3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e6325616-d04b-4558-b7b6-984aad6274ed	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a53bb49c-baa0-4fdb-987d-ccd5fb3d2654	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f1da26d6-c963-4f76-b2ab-861400e1860c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	169cbf3c-6271-4b8b-9337-611b71e3e527	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
433d694b-2eec-49ef-9a93-bd677a068e15	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	abf7ecbe-fcda-456e-9442-8d40a872b178	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
240e7fd8-9db0-4510-b697-d91dfc8bf0e7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d31af913-00cb-4f5a-bdff-6c979ced0e50	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dc038b32-aa91-47c1-ad86-ceac9e478bad	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	09bbaaf7-85f7-44cb-b90d-de2f184a2e8b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e8993fa2-abe3-4c94-a644-4cad3ddf2eea	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	65117db3-5fda-476b-a6b5-f155f74cace1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
316b76a5-390e-4fdf-8d66-6c654783f6e7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	877896af-dced-4232-8617-69b7cc5808c8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6aaa1d01-6939-48ad-8789-7a599473191d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a16c8803-ff6c-4d5b-a472-1eb42eab6286	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8a43d14c-8638-472d-82ca-17148db5e7d4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f58654a8-70f4-4d59-a386-0803fdfd6e91	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
10b1c0fc-81f4-4406-a4cf-31909be13bc8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	59c017a3-3214-4f79-927a-c165551c63b5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e341beec-296a-4785-b8e6-8448ca51f7d3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0e01cb82-5f8d-4d9f-84bb-2d48f61cb9dd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ac626f95-4a25-4857-acc3-9162de18a3f9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	da638ee4-1cbc-49b0-ae4f-a57c03bfabf5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
92fef0de-f940-4eee-ac4a-f1425417f2aa	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	80bb05d4-2d3b-4e3a-9d19-c5e0fe33ea22	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c2abb53a-adb6-4991-ab71-370fb583c6a7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3193cda8-5eed-49d8-aa7e-ad0c4c97a636	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
81a84814-1b96-4aa3-bc65-423c0aa9eeb3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d7a620a0-5fbf-4f04-8d38-664532512db1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0131a54a-64b7-489b-b95c-87f256438315	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	538a028e-3cb3-4a11-95d3-1b71531e9e59	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c3057130-4761-4f20-83a8-e8951fd60377	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6bdc71f3-07d4-492b-a93b-b1295c7aeedf	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ac998cee-85bb-458c-a312-2b6ec9a003e5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8bd69081-afa8-498d-aec8-e5be89b43cc3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f1df45ae-0b09-4d56-8604-6c08b39e86a0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2caa18a8-6c4d-4dfb-8e70-b80e8e600721	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c3b3144b-ec86-44f9-a377-a9e1734605c6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f786c3b6-6406-4d57-937b-40c9dcf3e356	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
49da7b62-e35f-4274-a4a3-b8532e5671e1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6f367e68-b796-4234-b210-d97fd947a9b7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e975bf23-2248-4bb4-8d66-7af70d99fe94	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c5f00c32-c96a-47cf-a7f9-93fc39a71674	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
437be3a3-1633-40d4-a165-436d2a9d7260	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a78f2894-e1fb-403c-97e7-cf75f80796a5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
75ec4f4b-1dc3-4580-aff6-83d8c1f642c8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6dcf628a-dc1b-449a-9728-7ac67c733bf2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b8aaaefb-f8d5-4469-ba81-45a372bd01a5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	62fced1e-eb3e-4b86-8b29-30b64d97165e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e4a12971-3439-4d86-98ce-81234d28abd7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c0429ac0-e0a3-4107-b7b3-ea5e3670f23c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2c2770c4-bf7a-43ae-a213-02a408197837	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2dc7d586-33f2-4d7f-9e8b-48746a754d6a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4f2e74d6-2ee1-494a-9d66-8f4a1b6cd48e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	16be242a-3f77-41a0-bdfc-32c853821d02	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7fca92b0-451a-4c82-b390-158c6831452c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	caae4a66-3d85-489d-b797-e0290f219006	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5f6935e5-e248-4aa3-91db-ba451dfc74f0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ba3ed4bc-5eb7-4fa7-ac58-3e4e63d4e672	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5d03eead-148f-4850-898f-d0f4c25b07b3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	16504c0f-5ba1-4a0b-9aa7-9983c86bd521	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
236c6e2f-b2a8-4521-adde-b348cbf10fb1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9e303fc8-5621-4d84-b724-3ebcc0a516b0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ffd8ba5b-dfa6-449d-8cc9-ce0fc3b33b8c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	90ae287a-7e1b-45f3-9a0a-8d9a1f3f9e55	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9d1ed48b-8cd5-4691-8e61-221c9bc28c62	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	74399023-f560-4bf1-8f42-e1ea78f38107	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
427653c2-68d5-4690-8e4d-533cf6f5ffad	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2ebb3b21-3757-4941-ba83-4cf1301bc76f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4570a1df-cabf-4843-a00b-c5748cbb8e26	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9dc67fb2-9f0d-4362-8f87-f481cd890791	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
276be408-363c-4c69-8a8d-f27eebc932b1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	33de1141-3175-4b7c-8ded-b12260d5edbc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ec4b81ed-c773-4a46-9606-50cd85f3d7f1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c649f95d-3372-42a8-bf65-3baa4769cffc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b3153921-241c-46b1-9fc9-4bcb2becc4d1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6d934cf7-354c-4409-9648-f6020c124f9c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c66e039e-5550-48fa-9504-87ec3c373def	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7efdeb2d-01f7-4c06-8a79-8b3b27f3e27b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a56dcd37-e6a7-414e-b36b-d613898f11dd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a72a0e17-4b69-4003-9eba-2a38a4daeccc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
93456cf6-1d19-44e8-8f01-111fa1f1dbd9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e5aa9432-e392-45a3-86ae-fbe6f5b6437b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
719ff3cd-0f22-44e0-b6aa-c5fa94c89135	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c967d08e-c47b-4479-9824-4d62aa4f9fba	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
84ded7a0-9472-4eef-8fd9-4d05ad6baecf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5aef4e1a-8ff6-49be-afac-1c48c0d0f5f2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
61f99f44-d41b-4f1f-9a01-62d4c8dc3429	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f8789321-4f34-4bcf-b5dd-cc3a216c2cd4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bb4176b0-2cea-424e-9899-3b2b3b43e94d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e0ab5d4c-49f1-42b5-9f72-c8d675601b5d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
86a15e33-b522-47fd-8fa7-7a6a1000e73a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8fa7d147-6c53-4bc3-a4ae-1902081d74d1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
60343920-639d-4bc4-9356-732ef257c638	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	66be0f17-0004-4472-b74a-abda41ea617b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8af3f066-8f2f-4d4d-86ea-0e677ea2fe2d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e541a003-9b58-461c-843b-b4d585ec3515	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d164f05d-3c8b-4705-9f62-7b6c078c5fa8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7a61bc8c-51fb-4ad1-b421-6279f74ae448	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
848e3d45-5b49-46af-a847-a06207903eaa	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9bb9aee1-2bf4-4df2-9f4b-28a33f9a9668	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
127f798d-e68a-40cb-8e34-09532edb47dc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b4d366ff-1e42-4156-b915-1ee81efffff4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cc159707-3982-4430-a230-031344055dd6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	93e08fbb-4f1a-40aa-9fe1-3b6373cc50bf	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1c2955a1-4a4e-4d11-a1c8-e6a3d43b55b9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	17ef3a3f-ff17-4da3-88f8-6bb9bbd55c83	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6561d39d-e216-4edb-a4f2-8e80cabd5fce	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9cc32b94-4411-4058-a76e-d2435863401d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2d4b8d16-a662-4c59-a545-962abb6b05c8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	143838f1-2c57-463f-b08f-83726d7e393b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3caf6479-38a9-4e25-8b77-06142d5a7eba	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4085f94c-e7af-46b0-9550-9f9723489e4b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2fa2dbf0-f1a8-44e4-aa57-9320211dd980	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1ba0dc0e-33ba-47c7-9f6d-c418d5d9e0a2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cd35c363-7c51-4309-a125-e1b00056620c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	50b9c969-9728-4303-ae2a-005d1cecf4ee	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
edd143c1-638a-4ebf-82ae-48d4169ad3ba	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	17bfb27c-8cca-45ff-8ebb-1973bfc2f07a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4400b624-67e9-415c-a9a6-314ee6cdfb30	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a211a911-2a1b-42a4-827d-1dc4d4f60170	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fe45fd7b-d770-4713-acba-45a1d0359d62	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d25383e3-8123-45d0-b355-6cf499292ad6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
af564aed-3ea3-470f-84f8-bcd289976ba3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7cecdd78-09e7-4f82-9665-8cbe8d1d696c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
77964252-5687-4a7b-9986-5f1f2909ff2c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cce1f48a-dec5-4b80-ad48-4047c478d916	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fd93b552-320b-42c0-91a5-d79788e3ed25	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	70fc6ba9-c15e-4e56-a35d-fc7715f399e2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5b111af4-a5d8-4c88-93c7-214ab889a38a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b09755dd-1b36-4a7d-884e-340595abbc51	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3a09754d-5edd-4c59-8a98-8b944e6d32b4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ad4c1625-9bd3-438c-a3ee-d1f6642e92eb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
098170f1-eff9-4074-a072-f9e3568695b9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	02417dd0-088a-40ae-b1df-20b377276958	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0aaaec02-6806-4d0a-b7e4-037231c63e50	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c7989ae3-626d-4978-a4b7-9be0ead046ab	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5e85b4d8-56b0-4059-b190-f4efa58fb41e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e691b0a9-1700-485d-870c-1be5f26dfe87	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
110fda68-f230-4cfb-9a46-6e81d8f232f0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bfe45e3d-ab2d-471f-addb-f651c750db5b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
508cf88f-dbcc-4625-a05d-e9dfe15bc152	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9b7fdcc4-4a4f-4280-9285-d127bb15d236	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a573b216-5279-4222-acfe-9f423b748524	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a42a572f-62b3-4109-b08e-b2b299901f89	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
24249176-3ae9-4583-bb80-f7196149a831	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1402e4f3-e2b9-4b95-8c6d-9f84cde6a8d2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5f0f87da-71bc-4618-ab55-5164861724cb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6f2ce70c-ac7a-4718-aff2-4983cb5bfdcb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b7337818-6b1d-40bf-ac0d-81795f8efa88	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0b466c96-8f53-4324-bc1a-30b6a7e4e096	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b278c721-a02c-4e83-93fe-cbd02d0aade7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2fdea443-fefd-4efe-aa32-6c270ce16c66	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d49de86e-8c10-4b66-ac0c-35749585677f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c01b1fad-d58b-42c7-8c25-05f03eea24b4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c8879176-8f9f-493b-a773-cf8da954f9fb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	05a11507-3926-43b2-805a-ebae1d0f8cca	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9e00511e-c047-439d-83e6-49ff70916294	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bb46be5a-ca94-4ecf-ade5-1e57560e2556	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c09267e1-557d-4a0b-8f22-938103997012	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5d47c135-506b-4368-a383-69f213935bac	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fdee42de-b5df-4d78-b0ee-8465349ea88c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ae1ba01a-2587-4424-8a96-b745a28e68a7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5483c14b-ebd4-48d5-9a8e-258ee6f4b31e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e0df7f49-5fe1-4198-95eb-032168baa536	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8747f170-8cc9-460a-a53b-2e0fdbcc0de1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c9ab71ca-a401-4940-8235-f6a0d553b0d2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3fdc39e8-92b1-4ef4-b7c2-e18acd5255aa	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d0f96c89-4517-4158-84ad-b71ce7be3364	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
557bfbda-af73-4686-9d6c-35d204abf472	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c20661f5-e173-4c22-8753-f9ef6033c16b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b04004bd-2b0b-48b2-858b-96ba254d28fb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c033aee5-9862-4b4b-b4af-275de7508b7e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
483e82bf-ae66-49bd-8d0b-233414c2979d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	356127df-0319-4689-9c8a-d1524d102144	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
25bdbfe9-805e-46e9-8b72-d54a5c1f9804	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a77fe6c0-d872-459f-a6af-7733145e314d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1b838d04-74b8-431d-9959-3045de3316ca	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d3bfe5a5-d0f2-44ea-b098-4df6f8613815	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9e7606ec-ff15-4b70-835d-3af1f6be8706	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8b7bbc46-6476-4677-8123-1b9523aff408	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8c4d6fa2-4091-49c5-a20d-6e213721e8df	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f68b608e-0518-4ae9-88c2-364b3a6e4b77	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
951e1227-e585-4db6-896d-efe565d22906	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d97cbaf2-20af-41eb-99fa-4148d159e97c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5fac1635-5c77-42ce-b358-c360aaa0afc9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2e525182-45cb-4738-a898-55b428fb3c9b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b4e87d7e-7190-462b-bf49-b6de8f1736fd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1029b42c-e410-46a1-bffc-3f8797b0f366	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9aa7cba6-095e-444e-9dde-d0c1415b5993	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	fb7aac21-100a-4694-a9d2-abb437f80c97	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6cd07233-f84b-4b78-9f52-4851596298c2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0cea2f3b-25ca-4a41-879e-c6e544a3230b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a2cab2d6-08da-4292-b5dc-1e5f20ea74f0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	672f94e6-adc0-45fb-b8aa-a78432c5e195	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ddaebfa5-dee8-4ba2-a5f4-ae8b922868b1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	88d85a38-2041-489f-9b7d-c7245dd873a6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
69722016-1c7a-4e63-9704-742507545f2b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e22be5f0-9d4e-46a4-aafe-4ff0de5ca448	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c9b7bb97-c0a3-4100-aaa1-5c30515b78a5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	00a37083-5244-422b-826f-d55da90c5d70	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f94a7b5c-d4f4-4979-8f01-02018e389d23	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	548068fd-a938-4214-8630-8fb354dc2aab	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1ffd4a72-63e5-45d4-a2df-ab630822e30f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6f37805f-6ab9-4e12-94f4-ffd7c22e9243	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f8956496-6948-425b-8365-322c9fd1b03e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	26e8f90b-85ff-4f5b-92fc-a8e7e904f37f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f7c94bf0-c9c0-4c75-9c51-bf08e1b49695	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9db7cc26-8de2-49d4-8b67-ae1659ac23fe	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ba953380-d6dd-4d2c-abe8-d763f9ef85fb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6a3444f1-e78a-4012-bd43-f0bc032fc6ea	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
57b1d46c-771d-4300-9a6f-e83592427307	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5f4ca73a-f9fd-4eb2-a061-2442ecea2636	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
21387857-fe52-4b22-8cc0-7db257594535	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0496b591-852e-4446-96f9-f547c088d6b2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ad01e950-6848-4415-8411-f31f54a77ea6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4344b047-0643-49d1-aa5b-0556d39da7ea	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9bc27ef8-9c8a-4a19-b996-4901ed8e5186	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b6652629-f529-4de3-a344-2665697f023a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
45e1b800-1025-45b8-9a98-240e266743ba	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cec31a8e-b07c-4399-b6e0-8d11513a65bd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1faf31e3-58e9-4d06-9b59-26250a74985d	cd112fe5-0c94-42f4-b221-78aa67a88c28	f7b79e33-683f-4dbe-a9de-f85b11a86d7b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bf6b63e6-5b19-47e2-89e3-c8f21e47a1d5	cd112fe5-0c94-42f4-b221-78aa67a88c28	ed3934dd-2168-4345-bba3-5f6a0e158ec0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f1cb0d0f-2812-4562-ab09-628681e89bd1	cd112fe5-0c94-42f4-b221-78aa67a88c28	721c3aac-5d68-4853-94de-c82abea3ca09	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fce14ba6-b448-47ce-81fd-95df32a1cbaf	cd112fe5-0c94-42f4-b221-78aa67a88c28	3d49dcf7-6674-4d6f-8925-6b8d20ace487	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fc33016d-9178-4e5c-a38b-968c5480f9c9	cd112fe5-0c94-42f4-b221-78aa67a88c28	b64f99b8-39b4-4a9b-ba99-29f88e7dcd09	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
800f9a72-4ccc-4b7d-9db9-c9472a342ce7	cd112fe5-0c94-42f4-b221-78aa67a88c28	b45d5d5e-3ab0-4b25-968e-feec018d523f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
65112ed8-51f9-4a51-956d-b3a1f1f4e34e	cd112fe5-0c94-42f4-b221-78aa67a88c28	8c754871-b2ea-4aae-810c-712852326602	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f0f2a30a-01e4-4ffc-852d-d40db1f042f6	cd112fe5-0c94-42f4-b221-78aa67a88c28	1c297820-d0f4-4007-a68f-0b4e04c3b86f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3dc63de7-52b2-45e9-ad23-ab3b72f78052	cd112fe5-0c94-42f4-b221-78aa67a88c28	8b19b7b4-0d72-4b01-869b-8a3acb2c53be	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
53da8831-5a62-4e93-a0fa-690cedacfc52	cd112fe5-0c94-42f4-b221-78aa67a88c28	56ef68eb-af96-4c0e-965e-629e302e2481	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
58ee871a-e1ee-4cb9-a840-b7027a8982f5	cd112fe5-0c94-42f4-b221-78aa67a88c28	f72bfcc4-7ff1-4f9e-89df-10d4112cc55b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
89367b7b-58cc-433f-9cb0-25e2b58d271d	cd112fe5-0c94-42f4-b221-78aa67a88c28	f520b52a-47ad-4238-8611-3433f61a6b05	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bc72bb8a-95b9-4586-bd39-d08283982323	cd112fe5-0c94-42f4-b221-78aa67a88c28	8eddb00b-2b5b-47b3-ada3-33b4ef48bdad	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b6eb451b-5c92-429b-bd10-c18ab4e1d913	cd112fe5-0c94-42f4-b221-78aa67a88c28	cff92809-f5a6-457f-a341-a91d1f82a83a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
910415dc-f9d5-4401-b411-17a12b90aea5	cd112fe5-0c94-42f4-b221-78aa67a88c28	95996d13-95a6-4244-be81-70a4e554ac6c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
26e366bd-89dd-4997-854d-3e10405298fd	cd112fe5-0c94-42f4-b221-78aa67a88c28	776e8ea5-5869-4535-9329-3ef68ecfe2a3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d6971cb8-c1e0-49bb-b9ae-0eacf25b2514	cd112fe5-0c94-42f4-b221-78aa67a88c28	a53bb49c-baa0-4fdb-987d-ccd5fb3d2654	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
03c95537-cf38-49da-82d2-5dc7dcfb67c8	cd112fe5-0c94-42f4-b221-78aa67a88c28	169cbf3c-6271-4b8b-9337-611b71e3e527	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e113fa69-21b0-451e-a837-e23c432359f5	cd112fe5-0c94-42f4-b221-78aa67a88c28	abf7ecbe-fcda-456e-9442-8d40a872b178	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9ea3ef7c-aafa-4a7f-a30a-b2dce2ef0e91	cd112fe5-0c94-42f4-b221-78aa67a88c28	d31af913-00cb-4f5a-bdff-6c979ced0e50	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
01ee625a-9d60-4d2f-b465-83d4598d1794	cd112fe5-0c94-42f4-b221-78aa67a88c28	09bbaaf7-85f7-44cb-b90d-de2f184a2e8b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4acc91ed-3dc0-4313-abc3-7c1f47f3ec9b	cd112fe5-0c94-42f4-b221-78aa67a88c28	65117db3-5fda-476b-a6b5-f155f74cace1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3228240c-4039-4481-9f40-2602b8d65f5e	cd112fe5-0c94-42f4-b221-78aa67a88c28	877896af-dced-4232-8617-69b7cc5808c8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
24539aad-58bf-4da5-bef9-baeaedba1f6a	cd112fe5-0c94-42f4-b221-78aa67a88c28	a16c8803-ff6c-4d5b-a472-1eb42eab6286	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
231173cc-26f2-4ad2-ac98-47e2dddadba9	cd112fe5-0c94-42f4-b221-78aa67a88c28	f58654a8-70f4-4d59-a386-0803fdfd6e91	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8a73fb64-1147-41f9-b6fa-3af7ab6521c3	cd112fe5-0c94-42f4-b221-78aa67a88c28	59c017a3-3214-4f79-927a-c165551c63b5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4d3f3f02-8a4f-49dc-a574-164bb313cad2	cd112fe5-0c94-42f4-b221-78aa67a88c28	0e01cb82-5f8d-4d9f-84bb-2d48f61cb9dd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ebba84b5-ecd4-4931-a18f-066d0a4e591d	cd112fe5-0c94-42f4-b221-78aa67a88c28	da638ee4-1cbc-49b0-ae4f-a57c03bfabf5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
aa3ba8df-957a-4a0a-bf46-2e626358a9bc	cd112fe5-0c94-42f4-b221-78aa67a88c28	80bb05d4-2d3b-4e3a-9d19-c5e0fe33ea22	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
81a8b04c-528e-4919-80c5-ff7a1c15af04	cd112fe5-0c94-42f4-b221-78aa67a88c28	3193cda8-5eed-49d8-aa7e-ad0c4c97a636	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
94f51b76-e6f6-4391-b3ae-747c11f936ed	cd112fe5-0c94-42f4-b221-78aa67a88c28	d7a620a0-5fbf-4f04-8d38-664532512db1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
52c1f36d-3530-497d-8a21-4030132dd4a6	cd112fe5-0c94-42f4-b221-78aa67a88c28	538a028e-3cb3-4a11-95d3-1b71531e9e59	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6922b42f-ef00-4950-af78-ab4af7276c85	cd112fe5-0c94-42f4-b221-78aa67a88c28	6bdc71f3-07d4-492b-a93b-b1295c7aeedf	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3ffc94bd-6027-4485-a418-991849f7afd2	cd112fe5-0c94-42f4-b221-78aa67a88c28	8bd69081-afa8-498d-aec8-e5be89b43cc3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
37d4ac9f-08fd-4002-acc3-5cc516d17d32	cd112fe5-0c94-42f4-b221-78aa67a88c28	2caa18a8-6c4d-4dfb-8e70-b80e8e600721	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5272ea99-dce9-48a7-9ece-61866c2c6adf	cd112fe5-0c94-42f4-b221-78aa67a88c28	f786c3b6-6406-4d57-937b-40c9dcf3e356	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
015bab58-4b80-40fa-b16e-8882d8f7e12f	cd112fe5-0c94-42f4-b221-78aa67a88c28	6f367e68-b796-4234-b210-d97fd947a9b7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d5cb8201-fe69-49a4-bf8d-1e832264de5f	cd112fe5-0c94-42f4-b221-78aa67a88c28	c5f00c32-c96a-47cf-a7f9-93fc39a71674	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e7b87a32-19e2-4fee-93d7-993588865a70	cd112fe5-0c94-42f4-b221-78aa67a88c28	a78f2894-e1fb-403c-97e7-cf75f80796a5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fbf63390-a0f6-425d-b234-58ce5e51ce70	cd112fe5-0c94-42f4-b221-78aa67a88c28	6dcf628a-dc1b-449a-9728-7ac67c733bf2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4be1c33f-a079-4d5d-9fef-01cdbe3adfb9	cd112fe5-0c94-42f4-b221-78aa67a88c28	62fced1e-eb3e-4b86-8b29-30b64d97165e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ba10de73-a0c7-4605-a442-446b2bbaeab1	cd112fe5-0c94-42f4-b221-78aa67a88c28	c0429ac0-e0a3-4107-b7b3-ea5e3670f23c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d654daed-2db5-47aa-ac5c-cbbed35d3a52	cd112fe5-0c94-42f4-b221-78aa67a88c28	2dc7d586-33f2-4d7f-9e8b-48746a754d6a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
83c00c51-fa43-489f-b867-e225394e4e44	cd112fe5-0c94-42f4-b221-78aa67a88c28	16be242a-3f77-41a0-bdfc-32c853821d02	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d628955d-4d12-4a73-9ad0-f2ed0a24f43d	cd112fe5-0c94-42f4-b221-78aa67a88c28	caae4a66-3d85-489d-b797-e0290f219006	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
838ed0df-908a-4fba-bd68-d5fe6a828b85	cd112fe5-0c94-42f4-b221-78aa67a88c28	ba3ed4bc-5eb7-4fa7-ac58-3e4e63d4e672	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
50ddc002-e82a-414f-bea7-0be9bcee8fd6	cd112fe5-0c94-42f4-b221-78aa67a88c28	16504c0f-5ba1-4a0b-9aa7-9983c86bd521	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a3da3194-b0a0-43f5-bb39-563c4ce30d4a	cd112fe5-0c94-42f4-b221-78aa67a88c28	9e303fc8-5621-4d84-b724-3ebcc0a516b0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
22dfe1ac-65e0-401f-acfd-08decce35312	cd112fe5-0c94-42f4-b221-78aa67a88c28	90ae287a-7e1b-45f3-9a0a-8d9a1f3f9e55	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5574a721-6cbd-4c66-be81-9fb312f5e8f6	cd112fe5-0c94-42f4-b221-78aa67a88c28	74399023-f560-4bf1-8f42-e1ea78f38107	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4dca0eed-704c-407e-bee1-3cc1db898d8b	cd112fe5-0c94-42f4-b221-78aa67a88c28	2ebb3b21-3757-4941-ba83-4cf1301bc76f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5ba42558-0bba-43f7-994c-9349d5de3752	cd112fe5-0c94-42f4-b221-78aa67a88c28	9dc67fb2-9f0d-4362-8f87-f481cd890791	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5c8b9710-3a20-469e-b6bb-db5a356fad68	cd112fe5-0c94-42f4-b221-78aa67a88c28	33de1141-3175-4b7c-8ded-b12260d5edbc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5fd3ea47-4239-494b-aebd-4f22741eac78	cd112fe5-0c94-42f4-b221-78aa67a88c28	c649f95d-3372-42a8-bf65-3baa4769cffc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8862278f-99c4-43cf-947f-22b205b19ae3	cd112fe5-0c94-42f4-b221-78aa67a88c28	6d934cf7-354c-4409-9648-f6020c124f9c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b507c936-ea02-42a4-860a-5667a9f2d667	cd112fe5-0c94-42f4-b221-78aa67a88c28	7efdeb2d-01f7-4c06-8a79-8b3b27f3e27b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b1bad239-98e3-4d23-8a9e-1e9ce4d71acd	cd112fe5-0c94-42f4-b221-78aa67a88c28	a72a0e17-4b69-4003-9eba-2a38a4daeccc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d044ac14-d21a-4612-87c8-2ac87aaff50d	cd112fe5-0c94-42f4-b221-78aa67a88c28	e5aa9432-e392-45a3-86ae-fbe6f5b6437b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cc71db3e-6cb6-460b-a481-10aac6a4dc89	cd112fe5-0c94-42f4-b221-78aa67a88c28	c967d08e-c47b-4479-9824-4d62aa4f9fba	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
09fd949f-2fc3-4231-932a-cc96dbedabba	cd112fe5-0c94-42f4-b221-78aa67a88c28	5aef4e1a-8ff6-49be-afac-1c48c0d0f5f2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ff7bba14-6bff-4bef-bd88-b5aa085f8f36	cd112fe5-0c94-42f4-b221-78aa67a88c28	f8789321-4f34-4bcf-b5dd-cc3a216c2cd4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
609b5483-14c7-42a7-aa21-00611dd9a360	cd112fe5-0c94-42f4-b221-78aa67a88c28	e0ab5d4c-49f1-42b5-9f72-c8d675601b5d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
35b5af4a-21fd-4d75-94a5-7dec92d43b59	cd112fe5-0c94-42f4-b221-78aa67a88c28	8fa7d147-6c53-4bc3-a4ae-1902081d74d1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7c42b2c9-6b41-4a53-948b-4e2cf346303c	cd112fe5-0c94-42f4-b221-78aa67a88c28	66be0f17-0004-4472-b74a-abda41ea617b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
175c4e09-bdb6-4f28-a7d2-43f2529cfff9	cd112fe5-0c94-42f4-b221-78aa67a88c28	e541a003-9b58-461c-843b-b4d585ec3515	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bddb5319-0f19-4270-9ef2-4de08fd749e3	cd112fe5-0c94-42f4-b221-78aa67a88c28	7a61bc8c-51fb-4ad1-b421-6279f74ae448	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
61116c41-d8a0-4cfc-ba3c-33fe4d16d193	cd112fe5-0c94-42f4-b221-78aa67a88c28	9bb9aee1-2bf4-4df2-9f4b-28a33f9a9668	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
73574c6d-cab8-440d-b2dc-6a1f05f80d4f	cd112fe5-0c94-42f4-b221-78aa67a88c28	b4d366ff-1e42-4156-b915-1ee81efffff4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d56b38e1-8080-414c-b7de-91c4118a3a69	cd112fe5-0c94-42f4-b221-78aa67a88c28	93e08fbb-4f1a-40aa-9fe1-3b6373cc50bf	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
949bcd31-c8bc-4c19-8ad3-7657adce9081	cd112fe5-0c94-42f4-b221-78aa67a88c28	17ef3a3f-ff17-4da3-88f8-6bb9bbd55c83	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
75d8a6a4-ccb2-4309-a732-ee5530aa9e4f	cd112fe5-0c94-42f4-b221-78aa67a88c28	9cc32b94-4411-4058-a76e-d2435863401d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0af4f6c8-eb45-44af-a9c8-7fca5a52e8af	cd112fe5-0c94-42f4-b221-78aa67a88c28	143838f1-2c57-463f-b08f-83726d7e393b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c715f196-e36c-4450-834c-79f7b1b57421	cd112fe5-0c94-42f4-b221-78aa67a88c28	4085f94c-e7af-46b0-9550-9f9723489e4b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5ba74217-fe8f-4fe4-a914-ec7cbf3570ad	cd112fe5-0c94-42f4-b221-78aa67a88c28	1ba0dc0e-33ba-47c7-9f6d-c418d5d9e0a2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0d284687-49e9-46f1-bb58-d6267ee3c467	cd112fe5-0c94-42f4-b221-78aa67a88c28	50b9c969-9728-4303-ae2a-005d1cecf4ee	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d42e24ba-996d-4ce5-bcbf-ddbafce09d63	cd112fe5-0c94-42f4-b221-78aa67a88c28	17bfb27c-8cca-45ff-8ebb-1973bfc2f07a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
55fe60c8-6f76-4600-be29-e1ddc08180e4	cd112fe5-0c94-42f4-b221-78aa67a88c28	a211a911-2a1b-42a4-827d-1dc4d4f60170	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d8c01b65-a3f0-47a3-bd70-ed64b2ff7385	cd112fe5-0c94-42f4-b221-78aa67a88c28	d25383e3-8123-45d0-b355-6cf499292ad6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
851d7b58-0ed8-4671-b335-be0245849f47	cd112fe5-0c94-42f4-b221-78aa67a88c28	7cecdd78-09e7-4f82-9665-8cbe8d1d696c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
781ca56a-732f-4af5-95fe-121d5109affa	cd112fe5-0c94-42f4-b221-78aa67a88c28	cce1f48a-dec5-4b80-ad48-4047c478d916	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e877ec6a-bcb7-4487-bb42-c27360eafe26	cd112fe5-0c94-42f4-b221-78aa67a88c28	70fc6ba9-c15e-4e56-a35d-fc7715f399e2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a1ea1cf6-9af2-41ac-805f-a976da74748d	cd112fe5-0c94-42f4-b221-78aa67a88c28	b09755dd-1b36-4a7d-884e-340595abbc51	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
56578d2f-37a0-4d6f-bb3a-6a8393e2fcf3	cd112fe5-0c94-42f4-b221-78aa67a88c28	ad4c1625-9bd3-438c-a3ee-d1f6642e92eb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e39dca3f-1fd7-43d9-8bfe-d613f8cc0286	cd112fe5-0c94-42f4-b221-78aa67a88c28	02417dd0-088a-40ae-b1df-20b377276958	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5d5bff56-ee0a-435f-b9e1-ef65a89b0dee	cd112fe5-0c94-42f4-b221-78aa67a88c28	c7989ae3-626d-4978-a4b7-9be0ead046ab	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b6bf212c-1182-4a14-ac77-1574f9ac437b	cd112fe5-0c94-42f4-b221-78aa67a88c28	e691b0a9-1700-485d-870c-1be5f26dfe87	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
09002374-c572-4978-a13e-8f76d7d2a368	cd112fe5-0c94-42f4-b221-78aa67a88c28	bfe45e3d-ab2d-471f-addb-f651c750db5b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0eff7deb-95aa-416f-8854-52ac8b173880	cd112fe5-0c94-42f4-b221-78aa67a88c28	9b7fdcc4-4a4f-4280-9285-d127bb15d236	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2d9f5c5d-a1d5-4286-9687-e28792b633cb	cd112fe5-0c94-42f4-b221-78aa67a88c28	a42a572f-62b3-4109-b08e-b2b299901f89	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
70661e39-04c5-4dcd-b2cd-2ff2876471d2	cd112fe5-0c94-42f4-b221-78aa67a88c28	1402e4f3-e2b9-4b95-8c6d-9f84cde6a8d2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
432162f0-a6eb-480a-96ab-3a0eb597fdd1	cd112fe5-0c94-42f4-b221-78aa67a88c28	6f2ce70c-ac7a-4718-aff2-4983cb5bfdcb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
86b16e9a-1cff-4c8a-ad3f-505e07b19094	cd112fe5-0c94-42f4-b221-78aa67a88c28	0b466c96-8f53-4324-bc1a-30b6a7e4e096	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7e9e69e7-21e4-458d-b221-bf0ab7dc57a9	cd112fe5-0c94-42f4-b221-78aa67a88c28	2fdea443-fefd-4efe-aa32-6c270ce16c66	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7ef53415-25f4-4383-ba0a-bdfe302e5c4c	cd112fe5-0c94-42f4-b221-78aa67a88c28	c01b1fad-d58b-42c7-8c25-05f03eea24b4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
67a9f82a-58bd-4c5b-9c30-2f8980604997	cd112fe5-0c94-42f4-b221-78aa67a88c28	05a11507-3926-43b2-805a-ebae1d0f8cca	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bb27ec00-d7d4-42c9-8b8a-0c868e4cb276	cd112fe5-0c94-42f4-b221-78aa67a88c28	bb46be5a-ca94-4ecf-ade5-1e57560e2556	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6055c1c9-2753-4579-9fa8-8c7c4f56f417	cd112fe5-0c94-42f4-b221-78aa67a88c28	5d47c135-506b-4368-a383-69f213935bac	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1cea29e0-75d4-4d91-97e1-236ba81d95ca	cd112fe5-0c94-42f4-b221-78aa67a88c28	ae1ba01a-2587-4424-8a96-b745a28e68a7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6adf4f0d-6f0a-4bb7-a8e8-890dfe65c898	cd112fe5-0c94-42f4-b221-78aa67a88c28	e0df7f49-5fe1-4198-95eb-032168baa536	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0a0d6172-afee-41ba-bf44-310ab5da4b14	cd112fe5-0c94-42f4-b221-78aa67a88c28	c9ab71ca-a401-4940-8235-f6a0d553b0d2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bb40cc37-a435-41de-96e5-d53a7a58efb7	cd112fe5-0c94-42f4-b221-78aa67a88c28	d0f96c89-4517-4158-84ad-b71ce7be3364	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
426be290-d7c2-4ece-900b-8777c46668ad	cd112fe5-0c94-42f4-b221-78aa67a88c28	c20661f5-e173-4c22-8753-f9ef6033c16b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
97aa2642-fc24-4fa6-bd2b-e88260062fc3	cd112fe5-0c94-42f4-b221-78aa67a88c28	c033aee5-9862-4b4b-b4af-275de7508b7e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ca543fa2-00d1-43c1-b4e8-8ce91ed36030	cd112fe5-0c94-42f4-b221-78aa67a88c28	356127df-0319-4689-9c8a-d1524d102144	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
219a90bc-d661-449d-b9aa-9e935fb184bc	cd112fe5-0c94-42f4-b221-78aa67a88c28	a77fe6c0-d872-459f-a6af-7733145e314d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b738704d-c0ec-479a-a2e8-cdb312c24eb4	cd112fe5-0c94-42f4-b221-78aa67a88c28	d3bfe5a5-d0f2-44ea-b098-4df6f8613815	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
21a95a8e-01b6-4d51-8459-f54f09f3b451	cd112fe5-0c94-42f4-b221-78aa67a88c28	8b7bbc46-6476-4677-8123-1b9523aff408	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b2122000-4321-407f-96c0-3b590169b3a5	cd112fe5-0c94-42f4-b221-78aa67a88c28	f68b608e-0518-4ae9-88c2-364b3a6e4b77	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a9a5885d-0b9b-434b-9cfa-c664e585e497	cd112fe5-0c94-42f4-b221-78aa67a88c28	d97cbaf2-20af-41eb-99fa-4148d159e97c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3c324c48-a402-4a7e-af0c-74e94e3f697c	cd112fe5-0c94-42f4-b221-78aa67a88c28	2e525182-45cb-4738-a898-55b428fb3c9b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a3005a8b-26cb-49c9-9be3-b8c18cfb2867	cd112fe5-0c94-42f4-b221-78aa67a88c28	1029b42c-e410-46a1-bffc-3f8797b0f366	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a182bf82-1bfe-43d9-bd60-e9b9f0582917	cd112fe5-0c94-42f4-b221-78aa67a88c28	fb7aac21-100a-4694-a9d2-abb437f80c97	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b5548672-6f41-4d2e-8583-77b3fa387f3f	cd112fe5-0c94-42f4-b221-78aa67a88c28	0cea2f3b-25ca-4a41-879e-c6e544a3230b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3fbe9b36-8012-4efc-988b-dd1f4709b2c6	cd112fe5-0c94-42f4-b221-78aa67a88c28	672f94e6-adc0-45fb-b8aa-a78432c5e195	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
dd4b2032-a642-4b6b-b7bf-50b4299414bc	cd112fe5-0c94-42f4-b221-78aa67a88c28	88d85a38-2041-489f-9b7d-c7245dd873a6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
dca29559-d84e-4adb-995f-3808c74aa2c5	cd112fe5-0c94-42f4-b221-78aa67a88c28	e22be5f0-9d4e-46a4-aafe-4ff0de5ca448	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
37dff363-afe1-45f2-8e30-8d47ee6e6ab8	cd112fe5-0c94-42f4-b221-78aa67a88c28	00a37083-5244-422b-826f-d55da90c5d70	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c3e6946b-5e44-49df-89e0-ef517dd5ad3e	cd112fe5-0c94-42f4-b221-78aa67a88c28	548068fd-a938-4214-8630-8fb354dc2aab	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
19c849ee-7a5b-4fbb-9e33-934eceac1b47	cd112fe5-0c94-42f4-b221-78aa67a88c28	6f37805f-6ab9-4e12-94f4-ffd7c22e9243	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
15a9936b-6e35-4cf0-94ec-201669bdeb9c	cd112fe5-0c94-42f4-b221-78aa67a88c28	26e8f90b-85ff-4f5b-92fc-a8e7e904f37f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
62b31be2-29e9-4516-8180-a9f36890c948	cd112fe5-0c94-42f4-b221-78aa67a88c28	9db7cc26-8de2-49d4-8b67-ae1659ac23fe	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
37d3b934-2f8d-47b2-b6c9-ce7bd7b0993c	cd112fe5-0c94-42f4-b221-78aa67a88c28	6a3444f1-e78a-4012-bd43-f0bc032fc6ea	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2bb47654-50bd-4df8-9028-2543d604d071	cd112fe5-0c94-42f4-b221-78aa67a88c28	5f4ca73a-f9fd-4eb2-a061-2442ecea2636	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
20f1093e-8e97-4b18-a0f8-eee71a8ba347	cd112fe5-0c94-42f4-b221-78aa67a88c28	0496b591-852e-4446-96f9-f547c088d6b2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
683f25b6-7a87-4ad0-9b44-6c6224a177e0	cd112fe5-0c94-42f4-b221-78aa67a88c28	4344b047-0643-49d1-aa5b-0556d39da7ea	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
614a8162-f456-4d79-a18f-a7f124603e68	cd112fe5-0c94-42f4-b221-78aa67a88c28	b6652629-f529-4de3-a344-2665697f023a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e7c68729-957e-42fa-a9ba-20fa17570751	cd112fe5-0c94-42f4-b221-78aa67a88c28	cec31a8e-b07c-4399-b6e0-8d11513a65bd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ad2f06e1-6f9b-4ca3-964d-37690ecd34ed	33ba105b-d0a6-4667-b6e9-927859eb4481	f7b79e33-683f-4dbe-a9de-f85b11a86d7b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b71e348e-3e9d-46ac-b93a-7e36fd8781ad	33ba105b-d0a6-4667-b6e9-927859eb4481	ed3934dd-2168-4345-bba3-5f6a0e158ec0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6d94a6aa-b622-49ae-9670-4a6003e3d934	33ba105b-d0a6-4667-b6e9-927859eb4481	721c3aac-5d68-4853-94de-c82abea3ca09	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6b42508b-e42c-48f9-ad9e-f0fa668ff2db	33ba105b-d0a6-4667-b6e9-927859eb4481	3d49dcf7-6674-4d6f-8925-6b8d20ace487	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1a9f73ac-0f17-4fe8-9230-66731f1f653b	33ba105b-d0a6-4667-b6e9-927859eb4481	b64f99b8-39b4-4a9b-ba99-29f88e7dcd09	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
65eb7ebc-e5d5-42a9-b0d7-6aa755413935	33ba105b-d0a6-4667-b6e9-927859eb4481	b45d5d5e-3ab0-4b25-968e-feec018d523f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4cff38b8-3529-4e38-a1ce-788d16bed243	33ba105b-d0a6-4667-b6e9-927859eb4481	8c754871-b2ea-4aae-810c-712852326602	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1276dfec-bd12-46d2-bc65-1dad2ccad1b2	33ba105b-d0a6-4667-b6e9-927859eb4481	1c297820-d0f4-4007-a68f-0b4e04c3b86f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a8e6d0b2-b7fe-466d-8efa-b97e89299c07	33ba105b-d0a6-4667-b6e9-927859eb4481	8b19b7b4-0d72-4b01-869b-8a3acb2c53be	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f9371f95-9d64-4059-a1f7-9ad7b5e0c039	33ba105b-d0a6-4667-b6e9-927859eb4481	56ef68eb-af96-4c0e-965e-629e302e2481	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
53cde181-d193-43d5-9222-6163c72686fc	33ba105b-d0a6-4667-b6e9-927859eb4481	f72bfcc4-7ff1-4f9e-89df-10d4112cc55b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
42691916-57e2-440f-8c52-0183a5ed573c	33ba105b-d0a6-4667-b6e9-927859eb4481	f520b52a-47ad-4238-8611-3433f61a6b05	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2e2ba49f-4a5a-4ab0-92f8-2b3bc2c7bf82	33ba105b-d0a6-4667-b6e9-927859eb4481	8eddb00b-2b5b-47b3-ada3-33b4ef48bdad	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
66fe0736-b0a2-4c13-afa3-2a41a9ad0c86	33ba105b-d0a6-4667-b6e9-927859eb4481	cff92809-f5a6-457f-a341-a91d1f82a83a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6d587a6f-45c0-49fc-b152-9d7cdcb1bc0a	33ba105b-d0a6-4667-b6e9-927859eb4481	95996d13-95a6-4244-be81-70a4e554ac6c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
17bf87e5-ad4d-4c41-9ddb-407bb5e4bc38	33ba105b-d0a6-4667-b6e9-927859eb4481	776e8ea5-5869-4535-9329-3ef68ecfe2a3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c3acf5ba-8b86-4175-9873-50fe1e1d73e6	33ba105b-d0a6-4667-b6e9-927859eb4481	a53bb49c-baa0-4fdb-987d-ccd5fb3d2654	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
595967c3-7716-4a9e-b540-cc46481fd9db	33ba105b-d0a6-4667-b6e9-927859eb4481	169cbf3c-6271-4b8b-9337-611b71e3e527	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
24a8ef44-8503-44af-8ad3-63065739f78d	33ba105b-d0a6-4667-b6e9-927859eb4481	abf7ecbe-fcda-456e-9442-8d40a872b178	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
583eee9e-b04f-4d37-9a82-fef4d4cff222	33ba105b-d0a6-4667-b6e9-927859eb4481	d31af913-00cb-4f5a-bdff-6c979ced0e50	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e7fbb0cd-0478-4b73-a6b9-63e7818b598b	33ba105b-d0a6-4667-b6e9-927859eb4481	09bbaaf7-85f7-44cb-b90d-de2f184a2e8b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
05d3ed9f-4f6f-4d0d-99be-71444c8c1b78	33ba105b-d0a6-4667-b6e9-927859eb4481	65117db3-5fda-476b-a6b5-f155f74cace1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
132ef3c7-f035-4533-a0fa-90edb7bed72d	33ba105b-d0a6-4667-b6e9-927859eb4481	877896af-dced-4232-8617-69b7cc5808c8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
35dc3d29-ccd3-4956-8218-4d40a2aa48ce	33ba105b-d0a6-4667-b6e9-927859eb4481	a16c8803-ff6c-4d5b-a472-1eb42eab6286	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bae941a0-2128-44a3-ada7-ba18269cc6c4	33ba105b-d0a6-4667-b6e9-927859eb4481	f58654a8-70f4-4d59-a386-0803fdfd6e91	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bc8a77d3-9f11-401b-96b3-6143102e7bf4	33ba105b-d0a6-4667-b6e9-927859eb4481	59c017a3-3214-4f79-927a-c165551c63b5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a60c7e0e-392f-4e04-bf46-e648c0da0498	33ba105b-d0a6-4667-b6e9-927859eb4481	0e01cb82-5f8d-4d9f-84bb-2d48f61cb9dd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
67b683f9-b58f-41aa-92ff-f734244e0cec	33ba105b-d0a6-4667-b6e9-927859eb4481	da638ee4-1cbc-49b0-ae4f-a57c03bfabf5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ec5f1c8e-ad4f-4d32-b02b-d0abb29095ea	33ba105b-d0a6-4667-b6e9-927859eb4481	80bb05d4-2d3b-4e3a-9d19-c5e0fe33ea22	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
81b1d70b-97d2-4272-a166-d86d149a7ba1	33ba105b-d0a6-4667-b6e9-927859eb4481	3193cda8-5eed-49d8-aa7e-ad0c4c97a636	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9680e394-d2b1-466b-b815-1565afd0de44	33ba105b-d0a6-4667-b6e9-927859eb4481	d7a620a0-5fbf-4f04-8d38-664532512db1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e17ddbeb-9211-43b3-b15e-864ea7d06b14	33ba105b-d0a6-4667-b6e9-927859eb4481	538a028e-3cb3-4a11-95d3-1b71531e9e59	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1cf41927-32c5-4971-8465-ba9221ac249a	33ba105b-d0a6-4667-b6e9-927859eb4481	6bdc71f3-07d4-492b-a93b-b1295c7aeedf	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2e267c38-707e-4e5c-9563-e7fb0375a454	33ba105b-d0a6-4667-b6e9-927859eb4481	8bd69081-afa8-498d-aec8-e5be89b43cc3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bf07f5eb-3523-4d2c-acc4-3ddc48a691c5	33ba105b-d0a6-4667-b6e9-927859eb4481	2caa18a8-6c4d-4dfb-8e70-b80e8e600721	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2ec0adda-f1ef-46ae-bd5e-1e8fd53baf1a	33ba105b-d0a6-4667-b6e9-927859eb4481	f786c3b6-6406-4d57-937b-40c9dcf3e356	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0683a13c-d3e2-4a07-bc67-114864988285	33ba105b-d0a6-4667-b6e9-927859eb4481	6f367e68-b796-4234-b210-d97fd947a9b7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6c94053c-dc01-4a27-99a4-4ee46b45f0f8	33ba105b-d0a6-4667-b6e9-927859eb4481	c5f00c32-c96a-47cf-a7f9-93fc39a71674	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4ac74056-ce55-4f6b-96b4-0915d8c20085	33ba105b-d0a6-4667-b6e9-927859eb4481	a78f2894-e1fb-403c-97e7-cf75f80796a5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8c979e95-5747-4e55-8b80-94d1988f2d04	33ba105b-d0a6-4667-b6e9-927859eb4481	6dcf628a-dc1b-449a-9728-7ac67c733bf2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
208c0d81-02b9-49e0-b22b-f390eebd9edd	33ba105b-d0a6-4667-b6e9-927859eb4481	62fced1e-eb3e-4b86-8b29-30b64d97165e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e96dcf24-6ecf-4646-8029-fab8a9bb64c7	33ba105b-d0a6-4667-b6e9-927859eb4481	c0429ac0-e0a3-4107-b7b3-ea5e3670f23c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
27ce2ea8-d132-41ed-a968-092bb5614817	33ba105b-d0a6-4667-b6e9-927859eb4481	2dc7d586-33f2-4d7f-9e8b-48746a754d6a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e5ee6998-8e35-4ea7-a8e0-3f93cbdca9be	33ba105b-d0a6-4667-b6e9-927859eb4481	16be242a-3f77-41a0-bdfc-32c853821d02	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9fca5b6c-ea09-4fe3-951b-6f84b4067340	33ba105b-d0a6-4667-b6e9-927859eb4481	caae4a66-3d85-489d-b797-e0290f219006	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b5b83447-4922-4ebc-9552-926c688babce	33ba105b-d0a6-4667-b6e9-927859eb4481	ba3ed4bc-5eb7-4fa7-ac58-3e4e63d4e672	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c94347f3-d2a5-48d8-ada3-0fa4c84caea1	33ba105b-d0a6-4667-b6e9-927859eb4481	16504c0f-5ba1-4a0b-9aa7-9983c86bd521	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ce39c4ee-7fb1-4df0-92a7-4d63697c4a73	33ba105b-d0a6-4667-b6e9-927859eb4481	9e303fc8-5621-4d84-b724-3ebcc0a516b0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
39284450-c18b-49de-b1aa-739538937fcf	33ba105b-d0a6-4667-b6e9-927859eb4481	90ae287a-7e1b-45f3-9a0a-8d9a1f3f9e55	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d0403f43-5b77-4022-bd9d-e427ee4f5759	33ba105b-d0a6-4667-b6e9-927859eb4481	74399023-f560-4bf1-8f42-e1ea78f38107	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bed44a3f-50f6-473e-b665-d96ccd26ab2e	33ba105b-d0a6-4667-b6e9-927859eb4481	2ebb3b21-3757-4941-ba83-4cf1301bc76f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
925b4415-66a7-491b-bbb3-fc0da4da4d52	33ba105b-d0a6-4667-b6e9-927859eb4481	9dc67fb2-9f0d-4362-8f87-f481cd890791	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
799a1ccd-a06d-42d3-a0a0-2fb0d18ff0ba	33ba105b-d0a6-4667-b6e9-927859eb4481	33de1141-3175-4b7c-8ded-b12260d5edbc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ff01b0fe-a39d-4242-83f8-42cc2ee322b9	33ba105b-d0a6-4667-b6e9-927859eb4481	c649f95d-3372-42a8-bf65-3baa4769cffc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5dc9646e-35cc-4a49-be7d-397fe1361687	33ba105b-d0a6-4667-b6e9-927859eb4481	6d934cf7-354c-4409-9648-f6020c124f9c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f99c321c-3728-4910-8f1d-5e220ae6e4b6	33ba105b-d0a6-4667-b6e9-927859eb4481	7efdeb2d-01f7-4c06-8a79-8b3b27f3e27b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f3760412-4d41-423c-936d-41afba466824	33ba105b-d0a6-4667-b6e9-927859eb4481	a72a0e17-4b69-4003-9eba-2a38a4daeccc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c7138f20-23db-47a8-bf51-9ebdd7f95926	33ba105b-d0a6-4667-b6e9-927859eb4481	e5aa9432-e392-45a3-86ae-fbe6f5b6437b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4cc42489-77d8-4205-be22-021723736d34	33ba105b-d0a6-4667-b6e9-927859eb4481	c967d08e-c47b-4479-9824-4d62aa4f9fba	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
11f28e62-94a7-4036-9d68-d96666a87645	33ba105b-d0a6-4667-b6e9-927859eb4481	5aef4e1a-8ff6-49be-afac-1c48c0d0f5f2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6e561ec1-2f60-4d8d-bb9b-d628d0c85361	33ba105b-d0a6-4667-b6e9-927859eb4481	f8789321-4f34-4bcf-b5dd-cc3a216c2cd4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a9a13698-a86e-468c-b3fd-d95ef25297c5	33ba105b-d0a6-4667-b6e9-927859eb4481	e0ab5d4c-49f1-42b5-9f72-c8d675601b5d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
50415b93-2b64-4dc4-8425-58397f1482a5	33ba105b-d0a6-4667-b6e9-927859eb4481	8fa7d147-6c53-4bc3-a4ae-1902081d74d1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dc04119b-76fe-46d0-a1d3-7ed37d11771b	33ba105b-d0a6-4667-b6e9-927859eb4481	66be0f17-0004-4472-b74a-abda41ea617b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a5cfa287-c931-443a-9c79-e3b0b5713eb1	33ba105b-d0a6-4667-b6e9-927859eb4481	e541a003-9b58-461c-843b-b4d585ec3515	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3b2bbe96-5f23-4282-9004-a55b95431e5f	33ba105b-d0a6-4667-b6e9-927859eb4481	7a61bc8c-51fb-4ad1-b421-6279f74ae448	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
218d1f04-c8ca-4ed5-902a-640df177909c	33ba105b-d0a6-4667-b6e9-927859eb4481	9bb9aee1-2bf4-4df2-9f4b-28a33f9a9668	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e4e7caeb-297b-4976-a354-fc00538e0ce2	33ba105b-d0a6-4667-b6e9-927859eb4481	b4d366ff-1e42-4156-b915-1ee81efffff4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2dd9bd26-4685-4ead-8c3f-13444b501775	33ba105b-d0a6-4667-b6e9-927859eb4481	93e08fbb-4f1a-40aa-9fe1-3b6373cc50bf	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f4d2f869-4c26-48a9-8ef8-ccf6e189f745	33ba105b-d0a6-4667-b6e9-927859eb4481	17ef3a3f-ff17-4da3-88f8-6bb9bbd55c83	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8c8f9765-fae1-40a3-8647-f467173c353a	33ba105b-d0a6-4667-b6e9-927859eb4481	9cc32b94-4411-4058-a76e-d2435863401d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ab77cb1c-ee0a-4cea-bbbf-676317dfcce9	33ba105b-d0a6-4667-b6e9-927859eb4481	143838f1-2c57-463f-b08f-83726d7e393b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
47d4a79a-89ce-42fd-b1e8-827b5a81803c	33ba105b-d0a6-4667-b6e9-927859eb4481	4085f94c-e7af-46b0-9550-9f9723489e4b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
11672699-e746-4442-9f31-67f765a039a1	33ba105b-d0a6-4667-b6e9-927859eb4481	1ba0dc0e-33ba-47c7-9f6d-c418d5d9e0a2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
669e6b41-397f-4fb5-a0b3-50f664394581	33ba105b-d0a6-4667-b6e9-927859eb4481	50b9c969-9728-4303-ae2a-005d1cecf4ee	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
12675ec4-806c-4d6b-83e6-dc63e968eca9	33ba105b-d0a6-4667-b6e9-927859eb4481	17bfb27c-8cca-45ff-8ebb-1973bfc2f07a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5373f648-a926-47fa-9744-b35d396d4897	33ba105b-d0a6-4667-b6e9-927859eb4481	a211a911-2a1b-42a4-827d-1dc4d4f60170	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
98346217-dc93-4173-b530-a1a06c9dd871	33ba105b-d0a6-4667-b6e9-927859eb4481	d25383e3-8123-45d0-b355-6cf499292ad6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d25fb55a-fa9d-4a0f-80a3-1386d7ac482c	33ba105b-d0a6-4667-b6e9-927859eb4481	7cecdd78-09e7-4f82-9665-8cbe8d1d696c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c729c464-4d9f-4897-87e6-bc2064efeb55	33ba105b-d0a6-4667-b6e9-927859eb4481	cce1f48a-dec5-4b80-ad48-4047c478d916	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3c82d3e1-3700-4e72-be15-67c9e5908630	33ba105b-d0a6-4667-b6e9-927859eb4481	70fc6ba9-c15e-4e56-a35d-fc7715f399e2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bf5159aa-b662-4ed3-a5fc-11759aca2aa0	33ba105b-d0a6-4667-b6e9-927859eb4481	b09755dd-1b36-4a7d-884e-340595abbc51	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
afd6596b-1829-4205-80ea-c16f938cc50f	33ba105b-d0a6-4667-b6e9-927859eb4481	ad4c1625-9bd3-438c-a3ee-d1f6642e92eb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3d8301c8-962c-49c8-80fd-6a4cab0caa3e	33ba105b-d0a6-4667-b6e9-927859eb4481	02417dd0-088a-40ae-b1df-20b377276958	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3e5713e6-c71a-4957-9df3-bece2930addd	33ba105b-d0a6-4667-b6e9-927859eb4481	c7989ae3-626d-4978-a4b7-9be0ead046ab	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7eb30188-d4ec-498f-9235-9de0fa5a3a32	33ba105b-d0a6-4667-b6e9-927859eb4481	e691b0a9-1700-485d-870c-1be5f26dfe87	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f9c87044-3dd9-4404-9709-4501a539ff98	33ba105b-d0a6-4667-b6e9-927859eb4481	bfe45e3d-ab2d-471f-addb-f651c750db5b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f09439cc-15c6-4529-a3bb-712ce861a140	33ba105b-d0a6-4667-b6e9-927859eb4481	9b7fdcc4-4a4f-4280-9285-d127bb15d236	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1c9bf14a-2ab0-4205-9160-812fcfcbc432	33ba105b-d0a6-4667-b6e9-927859eb4481	a42a572f-62b3-4109-b08e-b2b299901f89	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a971968a-4d3e-4150-a88a-359053df6324	33ba105b-d0a6-4667-b6e9-927859eb4481	1402e4f3-e2b9-4b95-8c6d-9f84cde6a8d2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
14d9505f-82ea-43bd-a217-1a0047a7904e	33ba105b-d0a6-4667-b6e9-927859eb4481	6f2ce70c-ac7a-4718-aff2-4983cb5bfdcb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3761310a-7376-4c05-b071-4f4dfca040b4	33ba105b-d0a6-4667-b6e9-927859eb4481	0b466c96-8f53-4324-bc1a-30b6a7e4e096	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
32939f65-1951-44dc-bede-16d5fc292ee2	33ba105b-d0a6-4667-b6e9-927859eb4481	2fdea443-fefd-4efe-aa32-6c270ce16c66	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3ea19eb3-65e7-4946-9870-aca34640ee04	33ba105b-d0a6-4667-b6e9-927859eb4481	c01b1fad-d58b-42c7-8c25-05f03eea24b4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
383d2115-7895-42e1-b030-0e5c9359cc89	33ba105b-d0a6-4667-b6e9-927859eb4481	05a11507-3926-43b2-805a-ebae1d0f8cca	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4c26d306-c450-4052-9afa-570c57d077f1	33ba105b-d0a6-4667-b6e9-927859eb4481	bb46be5a-ca94-4ecf-ade5-1e57560e2556	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8e7b0608-4930-436b-8289-b5be482f208b	33ba105b-d0a6-4667-b6e9-927859eb4481	5d47c135-506b-4368-a383-69f213935bac	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c090c224-e66b-496f-9dcf-26e4610b20cc	33ba105b-d0a6-4667-b6e9-927859eb4481	ae1ba01a-2587-4424-8a96-b745a28e68a7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b5b16e1d-65c1-4eae-8c98-d750aefa9c62	33ba105b-d0a6-4667-b6e9-927859eb4481	e0df7f49-5fe1-4198-95eb-032168baa536	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
49d6e398-1595-4dab-bf9f-81313392655a	33ba105b-d0a6-4667-b6e9-927859eb4481	c9ab71ca-a401-4940-8235-f6a0d553b0d2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
45795b66-2a97-4372-acb5-45e376a0f9ad	33ba105b-d0a6-4667-b6e9-927859eb4481	d0f96c89-4517-4158-84ad-b71ce7be3364	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ef0425f6-a691-4359-8521-3144fc6d506b	33ba105b-d0a6-4667-b6e9-927859eb4481	c20661f5-e173-4c22-8753-f9ef6033c16b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0ed0ee78-1a31-4ba1-a9cd-a64bcd3ca2b7	33ba105b-d0a6-4667-b6e9-927859eb4481	c033aee5-9862-4b4b-b4af-275de7508b7e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0643b639-2d7f-42fe-b997-323ef700355d	33ba105b-d0a6-4667-b6e9-927859eb4481	356127df-0319-4689-9c8a-d1524d102144	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
22d25e9e-1dca-452f-a40b-3f779d7e9063	33ba105b-d0a6-4667-b6e9-927859eb4481	a77fe6c0-d872-459f-a6af-7733145e314d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9265f62f-8518-479e-b708-9d6990c0cf18	33ba105b-d0a6-4667-b6e9-927859eb4481	d3bfe5a5-d0f2-44ea-b098-4df6f8613815	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
78836b51-91a3-4577-9065-03be4f023517	33ba105b-d0a6-4667-b6e9-927859eb4481	8b7bbc46-6476-4677-8123-1b9523aff408	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
10756973-9fe7-4552-be48-cbfff2e613f1	33ba105b-d0a6-4667-b6e9-927859eb4481	f68b608e-0518-4ae9-88c2-364b3a6e4b77	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0cd89054-1dfd-4f48-b103-f5d876a8daaf	33ba105b-d0a6-4667-b6e9-927859eb4481	d97cbaf2-20af-41eb-99fa-4148d159e97c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
474e596c-33d2-4acd-8859-fc3618f8e318	33ba105b-d0a6-4667-b6e9-927859eb4481	2e525182-45cb-4738-a898-55b428fb3c9b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b634f8be-f9b2-4079-9f0c-26078669ab1f	33ba105b-d0a6-4667-b6e9-927859eb4481	1029b42c-e410-46a1-bffc-3f8797b0f366	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7bc701a6-4641-4d91-b4d6-c70433f63631	33ba105b-d0a6-4667-b6e9-927859eb4481	fb7aac21-100a-4694-a9d2-abb437f80c97	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4a5d2612-4e5e-4abd-a81f-b8f3de0a6234	33ba105b-d0a6-4667-b6e9-927859eb4481	0cea2f3b-25ca-4a41-879e-c6e544a3230b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8da139aa-ec5c-4ce1-9d42-2cf1b07b04ed	33ba105b-d0a6-4667-b6e9-927859eb4481	672f94e6-adc0-45fb-b8aa-a78432c5e195	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b8fc3d50-69b5-4111-8c86-fe0781adce86	33ba105b-d0a6-4667-b6e9-927859eb4481	88d85a38-2041-489f-9b7d-c7245dd873a6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6dc51f32-bde6-40f9-bcd5-cc99c57d5085	33ba105b-d0a6-4667-b6e9-927859eb4481	e22be5f0-9d4e-46a4-aafe-4ff0de5ca448	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ac7fb845-0fab-4001-bae7-efdb21956456	33ba105b-d0a6-4667-b6e9-927859eb4481	00a37083-5244-422b-826f-d55da90c5d70	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
cb80497f-6c85-4f67-abdd-c7e153394630	33ba105b-d0a6-4667-b6e9-927859eb4481	548068fd-a938-4214-8630-8fb354dc2aab	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3dbc9f92-0cfe-435b-9890-2d87555e276e	33ba105b-d0a6-4667-b6e9-927859eb4481	6f37805f-6ab9-4e12-94f4-ffd7c22e9243	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c31729f1-ba7a-4c01-92f1-f0e02d070fe6	33ba105b-d0a6-4667-b6e9-927859eb4481	26e8f90b-85ff-4f5b-92fc-a8e7e904f37f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
66417343-b7c1-43c4-9499-1edaa4477288	33ba105b-d0a6-4667-b6e9-927859eb4481	9db7cc26-8de2-49d4-8b67-ae1659ac23fe	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
98478625-4c1a-480d-b980-6e14ce840309	33ba105b-d0a6-4667-b6e9-927859eb4481	6a3444f1-e78a-4012-bd43-f0bc032fc6ea	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a56634d5-fca8-4a91-bae6-28ebf91da8c8	33ba105b-d0a6-4667-b6e9-927859eb4481	5f4ca73a-f9fd-4eb2-a061-2442ecea2636	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
95313603-2c8f-46e9-9bc3-aea94ec61b02	33ba105b-d0a6-4667-b6e9-927859eb4481	0496b591-852e-4446-96f9-f547c088d6b2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
826b893c-2399-47af-8142-24853aa83aaa	33ba105b-d0a6-4667-b6e9-927859eb4481	4344b047-0643-49d1-aa5b-0556d39da7ea	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dae8394f-a73e-42bf-924a-d6c1e4f861b9	33ba105b-d0a6-4667-b6e9-927859eb4481	b6652629-f529-4de3-a344-2665697f023a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
16073e56-76f5-4dd3-9d2d-c54d98f57e93	33ba105b-d0a6-4667-b6e9-927859eb4481	cec31a8e-b07c-4399-b6e0-8d11513a65bd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
\.


--
-- Data for Name: phenotypes; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.phenotypes (id, gene_id, allele_1_function, allele_2_function, score_range_start, score_range_end, phenotype, status, active, created_at, updated_at) FROM stdin;
95d47b90-0673-4955-993f-68cd238753c1	39f5387b-4a50-4696-99ae-6c9062e70c52	Normal Function	Normal Function	\N	\N	Normal Function	5	t	2024-05-23 21:17:24.840055+00	2024-05-23 21:17:24.840055+00
2376f313-d9c3-4372-b97d-0ad88f521159	39f5387b-4a50-4696-99ae-6c9062e70c52	Normal Function	Decreased Function	\N	\N	Decreased Function	5	t	2024-05-23 21:17:24.840055+00	2024-05-23 21:17:24.840055+00
1d3bbe93-7866-4e91-b5da-01557af46942	39f5387b-4a50-4696-99ae-6c9062e70c52	Decreased Function	Decreased Function	\N	\N	Poor Function	5	t	2024-05-23 21:17:24.840055+00	2024-05-23 21:17:24.840055+00
5ba45b1b-e891-442d-955c-10ad6c6fe3f7	01b74a5e-f95b-4086-a5b7-899a8de1f228	Increased Function	Increased Function	\N	\N	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
11b4d234-d7d0-4e24-9201-858d6d428695	01b74a5e-f95b-4086-a5b7-899a8de1f228	Normal Function	Increased Function	\N	\N	Rapid Metabolizer	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
348e21d0-9f5a-44a9-a4cb-91d198fd73c6	01b74a5e-f95b-4086-a5b7-899a8de1f228	Decreased Function	Decreased Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
c2a4d9b2-4f70-4d6f-963e-c75cfcb08594	01b74a5e-f95b-4086-a5b7-899a8de1f228	Decreased Function	No Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
e00af374-bc00-4f9f-8bfd-206630894d88	01b74a5e-f95b-4086-a5b7-899a8de1f228	No Function	No Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
9e5fd3f9-ad7d-4645-8960-b9c6cef20929	01b74a5e-f95b-4086-a5b7-899a8de1f228	Normal Function	Normal Function	\N	\N	Normal Metabolizer	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
a3a6a10c-2bc8-44ab-8390-866559b353ce	01b74a5e-f95b-4086-a5b7-899a8de1f228	Normal Function	Decreased Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
37ea209d-44ce-47e2-aa7f-d3349d841048	01b74a5e-f95b-4086-a5b7-899a8de1f228	Normal Function	No Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
0f9f9db1-c6d1-490f-b1fb-40396c8e5f01	01b74a5e-f95b-4086-a5b7-899a8de1f228	Increased Function	Decreased Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
e5cbd48d-3a0b-4147-bd97-556be3d0ef21	01b74a5e-f95b-4086-a5b7-899a8de1f228	Increased Function	No Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
9fb3540b-ad05-4ab6-a900-d830610cf690	01b74a5e-f95b-4086-a5b7-899a8de1f228	Uncertain Function	Increased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
bd716812-23eb-40eb-a514-1ab55710485e	01b74a5e-f95b-4086-a5b7-899a8de1f228	Uncertain Function	Normal Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
4b62fcbc-8c82-4b2c-bfec-236884010977	01b74a5e-f95b-4086-a5b7-899a8de1f228	Uncertain Function	Decreased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
65859f18-a329-4da5-ac4c-5553424c0699	01b74a5e-f95b-4086-a5b7-899a8de1f228	Uncertain Function	No Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
90e98cb5-4959-485e-9630-e51ce2ba2cb6	01b74a5e-f95b-4086-a5b7-899a8de1f228	Uncertain Function	Uncertain Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
dae80686-478c-425f-9019-c34c9574b0ee	01b74a5e-f95b-4086-a5b7-899a8de1f228	Unknown Function	Increased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
5db90d9e-d037-41fb-90d9-9908572ac7aa	01b74a5e-f95b-4086-a5b7-899a8de1f228	Unknown Function	Normal Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
1e7dbe7f-e8f6-4546-b95a-63b50af6d9da	01b74a5e-f95b-4086-a5b7-899a8de1f228	Unknown Function	Decreased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
0b3ebcc2-38d4-4962-bf46-1db659a2dfab	01b74a5e-f95b-4086-a5b7-899a8de1f228	Unknown Function	No Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
5216d712-be1a-4fac-aa55-950388d1bf6f	01b74a5e-f95b-4086-a5b7-899a8de1f228	Unknown Function	Unknown Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
ce51812c-311a-41d8-90de-b2dfdbbc6d13	01b74a5e-f95b-4086-a5b7-899a8de1f228	Uncertain Function	Unknown Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.842437+00	2024-05-23 21:17:24.842437+00
531bed1e-33ce-41b0-80e4-dc8d51ba7349	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	Normal Function	Normal Function	\N	\N	Low Sensitivity	5	t	2024-05-23 21:17:24.845033+00	2024-05-23 21:17:24.845033+00
c8cb78ce-9a59-42c4-b6bf-e60397ff91d5	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	Normal Function	Decreased Function	\N	\N	High Sensitivity	5	t	2024-05-23 21:17:24.845033+00	2024-05-23 21:17:24.845033+00
25c7c4eb-18f6-4b14-b3c4-856e72885dda	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	Decreased Function	Decreased Function	\N	\N	High Sensitivity	5	t	2024-05-23 21:17:24.845033+00	2024-05-23 21:17:24.845033+00
5a4cf3f9-2dbf-4df6-8e32-df20f6d714bc	e8d718e4-4831-496c-8448-16ad044c2e9d	Normal Function	Normal Function	2.00	2.00	Normal Metabolizer	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
45ed0d94-59bc-428a-84ec-df7d313af56b	e8d718e4-4831-496c-8448-16ad044c2e9d	Normal Function	Decreased Function	1.50	1.50	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
c165a04c-176f-41b1-9db3-390569edbf65	e8d718e4-4831-496c-8448-16ad044c2e9d	Normal Function	No Function	1.00	1.00	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
c5922ca7-8aa7-4db8-9cd5-45ecf04e281c	e8d718e4-4831-496c-8448-16ad044c2e9d	Decreased Function	Decreased Function	1.00	1.00	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
4ec97660-d15e-48e3-9a93-9e3ea3e24412	e8d718e4-4831-496c-8448-16ad044c2e9d	Decreased Function	No Function	0.50	0.50	Poor Metabolizer	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
3aa1a0ad-f676-4855-a3e8-c3771091a200	e8d718e4-4831-496c-8448-16ad044c2e9d	No Function	No Function	0.00	0.00	Poor Metabolizer	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
79c6ce3e-0b3f-49a0-b55f-89310e472c47	e8d718e4-4831-496c-8448-16ad044c2e9d	Uncertain Function	Normal Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
237f63e7-38a2-4cee-93f5-e7ada17214d8	e8d718e4-4831-496c-8448-16ad044c2e9d	Uncertain Function	Decreased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
3d32de8f-cdee-4ce3-b4ab-fa6cd8ef3c8d	e8d718e4-4831-496c-8448-16ad044c2e9d	Uncertain Function	No Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
f1618d40-6905-46ca-bb64-a14e9bfb6c59	e8d718e4-4831-496c-8448-16ad044c2e9d	Uncertain Function	Uncertain Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
a38edcb0-1a84-4907-b483-05529d4bb72e	e8d718e4-4831-496c-8448-16ad044c2e9d	Unknown Function	Normal Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
6d4993c7-33ee-4d81-8bd0-5a4e5204f3be	e8d718e4-4831-496c-8448-16ad044c2e9d	Unknown Function	Decreased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
32b84cbe-f79e-4718-a79c-ce6e578db2a7	e8d718e4-4831-496c-8448-16ad044c2e9d	Unknown Function	No Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
3e526cc4-252e-476f-a74e-6e5fb27d9e22	e8d718e4-4831-496c-8448-16ad044c2e9d	Unknown Function	Unknown Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
4e29d932-4391-4872-a836-0c9f6b7245bc	e8d718e4-4831-496c-8448-16ad044c2e9d	Uncertain Function	Unknown Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.847268+00	2024-05-23 21:17:24.847268+00
e2294a93-ed9e-45a5-b0ed-2c35927641c9	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Increased Function	Increased Function	\N	\N	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
a9ba3047-d372-498a-b2e6-3a4d410142bd	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Increased Function	Normal Function	\N	\N	Rapid Metabolizer	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
f035ad5d-807a-4058-a282-bede20389e5a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	No Function	No Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
e1b1a65f-bf0e-48a9-98e4-6b4be3baa241	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Normal Function	Normal Function	\N	\N	Normal Metabolizer	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
35317563-ba34-4e71-bcb2-f86db1f173b5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Decreased Function	No Function	\N	\N	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
730282bb-b8b5-4078-9dec-0c5c2ec4fcd1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Decreased Function	Normal Function	\N	\N	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
e8e3a05d-bf1f-490d-88b5-68b5fa3dd5bb	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Decreased Function	Increased Function	\N	\N	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
5e2f1bf4-5380-4527-ae89-541b6d0d8510	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Decreased Function	Decreased Function	\N	\N	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
52326fd9-2a41-45b9-9e0a-a07b51d52826	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Normal Function	No Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
93c5cf76-e3a1-4ebe-ad5c-acc93441cbf8	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Increased Function	No Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
2e3bb4a4-eaef-4d83-9342-92ae1684fbbc	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Uncertain Function	Uncertain Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
8931b9a0-19c0-47e9-b2b3-6ecba2617096	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Uncertain Function	Increased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
26ee3c1d-1a43-4662-bcdf-e37535d9f938	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Uncertain Function	Normal Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
ed144492-245a-4806-91c5-6fe80ff0a636	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Uncertain Function	Decreased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
9c4a27ee-54e5-478a-9336-ec11aa965c2f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	Uncertain Function	No Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.849723+00	2024-05-23 21:17:24.849723+00
a86e11a3-5e61-46e3-b2a1-dcdf0c219cbd	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	\N	\N	2.26	99.00	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
a9c8328b-2ea6-4355-b526-5919386b970a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	\N	\N	1.25	2.25	Normal Metabolizer	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
47084499-af21-41cc-843b-3f536a743ea7	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	\N	\N	0.01	1.24	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
52f43f25-9f40-48fa-86aa-f3380b02b02f	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	\N	\N	0.00	0.00	Poor Metabolizer	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
5fdd590d-e61f-4a59-bbac-2d5b0248c2bb	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	Unknown Function	Increased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
57852adc-f056-46a0-bace-e451e73e4801	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	Uncertain Function	Increased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
982f2f75-de7f-4bfe-a70f-8f902124d3db	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	Uncertain Function	Decreased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
d4782643-740e-4df2-8230-9dfc9d6c8203	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	Uncertain Function	Normal Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
5ab6c0b7-aff2-4616-8045-962137df541b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	Uncertain Function	No Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
6a3551d2-958c-4fdd-9e5a-60f09262c095	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	Uncertain Function	Uncertain Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
34d0ec25-f962-47e1-a6d7-17e6bd9b4c37	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	Unknown Function	Decreased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
1bcdfac9-91b3-4f10-9aec-43d5bb3c0a47	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	Unknown Function	Normal Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
925a9206-2d38-4c8d-90f0-f44ac3eccaf5	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	Unknown Function	No Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
8c1133a5-e4b7-4906-86a1-fb3d4af67d84	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	Unknown Function	Unknown Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
a26c9529-e7bd-4ae3-a090-6a9273bcbe46	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	Uncertain Function	Unknown Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.852333+00	2024-05-23 21:17:24.852333+00
74db90b3-f708-41a5-8ec3-bfbbae00461c	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	Unknown Function	Normal Function	\N	\N	Possible Intermediate Metabolizer	5	t	2024-05-23 21:17:24.855052+00	2024-05-23 21:17:24.855052+00
8cfbfe4e-6d7f-4115-89e6-bffa9854e528	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	No Function	No Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.855052+00	2024-05-23 21:17:24.855052+00
5f7d586c-a911-4140-be07-332f6d669842	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	Normal Function	Normal Function	\N	\N	Normal Metabolizer	5	t	2024-05-23 21:17:24.855052+00	2024-05-23 21:17:24.855052+00
ff03d97f-e18d-4b02-ad90-e032ee5d3b4e	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	Normal Function	No Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.855052+00	2024-05-23 21:17:24.855052+00
1fcc5ef9-16b0-4968-be0f-32dbde5d01d6	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	Unknown Function	No Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.855052+00	2024-05-23 21:17:24.855052+00
d14ef8ba-21e6-408f-b5df-a73d848c4de5	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	Unknown Function	Unknown Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.855052+00	2024-05-23 21:17:24.855052+00
cc42659b-47cc-45c6-9f2d-d5751ac2973b	93d511ec-e5fc-4832-9581-813842b25860	Possibly Decreased Function	Possibly Decreased Function	\N	\N	Reduced Function	5	t	2024-05-23 21:17:24.85743+00	2024-05-23 21:17:24.85743+00
8b316536-b524-4579-8be5-dc4f76a1fc0a	93d511ec-e5fc-4832-9581-813842b25860	Possibly Decreased Function	Normal Function	\N	\N	Reduced Function	5	t	2024-05-23 21:17:24.85743+00	2024-05-23 21:17:24.85743+00
47891ca6-fba2-405c-88f6-49154763f189	93d511ec-e5fc-4832-9581-813842b25860	Normal Function	Normal Function	\N	\N	Normal Function	5	t	2024-05-23 21:17:24.85743+00	2024-05-23 21:17:24.85743+00
a74981cb-9a29-4d7c-afcd-81dcbeaed6fa	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	Normal Function	Normal Function	2.00	2.00	Normal Metabolizer	5	t	2024-05-23 21:17:24.85963+00	2024-05-23 21:17:24.85963+00
b1e850b4-7896-4fdd-ae60-bed561d72797	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	Normal Function	Decreased Function	1.50	1.50	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.85963+00	2024-05-23 21:17:24.85963+00
64c55a3a-3350-4471-ad31-c375096021c3	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	Normal Function	No Function	1.00	1.00	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.85963+00	2024-05-23 21:17:24.85963+00
90edf8b3-a04a-490f-a5bf-01648da3158a	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	Decreased Function	Decreased Function	1.00	1.00	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.85963+00	2024-05-23 21:17:24.85963+00
7d1d9163-1437-4ad9-a621-33c6026a4a64	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	Decreased Function	No Function	0.50	0.50	Poor Metabolizer	5	t	2024-05-23 21:17:24.85963+00	2024-05-23 21:17:24.85963+00
34dfc6c2-10ba-4533-9c14-f41206ede23d	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	No Function	No Function	0.00	0.00	Poor Metabolizer	5	t	2024-05-23 21:17:24.85963+00	2024-05-23 21:17:24.85963+00
5c3c2546-e16b-4e58-b891-24600acb56d4	9be7b66e-d066-4d98-bc30-ec1511489398	Normal Function	Normal Function	\N	\N	Normal Function	5	t	2024-05-23 21:17:24.861881+00	2024-05-23 21:17:24.861881+00
8ba275f0-1b63-4e9d-add9-ab30cca03f40	9be7b66e-d066-4d98-bc30-ec1511489398	Normal Function	Decreased Function	\N	\N	Decreased or Normal Function	5	t	2024-05-23 21:17:24.861881+00	2024-05-23 21:17:24.861881+00
0c1b4e8c-85f0-43fa-b16f-55b1c9940f2a	9be7b66e-d066-4d98-bc30-ec1511489398	Normal Function	Poor Function	\N	\N	Decreased or Normal Function	5	t	2024-05-23 21:17:24.861881+00	2024-05-23 21:17:24.861881+00
4ec88efa-2d37-490d-9b22-aa1ff4c87488	9be7b66e-d066-4d98-bc30-ec1511489398	Decreased Function	Decreased Function	\N	\N	Decreased Function	5	t	2024-05-23 21:17:24.861881+00	2024-05-23 21:17:24.861881+00
7d086b08-28e9-4f52-bad5-9df4838a22b8	9be7b66e-d066-4d98-bc30-ec1511489398	Decreased Function	Poor Function	\N	\N	Decreased Function	5	t	2024-05-23 21:17:24.861881+00	2024-05-23 21:17:24.861881+00
67b1385c-c0ac-4352-9929-75049b73347f	9be7b66e-d066-4d98-bc30-ec1511489398	Poor Function	Poor Function	\N	\N	Poor Function	5	t	2024-05-23 21:17:24.861881+00	2024-05-23 21:17:24.861881+00
d687e545-3c5a-48aa-bbac-19ad99b8562a	daa86f03-86c6-4a8d-abab-476fcd043c9c	No Function	No Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.864193+00	2024-05-23 21:17:24.864193+00
3613b6e5-f6fd-4db0-840a-d48b57232c7c	daa86f03-86c6-4a8d-abab-476fcd043c9c	Normal Function	Normal Function	\N	\N	Normal Metabolizer	5	t	2024-05-23 21:17:24.864193+00	2024-05-23 21:17:24.864193+00
de81a170-ce3f-4af3-962f-43f453dfe0ef	daa86f03-86c6-4a8d-abab-476fcd043c9c	Normal Function	No Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.864193+00	2024-05-23 21:17:24.864193+00
5b55ce1b-750d-498a-a534-b3cd00c16c70	daa86f03-86c6-4a8d-abab-476fcd043c9c	No Function	Strongly Decreased Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.864193+00	2024-05-23 21:17:24.864193+00
30b1336b-9132-4c49-84f4-25cddf89d2c9	daa86f03-86c6-4a8d-abab-476fcd043c9c	Decreased Function	Strongly Decreased Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.864193+00	2024-05-23 21:17:24.864193+00
74849419-8103-4873-8d9d-433b60362e09	daa86f03-86c6-4a8d-abab-476fcd043c9c	Strongly Decreased Function	Strongly Decreased Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.864193+00	2024-05-23 21:17:24.864193+00
272596e7-1a73-4ceb-8a71-4f47afd3acd9	daa86f03-86c6-4a8d-abab-476fcd043c9c	Normal Function	Strongly Decreased Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.864193+00	2024-05-23 21:17:24.864193+00
57e0f392-a4a3-49ea-9120-8740c84713f3	daa86f03-86c6-4a8d-abab-476fcd043c9c	Normal Function	Decreased Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.864193+00	2024-05-23 21:17:24.864193+00
3d455389-000b-49ff-a95e-966323296e09	daa86f03-86c6-4a8d-abab-476fcd043c9c	No Function	Decreased Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.864193+00	2024-05-23 21:17:24.864193+00
97450ec1-0177-4847-927c-0a91821871bb	daa86f03-86c6-4a8d-abab-476fcd043c9c	Decreased Function	Decreased Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.864193+00	2024-05-23 21:17:24.864193+00
c44e7b93-2d0e-4fe7-9aa3-e34e55e296b8	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Uncertain Function	No Function	\N	\N	Possible Decreased Function	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
536cafa6-fcf6-40d2-9226-550bc67cff5c	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Unknown Function	No Function	\N	\N	Possible Decreased Function	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
f5fba387-4b87-4318-b448-9800c7c9c259	22fb682a-e57d-4ad2-8dc5-8159f28a9862	No Function	No Function	\N	\N	Poor Function	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
c2a0d594-47f2-4398-9c43-41889c814dd2	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Increased Function	Normal Function	\N	\N	Normal Function	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
c0e32eb8-0075-4201-848b-533210c0ca5e	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Normal Function	Normal Function	\N	\N	Normal Function	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
6a0e9c72-af65-442e-8700-44e77ea58b58	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Unknown Function	Unknown Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
e240e30d-75a5-4efc-b3de-757090d4729a	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Increased Function	Uncertain Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
78b9f9a0-c0bd-4676-82de-0c2e409f1c42	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Increased Function	Unknown Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
e0e51965-ab18-40a9-9ab0-eb72dda78c60	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Uncertain Function	Normal Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
92e8a881-9712-4dfe-8324-9a75c5fedc02	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Uncertain Function	Uncertain Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
b09982f0-0a85-4921-ba8a-30bbebf73633	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Unknown Function	Normal Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
e501665b-4121-4fcc-8994-b2f91ac47209	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Unknown Function	Uncertain Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
8deaa63f-fb89-4bec-8930-c37a1c6a1f71	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Increased Function	Increased Function	\N	\N	Increased Function	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
c29f3ad7-3c41-433e-989c-24fef96adaca	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Increased Function	No Function	\N	\N	Decreased Function	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
e71b387a-90e1-4f5e-afb8-70550cbc3f31	22fb682a-e57d-4ad2-8dc5-8159f28a9862	Normal Function	No Function	\N	\N	Decreased Function	5	t	2024-05-23 21:17:24.86676+00	2024-05-23 21:17:24.86676+00
f0b25d29-e251-4b9a-bccd-f69c75dbeee5	9ca2999f-1b56-4ee8-a254-2da4415cbb72	Uncertain Function	No Function	\N	\N	Possible Intermediate Metabolizer	5	t	2024-05-23 21:17:24.869293+00	2024-05-23 21:17:24.869293+00
1b22da35-0ef5-4a01-a887-87132d528567	9ca2999f-1b56-4ee8-a254-2da4415cbb72	Unknown Function	No Function	\N	\N	Possible Intermediate Metabolizer	5	t	2024-05-23 21:17:24.869293+00	2024-05-23 21:17:24.869293+00
5a866bfe-f25a-4a40-b489-ce7d8f8d83aa	9ca2999f-1b56-4ee8-a254-2da4415cbb72	No Function	No Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.869293+00	2024-05-23 21:17:24.869293+00
6c8f0f90-41da-422e-95b5-84842182b06d	9ca2999f-1b56-4ee8-a254-2da4415cbb72	Normal Function	Normal Function	\N	\N	Normal Metabolizer	5	t	2024-05-23 21:17:24.869293+00	2024-05-23 21:17:24.869293+00
f43de718-439e-4b9b-b20c-0a5054ca5bc6	9ca2999f-1b56-4ee8-a254-2da4415cbb72	Normal Function	No Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.869293+00	2024-05-23 21:17:24.869293+00
0ddbb97e-1ce2-4500-bc64-2e9006d0ef28	9ca2999f-1b56-4ee8-a254-2da4415cbb72	Uncertain Function	Normal Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.869293+00	2024-05-23 21:17:24.869293+00
543fee62-b2e9-4eb5-9314-d1d32df155aa	9ca2999f-1b56-4ee8-a254-2da4415cbb72	Uncertain Function	Uncertain Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.869293+00	2024-05-23 21:17:24.869293+00
1fa96987-11f2-4ae8-87da-b809fcbd49d6	9ca2999f-1b56-4ee8-a254-2da4415cbb72	Unknown Function	Normal Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.869293+00	2024-05-23 21:17:24.869293+00
1ba50348-39d4-4c98-b43b-76c82129d606	9ca2999f-1b56-4ee8-a254-2da4415cbb72	Unknown Function	Unknown Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.869293+00	2024-05-23 21:17:24.869293+00
2970ac50-b8ef-46b2-affe-dd655755cdab	9ca2999f-1b56-4ee8-a254-2da4415cbb72	Unknown Function	Uncertain Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.869293+00	2024-05-23 21:17:24.869293+00
e4ed1e8b-1046-4c86-8d25-659046e6bcff	58f41405-4198-4822-b10e-eb43cd77bc27	Decreased Function	Decreased Function	\N	\N	Poor Metabolizer	5	t	2024-05-23 21:17:24.87144+00	2024-05-23 21:17:24.87144+00
b8969d12-9ecc-49aa-a0f7-60fc1b834d5c	58f41405-4198-4822-b10e-eb43cd77bc27	Increased Function	Increased Function	\N	\N	Normal Metabolizer	5	t	2024-05-23 21:17:24.87144+00	2024-05-23 21:17:24.87144+00
ce3bffd5-cac1-489b-bd8e-827fe2721774	58f41405-4198-4822-b10e-eb43cd77bc27	Increased Function	Normal Function	\N	\N	Normal Metabolizer	5	t	2024-05-23 21:17:24.87144+00	2024-05-23 21:17:24.87144+00
198bd8de-86d0-463e-874a-6f1b258ac249	58f41405-4198-4822-b10e-eb43cd77bc27	Normal Function	Normal Function	\N	\N	Normal Metabolizer	5	t	2024-05-23 21:17:24.87144+00	2024-05-23 21:17:24.87144+00
51496c53-a34c-4d94-8347-5e9020dc0677	58f41405-4198-4822-b10e-eb43cd77bc27	Increased Function	Decreased Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.87144+00	2024-05-23 21:17:24.87144+00
9fab4a3a-a708-4eab-8807-28306e2bf6a3	58f41405-4198-4822-b10e-eb43cd77bc27	Normal Function	Decreased Function	\N	\N	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.87144+00	2024-05-23 21:17:24.87144+00
7fc5419c-ea70-4d21-b7ac-050dd55ea9d9	58f41405-4198-4822-b10e-eb43cd77bc27	Unknown Function	Increased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.87144+00	2024-05-23 21:17:24.87144+00
03f8a7b8-0a5d-48ef-a2d5-f542e4c9ab86	58f41405-4198-4822-b10e-eb43cd77bc27	Unknown Function	Normal Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.87144+00	2024-05-23 21:17:24.87144+00
cdb54592-315f-43f2-a583-4afcd34ab938	58f41405-4198-4822-b10e-eb43cd77bc27	Unknown Function	Decreased Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.87144+00	2024-05-23 21:17:24.87144+00
adac33dc-daca-4bb9-b412-8f124b690281	58f41405-4198-4822-b10e-eb43cd77bc27	Unknown Function	Unknown Function	\N	\N	Indeterminate	5	t	2024-05-23 21:17:24.87144+00	2024-05-23 21:17:24.87144+00
9d864659-56a6-4fc8-99cc-69b1ab067407	c0f1136b-6463-4304-a473-cae1f384fc8e	Normal Function	Normal Function	\N	\N	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.873652+00	2024-05-23 21:17:24.873652+00
3afd2913-703c-4d48-844b-614cc79b2eeb	c0f1136b-6463-4304-a473-cae1f384fc8e	Decreased Function	Normal Function	\N	\N	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.873652+00	2024-05-23 21:17:24.873652+00
7960117c-dbc4-4c85-94dc-c4e42a02aea5	c0f1136b-6463-4304-a473-cae1f384fc8e	Decreased Function	Decreased Function	\N	\N	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.873652+00	2024-05-23 21:17:24.873652+00
3966b0ed-a44a-4591-b244-1cffbdc0adf8	b31967bd-f6da-49d9-ba4e-cafdd7786116	Low Risk	Low Risk	\N	\N	Low Risk	5	t	2024-05-23 21:17:24.875705+00	2024-05-23 21:17:24.875705+00
cb90e845-4e40-4609-894c-7e3946252bc9	b31967bd-f6da-49d9-ba4e-cafdd7786116	High Risk	Low Risk	\N	\N	High Risk	5	t	2024-05-23 21:17:24.875705+00	2024-05-23 21:17:24.875705+00
220a428d-f5d4-4483-9494-04f832b9e97a	b31967bd-f6da-49d9-ba4e-cafdd7786116	High Risk	High Risk	\N	\N	High Risk	5	t	2024-05-23 21:17:24.875705+00	2024-05-23 21:17:24.875705+00
\.


--
-- Data for Name: master_version_phenotypes; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.master_version_phenotypes (id, master_version_id, phenotype_id, created_at, updated_at) FROM stdin;
1d9674a0-c155-4f38-8274-002b06995471	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	95d47b90-0673-4955-993f-68cd238753c1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
25ccc604-d8bc-4b6e-a8c7-249e1fc8409d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2376f313-d9c3-4372-b97d-0ad88f521159	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2d1931d5-a9d5-44d1-83da-bb5c92295b6d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1d3bbe93-7866-4e91-b5da-01557af46942	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
98db08f7-e4cd-4042-8c37-1c0d9cbf1d75	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5ba45b1b-e891-442d-955c-10ad6c6fe3f7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c7110c06-f828-4e7c-b15f-c09821acd247	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	11b4d234-d7d0-4e24-9201-858d6d428695	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e533b1e9-55e9-4660-92bd-0b396940f530	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	348e21d0-9f5a-44a9-a4cb-91d198fd73c6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5c8f311d-0dda-43cc-8a3e-295eafc70c5d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c2a4d9b2-4f70-4d6f-963e-c75cfcb08594	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7791398c-5750-4dd0-aeb0-68d33fd87474	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e00af374-bc00-4f9f-8bfd-206630894d88	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a1eec7d1-83b4-4be3-a6b4-51f9da590969	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9e5fd3f9-ad7d-4645-8960-b9c6cef20929	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
09408b31-2395-434e-8630-09c300829073	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a3a6a10c-2bc8-44ab-8390-866559b353ce	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
38f9d937-9971-4fc6-94c4-89b515563102	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	37ea209d-44ce-47e2-aa7f-d3349d841048	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c842d3da-6eec-49fe-8585-9cec2bba290d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0f9f9db1-c6d1-490f-b1fb-40396c8e5f01	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
867f4caf-cdae-4197-a56e-0cb970403d62	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e5cbd48d-3a0b-4147-bd97-556be3d0ef21	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cefbe8a7-e0ca-4bdf-92e6-fc5e84288a92	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9fb3540b-ad05-4ab6-a900-d830610cf690	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
05f66eee-6441-4ee3-86f4-f69db2dca78f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bd716812-23eb-40eb-a514-1ab55710485e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
da7a1923-ddf0-4efe-a7c6-350ec4ed9a3f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4b62fcbc-8c82-4b2c-bfec-236884010977	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
33b4786e-0a99-42fb-86d0-428896166be0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	65859f18-a329-4da5-ac4c-5553424c0699	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
247b4ef8-63a9-45a9-ae3d-031e36ba1080	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	90e98cb5-4959-485e-9630-e51ce2ba2cb6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3ccaba98-5d2f-4409-b219-247efbe04223	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	dae80686-478c-425f-9019-c34c9574b0ee	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
01c6f62c-c1b3-49a0-a345-6d4574c66369	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5db90d9e-d037-41fb-90d9-9908572ac7aa	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bcd11f5a-6da9-4b2b-ae9a-947242248080	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1e7dbe7f-e8f6-4546-b95a-63b50af6d9da	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1b9635e4-f7a1-44e8-b8bf-127399e65aae	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0b3ebcc2-38d4-4962-bf46-1db659a2dfab	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7e127063-59fe-4f84-b46a-c2d7cb3c4f3a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5216d712-be1a-4fac-aa55-950388d1bf6f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
16061c06-bbee-43be-b9c7-0fa853adca77	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ce51812c-311a-41d8-90de-b2dfdbbc6d13	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
68bb8086-7dd1-4d6b-ba6c-c1b80583b01f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	531bed1e-33ce-41b0-80e4-dc8d51ba7349	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
922e4c30-1c17-4c34-8231-ba67aeada437	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c8cb78ce-9a59-42c4-b6bf-e60397ff91d5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
08d5c559-6992-4718-8335-8fbf2ee84fd4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	25c7c4eb-18f6-4b14-b3c4-856e72885dda	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
73f1581e-c492-48ee-a407-784eb6cf8f54	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5a4cf3f9-2dbf-4df6-8e32-df20f6d714bc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
22869cc8-8b62-4f91-94af-c420cae45501	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	45ed0d94-59bc-428a-84ec-df7d313af56b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1ae48b68-b834-4353-967d-dc3d94753f8e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c165a04c-176f-41b1-9db3-390569edbf65	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
154ee1d0-33b1-495d-9367-4b239cc275e0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c5922ca7-8aa7-4db8-9cd5-45ecf04e281c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
eedfcb74-6fa9-494e-9520-710e49cd22c9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4ec97660-d15e-48e3-9a93-9e3ea3e24412	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c7afd2df-72dd-4912-a271-fa9239d849ed	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3aa1a0ad-f676-4855-a3e8-c3771091a200	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
85a73f28-d21d-45f4-87a0-9d9377fc4c62	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	79c6ce3e-0b3f-49a0-b55f-89310e472c47	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8027539b-acbd-4445-910e-b806b0ee5a1f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	237f63e7-38a2-4cee-93f5-e7ada17214d8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
90e3d6cf-faa2-4674-a0a7-d39ef81fa626	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3d32de8f-cdee-4ce3-b4ab-fa6cd8ef3c8d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dbf15f71-09bf-4852-a52b-6c77422253dd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f1618d40-6905-46ca-bb64-a14e9bfb6c59	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0bbec3ff-632e-470e-8e3c-96a89bf6dd1f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a38edcb0-1a84-4907-b483-05529d4bb72e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e2c420c0-4915-49c4-9d96-1b2176ad039c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6d4993c7-33ee-4d81-8bd0-5a4e5204f3be	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f683cdaa-bed8-47bc-9057-253256ef5ab1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	32b84cbe-f79e-4718-a79c-ce6e578db2a7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a3fed9cc-88eb-48ee-9d90-8821b745b3b8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3e526cc4-252e-476f-a74e-6e5fb27d9e22	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
01f956de-ee2e-4090-b69d-ed65dadc9277	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4e29d932-4391-4872-a836-0c9f6b7245bc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b8739894-8e3d-434e-abc5-06644f54458c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e2294a93-ed9e-45a5-b0ed-2c35927641c9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
30597ad8-8848-4307-a440-7f5bf3d17ad1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a9ba3047-d372-498a-b2e6-3a4d410142bd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2c2f5de5-a9b9-46eb-9a31-afcadfd71fbf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f035ad5d-807a-4058-a282-bede20389e5a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8df9b30f-425b-40c2-8303-8c7b0c3510c8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e1b1a65f-bf0e-48a9-98e4-6b4be3baa241	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
831bb022-bfaf-418b-bbb5-676a41c81a57	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	35317563-ba34-4e71-bcb2-f86db1f173b5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f1064ac9-cf52-455e-9896-8f3d51016ec5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	730282bb-b8b5-4078-9dec-0c5c2ec4fcd1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
36a6a5fd-aff8-4284-86de-a086e156970d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e8e3a05d-bf1f-490d-88b5-68b5fa3dd5bb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
62a441f9-6a14-4f22-8b79-90f12ca59314	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5e2f1bf4-5380-4527-ae89-541b6d0d8510	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
449bcc10-1a8c-49a3-a322-ea8b5fcc5c10	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	52326fd9-2a41-45b9-9e0a-a07b51d52826	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fcafb15b-c41f-4b7a-a045-b788d986b868	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	93c5cf76-e3a1-4ebe-ad5c-acc93441cbf8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8f397222-4851-4c2b-8669-e70cba69be21	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2e3bb4a4-eaef-4d83-9342-92ae1684fbbc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3086d7a7-5836-447b-9f5d-0a32d4310b0c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8931b9a0-19c0-47e9-b2b3-6ecba2617096	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c9c07cec-796d-4bd5-acc5-b42e12cc9657	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	26ee3c1d-1a43-4662-bcdf-e37535d9f938	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
22436b25-6a0e-4bea-8bc3-1190f165ae44	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ed144492-245a-4806-91c5-6fe80ff0a636	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6f4a554e-98ef-4082-8a4f-02565c228439	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9c4a27ee-54e5-478a-9336-ec11aa965c2f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
03128eec-6fc0-40d2-848b-731fadd49234	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a86e11a3-5e61-46e3-b2a1-dcdf0c219cbd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
53e948bd-6fcd-4316-b6cd-61f9b7fb4950	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a9c8328b-2ea6-4355-b526-5919386b970a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4227fb00-707c-45fe-ab67-d5bcc97edf3d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	47084499-af21-41cc-843b-3f536a743ea7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
882fbe64-f839-4c75-b782-e2806d3797d3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	52f43f25-9f40-48fa-86aa-f3380b02b02f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3d7d3204-1f44-4403-91b1-a01c78dd4091	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5fdd590d-e61f-4a59-bbac-2d5b0248c2bb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
165e81c2-289e-4bed-9bbc-9a95d51f9167	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	57852adc-f056-46a0-bace-e451e73e4801	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6ecd17b7-94b1-4b70-aaa8-a40fead0dc2a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	982f2f75-de7f-4bfe-a70f-8f902124d3db	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
00cfe726-6773-4e8b-bcb0-eeb553274b62	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d4782643-740e-4df2-8230-9dfc9d6c8203	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e252765e-9611-4e97-b159-6b301ef37475	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5ab6c0b7-aff2-4616-8045-962137df541b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
68cc8af5-8559-4bb5-9a46-07d01f060b41	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6a3551d2-958c-4fdd-9e5a-60f09262c095	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8271a22d-f0bd-4cba-bb32-c8acefa14a20	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	34d0ec25-f962-47e1-a6d7-17e6bd9b4c37	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c0908348-4a3a-4e42-9b2d-1755d26110bd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1bcdfac9-91b3-4f10-9aec-43d5bb3c0a47	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a1b7898e-b742-4987-9d12-26bb407a93f8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	925a9206-2d38-4c8d-90f0-f44ac3eccaf5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
383cae3e-cb20-48dc-9225-da4603c779ab	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8c1133a5-e4b7-4906-86a1-fb3d4af67d84	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3b1cc5af-36ff-470c-88a7-79680b91fb83	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a26c9529-e7bd-4ae3-a090-6a9273bcbe46	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
31bfd17f-6f70-4721-a814-ff13e1986f2b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	74db90b3-f708-41a5-8ec3-bfbbae00461c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
73df578a-9adb-4ae8-b22f-54e9a0c7e012	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8cfbfe4e-6d7f-4115-89e6-bffa9854e528	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6b8f934e-4afd-4d90-8766-eb99b6990159	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5f7d586c-a911-4140-be07-332f6d669842	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1f4611cd-cc34-4b6a-ba47-3155ca2ac114	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ff03d97f-e18d-4b02-ad90-e032ee5d3b4e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1a1ce0ed-c8f2-4924-b086-f9dab70f72fd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1fcc5ef9-16b0-4968-be0f-32dbde5d01d6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
77c9db79-d709-4455-9736-0c27f6e19f9c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d14ef8ba-21e6-408f-b5df-a73d848c4de5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
70bc0a41-d66f-43a1-a80d-7109750c7a45	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cc42659b-47cc-45c6-9f2d-d5751ac2973b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a197f45d-82dd-4992-9e02-65903381a7ce	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8b316536-b524-4579-8be5-dc4f76a1fc0a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ec78fa5f-404f-4291-8374-26e0943903c3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	47891ca6-fba2-405c-88f6-49154763f189	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9ee9e489-8260-4b6a-8a7e-bef0c16c752e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a74981cb-9a29-4d7c-afcd-81dcbeaed6fa	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ccd562bd-dd0c-49b8-ac54-10d036ee9311	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b1e850b4-7896-4fdd-ae60-bed561d72797	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
860680c8-30f2-417f-a1e2-89796e865061	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	64c55a3a-3350-4471-ad31-c375096021c3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b8b1da47-a735-4397-9e31-110f6aa7245b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	90edf8b3-a04a-490f-a5bf-01648da3158a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
95e4d067-00c3-4c47-9765-893d841a7ef7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7d1d9163-1437-4ad9-a621-33c6026a4a64	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7c34ef03-85cc-4988-9b7b-b2bc69a56dcf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	34dfc6c2-10ba-4533-9c14-f41206ede23d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3508edef-68ca-4fb6-8bba-142dcc310460	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5c3c2546-e16b-4e58-b891-24600acb56d4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fb4a8791-db00-41c7-be2c-aaa79d9c0578	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8ba275f0-1b63-4e9d-add9-ab30cca03f40	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5d4155c5-8dc3-4e10-aee6-8ed93ed10353	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0c1b4e8c-85f0-43fa-b16f-55b1c9940f2a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a675ccbf-3080-4476-9a47-e5a9d6b7e07e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4ec88efa-2d37-490d-9b22-aa1ff4c87488	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ed9808d2-8837-4c8a-a4e0-d9c2f5c21c44	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7d086b08-28e9-4f52-bad5-9df4838a22b8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c4255561-f276-40b1-a5a6-a33b1a0da351	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	67b1385c-c0ac-4352-9929-75049b73347f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
002a15da-b98e-4510-9ec5-042983b32ba9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d687e545-3c5a-48aa-bbac-19ad99b8562a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e8ec9027-d201-4fe9-ad6a-7b6c07638d86	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3613b6e5-f6fd-4db0-840a-d48b57232c7c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3f131a7c-64b2-44f4-b7ca-2a1a496a2f22	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	de81a170-ce3f-4af3-962f-43f453dfe0ef	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4b0da84c-462e-4074-8fff-dc8b74ccfb3a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5b55ce1b-750d-498a-a534-b3cd00c16c70	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
435865f1-fb7a-4fb9-a8b7-cccce3bc97a5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	30b1336b-9132-4c49-84f4-25cddf89d2c9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
84525ec7-f657-47b3-b09f-53f501cf513d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	74849419-8103-4873-8d9d-433b60362e09	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
051d6c8a-9d17-4b74-ba52-3f14e062adbc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	272596e7-1a73-4ceb-8a71-4f47afd3acd9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cba4aa0f-16fa-460e-8cbf-84f17bbdbc36	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	57e0f392-a4a3-49ea-9120-8740c84713f3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d5b63343-2a3f-497a-8f2c-d400ba58622f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3d455389-000b-49ff-a95e-966323296e09	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b84da85f-271f-4855-8933-bcf0cf374cd7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	97450ec1-0177-4847-927c-0a91821871bb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c3d9f1eb-f82f-4a22-a73f-c36d72b49c60	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c44e7b93-2d0e-4fe7-9aa3-e34e55e296b8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8406ec02-f468-4f5d-9e02-efa8f7f76880	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	536cafa6-fcf6-40d2-9226-550bc67cff5c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b57c4e6d-e9ef-4e03-807d-2cd41772e406	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f5fba387-4b87-4318-b448-9800c7c9c259	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b1763c48-6f4b-4931-ad93-06ab3a9eb6dd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c2a0d594-47f2-4398-9c43-41889c814dd2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
32bf036c-8c8d-42c4-894a-7f9c0f47e76c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c0e32eb8-0075-4201-848b-533210c0ca5e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3f898f18-806b-41ff-b5ce-1ec312c8609b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6a0e9c72-af65-442e-8700-44e77ea58b58	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f20bfe9f-b2a9-47cd-81a2-233c50e5178e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e240e30d-75a5-4efc-b3de-757090d4729a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1aaabb1a-c620-488d-b963-02f16679d479	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	78b9f9a0-c0bd-4676-82de-0c2e409f1c42	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ea8ca15e-00c4-4039-8f7b-01c69bf5e8f8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e0e51965-ab18-40a9-9ab0-eb72dda78c60	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f1949728-7860-4f11-892e-2ced62326dff	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	92e8a881-9712-4dfe-8324-9a75c5fedc02	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4c228cfd-ef12-4a39-adfb-9adae1ba27c1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b09982f0-0a85-4921-ba8a-30bbebf73633	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
74ad45c0-b8d9-4238-bf1a-ac71dc33c5dc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e501665b-4121-4fcc-8994-b2f91ac47209	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a49633ae-0a5b-47dd-8a8e-d275db44551c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8deaa63f-fb89-4bec-8930-c37a1c6a1f71	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b8476dfe-c7a2-42ec-8eff-acb6e72186f3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c29f3ad7-3c41-433e-989c-24fef96adaca	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3e67f9f4-2c90-411e-b5f0-14a73dc91cd4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e71b387a-90e1-4f5e-afb8-70550cbc3f31	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c9829f83-deda-4412-bb10-c1e827e62f69	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f0b25d29-e251-4b9a-bccd-f69c75dbeee5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b007a370-9a59-4a54-ad52-f000ccc10994	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1b22da35-0ef5-4a01-a887-87132d528567	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b2b13f62-e2ed-4ffb-ace7-c6133b807c34	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5a866bfe-f25a-4a40-b489-ce7d8f8d83aa	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4c1542c6-a5e5-42a1-a0f8-fa5fbf5981d4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6c8f0f90-41da-422e-95b5-84842182b06d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f245cd8f-ed4e-432f-a0a3-5b683dbcdaa9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f43de718-439e-4b9b-b20c-0a5054ca5bc6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8e31cd5e-fb73-4ff3-bd01-0bc167d0bac7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0ddbb97e-1ce2-4500-bc64-2e9006d0ef28	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a82485f5-a92c-4318-8697-1f2057d2b0e6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	543fee62-b2e9-4eb5-9314-d1d32df155aa	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
167f98de-13da-489a-842d-4ef1c2f66041	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1fa96987-11f2-4ae8-87da-b809fcbd49d6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
85f1f880-b179-45fe-85ce-56dd449db59c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1ba50348-39d4-4c98-b43b-76c82129d606	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8a50a035-c5bb-4709-95aa-85fd271ed150	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2970ac50-b8ef-46b2-affe-dd655755cdab	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c1c46cdc-97d8-455a-9234-5ad8706506e3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e4ed1e8b-1046-4c86-8d25-659046e6bcff	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1f93414d-b2fc-44d8-abaf-1db87cec5ef3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b8969d12-9ecc-49aa-a0f7-60fc1b834d5c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f31bdb70-fa5f-4ea3-8cf1-5aaa112f31d9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ce3bffd5-cac1-489b-bd8e-827fe2721774	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8f04bb8a-1535-4756-ac7d-507ecccd3ffa	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	198bd8de-86d0-463e-874a-6f1b258ac249	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
be331516-eb77-483a-bee9-1a1c87a31790	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	51496c53-a34c-4d94-8347-5e9020dc0677	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f8509dc5-f5a9-41fb-b9dc-3f5308f90bfc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9fab4a3a-a708-4eab-8807-28306e2bf6a3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7e4c8558-7787-4004-931d-b8de2712965b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7fc5419c-ea70-4d21-b7ac-050dd55ea9d9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a93b4322-dc25-4808-a4ed-64073564485a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	03f8a7b8-0a5d-48ef-a2d5-f542e4c9ab86	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f88194de-8770-4663-a293-2d4781333bc2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cdb54592-315f-43f2-a583-4afcd34ab938	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
80c02aa2-f4c0-4109-8704-a0d0a86ee99c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	adac33dc-daca-4bb9-b412-8f124b690281	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a7e95ff8-e66f-4641-87ee-72e57f082c1e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9d864659-56a6-4fc8-99cc-69b1ab067407	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d18bb1d0-4246-4098-8999-05e6c5dbde1d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3afd2913-703c-4d48-844b-614cc79b2eeb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
adc11d27-c446-46c6-94f3-7e0a28d9cfa3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7960117c-dbc4-4c85-94dc-c4e42a02aea5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ac5fb5fc-fe20-48e1-8f3a-21966a3708a2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3966b0ed-a44a-4591-b244-1cffbdc0adf8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
28ef2814-1b88-43ba-a026-79bfaeac3ff4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cb90e845-4e40-4609-894c-7e3946252bc9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
222d5677-3631-4cbf-b87f-5a98546ff405	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	220a428d-f5d4-4483-9494-04f832b9e97a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5b7ad6f2-6e00-4269-bf9a-df5c9f6367ea	cd112fe5-0c94-42f4-b221-78aa67a88c28	95d47b90-0673-4955-993f-68cd238753c1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f478e51f-ce2e-44e6-99e3-14fdc866338d	cd112fe5-0c94-42f4-b221-78aa67a88c28	2376f313-d9c3-4372-b97d-0ad88f521159	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
84e87424-2166-4a08-b41a-42aabc28d574	cd112fe5-0c94-42f4-b221-78aa67a88c28	1d3bbe93-7866-4e91-b5da-01557af46942	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
33befe6d-fec8-4ee3-862f-81ab5d3fd17e	cd112fe5-0c94-42f4-b221-78aa67a88c28	5ba45b1b-e891-442d-955c-10ad6c6fe3f7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c1d35673-94f2-4a00-a239-05e509829fd4	cd112fe5-0c94-42f4-b221-78aa67a88c28	11b4d234-d7d0-4e24-9201-858d6d428695	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6c352163-7c07-473a-927f-d929e62861fe	cd112fe5-0c94-42f4-b221-78aa67a88c28	348e21d0-9f5a-44a9-a4cb-91d198fd73c6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0e7f784a-31c8-4350-9fe3-8236f5d9000c	cd112fe5-0c94-42f4-b221-78aa67a88c28	c2a4d9b2-4f70-4d6f-963e-c75cfcb08594	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e55db9f8-6ec1-4b39-a30a-a6439c300aad	cd112fe5-0c94-42f4-b221-78aa67a88c28	e00af374-bc00-4f9f-8bfd-206630894d88	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3b30fe39-bad0-429d-840a-b61b93c40338	cd112fe5-0c94-42f4-b221-78aa67a88c28	9e5fd3f9-ad7d-4645-8960-b9c6cef20929	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
86d54b71-b2ea-446b-b183-2e78b2fa4ce5	cd112fe5-0c94-42f4-b221-78aa67a88c28	a3a6a10c-2bc8-44ab-8390-866559b353ce	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6ca5c1a8-2666-4f6e-8e91-238d096b9b75	cd112fe5-0c94-42f4-b221-78aa67a88c28	37ea209d-44ce-47e2-aa7f-d3349d841048	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
aa47f308-c30d-4649-ab99-c14d1fb44e4e	cd112fe5-0c94-42f4-b221-78aa67a88c28	0f9f9db1-c6d1-490f-b1fb-40396c8e5f01	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c420137a-43ff-4649-923b-2f6de5e78b8e	cd112fe5-0c94-42f4-b221-78aa67a88c28	e5cbd48d-3a0b-4147-bd97-556be3d0ef21	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2fc9b38b-b2ed-4366-b91e-cf0e04b1cba4	cd112fe5-0c94-42f4-b221-78aa67a88c28	9fb3540b-ad05-4ab6-a900-d830610cf690	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cee137aa-a4cf-4337-b525-4d3f992de18c	cd112fe5-0c94-42f4-b221-78aa67a88c28	bd716812-23eb-40eb-a514-1ab55710485e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cf658984-1ee5-4632-b058-7f8b0ed9e01c	cd112fe5-0c94-42f4-b221-78aa67a88c28	4b62fcbc-8c82-4b2c-bfec-236884010977	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1f4bae19-5a05-4305-9029-76116fbe68f7	cd112fe5-0c94-42f4-b221-78aa67a88c28	65859f18-a329-4da5-ac4c-5553424c0699	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d5ddab6d-d04a-4f81-b73b-35dd0fc52ae0	cd112fe5-0c94-42f4-b221-78aa67a88c28	90e98cb5-4959-485e-9630-e51ce2ba2cb6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e0c9caf7-4609-4981-8cb8-b974b2c3ff9a	cd112fe5-0c94-42f4-b221-78aa67a88c28	dae80686-478c-425f-9019-c34c9574b0ee	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9f55609b-e014-42d6-a913-cff96cc77f48	cd112fe5-0c94-42f4-b221-78aa67a88c28	5db90d9e-d037-41fb-90d9-9908572ac7aa	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
76f21169-f7a8-43ba-a0f6-e08f5c7e2dc1	cd112fe5-0c94-42f4-b221-78aa67a88c28	1e7dbe7f-e8f6-4546-b95a-63b50af6d9da	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3ea3c778-252a-4999-9ca3-212f4bc319a8	cd112fe5-0c94-42f4-b221-78aa67a88c28	0b3ebcc2-38d4-4962-bf46-1db659a2dfab	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
985aa6de-be8f-4bc9-9a46-0afd63f26e10	cd112fe5-0c94-42f4-b221-78aa67a88c28	5216d712-be1a-4fac-aa55-950388d1bf6f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0f271339-08e9-47d7-ba6a-c1c9a0af3f39	cd112fe5-0c94-42f4-b221-78aa67a88c28	ce51812c-311a-41d8-90de-b2dfdbbc6d13	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
76c5a6d6-7324-4ebc-b777-8ce4e299b74b	cd112fe5-0c94-42f4-b221-78aa67a88c28	531bed1e-33ce-41b0-80e4-dc8d51ba7349	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c1b08eb9-8163-40bb-a8f0-1468398a2041	cd112fe5-0c94-42f4-b221-78aa67a88c28	c8cb78ce-9a59-42c4-b6bf-e60397ff91d5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2d569f47-3664-4307-9472-34b8bde86e58	cd112fe5-0c94-42f4-b221-78aa67a88c28	25c7c4eb-18f6-4b14-b3c4-856e72885dda	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f0d9f25a-8948-4a8f-95dc-30c50116f00b	cd112fe5-0c94-42f4-b221-78aa67a88c28	5a4cf3f9-2dbf-4df6-8e32-df20f6d714bc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ea7fb3ed-cfc8-4012-b70f-1cec8e45bcb5	cd112fe5-0c94-42f4-b221-78aa67a88c28	45ed0d94-59bc-428a-84ec-df7d313af56b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
43e99c20-0c5e-4c2c-9842-7aa606df24a8	cd112fe5-0c94-42f4-b221-78aa67a88c28	c165a04c-176f-41b1-9db3-390569edbf65	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
902f0381-ea42-4f5f-93c2-84f7e0fa4125	cd112fe5-0c94-42f4-b221-78aa67a88c28	c5922ca7-8aa7-4db8-9cd5-45ecf04e281c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d4942008-d511-42e1-9324-c0325852ce19	cd112fe5-0c94-42f4-b221-78aa67a88c28	4ec97660-d15e-48e3-9a93-9e3ea3e24412	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
74ecd728-540d-4d22-b3f6-2941c99599b1	cd112fe5-0c94-42f4-b221-78aa67a88c28	3aa1a0ad-f676-4855-a3e8-c3771091a200	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a329a646-4883-4cd0-a0fc-bf00051930f3	cd112fe5-0c94-42f4-b221-78aa67a88c28	79c6ce3e-0b3f-49a0-b55f-89310e472c47	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ade9ff35-82bd-4d8e-92ef-220c119ae02e	cd112fe5-0c94-42f4-b221-78aa67a88c28	237f63e7-38a2-4cee-93f5-e7ada17214d8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a6da763f-c6ac-4c9a-9cbf-3c982229d324	cd112fe5-0c94-42f4-b221-78aa67a88c28	3d32de8f-cdee-4ce3-b4ab-fa6cd8ef3c8d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ecf8f57b-df5c-4212-8340-b32d8d50c509	cd112fe5-0c94-42f4-b221-78aa67a88c28	f1618d40-6905-46ca-bb64-a14e9bfb6c59	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
62aa78b3-259c-48d3-82a1-ceae5ce94289	cd112fe5-0c94-42f4-b221-78aa67a88c28	a38edcb0-1a84-4907-b483-05529d4bb72e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
93da167e-e944-4430-9a09-da5651ba46e5	cd112fe5-0c94-42f4-b221-78aa67a88c28	6d4993c7-33ee-4d81-8bd0-5a4e5204f3be	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8de60d89-6a20-4151-95a6-4fd55cf6b019	cd112fe5-0c94-42f4-b221-78aa67a88c28	32b84cbe-f79e-4718-a79c-ce6e578db2a7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a61e7ad5-3a66-4a42-982c-77298df3dbfa	cd112fe5-0c94-42f4-b221-78aa67a88c28	3e526cc4-252e-476f-a74e-6e5fb27d9e22	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
276eab6b-0bd5-4ddb-8333-4002aba24df0	cd112fe5-0c94-42f4-b221-78aa67a88c28	4e29d932-4391-4872-a836-0c9f6b7245bc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
232b2ef8-ff8d-4fc2-9c64-2bded94b8b74	cd112fe5-0c94-42f4-b221-78aa67a88c28	e2294a93-ed9e-45a5-b0ed-2c35927641c9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2655cb8e-3c2e-4b25-b872-a408104fa373	cd112fe5-0c94-42f4-b221-78aa67a88c28	a9ba3047-d372-498a-b2e6-3a4d410142bd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d66c5e63-bba5-412c-9dfa-ed58841353e4	cd112fe5-0c94-42f4-b221-78aa67a88c28	f035ad5d-807a-4058-a282-bede20389e5a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1975b09c-113e-4708-b20d-3a2477673266	cd112fe5-0c94-42f4-b221-78aa67a88c28	e1b1a65f-bf0e-48a9-98e4-6b4be3baa241	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
407e2911-a1fe-4f7f-b509-1b8b167d5551	cd112fe5-0c94-42f4-b221-78aa67a88c28	35317563-ba34-4e71-bcb2-f86db1f173b5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
339d5971-73ec-4162-be08-9e77c6bf90ac	cd112fe5-0c94-42f4-b221-78aa67a88c28	730282bb-b8b5-4078-9dec-0c5c2ec4fcd1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7677c3fb-c644-4370-bb14-07b8e5526a0e	cd112fe5-0c94-42f4-b221-78aa67a88c28	e8e3a05d-bf1f-490d-88b5-68b5fa3dd5bb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
221f0c9b-49c0-46cc-9906-f2037d1443a8	cd112fe5-0c94-42f4-b221-78aa67a88c28	5e2f1bf4-5380-4527-ae89-541b6d0d8510	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9ad6b56a-3701-4a7b-83ef-54c10b2ba180	cd112fe5-0c94-42f4-b221-78aa67a88c28	52326fd9-2a41-45b9-9e0a-a07b51d52826	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8b617686-40f7-482f-b570-00687c595c9f	cd112fe5-0c94-42f4-b221-78aa67a88c28	93c5cf76-e3a1-4ebe-ad5c-acc93441cbf8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
aea2f621-0166-4245-a5f0-1bb337fb13a2	cd112fe5-0c94-42f4-b221-78aa67a88c28	2e3bb4a4-eaef-4d83-9342-92ae1684fbbc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a995fe91-af5f-4448-93c5-d588d9b94db8	cd112fe5-0c94-42f4-b221-78aa67a88c28	8931b9a0-19c0-47e9-b2b3-6ecba2617096	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2b1c90e5-e42c-475a-b7b7-3584277b784a	cd112fe5-0c94-42f4-b221-78aa67a88c28	26ee3c1d-1a43-4662-bcdf-e37535d9f938	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c25b9a55-86cb-4282-a553-5cda130309b9	cd112fe5-0c94-42f4-b221-78aa67a88c28	ed144492-245a-4806-91c5-6fe80ff0a636	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4f69b7fb-ffb9-4795-8f42-e9b764ceda23	cd112fe5-0c94-42f4-b221-78aa67a88c28	9c4a27ee-54e5-478a-9336-ec11aa965c2f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6c491b89-66fd-4a70-94a3-e8dae5bb5e05	cd112fe5-0c94-42f4-b221-78aa67a88c28	a86e11a3-5e61-46e3-b2a1-dcdf0c219cbd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
332fe8d1-4b5f-45c0-b1bf-1843d4f29a29	cd112fe5-0c94-42f4-b221-78aa67a88c28	a9c8328b-2ea6-4355-b526-5919386b970a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c929b21a-2956-4e18-8c52-683a9758474c	cd112fe5-0c94-42f4-b221-78aa67a88c28	47084499-af21-41cc-843b-3f536a743ea7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
70e363a5-1145-494b-a0d4-5b41cfa4681d	cd112fe5-0c94-42f4-b221-78aa67a88c28	52f43f25-9f40-48fa-86aa-f3380b02b02f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
14fe154a-23dc-4ac9-baf8-48ac76ea2ee8	cd112fe5-0c94-42f4-b221-78aa67a88c28	5fdd590d-e61f-4a59-bbac-2d5b0248c2bb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a7e2c162-4a55-426a-9c03-75d96afe4ab1	cd112fe5-0c94-42f4-b221-78aa67a88c28	57852adc-f056-46a0-bace-e451e73e4801	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fe7a6e52-5ccf-47d3-9b1a-e7a24891b15f	cd112fe5-0c94-42f4-b221-78aa67a88c28	982f2f75-de7f-4bfe-a70f-8f902124d3db	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b4968adb-3500-4d25-9082-547e8ea8aab4	cd112fe5-0c94-42f4-b221-78aa67a88c28	d4782643-740e-4df2-8230-9dfc9d6c8203	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0c0f71a3-cb5f-41a3-89fd-b40136e0c0cb	cd112fe5-0c94-42f4-b221-78aa67a88c28	5ab6c0b7-aff2-4616-8045-962137df541b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2711e05d-c837-48b3-8c10-47d0ac419d9e	cd112fe5-0c94-42f4-b221-78aa67a88c28	6a3551d2-958c-4fdd-9e5a-60f09262c095	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
083956bf-0af2-4e5c-95ed-48cae5071735	cd112fe5-0c94-42f4-b221-78aa67a88c28	34d0ec25-f962-47e1-a6d7-17e6bd9b4c37	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2cdaf8e1-f5b7-4689-b456-4997230280be	cd112fe5-0c94-42f4-b221-78aa67a88c28	1bcdfac9-91b3-4f10-9aec-43d5bb3c0a47	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
af0a0bf7-bc84-4361-a2db-c0367f964a80	cd112fe5-0c94-42f4-b221-78aa67a88c28	925a9206-2d38-4c8d-90f0-f44ac3eccaf5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9f9bc60a-34dc-4e61-8898-31b37ce5d0a1	cd112fe5-0c94-42f4-b221-78aa67a88c28	8c1133a5-e4b7-4906-86a1-fb3d4af67d84	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9d70900c-2188-4c0b-839a-8c114bee84e7	cd112fe5-0c94-42f4-b221-78aa67a88c28	a26c9529-e7bd-4ae3-a090-6a9273bcbe46	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7103fe3b-1e2a-4f1c-9142-805b729cf9cf	cd112fe5-0c94-42f4-b221-78aa67a88c28	74db90b3-f708-41a5-8ec3-bfbbae00461c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b71d291f-432d-4478-8516-11c8752c5175	cd112fe5-0c94-42f4-b221-78aa67a88c28	8cfbfe4e-6d7f-4115-89e6-bffa9854e528	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d3863b4b-7caf-4890-8f7b-bb0e3873ee01	cd112fe5-0c94-42f4-b221-78aa67a88c28	5f7d586c-a911-4140-be07-332f6d669842	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fe5f946b-03ea-4a8a-847a-c67c6520a1fa	cd112fe5-0c94-42f4-b221-78aa67a88c28	ff03d97f-e18d-4b02-ad90-e032ee5d3b4e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ec359c05-d04b-46e5-aa86-07285bfd0e2b	cd112fe5-0c94-42f4-b221-78aa67a88c28	1fcc5ef9-16b0-4968-be0f-32dbde5d01d6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bc470d89-12c1-4dda-8be4-1eb40715c972	cd112fe5-0c94-42f4-b221-78aa67a88c28	d14ef8ba-21e6-408f-b5df-a73d848c4de5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
68a26199-c9a2-4f41-9b17-1b5de56163cc	cd112fe5-0c94-42f4-b221-78aa67a88c28	cc42659b-47cc-45c6-9f2d-d5751ac2973b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4b1c9388-5033-43c4-8f1d-e89f06d18363	cd112fe5-0c94-42f4-b221-78aa67a88c28	8b316536-b524-4579-8be5-dc4f76a1fc0a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
339b9d45-6f12-462a-a5a6-35d9ddfdfd46	cd112fe5-0c94-42f4-b221-78aa67a88c28	47891ca6-fba2-405c-88f6-49154763f189	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7c52be9f-6886-42b9-a7c6-46e49cca44b9	cd112fe5-0c94-42f4-b221-78aa67a88c28	a74981cb-9a29-4d7c-afcd-81dcbeaed6fa	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fbef8473-5eaa-424e-8070-5535dc2e4c81	cd112fe5-0c94-42f4-b221-78aa67a88c28	b1e850b4-7896-4fdd-ae60-bed561d72797	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
388caaf1-57cb-411d-8596-fc02624928e4	cd112fe5-0c94-42f4-b221-78aa67a88c28	64c55a3a-3350-4471-ad31-c375096021c3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7214cc31-aa2b-4c36-ab45-5baa2d38643d	cd112fe5-0c94-42f4-b221-78aa67a88c28	90edf8b3-a04a-490f-a5bf-01648da3158a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
370de6e6-6ac2-4b64-be5d-fadc0052a2d5	cd112fe5-0c94-42f4-b221-78aa67a88c28	7d1d9163-1437-4ad9-a621-33c6026a4a64	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
eaaadabf-8d31-4c93-8e72-9b8858a39206	cd112fe5-0c94-42f4-b221-78aa67a88c28	34dfc6c2-10ba-4533-9c14-f41206ede23d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
dcef4cb7-b4a2-45d7-9d94-ff1954e6155b	cd112fe5-0c94-42f4-b221-78aa67a88c28	5c3c2546-e16b-4e58-b891-24600acb56d4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a98d0f21-79ba-44b2-befd-4249c0cb19c8	cd112fe5-0c94-42f4-b221-78aa67a88c28	8ba275f0-1b63-4e9d-add9-ab30cca03f40	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4a3b1cdc-98b4-4e01-a5fb-146a489488af	cd112fe5-0c94-42f4-b221-78aa67a88c28	0c1b4e8c-85f0-43fa-b16f-55b1c9940f2a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
114efb1b-8ff8-46a5-bb19-14e476ca84f4	cd112fe5-0c94-42f4-b221-78aa67a88c28	4ec88efa-2d37-490d-9b22-aa1ff4c87488	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
38ef429a-c814-49e4-98ee-e32d7b99731d	cd112fe5-0c94-42f4-b221-78aa67a88c28	7d086b08-28e9-4f52-bad5-9df4838a22b8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4741f393-c665-4749-8e72-777664674c3b	cd112fe5-0c94-42f4-b221-78aa67a88c28	67b1385c-c0ac-4352-9929-75049b73347f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ad8b44ef-cf9a-4d1f-9008-895db0277430	cd112fe5-0c94-42f4-b221-78aa67a88c28	d687e545-3c5a-48aa-bbac-19ad99b8562a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
db932011-1584-4eb5-96fb-4e9251c15c9a	cd112fe5-0c94-42f4-b221-78aa67a88c28	3613b6e5-f6fd-4db0-840a-d48b57232c7c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
879b4c22-e4d1-4c2f-9471-18674ea9ab7d	cd112fe5-0c94-42f4-b221-78aa67a88c28	de81a170-ce3f-4af3-962f-43f453dfe0ef	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4353e301-42ea-4a6f-a16d-a3974a03f564	cd112fe5-0c94-42f4-b221-78aa67a88c28	5b55ce1b-750d-498a-a534-b3cd00c16c70	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4cdcc40b-3a75-47aa-85ba-2adff62c3fd4	cd112fe5-0c94-42f4-b221-78aa67a88c28	30b1336b-9132-4c49-84f4-25cddf89d2c9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
07ad168b-5d8a-43a4-b4c3-12c778fdaa84	cd112fe5-0c94-42f4-b221-78aa67a88c28	74849419-8103-4873-8d9d-433b60362e09	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
049c401b-f95c-4523-8ba6-3b9e3d9e1d8f	cd112fe5-0c94-42f4-b221-78aa67a88c28	272596e7-1a73-4ceb-8a71-4f47afd3acd9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4d2027e3-2f86-4652-812d-f10d756071d3	cd112fe5-0c94-42f4-b221-78aa67a88c28	57e0f392-a4a3-49ea-9120-8740c84713f3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cb7c34cd-ac31-4fa8-a0ee-b2163e3a9940	cd112fe5-0c94-42f4-b221-78aa67a88c28	3d455389-000b-49ff-a95e-966323296e09	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
560d6c60-7928-4bac-b6e1-ce7854694488	cd112fe5-0c94-42f4-b221-78aa67a88c28	97450ec1-0177-4847-927c-0a91821871bb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7f784939-4794-4de6-832c-b581b3d9ecba	cd112fe5-0c94-42f4-b221-78aa67a88c28	c44e7b93-2d0e-4fe7-9aa3-e34e55e296b8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c30de2a8-f448-4789-b6f2-3d3ff8daa4cd	cd112fe5-0c94-42f4-b221-78aa67a88c28	536cafa6-fcf6-40d2-9226-550bc67cff5c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1e752139-9844-431a-a498-db2c33f4ff82	cd112fe5-0c94-42f4-b221-78aa67a88c28	f5fba387-4b87-4318-b448-9800c7c9c259	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a0e1751e-cb95-4379-b32a-b198494642c9	cd112fe5-0c94-42f4-b221-78aa67a88c28	c2a0d594-47f2-4398-9c43-41889c814dd2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5f0ed8a0-410b-43db-819e-b19b655059c2	cd112fe5-0c94-42f4-b221-78aa67a88c28	c0e32eb8-0075-4201-848b-533210c0ca5e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
306b1d6c-0be8-4126-afc6-d1878a304a73	cd112fe5-0c94-42f4-b221-78aa67a88c28	6a0e9c72-af65-442e-8700-44e77ea58b58	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b5783768-cb70-4493-9d77-7b1c9215f403	cd112fe5-0c94-42f4-b221-78aa67a88c28	e240e30d-75a5-4efc-b3de-757090d4729a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2d9b9592-5e17-4265-ac12-c65e114e14a7	cd112fe5-0c94-42f4-b221-78aa67a88c28	78b9f9a0-c0bd-4676-82de-0c2e409f1c42	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a933422b-d1a2-414a-af74-3681b0b02a00	cd112fe5-0c94-42f4-b221-78aa67a88c28	e0e51965-ab18-40a9-9ab0-eb72dda78c60	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
078c4b26-97cd-47a4-a8da-58905ece2b02	cd112fe5-0c94-42f4-b221-78aa67a88c28	92e8a881-9712-4dfe-8324-9a75c5fedc02	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
19563858-2f3a-49c3-9b5a-e6922363d30f	cd112fe5-0c94-42f4-b221-78aa67a88c28	b09982f0-0a85-4921-ba8a-30bbebf73633	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
54f71b30-4b0c-4dcc-8d52-1079ba72134f	cd112fe5-0c94-42f4-b221-78aa67a88c28	e501665b-4121-4fcc-8994-b2f91ac47209	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e523e988-647f-4ba5-bd38-5014690c4e9c	cd112fe5-0c94-42f4-b221-78aa67a88c28	8deaa63f-fb89-4bec-8930-c37a1c6a1f71	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
24eab381-8ce8-4bdb-8190-b00ea141086d	cd112fe5-0c94-42f4-b221-78aa67a88c28	c29f3ad7-3c41-433e-989c-24fef96adaca	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6222b670-a32b-422a-aa7a-4d5ed220a379	cd112fe5-0c94-42f4-b221-78aa67a88c28	e71b387a-90e1-4f5e-afb8-70550cbc3f31	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
067b6acb-5311-4487-8e42-12cd5f1e950e	cd112fe5-0c94-42f4-b221-78aa67a88c28	f0b25d29-e251-4b9a-bccd-f69c75dbeee5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
70fe551e-3c52-4e03-832b-29918e1ce09d	cd112fe5-0c94-42f4-b221-78aa67a88c28	1b22da35-0ef5-4a01-a887-87132d528567	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b311d0a6-d344-4c1b-be4f-701d886f521a	cd112fe5-0c94-42f4-b221-78aa67a88c28	5a866bfe-f25a-4a40-b489-ce7d8f8d83aa	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c999d13c-84fb-469e-b350-ca2289011344	cd112fe5-0c94-42f4-b221-78aa67a88c28	6c8f0f90-41da-422e-95b5-84842182b06d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
54e6d385-db35-437f-92dd-932f4956f7b3	cd112fe5-0c94-42f4-b221-78aa67a88c28	f43de718-439e-4b9b-b20c-0a5054ca5bc6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5f9e1507-0fd3-4060-a369-2a373433d90a	cd112fe5-0c94-42f4-b221-78aa67a88c28	0ddbb97e-1ce2-4500-bc64-2e9006d0ef28	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b2706b6f-a643-404a-966a-151a109c8815	cd112fe5-0c94-42f4-b221-78aa67a88c28	543fee62-b2e9-4eb5-9314-d1d32df155aa	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
306950ae-ef26-4edd-8779-ec1b31628cd9	cd112fe5-0c94-42f4-b221-78aa67a88c28	1fa96987-11f2-4ae8-87da-b809fcbd49d6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
34d85fe1-c089-4385-91f1-ffbfe1afc847	cd112fe5-0c94-42f4-b221-78aa67a88c28	1ba50348-39d4-4c98-b43b-76c82129d606	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
88017dec-6be1-45e2-b823-e9ae6de20e40	cd112fe5-0c94-42f4-b221-78aa67a88c28	2970ac50-b8ef-46b2-affe-dd655755cdab	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
842a2ea7-1c03-4d80-90a9-aee0697cdfa9	cd112fe5-0c94-42f4-b221-78aa67a88c28	e4ed1e8b-1046-4c86-8d25-659046e6bcff	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8f02aaea-23d3-4330-b92b-d013650664ff	cd112fe5-0c94-42f4-b221-78aa67a88c28	b8969d12-9ecc-49aa-a0f7-60fc1b834d5c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a743c593-0f5b-4d43-84b7-8e34c44cc842	cd112fe5-0c94-42f4-b221-78aa67a88c28	ce3bffd5-cac1-489b-bd8e-827fe2721774	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a654d4e5-6bcb-419e-a4e6-b3a8e5270e74	cd112fe5-0c94-42f4-b221-78aa67a88c28	198bd8de-86d0-463e-874a-6f1b258ac249	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
691f9cef-2fdd-477e-8ebd-30f307487797	cd112fe5-0c94-42f4-b221-78aa67a88c28	51496c53-a34c-4d94-8347-5e9020dc0677	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6f068ac8-b6e4-4ef5-b6f3-61c2366e1e95	cd112fe5-0c94-42f4-b221-78aa67a88c28	9fab4a3a-a708-4eab-8807-28306e2bf6a3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
13c066b1-51d9-4ad8-8e7b-f991c62e6742	cd112fe5-0c94-42f4-b221-78aa67a88c28	7fc5419c-ea70-4d21-b7ac-050dd55ea9d9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d668bc06-27ac-4167-94f5-6e36fce56d76	cd112fe5-0c94-42f4-b221-78aa67a88c28	03f8a7b8-0a5d-48ef-a2d5-f542e4c9ab86	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e3438132-04ab-4470-bf0f-4a6ddf664cb0	cd112fe5-0c94-42f4-b221-78aa67a88c28	cdb54592-315f-43f2-a583-4afcd34ab938	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
629323ca-b823-48aa-90d8-a1ba374e0ad5	cd112fe5-0c94-42f4-b221-78aa67a88c28	adac33dc-daca-4bb9-b412-8f124b690281	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c012c893-f15f-49a1-b280-2669b36dbaa6	cd112fe5-0c94-42f4-b221-78aa67a88c28	9d864659-56a6-4fc8-99cc-69b1ab067407	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ca08265e-1d1f-4a0f-a96b-3ade26627f02	cd112fe5-0c94-42f4-b221-78aa67a88c28	3afd2913-703c-4d48-844b-614cc79b2eeb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
015728b2-eee4-41ff-a2f8-8d16813e3b46	cd112fe5-0c94-42f4-b221-78aa67a88c28	7960117c-dbc4-4c85-94dc-c4e42a02aea5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bc80edfa-2a2a-4c03-967e-813f7500ce0e	cd112fe5-0c94-42f4-b221-78aa67a88c28	3966b0ed-a44a-4591-b244-1cffbdc0adf8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e29a7147-f5d7-4bf3-a7a8-a34ff3b6bc3a	cd112fe5-0c94-42f4-b221-78aa67a88c28	cb90e845-4e40-4609-894c-7e3946252bc9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
57d05b59-494a-4127-b516-06200c750398	cd112fe5-0c94-42f4-b221-78aa67a88c28	220a428d-f5d4-4483-9494-04f832b9e97a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ae0a7f82-6859-4619-b5f2-08112d5ff6eb	33ba105b-d0a6-4667-b6e9-927859eb4481	95d47b90-0673-4955-993f-68cd238753c1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3af91c34-e307-471a-95fe-529c99857ce6	33ba105b-d0a6-4667-b6e9-927859eb4481	2376f313-d9c3-4372-b97d-0ad88f521159	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
158780aa-c5e1-4a88-b19b-c2ad9ca09834	33ba105b-d0a6-4667-b6e9-927859eb4481	1d3bbe93-7866-4e91-b5da-01557af46942	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
76fe35c2-73e9-4781-8a38-ed79081c6cf1	33ba105b-d0a6-4667-b6e9-927859eb4481	5ba45b1b-e891-442d-955c-10ad6c6fe3f7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d37bb1d4-7b8a-4f4f-b5ec-d35f62f2cd98	33ba105b-d0a6-4667-b6e9-927859eb4481	11b4d234-d7d0-4e24-9201-858d6d428695	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f9724557-ec5a-459c-8c31-d5d59d29eb6a	33ba105b-d0a6-4667-b6e9-927859eb4481	348e21d0-9f5a-44a9-a4cb-91d198fd73c6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
83cce5b9-497b-4867-8e66-a730b4958b58	33ba105b-d0a6-4667-b6e9-927859eb4481	c2a4d9b2-4f70-4d6f-963e-c75cfcb08594	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1ba93d47-794d-4617-8ac3-f98d74cf1594	33ba105b-d0a6-4667-b6e9-927859eb4481	e00af374-bc00-4f9f-8bfd-206630894d88	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
73af7f16-35b1-43f8-b302-7fc090fffa96	33ba105b-d0a6-4667-b6e9-927859eb4481	9e5fd3f9-ad7d-4645-8960-b9c6cef20929	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bd2e0b38-ceb3-4a38-8df6-3f3b0f974e64	33ba105b-d0a6-4667-b6e9-927859eb4481	a3a6a10c-2bc8-44ab-8390-866559b353ce	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bf3c20d9-64f6-4643-99da-53905c29c0a5	33ba105b-d0a6-4667-b6e9-927859eb4481	37ea209d-44ce-47e2-aa7f-d3349d841048	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
01881b73-892d-4bab-932f-3e881e2f6f62	33ba105b-d0a6-4667-b6e9-927859eb4481	0f9f9db1-c6d1-490f-b1fb-40396c8e5f01	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1af4c60d-2aed-4340-ae6c-cfa3a5e65e62	33ba105b-d0a6-4667-b6e9-927859eb4481	e5cbd48d-3a0b-4147-bd97-556be3d0ef21	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0f373361-2713-49f5-8ca1-fa21aaf3a4e5	33ba105b-d0a6-4667-b6e9-927859eb4481	9fb3540b-ad05-4ab6-a900-d830610cf690	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b4ea3ec6-7d82-465a-bab5-75318b8692f2	33ba105b-d0a6-4667-b6e9-927859eb4481	bd716812-23eb-40eb-a514-1ab55710485e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
928c3a20-1126-45bb-80c9-82076fe7fff9	33ba105b-d0a6-4667-b6e9-927859eb4481	4b62fcbc-8c82-4b2c-bfec-236884010977	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3189ac52-d8db-48ef-97ad-fc693f2a6dd5	33ba105b-d0a6-4667-b6e9-927859eb4481	65859f18-a329-4da5-ac4c-5553424c0699	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ae5cc2e1-ab9b-4a8f-b3ce-de0cc071f25d	33ba105b-d0a6-4667-b6e9-927859eb4481	90e98cb5-4959-485e-9630-e51ce2ba2cb6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
cdeee99d-9a49-4ce2-827f-529685587b1b	33ba105b-d0a6-4667-b6e9-927859eb4481	dae80686-478c-425f-9019-c34c9574b0ee	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c3b1ebd9-5d57-432b-8154-43ec00bc6264	33ba105b-d0a6-4667-b6e9-927859eb4481	5db90d9e-d037-41fb-90d9-9908572ac7aa	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
28365219-5a33-493c-91cd-e55bc3b1a4c8	33ba105b-d0a6-4667-b6e9-927859eb4481	1e7dbe7f-e8f6-4546-b95a-63b50af6d9da	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
71caa05d-123b-4164-9273-316664fda91d	33ba105b-d0a6-4667-b6e9-927859eb4481	0b3ebcc2-38d4-4962-bf46-1db659a2dfab	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6ac4494c-4b30-4d7a-912d-dec931068df0	33ba105b-d0a6-4667-b6e9-927859eb4481	5216d712-be1a-4fac-aa55-950388d1bf6f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0aa038d6-5ceb-4349-ae29-6d406d5a2238	33ba105b-d0a6-4667-b6e9-927859eb4481	ce51812c-311a-41d8-90de-b2dfdbbc6d13	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4036698e-b87b-4621-852c-c132e0498b9b	33ba105b-d0a6-4667-b6e9-927859eb4481	531bed1e-33ce-41b0-80e4-dc8d51ba7349	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
586bd0bc-3cdb-4420-9030-8d739f541f69	33ba105b-d0a6-4667-b6e9-927859eb4481	c8cb78ce-9a59-42c4-b6bf-e60397ff91d5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d25fa5d5-7a73-4a27-bc6e-1c8f86f19765	33ba105b-d0a6-4667-b6e9-927859eb4481	25c7c4eb-18f6-4b14-b3c4-856e72885dda	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3222d4fe-4e2d-46c6-b1c7-6292f34965eb	33ba105b-d0a6-4667-b6e9-927859eb4481	5a4cf3f9-2dbf-4df6-8e32-df20f6d714bc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d411b144-743d-4e31-a9b5-19da789da159	33ba105b-d0a6-4667-b6e9-927859eb4481	45ed0d94-59bc-428a-84ec-df7d313af56b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
96ed696d-89f5-43f3-9696-bc0228e8ec9f	33ba105b-d0a6-4667-b6e9-927859eb4481	c165a04c-176f-41b1-9db3-390569edbf65	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3418f138-9265-4c3c-99f7-a5cebaba112b	33ba105b-d0a6-4667-b6e9-927859eb4481	c5922ca7-8aa7-4db8-9cd5-45ecf04e281c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f7fa610a-5fca-47a1-8a29-dc1ddb4b061d	33ba105b-d0a6-4667-b6e9-927859eb4481	4ec97660-d15e-48e3-9a93-9e3ea3e24412	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ad7abc11-69be-4218-a4d5-b74e7c524ee9	33ba105b-d0a6-4667-b6e9-927859eb4481	3aa1a0ad-f676-4855-a3e8-c3771091a200	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f28d99ef-6627-4e75-8665-0c5009fc2dd6	33ba105b-d0a6-4667-b6e9-927859eb4481	79c6ce3e-0b3f-49a0-b55f-89310e472c47	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
aed382ae-15fe-4411-a72a-a1eb1665d33f	33ba105b-d0a6-4667-b6e9-927859eb4481	237f63e7-38a2-4cee-93f5-e7ada17214d8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
caca2972-1e26-440e-98fa-8523dffa9d4f	33ba105b-d0a6-4667-b6e9-927859eb4481	3d32de8f-cdee-4ce3-b4ab-fa6cd8ef3c8d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d8c1c42f-187f-4699-95cf-29acca1a5ba0	33ba105b-d0a6-4667-b6e9-927859eb4481	f1618d40-6905-46ca-bb64-a14e9bfb6c59	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ea2d9806-b33c-4745-a94c-9e3721ef7a22	33ba105b-d0a6-4667-b6e9-927859eb4481	a38edcb0-1a84-4907-b483-05529d4bb72e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9c986220-b751-44ac-ae45-9ef29e655521	33ba105b-d0a6-4667-b6e9-927859eb4481	6d4993c7-33ee-4d81-8bd0-5a4e5204f3be	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
23534299-39b0-4aec-a4cf-98ab406ddee3	33ba105b-d0a6-4667-b6e9-927859eb4481	32b84cbe-f79e-4718-a79c-ce6e578db2a7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dcf12e20-19e3-494e-b7ef-7165c2afb77e	33ba105b-d0a6-4667-b6e9-927859eb4481	3e526cc4-252e-476f-a74e-6e5fb27d9e22	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3a04e99f-f4e6-4e0d-8831-4c6361243d5e	33ba105b-d0a6-4667-b6e9-927859eb4481	4e29d932-4391-4872-a836-0c9f6b7245bc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3e57268a-1eee-4258-a19d-0d03be829058	33ba105b-d0a6-4667-b6e9-927859eb4481	e2294a93-ed9e-45a5-b0ed-2c35927641c9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
faa692ec-6c9b-4b88-8b69-d751b58d12ad	33ba105b-d0a6-4667-b6e9-927859eb4481	a9ba3047-d372-498a-b2e6-3a4d410142bd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c1252025-b214-4e92-911f-1b8966aef337	33ba105b-d0a6-4667-b6e9-927859eb4481	f035ad5d-807a-4058-a282-bede20389e5a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7d3de090-3b64-4606-81f1-a48b15e3ddaf	33ba105b-d0a6-4667-b6e9-927859eb4481	e1b1a65f-bf0e-48a9-98e4-6b4be3baa241	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
107d45e4-bd34-41ae-9950-33d21a6a2749	33ba105b-d0a6-4667-b6e9-927859eb4481	35317563-ba34-4e71-bcb2-f86db1f173b5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ae3cf72d-b4dc-46dc-812a-1b02375c294a	33ba105b-d0a6-4667-b6e9-927859eb4481	730282bb-b8b5-4078-9dec-0c5c2ec4fcd1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
18cf6f25-b277-40ce-a875-c02bfc3758ed	33ba105b-d0a6-4667-b6e9-927859eb4481	e8e3a05d-bf1f-490d-88b5-68b5fa3dd5bb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
eed4a5e6-d3ab-4ca7-95ce-9985a053a36d	33ba105b-d0a6-4667-b6e9-927859eb4481	5e2f1bf4-5380-4527-ae89-541b6d0d8510	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
53f12601-c5cb-4353-a250-c7ad487fc6e2	33ba105b-d0a6-4667-b6e9-927859eb4481	52326fd9-2a41-45b9-9e0a-a07b51d52826	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c73b4d7b-4447-4914-be9c-7059e5d90c9c	33ba105b-d0a6-4667-b6e9-927859eb4481	93c5cf76-e3a1-4ebe-ad5c-acc93441cbf8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
157183c1-df3b-4d5f-89a8-36e6a6f832cc	33ba105b-d0a6-4667-b6e9-927859eb4481	2e3bb4a4-eaef-4d83-9342-92ae1684fbbc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1612579f-bcfc-4e52-9eef-1caa35d68b95	33ba105b-d0a6-4667-b6e9-927859eb4481	8931b9a0-19c0-47e9-b2b3-6ecba2617096	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f351d6b6-805b-4896-8b79-19f3b00c6b50	33ba105b-d0a6-4667-b6e9-927859eb4481	26ee3c1d-1a43-4662-bcdf-e37535d9f938	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bb4398fb-955f-45be-b653-504559558fcc	33ba105b-d0a6-4667-b6e9-927859eb4481	ed144492-245a-4806-91c5-6fe80ff0a636	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
85185ffe-abfc-4a53-b5d4-dea8142699e7	33ba105b-d0a6-4667-b6e9-927859eb4481	9c4a27ee-54e5-478a-9336-ec11aa965c2f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1e127e91-8816-4cb3-957e-b7751cd207d3	33ba105b-d0a6-4667-b6e9-927859eb4481	a86e11a3-5e61-46e3-b2a1-dcdf0c219cbd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
16ee8658-772d-4d5e-aa63-eec5edf7d9ee	33ba105b-d0a6-4667-b6e9-927859eb4481	a9c8328b-2ea6-4355-b526-5919386b970a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fb8786bf-26a9-4b63-8c82-33abf2f0832f	33ba105b-d0a6-4667-b6e9-927859eb4481	47084499-af21-41cc-843b-3f536a743ea7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ad6b50a4-31a6-4ba6-9c2e-7cb82511d21a	33ba105b-d0a6-4667-b6e9-927859eb4481	52f43f25-9f40-48fa-86aa-f3380b02b02f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
474b3bc3-4ffe-43bc-b1ff-6b0dc2ddeaaf	33ba105b-d0a6-4667-b6e9-927859eb4481	5fdd590d-e61f-4a59-bbac-2d5b0248c2bb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f72fb8c1-00fc-41e7-ada7-1da0abe32d26	33ba105b-d0a6-4667-b6e9-927859eb4481	57852adc-f056-46a0-bace-e451e73e4801	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
55980694-111e-4b8a-9358-e6718fd52277	33ba105b-d0a6-4667-b6e9-927859eb4481	982f2f75-de7f-4bfe-a70f-8f902124d3db	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
541cff67-35ea-450b-9406-9b17ea40671d	33ba105b-d0a6-4667-b6e9-927859eb4481	d4782643-740e-4df2-8230-9dfc9d6c8203	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
28b65e68-772f-4c64-a210-ea74e9505955	33ba105b-d0a6-4667-b6e9-927859eb4481	5ab6c0b7-aff2-4616-8045-962137df541b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9636fbba-f042-42ac-b08e-c6374c265c49	33ba105b-d0a6-4667-b6e9-927859eb4481	6a3551d2-958c-4fdd-9e5a-60f09262c095	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
75c01f07-81b1-48c8-9bf8-84a7a996d604	33ba105b-d0a6-4667-b6e9-927859eb4481	34d0ec25-f962-47e1-a6d7-17e6bd9b4c37	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b77c1bd5-4048-411a-ab6a-8048e2705e13	33ba105b-d0a6-4667-b6e9-927859eb4481	1bcdfac9-91b3-4f10-9aec-43d5bb3c0a47	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
76812246-162f-483a-81c4-028da665cd15	33ba105b-d0a6-4667-b6e9-927859eb4481	925a9206-2d38-4c8d-90f0-f44ac3eccaf5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d3229c0a-3295-42d0-80fd-2c4fb5f60750	33ba105b-d0a6-4667-b6e9-927859eb4481	8c1133a5-e4b7-4906-86a1-fb3d4af67d84	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9fdf2792-b354-4f75-ac09-6b98315ce8b4	33ba105b-d0a6-4667-b6e9-927859eb4481	a26c9529-e7bd-4ae3-a090-6a9273bcbe46	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3928f8af-4104-4350-a1ed-c2f913f75999	33ba105b-d0a6-4667-b6e9-927859eb4481	74db90b3-f708-41a5-8ec3-bfbbae00461c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
64f836bc-5f88-491c-a24c-3a46d815c3b4	33ba105b-d0a6-4667-b6e9-927859eb4481	8cfbfe4e-6d7f-4115-89e6-bffa9854e528	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
26afd5eb-b084-4802-b1ee-143c857f241c	33ba105b-d0a6-4667-b6e9-927859eb4481	5f7d586c-a911-4140-be07-332f6d669842	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
362e5897-8c80-4f7b-9b37-4cde98fae406	33ba105b-d0a6-4667-b6e9-927859eb4481	ff03d97f-e18d-4b02-ad90-e032ee5d3b4e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
09913506-1328-4b6d-8aeb-d95954c0542b	33ba105b-d0a6-4667-b6e9-927859eb4481	1fcc5ef9-16b0-4968-be0f-32dbde5d01d6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0c9e4b85-a494-4834-8d34-389feac55c4f	33ba105b-d0a6-4667-b6e9-927859eb4481	d14ef8ba-21e6-408f-b5df-a73d848c4de5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ca032f52-0658-4e86-92fa-c3ff8d9cd6e1	33ba105b-d0a6-4667-b6e9-927859eb4481	cc42659b-47cc-45c6-9f2d-d5751ac2973b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0709d261-e059-400e-9fec-358d558f30f3	33ba105b-d0a6-4667-b6e9-927859eb4481	8b316536-b524-4579-8be5-dc4f76a1fc0a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bf0250ad-4378-4574-ba48-435b5a3c5fdd	33ba105b-d0a6-4667-b6e9-927859eb4481	47891ca6-fba2-405c-88f6-49154763f189	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0170b482-68fc-49bf-8e6b-742251580c73	33ba105b-d0a6-4667-b6e9-927859eb4481	a74981cb-9a29-4d7c-afcd-81dcbeaed6fa	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2635e904-b00a-4e67-8e36-fea8204fc024	33ba105b-d0a6-4667-b6e9-927859eb4481	b1e850b4-7896-4fdd-ae60-bed561d72797	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8b60db14-8149-4c03-8f4c-1a4be795349e	33ba105b-d0a6-4667-b6e9-927859eb4481	64c55a3a-3350-4471-ad31-c375096021c3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ff958bef-6671-46a8-b91f-0c69260588bc	33ba105b-d0a6-4667-b6e9-927859eb4481	90edf8b3-a04a-490f-a5bf-01648da3158a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
13f0a27f-8966-48d4-b5e0-9c032c10da30	33ba105b-d0a6-4667-b6e9-927859eb4481	7d1d9163-1437-4ad9-a621-33c6026a4a64	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bed14d9f-5a4c-4848-943f-d2802af12863	33ba105b-d0a6-4667-b6e9-927859eb4481	34dfc6c2-10ba-4533-9c14-f41206ede23d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6383eac9-7ede-4a2f-9a62-e77f8c4203c7	33ba105b-d0a6-4667-b6e9-927859eb4481	5c3c2546-e16b-4e58-b891-24600acb56d4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7f61a291-69f3-49de-8b5d-82b3d51ab133	33ba105b-d0a6-4667-b6e9-927859eb4481	8ba275f0-1b63-4e9d-add9-ab30cca03f40	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2af4e40f-1a99-4194-9936-2a580c7c59d3	33ba105b-d0a6-4667-b6e9-927859eb4481	0c1b4e8c-85f0-43fa-b16f-55b1c9940f2a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
01aadc68-6256-4cf8-8294-eb0fdb2c896e	33ba105b-d0a6-4667-b6e9-927859eb4481	4ec88efa-2d37-490d-9b22-aa1ff4c87488	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
024bfd38-cf02-4a8c-a05a-30a09efa9836	33ba105b-d0a6-4667-b6e9-927859eb4481	7d086b08-28e9-4f52-bad5-9df4838a22b8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
20939983-7656-4473-9e19-a73c0083c104	33ba105b-d0a6-4667-b6e9-927859eb4481	67b1385c-c0ac-4352-9929-75049b73347f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2c7618af-e6a2-4639-a3ee-e095c331682c	33ba105b-d0a6-4667-b6e9-927859eb4481	d687e545-3c5a-48aa-bbac-19ad99b8562a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d2d425ba-102d-4165-b7d2-9f81d23e9614	33ba105b-d0a6-4667-b6e9-927859eb4481	3613b6e5-f6fd-4db0-840a-d48b57232c7c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
59dd23a7-781e-4dc0-886c-097fc993e38c	33ba105b-d0a6-4667-b6e9-927859eb4481	de81a170-ce3f-4af3-962f-43f453dfe0ef	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
12d9a602-582a-4e14-a16d-26a6f6e94063	33ba105b-d0a6-4667-b6e9-927859eb4481	5b55ce1b-750d-498a-a534-b3cd00c16c70	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
968bafdc-b4f5-47fc-953e-765eabf885bf	33ba105b-d0a6-4667-b6e9-927859eb4481	30b1336b-9132-4c49-84f4-25cddf89d2c9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b920e3c1-38be-484c-bd3f-263185ce1693	33ba105b-d0a6-4667-b6e9-927859eb4481	74849419-8103-4873-8d9d-433b60362e09	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6f65139c-e892-478e-bbdf-3a34f15f1cc2	33ba105b-d0a6-4667-b6e9-927859eb4481	272596e7-1a73-4ceb-8a71-4f47afd3acd9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ee235c47-537d-45cd-a74d-d67edc27cc1b	33ba105b-d0a6-4667-b6e9-927859eb4481	57e0f392-a4a3-49ea-9120-8740c84713f3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dba3d35d-5bd4-4c0e-a611-fcfeb566926f	33ba105b-d0a6-4667-b6e9-927859eb4481	3d455389-000b-49ff-a95e-966323296e09	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
32738eaa-7d85-43b8-8548-e1b270791af7	33ba105b-d0a6-4667-b6e9-927859eb4481	97450ec1-0177-4847-927c-0a91821871bb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d49907fb-8ff8-43b2-89ab-37e4490470ea	33ba105b-d0a6-4667-b6e9-927859eb4481	c44e7b93-2d0e-4fe7-9aa3-e34e55e296b8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
abb5904a-b7a6-48f5-9586-8d9d96da7f80	33ba105b-d0a6-4667-b6e9-927859eb4481	536cafa6-fcf6-40d2-9226-550bc67cff5c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3315a237-cd63-4541-8ac2-e4b906dc63e8	33ba105b-d0a6-4667-b6e9-927859eb4481	f5fba387-4b87-4318-b448-9800c7c9c259	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4e1b7a9b-0b68-47a4-af8f-5a6b653b9162	33ba105b-d0a6-4667-b6e9-927859eb4481	c2a0d594-47f2-4398-9c43-41889c814dd2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e711d430-1e96-4831-8b8e-faff37094ea6	33ba105b-d0a6-4667-b6e9-927859eb4481	c0e32eb8-0075-4201-848b-533210c0ca5e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0157dc67-5130-4bc1-b68f-a452948d5edb	33ba105b-d0a6-4667-b6e9-927859eb4481	6a0e9c72-af65-442e-8700-44e77ea58b58	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
772be8f5-129e-4102-a894-19a7942e1228	33ba105b-d0a6-4667-b6e9-927859eb4481	e240e30d-75a5-4efc-b3de-757090d4729a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6dd205a8-caac-442b-acc4-e90a120df870	33ba105b-d0a6-4667-b6e9-927859eb4481	78b9f9a0-c0bd-4676-82de-0c2e409f1c42	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
524e4516-6473-48a7-9cec-3af2f15182db	33ba105b-d0a6-4667-b6e9-927859eb4481	e0e51965-ab18-40a9-9ab0-eb72dda78c60	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1632eb44-9070-4042-bb91-97e7779e4ac8	33ba105b-d0a6-4667-b6e9-927859eb4481	92e8a881-9712-4dfe-8324-9a75c5fedc02	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d767ed58-d289-432b-88e3-b82fc16934a6	33ba105b-d0a6-4667-b6e9-927859eb4481	b09982f0-0a85-4921-ba8a-30bbebf73633	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3d1c5977-324b-4a91-b92c-1ba05a9dc51a	33ba105b-d0a6-4667-b6e9-927859eb4481	e501665b-4121-4fcc-8994-b2f91ac47209	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ff894ebe-8baa-499f-b57f-1ac3af041a35	33ba105b-d0a6-4667-b6e9-927859eb4481	8deaa63f-fb89-4bec-8930-c37a1c6a1f71	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9bdd1fdc-b604-44aa-9d9e-e8e16e67ddca	33ba105b-d0a6-4667-b6e9-927859eb4481	c29f3ad7-3c41-433e-989c-24fef96adaca	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2c7bf2b4-8628-4181-bdcc-84ad7a24d743	33ba105b-d0a6-4667-b6e9-927859eb4481	e71b387a-90e1-4f5e-afb8-70550cbc3f31	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5982aa57-912c-4638-8795-b213436c78c3	33ba105b-d0a6-4667-b6e9-927859eb4481	f0b25d29-e251-4b9a-bccd-f69c75dbeee5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
550e279b-5d34-495e-be5b-55d8b48d0a3e	33ba105b-d0a6-4667-b6e9-927859eb4481	1b22da35-0ef5-4a01-a887-87132d528567	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
43fe48a8-8660-439b-aaea-67924d2a08d0	33ba105b-d0a6-4667-b6e9-927859eb4481	5a866bfe-f25a-4a40-b489-ce7d8f8d83aa	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6ac9cf16-39ab-4ad7-9488-3cdc21e74dda	33ba105b-d0a6-4667-b6e9-927859eb4481	6c8f0f90-41da-422e-95b5-84842182b06d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
53e4b3a5-f897-4a4b-a21a-321049f41956	33ba105b-d0a6-4667-b6e9-927859eb4481	f43de718-439e-4b9b-b20c-0a5054ca5bc6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
82816125-ace7-4316-b08f-2404c2638b22	33ba105b-d0a6-4667-b6e9-927859eb4481	0ddbb97e-1ce2-4500-bc64-2e9006d0ef28	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d2859c5a-124a-4214-90a2-7ce7f5dbd08f	33ba105b-d0a6-4667-b6e9-927859eb4481	543fee62-b2e9-4eb5-9314-d1d32df155aa	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e1f3191b-c2d8-441a-9da8-9600432504dc	33ba105b-d0a6-4667-b6e9-927859eb4481	1fa96987-11f2-4ae8-87da-b809fcbd49d6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
437ab45c-9ddd-43f9-8137-821783c097fe	33ba105b-d0a6-4667-b6e9-927859eb4481	1ba50348-39d4-4c98-b43b-76c82129d606	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c1bc4189-5b0f-4b4f-93c9-0d0bbd9184fa	33ba105b-d0a6-4667-b6e9-927859eb4481	2970ac50-b8ef-46b2-affe-dd655755cdab	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
30825463-7fa8-457b-bb76-01f50bea1b59	33ba105b-d0a6-4667-b6e9-927859eb4481	e4ed1e8b-1046-4c86-8d25-659046e6bcff	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2c7dcffd-1f78-4c92-9016-e011d45e58c2	33ba105b-d0a6-4667-b6e9-927859eb4481	b8969d12-9ecc-49aa-a0f7-60fc1b834d5c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fe973af5-1827-411a-b2ea-9eeb11cf61ee	33ba105b-d0a6-4667-b6e9-927859eb4481	ce3bffd5-cac1-489b-bd8e-827fe2721774	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
98d2a92d-2022-433a-9e06-0616e46ab677	33ba105b-d0a6-4667-b6e9-927859eb4481	198bd8de-86d0-463e-874a-6f1b258ac249	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
31327998-9546-4a4c-9364-829aae992a14	33ba105b-d0a6-4667-b6e9-927859eb4481	51496c53-a34c-4d94-8347-5e9020dc0677	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
38fb7313-bd67-41d7-b4eb-1c9e4cbea7b4	33ba105b-d0a6-4667-b6e9-927859eb4481	9fab4a3a-a708-4eab-8807-28306e2bf6a3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ba6881df-14e7-4e65-bc7e-bfd4839591a1	33ba105b-d0a6-4667-b6e9-927859eb4481	7fc5419c-ea70-4d21-b7ac-050dd55ea9d9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5664f7bb-f972-42af-900a-0647de60bcc4	33ba105b-d0a6-4667-b6e9-927859eb4481	03f8a7b8-0a5d-48ef-a2d5-f542e4c9ab86	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ae325dd4-dcab-4889-a7e9-4ea1f8901afd	33ba105b-d0a6-4667-b6e9-927859eb4481	cdb54592-315f-43f2-a583-4afcd34ab938	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a5713832-6fe8-46a5-9c24-c55124c51c85	33ba105b-d0a6-4667-b6e9-927859eb4481	adac33dc-daca-4bb9-b412-8f124b690281	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
af863bfd-e7ff-4a9a-a921-ed5ba70d4094	33ba105b-d0a6-4667-b6e9-927859eb4481	9d864659-56a6-4fc8-99cc-69b1ab067407	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3b0916cd-64f1-4938-8214-46f95b910ca6	33ba105b-d0a6-4667-b6e9-927859eb4481	3afd2913-703c-4d48-844b-614cc79b2eeb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
48c015cf-cfa9-4f16-b158-7c12a402bc10	33ba105b-d0a6-4667-b6e9-927859eb4481	7960117c-dbc4-4c85-94dc-c4e42a02aea5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1b5754d1-50b0-40e9-81a1-851d964cb83d	33ba105b-d0a6-4667-b6e9-927859eb4481	3966b0ed-a44a-4591-b244-1cffbdc0adf8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
82f3d800-c3af-47cb-8b1c-4142e07e2e00	33ba105b-d0a6-4667-b6e9-927859eb4481	cb90e845-4e40-4609-894c-7e3946252bc9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
37080f0b-8cfc-4a65-8a29-54f5bb7d968c	33ba105b-d0a6-4667-b6e9-927859eb4481	220a428d-f5d4-4483-9494-04f832b9e97a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
\.


--
-- Data for Name: recommendations; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.recommendations (id, name, drug_id, gene_ids, clinicalguidance, citation, severity, clinicalimpact, status, active, created_at, updated_at) FROM stdin;
4990a392-3b4c-4892-9e6c-76e6cecc9280	Clopidogrel-CYP2C19 Poor Metabolizer	d3dddc1d-8bc5-4714-b254-50dec124bbaf	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	For acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) cardiovascular indications: Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication. \n\nFor non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications: Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.\n\nFor neurovascular indications:  Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or transient ischemic attack (TIA). Selection of therapy should depend on individual patient treatment goals and risks for adverse events.	Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967. doi:10.1002/cpt.2526	Warning (Yellow column)	Increased risk for adverse cardiac and cerebrovascular events and increased on-treatment platelet reactivity due to significantly reduced clopidogrel active metabolite formation.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f503feb9-7558-4ff5-bd66-16fad0cd8a5a	Clopidogrel-CYP2C19 Likely Poor Metabolizer	d3dddc1d-8bc5-4714-b254-50dec124bbaf	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	For acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) cardiovascular indications: Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication. \n\nFor non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications: Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.\n\nFor neurovascular indications:  Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or transient ischemic attack (TIA). Selection of therapy should depend on individual patient treatment goals and risks for adverse events.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967. doi:10.1002/cpt.2526	Warning (Yellow column)	Increased risk for adverse cardiac and cerebrovascular events and increased on-treatment platelet reactivity due to significantly reduced clopidogrel active metabolite formation.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
691a50fb-a2af-4bd5-a85f-1ad3ab57af73	Clopidogrel-CYP2C19 Intermediate Metabolizer	d3dddc1d-8bc5-4714-b254-50dec124bbaf	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	For acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) cardiovascular indications: Avoid standard dose (75&nbsp;mg/day) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication. \n\nFor neurovascular indications:  Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or transient ischemic attack (TIA). Selection of therapy should depend on individual patient treatment goals and risks for adverse events.	Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967. doi:10.1002/cpt.2526	Warning (Yellow column)	Increased risk for adverse cardiac and cerebrovascular events and increased on-treatment platelet reactivity due to reduced clopidogrel active metabolite formation.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3c64be84-c28a-424c-a87e-e06458e58587	Clopidogrel-CYP2C19 Likely Intermediate Metabolizer	d3dddc1d-8bc5-4714-b254-50dec124bbaf	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	For acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) cardiovascular indications: Avoid standard dose (75&nbsp;mg/day) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.\n\nFor neurovascular indications:  Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or transient ischemic attack (TIA). Selection of therapy should depend on individual patient treatment goals and risks for adverse events.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967. doi:10.1002/cpt.2526	Warning (Yellow column)	Increased risk for adverse cardiac and cerebrovascular events and increased on-treatment platelet reactivity due to reduced clopidogrel active metabolite formation.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7949de13-fe43-4946-bfa4-65b756b42e50	Clopidogrel-CYP2C19 Normal Metabolizer	d3dddc1d-8bc5-4714-b254-50dec124bbaf	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967. doi:10.1002/cpt.2526	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
793158bd-aacb-4a8c-9d27-31879e222317	Clopidogrel-CYP2C19 Rapid Metabolizer	d3dddc1d-8bc5-4714-b254-50dec124bbaf	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967. doi:10.1002/cpt.2526	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
19251ea9-c41b-4207-88bb-373d1b618a92	Clopidogrel-CYP2C19 Ultra-rapid Metabolizer	d3dddc1d-8bc5-4714-b254-50dec124bbaf	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967. doi:10.1002/cpt.2526	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3a504cc4-966c-440a-9a63-26ec0e9564f1	Clopidogrel-CYP2C19 Indeterminate	d3dddc1d-8bc5-4714-b254-50dec124bbaf	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967. doi:10.1002/cpt.2526	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b5a9ac55-68d4-4e2a-8eeb-ddb909d8db78	Omeprazole-CYP2C19 Ultra-rapid Metabolizer	ccab952d-1055-4d11-8de5-db50dd24f9b1	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased risk of therapeutic failure due to decreased plasma concentrations of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6058eb73-6738-467c-8b91-9c84eaa70f2b	Lansoprazole-CYP2C19 Ultra-rapid Metabolizer	bbb98d14-f488-4791-894c-4107ed94eba6	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased risk of therapeutic failure due to decreased plasma concentrations of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7b46531a-93f6-491d-8aee-57b3b17204ad	Pantoprazole-CYP2C19 Ultra-rapid Metabolizer	e7a7c1bc-8557-49f0-9b21-32b50749a4df	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased risk of therapeutic failure due to decreased plasma concentrations of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9618fc26-e1b3-493b-a61a-232a7ab79955	Dexlansoprazole-CYP2C19 Ultra-rapid Metabolizer	a688ed6b-9656-47e2-baf1-0809d34b6878	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased risk of therapeutic failure due to decreased plasma concentrations of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
02ec260b-4589-406a-b044-b1983e374c69	Omeprazole-CYP2C19 Rapid Metabolizer	ccab952d-1055-4d11-8de5-db50dd24f9b1	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. Consider increasing dose by 50&#8208;100% for the treatment of <em>Helicobacter pylori</em> infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased risk of therapeutic failure due to decreased plasma concentrations of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
598bcaca-dbe2-495c-9a83-0a5551d475e1	Lansoprazole-CYP2C19 Rapid Metabolizer	bbb98d14-f488-4791-894c-4107ed94eba6	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. Consider increasing dose by 50&#8208;100% for the treatment of <em>Helicobacter pylori</em> infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased risk of therapeutic failure due to decreased plasma concentrations of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
531a543f-77f0-4b07-9f69-500c04f6da30	Pantoprazole-CYP2C19 Rapid Metabolizer	e7a7c1bc-8557-49f0-9b21-32b50749a4df	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. Consider increasing dose by 50&#8208;100% for the treatment of <em>Helicobacter pylori</em> infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased risk of therapeutic failure due to decreased plasma concentrations of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
84012120-00e5-42b9-8fc8-12541cda050f	Dexlansoprazole-CYP2C19 Rapid Metabolizer	a688ed6b-9656-47e2-baf1-0809d34b6878	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. Consider increasing dose by 50&#8208;100% for the treatment of <em>Helicobacter pylori</em> infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased risk of therapeutic failure due to decreased plasma concentrations of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
536a7bad-ec25-4edd-9105-98c3446de139	Omeprazole-CYP2C19 Normal Metabolizer	ccab952d-1055-4d11-8de5-db50dd24f9b1	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. Consider increasing dose by 50&#8208;100% for the treatment of <em>Helicobacter pylori</em> infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Normal metabolism of proton pump inhibitors (PPIs), however, may be at increased risk of therapeutic failure when compared to CYP2C19 intermediate or poor metabolizers depending on indication.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
40dc3eae-9e1c-454a-bb51-44f197d5134b	Lansoprazole-CYP2C19 Normal Metabolizer	bbb98d14-f488-4791-894c-4107ed94eba6	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. Consider increasing dose by 50&#8208;100% for the treatment of <em>Helicobacter pylori</em> infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Normal metabolism of proton pump inhibitors (PPIs), however, may be at increased risk of therapeutic failure when compared to CYP2C19 intermediate or poor metabolizers depending on indication.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2b4f1a89-f719-42ca-a334-5529cf2c7ce6	Clomipramine-CYP2C19 Intermediate Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
205a9fe5-b317-4c05-8803-1c7d98cc6728	Pantoprazole-CYP2C19 Normal Metabolizer	e7a7c1bc-8557-49f0-9b21-32b50749a4df	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. Consider increasing dose by 50&#8208;100% for the treatment of <em>Helicobacter pylori</em> infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Normal metabolism of proton pump inhibitors (PPIs), however, may be at increased risk of therapeutic failure when compared to CYP2C19 intermediate or poor metabolizers depending on indication.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
10c56e6a-d65e-4219-b25c-fb624f36a9f8	Dexlansoprazole-CYP2C19 Normal Metabolizer	a688ed6b-9656-47e2-baf1-0809d34b6878	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. Consider increasing dose by 50&#8208;100% for the treatment of <em>Helicobacter pylori</em> infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Normal metabolism of proton pump inhibitors (PPIs), however, may be at increased risk of therapeutic failure when compared to CYP2C19 intermediate or poor metabolizers depending on indication.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e1f29232-3703-4517-87da-65791a162ce3	Omeprazole-CYP2C19 Likely Intermediate Metabolizer	ccab952d-1055-4d11-8de5-db50dd24f9b1	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Likely increased chance of efficacy and potentially toxicity due to likely increased plasma concentrations of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
28d9a28e-7ece-4ad3-925e-1b976941fa52	Lansoprazole-CYP2C19 Likely Intermediate Metabolizer	bbb98d14-f488-4791-894c-4107ed94eba6	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Likely increased chance of efficacy and potentially toxicity due to likely increased plasma concentrations of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8a01b626-ae72-465a-8ba1-5acf0209963d	Pantoprazole-CYP2C19 Likely Intermediate Metabolizer	e7a7c1bc-8557-49f0-9b21-32b50749a4df	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Likely increased chance of efficacy and potentially toxicity due to likely increased plasma concentrations of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9fd4903a-b359-4b5c-9e5d-d93e2658fc24	Dexlansoprazole-CYP2C19 Likely Intermediate Metabolizer	a688ed6b-9656-47e2-baf1-0809d34b6878	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Likely increased chance of efficacy and potentially toxicity due to likely increased plasma concentrations of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d887e66d-5595-458a-a9f4-bf98386d8f53	Omeprazole-CYP2C19 Intermediate Metabolizer	ccab952d-1055-4d11-8de5-db50dd24f9b1	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased chance of efficacy and potentially toxicity due to increased plasma concentration of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
48ba79eb-951a-4707-9e23-490d8b0b418f	Lansoprazole-CYP2C19 Intermediate Metabolizer	bbb98d14-f488-4791-894c-4107ed94eba6	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased chance of efficacy and potentially toxicity due to increased plasma concentration of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0833fc29-cdeb-4cbc-84a4-0dca5f35edfb	Doxepin-CYP2C19 Intermediate Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8c2fba7d-1d6f-424f-a644-28d7e38d9f9d	Pantoprazole-CYP2C19 Intermediate Metabolizer	e7a7c1bc-8557-49f0-9b21-32b50749a4df	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased chance of efficacy and potentially toxicity due to increased plasma concentration of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0eaeeb04-a26a-4b46-8b2a-9070ee200a4f	Dexlansoprazole-CYP2C19 Intermediate Metabolizer	a688ed6b-9656-47e2-baf1-0809d34b6878	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased chance of efficacy and potentially toxicity due to increased plasma concentration of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4365e77c-0942-43a1-8f31-782a88bfa265	Omeprazole-CYP2C19 Likely Poor Metabolizer	ccab952d-1055-4d11-8de5-db50dd24f9b1	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Likely increased chance of efficacy and potentially toxicity due to likely increased plasma concentration of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
729ba811-064c-4357-8225-b3c6f7030db8	Lansoprazole-CYP2C19 Likely Poor Metabolizer	bbb98d14-f488-4791-894c-4107ed94eba6	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Likely increased chance of efficacy and potentially toxicity due to likely increased plasma concentration of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7ec93d74-6bfb-4924-b6a3-ac894e5c05e7	Pantoprazole-CYP2C19 Likely Poor Metabolizer	e7a7c1bc-8557-49f0-9b21-32b50749a4df	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Likely increased chance of efficacy and potentially toxicity due to likely increased plasma concentration of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c3f1ab59-6be3-41e2-a68c-6cf4e714bfd5	Dexlansoprazole-CYP2C19 Likely Poor Metabolizer	a688ed6b-9656-47e2-baf1-0809d34b6878	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Likely increased chance of efficacy and potentially toxicity due to likely increased plasma concentration of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
16cf6405-f1c7-44eb-94ab-928300c777fb	Omeprazole-CYP2C19 Poor Metabolizer	ccab952d-1055-4d11-8de5-db50dd24f9b1	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased chance of efficacy and potentially toxicity due to increased plasma concentration of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dddc0c93-7015-4dbe-b810-bc750fdb8081	Lansoprazole-CYP2C19 Poor Metabolizer	bbb98d14-f488-4791-894c-4107ed94eba6	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased chance of efficacy and potentially toxicity due to increased plasma concentration of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d203898d-4125-4c0b-83a0-67d7b0524773	Pantoprazole-CYP2C19 Poor Metabolizer	e7a7c1bc-8557-49f0-9b21-32b50749a4df	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased chance of efficacy and potentially toxicity due to increased plasma concentration of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
12a807dc-7d5c-4e37-98c8-b07a28f98f1f	Dexlansoprazole-CYP2C19 Poor Metabolizer	a688ed6b-9656-47e2-baf1-0809d34b6878	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Caution (Yellow Column)	Increased chance of efficacy and potentially toxicity due to increased plasma concentration of proton pump inhibitors (PPIs) when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
50771793-e857-4b72-a9e9-de879aa12ed9	Omeprazole-CYP2C19 Indeterminate Metabolizer	ccab952d-1055-4d11-8de5-db50dd24f9b1	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f0e37aef-c08c-4f09-8df6-9067a8d97297	Lansoprazole-CYP2C19 Indeterminate Metabolizer	bbb98d14-f488-4791-894c-4107ed94eba6	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
47cf9f8f-8c8a-4ea2-870a-39f5e7c0ea63	Pantoprazole-CYP2C19 Indeterminate Metabolizer	e7a7c1bc-8557-49f0-9b21-32b50749a4df	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5b444f2d-dbf7-4ffb-a977-815ed4401b60	Dexlansoprazole-CYP2C19 Indeterminate Metabolizer	a688ed6b-9656-47e2-baf1-0809d34b6878	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c33b9bde-3627-44f0-920f-5f625d66c7a8	Amitriptyline-CYP2C19  Ultra-rapid Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
53a404fc-6ac5-4648-b0b9-eb402c5af60a	Amitriptyline-CYP2C19  Rapid Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1391ee7c-4070-4701-a19b-83ac9bc570e3	Amitriptyline- CYP2C19 Normal Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
56b49b61-640c-4a0c-af50-34c4d57ff002	Amitriptyline- CYP2C19 Likely Intermediate Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c089d975-1478-4949-9a4c-7ea5b89061c3	Amitriptyline- CYP2C19 Intermediate Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9fae4973-bf8d-4639-a8d8-42dd1d8a86d6	Imipramine-CYP2C19 Intermediate Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c4886f97-4057-4283-8941-90955ca6b136	Trimipramine-CYP2C19 Intermediate Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6dc9160e-efc5-476d-b7c8-cf23aa67617b	Amitriptyline- CYP2C19 Poor Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
538e80b2-97b3-49e5-8f4b-c8c6cffae1d1	Amitriptyline- CYP2C19 Likely Poor Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f7fbaa70-2085-4992-830f-9e62bcfdcae6	Amitriptyline- CYP2C19 Indeterminate	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
66d63a0e-4ded-4fe6-8027-df0e5f58883d	Clomipramine-CYP2C19  Ultra-rapid Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
61d4a736-de0a-46ba-b13e-b1b9bc458354	Clomipramine-CYP2C19  Rapid Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
afc9aa8d-45bd-4f93-a36f-a1cab277977b	Clomipramine-CYP2C19 Normal Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8c0befb0-b6df-4e35-89fa-2830f348aac2	Clomipramine-CYP2C19 Likely Intermediate Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6647e799-322d-4d68-9671-9ee75b221763	Clomipramine-CYP2C19 Poor Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
41b2fefe-fb02-465a-88f1-70d3f4f0035c	Clomipramine-CYP2C19 Likely Poor Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9f01b9b9-ff84-4dc4-bdca-bffbc706a4e0	Clomipramine- CYP2C19 Indeterminate	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
499e5da1-163e-4a5b-a7d2-4c18ecbd25df	Doxepin-CYP2C19  Ultra-rapid Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5b13adac-657f-45ac-8a63-738966d2211a	Doxepin-CYP2C19  Rapid Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f78ac58f-8207-4be5-ab66-2f6633a85d31	Doxepin-CYP2C19 Normal Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9e7558b0-fdf3-4975-8d43-2aeacf9d81c1	Doxepin-CYP2C19 Likely Intermediate Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0a132e5e-f8e6-4d23-8003-30c349d2e9bc	Doxepin-CYP2C19 Poor Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4c135345-c7fe-45d2-acab-3882fdf834fa	Doxepin-CYP2C19 Likely Poor Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fe5a045d-c3ed-4aa8-a426-e9e6166cfd9e	Doxepin- CYP2C19 Indeterminate	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
40104ccc-87fe-4b55-995a-a00743d035cc	Imipramine-CYP2C19  Ultra-rapid Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
059bc02f-d224-44e3-8553-258d81dd7993	Imipramine-CYP2C19  Rapid Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines  when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2fc748cd-dbbb-488b-8aa0-4f6ddba22f7a	Imipramine-CYP2C19 Normal Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
742e478d-aaf0-42ba-8fa9-8267808b64c3	Imipramine-CYP2C19 Likely Intermediate Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
25315b4a-2e27-43af-9256-47ba33a1178a	Imipramine-CYP2C19 Poor Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
81b62720-ffca-43c8-9e58-5c7a53176400	Imipramine-CYP2C19 Likely Poor Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
895cc18e-a7f6-4589-ae67-1360384f09b5	Imipramine-CYP2C19 Indeterminate	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0e4f9b52-d222-4f74-b710-b4a324153034	Trimipramine-CYP2C19  Ultra-rapid Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c9d037ea-a00d-449a-96e5-d89b605ba3e6	Trimipramine-CYP2C19  Rapid Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
46459ef6-baf6-4729-8232-2a51fc6491a6	Trimipramine-CYP2C19 Normal Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cdf9a600-84ef-4ea6-99ed-6acd5df192bb	Trimipramine-CYP2C19 Likely Intermediate Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
63b14f7a-e198-4551-925e-1f9c5d07fb16	Trimipramine-CYP2C19 Poor Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a1f30561-736f-4915-92de-9adbb25f699d	Trimipramine-CYP2C19 Likely Poor Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a866e0cb-98f3-4d96-985c-0dc4677efedf	Trimipramine-CYP2C19 Indeterminate	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
61098814-7560-4818-a607-9981f1941e2e	Amitriptyline-CYP2C19 Indeterminate & CYP2D6 Normal Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a6c8842-25ec-4eb6-a97a-5fdfa19bbcde	Amitriptyline-CYP2C19 Normal Metabolizer & CYP2D6 Normal Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8db07b1f-725c-41bf-85f2-1c296043dd9d	Amitriptyline-CYP2C19 Intermediate Metabolizer & CYP2D6 Normal Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
db4436b6-95e1-4705-875e-43be52ed6487	Amitriptyline-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Normal Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f6540e59-0d52-4780-a526-60f9841eed98	Amitriptyline-CYP2C19  Ultra-rapid Metabolizer & CYP2D6 Normal Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
57f17ad0-6463-4a12-8b3b-e6cbeb8909bf	Doxepin-CYP2C19 Intermediate Metabolizer & CYP2D6 Normal Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
511b07e2-02ca-4bf2-83ea-5811dd5cdf9d	Amitriptyline-CYP2C19  Rapid Metabolizer & CYP2D6 Normal Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6974d20f-96de-427a-b03d-9b0d9ac53f02	Amitriptyline- CYP2C19 Poor Metabolizer & CYP2D6 Normal Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1e6b46de-fef6-4e73-bea8-1131c9da0faf	Amitriptyline- CYP2C19 Likely Poor Metabolizer & CYP2D6 Normal Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e8ada8df-d99c-42cb-9d07-95078a422753	Clomipramine-CYP2C19 Indeterminate & CYP2D6 Normal Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b04c8eef-dd06-491f-a009-d3ad1d932f8c	Clomipramine-CYP2C19 Normal Metabolizer & CYP2D6 Normal Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8283c783-6023-4122-8213-70c33cbf129c	Clomipramine-CYP2C19 Intermediate Metabolizer & CYP2D6 Normal Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1aaadbd1-4a0b-4dc9-b559-0cf1c764f18e	Clomipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Normal Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6c1a87f2-c162-4064-922f-74c78b11de16	Doxepin-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Normal Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4c73a2b0-f6d6-4e40-b20a-3c6ec7225dd1	Clomipramine-CYP2C19  Ultra-rapid Metabolizer & CYP2D6 Normal Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3e72bd22-b876-4baf-bfde-85028574fbf6	Clomipramine-CYP2C19  Rapid Metabolizer & CYP2D6 Normal Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fb1e82e3-ae3f-4854-abbf-b279a661cfd8	Clomipramine-CYP2C19 Poor Metabolizer & CYP2D6 Normal Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6fe3e0b2-7449-4185-995c-72b93d510215	Clomipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Normal Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dd2c65de-a5b2-4b58-aa90-32c12ccf2330	Doxepin-CYP2C19 Indeterminate & CYP2D6 Normal Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f1d069d8-8c7f-41e6-8ee9-291314a4b685	Doxepin-CYP2C19 Normal Metabolizer & CYP2D6 Normal Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8d8efd4c-fa83-43d0-94f1-11e62628c902	Doxepin-CYP2C19  Ultra-rapid Metabolizer & CYP2D6 Normal Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3797615d-07a8-4908-8cba-7cccab96e045	Doxepin-CYP2C19  Rapid Metabolizer & CYP2D6 Normal Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3fd4eb3b-297a-4f8c-bd5e-b4196dcff5e3	Doxepin-CYP2C19 Poor Metabolizer & CYP2D6 Normal Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2be467bb-d12f-4e98-bd8b-6f4758ced2b0	Doxepin-CYP2C19 Likely Poor Metabolizer & CYP2D6 Normal Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
545ed5fa-bcaf-4fee-8808-dcbe9d23b1da	Imipramine-CYP2C19 Indeterminate & CYP2D6 Normal Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
38bade80-dbd6-41f2-b0b0-1974688afd52	Imipramine-CYP2C19 Normal Metabolizer & CYP2D6 Normal Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c38ab09a-a847-4650-bda4-47d2e50b8056	Imipramine-CYP2C19 Intermediate Metabolizer & CYP2D6 Normal Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1f8dc229-e77a-47e9-aaa8-fc3da2d1f49f	Imipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Normal Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
781ddc71-2043-4803-ae4b-64a7721540a7	Imipramine-CYP2C19  Ultra-rapid Metabolizer & CYP2D6 Normal Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f209020c-301e-4e87-9540-ed64fc9e8649	Imipramine-CYP2C19  Rapid Metabolizer & CYP2D6 Normal Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3521ea4a-ee23-4a5b-88e8-3b3ade993b78	Imipramine-CYP2C19 Poor Metabolizer & CYP2D6 Normal Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9f46890b-c706-40f9-918c-dd3089fa0e2c	Imipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Normal Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
67b1c83a-f169-43e5-bcc6-368742ea501e	Trimipramine-CYP2C19 Indeterminate & CYP2D6 Normal Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a7d10d60-2391-4b6d-a40e-ecc3d0d3c465	Trimipramine-CYP2C19 Normal Metabolizer & CYP2D6 Normal Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cf72ce66-04be-42dd-ad3f-91540f939fbc	Trimipramine-CYP2C19 Intermediate Metabolizer & CYP2D6 Normal Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
30356105-2abd-43e1-8238-53d90f9c41ae	Trimipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Normal Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
017f6ae5-a216-4127-8e79-dae82f965089	Trimipramine-CYP2C19  Ultra-rapid Metabolizer & CYP2D6 Normal Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bea5204d-3497-482e-8e3b-71493cec4054	Trimipramine-CYP2C19  Rapid Metabolizer & CYP2D6 Normal Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d4b50761-d7e3-40a3-85de-0cb0d97b4daa	Trimipramine-CYP2C19 Poor Metabolizer & CYP2D6 Normal Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0d1c3c4b-be80-4802-961c-6d5468239bb7	Citalopram-CYP2C19  Intermediate Metabolizer	8eea746d-0da5-4cd2-b726-b6bdc02022fc	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5c22a73a-e94a-4bcb-8a50-187c981e2336	Sertraline-CYP2C19 Rapid Metabolizer & CYP2B6 Intermediate Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
01314dd5-13d2-44de-b703-8ceacbd79df7	Trimipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Normal Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8a9c7a66-b27b-4619-bf0d-787bcd8ef0fa	Amitriptyline-CYP2C19 Indeterminate & CYP2D6 Ultra-rapid Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
eed94fb6-6fac-46df-9ef5-70c5f99ed297	Amitriptyline-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Ultra-rapid Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8e585878-b6f4-4d2c-b2e9-c9e1f7cf50e9	Amitriptyline-CYP2C19 Rapid Metabolizer & CYP2D6 Ultra-rapid Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
179f878d-f262-484b-9e99-2f9b9fd8ac88	Escitalopram-CYP2C19  Intermediate Metabolizer	e5d6cd1f-e2cb-4aba-9cf2-98163c4df828	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e466907c-b69b-4f4a-9b28-644b090e2325	Sertraline-CYP2C19 Normal Metabolizer & CYP2B6 Intermediate Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
179bb60a-ae3b-4e11-ba9d-28f53ed1812f	Amitriptyline-CYP2C19 Normal Metabolizer & CYP2D6 Ultra-rapid Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use.  If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ac41272c-0a4d-4ba5-b740-2fb9847104fd	Amitriptyline-CYP2C19 Intermediate Metabolizer & CYP2D6 Ultra-rapid Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ec452ceb-2f97-4fbf-bacf-d447ed7a4c1f	Amitriptyline-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Ultra-rapid Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a623867-95a1-428b-b8a1-40fb7b8273e9	Amitriptyline-CYP2C19 Likely Poor Metabolizer & CYP2D6 Ultra-rapid Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
db798725-9768-4608-9bdd-34cec117e875	Citalopram-CYP2C19  Likely Intermediate Metabolizer	8eea746d-0da5-4cd2-b726-b6bdc02022fc	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d655db93-b004-461e-888f-384f31dd7b29	Sertraline-CYP2C19 Intermediate Metabolizer & CYP2B6 Intermediate Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
81d0d03d-737a-4a93-92c4-b57c4a21f779	Amitriptyline-CYP2C19 Poor Metabolizer & CYP2D6 Ultra-rapid Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
791e44b7-9ee0-46e2-9a18-40e0b42dd23b	Clomipramine-CYP2C19 Indeterminate & CYP2D6 Ultra-rapid Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c923c6a6-2cc8-4469-946e-3b6971dbf060	Clomipramine-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Ultra-rapid Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2657705a-9ada-490e-b519-528ccf60fb97	Clomipramine-CYP2C19 Rapid Metabolizer & CYP2D6 Ultra-rapid Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7467a7ab-8c99-4c65-a227-190291a159b1	Clomipramine-CYP2C19 Normal Metabolizer & CYP2D6 Ultra-rapid Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e2a2c57e-d46a-4105-9357-f2e75087645f	Clomipramine-CYP2C19 Intermediate Metabolizer & CYP2D6 Ultra-rapid Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f285714b-68b7-4147-9724-86f059dbe6f4	Clomipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Ultra-rapid Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1a10896b-8cff-410c-b71b-90ab9dcc91ef	Clomipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Ultra-rapid Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
55fddcad-8c3a-4d8a-8ecb-d068c244d942	Clomipramine-CYP2C19 Poor Metabolizer & CYP2D6 Ultra-rapid Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3ca6aa15-539e-4ba6-aeb6-a0e1a4af12e6	Escitalopram-CYP2C19  Likely Intermediate Metabolizer	e5d6cd1f-e2cb-4aba-9cf2-98163c4df828	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f25a391c-375a-4752-9d61-7d278001ed59	Tacrolimus-CYP3A5 Indeterminate	0d36fae9-d172-4bed-ab68-125ee9d62392	{cd3bc960-aea4-40fb-a1ad-f54c10b7228b}	\N	Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015;98(1):19-24. doi:10.1002/cpt.113	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
11e21752-5717-47b1-8b96-f092dff10b39	Doxepin-CYP2C19 Indeterminate & CYP2D6 Ultra-rapid Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3ccbd001-7efb-4a38-aa4b-01b130232e69	Doxepin-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Ultra-rapid Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use.  If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2164853b-b028-460c-8cbb-f38e127d12fa	Doxepin-CYP2C19 Rapid Metabolizer & CYP2D6 Ultra-rapid Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ee7fc232-90fe-418a-a120-5bdf4277dd6d	Doxepin-CYP2C19 Normal Metabolizer & CYP2D6 Ultra-rapid Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
339bf2dd-5330-46cd-a893-6c81233bf761	Doxepin-CYP2C19 Intermediate Metabolizer & CYP2D6 Ultra-rapid Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b9c33ecb-37a2-47ba-8d9c-9e0ae3980f4a	Doxepin-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Ultra-rapid Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
820e292a-cb17-4727-aabc-4d9b6f7fa9be	Doxepin-CYP2C19 Likely Poor Metabolizer & CYP2D6 Ultra-rapid Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9f40b8e0-7bf5-4a87-8341-0d4e5f294fa7	Doxepin-CYP2C19 Poor Metabolizer & CYP2D6 Ultra-rapid Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7a3764ce-ed85-470c-8bb6-b9de2fbdb95f	Imipramine-CYP2C19 Indeterminate & CYP2D6 Ultra-rapid Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ca9877ee-7d6f-472b-9e97-ea942f28bdc7	Sertraline- CYP2C19 Poor Metabolizer & CYP2B6 Ultra-rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to reduced metabolism to less active compounds when compared to CYP2C19 normal metabolizers.  Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c6f235c2-afd2-4d7a-a99e-535a9ebe588c	Imipramine-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Ultra-rapid Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ada2db34-cea6-471c-93de-f42de5ff3d66	Imipramine-CYP2C19 Rapid Metabolizer & CYP2D6 Ultra-rapid Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a8ed83e9-940d-4cd2-bb60-b43940d20a0c	Imipramine-CYP2C19 Normal Metabolizer & CYP2D6 Ultra-rapid Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f67ca84e-9da8-4aa3-a075-5d1119802f9b	Imipramine-CYP2C19 Intermediate Metabolizer & CYP2D6 Ultra-rapid Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0ffa64f2-ab01-40ce-a404-f02d08aacda3	Trimipramine-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Ultra-rapid Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3e3f77b4-4ff2-481d-907d-0e0506f225bf	Imipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Ultra-rapid Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ec657423-2bfd-416d-b911-1cd5f5a747da	Imipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Ultra-rapid Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
95069c11-8df1-4295-a5ff-eca483de3063	Imipramine-CYP2C19 Poor Metabolizer & CYP2D6 Ultra-rapid Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
95aaf308-5f38-4161-87db-833a6f2f6ea3	Trimipramine-CYP2C19 Indeterminate & CYP2D6 Ultra-rapid Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
aeb6148d-78b2-42a4-aab2-8e2413536702	Sertraline- CYP2C19  Poor Metabolizer & CYP2B6 Rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to reduced metabolism to less active compounds when compared to CYP2C19 normal metabolizers.  Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
80d1c48c-b87f-4017-a75b-50b5f363857d	Trimipramine-CYP2C19 Rapid Metabolizer & CYP2D6 Ultra-rapid Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
38fa1334-0907-4b38-aaf6-65aa99ef83dc	Trimipramine-CYP2C19 Normal Metabolizer & CYP2D6 Ultra-rapid Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
152fd163-e248-4062-8a75-6dd5aa945840	Trimipramine-CYP2C19 Intermediate Metabolizer & CYP2D6 Ultra-rapid Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e89d3bec-39a3-486c-bf99-43c4f1846dce	Trimipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Ultra-rapid Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
89fed694-8cfd-4818-ae01-505934ec2f8c	Clomipramine-CYP2C19 Normal Metabolizer & CYP2D6 Intermediate Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8d2b0e69-dfe0-4c1a-bbe2-359d28446b6e	Trimipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Ultra-rapid Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
53393c97-98e4-40f4-9a54-010fe4295dd0	Trimipramine-CYP2C19 Poor Metabolizer & CYP2D6 Ultra-rapid Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a9b502fc-20fb-46d3-83da-9df724b3a099	Amitriptyline-CYP2C19 Indeterminate & CYP2D6 Intermediate Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2915914e-f69b-4cfd-ad01-111dfa753770	Amitriptyline-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Intermediate Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
06a2b0e0-cbb2-49ad-9184-f27371a0171e	Sertraline-CYP2C19 Likely Intermediate Metabolizer & CYP2B6 Intermediate Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
106c01d9-57ca-4434-9986-1ebec31ceff1	Venlafaxine-CYP2D6 Normal Metabolizer	bb526458-a0a7-42be-b95d-69eed3cf71b7	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d5a41768-aecb-4878-96dc-e54fd9392aba	Amitriptyline-CYP2C19 Rapid Metabolizer & CYP2D6 Intermediate Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ac3c530c-fac5-4b4b-b3b3-e75fc8a35fa6	Amitriptyline-CYP2C19 Normal Metabolizer & CYP2D6 Intermediate Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3cf0a06e-ad71-4347-b0a4-6f6aed6baf23	Amitriptyline-CYP2C19 Intermediate Metabolizer & CYP2D6 Intermediate Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
901264cf-8113-4bf9-8da6-018424e03196	Amitriptyline-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Intermediate Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
331f2b6f-bfd1-425d-8874-19c3f1eaa5e9	Clomipramine-CYP2C19 Rapid Metabolizer & CYP2D6 Intermediate Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider alternative drug not metabolized by CYP2C19. If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
aa35fda4-f6b3-4212-ae86-2410b168841a	Amitriptyline-CYP2C19 Likely Poor Metabolizer & CYP2D6 Intermediate Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use. If TCA use is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5aed1819-fdf8-4a20-8211-2cbcef8cb2ab	Amitriptyline-CYP2C19 Poor Metabolizer & CYP2D6 Intermediate Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use. If TCA use is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e4160613-c418-4b30-93c2-3b35964ba568	Clomipramine-CYP2C19 Indeterminate & CYP2D6 Intermediate Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f087e915-83b1-46d8-9c8f-a1d1b2e57eb1	Clomipramine-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Intermediate Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider alternative drug not metabolized by CYP2C19. If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
20e0e3dd-4f94-48f7-83b6-4eb88f9c86b8	Sertraline-CYP2C19 Likely Poor Metabolizer & CYP2B6 Normal Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism to less active compounds when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c6021acf-f869-4c5b-89e7-af209997b0e3	Clomipramine-CYP2C19 Intermediate Metabolizer & CYP2D6 Intermediate Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
eaac721f-eeee-4f0c-9976-57cdc5c1da8a	Clomipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Intermediate Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cab79f25-9629-477a-81bb-7e00da7a13a4	Clomipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Intermediate Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use. If TCA use is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a12d4e91-d5b7-440f-a3f2-2bfeee78a54d	Clomipramine-CYP2C19 Poor Metabolizer & CYP2D6 Intermediate Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use. If TCA use is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f88b35ea-f95e-419c-8173-af39e9fc801c	Citalopram-CYP2C19  Poor Metabolizer	8eea746d-0da5-4cd2-b726-b6bdc02022fc	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram is clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.\n\nPer the FDA warning, citalopram 20&nbsp;mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20&nbsp;mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to reduced metabolism to less active compounds when compared to CYP2C19 normal and intermediate metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6cb63dfc-41a4-457a-a201-8dde951d3915	Doxepin-CYP2C19 Indeterminate & CYP2D6 Intermediate Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c4919058-d2ea-444c-b75d-3cd53d7ae5ec	Doxepin-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Intermediate Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider alternative drug not metabolized by CYP2C19. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
612f91ab-09d3-436b-a92f-c5d2ef53267a	Doxepin-CYP2C19 Rapid Metabolizer & CYP2D6 Intermediate Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider alternative drug not metabolized by CYP2C19. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
046d9d4e-5416-4f1f-b548-f9c117fcc2a5	Doxepin-CYP2C19 Normal Metabolizer & CYP2D6 Intermediate Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
61c60468-4b7a-4b50-9e9e-f22ef0db9d5b	Doxepin-CYP2C19 Intermediate Metabolizer & CYP2D6 Intermediate Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e5817e5b-dd37-4327-8d64-ce51cd97298d	Celecoxib-CYP2C9 Normal Metabolizer	211b33bf-72c3-4545-a4b2-ea558809d086	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a5c5325e-d4d6-4d51-b1ec-ffe8d889410d	Doxepin-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Intermediate Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ee20fec2-5cec-48f3-9682-7d3a031013a1	Doxepin-CYP2C19 Likely Poor Metabolizer & CYP2D6 Intermediate Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use. If TCA use is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dfbe5ffa-8c3a-4431-8633-16a91c4c8e7a	Doxepin-CYP2C19 Poor Metabolizer & CYP2D6 Intermediate Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use. If TCA use is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
71440925-2e06-4ca1-b961-10571536c0de	Imipramine-CYP2C19 Indeterminate & CYP2D6 Intermediate Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ced86a58-1356-421c-9299-4e9101476764	Escitalopram-CYP2C19  Poor Metabolizer	e5d6cd1f-e2cb-4aba-9cf2-98163c4df828	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If escitalopram is clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to reduced metabolism to less active compounds when compared to CYP2C19 normal and intermediate metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
312a38b3-b8d2-407d-8194-3ac102a25feb	Imipramine-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Intermediate Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider alternative drug not metabolized by CYP2C19. If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b53f16d5-53c9-48f2-9365-b99075ef9d4a	Imipramine-CYP2C19 Rapid Metabolizer & CYP2D6 Intermediate Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider alternative drug not metabolized by CYP2C19. If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c8a7ace8-a004-4b25-a544-95cdb1f8fa24	Imipramine-CYP2C19 Normal Metabolizer & CYP2D6 Intermediate Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1135a2d2-1263-4fc8-a24e-5ae4a3056341	Imipramine-CYP2C19 Intermediate Metabolizer & CYP2D6 Intermediate Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8761727b-6676-4df3-b494-11578e16a4f5	Imipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Intermediate Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
436bd090-b753-4806-bd98-1f8affac5d9c	Imipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Intermediate Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use. If TCA use is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
03e00c6d-d796-4098-aa58-0be80ac18bf7	Imipramine-CYP2C19 Poor Metabolizer & CYP2D6 Intermediate Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use. If TCA use is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9d9fd90c-4512-47d7-82bc-d63082d752dd	Trimipramine-CYP2C19 Indeterminate & CYP2D6 Intermediate Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
46538421-9341-4d9d-bae6-05b9a40d28b4	Trimipramine-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Intermediate Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider alternative drug not metabolized by CYP2C19. If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e8dcb1f1-8d31-4723-9b38-18dc2d6a7ecc	Sertraline-CYP2C19 Likely Poor Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to reduced metabolism to less active compounds when compared to CYP2C19 normal and intermediate metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4ee55aa6-4afc-414c-a234-ef10db07284c	Trimipramine-CYP2C19 Rapid Metabolizer & CYP2D6 Intermediate Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider alternative drug not metabolized by CYP2C19. If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d018434a-0d3f-4ab6-8284-d62db75dc61f	Trimipramine-CYP2C19 Normal Metabolizer & CYP2D6 Intermediate Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4d72a954-8a3a-4ab3-bbde-88f12cb8717d	Trimipramine-CYP2C19 Intermediate Metabolizer & CYP2D6 Intermediate Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2d1f4466-cdb5-45c3-baa7-214372c06081	Trimipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Intermediate Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9765fb91-5321-4271-8ad5-312e4f4a5209	Amitriptyline-CYP2C19 Rapid Metabolizer & CYP2D6 Poor Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
93f07369-806f-48f9-8563-5a9a733789e2	Trimipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Intermediate Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use. If TCA use is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3f3fac3c-5ddc-4858-9049-0bd1d8078c98	Trimipramine-CYP2C19 Poor Metabolizer & CYP2D6 Intermediate Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use. If TCA use is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b6c428a9-1989-4f40-9663-728a19e94c3d	Amitriptyline-CYP2C19 Indeterminate & CYP2D6 Poor Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c38b3bd2-d37c-404f-a6e5-2c988a872fd8	Amitriptyline-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Poor Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ee0ba439-f04e-4e69-b66e-081e84b7a563	Sertraline- CYP2C19 Indeterminate	6451a255-0983-473a-9fe4-6c24451820c3	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
244b6a83-a17e-42b9-bc6f-4a8a8e99f31b	Sertraline- CYP2C19 Ultra-rapid Metabolizer & CYP2B6 Ultra-rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
313d1c60-d5cc-4288-b42f-6aeb1aa0315d	Amitriptyline-CYP2C19 Normal Metabolizer & CYP2D6 Poor Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
487b6c10-98de-4894-82b0-a0a6dd2a7f8b	Amitriptyline-CYP2C19 Intermediate Metabolizer & CYP2D6 Poor Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0d203413-b7cb-43bd-b3cf-be3d2267d19d	Amitriptyline-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Poor Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
33b3289f-2079-4c5a-be64-de420cfc7060	Amitriptyline-CYP2C19 Likely Poor Metabolizer & CYP2D6 Poor Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
22d62f74-8bf3-4dd9-9202-020bd743bfc0	Sertraline- CYP2C19 Rapid Metabolizer & CYP2B6 Ultra-rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9fbb0636-93c2-4163-9a6b-c63ccf54122c	Sertraline- CYP2C19 Ultra-rapid Metabolizer & CYP2B6 Rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e9dc3d55-7e98-4995-9a71-7075d98e795b	Amitriptyline-CYP2C19 Poor Metabolizer & CYP2D6 Poor Metabolizer	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid amitriptyline use. If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
efd8793b-dfbe-417a-aa2e-716dffc38f8b	Clomipramine-CYP2C19 Indeterminate & CYP2D6 Poor Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
61c4342f-1a18-4720-bedb-566268cd56ba	Clomipramine-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Poor Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d01d74f7-08ab-4685-9a7d-1509e25ae1b6	Clomipramine-CYP2C19 Rapid Metabolizer & CYP2D6 Poor Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a02e39be-fa91-40a2-8450-3779cf175047	Clomipramine-CYP2C19 Normal Metabolizer & CYP2D6 Poor Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cf1fcdea-8ca0-4ffe-93bb-aaeebbf8c6a5	Clomipramine-CYP2C19 Intermediate Metabolizer & CYP2D6 Poor Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6925e912-9431-436a-b4a4-17450fab7ec0	Clomipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Poor Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
19e11347-c03a-42a8-8713-1d04deccc0c9	Clomipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Poor Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bc3bac42-753e-48e5-adc6-f969ac366645	Clomipramine-CYP2C19 Poor Metabolizer & CYP2D6 Poor Metabolizer	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid clomipramine use. If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a8efaa16-6511-424c-816c-e171ebfb0aca	Sertraline- CYP2C19 Rapid Metabolizer & CYP2B6 Rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a90c8987-c7b3-4f1c-bede-0cd4af926f11	Sertraline- CYP2C19 Normal Metabolizer & CYP2B6 Ultra-rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f471fd43-e84a-4e68-8e16-cb799b43116d	Doxepin-CYP2C19 Indeterminate & CYP2D6 Poor Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
62c94eec-08fb-4946-8d6e-fc91e9e1e3b3	Doxepin-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Poor Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
63eef403-d624-4098-8339-72d14df4caa3	Doxepin-CYP2C19 Rapid Metabolizer & CYP2D6 Poor Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8431b50d-5783-4016-b519-9ca0e3156205	Doxepin-CYP2C19 Normal Metabolizer & CYP2D6 Poor Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
890dd3d6-3af0-4be4-97ca-eafeb8573c09	Doxepin-CYP2C19 Intermediate Metabolizer & CYP2D6 Poor Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
448065cd-fe23-4b2e-8e12-fbbd33829233	Doxepin-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Poor Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2f83844c-9384-4458-8a87-73cc742c435c	Doxepin-CYP2C19 Likely Poor Metabolizer & CYP2D6 Poor Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
712dc761-2981-408d-b616-36e76f628864	Doxepin-CYP2C19 Poor Metabolizer & CYP2D6 Poor Metabolizer	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
54556387-fd94-43ea-9ef2-7f1c0054b976	Imipramine-CYP2C19 Indeterminate & CYP2D6 Poor Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
949af886-60f4-4fc2-ae20-8dfee15f4523	Sertraline- CYP2C19 Normal Metabolizer & CYP2B6 Rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
da3e26cd-9d4c-4e75-bf3b-28b8e4f1a2b7	Sertraline- CYP2C19 Intermediate Metabolizer & CYP2B6 Ultra-rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b0c14d48-72a8-4989-af5b-b8dd8c298e49	Imipramine-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Poor Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8ae12903-b894-4b8a-9bf6-96a3c0409581	Imipramine-CYP2C19 Rapid Metabolizer & CYP2D6 Poor Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bbff580f-6974-4a42-bc8e-f7053dc0bdb5	Imipramine-CYP2C19 Normal Metabolizer & CYP2D6 Poor Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
91053158-b4f4-456c-9ba0-f5f933222e5a	Imipramine-CYP2C19 Intermediate Metabolizer & CYP2D6 Poor Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
326cb7bf-998a-4499-8dfa-9ed5af4fe8e2	Imipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Poor Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5d2d76ae-b03e-46b9-9868-403471183594	Imipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Poor Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0ad836d4-e9a4-4c1b-ba2d-36a9a7a1f172	Imipramine-CYP2C19 Poor Metabolizer & CYP2D6 Poor Metabolizer	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid imipramine use. If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
209fb6f9-e81d-4a9e-a8a2-2d91138ee2e7	Trimipramine-CYP2C19 Indeterminate & CYP2D6 Poor Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2C19 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a53728d0-b13b-42b6-a1cd-9ee0c6813691	Trimipramine-CYP2C19 Ultra-rapid Metabolizer & CYP2D6 Poor Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
05bf30c8-b9ba-442e-adc6-e75cd0c13eba	Sertraline- CYP2C19 Intermediate Metabolizer & CYP2B6 Rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d3ab9f6c-2eb7-4dcf-8164-6d697dbe401c	Sertraline- CYP2C19 Likely Intermediate Metabolizer & CYP2B6 Ultra-rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6ed2ca88-75ee-46b2-a6c4-f3c039427c47	Trimipramine-CYP2C19 Rapid Metabolizer & CYP2D6 Poor Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5e892c09-3743-4225-9698-99f2edb38147	Trimipramine-CYP2C19 Normal Metabolizer & CYP2D6 Poor Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9a7018d0-4760-44e3-a28e-58cc3fa92ee4	Trimipramine-CYP2C19 Intermediate Metabolizer & CYP2D6 Poor Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
91c38df7-9df0-4e04-bda6-40394116f661	Trimipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Poor Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f35656cb-c73e-423d-b415-151045d39041	Nortriptyline- CYP2D6 Poor Metabolizer	0657dff9-1f56-42ed-af15-32d062f546db	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fb634a4a-2bd5-49ab-84ce-4c5db408d1ad	Trimipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Poor Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
50cbec59-9a2b-42a9-a453-c1c54d6f4b12	Trimipramine-CYP2C19 Poor Metabolizer & CYP2D6 Poor Metabolizer	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid trimipramine use. If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
44a7d6a5-b261-4ba6-9346-7b6009bfabf3	Nortriptyline-CYP2D6 Ultra-rapid Metabolizer	0657dff9-1f56-42ed-af15-32d062f546db	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c3c170ab-99dc-4370-9116-b635db7bac67	Nortriptyline-CYP2D6 Normal Metabolizer	0657dff9-1f56-42ed-af15-32d062f546db	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9af83db6-a91e-423c-b2ef-bf3fba38b6ef	Nortriptyline-CYP2D6 Indeterminate	0657dff9-1f56-42ed-af15-32d062f546db	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3e37dc98-958f-4283-906c-fac29b4ce27a	Nortriptyline-CYP2D6 Intermediate Metabolizer	0657dff9-1f56-42ed-af15-32d062f546db	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c7432204-89f9-4271-90c7-0ae0f2e3f0d0	Imipramine-CYP2C19  Intermediate Metabolizer & CYP2D6 Indeterminate	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0dc1abc0-9ce7-4c2f-8c97-e03a987e8a21	Desipramine-CYP2D6 Ultra-rapid Metabolizer	b86504f1-f2ff-4550-ba67-d164b88a33a8	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure due to increased metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e456e281-1ee2-45e1-8203-238bee1c3e80	Desipramine-CYP2D6 Normal Metabolizer	b86504f1-f2ff-4550-ba67-d164b88a33a8	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ae1aaa83-1643-4ba5-b768-eb73d5c1de49	Desipramine-CYP2D6 Indeterminate	b86504f1-f2ff-4550-ba67-d164b88a33a8	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2d702569-4e78-4d1a-bbe7-ee6a81b4dbcb	Desipramine-CYP2D6 Intermediate Metabolizer	b86504f1-f2ff-4550-ba67-d164b88a33a8	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
da74c625-7125-4e81-9db9-c203e9d6818f	Desipramine- CYP2D6 Poor Metabolizer	b86504f1-f2ff-4550-ba67-d164b88a33a8	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid TCA use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Higher plasma concentrations of active drug will increase the probability of side effects due to greatly reduced metabolism of tricyclic antidepressants (TCAs) to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
219fe38d-1f54-455d-be5c-9a91a03b5d66	Amitriptyline-CYP2C19  Ultra-rapid Metabolizer & CYP2D6 Indeterminate	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
94fbdc33-6f5c-40bb-ad15-8c82b52a96ab	Imipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Indeterminate	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0978d229-956d-4331-b5d2-01e7b8c8c9d8	Sertraline- CYP2C19 Likely Intermediate Metabolizer & CYP2B6 Rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fd22b8c8-c356-451f-afbb-27c2e3f52240	Amitriptyline-CYP2C19  Rapid Metabolizer & CYP2D6 Indeterminate	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
001f1f6c-61eb-4319-9ef8-d9ebaf9cb701	Amitriptyline-CYP2C19  Normal Metabolizer & CYP2D6 Indeterminate	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
94f63765-e9dc-42d9-a46a-0c8756a95984	Amitriptyline-CYP2C19  Intermediate Metabolizer & CYP2D6 Indeterminate	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c4ce1d94-5574-49d6-8583-4cd754c7d4d6	Amitriptyline-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Indeterminate	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d6c7ef74-720d-49e8-af44-164271bd6f96	Amitriptyline-CYP2C19 Likely Poor Metabolizer & CYP2D6 Indeterminate	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in this guideline refers to the recommended steady state dose.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cd1607b6-6b70-45eb-ae3b-91eca7e843f0	Amitriptyline-CYP2C19 Poor Metabolizer & CYP2D6 Indeterminate	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in this guideline refers to the recommended steady state dose.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a4b3cbd0-39fe-4b3e-b395-f4bd5f025c94	Amitriptyline-CYP2C19  Indeterminate & CYP2D6 Indeterminate	45477af2-958f-42d0-853a-8b9f9c7ce998	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
eb8da0e6-e6a3-418b-9b6b-2fcd2a09ccea	Trimipramine-CYP2C19  Intermediate Metabolizer & CYP2D6 Indeterminate	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
da332d3d-e43f-41bf-bb51-17f7a79a6f1c	Celecoxib-CYP2C9 Intermediate Metabolizer	211b33bf-72c3-4545-a4b2-ea558809d086	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bd8487f3-d855-4d04-b38d-de59be5ff422	Clomipramine-CYP2C19  Ultra-rapid Metabolizer & CYP2D6 Indeterminate	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8b8e9742-7065-4026-b027-2270f7f73413	Clomipramine-CYP2C19  Rapid Metabolizer & CYP2D6 Indeterminate	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
008bae1b-e8ea-46d2-8b92-4144def10086	Clomipramine-CYP2C19  Normal Metabolizer & CYP2D6 Indeterminate	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6cb0d03c-63dc-4161-93ad-096797488c3a	Clomipramine-CYP2C19  Intermediate Metabolizer & CYP2D6 Indeterminate	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a960a468-63a8-4fca-80e4-b199017bb514	Clomipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Indeterminate	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
159a6e4e-a06c-49fb-bb18-3b221f15c3ba	Clomipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Indeterminate	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in this guideline refers to the recommended steady state dose.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0cd2664b-2bc4-495f-aaaf-6fd7f4cef2dd	Trimipramine-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Indeterminate	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8c5b5a59-b6b2-40a5-afae-0609b70c5290	Sertraline-CYP2C19 Indeterminate & CYP2B6 Normal Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9485b506-3ee7-47e4-952f-4d1c017c1147	Clomipramine-CYP2C19 Poor Metabolizer & CYP2D6 Indeterminate	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs)without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in this guideline refers to the recommended steady state dose.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7cea84da-0c8d-4351-bc16-45a7448b237c	Clomipramine-CYP2C19  Indeterminate & CYP2D6 Indeterminate	6d583253-b4f1-4c41-a7b5-aa0e27d4335f	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
42dbbeda-ecf8-40c4-8e2a-c4fa100c1964	Doxepin-CYP2C19  Ultra-rapid Metabolizer & CYP2D6 Indeterminate	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9bdc2221-0b46-421c-9dda-b61693c31ec5	Doxepin-CYP2C19  Rapid Metabolizer & CYP2D6 Indeterminate	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
72fa3f0b-a4c2-44a4-8c50-08a07afdb951	Doxepin-CYP2C19  Normal Metabolizer & CYP2D6 Indeterminate	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
57e3cac5-5f91-4945-a32c-8e1fd68e7018	Doxepin-CYP2C19  Intermediate Metabolizer & CYP2D6 Indeterminate	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
664b28a6-6308-4db4-851e-ca19679b174b	Doxepin-CYP2C19 Likely Intermediate Metabolizer & CYP2D6 Indeterminate	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b3c3e95b-c711-4bfe-8c9a-28b34c89a235	Escitalopram-CYP2C19  Normal Metabolizer	e5d6cd1f-e2cb-4aba-9cf2-98163c4df828	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a499471-176d-4243-ba71-0bb4816dc54c	Sertraline-CYP2C19 Ultra-rapid Metabolizer & CYP2B6 Intermediate Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2e5d1445-6ae4-4e72-a21d-508ac3f52e6d	Doxepin-CYP2C19 Likely Poor Metabolizer & CYP2D6 Indeterminate	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in this guideline refers to the recommended steady state dose.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3ceba21f-c32a-4b08-b628-221f62dff14d	Doxepin-CYP2C19 Poor Metabolizer & CYP2D6 Indeterminate	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in this guideline refers to the recommended steady state dose.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4ad71a0f-ba54-4a3b-a07a-1c4049dd0ab3	Doxepin-CYP2C19  Indeterminate & CYP2D6 Indeterminate	09a32385-64b1-47b5-89c8-ead4799165a4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3a9d50fa-0d37-45eb-82cc-f20333d79f8d	Imipramine-CYP2C19  Ultra-rapid Metabolizer & CYP2D6 Indeterminate	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7595dd00-7a39-404d-97ad-ccaba60678a7	Imipramine-CYP2C19  Rapid Metabolizer & CYP2D6 Indeterminate	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
38a8e704-e0e5-4c94-9ee0-677956bf126a	Imipramine-CYP2C19  Normal Metabolizer & CYP2D6 Indeterminate	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c3883637-d0a9-47e0-aeeb-b2312b9214bd	Imipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Indeterminate	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in this guideline refers to the recommended steady state dose.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d0a65563-5711-494c-b3d7-29d9093b644c	Imipramine-CYP2C19 Poor Metabolizer & CYP2D6 Indeterminate	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in this guideline refers to the recommended steady state dose.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
69d240f6-e46f-47a7-ba08-953beffe59d9	Imipramine-CYP2C19  Indeterminate & CYP2D6 Indeterminate	ee2adcd3-4012-4ca7-b689-0c34f879cff0	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
75c94438-0508-4144-b6a2-f2c808f1dc77	Trimipramine-CYP2C19  Ultra-rapid Metabolizer & CYP2D6 Indeterminate	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
40f2ef16-f7b3-40d9-8d90-b78ab68d610e	Trimipramine-CYP2C19  Rapid Metabolizer & CYP2D6 Indeterminate	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in the CPIC guideline refers to the recommended steady state dose. TCAs may be prescribed for alternative indications in which much lower dosing strategies are utilized such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Greater conversion of tertiary amines to secondary amines may affect response or side effects due to increased metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cf31d9ad-fcc8-41f1-bd1e-bd0d292a2e5d	Trimipramine-CYP2C19  Normal Metabolizer & CYP2D6 Indeterminate	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
02dce982-e875-4a12-8729-f3be5de4c3f0	Trimipramine-CYP2C19 Likely Poor Metabolizer & CYP2D6 Indeterminate	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.\n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in this guideline refers to the recommended steady state dose.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
37c3d86e-82c1-4c44-a129-6c0d69b478a5	Trimipramine-CYP2C19 Poor Metabolizer & CYP2D6 Indeterminate	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. Tricyclic antidepressants (TCAs) without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. \n\nDosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a TCA, which is then increased over several days to the recommended steady state dose. The starting dose in this guideline refers to the recommended steady state dose.\n\nCYP2D6 genotype result is not available to further guide TCA dosing.	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Caution (Yellow Column)	Decreased conversion of tertiary amines to secondary amines may affect response or side effects due to greatly reduced metabolism of tertiary amines when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
960109a1-18dc-4dfd-b58c-57a3e4f9a2bc	Trimipramine-CYP2C19  Indeterminate & CYP2D6 Indeterminate	7f4e2cf7-21f6-4730-9934-d9d9b3523481	{32638f99-ec66-41e9-87db-40b5f6c8d7d6,aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bf76e1e5-1299-4692-89ef-7324e7c5397a	Citalopram-CYP2C19  Ultra-rapid Metabolizer	8eea746d-0da5-4cd2-b726-b6bdc02022fc	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram is clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Lower plasma concentrations decrease the probability of clinical benefit due to increased metabolism to less active compounds when compared to CYP2C19 rapid and normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4e0ca41d-205e-4cef-afba-d744417d3dc5	Escitalopram-CYP2C19  Ultra-rapid Metabolizer	e5d6cd1f-e2cb-4aba-9cf2-98163c4df828	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If escitalopram is clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Lower plasma concentrations decrease the probability of clinical benefit due to increased metabolism to less active compounds when compared to CYP2C19 rapid and normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1f32f97f-bc51-49c5-8e45-27fa3116248b	Citalopram-CYP2C19  Rapid Metabolizer	8eea746d-0da5-4cd2-b726-b6bdc02022fc	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b1c21740-2daa-4728-816e-da885b41c8a6	Escitalopram-CYP2C19  Rapid Metabolizer	e5d6cd1f-e2cb-4aba-9cf2-98163c4df828	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e2f99b3f-753c-4286-87f2-e4b7640537da	Citalopram-CYP2C19  Normal Metabolizer	8eea746d-0da5-4cd2-b726-b6bdc02022fc	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
30a8a1a9-4b95-4e29-bef2-4be4b072108b	Citalopram-CYP2C19 Likely Poor Metabolizer	8eea746d-0da5-4cd2-b726-b6bdc02022fc	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram is clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.\n\nPer the FDA warning, citalopram 20&nbsp;mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20&nbsp;mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to reduced metabolism to less active compounds when compared to CYP2C19 normal and intermediate metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b704be90-df98-4d90-8e3c-b1bb83e7dfda	Escitalopram-CYP2C19 Likely Poor Metabolizer	e5d6cd1f-e2cb-4aba-9cf2-98163c4df828	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If escitalopram is clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to reduced metabolism to less active compounds when compared to CYP2C19 normal and intermediate metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a71aa043-e695-40b9-b3e4-802815738815	Citalopram-CYP2C19  Indeterminate	8eea746d-0da5-4cd2-b726-b6bdc02022fc	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c41b06cf-c114-4b78-9e0d-007822fed668	Escitalopram-CYP2C19  Indeterminate	e5d6cd1f-e2cb-4aba-9cf2-98163c4df828	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
42cfed9c-0ca7-45a6-b865-fcd50c2b98b1	Sertraline- CYP2C19 Ultra-rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
47b65c87-8d48-47d8-8f5d-679066b826ef	Sertraline- CYP2C19 Rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e53d949c-5d2d-424b-b4d3-9663ecb3a63c	Sertraline- CYP2C19 Normal Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
71c1e0c6-2a75-4f7e-b15a-9f40991965a1	Sertraline- CYP2C19 Intermediate Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1e8842ac-3edd-44a9-b7cd-b745f2c73d52	Sertraline- CYP2C19 Likely Intermediate Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
907cbdb7-8ad8-4a26-9ff6-8cf664762487	Sertraline-CYP2C19 Poor Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to reduced metabolism to less active compounds when compared to CYP2C19 normal and intermediate metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
368db12d-3e0d-4d84-bf54-9e9adab15b80	Meloxicam-CYP2C9 Intermediate Metabolizer	5d66d6a8-1c96-4bbd-99fd-0eca947dace6	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d871940c-e5ba-4eb9-bf2e-d640b9227fb2	Sertraline- CYP2C19 Likely Poor Metabolizer & CYP2B6 Ultra-rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to reduced metabolism to less active compounds when compared to CYP2C19 normal metabolizers.  Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
afbc8441-e6da-496c-a859-f572c0f24c87	Sertraline- CYP2C19 Likely Poor Metabolizer & CYP2B6 Rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to reduced metabolism to less active compounds when compared to CYP2C19 normal metabolizers.  Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3a57da7c-3899-4cf6-a5ca-ec5d5fe6266d	Sertraline- CYP2C19 Indeterminate & CYP2B6 Ultra-rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7e687aff-c2f7-487f-84dc-e35e89c77b3f	Sertraline- CYP2C19 Indeterminate & CYP2B6 Rapid Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
598b197c-c3d4-4f5c-a80f-99aee838476b	Sertraline-CYP2C19 Ultra-rapid Metabolizer & CYP2B6 Normal Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0e3755b8-0455-4602-a94a-68baa6f15f36	Sertraline-CYP2C19 Rapid Metabolizer & CYP2B6 Normal Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a68076d9-b0f9-413f-82c8-e8d38e300beb	Sertraline-CYP2C19 Normal Metabolizer & CYP2B6 Normal Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f79acf6e-685f-4e61-9752-b66fc79264bf	Sertraline-CYP2C19 Intermediate Metabolizer & CYP2B6 Normal Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d1787421-8fab-475b-a59b-afbe7c83cf17	Sertraline-CYP2C19 Likely Intermediate Metabolizer & CYP2B6 Normal Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e0b53d97-a919-4be1-90c0-fd9e904c426f	Sertraline-CYP2C19 Poor Metabolizer & CYP2B6 Normal Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism to less active compounds when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6b2f2b9f-0085-4606-a483-c1b824cdcf65	Voriconazole-CYP2C19  Intermediate Metabolizer	390fc57c-6ae0-47bc-9512-cb4bdde98e97	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy [published correction appears in Clin Pharmacol Ther. 2018 Feb;103(2):349]. Clin Pharmacol Ther. 2017;102(1):45-51. doi:10.1002/cpt.583	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
065fa74f-cf8f-4741-9135-1b11f08adb76	Sertraline-CYP2C19 Poor Metabolizer & CYP2B6 Intermediate Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism to less active compounds when compared to CYP2C19 normal metabolizers.  Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
80844d0d-83f5-4cea-8291-01a7be3e7642	Sertraline-CYP2C19 Likely Poor Metabolizer & CYP2B6 Intermediate Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism to less active compounds when compared to CYP2C19 normal metabolizers.  Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a3c7e0f9-f240-4c26-b733-dfbdefee93cd	Sertraline-CYP2C19 Indeterminate & CYP2B6 Intermediate Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6a0f53d4-dd83-4f1d-94af-b4057980b1c1	Sertraline-CYP2C19 Ultra-rapid Metabolizer & CYP2B6 Poor Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7b6b0af0-3152-4195-b0e8-9c4b0c9aab1c	Sertraline-CYP2C19 Rapid Metabolizer & CYP2B6 Poor Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
66b52fb0-d809-4f6f-88a4-655cb4108adb	Sertraline-CYP2C19 Normal Metabolizer & CYP2B6 Poor Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0f816d16-a338-4dc2-8471-5384150a0b3e	Sertraline-CYP2C19 Intermediate Metabolizer & CYP2B6 Poor Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
20186d21-beb4-4d82-acd5-b16b9568dbdb	Sertraline-CYP2C19 Likely Intermediate Metabolizer & CYP2B6 Poor Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
84024871-ec04-4469-bd0d-b8afac1912b0	Sertraline-CYP2C19 Indeterminate & CYP2B6 Indeterminate	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
670993b0-cbb0-4293-9c29-1ab1a9466ed3	Sertraline-CYP2C19 Poor Metabolizer & CYP2B6 Poor Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers and CYP2B6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0873fe58-1bff-436e-89d4-6353b5467a70	Sertraline-CYP2C19 Likely Poor Metabolizer & CYP2B6 Poor Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers and CYP2B6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c8b8dc3d-1b43-482c-91fc-5b7970343b97	Sertraline-CYP2C19 Indeterminate & CYP2B6 Poor Metabolizer	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
89f3927d-ab29-4a1f-bb5f-11895f94abb1	Sertraline-CYP2C19 Ultra-rapid Metabolizer & CYP2B6 Indeterminate	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5498c9ce-31f9-43ad-9d8d-6a2c2fed6bfa	Sertraline-CYP2C19 Rapid Metabolizer & CYP2B6 Indeterminate	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2608e064-867a-4fd3-9923-028b4bbeca52	Sertraline-CYP2C19 Normal Metabolizer & CYP2B6 Indeterminate	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
57a944d8-51c9-4246-80a4-51348abb4a40	Sertraline-CYP2C19 Intermediate Metabolizer & CYP2B6 Indeterminate	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e4bb949c-487c-4198-a3c2-3a1cb3200e0e	Sertraline-CYP2C19 Likely Intermediate Metabolizer & CYP2B6 Indeterminate	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
848b05f2-a664-477c-abcd-dfcf4cef355a	Sertraline-CYP2C19 Poor Metabolizer & CYP2B6 Indeterminate	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a430761f-d4c1-40ba-a0a9-cb6b8ac68eec	Sertraline-CYP2C19 Likely Poor Metabolizer & CYP2B6 Indeterminate	6451a255-0983-473a-9fe4-6c24451820c3	{01b74a5e-f95b-4086-a5b7-899a8de1f228,32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
45e07a88-cfc0-48f6-b9d2-cab1b7f0b381	Paroxetine-CYP2D6 Ultra-rapid Metabolizer	9c6424db-aaf9-4e74-83b6-a7d7ac769720	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Select alternative drug not predominantly metabolized by CYP2D6.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Lower plasma concentrations decrease the probability of clinical benefit due to increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers.  The extent to which ultra-rapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
29031217-35da-4283-9304-306dba5aa4a8	Paroxetine-CYP2D6 Normal Metabolizer	9c6424db-aaf9-4e74-83b6-a7d7ac769720	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b630df0f-3f70-4473-a18f-da0a038feef0	Paroxetine-CYP2D6 Intermediate Metabolizer	9c6424db-aaf9-4e74-83b6-a7d7ac769720	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
416968a6-8555-4898-9e27-749ad4590b14	Paroxetine-CYP2D6 Poor Metabolizer	9c6424db-aaf9-4e74-83b6-a7d7ac769720	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 50% reduction in recommended starting dose, slower titration schedule, and a 50% lower maintenance dose as compared to CYP2D6 normal metabolizers.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8a6f4a10-f491-46e3-a644-e9de1bc10f0d	Paroxetine-CYP2D6 Indeterminate	9c6424db-aaf9-4e74-83b6-a7d7ac769720	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9c4e0713-911b-47a2-9455-f5fa809727e4	Fluvoxamine-CYP2D6 Ultra-rapid Metabolizer	b2601f06-506a-4651-838f-572e6d1c7387	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7ea80c70-a01f-432f-a97a-e3d27a45f040	Fluvoxamine-CYP2D6 Normal Metabolizer	b2601f06-506a-4651-838f-572e6d1c7387	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a949e31c-1a90-4e4d-b64f-abb8961b7503	Fluvoxamine-CYP2D6 Intermediate Metabolizer	b2601f06-506a-4651-838f-572e6d1c7387	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a31e98a4-fbc8-47a8-9eb0-ab0cea691825	Fluvoxamine-CYP2D6 Poor Metabolizer	b2601f06-506a-4651-838f-572e6d1c7387	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a 25&#8208;50% lower starting dose and slower titration schedule as compared to normal metabolizers or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of fluvoxamine to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fd3362a3-cb2c-41c6-936c-070fd526e4db	Fluvoxamine-CYP2D6 Indeterminate	b2601f06-506a-4651-838f-572e6d1c7387	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4e47687e-dd88-47ba-b779-8a31560bad7b	Venlafaxine-CYP2D6 Ultra-rapid Metabolizer	bb526458-a0a7-42be-b95d-69eed3cf71b7	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f57535ff-a57d-40a4-a42e-bbf1c9bbb8ff	Venlafaxine-CYP2D6 Intermediate Metabolizer	bb526458-a0a7-42be-b95d-69eed3cf71b7	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f70bbfb9-2af8-4cfa-90eb-b94c4d5e186d	Venlafaxine-CYP2D6 Poor Metabolizer	bb526458-a0a7-42be-b95d-69eed3cf71b7	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Risk for adverse effects due to greatly reduced venlafaxine active metabolite formation compared to CYP2D6 normal or intermediate metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7c170301-7eef-4433-942e-27307dfe0cd6	Venlafaxine-CYP2D6 Indeterminate	bb526458-a0a7-42be-b95d-69eed3cf71b7	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cf05fd28-ee79-48e2-9966-0a40a1ac8c2f	Vortioxetine-CYP2D6 Ultra-rapid Metabolizer	f7ee2591-da6d-4636-b5fe-1048587b608a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2cef2d1d-f12d-41e4-ad62-311bc103e8e0	Vortioxetine-CYP2D6 Normal Metabolizer	f7ee2591-da6d-4636-b5fe-1048587b608a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f530fa98-9cc0-4d57-b029-26b1342271e2	Vortioxetine-CYP2D6 Intermediate Metabolizer	f7ee2591-da6d-4636-b5fe-1048587b608a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d8d868e3-bced-4696-be25-b786faf42f4b	Vortioxetine-CYP2D6 Poor Metabolizer	f7ee2591-da6d-4636-b5fe-1048587b608a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Initiate 50% of starting dose (e.g., 5&nbsp;mg) and titrate to the maximum recommended dose of 10&nbsp;mg or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6e870847-537d-436b-9de1-ad964e35496c	Vortioxetine-CYP2D6 Indeterminate	f7ee2591-da6d-4636-b5fe-1048587b608a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	We do not want dosing recommendations to populate for standard dosing precautions but still want it to be on the drug-gene interactions table	Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d2dac919-c4e6-4b1c-a514-ef498cb5f8ff	Voriconazole-CYP2C19  Ultra-rapid Metabolizer	390fc57c-6ae0-47bc-9512-cb4bdde98e97	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.	Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy [published correction appears in Clin Pharmacol Ther. 2018 Feb;103(2):349]. Clin Pharmacol Ther. 2017;102(1):45-51. doi:10.1002/cpt.583	Caution (Yellow Column)	Decreased probability of clinical benefit due to increased metabolism to less active compounds when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
eb1da70f-7417-42ec-b300-ab7f113ab4fc	Voriconazole-CYP2C19  Rapid Metabolizer	390fc57c-6ae0-47bc-9512-cb4bdde98e97	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.	Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy [published correction appears in Clin Pharmacol Ther. 2018 Feb;103(2):349]. Clin Pharmacol Ther. 2017;102(1):45-51. doi:10.1002/cpt.583	Caution (Yellow Column)	Decreased probability of clinical benefit due to increased metabolism to less active compounds when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
25a09bbe-e244-4f48-8ad0-4ab93c8e60c3	Voriconazole-CYP2C19  Normal Metabolizer	390fc57c-6ae0-47bc-9512-cb4bdde98e97	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy [published correction appears in Clin Pharmacol Ther. 2018 Feb;103(2):349]. Clin Pharmacol Ther. 2017;102(1):45-51. doi:10.1002/cpt.583	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
04464365-8e0d-4032-a713-2b7f6f995e4d	Voriconazole-CYP2C19  Likely Intermediate Metabolizer	390fc57c-6ae0-47bc-9512-cb4bdde98e97	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy [published correction appears in Clin Pharmacol Ther. 2018 Feb;103(2):349]. Clin Pharmacol Ther. 2017;102(1):45-51. doi:10.1002/cpt.583	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
436cf968-febd-47f4-ad16-8d15a38c0b19	Voriconazole-CYP2C19  Poor Metabolizer	390fc57c-6ae0-47bc-9512-cb4bdde98e97	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer phenotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.	Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy [published correction appears in Clin Pharmacol Ther. 2018 Feb;103(2):349]. Clin Pharmacol Ther. 2017;102(1):45-51. doi:10.1002/cpt.583	Caution (Yellow Column)	Increased probability of adverse effects due to higher plasma concentrations of voriconazole when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a6fab1a6-6167-45c0-b133-a6a13058009f	Voriconazole-CYP2C19 Likely Poor Metabolizer	390fc57c-6ae0-47bc-9512-cb4bdde98e97	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer phenotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy [published correction appears in Clin Pharmacol Ther. 2018 Feb;103(2):349]. Clin Pharmacol Ther. 2017;102(1):45-51. doi:10.1002/cpt.583	Caution (Yellow Column)	Increased probability of adverse effects due to higher plasma concentrations of voriconazole when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c9b99c92-6f3c-48a3-b461-e53a77e5089e	Voriconazole-CYP2C19  Indeterminate	390fc57c-6ae0-47bc-9512-cb4bdde98e97	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy [published correction appears in Clin Pharmacol Ther. 2018 Feb;103(2):349]. Clin Pharmacol Ther. 2017;102(1):45-51. doi:10.1002/cpt.583	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c4fe7b95-219a-4f3f-b292-9ef2bd9d0be9	Clobazam-CYP2C19 Ultra-rapid Metabolizer	201ced5d-ae85-40f4-b9fa-3087689af5b4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Onfi (Clobazam). Package Insert. Lundbeck. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
23aedea7-888b-4842-ac00-ea22ad8cdfc0	Clobazam-CYP2C19 Rapid Metabolizer	201ced5d-ae85-40f4-b9fa-3087689af5b4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Onfi (Clobazam). Package Insert. Lundbeck. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0a78b3c5-32c7-4e39-a7f7-3b7539fd1ac7	Clobazam-CYP2C19 Normal Metabolizer	201ced5d-ae85-40f4-b9fa-3087689af5b4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Onfi (Clobazam). Package Insert. Lundbeck. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
593b2dc0-fc81-4c4e-99f0-f205a64645c1	Clobazam-CYP2C19 Intermediate Metabolizer	201ced5d-ae85-40f4-b9fa-3087689af5b4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Onfi (Clobazam). Package Insert. Lundbeck. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
208afe7d-23fc-4041-a42f-27addd6468f2	Clobazam-CYP2C19 Likely Intermediate Metabolizer	201ced5d-ae85-40f4-b9fa-3087689af5b4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Onfi (Clobazam). Package Insert. Lundbeck. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
06506681-6c43-44f3-8e1d-c405813477bf	Clobazam-CYP2C19 Poor Metabolizer	201ced5d-ae85-40f4-b9fa-3087689af5b4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	The starting dose should be 5&nbsp;mg daily and dose titration should proceed slowly per FDA package insert.	Onfi (Clobazam). Package Insert. Lundbeck. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of clobazam to less active compounds when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2158eccb-597a-4ae1-bd15-1574170db46e	Clobazam-CYP2C19 Likely Poor Metabolizer	201ced5d-ae85-40f4-b9fa-3087689af5b4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	The starting dose should be 5&nbsp;mg daily and dose titration should proceed slowly per FDA package insert.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Onfi (Clobazam). Package Insert. Lundbeck. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of clobazam to less active compounds when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4893928f-8614-4820-a175-456cc65a0775	Clobazam-CYP2C19 Indeterminate	201ced5d-ae85-40f4-b9fa-3087689af5b4	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Onfi (Clobazam). Package Insert. Lundbeck. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a0f5e4c7-bdd9-4be1-abe5-167048539bef	Efavirenz-CYP2B6  Ultra-rapid Metabolizer	6969532a-6460-4419-b7c5-bbd455af3a11	{01b74a5e-f95b-4086-a5b7-899a8de1f228}	\N	Desta Z, Gammal RS, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clin Pharmacol Ther. 2019;106(4):726-733. doi:10.1002/cpt.1477	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9d97449f-6cda-4f37-87a7-18c376816bad	Efavirenz-CYP2B6 Rapid Metabolizer	6969532a-6460-4419-b7c5-bbd455af3a11	{01b74a5e-f95b-4086-a5b7-899a8de1f228}	\N	Desta Z, Gammal RS, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clin Pharmacol Ther. 2019;106(4):726-733. doi:10.1002/cpt.1477	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
73e5fa1e-681e-4166-b550-9b208c24e3c0	Efavirenz-CYP2B6 Normal Metabolizer	6969532a-6460-4419-b7c5-bbd455af3a11	{01b74a5e-f95b-4086-a5b7-899a8de1f228}	\N	Desta Z, Gammal RS, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clin Pharmacol Ther. 2019;106(4):726-733. doi:10.1002/cpt.1477	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1ab89282-75d4-459c-8eea-032407a2742f	Tacrolimus-CYP3A5 Poor Metabolizer	0d36fae9-d172-4bed-ab68-125ee9d62392	{cd3bc960-aea4-40fb-a1ad-f54c10b7228b}	\N	Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015;98(1):19-24. doi:10.1002/cpt.113	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b9f56f93-10e1-40f6-ae9e-6667d6c33f86	Efavirenz-CYP2B6 Intermediate Metabolizer	6969532a-6460-4419-b7c5-bbd455af3a11	{01b74a5e-f95b-4086-a5b7-899a8de1f228}	Consider initiating efavirenz with decreased dose of 400&nbsp;mg/day.  If therapeutic drug monitoring is available and a decreased efavirenz dose is prescribed, consider obtaining steady state plasma efavirenz concentrations to ensure concentrations are in the suggested therapeutic range (~1 to 4&nbsp;mcg/mL). To prescribe efavirenz at a decreased dose of 400&nbsp;mg/day or 200&nbsp;mg/day in a multidrug regimen may require prescribing more than one pill once daily. If so, the provider should weigh the potential benefit of reduced dose against the potential detrimental impact of increased pill number.	Desta Z, Gammal RS, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clin Pharmacol Ther. 2019;106(4):726-733. doi:10.1002/cpt.1477	Caution (Yellow Column)	Increased risk of central nervous system adverse events due to increased plasma concentrations when compared to CYP2B6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f0c83e41-ae55-45ec-91cc-ff243bb9fc49	Efavirenz-CYP2B6 Poor Metabolizer	6969532a-6460-4419-b7c5-bbd455af3a11	{01b74a5e-f95b-4086-a5b7-899a8de1f228}	Consider initiating efavirenz with decreased dose of 400&nbsp;mg/day or 200&nbsp;mg/day.  If therapeutic drug monitoring is available and a decreased efavirenz dose is prescribed, consider obtaining steady state plasma efavirenz concentrations to ensure concentrations are in the suggested therapeutic range (~1 to 4&nbsp;mcg/mL). To prescribe efavirenz at a decreased dose of 400&nbsp;mg/day or 200&nbsp;mg/day in a multidrug regimen may require prescribing more than one pill once daily. If so, the provider should weigh the potential benefit of reduced dose against the potential detrimental impact of increased pill number.	Desta Z, Gammal RS, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clin Pharmacol Ther. 2019;106(4):726-733. doi:10.1002/cpt.1477	Caution (Yellow Column)	Significantly increased risk of central nervous system adverse events and treatment discontinuation due to increased plasma concentrations when compared to CYP2B6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ee52d85b-5bfb-4ca4-8979-5acb5fd6aaab	Efavirenz-CYP2B6 Indeterminate	6969532a-6460-4419-b7c5-bbd455af3a11	{01b74a5e-f95b-4086-a5b7-899a8de1f228}	\N	Desta Z, Gammal RS, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clin Pharmacol Ther. 2019;106(4):726-733. doi:10.1002/cpt.1477	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2540be8f-2a5d-4121-9514-7d547be6eef0	Tacrolimus-CYP3A5 Normal Metabolizer	0d36fae9-d172-4bed-ab68-125ee9d62392	{cd3bc960-aea4-40fb-a1ad-f54c10b7228b}	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3&nbsp;mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.\n\nThis recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function). \n\nTypically with other CYP enzymes, a normal metabolizer would be classified as having "normal" metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose, and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.	Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015;98(1):19-24. doi:10.1002/cpt.113	Caution (Yellow Column)	Decreased chance of achieving target tacrolimus concentrations due to increased metabolism when compared to CYP3A5 poor metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
517f2e8e-edc9-463d-baa3-bc3064f67e11	Tacrolimus-CYP3A5 Intermediate Metabolizer	0d36fae9-d172-4bed-ab68-125ee9d62392	{cd3bc960-aea4-40fb-a1ad-f54c10b7228b}	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3&nbsp;mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.\n\nThis recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function). \n\nTypically with other CYP enzymes, a normal metabolizer would be classified as having "normal" metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose, and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.	Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015;98(1):19-24. doi:10.1002/cpt.113	Caution (Yellow Column)	Decreased chance of achieving target tacrolimus concentrations due to increased metabolism when compared to CYP3A5 poor metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
24b93eee-c881-43d9-90b8-4f98fcf733fd	Celecoxib-CYP2C9 Intermediate Metabolizer	211b33bf-72c3-4545-a4b2-ea558809d086	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. \n\nIntermediate metabolizers might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability of toxicities due to moderately reduced metabolism and higher plasma concentrations.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a9287274-3195-4c95-bf47-a04481ddf04e	Celecoxib-CYP2C9 Poor Metabolizer	211b33bf-72c3-4545-a4b2-ea558809d086	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Initiate therapy with 25&#8208;50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25&#8208;50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in poor metabolizers). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants <em>in vivo</em>.  Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability and/or severity of toxicities due to significantly reduced metabolism, higher plasma concentrations, and prolonged half-life.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5f44ae08-08c7-4d94-997e-b20c26a3d3d2	Celecoxib-CYP2C9 Poor Metabolizer	211b33bf-72c3-4545-a4b2-ea558809d086	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Initiate therapy with 25&#8208;50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25&#8208;50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in poor metabolizers). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants <em>in vivo</em>. Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability and/or severity of toxicities due to significantly reduced metabolism, higher plasma concentrations, and prolonged half-life.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
068f197e-5bd0-49dd-9599-af0f7061a844	Celecoxib-CYP2C9 Indeterminate	211b33bf-72c3-4545-a4b2-ea558809d086	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
06a0b35f-3146-4b72-b224-df6264161bfd	Flurbiprofen-CYP2C9 Normal Metabolizer	a62bce88-9533-414c-9d39-1f7ac350aeb0	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8410c20f-f925-416c-925c-ce2365b9ffb2	Flurbiprofen-CYP2C9 Intermediate Metabolizer	a62bce88-9533-414c-9d39-1f7ac350aeb0	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
99c4170d-f79b-4b8d-8217-c744dc2a060f	Flurbiprofen-CYP2C9 Intermediate Metabolizer	a62bce88-9533-414c-9d39-1f7ac350aeb0	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. \n\nIntermediate metabolizers might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability of toxicities due to moderately reduced metabolism and higher plasma concentrations.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
46c22828-0861-4e49-91e4-91bfea02a02f	Flurbiprofen-CYP2C9 Poor Metabolizer	a62bce88-9533-414c-9d39-1f7ac350aeb0	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Initiate therapy with 25&#8208;50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25&#8208;50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 5 days for flurbiprofen after first dose in poor metabolizers). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants <em>in vivo</em>. Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability and/or severity of toxicities due to significantly reduced metabolism, higher plasma concentrations, and prolonged half-life.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
89453004-e027-4e98-8ff5-64f3fbdf698b	Flurbiprofen-CYP2C9 Poor Metabolizer	a62bce88-9533-414c-9d39-1f7ac350aeb0	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Initiate therapy with 25&#8208;50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25&#8208;50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 5 days for flurbiprofen after first dose in poor metabolizers). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants <em>in vivo</em>. Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability and/or severity of toxicities due to significantly reduced metabolism, higher plasma concentrations, and prolonged half-life.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b36eb4eb-bf6e-49e6-aedf-48ae1cb8d005	Flurbiprofen-CYP2C9 Indeterminate	a62bce88-9533-414c-9d39-1f7ac350aeb0	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
82aad02b-aa9c-4c64-88d7-b98df17dbb2c	Ibuprofen-CYP2C9 Normal Metabolizer	a98b7a68-c681-46fb-adba-f1541299fe59	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3a5b507a-96d7-49eb-85ae-fcba48c2dc7c	Ibuprofen-CYP2C9 Intermediate Metabolizer	a98b7a68-c681-46fb-adba-f1541299fe59	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ed6ed4cd-c259-4f7c-a04f-44bd558104fe	Ibuprofen-CYP2C9 Intermediate Metabolizer	a98b7a68-c681-46fb-adba-f1541299fe59	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. \n\nIntermediate metabolizers might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability of toxicities due to moderately reduced metabolism and higher plasma concentrations.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b52be0ae-2e8a-442e-abba-001c4757ff4c	Ibuprofen-CYP2C9 Poor Metabolizer	a98b7a68-c681-46fb-adba-f1541299fe59	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Initiate therapy with 25&#8208;50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25&#8208;50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 5 days for ibuprofen after first dose in poor metabolizers). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants <em>in vivo</em>. Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability and/or severity of toxicities due to significantly reduced metabolism, higher plasma concentrations, and prolonged half-life.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
02292b54-6e0c-49a9-abd6-137d37d05fb9	Ibuprofen-CYP2C9 Poor Metabolizer	a98b7a68-c681-46fb-adba-f1541299fe59	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Initiate therapy with 25&#8208;50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25&#8208;50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 5 days for ibuprofen after first dose in poor metabolizers). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants <em>in vivo</em>. Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability and/or severity of toxicities due to significantly reduced metabolism, higher plasma concentrations, and prolonged half-life.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1af26070-fbe3-4ca4-a831-8f3a71f8ddf7	Ibuprofen-CYP2C9 Indeterminate	a98b7a68-c681-46fb-adba-f1541299fe59	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b13c50e8-fac8-4820-ad35-6f9c21a76fe2	Meloxicam-CYP2C9 Normal Metabolizer	5d66d6a8-1c96-4bbd-99fd-0eca947dace6	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ba18a28e-ec17-477f-b172-69d82698b00d	Meloxicam-CYP2C9 Intermediate Metabolizer	5d66d6a8-1c96-4bbd-99fd-0eca947dace6	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants <em>in vivo</em> or choose a nonsterodial anti-inflammatory drug (NSAID) metabolized by CYP2C9 but with a shorter half-life (celecoxib, flurbiprofen, or ibuprofen).\n\nIntermediate metabolizers might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability of toxicities due to moderately reduced metabolism and higher plasma concentrations.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
83f3ffbb-4c99-4725-a5e0-e85f8d9ff1eb	Meloxicam-CYP2C9 Poor Metabolizer	5d66d6a8-1c96-4bbd-99fd-0eca947dace6	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants <em>in vivo</em> or choose a nonsterodial anti-inflammatory drug (NSAID) metabolized by CYP2C9 but with a shorter half-life (celecoxib, flurbiprofen, or ibuprofen).\n\nAlternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability and/or severity of toxicities due to significantly reduced metabolism, higher plasma concentrations, and prolonged half-life.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
35e4296d-3256-4876-8f03-5c7d8cee2479	Meloxicam-CYP2C9 Poor Metabolizer	5d66d6a8-1c96-4bbd-99fd-0eca947dace6	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants <em>in vivo</em> or choose a nonsterodial anti-inflammatory drug (NSAID) metabolized by CYP2C9 but with a shorter half-life (celecoxib, flurbiprofen, or ibuprofen).\n\nAlternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability and/or severity of toxicities due to significantly reduced metabolism, higher plasma concentrations, and prolonged half-life.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3b4c4e31-331e-4679-83c4-28bdf09b0496	Meloxicam-CYP2C9 Indeterminate	5d66d6a8-1c96-4bbd-99fd-0eca947dace6	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
15aab06f-f875-4279-afc8-aeb3f9b460d0	Piroxicam-CYP2C9 Normal Metabolizer	c6f6e292-35f2-49be-b0f5-b4a27f0616ec	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c05f727f-3ff4-48df-9e0f-d8467541c7ce	Piroxicam-CYP2C9 Intermediate Metabolizer	c6f6e292-35f2-49be-b0f5-b4a27f0616ec	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
406528a5-ea1f-4a4d-bdb2-e86febe02208	Piroxicam-CYP2C9 Intermediate Metabolizer	c6f6e292-35f2-49be-b0f5-b4a27f0616ec	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants <em>in vivo</em> or choose a nonsterodial anti-inflammatory drug (NSAID) metabolized by CYP2C9 but with a shorter half-life (celecoxib, flurbiprofen, or ibuprofen).\n\nAlternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability of toxicities due to moderately reduced metabolism and higher plasma concentrations.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2f645122-e172-4e06-ba4c-edc192dacc7a	Piroxicam-CYP2C9 Poor Metabolizer	c6f6e292-35f2-49be-b0f5-b4a27f0616ec	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants <em>in vivo</em> or choose a nonsterodial anti-inflammatory drug (NSAID) metabolized by CYP2C9 but with a shorter half-life (celecoxib, flurbiprofen, or ibuprofen).\n\nAlternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability and/or severity of toxicities due to significantly reduced metabolism, higher plasma concentrations, and prolonged half-life.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
59d737da-ddc3-432a-a9f7-7bae7c80f110	Simvastatin-SLCO1B1 Increased Function	90fc5fe6-2bc4-4696-bac1-6bd791233b21	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c7789c03-1712-4859-9961-9644654a60a9	Piroxicam-CYP2C9 Poor Metabolizer	c6f6e292-35f2-49be-b0f5-b4a27f0616ec	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants <em>in vivo</em> or choose a nonsterodial anti-inflammatory drug (NSAID) metabolized by CYP2C9 but with a shorter half-life (celecoxib, flurbiprofen, or ibuprofen).\n\nAlternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Caution (Yellow Column)	Increased probability and/or severity of toxicities due to significantly reduced metabolism, higher plasma concentrations, and prolonged half-life.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
69fe0f7e-4d2c-460c-9a63-bd1c895e83b1	Piroxicam-CYP2C9 Indeterminate	c6f6e292-35f2-49be-b0f5-b4a27f0616ec	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
448ccc1e-7cc0-43f7-9514-ce384c26dcbb	Phenytoin-CYP2C9 Normal Metabolizer	c204f810-40e0-4211-990d-c60df4443ab2	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
72343ed1-d562-42be-92b1-8e6fe9bccba6	Phenytoin-CYP2C9 Intermediate Metabolizer	c204f810-40e0-4211-990d-c60df4443ab2	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
daa6f6ae-7c26-4dce-bafd-59eb0c2a9292	Phenytoin-CYP2C9 Intermediate Metabolizer	c204f810-40e0-4211-990d-c60df4443ab2	{e8d718e4-4831-496c-8448-16ad044c2e9d}	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. \n\nRecommendation does not account for HLA-B*15:02 carrier status which is associated with Stevens-Johnson syndrome/toxic epidermal necrolysis. HLA-B*15:02 is more common in East and Central/South Asian populations.	Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008	Caution (Yellow Column)	Increased probability of toxicities due to reduced phenytoin metabolism and higher plasma concentrations.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a78a9d1b-f8a1-4084-a933-a7f3b0f9b35a	Phenytoin-CYP2C9 Poor Metabolizer	c204f810-40e0-4211-990d-c60df4443ab2	{e8d718e4-4831-496c-8448-16ad044c2e9d}	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. \n\nRecommendation does not account for HLA-B*15:02 carrier status which is associated with Stevens-Johnson syndrome/toxic epidermal necrolysis. HLA-B*15:02 is more common in East and Central/South Asian populations.	Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008	Caution (Yellow Column)	Increased probability of toxicities due to reduced phenytoin metabolism and higher plasma concentrations.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f1cc4ee1-b19c-4a8c-bf7e-290fba38d659	Phenytoin-CYP2C9 Poor Metabolizer	c204f810-40e0-4211-990d-c60df4443ab2	{e8d718e4-4831-496c-8448-16ad044c2e9d}	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. \n\nRecommendation does not account for HLA-B*15:02 carrier status which is associated with Stevens-Johnson syndrome/toxic epidermal necrolysis. HLA-B*15:02 is more common in East and Central/South Asian populations.	Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008	Caution (Yellow Column)	Increased probability of toxicities due to reduced phenytoin metabolism and higher plasma concentrations.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a38152f0-3250-42db-a86f-535983de5b41	Phenytoin-CYP2C9 Indeterminate	c204f810-40e0-4211-990d-c60df4443ab2	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4cc1d2da-0011-4393-bc32-4925c66b5dd0	Fosphenytoin-CYP2C9 Normal Metabolizer	496a2efb-e3a0-4c9a-9084-f8a922ed54f7	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3c2f8219-1cbe-4623-aef3-1ab472c7f5ee	Fosphenytoin-CYP2C9 Intermediate Metabolizer	496a2efb-e3a0-4c9a-9084-f8a922ed54f7	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d5f83d64-38fc-4463-88e2-9dae7aa83e9d	Fosphenytoin-CYP2C9 Intermediate Metabolizer	496a2efb-e3a0-4c9a-9084-f8a922ed54f7	{e8d718e4-4831-496c-8448-16ad044c2e9d}	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. \n\nRecommendation does not account for HLA-B*15:02 carrier status which is associated with Stevens-Johnson syndrome/toxic epidermal necrolysis. HLA-B*15:02 is more common in East and Central/South Asian populations.	Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008	Caution (Yellow Column)	Increased probability of toxicities due to reduced phenytoin metabolism and higher plasma concentrations.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b56f2302-aa58-4b21-874d-718c318d0285	Fosphenytoin-CYP2C9 Poor Metabolizer	496a2efb-e3a0-4c9a-9084-f8a922ed54f7	{e8d718e4-4831-496c-8448-16ad044c2e9d}	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. \n\nRecommendation does not account for HLA-B*15:02 carrier status which is associated with Stevens-Johnson syndrome/toxic epidermal necrolysis. HLA-B*15:02 is more common in East and Central/South Asian populations.	Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008	Caution (Yellow Column)	Increased probability of toxicities due to reduced phenytoin metabolism and higher plasma concentrations.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b0c1b34a-150a-4e8c-aa52-693c63fcd50e	Fosphenytoin-CYP2C9 Poor Metabolizer	496a2efb-e3a0-4c9a-9084-f8a922ed54f7	{e8d718e4-4831-496c-8448-16ad044c2e9d}	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. \n\nRecommendation does not account for HLA-B*15:02 carrier status which is associated with Stevens-Johnson syndrome/toxic epidermal necrolysis. HLA-B*15:02 is more common in East and Central/South Asian populations.	Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008	Caution (Yellow Column)	Increased probability of toxicities due to reduced phenytoin metabolism and higher plasma concentrations.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c1911d14-a326-4e6c-841f-095f713230a9	Fosphenytoin-CYP2C9 Indeterminate	496a2efb-e3a0-4c9a-9084-f8a922ed54f7	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
26833a3d-b940-4730-bdb6-771b8de5d6bb	Siponimod-CYP2C9 Poor Metabolizer *3/*3	41d89592-9cb5-42b0-bce0-025ad44d2d7c	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Siponimod is contraindicated per FDA package insert.	Mayzent (Siponimod). Package Insert. Novartis. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of siponimod to less active compounds when compared to CYP2C9 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a28ac42f-6e91-48db-8de2-cb446b788506	Siponimod-CYP2C9 Intermediate Metabolizer *1/*3	41d89592-9cb5-42b0-bce0-025ad44d2d7c	{e8d718e4-4831-496c-8448-16ad044c2e9d}	The recommended maintenance dosage is 1&nbsp;mg daily following titration per FDA package insert.	Mayzent (Siponimod). Package Insert. Novartis. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of siponimod to less active compounds when compared to CYP2C9 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
aacd58b9-7cd5-415d-a590-95539fa55722	Siponimod-CYP2C9 Poor Metabolizer *2/*3	41d89592-9cb5-42b0-bce0-025ad44d2d7c	{e8d718e4-4831-496c-8448-16ad044c2e9d}	The recommended maintenance dosage is 1&nbsp;mg daily following titration per FDA package insert.	Mayzent (Siponimod). Package Insert. Novartis. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of siponimod to less active compounds when compared to CYP2C9 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0db7301e-cabc-4125-9753-d1baa2c44135	Siponimod-CYP2C9  all other genotypes	41d89592-9cb5-42b0-bce0-025ad44d2d7c	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Mayzent (Siponimod). Package Insert. Novartis. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
38473a9a-ba04-4113-8ecd-fd86d62c9861	Atorvastatin-SLCO1B1 Normal Function	dc29bc5a-25d6-41cc-afa4-f65a8c29db88	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
49d74075-b2ad-4def-90eb-2a7ae764230d	Atorvastatin-SLCO1B1 Increased Function	dc29bc5a-25d6-41cc-afa4-f65a8c29db88	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
902fd70b-064b-43bf-a2bc-fdacb7b3be69	Atorvastatin-SLCO1B1 Decreased Function	dc29bc5a-25d6-41cc-afa4-f65a8c29db88	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤40&nbsp;mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40&nbsp;mg dose. If dose >40&nbsp;mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy).\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b232af8b-30f0-46dc-b691-e6e75fa357e7	Atorvastatin-SLCO1B1 Possible Decreased Function	dc29bc5a-25d6-41cc-afa4-f65a8c29db88	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤40&nbsp;mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40&nbsp;mg dose. If dose >40&nbsp;mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy).\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d73d50b0-1c32-4220-933f-0a71afcaa9d3	Rosuvastatin-ABCG2 Normal Function & SLCO1B1 Increased Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
92099359-d41b-417b-acca-3aa178b313d7	Atorvastatin-SLCO1B1 Poor Function	dc29bc5a-25d6-41cc-afa4-f65a8c29db88	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤20&nbsp;mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >20&nbsp;mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy). \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased atorvastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f52a7ac4-59f4-4a23-9fbd-544cd7a62687	Atorvastatin-SLCO1B1 Indeterminate	dc29bc5a-25d6-41cc-afa4-f65a8c29db88	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e939b98a-b455-415e-b937-b7e0b7b45397	Lovastatin-SLCO1B1 Normal Function	5994c882-0bbe-46da-bf00-c347377368c4	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6d01ada6-6047-4856-96f7-51abb0b3ef03	Lovastatin-SLCO1B1 Increased Function	5994c882-0bbe-46da-bf00-c347377368c4	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6f1e06ec-4bfa-4fbb-bfde-7b50b7dcb7b8	Lovastatin-SLCO1B1 Decreased Function	5994c882-0bbe-46da-bf00-c347377368c4	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20&nbsp;mg/day.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b0fb7fe3-abe5-449d-b539-e3ec0443fc47	Lovastatin-SLCO1B1 Possible Decreased Function	5994c882-0bbe-46da-bf00-c347377368c4	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20&nbsp;mg/day.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d03bf414-6c6c-4b16-a1b4-3c546a8a7fd1	Lovastatin-SLCO1B1 Poor Function	5994c882-0bbe-46da-bf00-c347377368c4	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe an alternative statin depending on the desired potency. \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased lovastatin acid exposure as compared to normal and decreased function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dbf6cd6d-402a-4f39-8f26-7ef9480b6c3b	Lovastatin-SLCO1B1 Indeterminate	5994c882-0bbe-46da-bf00-c347377368c4	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e4894564-51d5-4d0c-84bb-33e72708447d	Pitavastatin-SLCO1B1 Normal Function	d4638249-99fa-435e-b8ba-90e5b99b0748	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4a81eb90-d3f5-47bd-a87b-4403a611caa8	Pitavastatin-SLCO1B1 Increased Function	d4638249-99fa-435e-b8ba-90e5b99b0748	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c0f8cd81-ec14-4a0c-b792-afa5aa50ec6e	Pitavastatin-SLCO1B1 Decreased Function	d4638249-99fa-435e-b8ba-90e5b99b0748	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤2&nbsp;mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1&nbsp;mg. If dose >2&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., pitavastatin plus non-statin guideline directed medical therapy). \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1d057682-ba7f-4818-8bb9-62768de6c8d3	Pitavastatin-SLCO1B1 Possible Decreased Function	d4638249-99fa-435e-b8ba-90e5b99b0748	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤2&nbsp;mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1&nbsp;mg. If dose >2&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., pitavastatin plus non-statin guideline directed medical therapy). \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4c76a6a1-c667-4b15-86dc-a2cf45920bec	Pitavastatin-SLCO1B1 Poor Function	d4638249-99fa-435e-b8ba-90e5b99b0748	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤1&nbsp;mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose >1&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., pitavastatin plus non-statin guideline directed medical therapy).\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased pitavastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f9100cc8-a2e2-4d2b-8c52-ae60b0795e76	Pitavastatin-SLCO1B1 Indeterminate	d4638249-99fa-435e-b8ba-90e5b99b0748	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3051482a-c212-4398-9a8c-22bde46b7a24	Pravastatin-SLCO1B1 Normal Function	b5e19041-7ec3-492b-9746-1d79e3e937a0	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b334eed7-c4b2-4748-9f6e-448e29203a4a	Pravastatin-SLCO1B1 Increased Function	b5e19041-7ec3-492b-9746-1d79e3e937a0	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
44640921-5287-4001-afa2-d9892e9fd492	Pravastatin-SLCO1B1 Decreased Function	b5e19041-7ec3-492b-9746-1d79e3e937a0	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40&nbsp;mg per day.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased pravastatin exposure as compared to normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7bbcf2c3-6b90-4f3b-ba5f-ad6cd89f1fe7	Pravastatin-SLCO1B1 Possible Decreased Function	b5e19041-7ec3-492b-9746-1d79e3e937a0	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40&nbsp;mg per day.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased pravastatin exposure as compared to normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e7bdf9f3-95b8-4c5d-9518-ba50b6a96401	Pravastatin-SLCO1B1 Poor Function	b5e19041-7ec3-492b-9746-1d79e3e937a0	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤40&nbsp;mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40&nbsp;mg dose but higher potency is needed, consider a higher dose (>40&nbsp;mg) or an alternative statin or combination therapy (i.e., pravastatin plus non-statin guideline directed medical therapy). Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses >40&nbsp;mg.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased pravastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
54ebee77-6acf-42b4-95d9-7fb0fa2baeb7	Pravastatin-SLCO1B1 Indeterminate	b5e19041-7ec3-492b-9746-1d79e3e937a0	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0adbe8c9-1db4-4ac0-8f99-c93fc58d13a6	Simvastatin-SLCO1B1 Normal Function	90fc5fe6-2bc4-4696-bac1-6bd791233b21	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
34f0cf48-f9e2-4c8f-9ae0-3af955beae05	Simvastatin-SLCO1B1 Decreased Function	90fc5fe6-2bc4-4696-bac1-6bd791233b21	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to &lt;20&nbsp;mg/day.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased simvastatin acid exposure as compared to normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
20d0c2ee-a22e-4809-b788-2ef9fef37577	Simvastatin-SLCO1B1 Possible Decreased Function	90fc5fe6-2bc4-4696-bac1-6bd791233b21	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to &lt;20&nbsp;mg/day.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased simvastatin acid exposure as compared to normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
10853ff8-7f2b-4b0b-a6bf-222261507521	Simvastatin-SLCO1B1 Poor Function	90fc5fe6-2bc4-4696-bac1-6bd791233b21	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe an alternative statin depending on the desired potency. \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased simvastatin acid exposure as compared to normal and decreased function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
149dd0ad-9e4f-4618-ac18-c8ee94ff0132	Simvastatin-SLCO1B1 Indeterminate	90fc5fe6-2bc4-4696-bac1-6bd791233b21	{22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fcfb0a94-e078-4015-9e5b-ee4397f781eb	Fluvastatin-CYP2C9 Normal Metabolizer	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9cc22c49-1373-4181-be01-977f31108acb	Fluvastatin-CYP2C9 Intermediate Metabolizer	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Based on CYP2C9 status, prescribe ≤40&nbsp;mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy). SLCO1B1 genotype result is not available to further guide statin dosing.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to CYP2C9 normal metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
03c1bd46-23f7-4c52-8192-14a9ba8cf60c	Fluvastatin-CYP2C9 Poor Metabolizer	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d}	Based on CYP2C9 status, prescribe ≤20&nbsp;mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy). SLCO1B1 genotype result is not available to further guide statin dosing.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to CYP2C9 normal and intermediate metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
965cc39c-99a4-477f-9b6f-d3205c8bc09e	Fluvastatin-CYP2C9 Indeterminate	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f3738d5d-e775-4a3a-9ec1-2d877494cda8	Fluvastatin-CYP2C9 Normal Metabolizer & SLCO1B1 Increased Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cc3325b4-daf6-4866-81e2-70ad41ac137c	Fluvastatin-CYP2C9 Normal Metabolizer & SLCO1B1 Normal Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6c132ca3-e2ea-4936-b866-5a5e1e4d036e	Rosuvastatin-ABCG2 Normal Function & SLCO1B1 Normal Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1d913d6e-6ff5-4b5b-8b7d-1a0cffa931da	Fluvastatin-CYP2C9 Normal Metabolizer & SLCO1B1 Decreased Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40&nbsp;mg per day.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to SLCO1B1 normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4a01ad83-6e0a-40a2-b85b-cf5d60cfd330	Fluvastatin-CYP2C9 Normal Metabolizer & SLCO1B1 Possible Decreased Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40&nbsp;mg per day.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to SLCO1B1 normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6d4ba333-b115-4be4-9c37-e0ae7729e8d9	Fluvastatin-CYP2C9 Normal Metabolizer & SLCO1B1 Poor Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤40&nbsp;mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40&nbsp;mg per day but higher potency is needed, a higher dose (>40&nbsp;mg) or an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40&nbsp;mg per day.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ac0c6eef-ffdc-4eaa-8245-e1489668f35a	Fluvastatin-CYP2C9 Normal Metabolizer & SLCO1B1 Indeterminate	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b46e0b58-9c99-4ec2-8943-3dd1ae98c753	Fluvastatin-CYP2C9 Indeterminate & SLCO1B1 Increased Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
80b0a098-d72a-44e7-92ce-e73bdc7c30b6	Fluvastatin-CYP2C9 Indeterminate & SLCO1B1 Normal Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ccc9ee14-4c17-4f79-923b-453d26108f33	Fluvastatin-CYP2C9  Indeterminate & SLCO1B1 Decreased Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40&nbsp;mg per day. CYP2C9 phenotype could not be assigned based on genotyping. \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to SLCO1B1 normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2ef8f6d0-8dbd-4c97-9aeb-87fa1cf68bd6	Fluvastatin-CYP2C9  Indeterminate & SLCO1B1 Possible Decreased Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40&nbsp;mg per day. CYP2C9 phenotype could not be assigned based on genotyping. \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to SLCO1B1 normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
846d718e-7d96-40dd-99dc-53df7da1b893	Rosuvastatin-ABCG2 Normal Function & SLCO1B1 Indeterminate	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c836bca2-5364-4503-916f-d99e57df4e0c	Fluvastatin-CYP2C9  Indeterminate & SLCO1B1 Poor Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤40&nbsp;mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40&nbsp;mg per day but higher potency is needed, a higher dose (>40&nbsp;mg) or an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40&nbsp;mg per day. CYP2C9 phenotype could not be assigned based on genotyping. \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d4a8f643-3d09-48ba-93a5-130e4a701fc3	Fluvastatin-CYP2C9  Indeterminate & SLCO1B1 Indeterminate	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e396c7f9-6f57-4ed3-8a17-5d7e2a33e98d	Fluvastatin-CYP2C9 Intermediate Metabolizer & SLCO1B1 Increased Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤40&nbsp;mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy).\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to CYP2C9 normal metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8165476d-62fd-4f4d-9336-2113d2e21338	Fluvastatin-CYP2C9 Intermediate Metabolizer  & SLCO1B1 Normal Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤40&nbsp;mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy).\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to CYP2C9 normal metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d3cd4b2d-382b-43b8-a7f6-6542fb59fa45	Fluvastatin-CYP2C9 Intermediate Metabolizer & SLCO1B1 Decreased Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤20&nbsp;mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy).\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to SLCO1B1 normal function and compared to CYP2C9 normal metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8990165e-8c4d-4fa9-9076-e545a6eb271a	Fluvastatin-CYP2C9 Intermediate Metabolizer & SLCO1B1 Possible Decreased Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤20&nbsp;mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy).\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to SLCO1B1 normal function and compared to CYP2C9 normal metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
73b7742d-5e43-4115-beed-8bd04010ad2b	Fluvastatin-CYP2C9 Intermediate Metabolizer  & SLCO1B1 Poor Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe an alternative statin depending on the desired potency. \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to SLCO1B1 normal and decreased function and compared to CYP2C9 normal metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
11594ef9-e4bb-4741-8e7d-3f0d8ff075ac	Atazanavir-UGT1A1  Normal Metabolizer	9205ea26-5624-454e-8d1f-8bab4c2866a2	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Gammal RS, Court MH, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016;99(4):363-369. doi:10.1002/cpt.269	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b6835ffd-e222-4784-94ec-7293d0f2a034	Fluvastatin-CYP2C9   Intermediate Metabolizer & SLCO1B1 Indeterminate	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤40&nbsp;mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy). SLCO1B1 phenotype could not be assigned based on genotyping. \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to CYP2C9 normal metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4765ccb4-c263-4d70-b409-e0c7dc9152e4	Fluvastatin-CYP2C9 Poor Metabolizer & SLCO1B1 Increased Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤20&nbsp;mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy).\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to CYP2C9 normal and intermediate metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f4102737-995e-4a47-97df-963713abf9fe	Fluvastatin-CYP2C9 Poor Metabolizer  & SLCO1B1 Normal Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤20&nbsp;mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy).\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to CYP2C9 normal and intermediate metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4cc91b8e-9072-4f2f-b21f-a331a1746569	Fluvastatin-CYP2C9 Poor Metabolizer & SLCO1B1 Decreased Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe an alternative statin depending on the desired potency. \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to SLCO1B1 normal function and compared to CYP2C9 normal and intermediate metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cf22b938-6fbe-4ea0-b2f0-742cf9623324	Fluvastatin-CYP2C9 Poor Metabolizer  & SLCO1B1 Possible Decreased Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe an alternative statin depending on the desired potency. \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to SLCO1B1 normal function and compared to CYP2C9 normal and intermediate metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a5b42d8a-15df-4d5f-9f22-3bd90958ec57	Fluvastatin-CYP2C9 Poor Metabolizer   & SLCO1B1 Poor Function	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe an alternative statin depending on the desired potency. \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to SLCO1B1 normal and decreased function and compared to CYP2C9 normal or intermediate metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e39a3898-4d7a-4d77-bf4b-82441326c7a7	Fluvastatin-CYP2C9 Poor Metabolizer & SLCO1B1 Indeterminate	175bf2da-e1c3-4fc9-8e34-5fed366b1ec6	{e8d718e4-4831-496c-8448-16ad044c2e9d,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤20&nbsp;mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy). SLCO1B1 phenotype could not be assigned based on genotyping. \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased fluvastatin exposure as compared to CYP2C9 normal and intermediate metabolizers which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
eb996983-3b0e-41a2-8948-d6f9df98a7cd	Rosuvastatin-ABCG2 Normal Function & SLCO1B1 Decreased Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20&nbsp;mg.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure as compared to SLCO1B1 normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4ed9c81f-25c7-450c-bfdf-bffbdfaaf8d1	Rosuvastatin-ABCG2 Normal Function & SLCO1B1 Possible Decreased Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20&nbsp;mg.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure as compared to SLCO1B1 normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
92def23a-e6b1-4ac7-85de-27d5cbacfbce	Rosuvastatin-ABCG2 Normal Function & SLCO1B1 Poor Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤20&nbsp;mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. If dose > 20&nbsp;mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy).\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure as compared to SLCO1B1 normal and decreased function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f53ad995-a44e-4ace-8541-8fa19935705e	Rosuvastatin-ABCG2 Indeterminate & SLCO1B1 Increased Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d83f2786-950d-4627-b53d-85bd96988f7b	Rosuvastatin-ABCG2 Indeterminate & SLCO1B1 Normal Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6bd9a1d5-067a-48b5-8ed5-7a5a1c67d8a8	Rosuvastatin-ABCG2 Indeterminate & SLCO1B1 Indeterminate	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f119568d-c086-4d3b-bed5-6326b855176f	Rosuvastatin-ABCG2 Indeterminate & SLCO1B1 Decreased Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20&nbsp;mg. ABCG2 genotype result is not available to further guide statin therapy.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure as compared to SLCO1B1 normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
28348cbe-d2c3-4f96-a047-2e241886012a	Rosuvastatin-ABCG2 Indeterminate & SLCO1B1 Possible Decreased Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20&nbsp;mg. ABCG2 genotype result is not available to further guide statin therapy.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure as compared to SLCO1B1 normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8f1492f2-81f8-42c9-ae49-5617b3a65aac	Atazanavir-UGT1A1  Intermediate Metabolizer	9205ea26-5624-454e-8d1f-8bab4c2866a2	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Gammal RS, Court MH, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016;99(4):363-369. doi:10.1002/cpt.269	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4bf9e22e-4307-4033-8fa9-1f49af895170	Rosuvastatin-ABCG2 Indeterminate & SLCO1B1 Poor Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤20&nbsp;mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. If dose >20&nbsp;mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy). ABCG2 genotype result is not available to further guide statin therapy.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure as compared to SLCO1B1 normal and decreased function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
99d30d49-b799-41a9-b2d0-0b627d9c9e9f	Rosuvastatin-ABCG2 Decreased Function & SLCO1B1 Increased Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
08847c02-aecd-4110-9b90-e696659d27ab	Rosuvastatin-ABCG2 Decreased Function & SLCO1B1 Normal Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
00ca20cc-d92c-4708-bc23-e7fad854d6d2	Rosuvastatin-ABCG2 Decreased Function & SLCO1B1 Indeterminate	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	\N	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
129257fc-04f1-435b-9de2-a9956504496a	Rosuvastatin-ABCG2 Decreased Function & SLCO1B1 Decreased Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20&nbsp;mg.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure as compared to SLCO1B1 normal function and compared to ABCG2 normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6e891062-ab0e-490d-bb17-c51719f9bca9	Rosuvastatin-ABCG2 Decreased Function & SLCO1B1 Possible Decreased Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20&nbsp;mg.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure as compared to SLCO1B1 normal function and compared to ABCG2 normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
62ee02ce-049f-4a3f-a735-4ed4f7e4107a	Rosuvastatin-ABCG2 Decreased Function & SLCO1B1 Poor Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤20&nbsp;mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. If dose >20&nbsp;mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy).\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure as compared to SLCO1B1 normal and decreased function and compared to ABCG2 normal function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
64630fdc-75e4-4f45-97df-2b73a0eee21b	Rosuvastatin-ABCG2 Poor Function & SLCO1B1 Increased Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤20&nbsp;mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. If dose >20&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy). \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure compared to ABCG2 normal and decreased function which risk of myopathy is unknown.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d087b0e3-ee4e-4704-9dbd-f57f4af23c59	Pegloticase-G6PD Decreased Function	89341edd-8cb2-4bdf-9087-185c6b1591a6	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use of pegloticase is not recommended. Consider alternative therapy.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	High risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
de3d8bc9-187b-4610-866c-d98bfd124697	Rosuvastatin-ABCG2 Poor Function & SLCO1B1 Normal Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤20&nbsp;mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. If dose >20&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy). \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure compared to ABCG2 normal and decreased function which risk of myopathy is unknown.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
33956074-3708-4d03-b8a2-23a524002d46	Rosuvastatin-ABCG2 Poor Function & SLCO1B1 Indeterminate	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Based on ABCG2 status, prescribe ≤20&nbsp;mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. If dose >20&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy). SLCO1B1 genotype result is not available to further guide statin therapy.\n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure compared to ABCG2 normal and decreased function which risk of myopathy is unknown.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
97bf6485-a9e8-403f-82a6-1595d547e6c7	Rosuvastatin-ABCG2 Poor Function & SLCO1B1 Decreased Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤10&nbsp;mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. If dose >10&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy). \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure as compared to SLCO1B1 normal function and compared to ABCG2 normal and decreased function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e8a32a29-373a-46c2-bdd0-2bcf2067cfaa	Rosuvastatin-ABCG2 Poor Function & SLCO1B1 Possible Decreased Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤10&nbsp;mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. If dose >10&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy). \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure as compared to SLCO1B1 normal function and compared to ABCG2 normal and decreased function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
46c6947d-d3c1-4d87-a20d-f80c640815ba	Rosuvastatin-ABCG2 Poor Function & SLCO1B1 Poor Function	8b219877-2b13-4014-b662-403e37354242	{39f5387b-4a50-4696-99ae-6c9062e70c52,22fb682a-e57d-4ad2-8dc5-8159f28a9862}	Prescribe ≤10&nbsp;mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and population specific guidelines. If dose >10&nbsp;mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy). \n\nThe potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.	Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557	Caution (Yellow Column)	Increased rosuvastatin exposure as compared to SLCO1B1 normal and decreased function and compared to ABCG2 normal and decreased function which may translate to increased myopathy risk.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c23ca553-a768-4eef-b237-4f7a1963182f	Belinostat-UGT1A1  Normal Metabolizer	61c19ced-3a01-4312-ab9b-ec591541e877	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Beleodaq (belinostat). Package Insert. Acrotech Biopharma Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
30ea4649-210f-489d-8b25-eb7752952a58	Belinostat-UGT1A1  Intermediate Metabolizer	61c19ced-3a01-4312-ab9b-ec591541e877	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Beleodaq (belinostat). Package Insert. Acrotech Biopharma Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2753d745-4fde-44ad-a817-a926e2416c26	Belinostat-UGT1A1 Poor Metabolizer *28/*28	61c19ced-3a01-4312-ab9b-ec591541e877	{58f41405-4198-4822-b10e-eb43cd77bc27}	Reduce starting dose to 750&nbsp;mg/m&#178; in poor metabolizers. Recommendation for dose reduction is derived from the FDA package insert on UGT1A1 homozygous *28 individuals.	Beleodaq (belinostat). Package Insert. Acrotech Biopharma Inc. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of belinostat to less active compounds when compared to UGT1A1 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a52d2763-eaaa-4283-823e-698e31304ac7	Belinostat-UGT1A1 Poor Metabolizer	61c19ced-3a01-4312-ab9b-ec591541e877	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Beleodaq (belinostat). Package Insert. Acrotech Biopharma Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3cdce22c-e760-49b5-bb60-d1577acb2750	Belinostat-UGT1A1  Indeterminate	61c19ced-3a01-4312-ab9b-ec591541e877	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Beleodaq (belinostat). Package Insert. Acrotech Biopharma Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b98504a2-18f3-4d87-a127-101372b44237	Atazanavir-UGT1A1 Poor Metabolizer	9205ea26-5624-454e-8d1f-8bab4c2866a2	{58f41405-4198-4822-b10e-eb43cd77bc27}	Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).	Gammal RS, Court MH, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016;99(4):363-369. doi:10.1002/cpt.269	Caution (Yellow Column)	High likelihood of bilirubin-related discontinuation of atazanavir due to markedly decreased UGT1A1 activity.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3373dbf4-1675-4263-84a5-5cce2c8835c5	Atazanavir-UGT1A1  Indeterminate	9205ea26-5624-454e-8d1f-8bab4c2866a2	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Gammal RS, Court MH, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016;99(4):363-369. doi:10.1002/cpt.269	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
143bd3ec-ef82-49ae-9ef6-c32eb8c481ec	Dapsone-G6PD Normal Function	739f1e73-352a-42d9-9fd8-99f9cc80a0e5	{9be7b66e-d066-4d98-bc30-ec1511489398}	\N	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c0724f6b-1a47-441b-ada7-11a0b12cb944	Dapsone-G6PD Indeterminate	739f1e73-352a-42d9-9fd8-99f9cc80a0e5	{9be7b66e-d066-4d98-bc30-ec1511489398}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Unknown risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
52dee135-9501-426c-a3db-231ea6521fee	Dapsone-G6PD Decreased Function	739f1e73-352a-42d9-9fd8-99f9cc80a0e5	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use of dapsone is not recommended. Consider alternative therapy.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	High risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bcd2d343-b857-4fc5-a3a0-5c81ce009acf	Dapsone-G6PD Poor Function	739f1e73-352a-42d9-9fd8-99f9cc80a0e5	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use of dapsone is not recommended. Consider alternative therapy.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	High risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fcfc351f-a70e-4fe5-a31b-41d222f912a7	Dapsone-G6PD Decreased or Normal Function	739f1e73-352a-42d9-9fd8-99f9cc80a0e5	{9be7b66e-d066-4d98-bc30-ec1511489398}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Variable risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a0df12b1-415d-40d0-8bc1-03acd83f9918	Methylene Blue-G6PD Normal Function	0aa49471-3558-4909-bb35-acbf6817ac45	{9be7b66e-d066-4d98-bc30-ec1511489398}	\N	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
469870c6-7f05-4396-a9bf-71600605852f	Methylene Blue-G6PD Indeterminate	0aa49471-3558-4909-bb35-acbf6817ac45	{9be7b66e-d066-4d98-bc30-ec1511489398}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Unknown risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a9ac42a0-a727-4add-a3bb-5deddf2cadc1	Methylene Blue-G6PD Decreased Function	0aa49471-3558-4909-bb35-acbf6817ac45	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use of methylene blue is not recommended. Consider alternative therapy.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	High risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4975269a-144e-49f1-ad97-16f120d1cbd3	Methylene Blue-G6PD Poor Function	0aa49471-3558-4909-bb35-acbf6817ac45	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use of methylene blue is not recommended. Consider alternative therapy.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	High risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
743681fe-8f16-4ea4-94c1-1c7719d567ec	Methylene Blue-G6PD Decreased or Normal Function	0aa49471-3558-4909-bb35-acbf6817ac45	{9be7b66e-d066-4d98-bc30-ec1511489398}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Variable risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7a9151c4-2be6-4f64-9ee7-f158ca3471e1	Pegloticase-G6PD Normal Function	89341edd-8cb2-4bdf-9087-185c6b1591a6	{9be7b66e-d066-4d98-bc30-ec1511489398}	\N	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
708e26f3-fa66-4a29-a38c-5f544dd31662	Pegloticase-G6PD Indeterminate	89341edd-8cb2-4bdf-9087-185c6b1591a6	{9be7b66e-d066-4d98-bc30-ec1511489398}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Unknown risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
00ee0df7-f531-4d7d-92e4-b9db178dbc30	Pegloticase-G6PD Poor Function	89341edd-8cb2-4bdf-9087-185c6b1591a6	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use of pegloticase is not recommended. Consider alternative therapy.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	High risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2525a59c-0f76-4b6f-8802-c552221c2c8b	Pegloticase-G6PD Decreased or Normal Function	89341edd-8cb2-4bdf-9087-185c6b1591a6	{9be7b66e-d066-4d98-bc30-ec1511489398}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Variable risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fcbba7b9-fd30-47f8-931a-705573f4e87e	Rasburicase-G6PD Normal Function	093eb220-d638-4e4c-96cb-c191c947c13e	{9be7b66e-d066-4d98-bc30-ec1511489398}	\N	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9196af56-2465-49c7-9d81-ec5191deb357	Rasburicase-G6PD Indeterminate	093eb220-d638-4e4c-96cb-c191c947c13e	{9be7b66e-d066-4d98-bc30-ec1511489398}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Unknown risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4924cd3e-87c7-4838-bd40-de0f29768239	Rasburicase-G6PD Decreased Function	093eb220-d638-4e4c-96cb-c191c947c13e	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use of rasburicase is not recommended. Consider alternative therapy.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	High risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6f2d7423-305a-41e1-b471-ad6bbce92983	Rasburicase-G6PD Poor Function	093eb220-d638-4e4c-96cb-c191c947c13e	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use of rasburicase is not recommended. Consider alternative therapy.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	High risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
762c6869-1df4-41e7-a12e-5fde1ec2d3e1	Rasburicase-G6PD Decreased or Normal Function	093eb220-d638-4e4c-96cb-c191c947c13e	{9be7b66e-d066-4d98-bc30-ec1511489398}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Variable risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
36afdfac-e2ce-4bd3-9eaa-698000f13c57	Tafenoquine-G6PD Normal Function	4a935869-581c-46f9-9952-20e811affd82	{9be7b66e-d066-4d98-bc30-ec1511489398}	\N	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
989205c4-5925-4dce-ae16-a6a0f27c431f	Tafenoquine-G6PD Indeterminate	4a935869-581c-46f9-9952-20e811affd82	{9be7b66e-d066-4d98-bc30-ec1511489398}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Unknown risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3f3f8960-2894-4c63-b3d1-68045b53c92a	Tafenoquine-G6PD Decreased Function	4a935869-581c-46f9-9952-20e811affd82	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use of tafenoquine is not recommended. Consider alternative therapy.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	High risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5c68ca9a-48b5-4a77-87a7-b80a3699dbc5	Tafenoquine-G6PD Poor Function	4a935869-581c-46f9-9952-20e811affd82	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use of tafenoquine is not recommended. Consider alternative therapy.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	High risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
36e77366-636b-4e0d-81a0-209ec3226fc5	Tafenoquine-G6PD Decreased or Normal Function	4a935869-581c-46f9-9952-20e811affd82	{9be7b66e-d066-4d98-bc30-ec1511489398}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Variable risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3a1e4c0d-e0e9-4704-8238-9f1f02c8a307	Primaquine-G6PD Normal Function	7018114d-d8e8-48a7-9219-70b585abec26	{9be7b66e-d066-4d98-bc30-ec1511489398}	\N	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735, WHO Guidelines for malaria, 14 March 2023. Geneva: World Health Organization; 2023 (WHO/UCN/GMP/ 2023.01). License: CC BY-NC-SA 3.0 IGO., and Prevention CC for DC and. CDC - Malaria - Diagnosis & Treatment (United States) - Treatment (U.S.) - Guidelines for Clinicians (Part 1). Published June 28, 2023. Accessed October 6, 2023. https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4ccd6559-e071-4372-bbe2-e2a971cc6768	Thioguanine-TPMT Normal Metabolizer & NUDT15 Normal Metabolizer	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	\N	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
20f11418-baba-4b62-aa82-9d137f19396e	Primaquine-G6PD Indeterminate	7018114d-d8e8-48a7-9219-70b585abec26	{9be7b66e-d066-4d98-bc30-ec1511489398}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735, WHO Guidelines for malaria, 14 March 2023. Geneva: World Health Organization; 2023 (WHO/UCN/GMP/ 2023.01). License: CC BY-NC-SA 3.0 IGO., and Prevention CC for DC and. CDC - Malaria - Diagnosis & Treatment (United States) - Treatment (U.S.) - Guidelines for Clinicians (Part 1). Published June 28, 2023. Accessed October 6, 2023. https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html	Caution (Yellow Column)	Unknown risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8e4d7117-aac5-4564-b497-4d6ec589b631	Primaquine-G6PD Decreased Function	7018114d-d8e8-48a7-9219-70b585abec26	{9be7b66e-d066-4d98-bc30-ec1511489398}	Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed:&nbsp;\n<ol>\n    <li>Treating <em>Plasmodium vivax</em> or <em>Plasmodium ovale</em> malaria for radical cure of liver-stage infections: 0.75&nbsp;mg/kg once weekly for 8 weeks or 45&nbsp;mg once weekly for 8 weeks - with close monitoring for hemolysis.</li>\n    <li>Treating <em>Plasmodium falciparum</em> malaria by using primaquine single dose as a gametocytocide at 0.25&nbsp;mg/kg - without need for monitoring for hemolysis.</li>\n</ol>	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735, WHO Guidelines for malaria, 14 March 2023. Geneva: World Health Organization; 2023 (WHO/UCN/GMP/ 2023.01). License: CC BY-NC-SA 3.0 IGO., and Prevention CC for DC and. CDC - Malaria - Diagnosis & Treatment (United States) - Treatment (U.S.) - Guidelines for Clinicians (Part 1). Published June 28, 2023. Accessed October 6, 2023. https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html	Caution (Yellow Column)	High risk of acute hemolytic anemia with standard (or higher than standard) anti-relapse dosages for <em>Plasmodium vivax</em> or <em>Plasmodium ovale</em> of 0.25-0.5&nbsp;mg/kg daily for 14 days.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e2d34508-d906-4139-96ac-845f5ac22b58	Primaquine-G6PD Poor Function	7018114d-d8e8-48a7-9219-70b585abec26	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use of primaquine is not recommended. Consider alternative therapy.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735, WHO Guidelines for malaria, 14 March 2023. Geneva: World Health Organization; 2023 (WHO/UCN/GMP/ 2023.01). License: CC BY-NC-SA 3.0 IGO., and Prevention CC for DC and. CDC - Malaria - Diagnosis & Treatment (United States) - Treatment (U.S.) - Guidelines for Clinicians (Part 1). Published June 28, 2023. Accessed October 6, 2023. https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html	Caution (Yellow Column)	High risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6bd34503-6140-4c80-859b-baaa14ada3bb	Primaquine-G6PD Decreased or Normal Function	7018114d-d8e8-48a7-9219-70b585abec26	{9be7b66e-d066-4d98-bc30-ec1511489398}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735, WHO Guidelines for malaria, 14 March 2023. Geneva: World Health Organization; 2023 (WHO/UCN/GMP/ 2023.01). License: CC BY-NC-SA 3.0 IGO., and Prevention CC for DC and. CDC - Malaria - Diagnosis & Treatment (United States) - Treatment (U.S.) - Guidelines for Clinicians (Part 1). Published June 28, 2023. Accessed October 6, 2023. https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html	Caution (Yellow Column)	Variable risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
90d7d88b-fbcb-4a96-9e4b-51150e6187c4	Nitrofurantoin-G6PD Normal Function	79018e4d-e218-4e8f-971d-af3b1f95fbc0	{9be7b66e-d066-4d98-bc30-ec1511489398}	\N	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1fdb69e0-4372-424a-9f27-8f1be8b782db	Nitrofurantoin-G6PD Indeterminate	79018e4d-e218-4e8f-971d-af3b1f95fbc0	{9be7b66e-d066-4d98-bc30-ec1511489398}	If deemed necessary to ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Unknown risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
83cb1b24-e748-4fc0-945d-364f9f1dfe9e	Nitrofurantoin-G6PD Decreased Function	79018e4d-e218-4e8f-971d-af3b1f95fbc0	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use nitrofurantoin at standard doses with caution and with close monitoring for anemia.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Medium risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ca593b9c-ea6a-49e3-afb4-a36c38e6022c	Nitrofurantoin-G6PD Poor Function	79018e4d-e218-4e8f-971d-af3b1f95fbc0	{9be7b66e-d066-4d98-bc30-ec1511489398}	Use of nitrofurantoin is not recommended. Consider alternative therapy.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	High risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
48f4cf7a-891a-4289-9d09-a04ee52d2467	Nitrofurantoin-G6PD Decreased or Normal Function	79018e4d-e218-4e8f-971d-af3b1f95fbc0	{9be7b66e-d066-4d98-bc30-ec1511489398}	If deemed necessary to ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5):973-985. doi:10.1002/cpt.2735	Caution (Yellow Column)	Variable risk of acute hemolytic anemia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5f74ed26-98c9-456f-95a2-54ffe311b19a	Azathioprine-TPMT Normal Metabolizer & NUDT15 Normal Metabolizer	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	\N	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bf90d1be-4d92-4e8a-b25c-ff5ae900dd6c	Azathioprine-TPMT Normal Metabolizer & NUDT15 Indeterminate	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on TPMT status, start with normal starting dose (e.g., 2&#8208;3&nbsp;mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady state after each dose adjustment. \n\nNUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Unknown risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
91ec904c-c1cf-414c-a046-2ed695539265	Azathioprine-TPMT Normal Metabolizer & NUDT15 Intermediate Metabolizer	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Start with reduced starting doses (30%&#8208;80% of normal dose) if normal starting dose is 2&#8208;3 mg/kg/day (e.g., 0.6&#8208;2.4&nbsp;mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cd578b3a-2398-4268-882a-5df025decb87	Azathioprine-TPMT Normal Metabolizer & NUDT15 Poor Metabolizer	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy. \n\nFor malignant conditions: Start with drastically reduced normal daily doses (10% of normal dose) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a59340f-976f-4f1a-9471-eeff102efe40	Azathioprine-TPMT Intermediate Metabolizer & NUDT15 Normal Metabolizer	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Start with reduced starting doses (30%&#8208;80% of normal dose) if normal starting dose is 2&#8208;3&nbsp;mg/kg/day (e.g., 0.6&#8208;2.4&nbsp;mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9b5eebe1-3e82-4f10-9fa7-a97c553e6bc0	Azathioprine-TPMT Intermediate Metabolizer & NUDT15 Indeterminate	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on TPMT status, start with reduced starting doses (30%&#8208;80% of normal dose) if normal starting dose is 2&#8208;3&nbsp;mg/kg/day (e.g., 0.6&#8208;2.4&nbsp;mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady state after each dose adjustment. \n\nNUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
be966f62-f172-4c93-9bcb-d3ac1a34cdcd	Azathioprine-TPMT Intermediate Metabolizer & NUDT15 Intermediate Metabolizer	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Start with reduced starting doses (30%&#8208;80% of normal dose) if normal starting dose is 2&#8208;3&nbsp;mg/kg/day (e.g., 0.6&#8208;2.4&nbsp;mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared to those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4b51a8f8-4863-485f-ba7e-45aa5c056582	Azathioprine-TPMT Intermediate Metabolizer & NUDT15 Poor Metabolizer	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy. \n\nFor malignant conditions: Start with drastically reduced normal daily doses (10% of normal dose) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8207054d-016b-4566-aa6c-4a33f946b368	Azathioprine-TPMT Poor Metabolizer & NUDT15 Normal Metabolizer	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy. \n\nFor malignant conditions: Start with drastically reduced doses (10% of normal dose and reduce frequency to thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3f1bfec5-a2e1-4463-af4e-15f19632f398	Azathioprine-TPMT Poor Metabolizer & NUDT15 Indeterminate	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on TPMT status, for non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy. \n\nFor malignant conditions:  Start with drastically reduced doses (10% of normal dose and reduce frequency to thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. \n\nNUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c0cf6a76-07af-49ef-b2dd-8cc63c914c55	Azathioprine-TPMT Poor Metabolizer & NUDT15 Intermediate Metabolizer	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For non-malignant conditions:  Consider alternative non-thiopurine immunosuppressant therapy. \n\nFor malignant conditions: Start with drastically reduced doses (10% of normal dose and reduce frequency to thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bc9e9813-f31f-4ae8-8367-4a5e7e75ea4d	Azathioprine-TPMT Poor Metabolizer & NUDT15 Poor Metabolizer	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy. \n\nFor malignant conditions: Start with drastically reduced doses (10% of normal dose and reduce frequency to thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
298a2ce5-03e8-4bc3-90c2-f100bc798067	Azathioprine-TPMT Indeterminate & NUDT15 Indeterminate	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	\N	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
80a3d0d6-4fee-4d16-b0e4-da9b5b5f7e9a	Azathioprine-TPMT Indeterminate & NUDT15 Normal Metabolizer	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on NUDT15, start with normal starting dose (e.g., 2&#8208;3&nbsp;mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady state after each dose adjustment. \n\nTPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Unknown risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6a0804e8-8d14-413c-b77f-b8d925240ca6	Azathioprine-TPMT Indeterminate & NUDT15 Intermediate Metabolizer	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on NUDT15 status, start with reduced starting doses (30%&#8208;80% of normal dose) if normal starting dose is 2&#8208;3&nbsp;mg/kg/day (e.g., 0.6&#8208;2.4&nbsp;mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady state after each dose adjustment. \n\nTPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
88e8d64f-4ffe-45af-a5c2-bf41e05f5daa	Azathioprine-TPMT Indeterminate & NUDT15 Poor Metabolizer	e0acdb40-24e1-4e84-b477-352a1a69922f	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on NUDT15 status, for non-malignant conditions:  Consider alternative non-thiopurine immunosuppressant therapy. \n\nFor malignant conditions: Start with drastically reduced normal daily doses (10% of normal dose) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment.\n\nTPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
19e74b3a-e81d-4046-8e2f-155e3c44ea3c	Mercaptopurine-TPMT Normal Metabolizer & NUDT15 Normal Metabolizer	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	\N	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b0b55a81-cc70-4670-8381-fed9b85d4795	Mercaptopurine-TPMT Normal Metabolizer & NUDT15 Indeterminate	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on TPMT status, start with normal starting dose (e.g., 75&nbsp;mg/m&#178;/day or 1.5&nbsp;mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady state after each dose adjustment. \n\nNUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Unknown risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4cf7ced8-df93-4ae9-a25d-1630d6df5afd	Mercaptopurine-TPMT Normal Metabolizer & NUDT15 Intermediate Metabolizer	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Start with reduced starting doses (30%&#8208;80% of normal dose) if normal starting dose is ≥75&nbsp;mg/m&#178;/day or ≥1.5&nbsp;mg/kg/day (e.g., start at 22.5&#8208;60&nbsp;mg/m&#178;/day or 0.45&#8208;1.2&nbsp;mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already &lt;75&nbsp;mg/m&#178;/day or &lt;1.5&nbsp;mg/kg/day, dose reduction may not be recommended.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d87d39c4-b0c8-4785-a105-8474a8c48bad	Mercaptopurine-TPMT Normal Metabolizer & NUDT15 Poor Metabolizer	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For malignant conditions: Initiate dose at 10&nbsp;mg/m&#178;/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5b2821a5-e35e-44c4-8c13-d63d6345ba5a	Mercaptopurine-TPMT Intermediate Metabolizer & NUDT15 Normal Metabolizer	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Start with reduced starting doses (30%&#8208;80% of normal dose) if normal starting dose is ≥75&nbsp;mg/m&#178;/day or ≥1.5&nbsp;mg/kg/day (e.g., start at 22.5&#8208;60&nbsp;mg/m&#178;/day or 0.45&#8208;1.2&nbsp;mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already &lt;75&nbsp;mg/m&#178;/day or &lt;1.5&nbsp;mg/kg/day, dose reduction may not be recommended.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4ecc2531-c07c-4c78-8754-7bc14aeed18c	Deutetrabenazine-CYP2D6 Intermediate Metabolizer	8d963751-ff27-411b-8d4a-026d53335a9e	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Austedo (deutetrabenazine). Package Insert. Teva Neuroscience, Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ba096883-f4e9-4f53-84f9-1b14226e2593	Deutetrabenazine-CYP2D6 Poor Metabolizer	8d963751-ff27-411b-8d4a-026d53335a9e	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	The maximum recommended daily dose is 36&nbsp;mg.	Austedo (deutetrabenazine). Package Insert. Teva Neuroscience, Inc. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects (QT prolongation) due to greatly reduced metabolism of deutetrabenazine to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f6fa5712-a021-457c-bdbc-1d25071ac028	Mercaptopurine-TPMT Intermediate Metabolizer & NUDT15 Indeterminate	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on TPMT status, start with reduced starting doses (30%&#8208;80% of normal dose) if normal starting dose is ≥75&nbsp;mg/m&#178;/day or ≥1.5&nbsp;mg/kg/day (e.g., start at 22.5&#8208;60&nbsp;mg/m&#178;/day or 0.45&#8208;1.2&nbsp;mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already &lt;75&nbsp;mg/m&#178;/day or &lt;1.5&nbsp;mg/kg/day, dose reduction may not be recommended. \n\nNUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4baf01a8-d3df-461f-bd31-e3283aaec78e	Mercaptopurine-TPMT Intermediate Metabolizer & NUDT15 Intermediate Metabolizer	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Start with reduced starting doses (30%&#8208;80% of normal dose) if normal starting dose is ≥75&nbsp; mg/m&#178;/day or ≥1.5&nbsp;mg/kg/day (e.g., start at 22.5&#8208;60&nbsp;mg/m&#178;/day or 0.45&#8208;1.2&nbsp;mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already &lt;75&nbsp;mg/m&#178;/day or &lt;1.5&nbsp;mg/kg/day, dose reduction may not be recommended. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared to those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b803db15-e821-45f7-b77c-16b9409fc423	Mercaptopurine-TPMT Intermediate Metabolizer & NUDT15 Poor Metabolizer	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For malignant conditions: Initiate dose at 10&nbsp;mg/m&#178;/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6079583e-d988-4f99-91aa-99e0c0bb20f4	Mercaptopurine-TPMT Poor Metabolizer & NUDT15 Normal Metabolizer	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For malignant conditions: Start with drastically reduced doses (10% of normal dose and reduce frequency to thrice weekly instead of daily, e.g., 10&nbsp;mg/m&#178;/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ca91806e-64bb-4580-a882-d715e1c22f4c	Mercaptopurine-TPMT Poor Metabolizer & NUDT15 Indeterminate	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on TPMT status, for malignant conditions: Start with drastically reduced doses (10% of normal dose and reduce frequency to thrice weekly instead of daily, e.g., 10&nbsp;mg/m&#178;/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.\n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy. \n\nNUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cfb318fd-1e1e-4fd8-bcdb-bde939c66b76	Deutetrabenazine-CYP2D6 Indeterminate	8d963751-ff27-411b-8d4a-026d53335a9e	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Austedo (deutetrabenazine). Package Insert. Teva Neuroscience, Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2f782948-8df8-4550-923a-9d582b413d9d	Pitolisant-CYP2D6 Normal Metabolizer	025c0b65-bce6-4a78-9dca-54acad450ea2	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Wakix (pitolisant). Package Insert. Harmony Biosciences, LLC. 2022.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
df0f8567-fc9b-426c-aba7-632bf3a2f69e	Pitolisant-CYP2D6 Ultra-rapid Metabolizer	025c0b65-bce6-4a78-9dca-54acad450ea2	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Wakix (pitolisant). Package Insert. Harmony Biosciences, LLC. 2022.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
58a60da9-bb63-4882-b28d-a899d6e00f52	Mercaptopurine-TPMT Poor Metabolizer & NUDT15 Intermediate Metabolizer	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For malignant conditions: Start with drastically reduced doses (10% of normal dose and reduce frequency to thrice weekly instead of daily, e.g., 10&nbsp;mg/m&#178;/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7fd76e58-6082-4eb2-809b-5bce5cf8cd32	Mercaptopurine-TPMT Poor Metabolizer & NUDT15 Poor Metabolizer	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For malignant conditions: Start with drastically reduced doses (10% of normal dose and reduce frequency to thrice weekly instead of daily, e.g., 10&nbsp;mg/m&#178;/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0a8d7236-b26f-404d-94a4-08189f56d6d3	Mercaptopurine-TPMT Indeterminate & NUDT15 Indeterminate	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	\N	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f644f4d4-07d4-4a68-9ebb-2d867faf1a9a	Mercaptopurine-TPMT Indeterminate & NUDT15 Normal Metabolizer	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on NUDT15 status, start with normal starting dose (e.g., 75&nbsp;mg/m&#178;/day or 1.5&nbsp;mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady state after each dose adjustment. \n\nTPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Unknown risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a9123596-3d31-4156-9c2f-5c24dae4b8ff	Mercaptopurine-TPMT Indeterminate & NUDT15 Intermediate Metabolizer	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based NUDT15 status, start with reduced starting doses (30%&#8208;80% of normal dose) if normal starting dose is ≥75&nbsp;mg/m&#178;/day or ≥1.5&nbsp;mg/kg/day (e.g., start at 22.5&#8208;60&nbsp;mg/m&#178;/day or 0.45&#8208;1.2&nbsp;mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already &lt;75&nbsp;mg/m&#178;/day or &lt;1.5&nbsp;mg/kg/day, dose reduction may not be recommended. \n\nTPMT phenotype could not be assigned based on genotyping. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b7f0d91b-f540-4dbb-a1d6-67945f3de9fe	Mercaptopurine-TPMT Indeterminate & NUDT15 Poor Metabolizer	0e38efb2-fc40-4421-ab75-aaa7e5a0d4c6	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on NUDT15 status, for malignant conditions: Initiate dose at 10&nbsp;mg/m&#178;/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy. \n\nTPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
88feafc5-50e7-49cc-94ca-19ac20a62381	Pitolisant-CYP2D6 Intermediate Metabolizer	025c0b65-bce6-4a78-9dca-54acad450ea2	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Wakix (pitolisant). Package Insert. Harmony Biosciences, LLC. 2022.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c83b313a-6377-48f6-b423-61bcbd1befac	Thioguanine-TPMT Normal Metabolizer & NUDT15 Indeterminate	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on TPMT status, start with normal starting dose (e.g., 40&#8208;60&nbsp;mg/m&#178;/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady state after each dose adjustment \n\nNUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Unknown risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3d76ee07-337e-4e71-925b-5a4ad34a6217	Thioguanine-TPMT Normal Metabolizer & NUDT15 Intermediate Metabolizer	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥40&#8208;60&nbsp;mg/m&#178;/day (e.g., 20&#8208;48&nbsp;mg/m&#178;/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7278d8a2-1afa-47ea-8f45-aca80363e7fd	Thioguanine-TPMT Normal Metabolizer & NUDT15 Poor Metabolizer	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For malignant conditions: Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
eb4ca459-a7c5-418b-b663-72482539d188	Thioguanine-TPMT Intermediate Metabolizer & NUDT15 Normal Metabolizer	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥40&#8208;60&nbsp;mg/m&#178;/day (e.g., 20&#8208;48&nbsp;mg/m&#178;/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
97beb27d-91c6-4d5a-bde8-ce522ae7cf3f	Thioguanine-TPMT Intermediate Metabolizer & NUDT15 Indeterminate	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥40&#8208;60&nbsp;mg/m&#178;/day (e.g., 20&#8208;48&nbsp;mg/m&#178;/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.\n\nNUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e8397cbe-b0c5-4e24-a1b7-c4b70b096289	Thioguanine-TPMT Intermediate Metabolizer & NUDT15 Intermediate Metabolizer	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥40&#8208;60&nbsp;mg/m&#178;/day (e.g., 20&#8208;48&nbsp;mg/m&#178;/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared to those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
df2e1002-2afb-4016-90b8-e042eb0397a3	Pitolisant-CYP2D6 Poor Metabolizer	025c0b65-bce6-4a78-9dca-54acad450ea2	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	The maximum recommended dose is 17.8&nbsp;mg once daily.	Wakix (pitolisant). Package Insert. Harmony Biosciences, LLC. 2022.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of pitolisant to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c12b01cc-f893-4719-acb3-93037b400058	Thioguanine-TPMT Intermediate Metabolizer & NUDT15 Poor Metabolizer	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For malignant conditions: Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
721735a9-8a80-4464-8384-aa2969f9bed9	Thioguanine-TPMT Poor Metabolizer & NUDT15 Normal Metabolizer	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For malignant conditions: Start with drastically reduced doses (10% of normal dose and reduce frequency to thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4606b7b7-7fe5-4409-937f-2bea04577896	Thioguanine-TPMT Poor Metabolizer & NUDT15 Indeterminate	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on TPMT status, for malignant conditions: Start with drastically reduced doses (10% of normal dose and reduce frequency to thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy. \n\nNUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9c851f5b-3b22-4bdd-b23f-bfd4bedc71c3	Thioguanine-TPMT Poor Metabolizer & NUDT15 Intermediate Metabolizer	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For malignant conditions: Start with drastically reduced doses (10% of normal dose and reduce frequency to thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
043573ca-8b01-4937-880c-363faa091589	Thioguanine-TPMT Poor Metabolizer & NUDT15 Poor Metabolizer	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	For malignant conditions: Start with drastically reduced doses (10% of normal dose and reduce frequency to thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d6a7f0c5-56a8-40ab-8eae-7c5747555fe8	Thioguanine-TPMT Indeterminate & NUDT15 Indeterminate	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	\N	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
62f0715d-c698-419a-a5d0-fc9fda75bfb4	Pitolisant-CYP2D6 Indeterminate	025c0b65-bce6-4a78-9dca-54acad450ea2	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Wakix (pitolisant). Package Insert. Harmony Biosciences, LLC. 2022.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fba6af6e-fe6b-41ad-a222-4467da95e989	Eliglustat-CYP2D6 Normal Metabolizer	5369d927-542a-4b5c-9578-a3d0d6192064	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Cerdelga (eliglustat). Package Insert. Genzyme Ireland, Ltd. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9ddc5858-cec8-4a12-abb9-de920843f065	Ondansetron-CYP2D6 Normal Metabolizer	7c52c9c1-1c96-440d-95fe-82088a2ac2f0	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Bell GC, Caudle KE, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102(2):213-218. doi:10.1002/cpt.598	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
adf94e1e-154d-461e-97bf-23d2a7f41b5f	Thioguanine-TPMT Indeterminate & NUDT15 Normal Metabolizer	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on NUDT15, start with normal starting dose (e.g., 40&#8208;60&nbsp;mg/m&#178;/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady state after each dose adjustment. \n\nHowever, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Unknown risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cb0fcdda-d13d-4b13-b383-7233c3a91968	Thioguanine-TPMT Indeterminate & NUDT15 Intermediate Metabolizer	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥40&#8208;60&nbsp;mg/m&#178;/day (e.g., 20&#8208;48&nbsp;mg/m&#178;/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2&#8208;4 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. \n\nTPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0e2317c5-78bc-4fd9-8c1a-e0bc352c701d	Thioguanine-TPMT Indeterminate & NUDT15 Poor Metabolizer	129be50f-5d81-4be5-b75d-ce000c6a7250	{daa86f03-86c6-4a8d-abab-476fcd043c9c,9ca2999f-1b56-4ee8-a254-2da4415cbb72}	Based on NUDT15, for malignant conditions: Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4&#8208;6 weeks to reach steady state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. \n\nFor non-malignant conditions: Consider alternative non-thiopurine immunosuppressant therapy. \n\nTPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.	Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105. doi:10.1002/cpt.1304 and General background text Pharmacogenetics – <em>Nudixhydrolase 15 (NUDT15)</em>. Published online November 5, 2018. Accessed November 13, 2023. https://www.pharmgkb.org/page/dpwgMapping	Caution (Yellow Column)	Greatly increased risk of thiopurine-related leukopenia, neutropenia, and/or myelosuppression.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4c833ed7-ac64-43bf-b08e-7a0b66810842	Valbenazine-CYP2D6 Normal Metabolizer	420ab93f-1333-468a-959e-72aa4485e402	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Ingrezza (valbenazine). Package Insert. Neurocrine Biosciences, Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a841cca-0a94-4173-a2e3-94064c295dba	Valbenazine-CYP2D6 Ultra-rapid Metabolizer	420ab93f-1333-468a-959e-72aa4485e402	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Ingrezza (valbenazine). Package Insert. Neurocrine Biosciences, Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8ec38741-d1f6-4cfb-bde3-56bcefe7f9b0	Valbenazine-CYP2D6 Intermediate Metabolizer	420ab93f-1333-468a-959e-72aa4485e402	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Ingrezza (valbenazine). Package Insert. Neurocrine Biosciences, Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
aa063d12-8ac0-423b-be80-1ea10ce165e3	Valbenazine-CYP2D6 Poor Metabolizer	420ab93f-1333-468a-959e-72aa4485e402	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	The maximum recommended dose is 40&nbsp;mg daily.	Ingrezza (valbenazine). Package Insert. Neurocrine Biosciences, Inc. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects (QT prolongation) due to greatly reduced metabolism of valbenazine to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c6a21385-ae1b-48fb-a6a2-090dd3563729	Valbenazine-CYP2D6 Indeterminate	420ab93f-1333-468a-959e-72aa4485e402	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Ingrezza (valbenazine). Package Insert. Neurocrine Biosciences, Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
33b53ed0-62bb-4617-bec2-90d8bba22d3d	Tetrabenazine-CYP2D6 Normal Metabolizer	ab467f62-bb04-4815-90e2-5fc7578cbb66	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Xenazine (tetrabenazine). Package Insert. Lundbeck Pharmaceuticals, LLC. 2019.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
83ac9581-1559-427e-ac19-3aca64177e50	Tetrabenazine-CYP2D6 Ultra-rapid Metabolizer	ab467f62-bb04-4815-90e2-5fc7578cbb66	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Xenazine (tetrabenazine). Package Insert. Lundbeck Pharmaceuticals, LLC. 2019.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
df69d456-0455-4f98-af86-c2c83a75c8a2	Tetrabenazine-CYP2D6 Intermediate Metabolizer	ab467f62-bb04-4815-90e2-5fc7578cbb66	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Xenazine (tetrabenazine). Package Insert. Lundbeck Pharmaceuticals, LLC. 2019.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
518ec9ad-7df7-4d4b-8eff-04a6c3c36653	Tetrabenazine-CYP2D6 Poor Metabolizer	ab467f62-bb04-4815-90e2-5fc7578cbb66	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	The maximum recommended single dose is 25&nbsp;mg and total daily dose should not exceed 50&nbsp;mg.	Xenazine (tetrabenazine). Package Insert. Lundbeck Pharmaceuticals, LLC. 2019.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of tetrabenazine to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2d059afd-e97c-42b7-a1b3-a2e9cdbef966	Tetrabenazine-CYP2D6 Indeterminate	ab467f62-bb04-4815-90e2-5fc7578cbb66	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Xenazine (tetrabenazine). Package Insert. Lundbeck Pharmaceuticals, LLC. 2019.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5c1a91f9-a5f9-48aa-b130-3b611255c7ea	Deutetrabenazine-CYP2D6 Normal Metabolizer	8d963751-ff27-411b-8d4a-026d53335a9e	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Austedo (deutetrabenazine). Package Insert. Teva Neuroscience, Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
358f7ed5-56c9-4d88-abe7-39ecbc3864b8	Deutetrabenazine-CYP2D6 Ultra-rapid Metabolizer	8d963751-ff27-411b-8d4a-026d53335a9e	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Austedo (deutetrabenazine). Package Insert. Teva Neuroscience, Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d1c725e2-edf7-41db-b67b-e6b07a9124dd	Eliglustat-CYP2D6 Ultra-rapid Metabolizer	5369d927-542a-4b5c-9578-a3d0d6192064	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Ultra-rapid metabolizers of CYP2D6 may not achieve adequate concentrations to achieve therapeutic effect. Consider alternative therapy.	Cerdelga (eliglustat). Package Insert. Genzyme Ireland, Ltd. 2023.	Caution (Yellow Column)	Lower plasma concentrations decrease the probability of clinical benefit due to increased metabolism to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2cfdda52-727c-4980-9b51-f6cb8d569a36	Eliglustat-CYP2D6 Intermediate Metabolizer	5369d927-542a-4b5c-9578-a3d0d6192064	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Cerdelga (eliglustat). Package Insert. Genzyme Ireland, Ltd. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f3621ac9-9731-4356-adcf-f5cc7fbc5652	Eliglustat-CYP2D6 Poor Metabolizer	5369d927-542a-4b5c-9578-a3d0d6192064	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	The recommended dose is 84&nbsp;mg daily.	Cerdelga (eliglustat). Package Insert. Genzyme Ireland, Ltd. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase probability of adverse events (QT prolongation) due to reduced metabolism of eliglustat to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
290ed9b7-ebfd-4fdc-ac2d-310f72f83df1	Eliglustat-CYP2D6 Indeterminate	5369d927-542a-4b5c-9578-a3d0d6192064	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Cerdelga (eliglustat). Package Insert. Genzyme Ireland, Ltd. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
111623ca-05ec-4e32-9c32-384496708f96	Pimozide-CYP2D6 Normal Metabolizer	70fff4d0-4f7e-4e04-a677-64876a71e24d	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Orap (pimozide). Package Insert. Par Pharmaceuticals, Inc. 2017.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f15ee116-4252-45f1-944b-8a0325a927e5	Pimozide-CYP2D6 Ultra-rapid Metabolizer	70fff4d0-4f7e-4e04-a677-64876a71e24d	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Orap (pimozide). Package Insert. Par Pharmaceuticals, Inc. 2017.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1cfdd92a-7159-4181-8417-0ef11efffb3c	Pimozide-CYP2D6 Intermediate Metabolizer	70fff4d0-4f7e-4e04-a677-64876a71e24d	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Orap (pimozide). Package Insert. Par Pharmaceuticals, Inc. 2017.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
89660c46-97e8-416f-ae27-ac04c6e740f5	Pimozide-CYP2D6 Poor Metabolizer	70fff4d0-4f7e-4e04-a677-64876a71e24d	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	The maximum dose is 4&nbsp;mg daily in adults. Dosages should not be increased earlier than 14 days.	Orap (pimozide). Package Insert. Par Pharmaceuticals, Inc. 2017.	Caution (Yellow Column)	Higher plasma concentrations of pimozide may increase probability of adverse events.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3ad518c1-cba5-4b49-a75c-000da86b1655	Pimozide-CYP2D6 Indeterminate	70fff4d0-4f7e-4e04-a677-64876a71e24d	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Orap (pimozide). Package Insert. Par Pharmaceuticals, Inc. 2017.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e167a583-fb30-4951-9340-ba25f3500b66	Iloperidone-CYP2D6 Normal Metabolizer	b01d12bf-0ae0-4f32-b29d-2ad679892f0b	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Fanapt (Iloperidone). Package Insert. Vanda Pharmaceuticals, Inc. 2021.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
82fa6a07-a523-4391-bd0c-f3d1b90e5ba8	Iloperidone-CYP2D6 Ultra-rapid Metabolizer	b01d12bf-0ae0-4f32-b29d-2ad679892f0b	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Fanapt (Iloperidone). Package Insert. Vanda Pharmaceuticals, Inc. 2021.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3c340a19-7f91-432e-a3f2-1ef9c34f9c78	Iloperidone-CYP2D6 Intermediate Metabolizer	b01d12bf-0ae0-4f32-b29d-2ad679892f0b	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Fanapt (Iloperidone). Package Insert. Vanda Pharmaceuticals, Inc. 2021.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d024e83f-2ffd-4ca3-a4ed-e8115c78c09d	Iloperidone-CYP2D6 Poor Metabolizer	b01d12bf-0ae0-4f32-b29d-2ad679892f0b	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Reduce to half the usual dose and cautiously titrate based on response.	Fanapt (Iloperidone). Package Insert. Vanda Pharmaceuticals, Inc. 2021.	Caution (Yellow Column)	Higher plasma concentrations may increase probability of adverse events (QT prolongation) due to reduced metabolism of iloperidone to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
02192424-8888-4564-9c78-96b4268ac20a	Iloperidone-CYP2D6 Indeterminate	b01d12bf-0ae0-4f32-b29d-2ad679892f0b	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Fanapt (Iloperidone). Package Insert. Vanda Pharmaceuticals, Inc. 2021.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
56e47716-ac53-4d03-b072-67f621dc18eb	Brexpiprazole-CYP2D6 Normal Metabolizer	6a12dbea-1145-4203-911b-e536dbdd2f2b	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Rexulti (brexpiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d9d656a9-c247-41fc-9014-e7a6e02221d0	Brexpiprazole-CYP2D6 Ultra-rapid Metabolizer	6a12dbea-1145-4203-911b-e536dbdd2f2b	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Rexulti (brexpiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d7d58ee0-f368-4cd2-b434-79bb1d42d84a	Brexpiprazole-CYP2D6 Intermediate Metabolizer	6a12dbea-1145-4203-911b-e536dbdd2f2b	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Rexulti (brexpiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cc0a2281-81fa-4f0b-ad41-755b93e7d4c8	Brexpiprazole-CYP2D6 Poor Metabolizer	6a12dbea-1145-4203-911b-e536dbdd2f2b	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Reduce to half the usual dose based on indication. Cautiously titrate based on response.	Rexulti (brexpiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023.	Caution (Yellow Column)	Higher plasma concentrations of brexpiprazole may increase probability of adverse events.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
05698e9f-9315-452d-bff6-3a9c117e3236	Brexpiprazole-CYP2D6 Indeterminate	6a12dbea-1145-4203-911b-e536dbdd2f2b	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Rexulti (brexpiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3c31632e-fc0e-4eda-b4ec-99fe922ac61d	Metoclopramide-CYP2D6 Normal Metabolizer	1e6e3bf7-bfb4-40bc-b820-94e181a26f75	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Reglan (metoclopramide). Package Insert. ANI Pharmaceuticals, Inc. 2020.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
83bd502d-c6cd-4b40-91c6-5d243069fb36	Metoclopramide-CYP2D6 Ultra-rapid Metabolizer	1e6e3bf7-bfb4-40bc-b820-94e181a26f75	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Reglan (metoclopramide). Package Insert. ANI Pharmaceuticals, Inc. 2020.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e1ca767e-3a70-442c-b1d5-d92fb895b9c7	Metoclopramide-CYP2D6 Intermediate Metabolizer	1e6e3bf7-bfb4-40bc-b820-94e181a26f75	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Reglan (metoclopramide). Package Insert. ANI Pharmaceuticals, Inc. 2020.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a26f2142-d8f3-40bf-9327-ce73cd8e17bb	Metoclopramide-CYP2D6 Poor Metabolizer	1e6e3bf7-bfb4-40bc-b820-94e181a26f75	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	The maximum recommended total daily dose is 30&nbsp;mg for treatment of gastroesophageal reflux disease (GERD). For the treatment of diabetic gastroparesis the maximum recommended total daily dose is 20&nbsp;mg.	Reglan (metoclopramide). Package Insert. ANI Pharmaceuticals, Inc. 2020.	Caution (Yellow Column)	Higher plasma concentrations of metoclopramide may increase probability of adverse events.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
21d5d841-5807-4931-baeb-3de36b2dc53c	Metoclopramide-CYP2D6 Indeterminate	1e6e3bf7-bfb4-40bc-b820-94e181a26f75	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Reglan (metoclopramide). Package Insert. ANI Pharmaceuticals, Inc. 2020.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1ea9e3a4-13d8-4c2d-8e87-bded3021d6bf	Codeine-CYP2D6 Normal Metabolizer	752f1592-e6ce-48be-b907-f191400bf24c	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, <em>OPRM1</em>, and <em>COMT</em> Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896. doi:10.1002/cpt.2149	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f1371e95-3952-4515-b169-d487e8fa006f	Codeine-CYP2D6 Ultra-rapid Metabolizer	752f1592-e6ce-48be-b907-f191400bf24c	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, <em>OPRM1</em>, and <em>COMT</em> Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896. doi:10.1002/cpt.2149	Caution (Yellow Column)	Increased formation of morphine leading to higher risk of toxicity.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e6c38cb8-b3ef-47c1-a621-df282c4f5d03	Codeine-CYP2D6 Intermediate Metabolizer	752f1592-e6ce-48be-b907-f191400bf24c	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, <em>OPRM1</em>, and <em>COMT</em> Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896. doi:10.1002/cpt.2149	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
743943b8-a53c-41fa-ae92-ca5ca48cb031	Codeine-CYP2D6 Poor Metabolizer	752f1592-e6ce-48be-b907-f191400bf24c	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.	Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, <em>OPRM1</em>, and <em>COMT</em> Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896. doi:10.1002/cpt.2149	Caution (Yellow Column)	Greatly reduced morphine formation leading to diminished analgesia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5b77c20d-5298-49a8-8237-4f70a2bbb166	Codeine-CYP2D6 Indeterminate	752f1592-e6ce-48be-b907-f191400bf24c	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, <em>OPRM1</em>, and <em>COMT</em> Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896. doi:10.1002/cpt.2149	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5479dc5f-ae7c-43a3-9697-59c25ff67102	Tramadol-CYP2D6 Normal Metabolizer	17e1be64-4c39-48c8-a13b-5d3cd0357c4f	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, <em>OPRM1</em>, and <em>COMT</em> Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896. doi:10.1002/cpt.2149	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
62f6956f-c724-4cf2-afc8-023d642e0f41	Tramadol-CYP2D6 Ultra-rapid Metabolizer	17e1be64-4c39-48c8-a13b-5d3cd0357c4f	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, <em>OPRM1</em>, and <em>COMT</em> Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896. doi:10.1002/cpt.2149	Caution (Yellow Column)	Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
543068a9-8fc4-46f7-bdef-05cc09172a48	Tramadol-CYP2D6 Intermediate Metabolizer	17e1be64-4c39-48c8-a13b-5d3cd0357c4f	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, <em>OPRM1</em>, and <em>COMT</em> Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896. doi:10.1002/cpt.2149	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
71073869-267d-404b-88bc-3716117c9877	Tramadol-CYP2D6 Poor Metabolizer	17e1be64-4c39-48c8-a13b-5d3cd0357c4f	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Avoid tramadol use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid.	Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, <em>OPRM1</em>, and <em>COMT</em> Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896. doi:10.1002/cpt.2149	Caution (Yellow Column)	Greatly reduced O-desmethyltramadol (active metabolite) formation leading to diminished analgesia.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ff7e817a-b706-4f69-b6cc-19f06a9c75e4	Tramadol-CYP2D6 Indeterminate	17e1be64-4c39-48c8-a13b-5d3cd0357c4f	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, <em>OPRM1</em>, and <em>COMT</em> Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896. doi:10.1002/cpt.2149	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
86aaf5d3-990d-4211-b717-60da64f6fca4	Atomoxetine-CYP2D6 Normal Metabolizer	b42d7cb5-1fbb-4800-853c-56ed56c71801	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Initiate with a dose of 40&nbsp;mg/day and increase to 80&nbsp;mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100&nbsp;mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If &lt;200&nbsp;ng/mL, consider a proportional increase in dose to approach 400&nbsp;ng/mL. Dosages greater than 100&nbsp;mg/day may be needed to achieve target concentrations.\n\nTherapeutic range of 200 to 1000&nbsp;ng/mL has been proposed. Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations >400&nbsp;ng/mL. Doses above 120&nbsp;mg/day have not been evaluated.	Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for <em>Cytochrome P450 (CYP)2D6 </em> Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019;106(1):94-102. doi:10.1002/cpt.1409	Caution (Yellow Column)	Normal metabolizers of atomoxetine have a lower likelihood of response when compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy when compared to CYP2D6 poor metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6c39d722-fa9e-4fe7-98d1-4cff6a5d4b2b	Atomoxetine-CYP2D6 Ultra-rapid Metabolizer	b42d7cb5-1fbb-4800-853c-56ed56c71801	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Initiate with a dose of 40&nbsp;mg/day and increase to 80&nbsp;mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100&nbsp;mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If &lt;200&nbsp;ng/mL, consider a proportional increase in dose to approach 400&nbsp;ng/mL. Dosages greater than 100&nbsp;mg/day may be needed to achieve target concentrations.\n\nTherapeutic range of 200 to 1000&nbsp;ng/mL has been proposed. Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations >400&nbsp;ng/mL. Doses above 120&nbsp;mg/day have not been evaluated.	Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for <em>Cytochrome P450 (CYP)2D6 </em> Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019;106(1):94-102. doi:10.1002/cpt.1409	Caution (Yellow Column)	Based on very limited data available for CYP2D6 ultra-rapid metabolizers taking atomoxetine, it is unlikely ultra-rapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5a380c5b-1642-4f36-b9ad-8c533b2208fc	Atomoxetine-CYP2D6 Intermediate Metabolizer	b42d7cb5-1fbb-4800-853c-56ed56c71801	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Initiate with a dose of 40&nbsp;mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80&nbsp;mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2&#8208;4 hours after dosing. If concentration is &lt;200&nbsp;ng/mL, consider a proportional dose increase to achieve a concentration to approach 400&nbsp;ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.\n\nTherapeutic range of 200 to 1000&nbsp;ng/mL has been proposed. Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations >400&nbsp;ng/mL.	Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for <em>Cytochrome P450 (CYP)2D6 </em> Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019;106(1):94-102. doi:10.1002/cpt.1409	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to decreased metabolism when compared to CYP2D6 normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation due to reduced efficacy when compared to CYP2D6 poor metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ad130cf0-dd4f-4f2c-9a78-8c76bc7a794d	Atomoxetine-CYP2D6 Poor Metabolizer	b42d7cb5-1fbb-4800-853c-56ed56c71801	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Initiate with a dose of 40&nbsp;mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80&nbsp;mg/day. If response is inadequate after 2 weeks, consider obtaining a plasma concentration 2&#8208;4 hours after dosing. If concentration is &lt;200&nbsp;ng/mL, consider a proportional dose increase to achieve a concentration to approach 400&nbsp;ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.\n\nTherapeutic range of 200 to 1000&nbsp;ng/mL has been proposed. Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations >400&nbsp;ng/mL.	Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for <em>Cytochrome P450 (CYP)2D6 </em> Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019;106(1):94-102. doi:10.1002/cpt.1409	Caution (Yellow Column)	Significantly decreased metabolism of atomoxetine may result in higher concentrations when compared to non-poor metabolizers. This may increase the occurrence of treatment-emergent side effects, but also a greater improvement of ADHD symptoms as compared to non-poor metabolizers in those who tolerate treatment. Poor metabolizer status is associated with lower final dose requirements as compared to non-poor metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ece32bda-232d-4f38-88da-6224fef8a93a	Atomoxetine-CYP2D6 Indeterminate	b42d7cb5-1fbb-4800-853c-56ed56c71801	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for <em>Cytochrome P450 (CYP)2D6 </em> Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019;106(1):94-102. doi:10.1002/cpt.1409	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
30cdb8dc-6b03-4d0d-a20a-3336c9f0a537	Ondansetron-CYP2D6 Ultra-rapid Metabolizer	7c52c9c1-1c96-440d-95fe-82088a2ac2f0	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	Bell GC, Caudle KE, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102(2):213-218. doi:10.1002/cpt.598	Caution (Yellow Column)	Decreased response to ondansetron (i.e., vomiting) due to increased metabolism to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3218a59e-15fe-491a-ad1f-8f5b77766324	Ondansetron-CYP2D6 Intermediate Metabolizer	7c52c9c1-1c96-440d-95fe-82088a2ac2f0	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Bell GC, Caudle KE, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102(2):213-218. doi:10.1002/cpt.598	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bf499975-6f8c-4098-a10b-de971c75af31	Ondansetron-CYP2D6 Poor Metabolizer	7c52c9c1-1c96-440d-95fe-82088a2ac2f0	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Bell GC, Caudle KE, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102(2):213-218. doi:10.1002/cpt.598	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b71efee2-b438-4423-99ab-f84530927a58	Ondansetron-CYP2D6 Indeterminate	7c52c9c1-1c96-440d-95fe-82088a2ac2f0	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Bell GC, Caudle KE, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102(2):213-218. doi:10.1002/cpt.598	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e8eaa061-7cca-4172-b9a1-43fb0951dad1	Abacavir- HLA-B*5701 Low Risk	bd146e3e-bfdc-4cbd-a552-b20b6aa25ef3	{b31967bd-f6da-49d9-ba4e-cafdd7786116}	\N	Martin MA, Klein TE, Dong BJ, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012;91(4):734-738. doi:10.1038/clpt.2011.355 and Martin MA, Hoffman JM, Freimuth RR, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther. 2014;95(5):499-500. doi:10.1038/clpt.2014.38	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7e3ad6a3-cff0-4f76-af75-248dc9aa1faa	Abacavir- HLA-B*5701 High Risk	bd146e3e-bfdc-4cbd-a552-b20b6aa25ef3	{b31967bd-f6da-49d9-ba4e-cafdd7786116}	Abacavir is not recommended.  Consider alternative therapy.	Martin MA, Klein TE, Dong BJ, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012;91(4):734-738. doi:10.1038/clpt.2011.355 and Martin MA, Hoffman JM, Freimuth RR, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther. 2014;95(5):499-500. doi:10.1038/clpt.2014.38	Caution (Yellow Column)	Significantly increased risk of abacavir hypersensitivity.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
41373a30-bdf3-4bc6-b65b-1ebc08500900	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	\N	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e4b92bea-a98d-4112-b971-5434d3e2c46d	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 5-7&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by an additional 10-25%.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Normal to slighly decreased warfarin dose.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ece454a6-dfd7-45be-857a-7ee7e21a8985	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 5-7 mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Variable effect on warfarin dose based on ancestry.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ccd752a3-b8be-4a14-8945-1a67d9d196a2	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	\N	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6689f4bd-b72f-4121-9f3f-114353160c14	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 5-7&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Normal to slighly decreased warfarin dose.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
93277032-c93f-461a-a51d-e5b78b31548a	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 5-7 mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Variable effect on warfarin dose based on ancestry.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3fa77826-f8ca-4c21-9bf6-b34f43019217	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6b65e501-10b2-4acd-a0f0-f92713627a0f	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d036913a-b726-43e6-acc0-be191148c57d	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1914df22-66fe-47e4-8d8f-4109beb88612	Warfarin-CYP2C9 Activity Score 1.5 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	\N	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bdd99634-653b-4c38-8844-c7fa410af743	Warfarin-CYP2C9 Activity Score 1.5 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 5-7&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Normal to slighly decreased warfarin dose.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f12d1632-feb5-45b1-b72d-665cace4816d	Warfarin-CYP2C9 Activity Score 1.5 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 5-7&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Normal to increased warfarin dose.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
697b7bf9-8478-4465-b15a-4e7800a95cb3	Warfarin-CYP2C9 Activity Score 1.5 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 5-7&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Variable effect on warfarin dose based on ancestry.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cfb30a4f-a146-46b8-bb35-6111fa82ef6b	Warfarin-CYP2C9 Activity Score 1.5 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c2b4fa64-c2c1-4672-bfd8-4e7b5d8d43f6	Warfarin-CYP2C9 Activity Score 1.5 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a228493f-b29b-4acb-aee3-8e53a0b3b25d	Warfarin-CYP2C9 Activity Score 1.5 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e1162b96-7ad5-40bd-9594-490b56fd4d3c	Warfarin-CYP2C9 Activity Score 1.5 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a7c8e6dd-ba40-4c26-a44f-6f5d27b62698	Warfarin-CYP2C9 Activity Score 1.5 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0c7612e3-7c10-4ca1-8a9d-f350ee74117b	Warfarin-CYP2C9 Activity Score 1.5 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
06ecd909-ab38-4c7f-a0a8-16d6420a3308	Warfarin-CYP2C9 Activity Score 1.5 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
552f0633-1c38-47db-b88b-b426253df114	Warfarin-CYP2C9 Activity Score 1.5 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fcc9066a-29ee-40e8-a4cc-39e7d0ff5883	Warfarin-CYP2C9 Activity Score 1 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0a633284-cac8-4b8b-93db-6726538764c9	Warfarin-CYP2C9 Activity Score 1 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1e0f2164-5a78-4069-a1a5-a4fdaf48dd05	Warfarin-CYP2C9 Activity Score 1 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
abe1af21-8a38-4881-a466-76cea6c3a3f4	Warfarin-CYP2C9 Activity Score 1 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a887fc48-4cf9-436c-84da-c4778757bf7b	Warfarin-CYP2C9 Activity Score 1 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b975fd8d-8663-47ab-987d-56847a3e797a	Warfarin-CYP2C9 Activity Score 1 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
141ada26-3715-4066-8294-25b29b0dcc96	Warfarin-CYP2C9 Activity Score 1 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
102dc420-b7fd-4662-bad8-ba7f7cd724e3	Warfarin-CYP2C9 Activity Score 1 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4 mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8adc5622-f3c5-40a5-861d-805e0639cadf	Warfarin-CYP2C9 Activity Score 1 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4aab688b-d98d-4470-8886-09e2e48d999e	Warfarin-CYP2C9 Activity Score 1 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dd7c949b-bf77-4f9e-80a2-c454b47d8d62	Warfarin-CYP2C9 Activity Score 1 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
39028101-e53c-4b15-ba72-26da2dc7e756	Warfarin-CYP2C9 Activity Score 1 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cba9b16e-5cfd-4ee0-a182-f6af4d626517	Warfarin-CYP2C9 Activity Score 0.5 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ef143131-ceb0-4822-8f7f-b32e53f8cdb1	Warfarin-CYP2C9 Activity Score 0.5 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
50b7ab86-eb0d-4c7b-875d-6e448d2e0a70	Warfarin-CYP2C9 Activity Score 0.5 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider an additional 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bfc30775-59cd-4f86-831d-996eb2c5fa5a	Warfarin-CYP2C9 Activity Score 0.5 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ba1dd5db-9ee0-4da4-8752-eb43e9c8a295	Warfarin-CYP2C9 Activity Score 0.5 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
954a704a-4da5-4dc6-bf41-6daf029a96e4	Warfarin-CYP2C9 Activity Score 0.5 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
69d168d9-7240-4a60-82a2-92144d2356e8	Warfarin-CYP2C9 Activity Score 0.5 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
526db99b-3ca1-410d-998e-817c9d4625eb	Warfarin-CYP2C9 Activity Score 0.5 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8cac2333-470a-4711-92f4-7bede9c83f84	Warfarin-CYP2C9 Activity Score 0.5 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4e6d87e7-e15f-4b0c-9c5f-9d13c0c734eb	Warfarin-CYP2C9 Activity Score 0.5 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
92b08548-b122-4559-afc4-910e3450d7ce	Warfarin-CYP2C9 Activity Score 0.5 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f907e0e8-bb2d-4907-b6a2-a786210b9e87	Warfarin-CYP2C9 Activity Score 0.5 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
833a8dfb-88c7-49d4-8350-5e5921f37953	Warfarin-CYP2C9 Activity Score 0 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1e7fc55c-c6bc-41e7-aadc-8d88752f9803	Warfarin-CYP2C9 Activity Score 0 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a34bda89-e2a5-4c20-9188-95ba124d5ace	Warfarin-CYP2C9 Activity Score 0 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bb38aceb-1705-41ce-9c24-80775da5c812	Warfarin-CYP2C9 Activity Score 0 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cd321fa9-3214-4694-b6f2-db79ec682fd7	Warfarin-CYP2C9 Activity Score 0 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ad7384e8-902a-487a-82d3-55b33b122a3e	Warfarin-CYP2C9 Activity Score 0 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b5ed27f5-d452-4b07-84d9-539fe869388e	Warfarin-CYP2C9 Activity Score 0 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a0454995-d917-4e91-8ec5-e5991daddaa4	Warfarin-CYP2C9 Activity Score 0 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5227a011-383d-4c9b-a42a-06598a5c8547	Warfarin-CYP2C9 Activity Score 0 & CYP4F2 Normal Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9309fd3c-e584-4a76-a31c-3cd5e8f9b194	Warfarin-CYP2C9 Activity Score 0 & CYP4F2 Normal Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e0e8a240-ea37-4400-90d2-9a59f6c2e68d	Warfarin-CYP2C9 Activity Score 0 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8fa410bc-c485-4f90-931f-391e0fd81983	Warfarin-CYP2C9 Activity Score 0 & CYP4F2 Reduced Function & CYP2C High Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 0.5-2&nbsp;mg daily.\nIn African Americans, consider <b>decreasing</b> starting dose by 10-25%.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.\n\nBased on CYP2C9 phenotype, it may take longer (&gt;2 to 4 weeks) to reach steady state and to achieve stable INR effect.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Markedly decreased warfarin dose is expected.	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b12f0012-a731-47aa-a3a9-54d460c2b37e	Capecitabine-DPYD Normal Metabolizer	2cf72f48-6286-45df-b741-31bdd3ec6c00	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	\N	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.	Standard Precautions (Green column)	\N	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
6a026526-9603-4b87-8f16-701883f5a339	Capecitabine-DPYD Intermediate Metabolizer	2cf72f48-6286-45df-b741-31bdd3ec6c00	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).\n\nIncrease the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to decreased dihydropyrimidine dehydrogenase (DPD) activity.	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
28fd5f1a-fe9c-496d-8dd4-a1b10cd4e9ca	Capecitabine-DPYD Intermediate Metabolizer	2cf72f48-6286-45df-b741-31bdd3ec6c00	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).\n\nIncrease the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to decreased dihydropyrimidine dehydrogenase (DPD) activity.	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
1add5f41-2f7e-4730-a4b4-d327f2903039	Capecitabine-DPYD Poor Metabolizer	2cf72f48-6286-45df-b741-31bdd3ec6c00	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to complete dihydropyrimidine dehydrogenase (DPD) deficiency.	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
81d42f9d-b621-4589-bf2d-1e15e1823e31	Capecitabine-DPYD Poor Metabolizer	2cf72f48-6286-45df-b741-31bdd3ec6c00	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to complete dihydropyrimidine dehydrogenase (DPD) deficiency.	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
34baeb95-7a29-428a-8ec7-0c147b929dae	Capecitabine-DPYD Indeterminate	2cf72f48-6286-45df-b741-31bdd3ec6c00	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	\N	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.	Standard Precautions (Green column)	\N	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
b74a236e-a9ca-434d-a608-1f7f10b995e7	Fluorouracil-DPYD Normal Metabolizer	e8d4c4d1-7661-46ec-8922-99b775dd6ede	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	\N	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.	Standard Precautions (Green column)	\N	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
943f33e0-a76d-4f3c-806e-207882e10c4a	Fluorouracil-DPYD Intermediate Metabolizer	e8d4c4d1-7661-46ec-8922-99b775dd6ede	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).\n\nIncrease the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to decreased dihydropyrimidine dehydrogenase (DPD) activity.	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
97ff38cf-d4ab-4c53-a0bd-4032d39f19c8	Fluorouracil-DPYD Intermediate Metabolizer	e8d4c4d1-7661-46ec-8922-99b775dd6ede	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).\n\nIncrease the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to decreased dihydropyrimidine dehydrogenase (DPD) activity.	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
9d2f270e-3ae6-41bc-8429-ae6a0e6165f8	Fluorouracil-DPYD Poor Metabolizer	e8d4c4d1-7661-46ec-8922-99b775dd6ede	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to complete dihydropyrimidine dehydrogenase (DPD) deficiency.	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
242ce7e9-218c-43fe-9fe7-8ed55161f181	Fluorouracil-DPYD Poor Metabolizer	e8d4c4d1-7661-46ec-8922-99b775dd6ede	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to complete dihydropyrimidine dehydrogenase (DPD) deficiency.	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
d6580c21-3f56-4ce3-91a4-df9fdc3258ce	Fluorouracil-DPYD Indeterminate	e8d4c4d1-7661-46ec-8922-99b775dd6ede	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	\N	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.	Standard Precautions (Green column)	\N	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
75f0bc43-e2c5-44e3-a23a-a1328ac03bd4	Aripiprazole-CYP2D6 Normal Metabolizer	dc92f451-05c1-43e6-8bf1-8ff5e6de317a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Abilify (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2022., Abilify Maintena (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023., Aristada (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022. and ARISTADA INITIO (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022.	Standard Precautions (Green column)	\N	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
70d6fbbd-00aa-44d6-9770-8b12962a5086	Aripiprazole-CYP2D6 Ultra-rapid Metabolizer	dc92f451-05c1-43e6-8bf1-8ff5e6de317a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Abilify (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2022., Abilify Maintena (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023., Aristada (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022. and ARISTADA INITIO (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022.	Standard Precautions (Green column)	\N	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
8ab9e061-13ff-4f95-b3a6-3a54d6267fa1	Aripiprazole-CYP2D6 Intermediate Metabolizer	dc92f451-05c1-43e6-8bf1-8ff5e6de317a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Abilify (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2022., Abilify Maintena (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023., Aristada (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022. and ARISTADA INITIO (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022.	Standard Precautions (Green column)	\N	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
89f53ee0-88ab-4bf6-ac36-5167d91cbc3a	Aripiprazole-CYP2D6 Poor Metabolizer	dc92f451-05c1-43e6-8bf1-8ff5e6de317a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Abilify (aripiprazole): Reduce to half the usual dose and cautiously titrate based on response. \n\nAbilify Maintena (aripiprazole maintena):  The maximum recommended monthly dose is 300&nbsp;mg intramuscularly.\n\nAristada (aripiprazole lauroxil): The maximum recommended monthly dose is 441&nbsp;mg intramuscularly.\n\nARISTADA INITIO (aripriprazole lauroxil): Avoid use of ARISTADA INITIO as dosage adjustments are not possible.	Abilify (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2022., Abilify Maintena (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023., Aristada (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022. and ARISTADA INITIO (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022.	Caution (Yellow Column)	Higher plasma concentrations of aripiprazole may increase probability of adverse events.	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
432791e2-d04c-4f1a-a44c-c3f5ed0a04c4	Aripiprazole-CYP2D6 Indeterminate	dc92f451-05c1-43e6-8bf1-8ff5e6de317a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Abilify (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2022., Abilify Maintena (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023., Aristada (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022. and ARISTADA INITIO (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022.	Standard Precautions (Green column)	\N	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
014d2ddd-7bd7-46ab-b299-bd12f574b2e0	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 5-7&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Normal to increased warfarin dose.	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
4de01839-1ba3-49df-908d-440528adee29	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 5-7&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Normal to increased warfarin dose.	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
58246eac-11a3-422e-abb9-a550ef6b5b01	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4v&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
45d036cb-d08a-4f41-b3a3-0bc36f3e1ab6	Capecitabine-DPYD Normal Metabolizer	2cf72f48-6286-45df-b741-31bdd3ec6c00	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	\N	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6e5d11d0-a5fa-423b-8399-a722d91872a1	Capecitabine-DPYD Intermediate Metabolizer	2cf72f48-6286-45df-b741-31bdd3ec6c00	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).\n\nIncrease the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to decreased dihydropyrimidine dehydrogenase (DPD) activity.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
71606ef3-5fd7-4621-9cea-0b919bae8f57	Capecitabine-DPYD Intermediate Metabolizer	2cf72f48-6286-45df-b741-31bdd3ec6c00	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).\n\nIncrease the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to decreased dihydropyrimidine dehydrogenase (DPD) activity.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
92df571d-a4d9-4d3a-9aee-f736ee9f4aee	Capecitabine-DPYD Poor Metabolizer	2cf72f48-6286-45df-b741-31bdd3ec6c00	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to complete dihydropyrimidine dehydrogenase (DPD) deficiency.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d222bc28-f243-40af-b848-1f6cc875ccc9	Capecitabine-DPYD Poor Metabolizer	2cf72f48-6286-45df-b741-31bdd3ec6c00	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to complete dihydropyrimidine dehydrogenase (DPD) deficiency.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
246d7ca9-0b2a-4492-9870-94795b61ddc7	Capecitabine-DPYD Indeterminate	2cf72f48-6286-45df-b741-31bdd3ec6c00	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	\N	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
20877256-7129-435b-b16b-b433aa1d3e1e	Fluorouracil-DPYD Normal Metabolizer	e8d4c4d1-7661-46ec-8922-99b775dd6ede	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	\N	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
990a9f68-8d21-4898-a48e-ea450b94268a	Fluorouracil-DPYD Intermediate Metabolizer	e8d4c4d1-7661-46ec-8922-99b775dd6ede	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).\n\nIncrease the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to decreased dihydropyrimidine dehydrogenase (DPD) activity.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f890a885-6d44-43e0-be9d-c92a404aa074	Fluorouracil-DPYD Intermediate Metabolizer	e8d4c4d1-7661-46ec-8922-99b775dd6ede	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).\n\nIncrease the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to decreased dihydropyrimidine dehydrogenase (DPD) activity.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a2940828-84a6-4e6e-b6fd-9dad55f96b7a	Fluorouracil-DPYD Poor Metabolizer	e8d4c4d1-7661-46ec-8922-99b775dd6ede	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to complete dihydropyrimidine dehydrogenase (DPD) deficiency.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
417a7e81-4a0b-47cf-95e7-712a55328d1a	Fluorouracil-DPYD Poor Metabolizer	e8d4c4d1-7661-46ec-8922-99b775dd6ede	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/	Caution (Yellow Column)	Increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs due to complete dihydropyrimidine dehydrogenase (DPD) deficiency.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7a06a82e-2dd8-464c-a310-dc3b80d3759c	Fluorouracil-DPYD Indeterminate	e8d4c4d1-7661-46ec-8922-99b775dd6ede	{0f0237e6-0568-4790-ae5b-03b0cd6e6d20}	\N	Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216. doi:10.1002/cpt.911 and November 2018 update references on CPIC https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9223809b-3b12-4c9d-b3ea-b5f26c2848b7	Aripiprazole-CYP2D6 Normal Metabolizer	dc92f451-05c1-43e6-8bf1-8ff5e6de317a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Abilify (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2022., Abilify Asimtufii. Package Insert. Otsuka America Pharmaceutical Inc. 2024., Abilify Maintena (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023., Aristada (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022. and Aristada Initio (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bf714bac-d921-40e1-bddf-4c16fccd8868	Aripiprazole-CYP2D6 Ultra-rapid Metabolizer	dc92f451-05c1-43e6-8bf1-8ff5e6de317a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Abilify (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2022., Abilify Asimtufii. Package Insert. Otsuka America Pharmaceutical Inc. 2024., Abilify Maintena (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023., Aristada (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022. and Aristada Initio (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b80b1a76-e57c-4685-bec8-30a0dee24331	Aripiprazole-CYP2D6 Intermediate Metabolizer	dc92f451-05c1-43e6-8bf1-8ff5e6de317a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Abilify (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2022., Abilify Asimtufii. Package Insert. Otsuka America Pharmaceutical Inc. 2024., Abilify Maintena (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023., Aristada (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022. and Aristada Initio (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0df7591d-dc8d-4627-bb2b-351d7cd5f1f0	Aripiprazole-CYP2D6 Poor Metabolizer	dc92f451-05c1-43e6-8bf1-8ff5e6de317a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Abilify (aripiprazole): Reduce to half the usual dose and cautiously titrate based on response. \n\nAbilify Asimtufii (aripiprazole extended release): The recommended dose is 720&nbsp;mg intramuscularly every 2 months.\n\nAbilify Maintena (aripiprazole maintena):  The maximum recommended monthly dose is 300&nbsp;mg intramuscularly.\n\nAristada (aripiprazole lauroxil): The maximum recommended monthly dose is 441&nbsp;mg intramuscularly.\n\nAristada Initio (aripriprazole lauroxil): Avoid use of Aristada Initio as dosage adjustments are not possible.	Abilify (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2022., Abilify Asimtufii. Package Insert. Otsuka America Pharmaceutical Inc. 2024., Abilify Maintena (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023., Aristada (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022. and Aristada Initio (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022.	Caution (Yellow Column)	Higher plasma concentrations of aripiprazole may increase probability of adverse events.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bcc7949d-2326-4a0d-8428-64050ac20671	Aripiprazole-CYP2D6 Indeterminate	dc92f451-05c1-43e6-8bf1-8ff5e6de317a	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Abilify (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2022., Abilify Asimtufii. Package Insert. Otsuka America Pharmaceutical Inc. 2024., Abilify Maintena (aripiprazole). Package Insert. Otsuka Pharmaceutical Co. 2023., Aristada (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022. and Aristada Initio (aripiprazole lauroxil). Package Insert. Alkermes, Inc. 2022.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c94e7434-bc82-4bac-8bd1-7aa09be3be73	Warfarin-CYP2C9 Activity Score 2 & CYP4F2 Reduced Function & CYP2C Low Sensitivity	38f4957e-e9ac-409f-8507-61aaa2d7b47d	{59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35,e8d718e4-4831-496c-8448-16ad044c2e9d,93d511ec-e5fc-4832-9581-813842b25860,c0f1136b-6463-4304-a473-cae1f384fc8e}	FDA expected maintenance dose: 3-4&nbsp;mg daily.\nIn individuals with European or Asian ancestry, consider a 5-10% <b>increase</b> in starting dose.	Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668 and Warfarin (Coumadin). Package Insert. Aphena Pharma Solutions. 2012	Caution (Yellow Column)	Decreased warfarin dose is expected.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
778e07b2-3b2d-47c0-ad46-48dcf9215ae6	Thioridazine-CYP2D6 Normal Metabolizer	740a203d-6433-433a-862b-2d426f744d73	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Thioridazine. Package Insert. Mylan Institutional Inc. 2021.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
363d0bad-f2d6-4623-8ae3-e23875e04b94	Thioridazine-CYP2D6 Ultra-rapid Metabolizer	740a203d-6433-433a-862b-2d426f744d73	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Thioridazine. Package Insert. Mylan Institutional Inc. 2021.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c02279fe-75f5-4486-b5f4-9eaf84e0e8de	Thioridazine-CYP2D6 Intermediate Metabolizer	740a203d-6433-433a-862b-2d426f744d73	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Thioridazine. Package Insert. Mylan Institutional Inc. 2021.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
259bdeb5-e418-4538-8906-324ead26d15b	Thioridazine-CYP2D6 Poor Metabolizer	740a203d-6433-433a-862b-2d426f744d73	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	Thioridazine is contraindicated per FDA package insert.	Thioridazine. Package Insert. Mylan Institutional Inc. 2021.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects (QT prolongation) due to greatly reduced metabolism of thioridazine to less active compounds when compared to CYP2D6 normal metabolizers.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
72241839-cab9-4dcc-ba30-89f3194061d4	Thioridazine-CYP2D6 Indeterminate	740a203d-6433-433a-862b-2d426f744d73	{aba94ef2-e507-4963-84dd-24dc2d4f7ffc}	\N	Thioridazine. Package Insert. Mylan Institutional Inc. 2021.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5c192358-ce0e-45ad-b403-932aa9f8e416	Abrocitinib-CYP2C19 Ultra-rapid Metabolizer	b3ddb5f2-79af-45de-b3d9-5de0529fa09b	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Cibinqo (Abrocitinib). Package Insert. Pfizer Laboratories Div Pfizer Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ed07bfac-5fc8-4f2b-9305-f99bfae90985	Abrocitinib-CYP2C19 Rapid Metabolizer	b3ddb5f2-79af-45de-b3d9-5de0529fa09b	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Cibinqo (Abrocitinib). Package Insert. Pfizer Laboratories Div Pfizer Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
eee14ba1-80ab-4aaa-87c3-86b3e54bf004	Abrocitinib-CYP2C19 Normal Metabolizer	b3ddb5f2-79af-45de-b3d9-5de0529fa09b	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Cibinqo (Abrocitinib). Package Insert. Pfizer Laboratories Div Pfizer Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4054a070-5b5e-49af-a0f9-aaaac843c3c5	Abrocitinib-CYP2C19 Intermediate Metabolizer	b3ddb5f2-79af-45de-b3d9-5de0529fa09b	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Cibinqo (abrocitinib). Package Insert. Pfizer Laboratories Div Pfizer Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
10239fd8-886d-4e6d-8848-aab5b176dff4	Abrocitinib-CYP2C19 Likely Intermediate Metabolizer	b3ddb5f2-79af-45de-b3d9-5de0529fa09b	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Cibinqo (abrocitinib). Package Insert. Pfizer Laboratories Div Pfizer Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f24aa9a1-5921-41dd-a47d-35f63a437ccb	Abrocitinib-CYP2C19 Poor Metabolizer	b3ddb5f2-79af-45de-b3d9-5de0529fa09b	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	The recommended dose is 50&nbsp;mg once daily. If inadequate response, consider increasing the dosage to 100&nbsp;mg once daily.	Cibinqo (abrocitinib). Package Insert. Pfizer Laboratories Div Pfizer Inc. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of abrocitinib to less active compounds when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6205b20b-6bff-47be-b060-0dcf156c84ed	Abrocitinib-CYP2C19 Likely Poor Metabolizer	b3ddb5f2-79af-45de-b3d9-5de0529fa09b	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	The recommended dose is 50&nbsp;mg once daily. If inadequate response, consider increasing the dosage to 100&nbsp;mg once daily.\n\nThe strength of recommendation for "likely" phenotypes are the same as their respective confirmed phenotypes. "Likely" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding "likely" phenotype.	Cibinqo (abrocitinib). Package Insert. Pfizer Laboratories Div Pfizer Inc. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of abrocitinib to less active compounds when compared to CYP2C19 normal metabolizers.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d7155d1b-e011-4e81-9c5f-6fb6b1b4cc22	Abrocitinib-CYP2C19 Indeterminate	b3ddb5f2-79af-45de-b3d9-5de0529fa09b	{32638f99-ec66-41e9-87db-40b5f6c8d7d6}	\N	Cibinqo (abrocitinib). Package Insert. Pfizer Laboratories Div Pfizer Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
68d15dcc-2d84-4b66-ae05-7e08a115aea4	Irinotecan-UGT1A1  Normal Metabolizer	26a9b4b1-b8a0-4fc1-a724-6b279761a97e	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Camptosar (irinotecan). Package Insert. Pharmacia & Upjohn Company LLC. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ae39b796-add7-4fe2-b732-adb177cace7f	Irinotecan-UGT1A1  Intermediate Metabolizer	26a9b4b1-b8a0-4fc1-a724-6b279761a97e	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Camptosar (irinotecan). Package Insert. Pharmacia & Upjohn Company LLC. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0cf96b99-ac98-428f-8534-d9d7a25b1f65	Irinotecan-UGT1A1  Poor Metabolizer	26a9b4b1-b8a0-4fc1-a724-6b279761a97e	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Camptosar (irinotecan). Package Insert. Pharmacia & Upjohn Company LLC. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b7c5e060-b564-4d1d-b7f6-83212c978a9b	Irinotecan-UGT1A1 Poor Metabolizer	26a9b4b1-b8a0-4fc1-a724-6b279761a97e	{58f41405-4198-4822-b10e-eb43cd77bc27}	Consider a reduction in the starting dose by at least one level. Refer to FDA labeling for specific dosing recommendations.	Camptosar (irinotecan). Package Insert. Pharmacia & Upjohn Company LLC. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of irinotecan to inactive compounds.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8eaa9edb-3669-40dd-bfb9-9a2e33735487	Irinotecan-UGT1A1 Poor Metabolizer	26a9b4b1-b8a0-4fc1-a724-6b279761a97e	{58f41405-4198-4822-b10e-eb43cd77bc27}	Consider a reduction in the starting dose by at least one level. Refer to FDA labeling for specific dosing recommendations.	Camptosar (irinotecan). Package Insert. Pharmacia & Upjohn Company LLC. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of irinotecan to inactive compounds.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e1f43c98-4625-4dd4-adc1-a84c1f94eee0	Irinotecan-UGT1A1 Poor Metabolizer	26a9b4b1-b8a0-4fc1-a724-6b279761a97e	{58f41405-4198-4822-b10e-eb43cd77bc27}	Consider a reduction in the starting dose by at least one level. Refer to FDA labeling for specific dosing recommendations.	Camptosar (irinotecan). Package Insert. Pharmacia & Upjohn Company LLC. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of irinotecan to inactive compounds.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
76745f14-37c9-4317-b741-c1ebcf6a46b1	Irinotecan-UGT1A1  Indeterminate	26a9b4b1-b8a0-4fc1-a724-6b279761a97e	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Camptosar (irinotecan). Package Insert. Pharmacia & Upjohn Company LLC. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d548ac3e-54bf-406e-9384-98da6ef9a8b6	Irinotecan liposomal-UGT1A1  Normal Metabolizer	1784e3b7-771f-4c37-bc3b-1f17c9d6ad8f	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Onivyde (irinotecan liposomal). Package Insert. Ipsen Biopharmaceuticals, Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
efa2f5ad-3b4c-4bbe-89e8-6cf227db799c	Irinotecan liposomal-UGT1A1  Intermediate Metabolizer	1784e3b7-771f-4c37-bc3b-1f17c9d6ad8f	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Onivyde (irinotecan liposomal). Package Insert. Ipsen Biopharmaceuticals, Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5461966f-82bb-428a-95f8-de2117b7b7c9	Irinotecan liposomal-UGT1A1 Poor Metabolizer	1784e3b7-771f-4c37-bc3b-1f17c9d6ad8f	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Onivyde (irinotecan liposomal). Package Insert. Ipsen Biopharmaceuticals, Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b58c50c5-5a88-4ca5-b151-539231aa0e4f	Irinotecan liposomal-UGT1A1 Poor Metabolizer	1784e3b7-771f-4c37-bc3b-1f17c9d6ad8f	{58f41405-4198-4822-b10e-eb43cd77bc27}	The recommended starting dose is 50&nbsp;mg/m&#178;.  May increase the dose to 70&nbsp;mg/m&#178; as tolerated in subsequent cycles.	Onivyde (irinotecan liposomal). Package Insert. Ipsen Biopharmaceuticals, Inc. 2023.	Caution (Yellow Column)	Higher plasma concentrations may increase the probability of side effects due to greatly reduced metabolism of irinotecan to inactive compounds.	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4e0efc01-e1d7-48e6-9f37-82846dc00f9d	Irinotecan-UGT1A1  Indeterminate	26a9b4b1-b8a0-4fc1-a724-6b279761a97e	{58f41405-4198-4822-b10e-eb43cd77bc27}	\N	Onivyde (irinotecan liposomal). Package Insert. Ipsen Biopharmaceuticals, Inc. 2023.	Standard Precautions (Green column)	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
\.


--
-- Data for Name: master_version_recommendations; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.master_version_recommendations (id, master_version_id, recommendation_id, created_at, updated_at) FROM stdin;
ace2ca1a-50de-4a10-aea7-d5dfc6b29450	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4990a392-3b4c-4892-9e6c-76e6cecc9280	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1caeec5a-47ee-4809-8164-de13083919de	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f503feb9-7558-4ff5-bd66-16fad0cd8a5a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
03aca773-6a1b-4ee9-a9dc-1884a9b122cc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	691a50fb-a2af-4bd5-a85f-1ad3ab57af73	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b2741ce8-86d8-4ccb-b0b2-265de9812652	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3c64be84-c28a-424c-a87e-e06458e58587	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d3353874-08bf-4768-9a80-8a8fc60d144e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7949de13-fe43-4946-bfa4-65b756b42e50	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2b7e3b14-c406-4c95-8877-3e8421318a0d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	793158bd-aacb-4a8c-9d27-31879e222317	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1969f2a9-f578-4b5e-801f-c3d6aa012d95	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	19251ea9-c41b-4207-88bb-373d1b618a92	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
79cc0ce7-4604-4fb3-aec2-8bca22301514	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3a504cc4-966c-440a-9a63-26ec0e9564f1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
09cce927-d8f7-49a3-a39a-1ef2d0688f10	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b5a9ac55-68d4-4e2a-8eeb-ddb909d8db78	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
95eb0768-0fe1-47af-9c58-7b4d66ee640c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6058eb73-6738-467c-8b91-9c84eaa70f2b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a3420ca4-60fe-4180-97bd-fd13625ccd14	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7b46531a-93f6-491d-8aee-57b3b17204ad	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d91d6d40-1de5-4c96-bd89-041b738180bd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9618fc26-e1b3-493b-a61a-232a7ab79955	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dbe4acc1-5116-49be-bb80-3ee9f6ba8719	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	02ec260b-4589-406a-b044-b1983e374c69	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c7a886ff-4e04-4d3f-bd75-c843ce091a79	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	598bcaca-dbe2-495c-9a83-0a5551d475e1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
673088e1-d0ca-413b-a87f-14236295de17	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	531a543f-77f0-4b07-9f69-500c04f6da30	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
73a392f4-c84a-48c1-9d65-f483a6e9ef6e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	84012120-00e5-42b9-8fc8-12541cda050f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ae0c8753-6632-48a0-918b-75868e67a564	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	536a7bad-ec25-4edd-9105-98c3446de139	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
132513b4-9f09-456a-9557-4eab036c5170	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	40dc3eae-9e1c-454a-bb51-44f197d5134b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
293db4c2-00b1-4e24-ace5-69f5366cf790	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2b4f1a89-f719-42ca-a334-5529cf2c7ce6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
619b0842-bd58-4013-963c-0f28574b2d57	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	205a9fe5-b317-4c05-8803-1c7d98cc6728	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
21102287-b590-4165-a955-fd64436a2150	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	10c56e6a-d65e-4219-b25c-fb624f36a9f8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
83ee8289-231c-4d04-8d1d-50ab92f25093	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e1f29232-3703-4517-87da-65791a162ce3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9a2cbcb6-693f-42ad-ba34-9bb4774cfa26	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	28d9a28e-7ece-4ad3-925e-1b976941fa52	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
13bdbca9-4559-4edc-b54a-358d265f321b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8a01b626-ae72-465a-8ba1-5acf0209963d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9bbf1995-d4fe-450f-8239-6a1c78486fc6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9fd4903a-b359-4b5c-9e5d-d93e2658fc24	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
be2c611a-d653-4b4c-bb06-243ffe70d8a0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d887e66d-5595-458a-a9f4-bf98386d8f53	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3aae43fc-6715-4394-a693-8953cc506fc1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	48ba79eb-951a-4707-9e23-490d8b0b418f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ffc28570-e5cb-4a25-971e-5370ba3fbc73	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0833fc29-cdeb-4cbc-84a4-0dca5f35edfb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
950cf76e-aa1c-44ca-9623-b17fb2e755a0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8c2fba7d-1d6f-424f-a644-28d7e38d9f9d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
99cfb531-c68d-47a3-93a3-5a953b1cf391	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0eaeeb04-a26a-4b46-8b2a-9070ee200a4f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d943a557-3977-4692-961c-8b565c73bb90	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4365e77c-0942-43a1-8f31-782a88bfa265	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2637ec96-9481-493e-8e2c-b7b2d074376b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	729ba811-064c-4357-8225-b3c6f7030db8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9dbca8aa-b10b-49c6-9ab8-e0370dd92fcd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7ec93d74-6bfb-4924-b6a3-ac894e5c05e7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3999f957-67c7-4743-9bbb-e48fc10776c7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c3f1ab59-6be3-41e2-a68c-6cf4e714bfd5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cdb75dff-7095-472c-a782-397d830b4941	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	16cf6405-f1c7-44eb-94ab-928300c777fb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bde4900b-51ee-4b9f-928e-b0ba79127d58	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	dddc0c93-7015-4dbe-b810-bc750fdb8081	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
195d4aa3-3c13-41bc-bee7-10db495e07a2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d203898d-4125-4c0b-83a0-67d7b0524773	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c1f89f2c-0f3a-494b-b28f-a547ce696935	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	12a807dc-7d5c-4e37-98c8-b07a28f98f1f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
33d695c1-1416-43a9-8719-4cf1b24fd02f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	50771793-e857-4b72-a9e9-de879aa12ed9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
085a8ac3-d173-43ba-b680-a18d67514317	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f0e37aef-c08c-4f09-8df6-9067a8d97297	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1f57354c-cd69-4764-b317-ba44d88deefe	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	47cf9f8f-8c8a-4ea2-870a-39f5e7c0ea63	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
66b29407-eb63-4197-a796-1ea6ec396ccf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5b444f2d-dbf7-4ffb-a977-815ed4401b60	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c9a27c39-786a-443b-8e6e-734f0007ca07	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c33b9bde-3627-44f0-920f-5f625d66c7a8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ec1fa29e-934e-4a3b-8649-92f7ac2612af	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	53a404fc-6ac5-4648-b0b9-eb402c5af60a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5dee96bc-127b-4e35-b2e5-b8dcff2dd62e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1391ee7c-4070-4701-a19b-83ac9bc570e3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
85bf3309-c859-4aa2-8f0d-3d8bf1b313c3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	56b49b61-640c-4a0c-af50-34c4d57ff002	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
60748b74-9cfd-46ee-9582-233db9028fbf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c089d975-1478-4949-9a4c-7ea5b89061c3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2c024680-dd47-4329-ae00-ca1cd3e4f53d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9fae4973-bf8d-4639-a8d8-42dd1d8a86d6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
411f1fec-b3de-42b0-a21f-f375c55b9faa	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c4886f97-4057-4283-8941-90955ca6b136	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
31c034ab-cf58-4335-a619-fa742d9af317	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6dc9160e-efc5-476d-b7c8-cf23aa67617b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6bef366f-b1b9-43cc-9130-5a3debbc0995	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	538e80b2-97b3-49e5-8f4b-c8c6cffae1d1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e304a62b-2eb4-4a41-b12a-37574f8b216d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f7fbaa70-2085-4992-830f-9e62bcfdcae6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e48d0c30-8dbd-465e-ac51-00a0dec2e9a4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	66d63a0e-4ded-4fe6-8027-df0e5f58883d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e6de27b5-422b-4156-aab2-bbb864577530	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	61d4a736-de0a-46ba-b13e-b1b9bc458354	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6d2caa7d-83ea-4ebe-aa9f-3152df8589fb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	afc9aa8d-45bd-4f93-a36f-a1cab277977b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
596e1825-e5f4-4da7-a3df-6008b7662241	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8c0befb0-b6df-4e35-89fa-2830f348aac2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dc1e2e70-ab5b-48af-94be-da73df012796	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6647e799-322d-4d68-9671-9ee75b221763	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
986f338b-2492-425e-96cb-8a41bcf76225	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	41b2fefe-fb02-465a-88f1-70d3f4f0035c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
57e5c361-c89d-42c2-b5ed-d8bdc4a9976c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9f01b9b9-ff84-4dc4-bdca-bffbc706a4e0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
40ded03c-90e4-4a92-8fc1-c2997cafee79	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	499e5da1-163e-4a5b-a7d2-4c18ecbd25df	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4f3024e6-4b8f-4ad3-8f55-ab8043fd352c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5b13adac-657f-45ac-8a63-738966d2211a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
682d14f5-0a3e-4a56-b218-1e30c31c2362	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f78ac58f-8207-4be5-ab66-2f6633a85d31	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b9de56ad-b01b-422e-8610-5954d4fa4272	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9e7558b0-fdf3-4975-8d43-2aeacf9d81c1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
73a5c836-98d0-4957-bac8-410f2a46eb59	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0a132e5e-f8e6-4d23-8003-30c349d2e9bc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
acb81c93-ad8c-4b5b-b667-a49ffe87b3fe	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4c135345-c7fe-45d2-acab-3882fdf834fa	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4e5a45e0-4626-45cc-98f5-d1f97e694549	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	fe5a045d-c3ed-4aa8-a426-e9e6166cfd9e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
78d0dc28-2c9c-405b-a259-77f01398cc5c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	40104ccc-87fe-4b55-995a-a00743d035cc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0cfaec87-3874-4c1e-8a88-da17449a29d1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	059bc02f-d224-44e3-8553-258d81dd7993	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5d6648df-0630-49bf-81c5-94d19ff802a5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2fc748cd-dbbb-488b-8aa0-4f6ddba22f7a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c9241998-ff58-4b11-8ee7-b423aa9a5f4b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	742e478d-aaf0-42ba-8fa9-8267808b64c3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a3f501aa-7c43-4987-8544-453e9422fc1d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	25315b4a-2e27-43af-9256-47ba33a1178a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a8888b6c-b585-4480-a3fb-6068c94f9771	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	81b62720-ffca-43c8-9e58-5c7a53176400	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
440269e1-572d-4faa-8b9b-987059e221f0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	895cc18e-a7f6-4589-ae67-1360384f09b5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8dd5f2bd-9654-4fb1-bb94-a8fbd1ed2bec	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0e4f9b52-d222-4f74-b710-b4a324153034	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a28e5d5f-273d-47c3-bc51-fce7458c5dca	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c9d037ea-a00d-449a-96e5-d89b605ba3e6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6da26cb0-b66e-4180-a6eb-80e0f047870e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	46459ef6-baf6-4729-8232-2a51fc6491a6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d16c5afd-951f-4d7b-8a40-6642c659cf61	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cdf9a600-84ef-4ea6-99ed-6acd5df192bb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fdf7352d-e67d-4303-85af-3822546df919	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	63b14f7a-e198-4551-925e-1f9c5d07fb16	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
23ad4c6d-594d-40ca-8510-73d624927f3a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a1f30561-736f-4915-92de-9adbb25f699d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
75188f0d-7c53-4904-bd7d-4cbab71df7c3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a866e0cb-98f3-4d96-985c-0dc4677efedf	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
87b2c479-c392-485d-8e28-b8d12f0dd3ba	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	61098814-7560-4818-a607-9981f1941e2e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5b3c6456-1d57-44e0-960d-8423213ce6de	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2a6c8842-25ec-4eb6-a97a-5fdfa19bbcde	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5ad2a78a-1528-4a7a-8d69-d5a5e6fa4780	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8db07b1f-725c-41bf-85f2-1c296043dd9d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7caf2573-2048-4282-9b76-f1ecf0f3362d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	db4436b6-95e1-4705-875e-43be52ed6487	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0b2820cd-832f-4eec-8406-f9c4eb71d1e5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f6540e59-0d52-4780-a526-60f9841eed98	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b2316f05-6b4b-4fd9-9ca6-1e74bb7b5107	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	57f17ad0-6463-4a12-8b3b-e6cbeb8909bf	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f5adc58f-d0d2-4abd-a8f2-78116e345412	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	511b07e2-02ca-4bf2-83ea-5811dd5cdf9d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
86ba8f4c-f190-4de1-bf6a-6c96d1b7f8d6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6974d20f-96de-427a-b03d-9b0d9ac53f02	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
692a8274-e2e7-4208-81a1-7851edcc6abf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1e6b46de-fef6-4e73-bea8-1131c9da0faf	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a285b099-87cf-4747-8d55-4cb01ccce322	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e8ada8df-d99c-42cb-9d07-95078a422753	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
46a1d974-ec31-4bbc-937f-0b81cefd6c8d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b04c8eef-dd06-491f-a009-d3ad1d932f8c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3862e445-2120-4f0c-9c4e-0e3288e238d2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8283c783-6023-4122-8213-70c33cbf129c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0e85dc54-4921-4930-a0ab-387d089a59e9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1aaadbd1-4a0b-4dc9-b559-0cf1c764f18e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a5dcedad-b729-476a-8517-c76a6a8bdac7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6c1a87f2-c162-4064-922f-74c78b11de16	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2163cd88-18c5-432e-81ec-bcf9ffa9089f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4c73a2b0-f6d6-4e40-b20a-3c6ec7225dd1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0cc4fbdc-2a10-4247-996d-124bbe3feab5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3e72bd22-b876-4baf-bfde-85028574fbf6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e5b53237-daff-457b-804a-1455c8f4c93f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	fb1e82e3-ae3f-4854-abbf-b279a661cfd8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f6f938fe-3b1e-4cf2-aebc-b227e6135837	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6fe3e0b2-7449-4185-995c-72b93d510215	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1fd32c94-4382-4054-9cb6-cc3130022298	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	dd2c65de-a5b2-4b58-aa90-32c12ccf2330	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1e0d8cff-b378-4d5a-9792-89c3699c5777	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f1d069d8-8c7f-41e6-8ee9-291314a4b685	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
db7ec0e1-47c9-4c27-9576-f082598c0f87	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8d8efd4c-fa83-43d0-94f1-11e62628c902	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
76ca20ff-8d53-4dc6-97fc-c304cfc8cf8f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3797615d-07a8-4908-8cba-7cccab96e045	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
96ffc22e-6064-40be-ade3-065c9ae350e8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3fd4eb3b-297a-4f8c-bd5e-b4196dcff5e3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3fc02041-f225-490c-9ec5-e44a4d5db414	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2be467bb-d12f-4e98-bd8b-6f4758ced2b0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b97abefa-a091-40db-b04c-0777b09c5019	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	545ed5fa-bcaf-4fee-8808-dcbe9d23b1da	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
26106152-a858-4ea2-b81d-bd4c90a9c6ae	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	38bade80-dbd6-41f2-b0b0-1974688afd52	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c51953dc-bb7d-4499-af32-ccef9b92d95b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c38ab09a-a847-4650-bda4-47d2e50b8056	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7693ebc3-2a90-4c70-b908-a025283143dc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1f8dc229-e77a-47e9-aaa8-fc3da2d1f49f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c1d589d9-227c-4b88-a6f5-c1ec8649c331	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	781ddc71-2043-4803-ae4b-64a7721540a7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9750f55e-3541-4c89-9673-f30f497f94df	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f209020c-301e-4e87-9540-ed64fc9e8649	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
131d2c0e-6c8f-4427-ba54-9a048abfa164	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3521ea4a-ee23-4a5b-88e8-3b3ade993b78	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2628f173-b942-46b7-bf13-1036e18fb71f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9f46890b-c706-40f9-918c-dd3089fa0e2c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
42e6fd8e-81e3-42b0-997a-cfbb3c7ca10b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	67b1c83a-f169-43e5-bcc6-368742ea501e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
eb44a143-ecfd-48ef-9937-e64537468d10	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a7d10d60-2391-4b6d-a40e-ecc3d0d3c465	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f935ddf8-91f6-4e57-b766-1c18a1f2f6e7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cf72ce66-04be-42dd-ad3f-91540f939fbc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b830b95a-2634-48cd-a848-b511de291860	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	30356105-2abd-43e1-8238-53d90f9c41ae	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f6354040-cc66-4962-8888-a7435f9b6b80	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	017f6ae5-a216-4127-8e79-dae82f965089	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
88143862-e859-4f2b-9db1-508092c916d5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bea5204d-3497-482e-8e3b-71493cec4054	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
85f0d871-7d95-4bcb-9b75-423d9cd80722	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d4b50761-d7e3-40a3-85de-0cb0d97b4daa	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f035921d-d13f-434b-8ee8-3bdf09a1a1bc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0d1c3c4b-be80-4802-961c-6d5468239bb7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e88f09da-3b75-40bb-8027-f81540fb701d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5c22a73a-e94a-4bcb-8a50-187c981e2336	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5cd4d1aa-ddfd-481d-8815-1dd9ffb6adc7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	01314dd5-13d2-44de-b703-8ceacbd79df7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5192f0d1-ff25-495b-9c6d-1820c14d0697	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8a9c7a66-b27b-4619-bf0d-787bcd8ef0fa	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
11b404eb-0ef9-48cb-8274-9257096e7c2f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	eed94fb6-6fac-46df-9ef5-70c5f99ed297	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ab3ad48b-7a02-4f41-9a48-54ee2900f044	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8e585878-b6f4-4d2c-b2e9-c9e1f7cf50e9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
529c74fa-7297-4aff-ad1b-22b5a62897ee	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	179f878d-f262-484b-9e99-2f9b9fd8ac88	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7a926a0a-8714-4f8b-81d7-3e42aeae11e6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e466907c-b69b-4f4a-9b28-644b090e2325	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
311a9cd9-c0ba-4ac4-87de-165053c7e29e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	179bb60a-ae3b-4e11-ba9d-28f53ed1812f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3f943a23-87e7-4d7c-8c44-9c154927c724	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ac41272c-0a4d-4ba5-b740-2fb9847104fd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ea587db2-cdd9-4d1a-abc6-233edc94942b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ec452ceb-2f97-4fbf-bacf-d447ed7a4c1f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d8fc6463-ffc9-4ab5-a6df-b047ed119217	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2a623867-95a1-428b-b8a1-40fb7b8273e9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f22797aa-aeb8-4698-bb13-b78642560b33	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	db798725-9768-4608-9bdd-34cec117e875	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
26e4ed1e-6c6e-4626-ba84-3e070cd94e97	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d655db93-b004-461e-888f-384f31dd7b29	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
979aa86a-1104-4b78-88f3-22e1258d5428	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	81d0d03d-737a-4a93-92c4-b57c4a21f779	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dfc43299-0aa4-45f0-a5b3-c5f1333cf8ff	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	791e44b7-9ee0-46e2-9a18-40e0b42dd23b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7b5d8ea2-292e-455e-9fd9-9beda97a573d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c923c6a6-2cc8-4469-946e-3b6971dbf060	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
382cecdb-5eaf-4320-920a-e094289e48e3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2657705a-9ada-490e-b519-528ccf60fb97	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
69d8a574-55db-4fc5-b5ea-e3d51a3f3a30	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7467a7ab-8c99-4c65-a227-190291a159b1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8c75e5cf-5b0c-407c-af7a-047b1f620160	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e2a2c57e-d46a-4105-9357-f2e75087645f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b3655fe2-7d40-4667-9f5d-1f637ceabfea	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f285714b-68b7-4147-9724-86f059dbe6f4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
50037c84-8c99-4bec-b572-b1ce399f6153	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1a10896b-8cff-410c-b71b-90ab9dcc91ef	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cb102321-c95f-429d-8fae-27291a3333c2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	55fddcad-8c3a-4d8a-8ecb-d068c244d942	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d6b62b82-930e-493f-90dc-5c3e5ac986e9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3ca6aa15-539e-4ba6-aeb6-a0e1a4af12e6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bb4ef1fc-a2e0-48b8-b64c-fe0eea8d3e99	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f25a391c-375a-4752-9d61-7d278001ed59	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5537f80d-459b-49fb-a41d-033fb9207603	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	11e21752-5717-47b1-8b96-f092dff10b39	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7e6ea699-3cfa-4668-97dc-54006a752d86	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3ccbd001-7efb-4a38-aa4b-01b130232e69	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5761512e-2372-497a-b28e-1dffd0cfa432	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2164853b-b028-460c-8cbb-f38e127d12fa	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0ba94199-ea8d-4c0a-8318-d54e97dce1fd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ee7fc232-90fe-418a-a120-5bdf4277dd6d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c5d5c2cf-01c1-44a0-af03-682981b1a8a1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	339bf2dd-5330-46cd-a893-6c81233bf761	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6939951f-61e1-4400-89f1-1d0e99b45ce5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b9c33ecb-37a2-47ba-8d9c-9e0ae3980f4a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f4d8573d-36e7-4408-a1ef-a3d285b029e0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	820e292a-cb17-4727-aabc-4d9b6f7fa9be	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7716e53a-886b-4060-80e8-94d9f9154d55	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9f40b8e0-7bf5-4a87-8341-0d4e5f294fa7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1f6e252b-b8eb-4d51-a806-b0310314b3f4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7a3764ce-ed85-470c-8bb6-b9de2fbdb95f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6eed3ca2-ed37-4acd-ab30-6b26ad510240	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ca9877ee-7d6f-472b-9e97-ea942f28bdc7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2f7763a6-a3f4-4275-b764-63910f53d47d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c6f235c2-afd2-4d7a-a99e-535a9ebe588c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fd7cd003-39df-4ebf-8e07-a155b10f581f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ada2db34-cea6-471c-93de-f42de5ff3d66	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2b2eb5d8-23b7-4c4d-8020-24ccea002908	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a8ed83e9-940d-4cd2-bb60-b43940d20a0c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d940fa35-39fc-4e23-89cf-cf28a261ea9a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f67ca84e-9da8-4aa3-a075-5d1119802f9b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8e4db3ec-8fa1-41cc-89f5-57a3646a7b33	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0ffa64f2-ab01-40ce-a404-f02d08aacda3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bec1b5df-f6b5-48b7-bce4-9cb0ee685d2c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3e3f77b4-4ff2-481d-907d-0e0506f225bf	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9af569d2-9530-4d95-a43e-d93659a47ace	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ec657423-2bfd-416d-b911-1cd5f5a747da	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
668f235a-a080-449a-9fd9-2499b2937609	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	95069c11-8df1-4295-a5ff-eca483de3063	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
06619baf-51d1-49c5-a78b-7c1e8e0e59d1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	95aaf308-5f38-4161-87db-833a6f2f6ea3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d2a380e3-a43b-4f50-8872-2ca853f6859b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	aeb6148d-78b2-42a4-aab2-8e2413536702	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2e1244ed-a436-4c96-afb6-3490063d7505	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	80d1c48c-b87f-4017-a75b-50b5f363857d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
efdd209e-0af4-418b-a50a-4f73192727de	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	38fa1334-0907-4b38-aaf6-65aa99ef83dc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a369929e-b465-4026-91ac-3d319bb2e709	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	152fd163-e248-4062-8a75-6dd5aa945840	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
941d1036-167c-47b0-b36b-1b51591ae049	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e89d3bec-39a3-486c-bf99-43c4f1846dce	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2c126986-c355-459e-8037-c5799b5e3bed	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	89fed694-8cfd-4818-ae01-505934ec2f8c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
97a8dcab-5b87-4c42-9581-07f605a41a58	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8d2b0e69-dfe0-4c1a-bbe2-359d28446b6e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dc5c813a-185a-496b-8146-e03d79f12af1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	53393c97-98e4-40f4-9a54-010fe4295dd0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ec12e732-80bf-4dd3-9db6-e925d0b52b34	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a9b502fc-20fb-46d3-83da-9df724b3a099	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
14827d01-d22b-43a7-a392-b8df9adbc1e2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2915914e-f69b-4cfd-ad01-111dfa753770	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7e59fa6d-d15b-4b57-87a1-f183da978ffe	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	06a2b0e0-cbb2-49ad-9184-f27371a0171e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fccf2194-c200-4722-904f-57625655a290	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	106c01d9-57ca-4434-9986-1ebec31ceff1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
35210c02-276c-4a82-a686-c456d9a3dd3a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d5a41768-aecb-4878-96dc-e54fd9392aba	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
68a2f369-afee-43b7-8b05-a20bbcfd790a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ac3c530c-fac5-4b4b-b3b3-e75fc8a35fa6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a4297ea7-5fa7-414e-94c4-0ca9ccf02476	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3cf0a06e-ad71-4347-b0a4-6f6aed6baf23	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
336c0289-7a2c-4337-bf38-92e3618bcfe3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	901264cf-8113-4bf9-8da6-018424e03196	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2ba7d5c9-b5a6-4111-b875-9af8dbc19684	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	331f2b6f-bfd1-425d-8874-19c3f1eaa5e9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
429de38f-6bd9-42a9-b51e-057ab95bee5f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	aa35fda4-f6b3-4212-ae86-2410b168841a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f130afe5-de2e-49d2-bee2-aaa2643b015a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5aed1819-fdf8-4a20-8211-2cbcef8cb2ab	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dbf52a06-4ba7-4fd4-ac36-61adf8a978d4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e4160613-c418-4b30-93c2-3b35964ba568	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9a3e3820-25b4-4b95-87ce-fd4d1aa22243	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f087e915-83b1-46d8-9c8f-a1d1b2e57eb1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
83567fa9-87f6-4322-b7f8-eb7a034f243e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	20e0e3dd-4f94-48f7-83b6-4eb88f9c86b8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e3c3c1f9-fb24-4ca4-8a4d-c94ba63c85f6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c6021acf-f869-4c5b-89e7-af209997b0e3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5b3b0f4f-5554-462b-ac75-6b5903559017	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	eaac721f-eeee-4f0c-9976-57cdc5c1da8a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7169b411-b338-4fef-9502-5d8dfff242d1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cab79f25-9629-477a-81bb-7e00da7a13a4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b5d22c29-2da5-4957-9ef5-61888baf55da	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a12d4e91-d5b7-440f-a3f2-2bfeee78a54d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6b192ffa-d3eb-4635-9e83-d2ca7ba9f704	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f88b35ea-f95e-419c-8173-af39e9fc801c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5a150c97-923f-4a0d-9464-fbb6f8c147c2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6cb63dfc-41a4-457a-a201-8dde951d3915	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3a7625da-beb3-4613-af9b-acf27d3b0041	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c4919058-d2ea-444c-b75d-3cd53d7ae5ec	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
95ce1908-8543-490c-a3a3-119d85d6b2f1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	612f91ab-09d3-436b-a92f-c5d2ef53267a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ad0ff994-b07c-4012-81cb-17eb37e69462	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	046d9d4e-5416-4f1f-b548-f9c117fcc2a5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9d5fc340-203a-457e-9581-3a024d73017d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	61c60468-4b7a-4b50-9e9e-f22ef0db9d5b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d82b9bb0-e505-42c4-9b5f-d6262bd07310	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e5817e5b-dd37-4327-8d64-ce51cd97298d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
27ac7342-5030-4c71-9e38-71e1d2499319	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a5c5325e-d4d6-4d51-b1ec-ffe8d889410d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
94563e01-aa7a-43b2-9db7-e6fce0175974	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ee20fec2-5cec-48f3-9682-7d3a031013a1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ab1031a6-51ec-42dd-9180-cf0b81633b4d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	dfbe5ffa-8c3a-4431-8633-16a91c4c8e7a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8e2b1d40-2ead-4f08-8fce-0812a6d4edda	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	71440925-2e06-4ca1-b961-10571536c0de	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b39d3cbd-8812-429b-9d5d-81e5e1a5f4dc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ced86a58-1356-421c-9299-4e9101476764	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
00062b03-89e0-4d40-8a53-5473d125e320	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	312a38b3-b8d2-407d-8194-3ac102a25feb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ff44284c-6c1f-47d1-996e-26931d322f2b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b53f16d5-53c9-48f2-9365-b99075ef9d4a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7ed2be7b-f179-46a3-840e-d424b9104428	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c8a7ace8-a004-4b25-a544-95cdb1f8fa24	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
123dd6e8-e8b9-431a-b4bd-6bb0f1a65ea2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1135a2d2-1263-4fc8-a24e-5ae4a3056341	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
83c90b9d-7377-43d6-aafc-f8fdbba0d5b7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8761727b-6676-4df3-b494-11578e16a4f5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2b25d52f-1206-463c-af7f-9ea2f556b333	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	436bd090-b753-4806-bd98-1f8affac5d9c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
73e7a76e-b8d6-4376-8d3b-2a58cc2732ee	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	03e00c6d-d796-4098-aa58-0be80ac18bf7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
50bf5f69-5a80-4137-a265-89d80631b07f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9d9fd90c-4512-47d7-82bc-d63082d752dd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4a250e1a-0640-466e-aad8-48e8ff486148	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	46538421-9341-4d9d-bae6-05b9a40d28b4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3abe6f19-3f6d-4bed-8eab-2e9f62e48177	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e8dcb1f1-8d31-4723-9b38-18dc2d6a7ecc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d6301b60-2a58-4aa5-ab0d-147c390e6f7b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4ee55aa6-4afc-414c-a234-ef10db07284c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1294c163-827b-48fb-811b-5c6c5760969e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d018434a-0d3f-4ab6-8284-d62db75dc61f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9f95aec6-2014-4394-861b-c9c13ac82e7f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4d72a954-8a3a-4ab3-bbde-88f12cb8717d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
63e0b373-1921-46f2-997d-1383e0eadfec	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2d1f4466-cdb5-45c3-baa7-214372c06081	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c93f2ec7-634a-4c2a-8749-5dff3a42660d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9765fb91-5321-4271-8ad5-312e4f4a5209	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6a9b2716-d225-4480-9d92-10ecb060c5d8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	93f07369-806f-48f9-8563-5a9a733789e2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
968b9a42-fd9e-4257-a6d9-2aeb83b43294	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3f3fac3c-5ddc-4858-9049-0bd1d8078c98	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
92a266a4-5dd2-461c-9bc5-1419c5ec00ba	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b6c428a9-1989-4f40-9663-728a19e94c3d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1d616ba6-a765-4fd2-a7cb-74822d491842	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c38b3bd2-d37c-404f-a6e5-2c988a872fd8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3fff8a86-5ef5-46f2-98d3-f352f272e504	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ee0ba439-f04e-4e69-b66e-081e84b7a563	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f3bef6b2-f350-49d3-9686-b03a4bcbf505	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	244b6a83-a17e-42b9-bc6f-4a8a8e99f31b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c73528c7-12c3-4d93-bd0e-2a4297af5a65	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	313d1c60-d5cc-4288-b42f-6aeb1aa0315d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
16880f29-9f2d-468d-843f-4540d697076c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	487b6c10-98de-4894-82b0-a0a6dd2a7f8b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0da06ec7-9200-4e1b-b0cd-01bf1fd2b884	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0d203413-b7cb-43bd-b3cf-be3d2267d19d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
605e3df7-a34d-4af1-949e-bcd07bc33847	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	33b3289f-2079-4c5a-be64-de420cfc7060	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d59b2581-75e6-4fab-8198-e58f6bb3ea5d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	22d62f74-8bf3-4dd9-9202-020bd743bfc0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bb514477-5c4f-4e76-a47b-fedc41fb44ab	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9fbb0636-93c2-4163-9a6b-c63ccf54122c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
21db9d3e-bddf-41ea-96ba-13ddf6551990	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e9dc3d55-7e98-4995-9a71-7075d98e795b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cfe761f5-977b-4e62-9419-e044414eb095	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	efd8793b-dfbe-417a-aa2e-716dffc38f8b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0ceb3a30-b67f-4f09-b445-fc1cdfc9439b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	61c4342f-1a18-4720-bedb-566268cd56ba	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
aff8847a-46a8-41bc-8184-26e13ba1bfe4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d01d74f7-08ab-4685-9a7d-1509e25ae1b6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
470f1348-9ee2-406b-8abc-2d258c284030	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a02e39be-fa91-40a2-8450-3779cf175047	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2a196f49-f429-4661-910f-3bb34f11cbfc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cf1fcdea-8ca0-4ffe-93bb-aaeebbf8c6a5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
445195c2-7056-42f7-b3d6-582e571b7a3e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6925e912-9431-436a-b4a4-17450fab7ec0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c2b5293e-1109-44bc-bf5b-6302f6707e11	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	19e11347-c03a-42a8-8713-1d04deccc0c9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9623baaa-179a-483f-884e-e7a77246e6a7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bc3bac42-753e-48e5-adc6-f969ac366645	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8508e61b-7322-401c-aec5-e33c24201bb6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a8efaa16-6511-424c-816c-e171ebfb0aca	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3aeed200-124f-4ba5-8aec-2554b4575022	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a90c8987-c7b3-4f1c-bede-0cd4af926f11	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d8e1e39c-813c-4301-a3fe-aa87fe56b95f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f471fd43-e84a-4e68-8e16-cb799b43116d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a6452e76-07bf-4043-9b55-272b3e0c82d1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	62c94eec-08fb-4946-8d6e-fc91e9e1e3b3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
37abd539-3cb3-40c7-9d5a-fff936386fd9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	63eef403-d624-4098-8339-72d14df4caa3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
98f45120-3e90-45b8-b88c-91e191dc8527	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8431b50d-5783-4016-b519-9ca0e3156205	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fcd7aa9f-7568-4630-a901-aeb07a902c16	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	890dd3d6-3af0-4be4-97ca-eafeb8573c09	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
eed5c83a-f693-4b43-bacc-4579588f09fb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	448065cd-fe23-4b2e-8e12-fbbd33829233	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e839f23f-6957-4668-8ed3-5027f6929bc1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2f83844c-9384-4458-8a87-73cc742c435c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2ee7ff40-104d-4dea-93de-2b40aaa96760	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	712dc761-2981-408d-b616-36e76f628864	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ac47c4e2-3ebc-4a3c-9d79-f6143e636416	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	54556387-fd94-43ea-9ef2-7f1c0054b976	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
316159e3-64aa-4650-9b45-b4ce8ac40f51	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	949af886-60f4-4fc2-ae20-8dfee15f4523	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b08ed1ae-72d5-4fb9-b4b6-0fac6c8f655d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	da3e26cd-9d4c-4e75-bf3b-28b8e4f1a2b7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2186755c-1e42-4fcc-a301-fd3fdf082184	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b0c14d48-72a8-4989-af5b-b8dd8c298e49	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0a42b510-9b1b-4325-8741-c92203385a95	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8ae12903-b894-4b8a-9bf6-96a3c0409581	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fa36594b-736f-4bff-9b2f-a352eed6b527	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bbff580f-6974-4a42-bc8e-f7053dc0bdb5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5c62c6d0-f48e-471c-b81d-78736a7a548f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	91053158-b4f4-456c-9ba0-f5f933222e5a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a6aff962-c628-4a7c-ba00-0026aea82eb8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	326cb7bf-998a-4499-8dfa-9ed5af4fe8e2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d8ff66b6-632b-4994-a3a4-437f373ead13	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5d2d76ae-b03e-46b9-9868-403471183594	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f956120f-7077-4c02-8b7c-a2606911181d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0ad836d4-e9a4-4c1b-ba2d-36a9a7a1f172	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8793e49a-4f3f-4c7e-8be3-7b3ba5d0b98c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	209fb6f9-e81d-4a9e-a8a2-2d91138ee2e7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a6c50593-4545-4a88-a3df-672d12281a64	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a53728d0-b13b-42b6-a1cd-9ee0c6813691	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3867e820-a5f9-4baa-b387-973ce8fdb644	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	05bf30c8-b9ba-442e-adc6-e75cd0c13eba	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dcd0521d-14f5-4c69-a4c6-34f20ff08ace	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d3ab9f6c-2eb7-4dcf-8164-6d697dbe401c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6dcae494-c5a2-4f9b-af3a-73cc48c12462	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6ed2ca88-75ee-46b2-a6c4-f3c039427c47	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
57e023c5-f8af-43d1-8815-32820ab0f126	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5e892c09-3743-4225-9698-99f2edb38147	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e327dde2-a6e0-4d50-975c-5a092b835b6e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9a7018d0-4760-44e3-a28e-58cc3fa92ee4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5ea4ffe4-05fc-4ff7-9b30-95b8aed0b7e2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	91c38df7-9df0-4e04-bda6-40394116f661	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
18163663-e0b0-4265-aace-b22502517e7b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f35656cb-c73e-423d-b415-151045d39041	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1c1bb0a0-9567-4aff-a43c-8b0973ce2e4e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	fb634a4a-2bd5-49ab-84ce-4c5db408d1ad	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3a83065e-c283-4873-9fce-65428c091d94	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	50cbec59-9a2b-42a9-a453-c1c54d6f4b12	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e6bc8727-f412-4843-adaa-a4e4ecb36466	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	44a7d6a5-b261-4ba6-9346-7b6009bfabf3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
db30f19f-ca13-4ee6-9b16-9343dc1c6c50	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c3c170ab-99dc-4370-9116-b635db7bac67	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9638b034-e97a-4557-ba6a-e7ece1067924	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9af83db6-a91e-423c-b2ef-bf3fba38b6ef	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b0801b9e-5bf0-4ee8-b6ef-e7632b9bf7a2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3e37dc98-958f-4283-906c-fac29b4ce27a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9e6576ee-f70c-4af2-9581-b975c4c5c64f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c7432204-89f9-4271-90c7-0ae0f2e3f0d0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
489164ab-5a1a-4350-8fde-487af0df03f5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0dc1abc0-9ce7-4c2f-8c97-e03a987e8a21	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b6914725-8fa7-488f-84f3-9c6fec6e8b00	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e456e281-1ee2-45e1-8203-238bee1c3e80	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
aca3a737-300b-4dab-9d65-eefc89474bdd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ae1aaa83-1643-4ba5-b768-eb73d5c1de49	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
030fc97f-574e-40a2-844b-2b0653703824	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2d702569-4e78-4d1a-bbe7-ee6a81b4dbcb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
29bf13fd-eb39-4c31-9bd7-482ef6be2e25	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	da74c625-7125-4e81-9db9-c203e9d6818f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9e4fb209-720b-452a-ae87-9e088572a244	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	219fe38d-1f54-455d-be5c-9a91a03b5d66	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cf01db9b-4ba6-4fa1-9393-aef6c43349c0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	94fbdc33-6f5c-40bb-ad15-8c82b52a96ab	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4182581c-36fc-4a5b-bf57-74e1ad714062	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0978d229-956d-4331-b5d2-01e7b8c8c9d8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d088cc86-292d-457f-986d-76c9f5690748	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	fd22b8c8-c356-451f-afbb-27c2e3f52240	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
388e91aa-d975-4835-addf-b7042a0b7ce9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	001f1f6c-61eb-4319-9ef8-d9ebaf9cb701	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5c980bc5-eaaa-412d-9afa-b406d4f13416	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	94f63765-e9dc-42d9-a46a-0c8756a95984	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
40125b4a-9569-4fba-8bf7-be1c135a8f2d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c4ce1d94-5574-49d6-8583-4cd754c7d4d6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c5f09a0f-191b-424b-b7dc-660e4644693d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d6c7ef74-720d-49e8-af44-164271bd6f96	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cfde5347-e6ac-4688-a1e4-50680704ee66	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cd1607b6-6b70-45eb-ae3b-91eca7e843f0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2c598aa1-3387-49b2-9658-4a431f9df345	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a4b3cbd0-39fe-4b3e-b395-f4bd5f025c94	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8a4f08fb-bc32-40f4-a525-35691bd55d3f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	eb8da0e6-e6a3-418b-9b6b-2fcd2a09ccea	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dcc2c013-d0a7-40e4-b7f1-7729433f16ac	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	da332d3d-e43f-41bf-bb51-17f7a79a6f1c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
90f00c4b-f2cc-47c2-86e5-2c9d7f7d47ff	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bd8487f3-d855-4d04-b38d-de59be5ff422	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5c68b396-c1a8-47eb-9b5a-57f4ec962e3a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8b8e9742-7065-4026-b027-2270f7f73413	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0d10e15d-a430-4860-b74e-d5b603b4c246	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	008bae1b-e8ea-46d2-8b92-4144def10086	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
765097fb-2605-4ce5-8b33-55649bb8eb1c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6cb0d03c-63dc-4161-93ad-096797488c3a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
382f68ca-e3cc-4291-b97b-f1895289172c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a960a468-63a8-4fca-80e4-b199017bb514	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b8baf074-302e-4d39-a3b9-690fbfdf1651	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	159a6e4e-a06c-49fb-bb18-3b221f15c3ba	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cfb5d6f6-0850-4cb2-bbdd-94ba4923157b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0cd2664b-2bc4-495f-aaaf-6fd7f4cef2dd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a6456967-09ca-4fbd-b56c-158e7fafe96b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8c5b5a59-b6b2-40a5-afae-0609b70c5290	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
637feb46-014c-4893-929d-a91b27c3ea9d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9485b506-3ee7-47e4-952f-4d1c017c1147	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9f1d6196-5402-4fc6-9c5a-04132ad07021	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7cea84da-0c8d-4351-bc16-45a7448b237c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
77cb42b4-b261-4fe2-aa4e-0c98b5ca91cf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	42dbbeda-ecf8-40c4-8e2a-c4fa100c1964	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d8a9fa54-6575-46f6-9138-04930cf1e724	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9bdc2221-0b46-421c-9dda-b61693c31ec5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c2d8942e-aff5-4034-8f9b-cee38c8c8d7a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	72fa3f0b-a4c2-44a4-8c50-08a07afdb951	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
09e62e3a-1f9a-4d32-97ce-bcef585fa678	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	57e3cac5-5f91-4945-a32c-8e1fd68e7018	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d40a3734-981f-422a-9ea6-0406eaf6e7e7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	664b28a6-6308-4db4-851e-ca19679b174b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d2684c38-3421-4978-bb32-682fbcaf274d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b3c3e95b-c711-4bfe-8c9a-28b34c89a235	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
33f90025-8ad5-4a95-8033-66fdd27eaf89	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2a499471-176d-4243-ba71-0bb4816dc54c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a6737e89-e5c6-4c37-89de-0acab9ae37fd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2e5d1445-6ae4-4e72-a21d-508ac3f52e6d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8f08b611-4a71-437a-b37e-bde0833ae3af	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3ceba21f-c32a-4b08-b628-221f62dff14d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
817fb218-bcb6-42e1-bc94-90c886e31b9a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4ad71a0f-ba54-4a3b-a07a-1c4049dd0ab3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b15361ab-172a-44e9-b2e7-f5f47ff55706	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3a9d50fa-0d37-45eb-82cc-f20333d79f8d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2284488f-f9ec-4299-9995-63be1952ec6f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7595dd00-7a39-404d-97ad-ccaba60678a7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
25302f94-9edf-4d92-adbb-390dcb303ffe	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	38a8e704-e0e5-4c94-9ee0-677956bf126a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
201ed244-044c-45f0-9ecd-460791c7bb68	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c3883637-d0a9-47e0-aeeb-b2312b9214bd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b4b64db7-c657-4d10-a24a-b41949682af4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d0a65563-5711-494c-b3d7-29d9093b644c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
52fd842a-9327-4efb-b68c-06673ea3a1f3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	69d240f6-e46f-47a7-ba08-953beffe59d9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cbe92ba9-8b47-43b1-bb3a-a2cc02e8307c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	75c94438-0508-4144-b6a2-f2c808f1dc77	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1c22942f-43d0-4889-b4db-310f91ca9d56	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	40f2ef16-f7b3-40d9-8d90-b78ab68d610e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
db82789b-5bdd-4e9e-b610-1019df44f7e1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cf31d9ad-fcc8-41f1-bd1e-bd0d292a2e5d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
81213a40-af27-4514-9ccd-f1c8263ed89a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	02dce982-e875-4a12-8729-f3be5de4c3f0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4399cb47-73f3-4b1a-a391-fa7f43deed12	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	37c3d86e-82c1-4c44-a129-6c0d69b478a5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
28f550e2-1db2-4059-884d-269997c63a9c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	960109a1-18dc-4dfd-b58c-57a3e4f9a2bc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ce0ebef3-4a50-4b34-b49a-5a513a586b2d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bf76e1e5-1299-4692-89ef-7324e7c5397a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d1675ba2-b555-414d-adb3-ea143506039a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4e0ca41d-205e-4cef-afba-d744417d3dc5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9984bd4d-130b-4d32-a954-23a263847f7d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1f32f97f-bc51-49c5-8e45-27fa3116248b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
701c5ed1-bb4a-4519-b73b-646a417723a4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b1c21740-2daa-4728-816e-da885b41c8a6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bde3af29-bed9-4dc5-80bd-849174a50191	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e2f99b3f-753c-4286-87f2-e4b7640537da	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bab12072-60c7-4e75-8934-47edd601f805	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	30a8a1a9-4b95-4e29-bef2-4be4b072108b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
212c98e8-2e54-4b5b-925e-6aadb0ffa474	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b704be90-df98-4d90-8e3c-b1bb83e7dfda	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d227c517-b181-42ab-af96-9d62b31b5deb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a71aa043-e695-40b9-b3e4-802815738815	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9a778199-7097-4e6b-a42d-931756df60f4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c41b06cf-c114-4b78-9e0d-007822fed668	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
79076c4b-3d96-4a2e-ba19-8bceeaf5dd18	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	42cfed9c-0ca7-45a6-b865-fcd50c2b98b1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f4ba8ed0-695d-414a-8bf7-8e5468b02988	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	47b65c87-8d48-47d8-8f5d-679066b826ef	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
72c1bcab-6cac-479e-b5dc-507f12fe5246	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e53d949c-5d2d-424b-b4d3-9663ecb3a63c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e79b3f54-a9f6-4413-b7d6-e7b067b1d1ab	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	71c1e0c6-2a75-4f7e-b15a-9f40991965a1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
edd186d1-fc2d-4823-b627-dfcaf2da8beb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1e8842ac-3edd-44a9-b7cd-b745f2c73d52	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d55bf7da-6319-4541-b3a5-a7b92dbb1e1d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	907cbdb7-8ad8-4a26-9ff6-8cf664762487	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f991636d-7ff7-4f23-9dc7-d3e040a8dc1c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	368db12d-3e0d-4d84-bf54-9e9adab15b80	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
70114480-9031-45d7-8efa-30add6fc9266	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d871940c-e5ba-4eb9-bf2e-d640b9227fb2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
619f8952-b73d-4a09-99b7-41c92e8c9f20	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	afbc8441-e6da-496c-a859-f572c0f24c87	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0907d3ae-abb2-43c2-b220-2577587a4a9d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3a57da7c-3899-4cf6-a5ca-ec5d5fe6266d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cc15a98a-dc55-4663-97e8-23428232bbad	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7e687aff-c2f7-487f-84dc-e35e89c77b3f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
709872c1-2bd7-41d2-9cf2-ef33369e3c12	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	598b197c-c3d4-4f5c-a80f-99aee838476b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
07e036cd-dd16-42bf-8446-397c7a1a6040	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0e3755b8-0455-4602-a94a-68baa6f15f36	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
39d5ac1c-5de9-40c7-a0d4-28e17c137bec	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a68076d9-b0f9-413f-82c8-e8d38e300beb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ce1a75d8-3a54-4945-b9e3-d04bb4445b0d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f79acf6e-685f-4e61-9752-b66fc79264bf	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d7954694-ade0-4be5-a4d1-961c4d6a288f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d1787421-8fab-475b-a59b-afbe7c83cf17	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d115070e-94c0-45b7-90f7-4dd20f37a4f6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e0b53d97-a919-4be1-90c0-fd9e904c426f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
480b14fd-e938-4edd-a6ab-5bb20b5ae7e8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6b2f2b9f-0085-4606-a483-c1b824cdcf65	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c614c0b3-b0ea-4870-96de-2c01aa8c8de4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	065fa74f-cf8f-4741-9135-1b11f08adb76	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8af0432a-2501-406a-9683-7b7b519c78eb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	80844d0d-83f5-4cea-8291-01a7be3e7642	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
513cc684-6391-43a0-a196-dee4e972dbff	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a3c7e0f9-f240-4c26-b733-dfbdefee93cd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
74f9afef-6f84-4ef6-938e-940705fcd407	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6a0f53d4-dd83-4f1d-94af-b4057980b1c1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
678c1b57-6104-4a28-a24c-94d8b9237f7c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7b6b0af0-3152-4195-b0e8-9c4b0c9aab1c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a7431d96-06e6-4077-8b9a-66c4f72f6a79	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	66b52fb0-d809-4f6f-88a4-655cb4108adb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5a44a302-7517-480c-96e4-44ac6029d730	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0f816d16-a338-4dc2-8471-5384150a0b3e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
47f6dad2-2a2c-4f37-bb3b-047fa4af2dc3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	20186d21-beb4-4d82-acd5-b16b9568dbdb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b982e296-a636-4a9e-93aa-359bc8b895e7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	84024871-ec04-4469-bd0d-b8afac1912b0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
eb702271-ccf8-4a22-844e-20cd93fbcf66	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	670993b0-cbb0-4293-9c29-1ab1a9466ed3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9bf16063-3aef-4d7d-8dc8-8f3532a64751	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0873fe58-1bff-436e-89d4-6353b5467a70	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d44206e3-167a-4f5f-9327-5b0b8a93545b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c8b8dc3d-1b43-482c-91fc-5b7970343b97	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dbd12049-7dfe-4af7-b944-bcca37e0f12e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	89f3927d-ab29-4a1f-bb5f-11895f94abb1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
286ad26c-02ad-43d4-a6ba-f9d6c7a213e9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5498c9ce-31f9-43ad-9d8d-6a2c2fed6bfa	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4d3abebb-ec69-4d05-b71f-53c5916774e3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2608e064-867a-4fd3-9923-028b4bbeca52	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6989b829-45d8-4b3e-8de2-169e242dbed8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	57a944d8-51c9-4246-80a4-51348abb4a40	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
71930859-149e-47eb-9702-d6fce9722d49	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e4bb949c-487c-4198-a3c2-3a1cb3200e0e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b84093a9-d8b6-4b88-a88b-4241562320bd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	848b05f2-a664-477c-abcd-dfcf4cef355a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b767accb-7939-41d2-abc7-40595eae8613	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a430761f-d4c1-40ba-a0a9-cb6b8ac68eec	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
39e34bd9-1899-4663-a48e-1dc4c50fff23	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	45e07a88-cfc0-48f6-b9d2-cab1b7f0b381	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9a2b05e2-a976-4494-9e3e-ca8a717a9e5e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	29031217-35da-4283-9304-306dba5aa4a8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cb738af9-4ad7-4942-91e2-23abbb369d71	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b630df0f-3f70-4473-a18f-da0a038feef0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bf275781-51c5-4a07-8ed8-502926c86c18	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	416968a6-8555-4898-9e27-749ad4590b14	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0fbafb95-84c5-4b5b-8b88-6c5110511a34	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8a6f4a10-f491-46e3-a644-e9de1bc10f0d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
352106e3-57a5-446b-b324-7645c79105ab	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9c4e0713-911b-47a2-9455-f5fa809727e4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5a91564a-3eab-4999-b774-876ce37b48b4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7ea80c70-a01f-432f-a97a-e3d27a45f040	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
24c6362c-bc6d-4e71-b702-d7f4e92a974f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a949e31c-1a90-4e4d-b64f-abb8961b7503	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0cead07f-cc4d-4fd1-af0c-7d12296b3d8e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a31e98a4-fbc8-47a8-9eb0-ab0cea691825	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
53d68ba2-6e55-4414-8464-8cd2e2811ac6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	fd3362a3-cb2c-41c6-936c-070fd526e4db	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a29d34ca-c12d-40cb-8cca-e9ca8c8167a5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4e47687e-dd88-47ba-b779-8a31560bad7b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
182da781-b587-48f5-9629-0feced4dbb14	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f57535ff-a57d-40a4-a42e-bbf1c9bbb8ff	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b23184d1-8af3-4995-bcb0-dbbc8ca528db	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f70bbfb9-2af8-4cfa-90eb-b94c4d5e186d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e4f5f052-416b-47fb-833b-f182550418cf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7c170301-7eef-4433-942e-27307dfe0cd6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d3b4acd5-e782-4396-a69e-a6bc8bede5ab	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cf05fd28-ee79-48e2-9966-0a40a1ac8c2f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b32c54d1-53b8-418d-b402-f818a6b784c9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2cef2d1d-f12d-41e4-ad62-311bc103e8e0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7ab6a53b-0aca-48d3-b6e6-acb22585156e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f530fa98-9cc0-4d57-b029-26b1342271e2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ae3b4320-e582-40e0-b507-625d13792cb2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d8d868e3-bced-4696-be25-b786faf42f4b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
eba85ab3-dd6a-4f01-a575-74698d0ceccc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6e870847-537d-436b-9de1-ad964e35496c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e2097f0a-ab56-4abf-9eea-86688abce72b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d2dac919-c4e6-4b1c-a514-ef498cb5f8ff	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6f2b8034-5b10-464b-b532-b0f1ced08f6e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	eb1da70f-7417-42ec-b300-ab7f113ab4fc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5be6f377-d3ef-40f4-a9a9-8caa391a4dd0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	25a09bbe-e244-4f48-8ad0-4ab93c8e60c3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
65d07b8a-e42e-46b3-9825-a74d980e7cb6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	04464365-8e0d-4032-a713-2b7f6f995e4d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e0ade28f-dfbc-4143-89ab-edf4d9789de2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	436cf968-febd-47f4-ad16-8d15a38c0b19	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f3c76dce-9b30-4f08-b8cb-57dae1d62fc3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a6fab1a6-6167-45c0-b133-a6a13058009f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e05243dc-ca3f-4aeb-93b2-52e6931a32a8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c9b99c92-6f3c-48a3-b461-e53a77e5089e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c6cc0b1a-4c7a-48c9-833c-06028e007e1d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c4fe7b95-219a-4f3f-b292-9ef2bd9d0be9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bd3eb3b4-e9da-4f49-aa89-baa02e35c403	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	23aedea7-888b-4842-ac00-ea22ad8cdfc0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bfde7318-73f7-45ed-bb87-8ea4fa0b39c8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0a78b3c5-32c7-4e39-a7f7-3b7539fd1ac7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
591c3df2-e93b-4ef6-8da3-7553857eb433	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	593b2dc0-fc81-4c4e-99f0-f205a64645c1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2edf9fdc-82aa-40a9-8db9-f70fa8c16b8d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	208afe7d-23fc-4041-a42f-27addd6468f2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ca8f0792-a6f8-4036-940e-474e4bdefd62	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	06506681-6c43-44f3-8e1d-c405813477bf	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9f2cffad-b19f-4569-9d14-037e3df9e573	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2158eccb-597a-4ae1-bd15-1574170db46e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
14f7075c-81f9-4fa6-b38d-01f99d151eef	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4893928f-8614-4820-a175-456cc65a0775	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c7ae8ac7-b40e-4fe6-a9ff-62a7d1cfb5f7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a0f5e4c7-bdd9-4be1-abe5-167048539bef	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
760460ed-7f56-4e61-8867-6c707a2b2371	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9d97449f-6cda-4f37-87a7-18c376816bad	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
226f6115-83f9-40a1-850c-e4ca5df24959	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	73e5fa1e-681e-4166-b550-9b208c24e3c0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
beeee817-465e-4066-a19c-710fef2aba32	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1ab89282-75d4-459c-8eea-032407a2742f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2ef7c636-3c51-43d9-8c70-09f8d2d8e57d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b9f56f93-10e1-40f6-ae9e-6667d6c33f86	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0167348e-ff6a-4a04-a6a9-5040af3154b4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f0c83e41-ae55-45ec-91cc-ff243bb9fc49	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c1ad8187-f12f-42f6-8c5d-1aaa0fad21d7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ee52d85b-5bfb-4ca4-8979-5acb5fd6aaab	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
31bdfac8-34ed-4e22-8718-60f7145e4603	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b12f0012-a731-47aa-a3a9-54d460c2b37e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
22780f5b-245b-480e-921d-a7799d170276	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6a026526-9603-4b87-8f16-701883f5a339	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3ace64b4-88d2-45fb-97f0-7698e4b44fa4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	28fd5f1a-fe9c-496d-8dd4-a1b10cd4e9ca	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f15e388c-e85b-49f6-95ae-42ba8373f6f5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1add5f41-2f7e-4730-a4b4-d327f2903039	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0d1d9968-ebc2-4786-a324-212a1e47df90	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	81d42f9d-b621-4589-bf2d-1e15e1823e31	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
519d9178-11f8-4bf2-a2d8-bd8c5395704a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	34baeb95-7a29-428a-8ec7-0c147b929dae	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
834bdd70-d093-46da-8c1d-e12576fc7c9b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b74a236e-a9ca-434d-a608-1f7f10b995e7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f938eba9-7b3d-45c4-bdc2-b2037af5d7de	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	943f33e0-a76d-4f3c-806e-207882e10c4a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a9884bff-73b7-4da7-8a07-17e77e9f512e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	97ff38cf-d4ab-4c53-a0bd-4032d39f19c8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d4f22106-7aec-457e-b3e6-ca2fa7361920	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9d2f270e-3ae6-41bc-8429-ae6a0e6165f8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
915d081c-de65-4065-a4a5-09766f222b47	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	242ce7e9-218c-43fe-9fe7-8ed55161f181	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
877b4c50-bb81-422a-9a6a-4bb85738fab4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d6580c21-3f56-4ce3-91a4-df9fdc3258ce	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6886ba14-d7f9-48b1-aaec-6af0e1ed13c1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2540be8f-2a5d-4121-9514-7d547be6eef0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e6e5516a-ee3c-42f3-9e35-aceaeaa033f0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	517f2e8e-edc9-463d-baa3-bc3064f67e11	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2fb1b67f-83d1-44fd-b45b-b84a4236a996	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	24b93eee-c881-43d9-90b8-4f98fcf733fd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0999f172-83ff-4d50-ba7a-201bdf4eaa1a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a9287274-3195-4c95-bf47-a04481ddf04e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6afa64ab-6bea-4249-bd7b-f20e75d47701	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5f44ae08-08c7-4d94-997e-b20c26a3d3d2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d1a9c728-d74e-4b9d-9443-bde8bd0d515c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	068f197e-5bd0-49dd-9599-af0f7061a844	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f6530d33-97cb-4447-8296-86a97cbb9f69	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	06a0b35f-3146-4b72-b224-df6264161bfd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5b35a8a1-deca-45c3-9e9c-d61dda5c6548	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8410c20f-f925-416c-925c-ce2365b9ffb2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a4570b14-ff83-46d9-8d03-487961ab3b5d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	99c4170d-f79b-4b8d-8217-c744dc2a060f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
16164d8d-9052-4a0f-b34b-b50dc701bc7e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	46c22828-0861-4e49-91e4-91bfea02a02f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8b58dcf7-1e97-4106-be55-c0a811382037	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	89453004-e027-4e98-8ff5-64f3fbdf698b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e671a89d-87b0-4c38-b4c6-383a9ff762f1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b36eb4eb-bf6e-49e6-aedf-48ae1cb8d005	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
df49e4dc-32f9-4f65-918b-971848e7996b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	82aad02b-aa9c-4c64-88d7-b98df17dbb2c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f7bb7cf9-5ec7-4cb8-bce3-9cce6f478077	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3a5b507a-96d7-49eb-85ae-fcba48c2dc7c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
89a77ec2-93c0-44c1-8d13-c91543479838	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ed6ed4cd-c259-4f7c-a04f-44bd558104fe	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
82c4ea46-f02e-40e2-b99b-163b90f38674	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b52be0ae-2e8a-442e-abba-001c4757ff4c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4dc4672e-cfe3-48af-9351-2af937d54e8f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	02292b54-6e0c-49a9-abd6-137d37d05fb9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3e2f87a1-e295-46a8-962f-1ef54d075f5a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1af26070-fbe3-4ca4-a831-8f3a71f8ddf7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ab346ff2-0b04-4b27-8bce-4ad54facde14	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b13c50e8-fac8-4820-ad35-6f9c21a76fe2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b91bb37b-53d9-4477-ac8a-085d9e76ed98	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ba18a28e-ec17-477f-b172-69d82698b00d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
70bea061-5b28-49a9-b119-4fa44f75d40f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	83f3ffbb-4c99-4725-a5e0-e85f8d9ff1eb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ddea7ade-e6b3-4772-930e-fa3a5e8f0abb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	35e4296d-3256-4876-8f03-5c7d8cee2479	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6fac6ce7-3771-4ab5-aa84-d2fe07ad3818	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3b4c4e31-331e-4679-83c4-28bdf09b0496	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
29ad7f6c-c7be-4bc4-9a67-f10e20da35cc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	15aab06f-f875-4279-afc8-aeb3f9b460d0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2840f835-fead-4b4b-b323-e9ca551c4874	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c05f727f-3ff4-48df-9e0f-d8467541c7ce	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6301611e-313a-4aa4-95b0-c16be90c5d77	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	406528a5-ea1f-4a4d-bdb2-e86febe02208	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dae94f58-a400-49ca-8a3a-639ddcca2bf8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2f645122-e172-4e06-ba4c-edc192dacc7a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
75045739-e8a3-440d-8ad8-05fe120fa5ba	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	59d737da-ddc3-432a-a9f7-7bae7c80f110	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ef656415-2b38-471b-91a0-be18ccf7c62d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c7789c03-1712-4859-9961-9644654a60a9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a3b4377e-f349-45c7-a194-31eb6df0776d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	69fe0f7e-4d2c-460c-9a63-bd1c895e83b1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
33eabec4-ff40-4397-bce2-d1437692cbbe	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	448ccc1e-7cc0-43f7-9514-ce384c26dcbb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7ce56236-3403-479d-8acd-bdc70045b82f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	72343ed1-d562-42be-92b1-8e6fe9bccba6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b66465b0-387c-4b67-b5e7-602a6e53dc76	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	daa6f6ae-7c26-4dce-bafd-59eb0c2a9292	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4624620f-0884-4274-83a0-986c8ea594d1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a78a9d1b-f8a1-4084-a933-a7f3b0f9b35a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7a7ad51c-9444-4846-8d2e-69b4d076ae92	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f1cc4ee1-b19c-4a8c-bf7e-290fba38d659	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b603f92c-496e-4763-9d4c-9702504e49b1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a38152f0-3250-42db-a86f-535983de5b41	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
365fa35b-6147-47b1-8667-94b835ca9a64	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4cc1d2da-0011-4393-bc32-4925c66b5dd0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cc81b49e-5c28-420c-accf-e95def64582b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3c2f8219-1cbe-4623-aef3-1ab472c7f5ee	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
986009b9-3f35-45f2-97a8-86e091bfe5d8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d5f83d64-38fc-4463-88e2-9dae7aa83e9d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e724402d-ca84-49d5-ae82-19e405da2a51	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b56f2302-aa58-4b21-874d-718c318d0285	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b31c7acc-72b5-4c94-9a32-7e9fec013f40	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b0c1b34a-150a-4e8c-aa52-693c63fcd50e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
575c659b-90db-47af-a925-c54a14175b3a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c1911d14-a326-4e6c-841f-095f713230a9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
04054cf2-bc3c-4bd8-9056-8777865fa626	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	26833a3d-b940-4730-bdb6-771b8de5d6bb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f1394460-ec92-4a9a-acd9-2be40d1880c9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a28ac42f-6e91-48db-8de2-cb446b788506	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
75f9598e-1d1b-4f16-afa0-e86ac15fd42b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	aacd58b9-7cd5-415d-a590-95539fa55722	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8d440cce-2f9b-459f-bbd0-a214595b963d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0db7301e-cabc-4125-9753-d1baa2c44135	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3f5b7f56-f5b5-476a-b85a-ff3d5730ceb7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	38473a9a-ba04-4113-8ecd-fd86d62c9861	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e20ef786-fa88-4680-968b-1068e64dccbd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	49d74075-b2ad-4def-90eb-2a7ae764230d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
037b88a8-f763-498d-96bc-7abfcaa0ea78	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	902fd70b-064b-43bf-a2bc-fdacb7b3be69	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cf71ff09-c83b-4247-8aea-dac7d0dfd465	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b232af8b-30f0-46dc-b691-e6e75fa357e7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b0eea87e-e710-40fe-8202-03694faffe50	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d73d50b0-1c32-4220-933f-0a71afcaa9d3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
498c2cf5-880d-4e1c-a6e5-b22d56e28c71	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	92099359-d41b-417b-acca-3aa178b313d7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9187de26-710c-403b-a1d8-75928ac5095f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f52a7ac4-59f4-4a23-9fbd-544cd7a62687	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7cfba173-30cc-4360-bc83-40f1c4079c9a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e939b98a-b455-415e-b937-b7e0b7b45397	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a53598ec-2c53-4d23-83a1-082ee78501db	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6d01ada6-6047-4856-96f7-51abb0b3ef03	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ab4c8626-e845-4207-b467-8fd99db21fa8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6f1e06ec-4bfa-4fbb-bfde-7b50b7dcb7b8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
31844fcd-c750-4dab-8093-c5bf13d8f2a1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b0fb7fe3-abe5-449d-b539-e3ec0443fc47	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f4754eb5-6a5d-435d-ae20-a6c19ead6c36	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d03bf414-6c6c-4b16-a1b4-3c546a8a7fd1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2404feba-fb09-479a-93ae-25b021f175c8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	dbf6cd6d-402a-4f39-8f26-7ef9480b6c3b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8d283ec8-74a1-4f86-abba-24e1acd1dbb1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e4894564-51d5-4d0c-84bb-33e72708447d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8caa53bd-2ad1-4786-9c97-4ded70c6bc53	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4a81eb90-d3f5-47bd-a87b-4403a611caa8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
73a178cf-21dc-436d-b83f-eb276aff633b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c0f8cd81-ec14-4a0c-b792-afa5aa50ec6e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
95e9cc95-092a-4a69-83e4-2494ef5bedd0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1d057682-ba7f-4818-8bb9-62768de6c8d3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a6c9ef45-d85d-4fdc-ac43-f84c53c26242	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4c76a6a1-c667-4b15-86dc-a2cf45920bec	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
98e88128-c172-4deb-954b-9adb887a50f9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f9100cc8-a2e2-4d2b-8c52-ae60b0795e76	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
546b01bb-9d8d-4b25-a909-fb04a0949189	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3051482a-c212-4398-9a8c-22bde46b7a24	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9f309371-b18d-4ff9-8ab0-f87f4705497e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b334eed7-c4b2-4748-9f6e-448e29203a4a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
80cfdc73-8157-4932-b804-c2737627765b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	44640921-5287-4001-afa2-d9892e9fd492	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
be25f40a-6d0c-4f79-b230-9e0069d40871	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7bbcf2c3-6b90-4f3b-ba5f-ad6cd89f1fe7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9853eefe-30f5-487e-8c5f-3ed20bc3e8d8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e7bdf9f3-95b8-4c5d-9518-ba50b6a96401	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2bdf4e73-0c1c-40c1-82a8-75b9d54b6eaf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	54ebee77-6acf-42b4-95d9-7fb0fa2baeb7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1e74ba6e-979e-4df3-92dd-d7763e166148	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0adbe8c9-1db4-4ac0-8f99-c93fc58d13a6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
05b88c41-b957-4b22-8dcd-ac6edf7f909d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	34f0cf48-f9e2-4c8f-9ae0-3af955beae05	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9e62d0f9-6b2e-4e53-b798-e23c0e508209	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	20d0c2ee-a22e-4809-b788-2ef9fef37577	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d7aa6fdc-c23e-4653-a328-5e15b99e8a5b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	10853ff8-7f2b-4b0b-a6bf-222261507521	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
73d5d733-8194-42b4-82d3-6932dbe20a92	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	149dd0ad-9e4f-4618-ac18-c8ee94ff0132	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2c87e301-9a44-4b85-bec2-2cab613db6e1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	fcfb0a94-e078-4015-9e5b-ee4397f781eb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3a01ca6a-d87f-42d7-af11-81565ef29af4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9cc22c49-1373-4181-be01-977f31108acb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ff28c52c-6af4-441e-a1b3-e4395e0b8d37	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	03c1bd46-23f7-4c52-8192-14a9ba8cf60c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
48ced7da-b824-45d4-b571-842cb59e8a17	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	965cc39c-99a4-477f-9b6f-d3205c8bc09e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cb69f46e-aa7c-4e05-ae9d-d51c1bbfd535	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f3738d5d-e775-4a3a-9ec1-2d877494cda8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8fee743a-4508-461d-8961-efb906d3deb5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cc3325b4-daf6-4866-81e2-70ad41ac137c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
057ae23c-6103-4167-a5e2-e5c49f9f88ba	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6c132ca3-e2ea-4936-b866-5a5e1e4d036e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b9c5c5a1-9286-41d5-853c-772b4f96a8d8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1d913d6e-6ff5-4b5b-8b7d-1a0cffa931da	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
df43e954-525f-4080-aa88-958b63b0b111	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4a01ad83-6e0a-40a2-b85b-cf5d60cfd330	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5ac045b8-578e-473a-850c-2708cf56eed9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6d4ba333-b115-4be4-9c37-e0ae7729e8d9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
13466a11-d023-4bbd-a89f-1629e65dd561	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ac0c6eef-ffdc-4eaa-8245-e1489668f35a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
15ab3bc8-f4f6-43e4-bac3-a24895037ab4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b46e0b58-9c99-4ec2-8943-3dd1ae98c753	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4126324a-2425-4054-854f-80b59deaecf3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	80b0a098-d72a-44e7-92ce-e73bdc7c30b6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c9f611d2-ded5-40a9-97ec-32e2269e2c3a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ccc9ee14-4c17-4f79-923b-453d26108f33	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
63757a65-0234-49b5-83a5-e98f58ecb4f6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2ef8f6d0-8dbd-4c97-9aeb-87fa1cf68bd6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8b4c3d39-ae45-4d01-846d-95f06e2869af	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	846d718e-7d96-40dd-99dc-53df7da1b893	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c863af08-da58-41f6-9b25-d2e452ae79ce	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c836bca2-5364-4503-916f-d99e57df4e0c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2eabc8c5-0609-46d0-b774-8877db9df0dd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d4a8f643-3d09-48ba-93a5-130e4a701fc3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ff2208f5-80f4-4426-88bf-f9f8ef418178	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e396c7f9-6f57-4ed3-8a17-5d7e2a33e98d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
853148b6-590f-4052-811f-5d60b0fbe8ad	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8165476d-62fd-4f4d-9336-2113d2e21338	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a35f7592-7013-45f8-a353-7aafc06b0133	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d3cd4b2d-382b-43b8-a7f6-6542fb59fa45	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
70d63b1e-948c-4b4d-9783-880f9200223e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8990165e-8c4d-4fa9-9076-e545a6eb271a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
304d9d77-1ee0-4279-a70b-53028fdd6db8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	73b7742d-5e43-4115-beed-8bd04010ad2b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c6bfcafc-68b7-4586-8994-b089ff575622	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	11594ef9-e4bb-4741-8e7d-3f0d8ff075ac	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
44ca1247-4b52-4604-8241-f293f77eaac8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b6835ffd-e222-4784-94ec-7293d0f2a034	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0fe8ffab-99f2-4ec3-8d20-341fc4435311	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4765ccb4-c263-4d70-b409-e0c7dc9152e4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b02f01e3-ded2-4369-a09f-13a261edabc1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f4102737-995e-4a47-97df-963713abf9fe	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1cf48b9b-d5b6-4af9-8e27-5943239e62a9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4cc91b8e-9072-4f2f-b21f-a331a1746569	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
54d82336-8dea-4e39-a18b-0071b3828d3a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cf22b938-6fbe-4ea0-b2f0-742cf9623324	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a5385a70-427b-4d95-a2bc-c8cce2814cff	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a5b42d8a-15df-4d5f-9f22-3bd90958ec57	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
77257b8a-7858-4d89-859b-633c8ad4d337	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e39a3898-4d7a-4d77-bf4b-82441326c7a7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9c6d43eb-b2be-4b9b-b199-6aa59f950e27	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	eb996983-3b0e-41a2-8948-d6f9df98a7cd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7fe1e588-55ea-44c8-abe1-b1887a7f062a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4ed9c81f-25c7-450c-bfdf-bffbdfaaf8d1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
65bdc999-52e1-4761-8a5b-2a4e34dc9d2d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	92def23a-e6b1-4ac7-85de-27d5cbacfbce	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2deeb27e-8791-48d0-814d-ecd9b17d5594	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f53ad995-a44e-4ace-8541-8fa19935705e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ffd97cf0-e45e-4cf7-acd8-dec91f66d0cf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d83f2786-950d-4627-b53d-85bd96988f7b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
997a85ed-a632-409d-85bd-df069a162ba5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6bd9a1d5-067a-48b5-8ed5-7a5a1c67d8a8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
418ae4d7-dbd8-43f5-9e92-25c0f45abc10	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f119568d-c086-4d3b-bed5-6326b855176f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a93ddfd0-86bc-4b1d-8284-c72e296d9445	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	28348cbe-d2c3-4f96-a047-2e241886012a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f2553b29-5749-40fd-baab-016d1c3db569	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8f1492f2-81f8-42c9-ae49-5617b3a65aac	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
09b46440-62a2-4644-af20-f2a42f49d95c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4bf9e22e-4307-4033-8fa9-1f49af895170	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3e0d577d-451a-4168-b0b2-5ead3c163e8d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	99d30d49-b799-41a9-b2d0-0b627d9c9e9f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
02517261-9822-486f-b97f-1b4f31cdfbe1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	08847c02-aecd-4110-9b90-e696659d27ab	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a5013c47-c712-4d08-9b4b-f9a27adb4b99	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	00ca20cc-d92c-4708-bc23-e7fad854d6d2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
269fd0a8-e9cb-4c04-83f7-8942579434f8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	129257fc-04f1-435b-9de2-a9956504496a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
147963d2-c3ec-467a-a41f-11c7c1bef19a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6e891062-ab0e-490d-bb17-c51719f9bca9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cdfff0ad-5396-419c-990a-2699739f6851	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	62ee02ce-049f-4a3f-a735-4ed4f7e4107a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e09c2890-b862-499e-8e2d-4d7e8fa0f622	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	64630fdc-75e4-4f45-97df-2b73a0eee21b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c7999fa3-6d4b-4114-9c7b-59f3feedb31f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d087b0e3-ee4e-4704-9dbd-f57f4af23c59	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5e597f93-bf6c-4941-a7e2-6de4aacf49a4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	de3d8bc9-187b-4610-866c-d98bfd124697	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
29359c9a-b508-4082-8e8e-276c7bf96ce3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	33956074-3708-4d03-b8a2-23a524002d46	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
55dcb9eb-e206-4ac9-aa6d-01f570eb6076	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	97bf6485-a9e8-403f-82a6-1595d547e6c7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3ce51d1b-1b82-4188-ad7f-ea289b4bf867	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e8a32a29-373a-46c2-bdd0-2bcf2067cfaa	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8b4cc6b9-7cb7-4c96-8e14-c3dc75c7aed0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	46c6947d-d3c1-4d87-a20d-f80c640815ba	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
68cad6b3-5956-4a5e-83c0-99024a9d3259	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c23ca553-a768-4eef-b237-4f7a1963182f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
44961615-bbfa-4e84-a544-88368e371269	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	30ea4649-210f-489d-8b25-eb7752952a58	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
81fe5030-f721-4fb4-bfd7-4a5740256310	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2753d745-4fde-44ad-a817-a926e2416c26	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f98adb24-53fc-4d60-b8c0-f6e23ad5c971	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a52d2763-eaaa-4283-823e-698e31304ac7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
903bea9a-c5c9-4e00-a098-37d563379a9b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3cdce22c-e760-49b5-bb60-d1577acb2750	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cf355da3-4cb4-4dbc-a1df-622d81c79d04	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b98504a2-18f3-4d87-a127-101372b44237	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c47ba241-c63f-4adb-89d4-878c5442737b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3373dbf4-1675-4263-84a5-5cce2c8835c5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6227d429-ae3b-452a-a445-d08a0e973240	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	143bd3ec-ef82-49ae-9ef6-c32eb8c481ec	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
15e82a52-a9ad-4958-9dcb-68b37821a90d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c0724f6b-1a47-441b-ada7-11a0b12cb944	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fece6c31-63b5-4f06-a084-df841e2fafdc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	52dee135-9501-426c-a3db-231ea6521fee	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
71037c8a-b94d-4c05-80de-26166bb843fb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bcd2d343-b857-4fc5-a3a0-5c81ce009acf	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bbbb8860-3265-4dfa-83cd-53000a5b5d17	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	fcfc351f-a70e-4fe5-a31b-41d222f912a7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2f371f29-430c-41fe-a0e5-81ef8cbf6ef2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a0df12b1-415d-40d0-8bc1-03acd83f9918	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
047760c9-62e2-4ae7-8cc0-37a0067b4f4f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	469870c6-7f05-4396-a9bf-71600605852f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cf5b0336-37b1-4b68-9405-c70f10e92352	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a9ac42a0-a727-4add-a3bb-5deddf2cadc1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1ec18f6b-df1e-4437-bee3-83cde17a4b97	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4975269a-144e-49f1-ad97-16f120d1cbd3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2561e7de-edc7-4d93-b0e3-440181663065	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	743681fe-8f16-4ea4-94c1-1c7719d567ec	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
11bd713c-a831-480d-9c33-fc078e8a6b6c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7a9151c4-2be6-4f64-9ee7-f158ca3471e1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cf65f436-badd-45c9-b677-aacd7fd6a0ca	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	708e26f3-fa66-4a29-a38c-5f544dd31662	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ba7fa9dd-19a2-494e-b056-e701f59194fa	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	75f0bc43-e2c5-44e3-a23a-a1328ac03bd4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e044b734-f540-48b2-9aa3-3982b177f42a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	00ee0df7-f531-4d7d-92e4-b9db178dbc30	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
794fe3c7-4a85-460e-adf6-f029d5fe85d1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2525a59c-0f76-4b6f-8802-c552221c2c8b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3cde450b-7df2-4e13-979f-0a9dc94c0475	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	fcbba7b9-fd30-47f8-931a-705573f4e87e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dbfc4255-f24e-4d98-9837-0cf08b3a80f3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9196af56-2465-49c7-9d81-ec5191deb357	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
07d043bd-5d9f-4b1c-b743-89e536b87dca	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4924cd3e-87c7-4838-bd40-de0f29768239	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
f1927225-c1cc-4a96-880b-c8b831a90e48	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6f2d7423-305a-41e1-b471-ad6bbce92983	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
841f040b-5351-4e21-a3cf-96f6b72dc1cc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	762c6869-1df4-41e7-a12e-5fde1ec2d3e1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
707eb4af-94e5-4302-bdbc-d86bd0e16a00	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	36afdfac-e2ce-4bd3-9eaa-698000f13c57	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
abefef33-9c5a-4fa5-bdbb-1949413eb52c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	989205c4-5925-4dce-ae16-a6a0f27c431f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
14cb4cca-69fa-44d4-af05-7a088ab43615	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3f3f8960-2894-4c63-b3d1-68045b53c92a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5be73780-04e6-4fd9-8ed6-15a456a8b32c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5c68ca9a-48b5-4a77-87a7-b80a3699dbc5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d4bdfe5f-2450-4bc0-9fa0-87c5c681060d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	36e77366-636b-4e0d-81a0-209ec3226fc5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
86688951-409c-45a4-b940-c154e2bccc41	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3a1e4c0d-e0e9-4704-8238-9f1f02c8a307	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
96371818-c955-477f-adc6-d4b3aada92a7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4ccd6559-e071-4372-bbe2-e2a971cc6768	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7692b95d-58c4-41d6-8a23-d0efd9822081	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	20f11418-baba-4b62-aa82-9d137f19396e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c951e509-f361-4880-94ec-63b035829a69	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8e4d7117-aac5-4564-b497-4d6ec589b631	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9f008e59-6459-4064-a523-f6f200bdc917	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e2d34508-d906-4139-96ac-845f5ac22b58	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2434fe6d-65ff-449d-9b86-a64b0a106d97	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6bd34503-6140-4c80-859b-baaa14ada3bb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
93b04b51-235d-4d85-9629-ca9e2e892e2b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	90d7d88b-fbcb-4a96-9e4b-51150e6187c4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b1bc97ac-655b-425f-9903-de71e388f595	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1fdb69e0-4372-424a-9f27-8f1be8b782db	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e99e0ab3-0fee-4f60-b8c4-9a16b3b5187a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	83cb1b24-e748-4fc0-945d-364f9f1dfe9e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fab7a207-616c-4080-b884-f15e2e6594fd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ca593b9c-ea6a-49e3-afb4-a36c38e6022c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
98ffc3df-a142-4b29-a75c-e7c8c5d5842c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	48f4cf7a-891a-4289-9d09-a04ee52d2467	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
662ca70a-1635-485e-8df4-4974d1e7853d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5f74ed26-98c9-456f-95a2-54ffe311b19a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
21b20f77-8cf7-4e6d-ab46-4936bd497dcb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bf90d1be-4d92-4e8a-b25c-ff5ae900dd6c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
08abbf84-d7ba-4816-8df3-6059435c76e4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	91ec904c-c1cf-414c-a046-2ed695539265	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c96e277f-f46e-4f3d-806e-4e7f0b38a88c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cd578b3a-2398-4268-882a-5df025decb87	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9998d61d-6357-4433-b9f5-2627bedefaf8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2a59340f-976f-4f1a-9471-eeff102efe40	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b5626161-c9e3-4c60-b749-03b8810d5c91	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9b5eebe1-3e82-4f10-9fa7-a97c553e6bc0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3a862d5b-ff32-43ec-aa70-0f679e942086	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	be966f62-f172-4c93-9bcb-d3ac1a34cdcd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8274daea-9a13-4d74-8c5d-b1c45d399f0a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4b51a8f8-4863-485f-ba7e-45aa5c056582	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1f2ca1ea-3a48-4be4-82bb-7c6e6a132973	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8207054d-016b-4566-aa6c-4a33f946b368	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
aec09c27-3048-4cf3-8c21-d3aa3e5075bf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3f1bfec5-a2e1-4463-af4e-15f19632f398	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
204cdfe0-38a9-474a-b324-38e5e851490e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c0cf6a76-07af-49ef-b2dd-8cc63c914c55	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ca35c20b-d98d-40ad-80af-54036b5ef181	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bc9e9813-f31f-4ae8-8367-4a5e7e75ea4d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c7836966-a8b1-4166-9522-ae1fe826d50f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	298a2ce5-03e8-4bc3-90c2-f100bc798067	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
70307a95-e266-4e9b-aa43-19d69a1a74ef	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	80a3d0d6-4fee-4d16-b0e4-da9b5b5f7e9a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7311e173-1b16-4412-9117-721ecd5d64bd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6a0804e8-8d14-413c-b77f-b8d925240ca6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a3d39115-849a-4508-a28a-074d9d0c02eb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	88e8d64f-4ffe-45af-a5c2-bf41e05f5daa	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3c5b8e34-a1df-4cb3-adfa-b6a6e85c6910	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	19e74b3a-e81d-4046-8e2f-155e3c44ea3c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d3f8eb5c-823c-444d-ba4b-009a7dbc0965	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b0b55a81-cc70-4670-8381-fed9b85d4795	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
afcb7ad0-e2b0-4ab2-b032-e74e57b3a4da	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4cf7ced8-df93-4ae9-a25d-1630d6df5afd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
021ccd1f-eac5-4ea8-83a6-589bbd3494c8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d87d39c4-b0c8-4785-a105-8474a8c48bad	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8db4043a-b322-4067-abbe-9af5b40e1701	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5b2821a5-e35e-44c4-8c13-d63d6345ba5a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cd69c394-cb9e-460c-b4a3-b92968050f31	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4ecc2531-c07c-4c78-8754-7bc14aeed18c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d1253e61-3f08-496d-803a-d9fc47619751	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ba096883-f4e9-4f53-84f9-1b14226e2593	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fdd8453a-4c76-4ee3-9c6b-3466a8870999	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f6fa5712-a021-457c-bdbc-1d25071ac028	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2eba8bd2-a61c-44c2-b917-78840a7e4b0a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4baf01a8-d3df-461f-bd31-e3283aaec78e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
feb0ed28-0989-4b7b-aab3-9018dcbf882c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b803db15-e821-45f7-b77c-16b9409fc423	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ab007169-3a2d-4337-aaf2-442aa18bd471	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6079583e-d988-4f99-91aa-99e0c0bb20f4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ca32ad48-15f5-4df9-96d3-15b99d58ce52	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ca91806e-64bb-4580-a882-d715e1c22f4c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
38e337a1-be71-4650-bb66-f9ad74e2d0b6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cfb318fd-1e1e-4fd8-bcdb-bde939c66b76	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
600153c1-14f4-4577-918a-76a8fb4cfcc5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2f782948-8df8-4550-923a-9d582b413d9d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c9c15e9e-15c9-4d77-b5ce-3514f4b3ed8f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	df0f8567-fc9b-426c-aba7-632bf3a2f69e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5638be9d-8173-487c-b5cc-e0cfafe199ae	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	58a60da9-bb63-4882-b28d-a899d6e00f52	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c3719469-d04d-4ab7-8053-ba5adc00cb60	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7fd76e58-6082-4eb2-809b-5bce5cf8cd32	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
86e00e7a-22ab-4949-99bc-f0579998e620	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0a8d7236-b26f-404d-94a4-08189f56d6d3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b1d141b6-0bf4-4c60-b57c-2d64166dfb2f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f644f4d4-07d4-4a68-9ebb-2d867faf1a9a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
77877c58-6524-4cc1-b226-bb649f7f715f	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a9123596-3d31-4156-9c2f-5c24dae4b8ff	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
58d335de-5e3f-45f1-a943-a9cee1390711	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b7f0d91b-f540-4dbb-a1d6-67945f3de9fe	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e365fa94-0357-47b9-b255-a87cd9da9a97	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	88feafc5-50e7-49cc-94ca-19ac20a62381	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
050dbd85-d15b-4918-aced-eaca549eeded	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c83b313a-6377-48f6-b423-61bcbd1befac	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
55b0af3b-148c-4a07-a0fd-fb29e231f507	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3d76ee07-337e-4e71-925b-5a4ad34a6217	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dd1302b1-c8ad-4390-aaa6-0ba1d71d9abd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7278d8a2-1afa-47ea-8f45-aca80363e7fd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
01ce398d-0b72-45bb-a932-ad58bb4e29f1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	eb4ca459-a7c5-418b-b663-72482539d188	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e646a9b7-f74d-4b58-afd6-9228a479ef3b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	97beb27d-91c6-4d5a-bde8-ce522ae7cf3f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b5a366fe-16ec-4e78-8ad4-4333edf2be5a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e8397cbe-b0c5-4e24-a1b7-c4b70b096289	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
77dfbcb3-e8ff-4fb9-813d-7ced0c21a19d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	df2e1002-2afb-4016-90b8-e042eb0397a3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dfb8f1ad-c6ee-49e4-902f-1006d05f1317	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c12b01cc-f893-4719-acb3-93037b400058	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2616355b-94b4-4cbc-a82c-0ce5be78dd3c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	721735a9-8a80-4464-8384-aa2969f9bed9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
79901b75-6e1f-4098-a755-f9860c70d405	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4606b7b7-7fe5-4409-937f-2bea04577896	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
105c523a-780a-4482-b914-bdac93b5a60d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9c851f5b-3b22-4bdd-b23f-bfd4bedc71c3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5407ac26-c558-47e5-ad44-962bc2151b96	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	043573ca-8b01-4937-880c-363faa091589	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1027c183-ad02-43d6-947f-2b6e6d9e2c99	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d6a7f0c5-56a8-40ab-8eae-7c5747555fe8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a83e3db8-13b0-41d7-8989-019557f9f991	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	62f0715d-c698-419a-a5d0-fc9fda75bfb4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fd3a8c0b-455d-4274-ab85-a5e6d3f8d582	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	fba6af6e-fe6b-41ad-a222-4467da95e989	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
40cbc6ac-1ddd-4a6b-a7cf-3f4a4b6016a8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9ddc5858-cec8-4a12-abb9-de920843f065	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9326c630-ce2a-454b-9c16-94019d9e11a3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	adf94e1e-154d-461e-97bf-23d2a7f41b5f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5bdd4111-0cd6-4fdb-a6d0-ce4ec39051bb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cb0fcdda-d13d-4b13-b383-7233c3a91968	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5e23f0fb-bedc-41ec-b288-433ab6086915	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0e2317c5-78bc-4fd9-8c1a-e0bc352c701d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5995904d-a035-4e41-9a6b-0bc445325344	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4c833ed7-ac64-43bf-b08e-7a0b66810842	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d4afa99c-6b2e-42f9-b1d6-a009f02e6288	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2a841cca-0a94-4173-a2e3-94064c295dba	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
39897dd7-f549-49c1-b1a2-b3bc80a2b1a5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8ec38741-d1f6-4cfb-bde3-56bcefe7f9b0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d0ecd35e-0827-45dc-974c-0b0bcbab890c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	aa063d12-8ac0-423b-be80-1ea10ce165e3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8e56c3a3-cd85-4f38-9047-3d40370ee535	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c6a21385-ae1b-48fb-a6a2-090dd3563729	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d45f637c-62a4-42e2-a71d-1edd97811e12	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	33b53ed0-62bb-4617-bec2-90d8bba22d3d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ad3561e7-fc16-42c3-9d9a-a86a47d93658	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	83ac9581-1559-427e-ac19-3aca64177e50	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
67ac1d4b-484d-47a8-8ada-6b6074dc01e6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	df69d456-0455-4f98-af86-c2c83a75c8a2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d87b7eb2-b627-454e-9af1-5dec585f6673	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	518ec9ad-7df7-4d4b-8eff-04a6c3c36653	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2acff531-02c6-4833-9827-2cf13b937011	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2d059afd-e97c-42b7-a1b3-a2e9cdbef966	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8af2f3d0-4f65-4d5b-b1be-c2da52768b34	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5c1a91f9-a5f9-48aa-b130-3b611255c7ea	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b9f0a8eb-e0d8-424b-bb6f-3137505d142e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	358f7ed5-56c9-4d88-abe7-39ecbc3864b8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4c6f09e7-b44f-47e9-9920-4f5e30db2c7d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d1c725e2-edf7-41db-b67b-e6b07a9124dd	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
fdce7b5d-4c88-4f6a-9d44-8be876b4969b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	2cfdda52-727c-4980-9b51-f6cb8d569a36	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
62e8d415-5837-49bb-867d-ef2081ebe6d5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f3621ac9-9731-4356-adcf-f5cc7fbc5652	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9d8836f6-6533-4092-8379-d02a53e981e8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	290ed9b7-ebfd-4fdc-ac2d-310f72f83df1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e4f80d2f-242e-44db-8cc4-ab70bd28b403	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	111623ca-05ec-4e32-9c32-384496708f96	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cdeaf7ff-9b91-4b37-b3cf-cadea3766154	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f15ee116-4252-45f1-944b-8a0325a927e5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a9d37b3f-1fb7-4032-8918-a21be580f1e1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1cfdd92a-7159-4181-8417-0ef11efffb3c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a8630152-8879-444c-b313-3d1431a40da8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	89660c46-97e8-416f-ae27-ac04c6e740f5	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
7445d8f5-b0c7-4e54-bb37-306182fcb8dc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3ad518c1-cba5-4b49-a75c-000da86b1655	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dc85e5b2-5358-48d2-8c1a-b4b09eb391d1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e167a583-fb30-4951-9340-ba25f3500b66	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
90a454d9-45da-46cd-a825-cef32dae1782	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	82fa6a07-a523-4391-bd0c-f3d1b90e5ba8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
47e13417-1e34-4109-9290-acadec850706	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3c340a19-7f91-432e-a3f2-1ef9c34f9c78	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
8d9387b1-0e85-4da8-80a5-c68d83798303	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d024e83f-2ffd-4ca3-a4ed-e8115c78c09d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0560b4f6-d162-48a6-ae91-edc4ded3b809	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	02192424-8888-4564-9c78-96b4268ac20a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
cb9f36c0-a4c6-4e72-8c46-04cb41d8ff0b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	56e47716-ac53-4d03-b072-67f621dc18eb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
18c61f7f-9ced-455b-b929-65736fb0576d	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d9d656a9-c247-41fc-9014-e7a6e02221d0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
79b10c0a-0160-48aa-9d6f-6faa517449fb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d7d58ee0-f368-4cd2-b434-79bb1d42d84a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
54296e0e-e4e3-4efb-a6be-3085cf4c13c6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cc0a2281-81fa-4f0b-ad41-755b93e7d4c8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9062eeec-8180-4eeb-bec5-98195e17e550	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	05698e9f-9315-452d-bff6-3a9c117e3236	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
15b4cc2f-560b-4257-b10a-ef6b371923e5	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3c31632e-fc0e-4eda-b4ec-99fe922ac61d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c7e3ab67-f38f-4a3e-a9f5-4c089ba3e0a8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	83bd502d-c6cd-4b40-91c6-5d243069fb36	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0e1ae6db-974c-4aaf-b4b7-cbd0d3155744	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e1ca767e-3a70-442c-b1d5-d92fb895b9c7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ddb80875-872f-4a74-b35c-8ac226e21a08	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a26f2142-d8f3-40bf-9327-ce73cd8e17bb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b4ec61b3-df1b-4efe-9703-079e1847395e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	21d5d841-5807-4931-baeb-3de36b2dc53c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e22b7f4e-1a1e-43ff-9ee2-d44f4f0f7697	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	70d6fbbd-00aa-44d6-9770-8b12962a5086	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9816cd37-29fb-48bf-8f37-55606d658c4e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8ab9e061-13ff-4f95-b3a6-3a54d6267fa1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1ea4834d-d03e-424c-98aa-aebd11402712	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	89f53ee0-88ab-4bf6-ac36-5167d91cbc3a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c18aaab9-8986-4eba-83a8-437b31e071e0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	432791e2-d04c-4f1a-a44c-c3f5ed0a04c4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ddbc9996-a513-4a6d-8955-7290db9d6f66	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1ea9e3a4-13d8-4c2d-8e87-bded3021d6bf	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9055d5e8-b4bb-4ca5-b838-e370c4d9acce	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f1371e95-3952-4515-b169-d487e8fa006f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
29e855b5-8d11-4e92-a6ba-a8a11f534cdd	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e6c38cb8-b3ef-47c1-a621-df282c4f5d03	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4aa8ff3e-a819-49fc-ae2a-9f09f85d3011	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	743943b8-a53c-41fa-ae92-ca5ca48cb031	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1f510c7c-ab6e-4dfd-b1f3-3af7eb0495d1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5b77c20d-5298-49a8-8237-4f70a2bbb166	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
64a87a08-8079-4250-a865-30782ca69061	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5479dc5f-ae7c-43a3-9697-59c25ff67102	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0e7a28ae-6052-4cae-87e7-9e00fbd48571	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	62f6956f-c724-4cf2-afc8-023d642e0f41	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
608d4b1c-441d-436c-a833-d0797337f9a1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	543068a9-8fc4-46f7-bdef-05cc09172a48	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
57341263-6a53-42a0-a1ba-eb0ce488b29c	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	71073869-267d-404b-88bc-3716117c9877	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e379a30e-bfff-4572-abaf-e7edf153c38a	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ff7e817a-b706-4f69-b6cc-19f06a9c75e4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
15056eef-5e25-408d-a0df-ec85bc5dfc30	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	86aaf5d3-990d-4211-b717-60da64f6fca4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
29709453-a203-428b-9f2a-b962f1a0e0df	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6c39d722-fa9e-4fe7-98d1-4cff6a5d4b2b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ba8f03e2-8aa3-4b10-b22a-67a8b375b45e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5a380c5b-1642-4f36-b9ad-8c533b2208fc	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a209149f-3a1d-46c4-a9bb-dad4a0e353f7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ad130cf0-dd4f-4f2c-9a78-8c76bc7a794d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6247cbb3-9be7-4025-bacf-7182f92f82bf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ece32bda-232d-4f38-88da-6224fef8a93a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
41e9effa-a2b3-48e3-be12-9dc62554d284	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	30cdb8dc-6b03-4d0d-a20a-3336c9f0a537	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
000e4e0a-2f58-479e-a1f9-c958d6fa7381	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3218a59e-15fe-491a-ad1f-8f5b77766324	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
83ae0155-a025-44c6-b772-d1e44a13bf4e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bf499975-6f8c-4098-a10b-de971c75af31	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c9eb0edc-758e-43eb-be23-445e19ba95e6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b71efee2-b438-4423-99ab-f84530927a58	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e0ca0085-585f-4571-83f0-65bfaf3ff4cc	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e8eaa061-7cca-4172-b9a1-43fb0951dad1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a90c1884-b118-457c-ae37-7a2274f7f20b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	7e3ad6a3-cff0-4f76-af75-248dc9aa1faa	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a6cc6871-2fd1-4db2-a918-8978bb2c3815	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	41373a30-bdf3-4bc6-b65b-1ebc08500900	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e7a83095-b2a7-47d4-adfc-642e042e42c0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e4b92bea-a98d-4112-b971-5434d3e2c46d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d4746af2-f836-45d4-ba37-a26f77e11365	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	014d2ddd-7bd7-46ab-b299-bd12f574b2e0	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6a13594e-1fcc-4842-b7f3-ad1b792b1cb8	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ece454a6-dfd7-45be-857a-7ee7e21a8985	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
4bb856c3-d895-44d4-bd03-87da9a37d554	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ccd752a3-b8be-4a14-8945-1a67d9d196a2	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
81d8c31e-0cab-4c96-b8ca-548ee9ba4269	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6689f4bd-b72f-4121-9f3f-114353160c14	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0e9120dd-21d2-4627-be2c-f5bb51f25fef	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4de01839-1ba3-49df-908d-440528adee29	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
012f05f8-9596-4277-88e9-660d23238fee	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	93277032-c93f-461a-a51d-e5b78b31548a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
29f5a6e5-40a4-40fe-9ee1-733cc246d970	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	3fa77826-f8ca-4c21-9bf6-b34f43019217	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e6ce6aa4-604a-4bd9-ae47-b7c6097e1563	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	6b65e501-10b2-4acd-a0f0-f92713627a0f	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5b52b1f2-5d49-438f-9ac9-0e248126fc06	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	58246eac-11a3-422e-abb9-a550ef6b5b01	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a0998525-a735-48b5-9e06-e731aa8325a3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	d036913a-b726-43e6-acc0-be191148c57d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
35d4fa29-82f2-461d-8c6a-0224fcf031e2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1914df22-66fe-47e4-8d8f-4109beb88612	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e2f048a9-e82d-4626-98ef-00bf7abfdac0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bdd99634-653b-4c38-8844-c7fa410af743	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b43c7422-d037-40cf-b92a-21e4992afca0	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f12d1632-feb5-45b1-b72d-665cace4816d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
de22ddce-b914-4bf0-bf27-58ac5be001c9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	697b7bf9-8478-4465-b15a-4e7800a95cb3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
869c2634-1911-4315-80e4-52db8606e612	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cfb30a4f-a146-46b8-bb35-6111fa82ef6b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
00e64fef-7896-4936-9c9d-1258438c7454	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	c2b4fa64-c2c1-4672-bfd8-4e7b5d8d43f6	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
624c791b-371f-4aef-9f17-2670855ba1bb	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a228493f-b29b-4acb-aee3-8e53a0b3b25d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
afb33576-5c94-4f47-92ca-a860c34e2c39	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e1162b96-7ad5-40bd-9594-490b56fd4d3c	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bee77e1e-7d23-4ceb-ad3c-48d7da9f4916	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a7c8e6dd-ba40-4c26-a44f-6f5d27b62698	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ebcaf7b6-80ee-4d56-a693-16bd5230d85b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0c7612e3-7c10-4ca1-8a9d-f350ee74117b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d7201dd5-f7c8-43fe-9eee-9e30760e2ef6	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	06ecd909-ab38-4c7f-a0a8-16d6420a3308	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a0750ef1-0ccc-49f6-9bb1-87a6e02b48a7	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	552f0633-1c38-47db-b88b-b426253df114	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
09a829b2-e720-41b8-ae85-9cb6f3a69589	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	fcc9066a-29ee-40e8-a4cc-39e7d0ff5883	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
32c491ca-54f2-4c3b-aa8a-25624a51bab9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	0a633284-cac8-4b8b-93db-6726538764c9	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
aebac315-f2e7-46ec-ba65-4c39cd69d91b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1e0f2164-5a78-4069-a1a5-a4fdaf48dd05	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
54fe8b03-d213-4a45-acc2-f990ed91d405	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	abe1af21-8a38-4881-a466-76cea6c3a3f4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
50dc4b9e-373a-4318-b746-86db781605b9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a887fc48-4cf9-436c-84da-c4778757bf7b	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
bba2a338-246e-404e-b109-eb8e94e663a1	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b975fd8d-8663-47ab-987d-56847a3e797a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
0bf8cfba-481e-46a4-b8ba-21154ba1a30e	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	141ada26-3715-4066-8294-25b29b0dcc96	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
c98d10c9-0684-41bc-893c-b07f293c0e99	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	102dc420-b7fd-4662-bad8-ba7f7cd724e3	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
25acc9b0-6f22-4053-916c-6fb7542acf4b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8adc5622-f3c5-40a5-861d-805e0639cadf	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2e4371b3-587e-48c3-a58e-d659d37e8c14	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4aab688b-d98d-4470-8886-09e2e48d999e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3015b6d3-c788-4eaf-853b-930bb00fc9e2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	dd7c949b-bf77-4f9e-80a2-c454b47d8d62	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5b5be55c-0110-498a-aa10-08c11b03b2d2	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	39028101-e53c-4b15-ba72-26da2dc7e756	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
2a43dad2-83a3-4bfa-9b3a-c79fde096878	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cba9b16e-5cfd-4ee0-a182-f6af4d626517	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
9a2ee5b7-1607-4b54-8408-7f7f47ab5423	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ef143131-ceb0-4822-8f7f-b32e53f8cdb1	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
25134704-69fb-455f-a5d4-7ddcaae16ac9	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	50b7ab86-eb0d-4c7b-875d-6e448d2e0a70	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
22a8d976-2c1d-4aac-aed6-5d847bdb7773	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bfc30775-59cd-4f86-831d-996eb2c5fa5a	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
b2569aca-6fd7-4483-a605-3ebd39f9e7ab	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ba1dd5db-9ee0-4da4-8752-eb43e9c8a295	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
85333307-2f2f-4382-94b8-f55c59eedcd3	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	954a704a-4da5-4dc6-bf41-6daf029a96e4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
69c57ff6-c7bf-451f-ae10-2124dc296801	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	69d168d9-7240-4a60-82a2-92144d2356e8	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
36e5ac6c-e56d-4ced-a6ab-f7e9467eae49	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	526db99b-3ca1-410d-998e-817c9d4625eb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ddc3256b-c87f-4439-9c1f-12e6bad55395	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8cac2333-470a-4711-92f4-7bede9c83f84	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
ffec2f72-aedd-46c6-9a1e-850d27d0a7e4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	4e6d87e7-e15f-4b0c-9c5f-9d13c0c734eb	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
5d30bb1e-f289-4ddd-bdc3-b68618b0ed46	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	92b08548-b122-4559-afc4-910e3450d7ce	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
026d4a32-c1a2-45f6-ba05-f0a70a296178	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	f907e0e8-bb2d-4907-b6a2-a786210b9e87	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1378d226-1075-48b0-bb25-dfb2f380e079	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	833a8dfb-88c7-49d4-8350-5e5921f37953	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
3708579a-24b1-43a3-a68c-555cce07dbd4	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	1e7fc55c-c6bc-41e7-aadc-8d88752f9803	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
d856b7da-1141-4e2f-888c-33a2d4129242	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a34bda89-e2a5-4c20-9188-95ba124d5ace	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
43df99f6-e2e5-42d3-ae17-89945c6acf15	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	bb38aceb-1705-41ce-9c24-80775da5c812	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
e319ac40-090a-4d94-8be2-35190cbc0acf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	cd321fa9-3214-4694-b6f2-db79ec682fd7	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
66bb09ab-6331-4298-8923-ddceaf2f264b	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	ad7384e8-902a-487a-82d3-55b33b122a3e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
94a249de-6756-4f2e-b5ba-e6f97d7f4760	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	b5ed27f5-d452-4b07-84d9-539fe869388e	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
a9b9e123-9aa7-4d24-9516-50cfc43dc192	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	a0454995-d917-4e91-8ec5-e5991daddaa4	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
1767a0d5-cb72-4bf1-8869-65d755567260	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	5227a011-383d-4c9b-a42a-06598a5c8547	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
86658c74-c320-45ff-a0b1-c85235739a40	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	9309fd3c-e584-4a76-a31c-3cd5e8f9b194	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
6688f135-2e7b-4e9c-873d-0ad0e69e5fdf	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	e0e8a240-ea37-4400-90d2-9a59f6c2e68d	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
dc59939b-b7d7-4cb9-a4b2-d899265e4560	e349d8df-2f6c-4a55-b13c-ae85f2b8b310	8fa410bc-c485-4f90-931f-391e0fd81983	2024-05-23 21:17:25.389104+00	2024-05-23 21:17:25.389104+00
53eecbcd-7a08-4dc3-9f96-77099d0ef649	cd112fe5-0c94-42f4-b221-78aa67a88c28	4990a392-3b4c-4892-9e6c-76e6cecc9280	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d98e9988-2e53-4310-83f5-ab4188ed240b	cd112fe5-0c94-42f4-b221-78aa67a88c28	f503feb9-7558-4ff5-bd66-16fad0cd8a5a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
daa04269-fb28-415e-8626-71517c631873	cd112fe5-0c94-42f4-b221-78aa67a88c28	691a50fb-a2af-4bd5-a85f-1ad3ab57af73	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2f4038fb-b205-4fed-b91c-0d0552ba8855	cd112fe5-0c94-42f4-b221-78aa67a88c28	3c64be84-c28a-424c-a87e-e06458e58587	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7216e826-234b-4913-8f86-72f5aa8f681a	cd112fe5-0c94-42f4-b221-78aa67a88c28	7949de13-fe43-4946-bfa4-65b756b42e50	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fcbc02f7-d799-484c-b211-9691bb044758	cd112fe5-0c94-42f4-b221-78aa67a88c28	793158bd-aacb-4a8c-9d27-31879e222317	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
803975c1-9162-4d32-a602-dd4c2f85db84	cd112fe5-0c94-42f4-b221-78aa67a88c28	19251ea9-c41b-4207-88bb-373d1b618a92	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
24c3cd74-eddc-4e21-b205-ffcd33a44d52	cd112fe5-0c94-42f4-b221-78aa67a88c28	3a504cc4-966c-440a-9a63-26ec0e9564f1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
55622416-6f92-447d-8ffc-89c0afa10922	cd112fe5-0c94-42f4-b221-78aa67a88c28	b5a9ac55-68d4-4e2a-8eeb-ddb909d8db78	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7b26f5b1-3cf7-4bc5-988c-7d06d372dd62	cd112fe5-0c94-42f4-b221-78aa67a88c28	6058eb73-6738-467c-8b91-9c84eaa70f2b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9af7bdaf-cc38-4982-94b4-6e95ffd5d727	cd112fe5-0c94-42f4-b221-78aa67a88c28	7b46531a-93f6-491d-8aee-57b3b17204ad	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c1868553-b95f-4e4d-902a-73b1d3567792	cd112fe5-0c94-42f4-b221-78aa67a88c28	9618fc26-e1b3-493b-a61a-232a7ab79955	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9408ef39-7ae1-4ba6-bd49-1c0cb723f2d1	cd112fe5-0c94-42f4-b221-78aa67a88c28	02ec260b-4589-406a-b044-b1983e374c69	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e231cfaf-e6d2-4f7c-a888-b35e370fd327	cd112fe5-0c94-42f4-b221-78aa67a88c28	598bcaca-dbe2-495c-9a83-0a5551d475e1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c71f93b9-2b98-4ad0-a29c-7d7df5a4b880	cd112fe5-0c94-42f4-b221-78aa67a88c28	531a543f-77f0-4b07-9f69-500c04f6da30	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a65d1a43-1a5b-40dc-add8-dbb015ff6ab5	cd112fe5-0c94-42f4-b221-78aa67a88c28	84012120-00e5-42b9-8fc8-12541cda050f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9f6a32bc-c00c-4093-8882-1096e6569359	cd112fe5-0c94-42f4-b221-78aa67a88c28	536a7bad-ec25-4edd-9105-98c3446de139	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d3f83305-8928-4ad4-89cd-110aff621f98	cd112fe5-0c94-42f4-b221-78aa67a88c28	40dc3eae-9e1c-454a-bb51-44f197d5134b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b023add1-d0f7-4b85-9b14-dec909ce60db	cd112fe5-0c94-42f4-b221-78aa67a88c28	2b4f1a89-f719-42ca-a334-5529cf2c7ce6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c3f87fe3-0b75-4e25-a86b-e103971ad403	cd112fe5-0c94-42f4-b221-78aa67a88c28	205a9fe5-b317-4c05-8803-1c7d98cc6728	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9931188e-41b2-4347-a6a5-948619bae90e	cd112fe5-0c94-42f4-b221-78aa67a88c28	10c56e6a-d65e-4219-b25c-fb624f36a9f8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1e22c4d2-af24-4525-a73e-338ba5f79c27	cd112fe5-0c94-42f4-b221-78aa67a88c28	e1f29232-3703-4517-87da-65791a162ce3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
641b880a-920d-44d4-a944-7b045ca0a664	cd112fe5-0c94-42f4-b221-78aa67a88c28	28d9a28e-7ece-4ad3-925e-1b976941fa52	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3464dddb-fd73-4b0e-b66d-7ad5237eeb8a	cd112fe5-0c94-42f4-b221-78aa67a88c28	8a01b626-ae72-465a-8ba1-5acf0209963d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5a92845f-5433-4844-9a89-a450574d22ea	cd112fe5-0c94-42f4-b221-78aa67a88c28	9fd4903a-b359-4b5c-9e5d-d93e2658fc24	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
91b645e5-dfd1-4247-9eb7-048253c623e6	cd112fe5-0c94-42f4-b221-78aa67a88c28	d887e66d-5595-458a-a9f4-bf98386d8f53	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bc04624d-d469-4ebd-b660-0c1b21feb32d	cd112fe5-0c94-42f4-b221-78aa67a88c28	48ba79eb-951a-4707-9e23-490d8b0b418f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a341cc1e-65d1-4194-aba8-0f0498c54fbb	cd112fe5-0c94-42f4-b221-78aa67a88c28	0833fc29-cdeb-4cbc-84a4-0dca5f35edfb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ceee77b7-b05d-4a6f-b194-69b5f1dfab3d	cd112fe5-0c94-42f4-b221-78aa67a88c28	8c2fba7d-1d6f-424f-a644-28d7e38d9f9d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2d66c24e-7cf7-4139-b608-68c7ebf2487e	cd112fe5-0c94-42f4-b221-78aa67a88c28	0eaeeb04-a26a-4b46-8b2a-9070ee200a4f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5a2120d6-0511-4c3f-a18b-85b811a38d39	cd112fe5-0c94-42f4-b221-78aa67a88c28	4365e77c-0942-43a1-8f31-782a88bfa265	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bbe4b24f-e800-4afb-9f18-fe2551230227	cd112fe5-0c94-42f4-b221-78aa67a88c28	729ba811-064c-4357-8225-b3c6f7030db8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9547a8e3-c310-4377-b511-73988bf89b7a	cd112fe5-0c94-42f4-b221-78aa67a88c28	7ec93d74-6bfb-4924-b6a3-ac894e5c05e7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6a74facb-be2d-4eec-816e-4150b640f404	cd112fe5-0c94-42f4-b221-78aa67a88c28	c3f1ab59-6be3-41e2-a68c-6cf4e714bfd5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
73f57d26-14d3-4780-b990-38597944ccc9	cd112fe5-0c94-42f4-b221-78aa67a88c28	16cf6405-f1c7-44eb-94ab-928300c777fb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
dc439d14-4254-4978-887d-b2caec53840b	cd112fe5-0c94-42f4-b221-78aa67a88c28	dddc0c93-7015-4dbe-b810-bc750fdb8081	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e7b2c1da-f755-4401-a59b-9e8a05412f3b	cd112fe5-0c94-42f4-b221-78aa67a88c28	d203898d-4125-4c0b-83a0-67d7b0524773	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
aff1c7c1-d681-4a2d-b0c0-c08b852180bf	cd112fe5-0c94-42f4-b221-78aa67a88c28	12a807dc-7d5c-4e37-98c8-b07a28f98f1f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b3e81c4a-a0bb-4c1e-b121-93c1ac9494dc	cd112fe5-0c94-42f4-b221-78aa67a88c28	50771793-e857-4b72-a9e9-de879aa12ed9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c78bc694-f879-423f-a0b3-a9b09251fc10	cd112fe5-0c94-42f4-b221-78aa67a88c28	f0e37aef-c08c-4f09-8df6-9067a8d97297	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
967a6626-ea2a-4b68-bffe-11661958233e	cd112fe5-0c94-42f4-b221-78aa67a88c28	47cf9f8f-8c8a-4ea2-870a-39f5e7c0ea63	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cd8388f7-c649-4b6d-a0b8-028340c42979	cd112fe5-0c94-42f4-b221-78aa67a88c28	5b444f2d-dbf7-4ffb-a977-815ed4401b60	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
53258543-b0b2-470d-9d7a-709a2c02a60e	cd112fe5-0c94-42f4-b221-78aa67a88c28	c33b9bde-3627-44f0-920f-5f625d66c7a8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
dd56c963-9b03-4505-ad72-5943b28166f4	cd112fe5-0c94-42f4-b221-78aa67a88c28	53a404fc-6ac5-4648-b0b9-eb402c5af60a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a32563fb-af90-4bf4-ab25-68bd80fd4fc4	cd112fe5-0c94-42f4-b221-78aa67a88c28	1391ee7c-4070-4701-a19b-83ac9bc570e3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5cac9edd-c570-4db5-8bf5-9a9c2f172532	cd112fe5-0c94-42f4-b221-78aa67a88c28	56b49b61-640c-4a0c-af50-34c4d57ff002	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0175cbee-0bfe-4f3b-991f-324ac7b7fc9c	cd112fe5-0c94-42f4-b221-78aa67a88c28	c089d975-1478-4949-9a4c-7ea5b89061c3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2e40a86c-4449-4436-867d-b23ff456af51	cd112fe5-0c94-42f4-b221-78aa67a88c28	9fae4973-bf8d-4639-a8d8-42dd1d8a86d6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
27db8c2f-6e74-4589-a84e-804535089824	cd112fe5-0c94-42f4-b221-78aa67a88c28	c4886f97-4057-4283-8941-90955ca6b136	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a390eb1d-58a2-4146-be9d-57b719aadb44	cd112fe5-0c94-42f4-b221-78aa67a88c28	6dc9160e-efc5-476d-b7c8-cf23aa67617b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f82be6a6-f227-45a5-b1ed-ab7db5738700	cd112fe5-0c94-42f4-b221-78aa67a88c28	538e80b2-97b3-49e5-8f4b-c8c6cffae1d1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a1e06581-c3b8-4d9e-81d7-f28c0f362936	cd112fe5-0c94-42f4-b221-78aa67a88c28	f7fbaa70-2085-4992-830f-9e62bcfdcae6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4a4234b5-49f9-45b1-bfc4-0ebbfaf9a359	cd112fe5-0c94-42f4-b221-78aa67a88c28	66d63a0e-4ded-4fe6-8027-df0e5f58883d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d2dd676d-9f38-4070-932d-235e2ae1e111	cd112fe5-0c94-42f4-b221-78aa67a88c28	61d4a736-de0a-46ba-b13e-b1b9bc458354	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
02363a69-480c-475d-a5a2-2745ce09cdec	cd112fe5-0c94-42f4-b221-78aa67a88c28	afc9aa8d-45bd-4f93-a36f-a1cab277977b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0ca85ef6-c4db-4cec-96d3-c2e47a3d9025	cd112fe5-0c94-42f4-b221-78aa67a88c28	8c0befb0-b6df-4e35-89fa-2830f348aac2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fc7b8b31-e879-406c-a52c-650345e26090	cd112fe5-0c94-42f4-b221-78aa67a88c28	6647e799-322d-4d68-9671-9ee75b221763	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
522c03fc-809b-4345-9549-8282d0a1f192	cd112fe5-0c94-42f4-b221-78aa67a88c28	41b2fefe-fb02-465a-88f1-70d3f4f0035c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a9495338-6724-40ed-aa3f-33b59a5d59b4	cd112fe5-0c94-42f4-b221-78aa67a88c28	9f01b9b9-ff84-4dc4-bdca-bffbc706a4e0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
add1554c-b33c-49c4-810a-e9afaa63a173	cd112fe5-0c94-42f4-b221-78aa67a88c28	499e5da1-163e-4a5b-a7d2-4c18ecbd25df	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7d877ffe-7295-41f7-8897-1289a6cf3258	cd112fe5-0c94-42f4-b221-78aa67a88c28	5b13adac-657f-45ac-8a63-738966d2211a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f9f4b880-defc-45fa-9dfb-04ab3f5e18f3	cd112fe5-0c94-42f4-b221-78aa67a88c28	f78ac58f-8207-4be5-ab66-2f6633a85d31	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2a4b9821-77d4-4627-919c-9131f930ee89	cd112fe5-0c94-42f4-b221-78aa67a88c28	9e7558b0-fdf3-4975-8d43-2aeacf9d81c1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8b0122af-3295-4652-9d39-5471721f2f5e	cd112fe5-0c94-42f4-b221-78aa67a88c28	0a132e5e-f8e6-4d23-8003-30c349d2e9bc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
85a5c222-2ad9-4cff-acc7-338a4134b9ba	cd112fe5-0c94-42f4-b221-78aa67a88c28	4c135345-c7fe-45d2-acab-3882fdf834fa	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0569a2bc-40ca-4431-a1f9-c23b39c4a81b	cd112fe5-0c94-42f4-b221-78aa67a88c28	fe5a045d-c3ed-4aa8-a426-e9e6166cfd9e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d23e051e-16dc-47b4-81c9-841c29352064	cd112fe5-0c94-42f4-b221-78aa67a88c28	40104ccc-87fe-4b55-995a-a00743d035cc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
305ea628-3c21-4f32-9a71-17c06e4a4397	cd112fe5-0c94-42f4-b221-78aa67a88c28	059bc02f-d224-44e3-8553-258d81dd7993	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e8161429-1dee-4736-86a6-9d33a835c4c5	cd112fe5-0c94-42f4-b221-78aa67a88c28	2fc748cd-dbbb-488b-8aa0-4f6ddba22f7a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1caf194c-1e2d-4fe6-8120-31b75388e957	cd112fe5-0c94-42f4-b221-78aa67a88c28	742e478d-aaf0-42ba-8fa9-8267808b64c3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
31093118-958c-4825-a4b2-2339de24916b	cd112fe5-0c94-42f4-b221-78aa67a88c28	25315b4a-2e27-43af-9256-47ba33a1178a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
01c45d94-13a4-4cfd-ae90-b8c0249fe44b	cd112fe5-0c94-42f4-b221-78aa67a88c28	81b62720-ffca-43c8-9e58-5c7a53176400	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ea95ed85-0112-46aa-aa5d-c6fa69059a6e	cd112fe5-0c94-42f4-b221-78aa67a88c28	895cc18e-a7f6-4589-ae67-1360384f09b5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d658731d-4ebc-4148-a76a-90b0946b8869	cd112fe5-0c94-42f4-b221-78aa67a88c28	0e4f9b52-d222-4f74-b710-b4a324153034	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0f64934a-dcde-4096-b9d5-ca0372e66551	cd112fe5-0c94-42f4-b221-78aa67a88c28	c9d037ea-a00d-449a-96e5-d89b605ba3e6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4b0e3bc9-86b4-4b82-934b-09f0a999415d	cd112fe5-0c94-42f4-b221-78aa67a88c28	46459ef6-baf6-4729-8232-2a51fc6491a6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f5d022dd-7a0f-4b54-9b61-f9cd781eac5f	cd112fe5-0c94-42f4-b221-78aa67a88c28	cdf9a600-84ef-4ea6-99ed-6acd5df192bb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ca3518fc-a161-4c9c-9d13-a3186593ae84	cd112fe5-0c94-42f4-b221-78aa67a88c28	63b14f7a-e198-4551-925e-1f9c5d07fb16	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c1b123bd-ff11-48a4-9082-4cac41f65cbc	cd112fe5-0c94-42f4-b221-78aa67a88c28	a1f30561-736f-4915-92de-9adbb25f699d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b4dbc9fd-8d4e-4a52-93fe-147b869aa332	cd112fe5-0c94-42f4-b221-78aa67a88c28	a866e0cb-98f3-4d96-985c-0dc4677efedf	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3b3defeb-ed34-43f5-8761-78d8034a4700	cd112fe5-0c94-42f4-b221-78aa67a88c28	61098814-7560-4818-a607-9981f1941e2e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c72bdc21-3618-4c5e-abbf-41d2abfa9097	cd112fe5-0c94-42f4-b221-78aa67a88c28	2a6c8842-25ec-4eb6-a97a-5fdfa19bbcde	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a8319af7-7274-4336-acf4-78d5bd9daa83	cd112fe5-0c94-42f4-b221-78aa67a88c28	8db07b1f-725c-41bf-85f2-1c296043dd9d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e4b73be0-d81d-4cb8-8ad4-fb3b486c1c13	cd112fe5-0c94-42f4-b221-78aa67a88c28	db4436b6-95e1-4705-875e-43be52ed6487	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4354caab-db8f-4f8a-8227-8c13a610bb8e	cd112fe5-0c94-42f4-b221-78aa67a88c28	f6540e59-0d52-4780-a526-60f9841eed98	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ff2b52bd-bc39-473d-8c3f-c0f58ab045c0	cd112fe5-0c94-42f4-b221-78aa67a88c28	57f17ad0-6463-4a12-8b3b-e6cbeb8909bf	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
be0180ed-5abd-4ef2-8006-8388326b60f4	cd112fe5-0c94-42f4-b221-78aa67a88c28	511b07e2-02ca-4bf2-83ea-5811dd5cdf9d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
37c6a924-b1c0-47a5-ad0b-ace4b32fe91e	cd112fe5-0c94-42f4-b221-78aa67a88c28	6974d20f-96de-427a-b03d-9b0d9ac53f02	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6e083ba8-fecc-4d25-8fa8-8d56aedac662	cd112fe5-0c94-42f4-b221-78aa67a88c28	1e6b46de-fef6-4e73-bea8-1131c9da0faf	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
db0828c9-81ba-4678-b3be-592fc0c43d7b	cd112fe5-0c94-42f4-b221-78aa67a88c28	e8ada8df-d99c-42cb-9d07-95078a422753	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0f5441db-fd99-4b64-852b-445f06c371cb	cd112fe5-0c94-42f4-b221-78aa67a88c28	b04c8eef-dd06-491f-a009-d3ad1d932f8c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ff707544-e14f-48e1-a578-239776cdda8d	cd112fe5-0c94-42f4-b221-78aa67a88c28	8283c783-6023-4122-8213-70c33cbf129c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e01419d0-f123-41ef-9781-a68b630381a8	cd112fe5-0c94-42f4-b221-78aa67a88c28	1aaadbd1-4a0b-4dc9-b559-0cf1c764f18e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
495732fe-8e59-411c-9c4d-fa668d4ba36c	cd112fe5-0c94-42f4-b221-78aa67a88c28	6c1a87f2-c162-4064-922f-74c78b11de16	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ae033936-ee82-49ef-b69d-dc90e38c1ec3	cd112fe5-0c94-42f4-b221-78aa67a88c28	4c73a2b0-f6d6-4e40-b20a-3c6ec7225dd1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
89b71696-1861-42bb-97d6-20c7e5725616	cd112fe5-0c94-42f4-b221-78aa67a88c28	3e72bd22-b876-4baf-bfde-85028574fbf6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5ef3ab8c-388f-4c19-9f7d-1b0ec69e3441	cd112fe5-0c94-42f4-b221-78aa67a88c28	fb1e82e3-ae3f-4854-abbf-b279a661cfd8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
23556291-9fac-4300-b05b-8914790b28e6	cd112fe5-0c94-42f4-b221-78aa67a88c28	6fe3e0b2-7449-4185-995c-72b93d510215	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4fcb9f6a-2e53-41c2-a67c-20edba70e072	cd112fe5-0c94-42f4-b221-78aa67a88c28	dd2c65de-a5b2-4b58-aa90-32c12ccf2330	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ae842bbc-3391-4306-b447-a97f9fae1fe9	cd112fe5-0c94-42f4-b221-78aa67a88c28	f1d069d8-8c7f-41e6-8ee9-291314a4b685	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d76b6bf5-4be5-46c5-8554-9e13c3d69a76	cd112fe5-0c94-42f4-b221-78aa67a88c28	8d8efd4c-fa83-43d0-94f1-11e62628c902	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
602838ab-142d-443b-9c7c-db90a11a9043	cd112fe5-0c94-42f4-b221-78aa67a88c28	3797615d-07a8-4908-8cba-7cccab96e045	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
88eb1912-c7e1-48a1-af61-55d97725c277	cd112fe5-0c94-42f4-b221-78aa67a88c28	3fd4eb3b-297a-4f8c-bd5e-b4196dcff5e3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
95484b8e-8f30-4fd5-b0e0-8f12b432232b	cd112fe5-0c94-42f4-b221-78aa67a88c28	2be467bb-d12f-4e98-bd8b-6f4758ced2b0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1d029f67-05ca-4483-9330-56e1ce668c5c	cd112fe5-0c94-42f4-b221-78aa67a88c28	545ed5fa-bcaf-4fee-8808-dcbe9d23b1da	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
696b061a-fff4-498e-9617-0feaa7bceff1	cd112fe5-0c94-42f4-b221-78aa67a88c28	38bade80-dbd6-41f2-b0b0-1974688afd52	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8c9af5bc-d4bb-4072-b3e1-c1b63c6be6d4	cd112fe5-0c94-42f4-b221-78aa67a88c28	c38ab09a-a847-4650-bda4-47d2e50b8056	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
324762f7-9e0a-44f1-94b0-06b3e9a6e10c	cd112fe5-0c94-42f4-b221-78aa67a88c28	1f8dc229-e77a-47e9-aaa8-fc3da2d1f49f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
53f3e96c-1fcb-4776-bd1f-2ac48317205f	cd112fe5-0c94-42f4-b221-78aa67a88c28	781ddc71-2043-4803-ae4b-64a7721540a7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6f3d86df-2142-42b1-a28b-5c67cc563e1f	cd112fe5-0c94-42f4-b221-78aa67a88c28	f209020c-301e-4e87-9540-ed64fc9e8649	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4de2b687-6ec3-41be-8de6-a9f84e5fd088	cd112fe5-0c94-42f4-b221-78aa67a88c28	3521ea4a-ee23-4a5b-88e8-3b3ade993b78	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d99fe1aa-3028-4a95-9984-21a91b8bcbe3	cd112fe5-0c94-42f4-b221-78aa67a88c28	9f46890b-c706-40f9-918c-dd3089fa0e2c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
73cf568c-7b0e-4f9d-b96d-05fdd53c63d6	cd112fe5-0c94-42f4-b221-78aa67a88c28	67b1c83a-f169-43e5-bcc6-368742ea501e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
746f6921-1ab5-4b0a-a713-6834101f4b25	cd112fe5-0c94-42f4-b221-78aa67a88c28	a7d10d60-2391-4b6d-a40e-ecc3d0d3c465	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
49704b2b-7aa7-4d65-80a5-49aa6b1cd2a0	cd112fe5-0c94-42f4-b221-78aa67a88c28	cf72ce66-04be-42dd-ad3f-91540f939fbc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d87c3f90-c4ef-4fd7-9c4e-787626a0e2e0	cd112fe5-0c94-42f4-b221-78aa67a88c28	30356105-2abd-43e1-8238-53d90f9c41ae	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
777cf86e-cf0c-4293-b192-3e9988f70dde	cd112fe5-0c94-42f4-b221-78aa67a88c28	017f6ae5-a216-4127-8e79-dae82f965089	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
25840411-4ef0-49d3-85f4-a60edbe3e62b	cd112fe5-0c94-42f4-b221-78aa67a88c28	bea5204d-3497-482e-8e3b-71493cec4054	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5e074a91-106b-4475-bcce-5493e2912d3c	cd112fe5-0c94-42f4-b221-78aa67a88c28	d4b50761-d7e3-40a3-85de-0cb0d97b4daa	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0cbd9ad8-0cde-4bdd-a0d0-d8ed4a44eb0b	cd112fe5-0c94-42f4-b221-78aa67a88c28	0d1c3c4b-be80-4802-961c-6d5468239bb7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cf12d55e-0b62-4f07-bd37-eb8999909f9b	cd112fe5-0c94-42f4-b221-78aa67a88c28	5c22a73a-e94a-4bcb-8a50-187c981e2336	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
486f513b-3aff-47fb-bcaa-8ade083b7ca0	cd112fe5-0c94-42f4-b221-78aa67a88c28	01314dd5-13d2-44de-b703-8ceacbd79df7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f06e67ea-5dfc-4c95-bc71-dea7ba68bdf8	cd112fe5-0c94-42f4-b221-78aa67a88c28	8a9c7a66-b27b-4619-bf0d-787bcd8ef0fa	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9da3d706-5f99-48fe-a66e-14e4fda4c55d	cd112fe5-0c94-42f4-b221-78aa67a88c28	eed94fb6-6fac-46df-9ef5-70c5f99ed297	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
63f2defc-9315-4af2-8a87-01e26251906a	cd112fe5-0c94-42f4-b221-78aa67a88c28	8e585878-b6f4-4d2c-b2e9-c9e1f7cf50e9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
992ec374-3591-460a-a9f0-0fd92d315f63	cd112fe5-0c94-42f4-b221-78aa67a88c28	179f878d-f262-484b-9e99-2f9b9fd8ac88	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ac83d645-fb84-46cf-a84b-19613a8a7075	cd112fe5-0c94-42f4-b221-78aa67a88c28	e466907c-b69b-4f4a-9b28-644b090e2325	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0f29a017-4512-48dd-a9ee-e5ed487a6a72	cd112fe5-0c94-42f4-b221-78aa67a88c28	179bb60a-ae3b-4e11-ba9d-28f53ed1812f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a9df2219-93cf-4b74-819b-b1b99cc9765a	cd112fe5-0c94-42f4-b221-78aa67a88c28	ac41272c-0a4d-4ba5-b740-2fb9847104fd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cb6d6196-d2cf-418e-9970-7199c2cfe00c	cd112fe5-0c94-42f4-b221-78aa67a88c28	ec452ceb-2f97-4fbf-bacf-d447ed7a4c1f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
566bf3ac-cc1e-4b9c-9931-26a1663f27db	cd112fe5-0c94-42f4-b221-78aa67a88c28	2a623867-95a1-428b-b8a1-40fb7b8273e9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b8e7f4d2-ac8a-4aa3-92ef-dbe7ca1728ca	cd112fe5-0c94-42f4-b221-78aa67a88c28	db798725-9768-4608-9bdd-34cec117e875	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
19596c62-c425-44ba-a979-7e0df04771a6	cd112fe5-0c94-42f4-b221-78aa67a88c28	d655db93-b004-461e-888f-384f31dd7b29	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3a4577d3-208b-4e4a-af31-170c95997e90	cd112fe5-0c94-42f4-b221-78aa67a88c28	81d0d03d-737a-4a93-92c4-b57c4a21f779	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4dee8e4c-c4ba-45c4-b514-2925556a755e	cd112fe5-0c94-42f4-b221-78aa67a88c28	791e44b7-9ee0-46e2-9a18-40e0b42dd23b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a8a5be81-571a-481e-a95d-d6e6f931ddbe	cd112fe5-0c94-42f4-b221-78aa67a88c28	c923c6a6-2cc8-4469-946e-3b6971dbf060	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
dc6f374d-61cd-4406-bcd2-44ede02b981b	cd112fe5-0c94-42f4-b221-78aa67a88c28	2657705a-9ada-490e-b519-528ccf60fb97	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ea171e50-b211-4926-8dcd-e4911381de3a	cd112fe5-0c94-42f4-b221-78aa67a88c28	7467a7ab-8c99-4c65-a227-190291a159b1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9dc1301e-6dea-4ffd-8b52-891da513fc64	cd112fe5-0c94-42f4-b221-78aa67a88c28	e2a2c57e-d46a-4105-9357-f2e75087645f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c4237276-2a82-4f1b-8ae2-1f67128cd29a	cd112fe5-0c94-42f4-b221-78aa67a88c28	f285714b-68b7-4147-9724-86f059dbe6f4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f7ed5c86-1435-46b4-8e88-23f92eaba93d	cd112fe5-0c94-42f4-b221-78aa67a88c28	1a10896b-8cff-410c-b71b-90ab9dcc91ef	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1af87a09-c7fc-47c1-962a-e85105e284b1	cd112fe5-0c94-42f4-b221-78aa67a88c28	55fddcad-8c3a-4d8a-8ecb-d068c244d942	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
771f517a-7e6f-4803-8848-a79cca55c6f8	cd112fe5-0c94-42f4-b221-78aa67a88c28	3ca6aa15-539e-4ba6-aeb6-a0e1a4af12e6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5160b443-8a1c-4e7c-8218-cb4194555e99	cd112fe5-0c94-42f4-b221-78aa67a88c28	f25a391c-375a-4752-9d61-7d278001ed59	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f00a34b8-2bfc-4b47-95b5-e97ac7649e26	cd112fe5-0c94-42f4-b221-78aa67a88c28	11e21752-5717-47b1-8b96-f092dff10b39	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f49bd066-872c-4de0-8a0b-0afd4590b8dd	cd112fe5-0c94-42f4-b221-78aa67a88c28	3ccbd001-7efb-4a38-aa4b-01b130232e69	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
51cbb130-b0d0-4d08-b45e-24e1846372c4	cd112fe5-0c94-42f4-b221-78aa67a88c28	2164853b-b028-460c-8cbb-f38e127d12fa	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
77cb1468-0ab4-4da9-967b-44a3d0b171f2	cd112fe5-0c94-42f4-b221-78aa67a88c28	ee7fc232-90fe-418a-a120-5bdf4277dd6d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
82a57018-e402-44f6-a04c-2d4b8bfe989d	cd112fe5-0c94-42f4-b221-78aa67a88c28	339bf2dd-5330-46cd-a893-6c81233bf761	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7949c752-e7b6-4204-b610-88123c537db2	cd112fe5-0c94-42f4-b221-78aa67a88c28	b9c33ecb-37a2-47ba-8d9c-9e0ae3980f4a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
957379f4-e4cc-4f3b-8b16-c779eb8b5393	cd112fe5-0c94-42f4-b221-78aa67a88c28	820e292a-cb17-4727-aabc-4d9b6f7fa9be	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b70d80aa-4ccb-4ac8-a6e6-89cfae2b7a5a	cd112fe5-0c94-42f4-b221-78aa67a88c28	9f40b8e0-7bf5-4a87-8341-0d4e5f294fa7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bb7927ad-a811-419f-b557-1f3bd97ce420	cd112fe5-0c94-42f4-b221-78aa67a88c28	7a3764ce-ed85-470c-8bb6-b9de2fbdb95f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
22153275-fa9b-4379-a49a-774031e6d153	cd112fe5-0c94-42f4-b221-78aa67a88c28	ca9877ee-7d6f-472b-9e97-ea942f28bdc7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bd226272-cf93-43eb-aec9-433523e8e8bd	cd112fe5-0c94-42f4-b221-78aa67a88c28	c6f235c2-afd2-4d7a-a99e-535a9ebe588c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7400b209-940c-493f-99c6-b80ba397e30d	cd112fe5-0c94-42f4-b221-78aa67a88c28	ada2db34-cea6-471c-93de-f42de5ff3d66	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
add1b334-3967-4e67-ae6c-41d6fe5ce434	cd112fe5-0c94-42f4-b221-78aa67a88c28	a8ed83e9-940d-4cd2-bb60-b43940d20a0c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f5c118f5-3587-4dda-ab79-456da8baf6ed	cd112fe5-0c94-42f4-b221-78aa67a88c28	f67ca84e-9da8-4aa3-a075-5d1119802f9b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
80d6bc45-fd45-4764-b59b-c526983e56f6	cd112fe5-0c94-42f4-b221-78aa67a88c28	0ffa64f2-ab01-40ce-a404-f02d08aacda3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fa0ae345-51c0-47f5-ab8e-81eda96fbc6c	cd112fe5-0c94-42f4-b221-78aa67a88c28	3e3f77b4-4ff2-481d-907d-0e0506f225bf	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
293a971b-207c-4daa-be7b-0645890598bb	cd112fe5-0c94-42f4-b221-78aa67a88c28	ec657423-2bfd-416d-b911-1cd5f5a747da	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8403fb45-20bb-4b39-9719-f59ad71f55ac	cd112fe5-0c94-42f4-b221-78aa67a88c28	95069c11-8df1-4295-a5ff-eca483de3063	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
82fd14be-67eb-4b74-a5b8-578999b08a70	cd112fe5-0c94-42f4-b221-78aa67a88c28	95aaf308-5f38-4161-87db-833a6f2f6ea3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
62b4a432-3d2c-4640-9d96-a95ea831fedf	cd112fe5-0c94-42f4-b221-78aa67a88c28	aeb6148d-78b2-42a4-aab2-8e2413536702	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b0f3e190-3572-4574-86af-b4dc76a5f54e	cd112fe5-0c94-42f4-b221-78aa67a88c28	80d1c48c-b87f-4017-a75b-50b5f363857d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9c3d7124-4738-46ae-a7d0-936b17d112c9	cd112fe5-0c94-42f4-b221-78aa67a88c28	38fa1334-0907-4b38-aaf6-65aa99ef83dc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
221fe2be-2e54-4c58-a32d-36fa8e0c3cc5	cd112fe5-0c94-42f4-b221-78aa67a88c28	152fd163-e248-4062-8a75-6dd5aa945840	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
42018717-fbe1-49d6-b4aa-01a704325ca8	cd112fe5-0c94-42f4-b221-78aa67a88c28	e89d3bec-39a3-486c-bf99-43c4f1846dce	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3b4c6e13-c459-4124-8f83-61fe4cd1528d	cd112fe5-0c94-42f4-b221-78aa67a88c28	89fed694-8cfd-4818-ae01-505934ec2f8c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7b7a01f5-6960-4263-bf3f-4f9e28d0f6e5	cd112fe5-0c94-42f4-b221-78aa67a88c28	8d2b0e69-dfe0-4c1a-bbe2-359d28446b6e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bf505684-9f8d-4e85-806f-2717c7e073ab	cd112fe5-0c94-42f4-b221-78aa67a88c28	53393c97-98e4-40f4-9a54-010fe4295dd0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
142aa05c-d141-4ed9-b057-81ea6781c33a	cd112fe5-0c94-42f4-b221-78aa67a88c28	a9b502fc-20fb-46d3-83da-9df724b3a099	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5d613314-c630-453e-85ba-0b5ee8762cc8	cd112fe5-0c94-42f4-b221-78aa67a88c28	2915914e-f69b-4cfd-ad01-111dfa753770	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b66e05b1-d2df-4fd3-a571-cc2f6b217fad	cd112fe5-0c94-42f4-b221-78aa67a88c28	06a2b0e0-cbb2-49ad-9184-f27371a0171e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c23de15c-bc02-4190-8b67-786856158287	cd112fe5-0c94-42f4-b221-78aa67a88c28	106c01d9-57ca-4434-9986-1ebec31ceff1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
955863b0-2d14-4e4c-b0ee-298660062aa3	cd112fe5-0c94-42f4-b221-78aa67a88c28	d5a41768-aecb-4878-96dc-e54fd9392aba	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
811d359c-56c8-41b6-94d4-2e52e896f4f5	cd112fe5-0c94-42f4-b221-78aa67a88c28	ac3c530c-fac5-4b4b-b3b3-e75fc8a35fa6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2a6308ba-3ea1-470d-9f7f-89371056f4f0	cd112fe5-0c94-42f4-b221-78aa67a88c28	3cf0a06e-ad71-4347-b0a4-6f6aed6baf23	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
549f23a4-98ff-4eac-b04e-f4173c3ec4dd	cd112fe5-0c94-42f4-b221-78aa67a88c28	901264cf-8113-4bf9-8da6-018424e03196	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6cd40a14-0c7b-4a8f-afbb-cdf19b0b2e98	cd112fe5-0c94-42f4-b221-78aa67a88c28	331f2b6f-bfd1-425d-8874-19c3f1eaa5e9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d4d5b23d-9e4e-4325-854a-df5dba8ae041	cd112fe5-0c94-42f4-b221-78aa67a88c28	aa35fda4-f6b3-4212-ae86-2410b168841a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
139a528b-233d-4dc3-ba78-beaf3f4d19e6	cd112fe5-0c94-42f4-b221-78aa67a88c28	5aed1819-fdf8-4a20-8211-2cbcef8cb2ab	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6bec982c-94a6-4859-a194-229a3698cfbd	cd112fe5-0c94-42f4-b221-78aa67a88c28	e4160613-c418-4b30-93c2-3b35964ba568	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2fe1ebd9-16b7-427d-b406-f18281643f43	cd112fe5-0c94-42f4-b221-78aa67a88c28	f087e915-83b1-46d8-9c8f-a1d1b2e57eb1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a0fd006a-ece8-49cd-a4fe-3d658de2c2d8	cd112fe5-0c94-42f4-b221-78aa67a88c28	20e0e3dd-4f94-48f7-83b6-4eb88f9c86b8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8d418c14-f9cc-4d91-a217-187c71b5c4e8	cd112fe5-0c94-42f4-b221-78aa67a88c28	c6021acf-f869-4c5b-89e7-af209997b0e3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
40b272ca-45ad-4f85-a293-5479390f8d30	cd112fe5-0c94-42f4-b221-78aa67a88c28	eaac721f-eeee-4f0c-9976-57cdc5c1da8a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
605d9bfb-993a-485f-885d-cc8e1c106113	cd112fe5-0c94-42f4-b221-78aa67a88c28	cab79f25-9629-477a-81bb-7e00da7a13a4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
49169988-c8be-4489-b1f4-1766d0dbcb79	cd112fe5-0c94-42f4-b221-78aa67a88c28	a12d4e91-d5b7-440f-a3f2-2bfeee78a54d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d5e9f0f5-9922-4672-93d4-894f8e657bc1	cd112fe5-0c94-42f4-b221-78aa67a88c28	f88b35ea-f95e-419c-8173-af39e9fc801c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5e1f1e65-3df6-4f2a-8448-8dd02152fea1	cd112fe5-0c94-42f4-b221-78aa67a88c28	6cb63dfc-41a4-457a-a201-8dde951d3915	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d7e732e4-6bc4-4110-be3a-505303ea3c69	cd112fe5-0c94-42f4-b221-78aa67a88c28	c4919058-d2ea-444c-b75d-3cd53d7ae5ec	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
034f1813-aefc-4e58-a7a5-fc415479287e	cd112fe5-0c94-42f4-b221-78aa67a88c28	612f91ab-09d3-436b-a92f-c5d2ef53267a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1235efb0-213c-4eaa-9540-ac432258f5ea	cd112fe5-0c94-42f4-b221-78aa67a88c28	046d9d4e-5416-4f1f-b548-f9c117fcc2a5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4500cdcd-8e71-42ee-972a-5b7a4006e38a	cd112fe5-0c94-42f4-b221-78aa67a88c28	61c60468-4b7a-4b50-9e9e-f22ef0db9d5b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
24e10f5a-2335-4ecb-aa38-bac7f494bf51	cd112fe5-0c94-42f4-b221-78aa67a88c28	e5817e5b-dd37-4327-8d64-ce51cd97298d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f66626e6-4a2a-40bb-9388-a4030807fd43	cd112fe5-0c94-42f4-b221-78aa67a88c28	a5c5325e-d4d6-4d51-b1ec-ffe8d889410d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
43c24673-db43-46af-a815-d7d9cbd75ef2	cd112fe5-0c94-42f4-b221-78aa67a88c28	ee20fec2-5cec-48f3-9682-7d3a031013a1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
972f89a8-500b-4bce-9a7f-df2aaaaf5ef1	cd112fe5-0c94-42f4-b221-78aa67a88c28	dfbe5ffa-8c3a-4431-8633-16a91c4c8e7a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
abf49c02-b1d2-4084-8b7f-603e1b45b5b4	cd112fe5-0c94-42f4-b221-78aa67a88c28	71440925-2e06-4ca1-b961-10571536c0de	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
607f34af-7ca8-4d87-bb0d-adcbdfc91202	cd112fe5-0c94-42f4-b221-78aa67a88c28	ced86a58-1356-421c-9299-4e9101476764	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ff512af3-caa0-4198-a143-53717c091c5f	cd112fe5-0c94-42f4-b221-78aa67a88c28	312a38b3-b8d2-407d-8194-3ac102a25feb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fd205f9d-4cae-41ed-ac2a-4fbeceff1add	cd112fe5-0c94-42f4-b221-78aa67a88c28	b53f16d5-53c9-48f2-9365-b99075ef9d4a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
001ffffe-1dfb-4422-b4e2-b2c4006abe44	cd112fe5-0c94-42f4-b221-78aa67a88c28	c8a7ace8-a004-4b25-a544-95cdb1f8fa24	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
139c41e4-0b22-40bc-94cc-42632ab50f60	cd112fe5-0c94-42f4-b221-78aa67a88c28	1135a2d2-1263-4fc8-a24e-5ae4a3056341	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5c944ee5-f44a-4308-948a-0db7317e10eb	cd112fe5-0c94-42f4-b221-78aa67a88c28	8761727b-6676-4df3-b494-11578e16a4f5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
86e66a71-019b-4e0f-9ec2-f706c1f25a37	cd112fe5-0c94-42f4-b221-78aa67a88c28	436bd090-b753-4806-bd98-1f8affac5d9c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
efd51ea7-bd70-475c-aca5-a8a68ca8b2dc	cd112fe5-0c94-42f4-b221-78aa67a88c28	03e00c6d-d796-4098-aa58-0be80ac18bf7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b074a47f-e945-461b-805c-40cfdc8fc31f	cd112fe5-0c94-42f4-b221-78aa67a88c28	9d9fd90c-4512-47d7-82bc-d63082d752dd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
60e67814-3096-4bc0-8748-f96431ed7968	cd112fe5-0c94-42f4-b221-78aa67a88c28	46538421-9341-4d9d-bae6-05b9a40d28b4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f1033b94-6f96-4c59-b775-eae05100212b	cd112fe5-0c94-42f4-b221-78aa67a88c28	e8dcb1f1-8d31-4723-9b38-18dc2d6a7ecc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
49f31a88-8aa5-4a86-8116-a896cf43578a	cd112fe5-0c94-42f4-b221-78aa67a88c28	4ee55aa6-4afc-414c-a234-ef10db07284c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ae614499-3216-4f8c-b801-20016b348cea	cd112fe5-0c94-42f4-b221-78aa67a88c28	d018434a-0d3f-4ab6-8284-d62db75dc61f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a846d341-aa5d-46f5-a6b5-3e9295ee5888	cd112fe5-0c94-42f4-b221-78aa67a88c28	4d72a954-8a3a-4ab3-bbde-88f12cb8717d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
732b0cc9-af99-4297-8df9-29a8f07be585	cd112fe5-0c94-42f4-b221-78aa67a88c28	2d1f4466-cdb5-45c3-baa7-214372c06081	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bcfccaef-c3ad-4593-9708-e0f1e6e8df0f	cd112fe5-0c94-42f4-b221-78aa67a88c28	9765fb91-5321-4271-8ad5-312e4f4a5209	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7fe80107-cc72-4c36-8330-6236e2259491	cd112fe5-0c94-42f4-b221-78aa67a88c28	93f07369-806f-48f9-8563-5a9a733789e2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8fb0fd28-9f76-4569-831f-67c31f817a2f	cd112fe5-0c94-42f4-b221-78aa67a88c28	3f3fac3c-5ddc-4858-9049-0bd1d8078c98	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3b400d4c-491d-4f05-bdf3-4fd89b4984df	cd112fe5-0c94-42f4-b221-78aa67a88c28	b6c428a9-1989-4f40-9663-728a19e94c3d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a9cea8a7-8c00-41c2-bce9-eb557f2d7689	cd112fe5-0c94-42f4-b221-78aa67a88c28	c38b3bd2-d37c-404f-a6e5-2c988a872fd8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fd3d5c54-3ad1-4018-8e20-6286c3d66a0a	cd112fe5-0c94-42f4-b221-78aa67a88c28	ee0ba439-f04e-4e69-b66e-081e84b7a563	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
78ebab2a-8107-471c-9ecf-7b0ec2551142	cd112fe5-0c94-42f4-b221-78aa67a88c28	244b6a83-a17e-42b9-bc6f-4a8a8e99f31b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2bc0e10b-5d92-403f-9a72-1082fe8f287f	cd112fe5-0c94-42f4-b221-78aa67a88c28	313d1c60-d5cc-4288-b42f-6aeb1aa0315d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
99b03f4f-cd36-452a-8621-67fa3c95d083	cd112fe5-0c94-42f4-b221-78aa67a88c28	487b6c10-98de-4894-82b0-a0a6dd2a7f8b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6cc17af7-09fa-4368-be9e-f97666d8ecbb	cd112fe5-0c94-42f4-b221-78aa67a88c28	0d203413-b7cb-43bd-b3cf-be3d2267d19d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4f52020d-83ef-4cc5-b5b3-f5424680fb23	cd112fe5-0c94-42f4-b221-78aa67a88c28	33b3289f-2079-4c5a-be64-de420cfc7060	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a702d957-4594-4822-8c2a-28b13a69fa6b	cd112fe5-0c94-42f4-b221-78aa67a88c28	22d62f74-8bf3-4dd9-9202-020bd743bfc0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
18b23ec2-67e2-4139-ac33-650ccf8be03d	cd112fe5-0c94-42f4-b221-78aa67a88c28	9fbb0636-93c2-4163-9a6b-c63ccf54122c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5a5fd7b9-cc3c-49ed-9e18-13b9094bca09	cd112fe5-0c94-42f4-b221-78aa67a88c28	e9dc3d55-7e98-4995-9a71-7075d98e795b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
77da1de0-05e5-4267-b96d-f920e93af545	cd112fe5-0c94-42f4-b221-78aa67a88c28	efd8793b-dfbe-417a-aa2e-716dffc38f8b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ea5087fd-e311-453c-be57-0ea42ab30ac7	cd112fe5-0c94-42f4-b221-78aa67a88c28	61c4342f-1a18-4720-bedb-566268cd56ba	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e6c96db0-b14c-4142-80fb-c59a6e740726	cd112fe5-0c94-42f4-b221-78aa67a88c28	d01d74f7-08ab-4685-9a7d-1509e25ae1b6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d29f2fa4-76ef-4263-8d40-53dd470196a1	cd112fe5-0c94-42f4-b221-78aa67a88c28	a02e39be-fa91-40a2-8450-3779cf175047	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d1a52463-4206-46a3-8c71-c68bfcc06ffc	cd112fe5-0c94-42f4-b221-78aa67a88c28	cf1fcdea-8ca0-4ffe-93bb-aaeebbf8c6a5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c7b26ddd-94f0-44b0-bc66-a67a8548a11f	cd112fe5-0c94-42f4-b221-78aa67a88c28	6925e912-9431-436a-b4a4-17450fab7ec0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fc18746e-ebc3-4a82-8655-51d94843937b	cd112fe5-0c94-42f4-b221-78aa67a88c28	19e11347-c03a-42a8-8713-1d04deccc0c9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7bda6da0-f882-4f5a-9be5-401a66039ac9	cd112fe5-0c94-42f4-b221-78aa67a88c28	bc3bac42-753e-48e5-adc6-f969ac366645	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fad2f77b-4d80-4b49-bb30-def20db7413c	cd112fe5-0c94-42f4-b221-78aa67a88c28	a8efaa16-6511-424c-816c-e171ebfb0aca	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d052516b-3aa1-4d33-8b3e-70f62084eabc	cd112fe5-0c94-42f4-b221-78aa67a88c28	a90c8987-c7b3-4f1c-bede-0cd4af926f11	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9e19aea3-5017-4d60-a0e6-04f8398cab26	cd112fe5-0c94-42f4-b221-78aa67a88c28	f471fd43-e84a-4e68-8e16-cb799b43116d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8ca6de6d-b0ce-4f5e-a681-639d34d1d21a	cd112fe5-0c94-42f4-b221-78aa67a88c28	62c94eec-08fb-4946-8d6e-fc91e9e1e3b3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7f4b0348-1130-4a9a-b503-a6673afd4dc2	cd112fe5-0c94-42f4-b221-78aa67a88c28	63eef403-d624-4098-8339-72d14df4caa3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
51fea8ad-2e31-4631-97fa-ac79ca6d1f52	cd112fe5-0c94-42f4-b221-78aa67a88c28	8431b50d-5783-4016-b519-9ca0e3156205	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d2f6cc24-5206-4f6f-8d40-9e9d7c1de4eb	cd112fe5-0c94-42f4-b221-78aa67a88c28	890dd3d6-3af0-4be4-97ca-eafeb8573c09	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f67592b1-c87b-4178-bd75-dc09fd97e884	cd112fe5-0c94-42f4-b221-78aa67a88c28	448065cd-fe23-4b2e-8e12-fbbd33829233	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1b4ef949-175b-4d23-bb63-577efbe12059	cd112fe5-0c94-42f4-b221-78aa67a88c28	2f83844c-9384-4458-8a87-73cc742c435c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f32cc26a-a5c2-4981-97e6-94aabc54b275	cd112fe5-0c94-42f4-b221-78aa67a88c28	712dc761-2981-408d-b616-36e76f628864	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
eb0032aa-cf45-4da5-9e87-ee9458488ed9	cd112fe5-0c94-42f4-b221-78aa67a88c28	54556387-fd94-43ea-9ef2-7f1c0054b976	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
777939a9-35d9-4e70-9fec-1ef556620f4b	cd112fe5-0c94-42f4-b221-78aa67a88c28	949af886-60f4-4fc2-ae20-8dfee15f4523	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ed0d4532-cc4b-4f04-92af-74e0159bb486	cd112fe5-0c94-42f4-b221-78aa67a88c28	da3e26cd-9d4c-4e75-bf3b-28b8e4f1a2b7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4bb4424e-7911-4ac7-8c6d-fd4ef6bea61d	cd112fe5-0c94-42f4-b221-78aa67a88c28	b0c14d48-72a8-4989-af5b-b8dd8c298e49	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9dacbbb6-a502-470b-bf14-703c5e2599fc	cd112fe5-0c94-42f4-b221-78aa67a88c28	8ae12903-b894-4b8a-9bf6-96a3c0409581	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
11c07f77-3eb3-4312-abea-5fabb8ded9d3	cd112fe5-0c94-42f4-b221-78aa67a88c28	bbff580f-6974-4a42-bc8e-f7053dc0bdb5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6345f704-012c-43ac-b411-b8a49474aee3	cd112fe5-0c94-42f4-b221-78aa67a88c28	91053158-b4f4-456c-9ba0-f5f933222e5a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bb1d1643-7636-41bb-a6a4-b2dc66ea93b3	cd112fe5-0c94-42f4-b221-78aa67a88c28	326cb7bf-998a-4499-8dfa-9ed5af4fe8e2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0391f689-0129-4958-ac3d-71ccdb8b1f9a	cd112fe5-0c94-42f4-b221-78aa67a88c28	5d2d76ae-b03e-46b9-9868-403471183594	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
37051980-8ec1-404e-b472-559a3bf12919	cd112fe5-0c94-42f4-b221-78aa67a88c28	0ad836d4-e9a4-4c1b-ba2d-36a9a7a1f172	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2a5d29f8-8081-467e-9105-7decf3158b13	cd112fe5-0c94-42f4-b221-78aa67a88c28	209fb6f9-e81d-4a9e-a8a2-2d91138ee2e7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7acc988b-c33e-42d2-94ae-569e3300ac30	cd112fe5-0c94-42f4-b221-78aa67a88c28	a53728d0-b13b-42b6-a1cd-9ee0c6813691	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7e736864-b514-4e80-9b54-a77c1667b75a	cd112fe5-0c94-42f4-b221-78aa67a88c28	05bf30c8-b9ba-442e-adc6-e75cd0c13eba	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c34750ad-9796-446b-8a0d-ac181097dd37	cd112fe5-0c94-42f4-b221-78aa67a88c28	d3ab9f6c-2eb7-4dcf-8164-6d697dbe401c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
00917a62-4268-4836-81ca-31671b173dbe	cd112fe5-0c94-42f4-b221-78aa67a88c28	6ed2ca88-75ee-46b2-a6c4-f3c039427c47	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
77991c81-9834-417b-90a1-6684efd91621	cd112fe5-0c94-42f4-b221-78aa67a88c28	5e892c09-3743-4225-9698-99f2edb38147	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7cf8b0a4-63b4-42e0-9009-0583589adeb3	cd112fe5-0c94-42f4-b221-78aa67a88c28	9a7018d0-4760-44e3-a28e-58cc3fa92ee4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6362ec5a-c13b-486d-a3c4-d95e5aa2dfdb	cd112fe5-0c94-42f4-b221-78aa67a88c28	91c38df7-9df0-4e04-bda6-40394116f661	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
eca0d957-10ac-47b3-a38c-bd950bacda05	cd112fe5-0c94-42f4-b221-78aa67a88c28	f35656cb-c73e-423d-b415-151045d39041	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
24af0c6d-03a5-410c-8bb1-0fb396428bf6	cd112fe5-0c94-42f4-b221-78aa67a88c28	fb634a4a-2bd5-49ab-84ce-4c5db408d1ad	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
dbdb3496-ebb8-499e-9820-3e9f3eb83b6b	cd112fe5-0c94-42f4-b221-78aa67a88c28	50cbec59-9a2b-42a9-a453-c1c54d6f4b12	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5975a368-65d6-4e42-8fcf-5d449b77081f	cd112fe5-0c94-42f4-b221-78aa67a88c28	44a7d6a5-b261-4ba6-9346-7b6009bfabf3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f18ee0ff-8011-42a9-ac3d-95cd9eb43967	cd112fe5-0c94-42f4-b221-78aa67a88c28	c3c170ab-99dc-4370-9116-b635db7bac67	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f56d45fb-c0ba-4099-82b8-b6d117b791f2	cd112fe5-0c94-42f4-b221-78aa67a88c28	9af83db6-a91e-423c-b2ef-bf3fba38b6ef	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
41016d9e-490d-4732-9271-ed7d0404bbfb	cd112fe5-0c94-42f4-b221-78aa67a88c28	3e37dc98-958f-4283-906c-fac29b4ce27a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d79fabb5-4ff7-4b4d-a878-1a7cfcad6e3c	cd112fe5-0c94-42f4-b221-78aa67a88c28	c7432204-89f9-4271-90c7-0ae0f2e3f0d0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d7766cc0-76fb-48b4-a387-4c5f19fc94d5	cd112fe5-0c94-42f4-b221-78aa67a88c28	0dc1abc0-9ce7-4c2f-8c97-e03a987e8a21	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8201e0b3-73f3-46ae-9578-506c85be5a16	cd112fe5-0c94-42f4-b221-78aa67a88c28	e456e281-1ee2-45e1-8203-238bee1c3e80	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7186764b-f7fd-43f4-af03-84c1779f2ab9	cd112fe5-0c94-42f4-b221-78aa67a88c28	ae1aaa83-1643-4ba5-b768-eb73d5c1de49	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
efdb453e-0cc2-4821-8c28-9da3d9a10641	cd112fe5-0c94-42f4-b221-78aa67a88c28	2d702569-4e78-4d1a-bbe7-ee6a81b4dbcb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1563fdd6-6405-46c7-9f00-00d19a68be16	cd112fe5-0c94-42f4-b221-78aa67a88c28	da74c625-7125-4e81-9db9-c203e9d6818f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6d64ec52-85a0-4b4b-b018-4c48c87fe961	cd112fe5-0c94-42f4-b221-78aa67a88c28	219fe38d-1f54-455d-be5c-9a91a03b5d66	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0ea05525-8d28-4daa-b69b-d08311c79f11	cd112fe5-0c94-42f4-b221-78aa67a88c28	94fbdc33-6f5c-40bb-ad15-8c82b52a96ab	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
18434dab-bd53-47c5-8628-d64517c682ba	cd112fe5-0c94-42f4-b221-78aa67a88c28	0978d229-956d-4331-b5d2-01e7b8c8c9d8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b29079eb-44fa-4a5a-aa68-2378e00d323f	cd112fe5-0c94-42f4-b221-78aa67a88c28	fd22b8c8-c356-451f-afbb-27c2e3f52240	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e666d189-9cd1-4d9d-9a8e-0140ee32d7c3	cd112fe5-0c94-42f4-b221-78aa67a88c28	001f1f6c-61eb-4319-9ef8-d9ebaf9cb701	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
deb7a02b-ed3c-47ef-8fbc-37350a90188c	cd112fe5-0c94-42f4-b221-78aa67a88c28	94f63765-e9dc-42d9-a46a-0c8756a95984	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f3122d8f-75ff-4fc8-be3d-05d911f91261	cd112fe5-0c94-42f4-b221-78aa67a88c28	c4ce1d94-5574-49d6-8583-4cd754c7d4d6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
53ac662f-43bb-4fee-be9e-1fcdc94bee9f	cd112fe5-0c94-42f4-b221-78aa67a88c28	d6c7ef74-720d-49e8-af44-164271bd6f96	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6825d0bc-9ee5-440c-babb-2769e07dc7fc	cd112fe5-0c94-42f4-b221-78aa67a88c28	cd1607b6-6b70-45eb-ae3b-91eca7e843f0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c8128451-fc9e-4b55-918e-a9a60eea9619	cd112fe5-0c94-42f4-b221-78aa67a88c28	a4b3cbd0-39fe-4b3e-b395-f4bd5f025c94	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e3e8cab9-5e6e-4eb1-b26d-22406442d3a1	cd112fe5-0c94-42f4-b221-78aa67a88c28	eb8da0e6-e6a3-418b-9b6b-2fcd2a09ccea	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
39fd4c0b-b90a-450b-9410-8b8fa797e791	cd112fe5-0c94-42f4-b221-78aa67a88c28	da332d3d-e43f-41bf-bb51-17f7a79a6f1c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4fba3869-183f-476d-94a9-5cd5c4f41bde	cd112fe5-0c94-42f4-b221-78aa67a88c28	bd8487f3-d855-4d04-b38d-de59be5ff422	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d24a63e4-19c8-4c49-8af5-adf5a2ac14fe	cd112fe5-0c94-42f4-b221-78aa67a88c28	8b8e9742-7065-4026-b027-2270f7f73413	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ada7e640-6c55-48ec-9758-bf86382244d5	cd112fe5-0c94-42f4-b221-78aa67a88c28	008bae1b-e8ea-46d2-8b92-4144def10086	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
63a55982-363e-4ce0-9632-3e70a181d307	cd112fe5-0c94-42f4-b221-78aa67a88c28	6cb0d03c-63dc-4161-93ad-096797488c3a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2d2427b2-d680-444e-b721-491761656f46	cd112fe5-0c94-42f4-b221-78aa67a88c28	a960a468-63a8-4fca-80e4-b199017bb514	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cd3c48ab-afd4-49f3-b111-b7b73d71c1bf	cd112fe5-0c94-42f4-b221-78aa67a88c28	159a6e4e-a06c-49fb-bb18-3b221f15c3ba	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
214f8553-ab58-41d6-8470-f64396462250	cd112fe5-0c94-42f4-b221-78aa67a88c28	0cd2664b-2bc4-495f-aaaf-6fd7f4cef2dd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2fc1f6da-a135-4c4e-9801-95a0e01e5a86	cd112fe5-0c94-42f4-b221-78aa67a88c28	8c5b5a59-b6b2-40a5-afae-0609b70c5290	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
05142eba-d42e-436f-af3b-63c6e605065f	cd112fe5-0c94-42f4-b221-78aa67a88c28	9485b506-3ee7-47e4-952f-4d1c017c1147	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
dab83dbd-b257-4db6-bbbe-386d58f768b8	cd112fe5-0c94-42f4-b221-78aa67a88c28	7cea84da-0c8d-4351-bc16-45a7448b237c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7bacf0ed-fa90-4bbb-8be3-2346b26eb827	cd112fe5-0c94-42f4-b221-78aa67a88c28	42dbbeda-ecf8-40c4-8e2a-c4fa100c1964	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c06a691a-74f4-47dc-be58-3b1276a68788	cd112fe5-0c94-42f4-b221-78aa67a88c28	9bdc2221-0b46-421c-9dda-b61693c31ec5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
810ade65-7a91-49e7-ba87-75752ea4e446	cd112fe5-0c94-42f4-b221-78aa67a88c28	72fa3f0b-a4c2-44a4-8c50-08a07afdb951	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f3819883-42c0-45b1-8535-63a101d1aa19	cd112fe5-0c94-42f4-b221-78aa67a88c28	57e3cac5-5f91-4945-a32c-8e1fd68e7018	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
093a6714-6c4f-42dd-a6a8-24513ffa7cd0	cd112fe5-0c94-42f4-b221-78aa67a88c28	664b28a6-6308-4db4-851e-ca19679b174b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
27b13aa2-e0e2-468b-a1c6-27355342ee5a	cd112fe5-0c94-42f4-b221-78aa67a88c28	b3c3e95b-c711-4bfe-8c9a-28b34c89a235	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
409465f9-b08f-4aa8-b44e-9270fcd72041	cd112fe5-0c94-42f4-b221-78aa67a88c28	2a499471-176d-4243-ba71-0bb4816dc54c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3f243d26-9001-4c90-8b03-a5e08bcb0bad	cd112fe5-0c94-42f4-b221-78aa67a88c28	2e5d1445-6ae4-4e72-a21d-508ac3f52e6d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e173875a-e9d6-4374-905d-cde2999a9835	cd112fe5-0c94-42f4-b221-78aa67a88c28	3ceba21f-c32a-4b08-b628-221f62dff14d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fddb6831-6ffe-49df-a06d-f472d522128c	cd112fe5-0c94-42f4-b221-78aa67a88c28	4ad71a0f-ba54-4a3b-a07a-1c4049dd0ab3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
56d2a001-fa07-43ad-a4e0-6864506c3e02	cd112fe5-0c94-42f4-b221-78aa67a88c28	3a9d50fa-0d37-45eb-82cc-f20333d79f8d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c6c41621-e4a2-4467-9292-5da8471cfb4b	cd112fe5-0c94-42f4-b221-78aa67a88c28	7595dd00-7a39-404d-97ad-ccaba60678a7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
055cc117-e4a5-4e6b-9d3b-40fe5a136852	cd112fe5-0c94-42f4-b221-78aa67a88c28	38a8e704-e0e5-4c94-9ee0-677956bf126a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
eeb5aee9-7f95-4d65-833c-da21d8a74d59	cd112fe5-0c94-42f4-b221-78aa67a88c28	c3883637-d0a9-47e0-aeeb-b2312b9214bd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d3ec9578-6d4f-456f-b7d1-a7793143e6cf	cd112fe5-0c94-42f4-b221-78aa67a88c28	d0a65563-5711-494c-b3d7-29d9093b644c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cd9a10c4-3861-463d-81ce-2f1cebb96b81	cd112fe5-0c94-42f4-b221-78aa67a88c28	69d240f6-e46f-47a7-ba08-953beffe59d9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3738667c-c2bb-4285-8422-bc6acea8643c	cd112fe5-0c94-42f4-b221-78aa67a88c28	75c94438-0508-4144-b6a2-f2c808f1dc77	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5b918dc7-af2f-401f-ab64-a6b453e70f83	cd112fe5-0c94-42f4-b221-78aa67a88c28	40f2ef16-f7b3-40d9-8d90-b78ab68d610e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8c3c4037-bdbc-4c7b-a973-1711ad5ebad6	cd112fe5-0c94-42f4-b221-78aa67a88c28	cf31d9ad-fcc8-41f1-bd1e-bd0d292a2e5d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0a829726-2fa7-4ccf-a4ff-dae6518e3743	cd112fe5-0c94-42f4-b221-78aa67a88c28	02dce982-e875-4a12-8729-f3be5de4c3f0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c8fd1b26-0c1d-43d2-8cfd-1761452e9983	cd112fe5-0c94-42f4-b221-78aa67a88c28	37c3d86e-82c1-4c44-a129-6c0d69b478a5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d1ea9b0d-2dc4-49ef-a83c-17727db18654	cd112fe5-0c94-42f4-b221-78aa67a88c28	960109a1-18dc-4dfd-b58c-57a3e4f9a2bc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c7ab9041-26ee-499d-b1ae-991a983ca6b2	cd112fe5-0c94-42f4-b221-78aa67a88c28	bf76e1e5-1299-4692-89ef-7324e7c5397a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ef8ed493-d8d9-4145-8051-39c71b7869fc	cd112fe5-0c94-42f4-b221-78aa67a88c28	4e0ca41d-205e-4cef-afba-d744417d3dc5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
990d9a72-7ef1-4c9d-8866-351cf3b48ab2	cd112fe5-0c94-42f4-b221-78aa67a88c28	1f32f97f-bc51-49c5-8e45-27fa3116248b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fb817c75-0c55-4693-8915-f50aedf9398c	cd112fe5-0c94-42f4-b221-78aa67a88c28	b1c21740-2daa-4728-816e-da885b41c8a6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bc6d4757-ce3e-460e-8578-ef29430065bc	cd112fe5-0c94-42f4-b221-78aa67a88c28	e2f99b3f-753c-4286-87f2-e4b7640537da	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9af6d629-ab51-47a5-9038-62277c2722ec	cd112fe5-0c94-42f4-b221-78aa67a88c28	30a8a1a9-4b95-4e29-bef2-4be4b072108b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
23a2fafc-3075-46fd-8223-807c70ec8923	cd112fe5-0c94-42f4-b221-78aa67a88c28	b704be90-df98-4d90-8e3c-b1bb83e7dfda	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9a055954-b76c-4c5d-9ad7-14250786e619	cd112fe5-0c94-42f4-b221-78aa67a88c28	a71aa043-e695-40b9-b3e4-802815738815	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
269db6b3-a62b-4c63-a131-474ef0b695ff	cd112fe5-0c94-42f4-b221-78aa67a88c28	c41b06cf-c114-4b78-9e0d-007822fed668	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
04dd0c51-0078-485b-8a1c-62c57e0610e8	cd112fe5-0c94-42f4-b221-78aa67a88c28	42cfed9c-0ca7-45a6-b865-fcd50c2b98b1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
dd2656d7-c6ef-4345-abcd-a6a95a9f67c1	cd112fe5-0c94-42f4-b221-78aa67a88c28	47b65c87-8d48-47d8-8f5d-679066b826ef	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
da673e8f-41b8-4237-ab1c-9c35043b30a3	cd112fe5-0c94-42f4-b221-78aa67a88c28	e53d949c-5d2d-424b-b4d3-9663ecb3a63c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ff71eb1b-5224-432f-9914-15a775101825	cd112fe5-0c94-42f4-b221-78aa67a88c28	71c1e0c6-2a75-4f7e-b15a-9f40991965a1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
12f851eb-d961-486d-9103-be1fe73157d9	cd112fe5-0c94-42f4-b221-78aa67a88c28	1e8842ac-3edd-44a9-b7cd-b745f2c73d52	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b8f4e6bf-8be1-41e7-9a42-d376d33cec6d	cd112fe5-0c94-42f4-b221-78aa67a88c28	907cbdb7-8ad8-4a26-9ff6-8cf664762487	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
62bd45df-6016-4eba-9966-18d3cd1fca88	cd112fe5-0c94-42f4-b221-78aa67a88c28	368db12d-3e0d-4d84-bf54-9e9adab15b80	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b57af7ae-b354-46d3-9858-fec2d9d2ec70	cd112fe5-0c94-42f4-b221-78aa67a88c28	d871940c-e5ba-4eb9-bf2e-d640b9227fb2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a72a2bfc-63d9-423d-8e10-3e5cf4b33b7e	cd112fe5-0c94-42f4-b221-78aa67a88c28	afbc8441-e6da-496c-a859-f572c0f24c87	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
47c4818c-f73e-425f-8aab-61101519780a	cd112fe5-0c94-42f4-b221-78aa67a88c28	3a57da7c-3899-4cf6-a5ca-ec5d5fe6266d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9383c03d-0544-4c15-a8c8-a162643e9b31	cd112fe5-0c94-42f4-b221-78aa67a88c28	7e687aff-c2f7-487f-84dc-e35e89c77b3f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
881d814b-4607-4457-b85f-84598d9f73a8	cd112fe5-0c94-42f4-b221-78aa67a88c28	598b197c-c3d4-4f5c-a80f-99aee838476b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e86639f3-9dd7-4db2-a39c-ea47cd6b2eb2	cd112fe5-0c94-42f4-b221-78aa67a88c28	0e3755b8-0455-4602-a94a-68baa6f15f36	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8b4c3272-9009-423e-8f45-ac435fff4584	cd112fe5-0c94-42f4-b221-78aa67a88c28	a68076d9-b0f9-413f-82c8-e8d38e300beb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
62083970-4276-4c13-b720-da36492cfa70	cd112fe5-0c94-42f4-b221-78aa67a88c28	f79acf6e-685f-4e61-9752-b66fc79264bf	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b00f8e9e-84a9-4070-bac5-b3b4464c84f5	cd112fe5-0c94-42f4-b221-78aa67a88c28	d1787421-8fab-475b-a59b-afbe7c83cf17	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a91ba8a3-f06a-49e5-9a04-4ae48e53f1b3	cd112fe5-0c94-42f4-b221-78aa67a88c28	e0b53d97-a919-4be1-90c0-fd9e904c426f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5ef82e58-0108-49d0-99c4-f664e0624ec0	cd112fe5-0c94-42f4-b221-78aa67a88c28	6b2f2b9f-0085-4606-a483-c1b824cdcf65	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
84a51506-75ef-4086-9bbb-862d9a402652	cd112fe5-0c94-42f4-b221-78aa67a88c28	065fa74f-cf8f-4741-9135-1b11f08adb76	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
08c863f6-af3f-4bf7-baca-4d36f7f5a2ea	cd112fe5-0c94-42f4-b221-78aa67a88c28	80844d0d-83f5-4cea-8291-01a7be3e7642	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
94f45a53-213f-4633-8124-f17a36c19dab	cd112fe5-0c94-42f4-b221-78aa67a88c28	a3c7e0f9-f240-4c26-b733-dfbdefee93cd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d04e4ce1-318d-4797-8665-edfafcce61a0	cd112fe5-0c94-42f4-b221-78aa67a88c28	6a0f53d4-dd83-4f1d-94af-b4057980b1c1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
12297d39-97cf-4c01-a1ff-651af1b6f222	cd112fe5-0c94-42f4-b221-78aa67a88c28	7b6b0af0-3152-4195-b0e8-9c4b0c9aab1c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b2b1b6dd-8703-4270-a8ec-ae47a7111f4e	cd112fe5-0c94-42f4-b221-78aa67a88c28	66b52fb0-d809-4f6f-88a4-655cb4108adb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d329307c-8d9b-4da0-97fa-928b224b3f49	cd112fe5-0c94-42f4-b221-78aa67a88c28	0f816d16-a338-4dc2-8471-5384150a0b3e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
70e4e909-42b6-4ae3-8ec0-66f2cc5eb948	cd112fe5-0c94-42f4-b221-78aa67a88c28	20186d21-beb4-4d82-acd5-b16b9568dbdb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b195d513-90b8-48e5-8a5a-a300fd3e1143	cd112fe5-0c94-42f4-b221-78aa67a88c28	84024871-ec04-4469-bd0d-b8afac1912b0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
44474fd5-c405-4206-8392-4db06bd0aab4	cd112fe5-0c94-42f4-b221-78aa67a88c28	670993b0-cbb0-4293-9c29-1ab1a9466ed3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e30dac49-4f2a-41ac-9809-48e142ebd4bf	cd112fe5-0c94-42f4-b221-78aa67a88c28	0873fe58-1bff-436e-89d4-6353b5467a70	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f23036ac-4026-41d6-9842-327c45ed0904	cd112fe5-0c94-42f4-b221-78aa67a88c28	c8b8dc3d-1b43-482c-91fc-5b7970343b97	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3109610c-642f-4231-9d8d-e9660c5829bd	cd112fe5-0c94-42f4-b221-78aa67a88c28	89f3927d-ab29-4a1f-bb5f-11895f94abb1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0e16f7c2-a2e9-4aee-9c6c-d1837f2cdfa8	cd112fe5-0c94-42f4-b221-78aa67a88c28	5498c9ce-31f9-43ad-9d8d-6a2c2fed6bfa	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ee094489-2200-4edb-bf7c-dc65901f9ed5	cd112fe5-0c94-42f4-b221-78aa67a88c28	2608e064-867a-4fd3-9923-028b4bbeca52	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e5ae89f1-3a52-4ba2-8eff-3d1a2288c28a	cd112fe5-0c94-42f4-b221-78aa67a88c28	57a944d8-51c9-4246-80a4-51348abb4a40	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
326e5d45-3cac-43f4-9b48-b1f300fc4e43	cd112fe5-0c94-42f4-b221-78aa67a88c28	e4bb949c-487c-4198-a3c2-3a1cb3200e0e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1e562a54-6806-436c-b6e0-5906940c88a1	cd112fe5-0c94-42f4-b221-78aa67a88c28	848b05f2-a664-477c-abcd-dfcf4cef355a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8e46a236-753b-4414-8e35-31b8ae9c9cd1	cd112fe5-0c94-42f4-b221-78aa67a88c28	a430761f-d4c1-40ba-a0a9-cb6b8ac68eec	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e3ba7541-c695-4a4a-9b93-5ee94735140d	cd112fe5-0c94-42f4-b221-78aa67a88c28	45e07a88-cfc0-48f6-b9d2-cab1b7f0b381	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4abe8a0a-210f-432a-93a9-b045bb0c03a7	cd112fe5-0c94-42f4-b221-78aa67a88c28	29031217-35da-4283-9304-306dba5aa4a8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9239a0cc-3c47-4a79-b387-201a6a4a4909	cd112fe5-0c94-42f4-b221-78aa67a88c28	b630df0f-3f70-4473-a18f-da0a038feef0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
38abf2fe-c9c2-42fc-be57-483b8fe83ad6	cd112fe5-0c94-42f4-b221-78aa67a88c28	416968a6-8555-4898-9e27-749ad4590b14	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
18d23f8c-a4f9-44d3-95f0-64bc99f1ad51	cd112fe5-0c94-42f4-b221-78aa67a88c28	8a6f4a10-f491-46e3-a644-e9de1bc10f0d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
44bd6c2b-b98c-46c3-ba0c-47890ea9637c	cd112fe5-0c94-42f4-b221-78aa67a88c28	9c4e0713-911b-47a2-9455-f5fa809727e4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4c960b8c-cc2f-4c9b-b33a-cf14983bd649	cd112fe5-0c94-42f4-b221-78aa67a88c28	7ea80c70-a01f-432f-a97a-e3d27a45f040	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
627b22b9-0f7a-47db-a63e-36ce2ce991d1	cd112fe5-0c94-42f4-b221-78aa67a88c28	a949e31c-1a90-4e4d-b64f-abb8961b7503	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d53aa3d7-8b45-49f3-9575-103368e35524	cd112fe5-0c94-42f4-b221-78aa67a88c28	a31e98a4-fbc8-47a8-9eb0-ab0cea691825	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e77ba73c-0f64-4d85-8c85-8e2e61072c32	cd112fe5-0c94-42f4-b221-78aa67a88c28	fd3362a3-cb2c-41c6-936c-070fd526e4db	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8a332b26-2f36-40e6-b3c6-57f4b5b11067	cd112fe5-0c94-42f4-b221-78aa67a88c28	4e47687e-dd88-47ba-b779-8a31560bad7b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c392fdb3-2111-46b3-9f1e-5220445f3fb2	cd112fe5-0c94-42f4-b221-78aa67a88c28	f57535ff-a57d-40a4-a42e-bbf1c9bbb8ff	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c8500691-8157-412d-8441-cfbbf7ac0a95	cd112fe5-0c94-42f4-b221-78aa67a88c28	f70bbfb9-2af8-4cfa-90eb-b94c4d5e186d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
62fb943f-ac0f-486a-a5a0-04fdbf8d9f3d	cd112fe5-0c94-42f4-b221-78aa67a88c28	7c170301-7eef-4433-942e-27307dfe0cd6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
eaed1a7f-811a-41f7-9c5f-7f509704273a	cd112fe5-0c94-42f4-b221-78aa67a88c28	cf05fd28-ee79-48e2-9966-0a40a1ac8c2f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
16252ad9-3f56-4aac-87e5-c9af394dbc47	cd112fe5-0c94-42f4-b221-78aa67a88c28	2cef2d1d-f12d-41e4-ad62-311bc103e8e0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ee98cdf6-73e0-4e28-81c2-bcd966baef64	cd112fe5-0c94-42f4-b221-78aa67a88c28	f530fa98-9cc0-4d57-b029-26b1342271e2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
36208095-d0f0-412e-bcbd-3a3bb1858b38	cd112fe5-0c94-42f4-b221-78aa67a88c28	d8d868e3-bced-4696-be25-b786faf42f4b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4ae2b9f7-07bb-4033-837e-af9952cd275f	cd112fe5-0c94-42f4-b221-78aa67a88c28	6e870847-537d-436b-9de1-ad964e35496c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
62c47121-498c-4ccb-bd44-2360ee9969cf	cd112fe5-0c94-42f4-b221-78aa67a88c28	d2dac919-c4e6-4b1c-a514-ef498cb5f8ff	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9371b4f1-0e6e-4c26-85d1-a8786ab9e8a2	cd112fe5-0c94-42f4-b221-78aa67a88c28	eb1da70f-7417-42ec-b300-ab7f113ab4fc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f9f0e4bc-e889-403d-bcda-74c84224df17	cd112fe5-0c94-42f4-b221-78aa67a88c28	25a09bbe-e244-4f48-8ad0-4ab93c8e60c3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
347414aa-8393-4dad-99a2-57f22e25ceca	cd112fe5-0c94-42f4-b221-78aa67a88c28	04464365-8e0d-4032-a713-2b7f6f995e4d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
999bd684-4b01-4552-9b09-3dc40cb89552	cd112fe5-0c94-42f4-b221-78aa67a88c28	436cf968-febd-47f4-ad16-8d15a38c0b19	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a598ba80-fc79-4a52-8b18-5b1be9364190	cd112fe5-0c94-42f4-b221-78aa67a88c28	a6fab1a6-6167-45c0-b133-a6a13058009f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
80f8748b-b5a4-421e-86c8-80445016e69b	cd112fe5-0c94-42f4-b221-78aa67a88c28	c9b99c92-6f3c-48a3-b461-e53a77e5089e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7ad6f896-d7d5-4763-8d78-ec5cbaab8dac	cd112fe5-0c94-42f4-b221-78aa67a88c28	c4fe7b95-219a-4f3f-b292-9ef2bd9d0be9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ce835d09-9dd5-44a3-bab5-be7cc3b77792	cd112fe5-0c94-42f4-b221-78aa67a88c28	23aedea7-888b-4842-ac00-ea22ad8cdfc0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f1cb4cde-4d5a-4037-87a3-4392dcbccff1	cd112fe5-0c94-42f4-b221-78aa67a88c28	0a78b3c5-32c7-4e39-a7f7-3b7539fd1ac7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e8778ef1-c5db-4898-bd98-e48506d5f834	cd112fe5-0c94-42f4-b221-78aa67a88c28	593b2dc0-fc81-4c4e-99f0-f205a64645c1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7220635c-46db-464d-a5be-943c279d12e0	cd112fe5-0c94-42f4-b221-78aa67a88c28	208afe7d-23fc-4041-a42f-27addd6468f2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
17c90415-3b73-4f95-ab4e-2bdbfe34f6b6	cd112fe5-0c94-42f4-b221-78aa67a88c28	06506681-6c43-44f3-8e1d-c405813477bf	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
57b8b8e1-7c63-40e6-a8fd-3e2408645261	cd112fe5-0c94-42f4-b221-78aa67a88c28	2158eccb-597a-4ae1-bd15-1574170db46e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bf718a8e-33ca-4b39-a280-8611a832b75e	cd112fe5-0c94-42f4-b221-78aa67a88c28	4893928f-8614-4820-a175-456cc65a0775	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e058d48a-61db-4592-8948-3a4c4d2c459d	cd112fe5-0c94-42f4-b221-78aa67a88c28	a0f5e4c7-bdd9-4be1-abe5-167048539bef	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c215c0b3-628e-4637-b157-4795bac994ae	cd112fe5-0c94-42f4-b221-78aa67a88c28	9d97449f-6cda-4f37-87a7-18c376816bad	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8402b4f5-89fb-4a77-9391-39a080c6bfd5	cd112fe5-0c94-42f4-b221-78aa67a88c28	73e5fa1e-681e-4166-b550-9b208c24e3c0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a9939675-e0f9-4e08-8690-785aaaa68450	cd112fe5-0c94-42f4-b221-78aa67a88c28	1ab89282-75d4-459c-8eea-032407a2742f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d0d00c0e-a0b3-4a06-be43-dfeafc850f29	cd112fe5-0c94-42f4-b221-78aa67a88c28	b9f56f93-10e1-40f6-ae9e-6667d6c33f86	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b4277931-107d-4197-9824-76d3669eeec4	cd112fe5-0c94-42f4-b221-78aa67a88c28	f0c83e41-ae55-45ec-91cc-ff243bb9fc49	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c3222a25-57ce-4660-837e-f7cf5f6d73e6	cd112fe5-0c94-42f4-b221-78aa67a88c28	ee52d85b-5bfb-4ca4-8979-5acb5fd6aaab	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1971e0d1-3719-4f72-82e5-ccbd4bb3cd9e	cd112fe5-0c94-42f4-b221-78aa67a88c28	b12f0012-a731-47aa-a3a9-54d460c2b37e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
47ed5752-c426-4576-821c-db7a1dbd5232	cd112fe5-0c94-42f4-b221-78aa67a88c28	6a026526-9603-4b87-8f16-701883f5a339	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c8903a45-9bb9-4ca0-bae1-c7beebfad0f6	cd112fe5-0c94-42f4-b221-78aa67a88c28	28fd5f1a-fe9c-496d-8dd4-a1b10cd4e9ca	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
41d136b2-f848-4d4c-bd71-b17d699c175a	cd112fe5-0c94-42f4-b221-78aa67a88c28	1add5f41-2f7e-4730-a4b4-d327f2903039	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
496ca30d-79b4-45bb-88df-0b84073c1449	cd112fe5-0c94-42f4-b221-78aa67a88c28	81d42f9d-b621-4589-bf2d-1e15e1823e31	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cc083d92-9141-4410-b09e-84b439f88328	cd112fe5-0c94-42f4-b221-78aa67a88c28	34baeb95-7a29-428a-8ec7-0c147b929dae	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
eadb9f7a-1b3d-4423-bad1-cbf2dcbfddee	cd112fe5-0c94-42f4-b221-78aa67a88c28	b74a236e-a9ca-434d-a608-1f7f10b995e7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4c6c68d8-7a75-4f05-8b8d-17058dc1dbdc	cd112fe5-0c94-42f4-b221-78aa67a88c28	943f33e0-a76d-4f3c-806e-207882e10c4a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8d7112f0-156c-4efb-a00f-aa7882b1d474	cd112fe5-0c94-42f4-b221-78aa67a88c28	97ff38cf-d4ab-4c53-a0bd-4032d39f19c8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0f84d22a-4c91-4d26-b9dc-9b8d47980637	cd112fe5-0c94-42f4-b221-78aa67a88c28	9d2f270e-3ae6-41bc-8429-ae6a0e6165f8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d8f33b1b-25be-4940-a5c6-7bd518bd8928	cd112fe5-0c94-42f4-b221-78aa67a88c28	242ce7e9-218c-43fe-9fe7-8ed55161f181	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7bf2a1ed-eb4f-4fe6-8ce6-ca1fbc80c793	cd112fe5-0c94-42f4-b221-78aa67a88c28	d6580c21-3f56-4ce3-91a4-df9fdc3258ce	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5518cb5c-212c-4a3b-a174-8983e921ef46	cd112fe5-0c94-42f4-b221-78aa67a88c28	2540be8f-2a5d-4121-9514-7d547be6eef0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d50e6e6a-61c2-4134-ba93-48a2b957f9e6	cd112fe5-0c94-42f4-b221-78aa67a88c28	517f2e8e-edc9-463d-baa3-bc3064f67e11	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6d4475dd-5139-438f-b2fc-680305772d87	cd112fe5-0c94-42f4-b221-78aa67a88c28	24b93eee-c881-43d9-90b8-4f98fcf733fd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
710f28cd-362c-4208-bd82-6d75057c8e20	cd112fe5-0c94-42f4-b221-78aa67a88c28	a9287274-3195-4c95-bf47-a04481ddf04e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cd20e47f-41af-4240-845b-cb070d5885be	cd112fe5-0c94-42f4-b221-78aa67a88c28	5f44ae08-08c7-4d94-997e-b20c26a3d3d2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b046e71b-2ab7-4f30-9bc6-dfa1d9d11458	cd112fe5-0c94-42f4-b221-78aa67a88c28	068f197e-5bd0-49dd-9599-af0f7061a844	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
dde13aaa-eed0-4087-9a19-fc9f934c7775	cd112fe5-0c94-42f4-b221-78aa67a88c28	06a0b35f-3146-4b72-b224-df6264161bfd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
14a6e739-6e10-4623-9f51-027c13c2dbc5	cd112fe5-0c94-42f4-b221-78aa67a88c28	8410c20f-f925-416c-925c-ce2365b9ffb2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
78bfcb18-5ed8-457f-9fc7-3659b339a76d	cd112fe5-0c94-42f4-b221-78aa67a88c28	99c4170d-f79b-4b8d-8217-c744dc2a060f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e3e65d66-98d1-4e62-a86f-83fffba0ec87	cd112fe5-0c94-42f4-b221-78aa67a88c28	46c22828-0861-4e49-91e4-91bfea02a02f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ac785a58-bfd2-4e7e-8545-3c1447a32f09	cd112fe5-0c94-42f4-b221-78aa67a88c28	89453004-e027-4e98-8ff5-64f3fbdf698b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b8522157-a0cd-444c-ac75-45530007fae8	cd112fe5-0c94-42f4-b221-78aa67a88c28	b36eb4eb-bf6e-49e6-aedf-48ae1cb8d005	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4163ce69-7adb-4e7e-8f4a-c446a31a4bb4	cd112fe5-0c94-42f4-b221-78aa67a88c28	82aad02b-aa9c-4c64-88d7-b98df17dbb2c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6520a339-fdb7-4e9a-baf7-e03bc9d068e2	cd112fe5-0c94-42f4-b221-78aa67a88c28	3a5b507a-96d7-49eb-85ae-fcba48c2dc7c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a419c56d-4dae-46c9-97db-e845ed95c58b	cd112fe5-0c94-42f4-b221-78aa67a88c28	ed6ed4cd-c259-4f7c-a04f-44bd558104fe	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bfc9320b-38c6-488e-85a0-b743c3da70e1	cd112fe5-0c94-42f4-b221-78aa67a88c28	b52be0ae-2e8a-442e-abba-001c4757ff4c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
69756475-3117-45e5-99a6-32dd6285563a	cd112fe5-0c94-42f4-b221-78aa67a88c28	02292b54-6e0c-49a9-abd6-137d37d05fb9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1c2fa475-685d-4685-8573-84032a4275ab	cd112fe5-0c94-42f4-b221-78aa67a88c28	1af26070-fbe3-4ca4-a831-8f3a71f8ddf7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d3573efd-ff8b-4902-a871-725365ce8751	cd112fe5-0c94-42f4-b221-78aa67a88c28	b13c50e8-fac8-4820-ad35-6f9c21a76fe2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6ceeada5-2fdf-4483-93e3-598fbb2cce28	cd112fe5-0c94-42f4-b221-78aa67a88c28	ba18a28e-ec17-477f-b172-69d82698b00d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
68728acf-d4ed-4520-a880-0ed321360da2	cd112fe5-0c94-42f4-b221-78aa67a88c28	83f3ffbb-4c99-4725-a5e0-e85f8d9ff1eb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
45875855-19fd-4b77-8d28-bcee2464fd66	cd112fe5-0c94-42f4-b221-78aa67a88c28	35e4296d-3256-4876-8f03-5c7d8cee2479	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
15b88fa4-dd8a-4da3-83b5-ce8da5a58a01	cd112fe5-0c94-42f4-b221-78aa67a88c28	3b4c4e31-331e-4679-83c4-28bdf09b0496	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0228f137-4101-4227-9e54-fc6f8505009b	cd112fe5-0c94-42f4-b221-78aa67a88c28	15aab06f-f875-4279-afc8-aeb3f9b460d0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d76878b3-6d6a-484f-8f67-2b227a009a8b	cd112fe5-0c94-42f4-b221-78aa67a88c28	c05f727f-3ff4-48df-9e0f-d8467541c7ce	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6044e022-3fda-4377-8766-36f9aa210360	cd112fe5-0c94-42f4-b221-78aa67a88c28	406528a5-ea1f-4a4d-bdb2-e86febe02208	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4cf4f510-1b0f-44dc-b1f6-bec548664e9b	cd112fe5-0c94-42f4-b221-78aa67a88c28	2f645122-e172-4e06-ba4c-edc192dacc7a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6f4b9a26-b3ab-4e59-82b0-312b4387476e	cd112fe5-0c94-42f4-b221-78aa67a88c28	59d737da-ddc3-432a-a9f7-7bae7c80f110	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7dd3a0f7-3f87-4996-8aef-4424dd8445fa	cd112fe5-0c94-42f4-b221-78aa67a88c28	c7789c03-1712-4859-9961-9644654a60a9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
789faf88-ffea-44d1-8e12-0b17d8782422	cd112fe5-0c94-42f4-b221-78aa67a88c28	69fe0f7e-4d2c-460c-9a63-bd1c895e83b1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
baf68be6-1dfb-412a-96ea-6be870bdac8a	cd112fe5-0c94-42f4-b221-78aa67a88c28	448ccc1e-7cc0-43f7-9514-ce384c26dcbb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
88993f2d-d629-402e-b38e-cb66ddb0a3ba	cd112fe5-0c94-42f4-b221-78aa67a88c28	72343ed1-d562-42be-92b1-8e6fe9bccba6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
98ca7fda-73a1-43e9-b714-b6aa87304737	cd112fe5-0c94-42f4-b221-78aa67a88c28	daa6f6ae-7c26-4dce-bafd-59eb0c2a9292	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
241e790f-0ae1-4ddb-aefb-c12fd26c1b46	cd112fe5-0c94-42f4-b221-78aa67a88c28	a78a9d1b-f8a1-4084-a933-a7f3b0f9b35a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cce68cdb-6d5f-4348-8251-a89578b1631c	cd112fe5-0c94-42f4-b221-78aa67a88c28	f1cc4ee1-b19c-4a8c-bf7e-290fba38d659	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d1ec7a81-ac01-486d-b2bd-ece5aca58d9e	cd112fe5-0c94-42f4-b221-78aa67a88c28	a38152f0-3250-42db-a86f-535983de5b41	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9d14dbde-7410-4d77-9164-b5dac5ad986c	cd112fe5-0c94-42f4-b221-78aa67a88c28	4cc1d2da-0011-4393-bc32-4925c66b5dd0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e6e7cda6-f6f0-4b4d-a680-d02e6f374cd2	cd112fe5-0c94-42f4-b221-78aa67a88c28	3c2f8219-1cbe-4623-aef3-1ab472c7f5ee	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a356bfe5-db84-4210-bd5a-2241a7d0d99b	cd112fe5-0c94-42f4-b221-78aa67a88c28	d5f83d64-38fc-4463-88e2-9dae7aa83e9d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f26ac4c8-1d7e-4f91-97ff-4a768552d5a6	cd112fe5-0c94-42f4-b221-78aa67a88c28	b56f2302-aa58-4b21-874d-718c318d0285	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c86ffb5e-d8b7-4fdd-ae1a-64315c5130c6	cd112fe5-0c94-42f4-b221-78aa67a88c28	b0c1b34a-150a-4e8c-aa52-693c63fcd50e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
872ce90a-d2da-4d55-85a6-169be101745e	cd112fe5-0c94-42f4-b221-78aa67a88c28	c1911d14-a326-4e6c-841f-095f713230a9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5f199bcb-305d-4471-8045-302a4b63ca22	cd112fe5-0c94-42f4-b221-78aa67a88c28	26833a3d-b940-4730-bdb6-771b8de5d6bb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c723f7ec-398a-4feb-b42d-8eb580009887	cd112fe5-0c94-42f4-b221-78aa67a88c28	a28ac42f-6e91-48db-8de2-cb446b788506	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ff71f502-f103-4589-879f-02e59a1dff8e	cd112fe5-0c94-42f4-b221-78aa67a88c28	aacd58b9-7cd5-415d-a590-95539fa55722	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c2eeb072-0aa3-4aa3-8b07-e63541eef0cf	cd112fe5-0c94-42f4-b221-78aa67a88c28	0db7301e-cabc-4125-9753-d1baa2c44135	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c6e75807-4bc3-4370-a72a-e70b2982559c	cd112fe5-0c94-42f4-b221-78aa67a88c28	38473a9a-ba04-4113-8ecd-fd86d62c9861	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0ca30e95-37a0-437c-923b-3994c4fa3435	cd112fe5-0c94-42f4-b221-78aa67a88c28	49d74075-b2ad-4def-90eb-2a7ae764230d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f6032483-d092-49f4-98ab-ac236275d2df	cd112fe5-0c94-42f4-b221-78aa67a88c28	902fd70b-064b-43bf-a2bc-fdacb7b3be69	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bebc9f2d-d165-4007-bf1b-0bec75dad470	cd112fe5-0c94-42f4-b221-78aa67a88c28	b232af8b-30f0-46dc-b691-e6e75fa357e7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5eb744e8-6732-43b3-b732-1d61dfa941e2	cd112fe5-0c94-42f4-b221-78aa67a88c28	d73d50b0-1c32-4220-933f-0a71afcaa9d3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
65d77119-dc3f-41bb-8c54-73182784cd38	cd112fe5-0c94-42f4-b221-78aa67a88c28	92099359-d41b-417b-acca-3aa178b313d7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
101e35be-3761-4173-a07d-75edc0ab9ec4	cd112fe5-0c94-42f4-b221-78aa67a88c28	f52a7ac4-59f4-4a23-9fbd-544cd7a62687	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3668569d-453d-441c-bbc9-d3cfbbe1c919	cd112fe5-0c94-42f4-b221-78aa67a88c28	e939b98a-b455-415e-b937-b7e0b7b45397	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c80420f9-8407-4e2f-84cb-1c348649e623	cd112fe5-0c94-42f4-b221-78aa67a88c28	6d01ada6-6047-4856-96f7-51abb0b3ef03	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
82168adf-c2aa-4368-94e6-0a983814c149	cd112fe5-0c94-42f4-b221-78aa67a88c28	6f1e06ec-4bfa-4fbb-bfde-7b50b7dcb7b8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fe6178c7-10d7-42dc-babd-a01ad7a463df	cd112fe5-0c94-42f4-b221-78aa67a88c28	b0fb7fe3-abe5-449d-b539-e3ec0443fc47	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8754dba5-2b0c-468e-a6b6-c9e445d15713	cd112fe5-0c94-42f4-b221-78aa67a88c28	d03bf414-6c6c-4b16-a1b4-3c546a8a7fd1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2da08c29-413f-49b9-8722-98a358445815	cd112fe5-0c94-42f4-b221-78aa67a88c28	dbf6cd6d-402a-4f39-8f26-7ef9480b6c3b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
866c9dc4-7b3d-48b7-b07c-dcc724a1fef2	cd112fe5-0c94-42f4-b221-78aa67a88c28	e4894564-51d5-4d0c-84bb-33e72708447d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
be8dfa0d-f98f-41f7-84e9-8d8d37ef6118	cd112fe5-0c94-42f4-b221-78aa67a88c28	4a81eb90-d3f5-47bd-a87b-4403a611caa8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f299e2de-02f0-4e7d-a3c4-02343a5173dc	cd112fe5-0c94-42f4-b221-78aa67a88c28	c0f8cd81-ec14-4a0c-b792-afa5aa50ec6e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bc5e38ce-bb98-4d0b-b33b-79b1bf83d025	cd112fe5-0c94-42f4-b221-78aa67a88c28	1d057682-ba7f-4818-8bb9-62768de6c8d3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
26d9ed8f-6835-40ed-ab78-e8d478243ced	cd112fe5-0c94-42f4-b221-78aa67a88c28	4c76a6a1-c667-4b15-86dc-a2cf45920bec	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e09fda13-7755-404e-9629-d0d90f04c131	cd112fe5-0c94-42f4-b221-78aa67a88c28	f9100cc8-a2e2-4d2b-8c52-ae60b0795e76	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
45b6cc91-6cde-4a98-9b97-7d0a3bf6a0a6	cd112fe5-0c94-42f4-b221-78aa67a88c28	3051482a-c212-4398-9a8c-22bde46b7a24	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c31bface-60ee-463b-83db-266c2b087c08	cd112fe5-0c94-42f4-b221-78aa67a88c28	b334eed7-c4b2-4748-9f6e-448e29203a4a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
45c43be8-2a30-457c-9a15-314a6635ef45	cd112fe5-0c94-42f4-b221-78aa67a88c28	44640921-5287-4001-afa2-d9892e9fd492	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
708d93d3-7d52-4201-99a9-fc9075af3f2d	cd112fe5-0c94-42f4-b221-78aa67a88c28	7bbcf2c3-6b90-4f3b-ba5f-ad6cd89f1fe7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9e2619df-450e-47a8-838c-66c31d36f8d5	cd112fe5-0c94-42f4-b221-78aa67a88c28	e7bdf9f3-95b8-4c5d-9518-ba50b6a96401	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c3b88cf0-c027-4e4a-8c99-c790239f7c5f	cd112fe5-0c94-42f4-b221-78aa67a88c28	54ebee77-6acf-42b4-95d9-7fb0fa2baeb7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
43651658-2c3e-4ae5-9457-d6b755dd12fa	cd112fe5-0c94-42f4-b221-78aa67a88c28	0adbe8c9-1db4-4ac0-8f99-c93fc58d13a6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e2684297-5a8f-4356-b123-48274a33dc3b	cd112fe5-0c94-42f4-b221-78aa67a88c28	34f0cf48-f9e2-4c8f-9ae0-3af955beae05	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0ffa44a4-1a9f-4845-8067-0957c9d0f6b6	cd112fe5-0c94-42f4-b221-78aa67a88c28	20d0c2ee-a22e-4809-b788-2ef9fef37577	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
78570319-63d9-4271-8dae-c8cfc35f0efa	cd112fe5-0c94-42f4-b221-78aa67a88c28	10853ff8-7f2b-4b0b-a6bf-222261507521	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8e413a50-8ba6-4cfa-87b5-be1178af0c5e	cd112fe5-0c94-42f4-b221-78aa67a88c28	149dd0ad-9e4f-4618-ac18-c8ee94ff0132	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
404df368-2dd8-437d-b830-e1c5f36b2256	cd112fe5-0c94-42f4-b221-78aa67a88c28	fcfb0a94-e078-4015-9e5b-ee4397f781eb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bba729df-b19f-4d2f-9699-dd920ecc0bd0	cd112fe5-0c94-42f4-b221-78aa67a88c28	9cc22c49-1373-4181-be01-977f31108acb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
83684405-b0ae-42f4-a8f2-ead8f9ba5e6b	cd112fe5-0c94-42f4-b221-78aa67a88c28	03c1bd46-23f7-4c52-8192-14a9ba8cf60c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7f98670b-b480-4ea9-9cdf-a6fa08d16deb	cd112fe5-0c94-42f4-b221-78aa67a88c28	965cc39c-99a4-477f-9b6f-d3205c8bc09e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
602750ff-be67-4c00-b8af-ec3b4a949550	cd112fe5-0c94-42f4-b221-78aa67a88c28	f3738d5d-e775-4a3a-9ec1-2d877494cda8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
25314f2a-cca6-4256-a703-da98b1499276	cd112fe5-0c94-42f4-b221-78aa67a88c28	cc3325b4-daf6-4866-81e2-70ad41ac137c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
81ab7f40-180e-4583-823e-e834ca776bdc	cd112fe5-0c94-42f4-b221-78aa67a88c28	6c132ca3-e2ea-4936-b866-5a5e1e4d036e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f99b8f11-4681-4563-a9e6-0f8e94565acb	cd112fe5-0c94-42f4-b221-78aa67a88c28	1d913d6e-6ff5-4b5b-8b7d-1a0cffa931da	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0ba7f0d3-2e8d-435f-84f5-2f178d8fb25c	cd112fe5-0c94-42f4-b221-78aa67a88c28	4a01ad83-6e0a-40a2-b85b-cf5d60cfd330	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b3c27260-0e7c-4520-882c-739fb089d2d4	cd112fe5-0c94-42f4-b221-78aa67a88c28	6d4ba333-b115-4be4-9c37-e0ae7729e8d9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
96f8ea9e-01f0-4e43-9feb-b83df4e57930	cd112fe5-0c94-42f4-b221-78aa67a88c28	ac0c6eef-ffdc-4eaa-8245-e1489668f35a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
45382663-13c2-4d42-b54e-63eaee60489a	cd112fe5-0c94-42f4-b221-78aa67a88c28	b46e0b58-9c99-4ec2-8943-3dd1ae98c753	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c5778309-9c72-428c-90b1-55edf3f77c55	cd112fe5-0c94-42f4-b221-78aa67a88c28	80b0a098-d72a-44e7-92ce-e73bdc7c30b6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9cf98bbb-1a79-47c1-a0a6-d0195ef146b8	cd112fe5-0c94-42f4-b221-78aa67a88c28	ccc9ee14-4c17-4f79-923b-453d26108f33	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
af211fca-1b21-4869-832c-48ace6310a22	cd112fe5-0c94-42f4-b221-78aa67a88c28	2ef8f6d0-8dbd-4c97-9aeb-87fa1cf68bd6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
93654257-c77a-4a36-88a0-7b6fb55d72dc	cd112fe5-0c94-42f4-b221-78aa67a88c28	846d718e-7d96-40dd-99dc-53df7da1b893	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c2a29de2-be57-4ca3-800f-27834055d5ac	cd112fe5-0c94-42f4-b221-78aa67a88c28	c836bca2-5364-4503-916f-d99e57df4e0c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
63e219e3-a9d8-4392-a212-ebca8c13d8a3	cd112fe5-0c94-42f4-b221-78aa67a88c28	d4a8f643-3d09-48ba-93a5-130e4a701fc3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
04f4e37d-15f7-451d-a6f6-0afdcd507b99	cd112fe5-0c94-42f4-b221-78aa67a88c28	e396c7f9-6f57-4ed3-8a17-5d7e2a33e98d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8a0f698e-5183-48ff-bc63-28271aa74e92	cd112fe5-0c94-42f4-b221-78aa67a88c28	8165476d-62fd-4f4d-9336-2113d2e21338	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
104638d6-0e0b-472f-8abf-aba06b188c5d	cd112fe5-0c94-42f4-b221-78aa67a88c28	d3cd4b2d-382b-43b8-a7f6-6542fb59fa45	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
64e9b1b9-55e1-4fa4-aeca-adebea945538	cd112fe5-0c94-42f4-b221-78aa67a88c28	8990165e-8c4d-4fa9-9076-e545a6eb271a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c8fdebe4-c52d-4016-a431-3cf273292bf0	cd112fe5-0c94-42f4-b221-78aa67a88c28	73b7742d-5e43-4115-beed-8bd04010ad2b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0d562771-0a6e-4719-9cc6-1cb0be905c12	cd112fe5-0c94-42f4-b221-78aa67a88c28	11594ef9-e4bb-4741-8e7d-3f0d8ff075ac	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
87f26fcb-f8f8-4ac9-8d48-dee0407aad94	cd112fe5-0c94-42f4-b221-78aa67a88c28	b6835ffd-e222-4784-94ec-7293d0f2a034	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
10e6cdaa-6160-4b91-8d6e-a820d4f06c10	cd112fe5-0c94-42f4-b221-78aa67a88c28	4765ccb4-c263-4d70-b409-e0c7dc9152e4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c6118264-4780-4347-a35d-0abb40b7d466	cd112fe5-0c94-42f4-b221-78aa67a88c28	f4102737-995e-4a47-97df-963713abf9fe	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
55adfe3f-9d84-4356-b779-58943999bd50	cd112fe5-0c94-42f4-b221-78aa67a88c28	4cc91b8e-9072-4f2f-b21f-a331a1746569	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ec727b1f-c982-4124-afb1-8c2f44517d4e	cd112fe5-0c94-42f4-b221-78aa67a88c28	cf22b938-6fbe-4ea0-b2f0-742cf9623324	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d066e3fd-2873-4577-a7ac-f6a518be5d6a	cd112fe5-0c94-42f4-b221-78aa67a88c28	a5b42d8a-15df-4d5f-9f22-3bd90958ec57	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5dcb5080-7e63-4879-be07-49ce249161e0	cd112fe5-0c94-42f4-b221-78aa67a88c28	e39a3898-4d7a-4d77-bf4b-82441326c7a7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fa991f96-74f1-4d4a-b452-87d7a0541b12	cd112fe5-0c94-42f4-b221-78aa67a88c28	eb996983-3b0e-41a2-8948-d6f9df98a7cd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8227e17b-33eb-4bec-b0df-3595406e0a0d	cd112fe5-0c94-42f4-b221-78aa67a88c28	4ed9c81f-25c7-450c-bfdf-bffbdfaaf8d1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
41cbf31e-1c64-43b7-8e1c-ced288e9efba	cd112fe5-0c94-42f4-b221-78aa67a88c28	92def23a-e6b1-4ac7-85de-27d5cbacfbce	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
56f24469-9eae-43e5-a247-66328c57e826	cd112fe5-0c94-42f4-b221-78aa67a88c28	f53ad995-a44e-4ace-8541-8fa19935705e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
edbaecd3-2ad4-4c98-abe1-f3e8febd3922	cd112fe5-0c94-42f4-b221-78aa67a88c28	d83f2786-950d-4627-b53d-85bd96988f7b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9c8571a8-ef52-433e-9a86-6af80a7ae5ca	cd112fe5-0c94-42f4-b221-78aa67a88c28	6bd9a1d5-067a-48b5-8ed5-7a5a1c67d8a8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
81cdfcf3-5835-4849-a8f9-bcbe32d3bd78	cd112fe5-0c94-42f4-b221-78aa67a88c28	f119568d-c086-4d3b-bed5-6326b855176f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
78660e10-ed80-4454-b6e5-a1d4b8828e67	cd112fe5-0c94-42f4-b221-78aa67a88c28	28348cbe-d2c3-4f96-a047-2e241886012a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ff09997d-d2af-4985-85f9-e3aa359d9360	cd112fe5-0c94-42f4-b221-78aa67a88c28	8f1492f2-81f8-42c9-ae49-5617b3a65aac	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3562b740-b1de-4f73-960a-2628a141b188	cd112fe5-0c94-42f4-b221-78aa67a88c28	4bf9e22e-4307-4033-8fa9-1f49af895170	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
497473ab-920a-410d-8922-e822bbd2b4d8	cd112fe5-0c94-42f4-b221-78aa67a88c28	99d30d49-b799-41a9-b2d0-0b627d9c9e9f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
61728f58-596c-4602-b6cb-c82e6036ec03	cd112fe5-0c94-42f4-b221-78aa67a88c28	08847c02-aecd-4110-9b90-e696659d27ab	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
26e1b802-0ca3-443e-b7cd-5dd1f1badaf6	cd112fe5-0c94-42f4-b221-78aa67a88c28	00ca20cc-d92c-4708-bc23-e7fad854d6d2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
25dcfd3f-95a6-45e8-814f-8d88b36ff2d0	cd112fe5-0c94-42f4-b221-78aa67a88c28	129257fc-04f1-435b-9de2-a9956504496a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
084cca12-28f4-4b04-a55b-348fa9d3123d	cd112fe5-0c94-42f4-b221-78aa67a88c28	6e891062-ab0e-490d-bb17-c51719f9bca9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
37a6ed67-0dde-4348-acb3-2ec68f361953	cd112fe5-0c94-42f4-b221-78aa67a88c28	62ee02ce-049f-4a3f-a735-4ed4f7e4107a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ab468369-70e7-4dbe-9547-f47ef2e0ea1a	cd112fe5-0c94-42f4-b221-78aa67a88c28	64630fdc-75e4-4f45-97df-2b73a0eee21b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2b0183bc-b7ba-486d-8ec4-752ffabb8150	cd112fe5-0c94-42f4-b221-78aa67a88c28	d087b0e3-ee4e-4704-9dbd-f57f4af23c59	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0ebd4138-550a-45e3-a0fc-5d043e989988	cd112fe5-0c94-42f4-b221-78aa67a88c28	de3d8bc9-187b-4610-866c-d98bfd124697	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
10906db5-03d5-462c-b3f2-031d94fbea04	cd112fe5-0c94-42f4-b221-78aa67a88c28	33956074-3708-4d03-b8a2-23a524002d46	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b4eb876e-1a70-4df3-acc0-1b9b598cd7a9	cd112fe5-0c94-42f4-b221-78aa67a88c28	97bf6485-a9e8-403f-82a6-1595d547e6c7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bebd0063-e633-4497-92f9-1f3ee2523cd4	cd112fe5-0c94-42f4-b221-78aa67a88c28	e8a32a29-373a-46c2-bdd0-2bcf2067cfaa	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fd6adc40-ca2c-4df7-8d58-fac3f1faa866	cd112fe5-0c94-42f4-b221-78aa67a88c28	46c6947d-d3c1-4d87-a20d-f80c640815ba	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ea0e6eb9-3626-4f17-97b1-cc110551303e	cd112fe5-0c94-42f4-b221-78aa67a88c28	c23ca553-a768-4eef-b237-4f7a1963182f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fb35ac34-1897-41c1-a23c-00709cca0c69	cd112fe5-0c94-42f4-b221-78aa67a88c28	30ea4649-210f-489d-8b25-eb7752952a58	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fe5a707c-bbdb-43f0-a2fe-39edcf438ec5	cd112fe5-0c94-42f4-b221-78aa67a88c28	2753d745-4fde-44ad-a817-a926e2416c26	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
01b2f509-1136-4b1c-8b9a-83cc9b9d36e3	cd112fe5-0c94-42f4-b221-78aa67a88c28	a52d2763-eaaa-4283-823e-698e31304ac7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
22884616-ecde-4e1e-ab9a-2a3b153de464	cd112fe5-0c94-42f4-b221-78aa67a88c28	3cdce22c-e760-49b5-bb60-d1577acb2750	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
27e0109d-afcc-476a-b276-9cc53e382ea8	cd112fe5-0c94-42f4-b221-78aa67a88c28	b98504a2-18f3-4d87-a127-101372b44237	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
240a413f-37b7-4f1d-9f9c-60306f0182c3	cd112fe5-0c94-42f4-b221-78aa67a88c28	3373dbf4-1675-4263-84a5-5cce2c8835c5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3ea16b21-91f2-4ba7-9379-1acb7796d21e	cd112fe5-0c94-42f4-b221-78aa67a88c28	143bd3ec-ef82-49ae-9ef6-c32eb8c481ec	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f9e97e1f-91fc-4cbe-8e89-809cb0e00ffd	cd112fe5-0c94-42f4-b221-78aa67a88c28	c0724f6b-1a47-441b-ada7-11a0b12cb944	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b740109a-fd90-44be-a29b-7c68102547ab	cd112fe5-0c94-42f4-b221-78aa67a88c28	52dee135-9501-426c-a3db-231ea6521fee	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e1df5ea2-a3ff-4900-8947-700198078e85	cd112fe5-0c94-42f4-b221-78aa67a88c28	bcd2d343-b857-4fc5-a3a0-5c81ce009acf	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8e340e1b-e264-48f3-b684-ce26b8901e94	cd112fe5-0c94-42f4-b221-78aa67a88c28	fcfc351f-a70e-4fe5-a31b-41d222f912a7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cbfb2588-05be-42d7-813b-a498324ec385	cd112fe5-0c94-42f4-b221-78aa67a88c28	a0df12b1-415d-40d0-8bc1-03acd83f9918	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
dc6b729c-d42d-4d67-950e-225b5dc60e3a	cd112fe5-0c94-42f4-b221-78aa67a88c28	469870c6-7f05-4396-a9bf-71600605852f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2557e3b9-062d-4e38-aa98-0f2f4b7e7133	cd112fe5-0c94-42f4-b221-78aa67a88c28	a9ac42a0-a727-4add-a3bb-5deddf2cadc1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5d21bff3-2a40-47c0-aaec-1ff054ea1ddd	cd112fe5-0c94-42f4-b221-78aa67a88c28	4975269a-144e-49f1-ad97-16f120d1cbd3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
45c9d828-3d13-47df-b53b-074f6ccffaa6	cd112fe5-0c94-42f4-b221-78aa67a88c28	743681fe-8f16-4ea4-94c1-1c7719d567ec	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1fd72d87-51f7-401e-8116-289f003d4780	cd112fe5-0c94-42f4-b221-78aa67a88c28	7a9151c4-2be6-4f64-9ee7-f158ca3471e1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d56d5c6a-c33b-43da-9454-bc0ce33604de	cd112fe5-0c94-42f4-b221-78aa67a88c28	708e26f3-fa66-4a29-a38c-5f544dd31662	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
daa39963-d86a-4991-b4db-c4c0cceec280	cd112fe5-0c94-42f4-b221-78aa67a88c28	75f0bc43-e2c5-44e3-a23a-a1328ac03bd4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6f43c475-f13a-4fe8-8f64-4a79555b3c7a	cd112fe5-0c94-42f4-b221-78aa67a88c28	00ee0df7-f531-4d7d-92e4-b9db178dbc30	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d0f01727-b7f6-4728-9394-6f37f334eee7	cd112fe5-0c94-42f4-b221-78aa67a88c28	2525a59c-0f76-4b6f-8802-c552221c2c8b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b86b0d30-2d29-48d3-8a34-4f7cec065590	cd112fe5-0c94-42f4-b221-78aa67a88c28	fcbba7b9-fd30-47f8-931a-705573f4e87e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7e450bd2-0eac-41c8-a4ae-f1b1383de594	cd112fe5-0c94-42f4-b221-78aa67a88c28	9196af56-2465-49c7-9d81-ec5191deb357	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
99e56c47-7a18-481f-b30a-8b1454cbb551	cd112fe5-0c94-42f4-b221-78aa67a88c28	4924cd3e-87c7-4838-bd40-de0f29768239	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
32e64833-9496-47e7-b0a2-74406ca60c2c	cd112fe5-0c94-42f4-b221-78aa67a88c28	6f2d7423-305a-41e1-b471-ad6bbce92983	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
644316c4-4e9d-494a-b6a5-9d4a8cb35790	cd112fe5-0c94-42f4-b221-78aa67a88c28	762c6869-1df4-41e7-a12e-5fde1ec2d3e1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b6783628-0e2c-45f9-9fc4-cbcce055bf5d	cd112fe5-0c94-42f4-b221-78aa67a88c28	36afdfac-e2ce-4bd3-9eaa-698000f13c57	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3c72ce7e-7eb7-4a98-a03f-df127431edc2	cd112fe5-0c94-42f4-b221-78aa67a88c28	989205c4-5925-4dce-ae16-a6a0f27c431f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
361e798f-2468-46e7-8b9c-4faf24d6ff70	cd112fe5-0c94-42f4-b221-78aa67a88c28	3f3f8960-2894-4c63-b3d1-68045b53c92a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
979cd316-296c-4588-a9de-f65b149a7e43	cd112fe5-0c94-42f4-b221-78aa67a88c28	5c68ca9a-48b5-4a77-87a7-b80a3699dbc5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
19c8f4f9-318b-4fee-999d-17b4cc315899	cd112fe5-0c94-42f4-b221-78aa67a88c28	36e77366-636b-4e0d-81a0-209ec3226fc5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
454e8a93-4d07-49e8-b9ea-2e07b49817b1	cd112fe5-0c94-42f4-b221-78aa67a88c28	3a1e4c0d-e0e9-4704-8238-9f1f02c8a307	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8fbac623-842c-4621-9d5d-bb183bbd1b26	cd112fe5-0c94-42f4-b221-78aa67a88c28	4ccd6559-e071-4372-bbe2-e2a971cc6768	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b4fd91f6-610c-4814-b813-71f06f6ce011	cd112fe5-0c94-42f4-b221-78aa67a88c28	20f11418-baba-4b62-aa82-9d137f19396e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1ea57e06-45a1-4521-8433-bc93ebb19530	cd112fe5-0c94-42f4-b221-78aa67a88c28	8e4d7117-aac5-4564-b497-4d6ec589b631	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ff0b7138-5c54-4f70-a91f-31373431495a	cd112fe5-0c94-42f4-b221-78aa67a88c28	e2d34508-d906-4139-96ac-845f5ac22b58	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a4cbbc77-e7d1-48fa-b357-1ef2bc1b3e8d	cd112fe5-0c94-42f4-b221-78aa67a88c28	6bd34503-6140-4c80-859b-baaa14ada3bb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2e142855-8136-414c-aba5-2014c5677873	cd112fe5-0c94-42f4-b221-78aa67a88c28	90d7d88b-fbcb-4a96-9e4b-51150e6187c4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cbb16c44-1533-483f-9cf4-cfe4074f4a88	cd112fe5-0c94-42f4-b221-78aa67a88c28	1fdb69e0-4372-424a-9f27-8f1be8b782db	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6e22ba28-bfae-4917-8c45-62ff7122665b	cd112fe5-0c94-42f4-b221-78aa67a88c28	83cb1b24-e748-4fc0-945d-364f9f1dfe9e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1634292c-4673-4a06-b9b5-e642235de203	cd112fe5-0c94-42f4-b221-78aa67a88c28	ca593b9c-ea6a-49e3-afb4-a36c38e6022c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
30cc6df4-3575-4bb8-95a1-c2c4881c664b	cd112fe5-0c94-42f4-b221-78aa67a88c28	48f4cf7a-891a-4289-9d09-a04ee52d2467	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7d07fd1a-40eb-4219-a0f3-ef8ceb70fba2	cd112fe5-0c94-42f4-b221-78aa67a88c28	5f74ed26-98c9-456f-95a2-54ffe311b19a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e270efed-cba6-40a9-b002-aaa8af28b2c3	cd112fe5-0c94-42f4-b221-78aa67a88c28	bf90d1be-4d92-4e8a-b25c-ff5ae900dd6c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bc7abead-a8ed-4ee0-b334-4595b98edf24	cd112fe5-0c94-42f4-b221-78aa67a88c28	91ec904c-c1cf-414c-a046-2ed695539265	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9418dc29-9661-4bc1-bcef-ae950b5e3c07	cd112fe5-0c94-42f4-b221-78aa67a88c28	cd578b3a-2398-4268-882a-5df025decb87	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1865d709-d079-40d7-a10a-358d49d9178d	cd112fe5-0c94-42f4-b221-78aa67a88c28	2a59340f-976f-4f1a-9471-eeff102efe40	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
77e27068-1b98-4959-a128-80f061d5310d	cd112fe5-0c94-42f4-b221-78aa67a88c28	9b5eebe1-3e82-4f10-9fa7-a97c553e6bc0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9d376bf7-3fea-419d-a0db-983d87f0ffe0	cd112fe5-0c94-42f4-b221-78aa67a88c28	be966f62-f172-4c93-9bcb-d3ac1a34cdcd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ac56c2ea-edc3-48ec-b8a3-a38e75fc8cca	cd112fe5-0c94-42f4-b221-78aa67a88c28	4b51a8f8-4863-485f-ba7e-45aa5c056582	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f0d09641-0555-4893-9da8-3e2955c3dd22	cd112fe5-0c94-42f4-b221-78aa67a88c28	8207054d-016b-4566-aa6c-4a33f946b368	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7d7c38d9-0877-4dba-a63a-8c94491641f6	cd112fe5-0c94-42f4-b221-78aa67a88c28	3f1bfec5-a2e1-4463-af4e-15f19632f398	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
472aa03d-d89e-45d5-ba32-f92ee791c462	cd112fe5-0c94-42f4-b221-78aa67a88c28	c0cf6a76-07af-49ef-b2dd-8cc63c914c55	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
07628cf1-528c-47cf-9448-145ad57c6489	cd112fe5-0c94-42f4-b221-78aa67a88c28	bc9e9813-f31f-4ae8-8367-4a5e7e75ea4d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5bd52bb0-0919-4eb3-88a9-5fdb694f66ad	cd112fe5-0c94-42f4-b221-78aa67a88c28	298a2ce5-03e8-4bc3-90c2-f100bc798067	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2885b0e4-2abb-4e22-af1e-1bb334926155	cd112fe5-0c94-42f4-b221-78aa67a88c28	80a3d0d6-4fee-4d16-b0e4-da9b5b5f7e9a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0a704984-a167-44f0-9925-9eec2eb7c33c	cd112fe5-0c94-42f4-b221-78aa67a88c28	6a0804e8-8d14-413c-b77f-b8d925240ca6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
898ed788-3346-4c7c-8baa-40bd4603a031	cd112fe5-0c94-42f4-b221-78aa67a88c28	88e8d64f-4ffe-45af-a5c2-bf41e05f5daa	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
780e96ae-80eb-4dcd-b532-3ff3b34f2e72	cd112fe5-0c94-42f4-b221-78aa67a88c28	19e74b3a-e81d-4046-8e2f-155e3c44ea3c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e04cbf08-5486-4d14-8410-89eb27866353	cd112fe5-0c94-42f4-b221-78aa67a88c28	b0b55a81-cc70-4670-8381-fed9b85d4795	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
394c9db6-b18f-4202-96a5-9de3acc84d10	cd112fe5-0c94-42f4-b221-78aa67a88c28	4cf7ced8-df93-4ae9-a25d-1630d6df5afd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2e1dae3f-a7e2-46b9-861e-6e1e71d5f68a	cd112fe5-0c94-42f4-b221-78aa67a88c28	d87d39c4-b0c8-4785-a105-8474a8c48bad	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0425a007-c04f-4cdd-b70b-01d264933e6c	cd112fe5-0c94-42f4-b221-78aa67a88c28	5b2821a5-e35e-44c4-8c13-d63d6345ba5a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
68eed410-cc4b-4049-b183-26f40843d584	cd112fe5-0c94-42f4-b221-78aa67a88c28	4ecc2531-c07c-4c78-8754-7bc14aeed18c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2905691f-2dd2-4363-9961-a29943b8bebd	cd112fe5-0c94-42f4-b221-78aa67a88c28	ba096883-f4e9-4f53-84f9-1b14226e2593	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e445183a-dead-4098-97c7-898d9695503a	cd112fe5-0c94-42f4-b221-78aa67a88c28	f6fa5712-a021-457c-bdbc-1d25071ac028	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4a84985d-6511-4e17-ab63-d543fdc76dca	cd112fe5-0c94-42f4-b221-78aa67a88c28	4baf01a8-d3df-461f-bd31-e3283aaec78e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ec07297c-0bd9-4339-aef0-28d548dcd63a	cd112fe5-0c94-42f4-b221-78aa67a88c28	b803db15-e821-45f7-b77c-16b9409fc423	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a598af26-ba9c-4476-968a-0109af38104b	cd112fe5-0c94-42f4-b221-78aa67a88c28	6079583e-d988-4f99-91aa-99e0c0bb20f4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f1b238a0-59a4-43de-8166-8fff903bd5da	cd112fe5-0c94-42f4-b221-78aa67a88c28	ca91806e-64bb-4580-a882-d715e1c22f4c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d771d657-bdb1-463d-a9cb-8719bd489caf	cd112fe5-0c94-42f4-b221-78aa67a88c28	cfb318fd-1e1e-4fd8-bcdb-bde939c66b76	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3c2fdb6f-94e8-4f38-aef4-d13af8aa3592	cd112fe5-0c94-42f4-b221-78aa67a88c28	2f782948-8df8-4550-923a-9d582b413d9d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
959fa952-412f-4f34-bd6b-f829d9a22b61	cd112fe5-0c94-42f4-b221-78aa67a88c28	df0f8567-fc9b-426c-aba7-632bf3a2f69e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a8754ff5-041f-43f1-8ebf-a7747652e057	cd112fe5-0c94-42f4-b221-78aa67a88c28	58a60da9-bb63-4882-b28d-a899d6e00f52	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
504755d9-55a1-4599-82eb-2c451eb0f2a5	cd112fe5-0c94-42f4-b221-78aa67a88c28	7fd76e58-6082-4eb2-809b-5bce5cf8cd32	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
90666e65-dedc-496e-9b30-24eaf01a8efe	cd112fe5-0c94-42f4-b221-78aa67a88c28	0a8d7236-b26f-404d-94a4-08189f56d6d3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fdd422c3-0cfc-49a1-8293-f39202692205	cd112fe5-0c94-42f4-b221-78aa67a88c28	f644f4d4-07d4-4a68-9ebb-2d867faf1a9a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
65f37392-9df6-43bc-a7f3-815cbaec97a4	cd112fe5-0c94-42f4-b221-78aa67a88c28	a9123596-3d31-4156-9c2f-5c24dae4b8ff	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b3664cf5-15a0-4030-af9b-c4840ae9df90	cd112fe5-0c94-42f4-b221-78aa67a88c28	b7f0d91b-f540-4dbb-a1d6-67945f3de9fe	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b5aa6120-3fd7-460b-8d48-031581151949	cd112fe5-0c94-42f4-b221-78aa67a88c28	88feafc5-50e7-49cc-94ca-19ac20a62381	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4106f932-f54a-4556-881d-8bb4900df09f	cd112fe5-0c94-42f4-b221-78aa67a88c28	c83b313a-6377-48f6-b423-61bcbd1befac	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b98c19e6-682e-44d5-b5a3-9ff08e0cff48	cd112fe5-0c94-42f4-b221-78aa67a88c28	3d76ee07-337e-4e71-925b-5a4ad34a6217	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6d20e484-de4d-4177-a032-4c39dec35c92	cd112fe5-0c94-42f4-b221-78aa67a88c28	7278d8a2-1afa-47ea-8f45-aca80363e7fd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
12123cbf-f07c-4938-82a1-6f0e781dab0e	cd112fe5-0c94-42f4-b221-78aa67a88c28	eb4ca459-a7c5-418b-b663-72482539d188	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2ac1dabe-fbf2-4050-bb26-9534ed271ee6	cd112fe5-0c94-42f4-b221-78aa67a88c28	97beb27d-91c6-4d5a-bde8-ce522ae7cf3f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b426d2b4-242e-43eb-9bbd-d521cca8c837	cd112fe5-0c94-42f4-b221-78aa67a88c28	e8397cbe-b0c5-4e24-a1b7-c4b70b096289	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
76e96a49-08a3-4694-9326-2e1501791632	cd112fe5-0c94-42f4-b221-78aa67a88c28	df2e1002-2afb-4016-90b8-e042eb0397a3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
287c3960-2079-43a8-91d6-f701fdc39f96	cd112fe5-0c94-42f4-b221-78aa67a88c28	c12b01cc-f893-4719-acb3-93037b400058	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1492818e-2f37-4a12-8ab6-5b43c3671022	cd112fe5-0c94-42f4-b221-78aa67a88c28	721735a9-8a80-4464-8384-aa2969f9bed9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9ae5754d-b32c-4d25-89a6-f85fc1e666cd	cd112fe5-0c94-42f4-b221-78aa67a88c28	4606b7b7-7fe5-4409-937f-2bea04577896	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
59fde257-af71-40d5-9a24-a9b4fbe85fd1	cd112fe5-0c94-42f4-b221-78aa67a88c28	9c851f5b-3b22-4bdd-b23f-bfd4bedc71c3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3b10bfd6-6281-4970-9b53-80aea7ba7bcf	cd112fe5-0c94-42f4-b221-78aa67a88c28	043573ca-8b01-4937-880c-363faa091589	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ff140c1f-cb12-44cd-9616-a0833166b9d4	cd112fe5-0c94-42f4-b221-78aa67a88c28	d6a7f0c5-56a8-40ab-8eae-7c5747555fe8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
876d26ae-1a31-4f4a-8ead-cb38bee44c2d	cd112fe5-0c94-42f4-b221-78aa67a88c28	62f0715d-c698-419a-a5d0-fc9fda75bfb4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a51e9d72-abf9-4897-b246-f64fd8b54b6c	cd112fe5-0c94-42f4-b221-78aa67a88c28	fba6af6e-fe6b-41ad-a222-4467da95e989	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9c02798f-d7df-4a69-b77e-0d2096adc06d	cd112fe5-0c94-42f4-b221-78aa67a88c28	9ddc5858-cec8-4a12-abb9-de920843f065	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2c38ce29-c519-40a0-b16d-d69aaa884805	cd112fe5-0c94-42f4-b221-78aa67a88c28	adf94e1e-154d-461e-97bf-23d2a7f41b5f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
40435aec-bfbf-4a36-a8f6-fd180c857b99	cd112fe5-0c94-42f4-b221-78aa67a88c28	cb0fcdda-d13d-4b13-b383-7233c3a91968	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0ee813d9-2579-4dfe-a775-4fdc119b8bfa	cd112fe5-0c94-42f4-b221-78aa67a88c28	0e2317c5-78bc-4fd9-8c1a-e0bc352c701d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f9f7f970-683f-47a1-8790-dd1e61035f43	cd112fe5-0c94-42f4-b221-78aa67a88c28	4c833ed7-ac64-43bf-b08e-7a0b66810842	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
50478785-1716-4e19-b42b-d163b0dd01e0	cd112fe5-0c94-42f4-b221-78aa67a88c28	2a841cca-0a94-4173-a2e3-94064c295dba	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f7ed44d9-499f-458d-a968-03ef6380019a	cd112fe5-0c94-42f4-b221-78aa67a88c28	8ec38741-d1f6-4cfb-bde3-56bcefe7f9b0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4eea4628-4152-46a6-bd98-d236e164fed8	cd112fe5-0c94-42f4-b221-78aa67a88c28	aa063d12-8ac0-423b-be80-1ea10ce165e3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9cc5e2b0-a519-4a4d-9445-391acdbeaa98	cd112fe5-0c94-42f4-b221-78aa67a88c28	c6a21385-ae1b-48fb-a6a2-090dd3563729	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
72019ef6-d284-4ecc-81d9-aef04c25efb9	cd112fe5-0c94-42f4-b221-78aa67a88c28	33b53ed0-62bb-4617-bec2-90d8bba22d3d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1667df05-805f-4863-b4be-47ee6e5c5b38	cd112fe5-0c94-42f4-b221-78aa67a88c28	83ac9581-1559-427e-ac19-3aca64177e50	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
36230d66-bbc8-4d3e-80b7-c8f53ca60e11	cd112fe5-0c94-42f4-b221-78aa67a88c28	df69d456-0455-4f98-af86-c2c83a75c8a2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
753310ac-d10f-4a91-b1d5-a54c9281d5ca	cd112fe5-0c94-42f4-b221-78aa67a88c28	518ec9ad-7df7-4d4b-8eff-04a6c3c36653	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
22bd09a7-b113-4b5a-9d1f-456af86906b6	cd112fe5-0c94-42f4-b221-78aa67a88c28	2d059afd-e97c-42b7-a1b3-a2e9cdbef966	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
830bbb46-28a7-4ecc-a601-2b0fd475eef1	cd112fe5-0c94-42f4-b221-78aa67a88c28	5c1a91f9-a5f9-48aa-b130-3b611255c7ea	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b60dbc55-b575-4388-a792-b53729ba51f1	cd112fe5-0c94-42f4-b221-78aa67a88c28	358f7ed5-56c9-4d88-abe7-39ecbc3864b8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d39649ea-218d-4a2d-b7f5-ace110ddfdf0	cd112fe5-0c94-42f4-b221-78aa67a88c28	d1c725e2-edf7-41db-b67b-e6b07a9124dd	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0303b748-879c-4495-9a4c-8993a6a8c320	cd112fe5-0c94-42f4-b221-78aa67a88c28	2cfdda52-727c-4980-9b51-f6cb8d569a36	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
55831641-e443-4f92-8c4c-93c9d70b2b92	cd112fe5-0c94-42f4-b221-78aa67a88c28	f3621ac9-9731-4356-adcf-f5cc7fbc5652	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9a5c2c2d-bb16-433d-a723-4b2aff30d9a4	cd112fe5-0c94-42f4-b221-78aa67a88c28	290ed9b7-ebfd-4fdc-ac2d-310f72f83df1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c043827b-e458-469a-91e8-a21b3290f814	cd112fe5-0c94-42f4-b221-78aa67a88c28	111623ca-05ec-4e32-9c32-384496708f96	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
db1b8960-8e02-45af-82d3-a4e638bcb75f	cd112fe5-0c94-42f4-b221-78aa67a88c28	f15ee116-4252-45f1-944b-8a0325a927e5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f5b25493-ec72-429c-8636-b75a8dd099c0	cd112fe5-0c94-42f4-b221-78aa67a88c28	1cfdd92a-7159-4181-8417-0ef11efffb3c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c828ad22-274d-4fcf-a7c9-5aa310e454e6	cd112fe5-0c94-42f4-b221-78aa67a88c28	89660c46-97e8-416f-ae27-ac04c6e740f5	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1513b121-00f6-4b4c-a595-2104e93b2a61	cd112fe5-0c94-42f4-b221-78aa67a88c28	3ad518c1-cba5-4b49-a75c-000da86b1655	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6b0f32bb-136c-44d1-9236-d29866c7b08b	cd112fe5-0c94-42f4-b221-78aa67a88c28	e167a583-fb30-4951-9340-ba25f3500b66	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6757ed6e-9111-49e3-a1cd-215f86415c36	cd112fe5-0c94-42f4-b221-78aa67a88c28	82fa6a07-a523-4391-bd0c-f3d1b90e5ba8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e18178b3-5ea7-4972-adc2-e50c836752f1	cd112fe5-0c94-42f4-b221-78aa67a88c28	3c340a19-7f91-432e-a3f2-1ef9c34f9c78	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
97df481f-cdbd-4d87-ad12-53e42be41f95	cd112fe5-0c94-42f4-b221-78aa67a88c28	d024e83f-2ffd-4ca3-a4ed-e8115c78c09d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
76d86110-6cae-4419-b6b7-b9dd7b9bc6fb	cd112fe5-0c94-42f4-b221-78aa67a88c28	02192424-8888-4564-9c78-96b4268ac20a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f9895ffe-73cc-497c-bcd9-c20875c84264	cd112fe5-0c94-42f4-b221-78aa67a88c28	56e47716-ac53-4d03-b072-67f621dc18eb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a5f23d7c-a257-4b79-a174-5018ed12da25	cd112fe5-0c94-42f4-b221-78aa67a88c28	d9d656a9-c247-41fc-9014-e7a6e02221d0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
14af18c3-9eba-435c-94c8-51b35828574c	cd112fe5-0c94-42f4-b221-78aa67a88c28	d7d58ee0-f368-4cd2-b434-79bb1d42d84a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a20105d5-9c8f-4fc2-9846-219736d9986c	cd112fe5-0c94-42f4-b221-78aa67a88c28	cc0a2281-81fa-4f0b-ad41-755b93e7d4c8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c66bb43b-401b-48ee-9f4a-bbe464952afe	cd112fe5-0c94-42f4-b221-78aa67a88c28	05698e9f-9315-452d-bff6-3a9c117e3236	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d607f1ed-0306-405d-9b66-4d403715b92a	cd112fe5-0c94-42f4-b221-78aa67a88c28	3c31632e-fc0e-4eda-b4ec-99fe922ac61d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5c9d6827-01dc-4b11-886b-ca998bdeceb3	cd112fe5-0c94-42f4-b221-78aa67a88c28	83bd502d-c6cd-4b40-91c6-5d243069fb36	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0fb7d69c-0016-4778-aa2c-672f0d4a903c	cd112fe5-0c94-42f4-b221-78aa67a88c28	e1ca767e-3a70-442c-b1d5-d92fb895b9c7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
5fd4f6ea-0a54-4af9-be25-bc0786cd06ec	cd112fe5-0c94-42f4-b221-78aa67a88c28	a26f2142-d8f3-40bf-9327-ce73cd8e17bb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
060970af-8bc3-49c4-aeab-5d1a863a78fd	cd112fe5-0c94-42f4-b221-78aa67a88c28	21d5d841-5807-4931-baeb-3de36b2dc53c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cf06de2e-e6b6-4738-8588-7cda8f5adc98	cd112fe5-0c94-42f4-b221-78aa67a88c28	70d6fbbd-00aa-44d6-9770-8b12962a5086	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
81a06643-3bf3-42f3-8a61-800237bb748b	cd112fe5-0c94-42f4-b221-78aa67a88c28	8ab9e061-13ff-4f95-b3a6-3a54d6267fa1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3af00aae-469b-4ebc-bbf6-de37a6d55f6f	cd112fe5-0c94-42f4-b221-78aa67a88c28	89f53ee0-88ab-4bf6-ac36-5167d91cbc3a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d4c01c2e-7d21-4c87-9184-db79e0a423f7	cd112fe5-0c94-42f4-b221-78aa67a88c28	432791e2-d04c-4f1a-a44c-c3f5ed0a04c4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
715e6cf0-b86c-4e97-87a7-82f17d1ae360	cd112fe5-0c94-42f4-b221-78aa67a88c28	1ea9e3a4-13d8-4c2d-8e87-bded3021d6bf	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
dc59c76c-197e-464e-9b17-7fb57daaa64f	cd112fe5-0c94-42f4-b221-78aa67a88c28	f1371e95-3952-4515-b169-d487e8fa006f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a0e4c7e3-62c5-47b2-b391-c5ff17e07247	cd112fe5-0c94-42f4-b221-78aa67a88c28	e6c38cb8-b3ef-47c1-a621-df282c4f5d03	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
664b01d9-dbff-4fb6-95f0-3c2ee1cc4df1	cd112fe5-0c94-42f4-b221-78aa67a88c28	743943b8-a53c-41fa-ae92-ca5ca48cb031	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
eef530da-8d8d-4328-a5ab-e0eda8a4048f	cd112fe5-0c94-42f4-b221-78aa67a88c28	5b77c20d-5298-49a8-8237-4f70a2bbb166	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c52eeefa-b962-46b0-a068-bab67bace241	cd112fe5-0c94-42f4-b221-78aa67a88c28	5479dc5f-ae7c-43a3-9697-59c25ff67102	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9608bd68-eb19-4e3d-9f4f-0d81a1d3afb6	cd112fe5-0c94-42f4-b221-78aa67a88c28	62f6956f-c724-4cf2-afc8-023d642e0f41	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c2e20845-b9ca-41e1-ad57-f07edafdd437	cd112fe5-0c94-42f4-b221-78aa67a88c28	543068a9-8fc4-46f7-bdef-05cc09172a48	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
75e61e20-21f4-491b-9d05-f5897566f300	cd112fe5-0c94-42f4-b221-78aa67a88c28	71073869-267d-404b-88bc-3716117c9877	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0e5ce3ac-2d4a-48b2-8f03-150aaa05e996	cd112fe5-0c94-42f4-b221-78aa67a88c28	ff7e817a-b706-4f69-b6cc-19f06a9c75e4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
63bf5849-7337-4884-9e40-a4fbfe62fa60	cd112fe5-0c94-42f4-b221-78aa67a88c28	86aaf5d3-990d-4211-b717-60da64f6fca4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1ecd6fbb-b8ae-402d-b43f-f67ff5944d5f	cd112fe5-0c94-42f4-b221-78aa67a88c28	6c39d722-fa9e-4fe7-98d1-4cff6a5d4b2b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9c323095-1f4f-4ba5-aedc-80e107f7bc99	cd112fe5-0c94-42f4-b221-78aa67a88c28	5a380c5b-1642-4f36-b9ad-8c533b2208fc	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2ec47fcb-2ba6-47ab-8d22-5d6b2d567180	cd112fe5-0c94-42f4-b221-78aa67a88c28	ad130cf0-dd4f-4f2c-9a78-8c76bc7a794d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e60705c6-c84c-4ff7-9ba1-faac8470a9b4	cd112fe5-0c94-42f4-b221-78aa67a88c28	ece32bda-232d-4f38-88da-6224fef8a93a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6e1deed2-2dd0-4d18-b622-8a89353d4642	cd112fe5-0c94-42f4-b221-78aa67a88c28	30cdb8dc-6b03-4d0d-a20a-3336c9f0a537	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e61180dc-8ee3-442c-a83a-f51837757004	cd112fe5-0c94-42f4-b221-78aa67a88c28	3218a59e-15fe-491a-ad1f-8f5b77766324	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
17d8ecbe-e6dd-4bec-a280-2451761e10a3	cd112fe5-0c94-42f4-b221-78aa67a88c28	bf499975-6f8c-4098-a10b-de971c75af31	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
15b5cc40-f60b-4fa5-beb5-eeb2854041f5	cd112fe5-0c94-42f4-b221-78aa67a88c28	b71efee2-b438-4423-99ab-f84530927a58	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6f2a04af-0420-4c28-a22c-e9533148bd2e	cd112fe5-0c94-42f4-b221-78aa67a88c28	e8eaa061-7cca-4172-b9a1-43fb0951dad1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
97089e79-db51-40d3-bec8-9872551f7879	cd112fe5-0c94-42f4-b221-78aa67a88c28	7e3ad6a3-cff0-4f76-af75-248dc9aa1faa	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d7d4f000-4d5b-4aaa-9bd9-18f18cfd6eeb	cd112fe5-0c94-42f4-b221-78aa67a88c28	41373a30-bdf3-4bc6-b65b-1ebc08500900	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e3f1a5b5-55ea-4608-981d-55d1bf16eea2	cd112fe5-0c94-42f4-b221-78aa67a88c28	e4b92bea-a98d-4112-b971-5434d3e2c46d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
8b0b1cbb-0cc0-4a0c-a87e-760c9798d4d9	cd112fe5-0c94-42f4-b221-78aa67a88c28	014d2ddd-7bd7-46ab-b299-bd12f574b2e0	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
304c07ac-8c40-4173-9d07-380d96916284	cd112fe5-0c94-42f4-b221-78aa67a88c28	ece454a6-dfd7-45be-857a-7ee7e21a8985	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1f7878ee-0e31-4c9e-b3e6-0994d8fedf18	cd112fe5-0c94-42f4-b221-78aa67a88c28	ccd752a3-b8be-4a14-8945-1a67d9d196a2	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d4eb2860-3517-47a1-b4ff-4847c18e1abf	cd112fe5-0c94-42f4-b221-78aa67a88c28	6689f4bd-b72f-4121-9f3f-114353160c14	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
169b26f4-c171-45be-a5e3-adfb9ade5c3d	cd112fe5-0c94-42f4-b221-78aa67a88c28	4de01839-1ba3-49df-908d-440528adee29	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d9c4675d-5409-4050-894e-f8a827f9260a	cd112fe5-0c94-42f4-b221-78aa67a88c28	93277032-c93f-461a-a51d-e5b78b31548a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
7efe7f92-9e79-454a-873c-0913bfc0a45c	cd112fe5-0c94-42f4-b221-78aa67a88c28	3fa77826-f8ca-4c21-9bf6-b34f43019217	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
85fff50a-3d59-4b07-9b74-48a1473aae97	cd112fe5-0c94-42f4-b221-78aa67a88c28	6b65e501-10b2-4acd-a0f0-f92713627a0f	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
3cd6893f-757e-4fdd-aa67-c323c7e802a1	cd112fe5-0c94-42f4-b221-78aa67a88c28	58246eac-11a3-422e-abb9-a550ef6b5b01	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a81af4ed-e2c8-4851-b50b-a1a6c00415e5	cd112fe5-0c94-42f4-b221-78aa67a88c28	d036913a-b726-43e6-acc0-be191148c57d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ec927e8a-cfc9-4214-9086-fc46879963f4	cd112fe5-0c94-42f4-b221-78aa67a88c28	1914df22-66fe-47e4-8d8f-4109beb88612	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
a55f3ca7-2272-4058-bdcd-827c7d562ce9	cd112fe5-0c94-42f4-b221-78aa67a88c28	bdd99634-653b-4c38-8844-c7fa410af743	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
23191513-70fe-48b0-ac4f-22b43dac8b55	cd112fe5-0c94-42f4-b221-78aa67a88c28	f12d1632-feb5-45b1-b72d-665cace4816d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6957cfdb-b17a-4b3e-8284-973f90d8d008	cd112fe5-0c94-42f4-b221-78aa67a88c28	697b7bf9-8478-4465-b15a-4e7800a95cb3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
107a928b-2e2a-4ad6-b126-b8d9a0d27f49	cd112fe5-0c94-42f4-b221-78aa67a88c28	cfb30a4f-a146-46b8-bb35-6111fa82ef6b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
160753a3-19fc-4f08-be8e-0f9c42b73927	cd112fe5-0c94-42f4-b221-78aa67a88c28	c2b4fa64-c2c1-4672-bfd8-4e7b5d8d43f6	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f6ea48bc-3ea7-42ea-ad55-5b0dbcf710f3	cd112fe5-0c94-42f4-b221-78aa67a88c28	a228493f-b29b-4acb-aee3-8e53a0b3b25d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ae8b1a70-f291-4414-a884-04157af6b0c7	cd112fe5-0c94-42f4-b221-78aa67a88c28	e1162b96-7ad5-40bd-9594-490b56fd4d3c	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
89d4d56c-f641-4704-8a92-440a6e33ca5f	cd112fe5-0c94-42f4-b221-78aa67a88c28	a7c8e6dd-ba40-4c26-a44f-6f5d27b62698	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e9552ec2-7cbb-4789-a8c7-6e97046b8a55	cd112fe5-0c94-42f4-b221-78aa67a88c28	0c7612e3-7c10-4ca1-8a9d-f350ee74117b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0c743b61-ab63-47a0-80de-9d2b0b8920e3	cd112fe5-0c94-42f4-b221-78aa67a88c28	06ecd909-ab38-4c7f-a0a8-16d6420a3308	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
953d707d-45ee-40f4-bd69-42db6a6f02f2	cd112fe5-0c94-42f4-b221-78aa67a88c28	552f0633-1c38-47db-b88b-b426253df114	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
ffbc600a-543e-48fa-9a1f-616739e7f916	cd112fe5-0c94-42f4-b221-78aa67a88c28	fcc9066a-29ee-40e8-a4cc-39e7d0ff5883	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
2f736dd5-8f57-44ac-b56e-ab88d53ae83b	cd112fe5-0c94-42f4-b221-78aa67a88c28	0a633284-cac8-4b8b-93db-6726538764c9	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
43e8ac22-0d78-4189-81ed-e19879e79bc6	cd112fe5-0c94-42f4-b221-78aa67a88c28	1e0f2164-5a78-4069-a1a5-a4fdaf48dd05	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
4f625d12-d302-4588-b3fb-5d7940590edc	cd112fe5-0c94-42f4-b221-78aa67a88c28	abe1af21-8a38-4881-a466-76cea6c3a3f4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
485d9ea2-6e9a-4893-a683-5cdea22efbd0	cd112fe5-0c94-42f4-b221-78aa67a88c28	a887fc48-4cf9-436c-84da-c4778757bf7b	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c7a643ee-963f-4ffc-af13-ca5aa247e87d	cd112fe5-0c94-42f4-b221-78aa67a88c28	b975fd8d-8663-47ab-987d-56847a3e797a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9a890952-11c7-4393-87e9-de94b868bbbb	cd112fe5-0c94-42f4-b221-78aa67a88c28	141ada26-3715-4066-8294-25b29b0dcc96	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6b221170-d64c-458b-bb0a-31eeeef9dfac	cd112fe5-0c94-42f4-b221-78aa67a88c28	102dc420-b7fd-4662-bad8-ba7f7cd724e3	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bbd044da-67b3-4237-8055-b815d2541fdb	cd112fe5-0c94-42f4-b221-78aa67a88c28	8adc5622-f3c5-40a5-861d-805e0639cadf	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1aa7d3b7-f41e-4f59-bbee-d7c0a7f9576d	cd112fe5-0c94-42f4-b221-78aa67a88c28	4aab688b-d98d-4470-8886-09e2e48d999e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
44310345-bcdf-4588-bcab-dd20bbe4b968	cd112fe5-0c94-42f4-b221-78aa67a88c28	dd7c949b-bf77-4f9e-80a2-c454b47d8d62	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
080fbf70-3298-4a66-b47f-8e02f55123e9	cd112fe5-0c94-42f4-b221-78aa67a88c28	39028101-e53c-4b15-ba72-26da2dc7e756	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
24e327f9-af8e-4517-9a04-266015b6176c	cd112fe5-0c94-42f4-b221-78aa67a88c28	cba9b16e-5cfd-4ee0-a182-f6af4d626517	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
801f5a50-51ad-4a41-9890-22d2dcfef7a8	cd112fe5-0c94-42f4-b221-78aa67a88c28	ef143131-ceb0-4822-8f7f-b32e53f8cdb1	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
39b69509-bd30-49c8-9abb-5a36724240cd	cd112fe5-0c94-42f4-b221-78aa67a88c28	50b7ab86-eb0d-4c7b-875d-6e448d2e0a70	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
302338d4-721d-4bd3-ae16-2b3277963ba0	cd112fe5-0c94-42f4-b221-78aa67a88c28	bfc30775-59cd-4f86-831d-996eb2c5fa5a	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
6b273284-f046-4216-a270-901cc7333cc3	cd112fe5-0c94-42f4-b221-78aa67a88c28	ba1dd5db-9ee0-4da4-8752-eb43e9c8a295	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1f582eaa-6f04-4ef3-8389-baba0940630d	cd112fe5-0c94-42f4-b221-78aa67a88c28	954a704a-4da5-4dc6-bf41-6daf029a96e4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
28936b2a-30a1-432b-9b28-c8bd974bd6be	cd112fe5-0c94-42f4-b221-78aa67a88c28	69d168d9-7240-4a60-82a2-92144d2356e8	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c14ea51d-7a59-4ef5-961c-54e8e2a0416d	cd112fe5-0c94-42f4-b221-78aa67a88c28	526db99b-3ca1-410d-998e-817c9d4625eb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
1cb3694e-8b5d-4e35-86ae-e5533a8f3fcb	cd112fe5-0c94-42f4-b221-78aa67a88c28	8cac2333-470a-4711-92f4-7bede9c83f84	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b1e22da5-a56d-41ab-8906-7bb770583bb4	cd112fe5-0c94-42f4-b221-78aa67a88c28	4e6d87e7-e15f-4b0c-9c5f-9d13c0c734eb	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
e9a36b20-c33c-4b19-98b4-2324bc63c483	cd112fe5-0c94-42f4-b221-78aa67a88c28	92b08548-b122-4559-afc4-910e3450d7ce	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
f2c19017-8927-4aae-ba9b-d45b90f4ef1c	cd112fe5-0c94-42f4-b221-78aa67a88c28	f907e0e8-bb2d-4907-b6a2-a786210b9e87	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
fbc3ad9c-9d93-4a5b-95ac-24a846fecf02	cd112fe5-0c94-42f4-b221-78aa67a88c28	833a8dfb-88c7-49d4-8350-5e5921f37953	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
c0df8b56-52a2-497d-bf7c-891e283bf671	cd112fe5-0c94-42f4-b221-78aa67a88c28	1e7fc55c-c6bc-41e7-aadc-8d88752f9803	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
733ae566-ecf3-44ab-ad74-30e806a8481b	cd112fe5-0c94-42f4-b221-78aa67a88c28	a34bda89-e2a5-4c20-9188-95ba124d5ace	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
bbed535b-ec52-4fc2-8182-0d5bde732c0e	cd112fe5-0c94-42f4-b221-78aa67a88c28	bb38aceb-1705-41ce-9c24-80775da5c812	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cd761d70-0461-4daf-91f0-2b532990025e	cd112fe5-0c94-42f4-b221-78aa67a88c28	cd321fa9-3214-4694-b6f2-db79ec682fd7	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
11b3f696-63a1-4d03-8a1c-dedc59e9f883	cd112fe5-0c94-42f4-b221-78aa67a88c28	ad7384e8-902a-487a-82d3-55b33b122a3e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
eaacf4cc-d770-4877-9017-d55993db1861	cd112fe5-0c94-42f4-b221-78aa67a88c28	b5ed27f5-d452-4b07-84d9-539fe869388e	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
9495fa1d-af6d-438a-9fad-ca37351ad0d4	cd112fe5-0c94-42f4-b221-78aa67a88c28	a0454995-d917-4e91-8ec5-e5991daddaa4	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
d76b6378-a55b-453d-9b27-32df2c0c0bc0	cd112fe5-0c94-42f4-b221-78aa67a88c28	5227a011-383d-4c9b-a42a-06598a5c8547	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
560d1c05-b0f3-4f01-9e56-280c55409960	cd112fe5-0c94-42f4-b221-78aa67a88c28	9309fd3c-e584-4a76-a31c-3cd5e8f9b194	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
cc8b29ab-a75e-4472-ad37-498484f4d1e6	cd112fe5-0c94-42f4-b221-78aa67a88c28	e0e8a240-ea37-4400-90d2-9a59f6c2e68d	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
0dc352de-e347-42ab-9be8-7d10e817cbf1	cd112fe5-0c94-42f4-b221-78aa67a88c28	8fa410bc-c485-4f90-931f-391e0fd81983	2024-05-23 21:19:14.508475+00	2024-05-23 21:19:14.508475+00
b9a858cd-c623-400c-9794-c58121224b4e	33ba105b-d0a6-4667-b6e9-927859eb4481	4990a392-3b4c-4892-9e6c-76e6cecc9280	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4e725892-7582-4bc6-9765-5c8d1ee59756	33ba105b-d0a6-4667-b6e9-927859eb4481	f503feb9-7558-4ff5-bd66-16fad0cd8a5a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d2de27d0-88a9-45ba-be5e-bdd915473824	33ba105b-d0a6-4667-b6e9-927859eb4481	691a50fb-a2af-4bd5-a85f-1ad3ab57af73	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a2f17c79-7cf4-498d-acfc-936cf3bcae8c	33ba105b-d0a6-4667-b6e9-927859eb4481	3c64be84-c28a-424c-a87e-e06458e58587	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fdd2e749-67c1-47b9-8dc8-cdc0f804a189	33ba105b-d0a6-4667-b6e9-927859eb4481	7949de13-fe43-4946-bfa4-65b756b42e50	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ad3b9c77-a9c6-407e-a94b-911a6c5e2d01	33ba105b-d0a6-4667-b6e9-927859eb4481	793158bd-aacb-4a8c-9d27-31879e222317	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
33d969cc-05dd-46e6-a121-0903900be11a	33ba105b-d0a6-4667-b6e9-927859eb4481	19251ea9-c41b-4207-88bb-373d1b618a92	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
49de8aec-38d2-4fca-8e0f-f99e43a6f269	33ba105b-d0a6-4667-b6e9-927859eb4481	3a504cc4-966c-440a-9a63-26ec0e9564f1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
aa07c503-2007-4a45-b1f7-16896aaae3fb	33ba105b-d0a6-4667-b6e9-927859eb4481	b5a9ac55-68d4-4e2a-8eeb-ddb909d8db78	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f233d808-0199-4b99-bec2-93877502790d	33ba105b-d0a6-4667-b6e9-927859eb4481	6058eb73-6738-467c-8b91-9c84eaa70f2b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
adebb729-9e73-4237-91e5-a388e20a8559	33ba105b-d0a6-4667-b6e9-927859eb4481	7b46531a-93f6-491d-8aee-57b3b17204ad	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1f63c4a5-e41b-47bd-bc60-79463aeeeb6d	33ba105b-d0a6-4667-b6e9-927859eb4481	9618fc26-e1b3-493b-a61a-232a7ab79955	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4028cb97-772a-4293-9705-1e79b207c3a2	33ba105b-d0a6-4667-b6e9-927859eb4481	02ec260b-4589-406a-b044-b1983e374c69	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ba2a5ebb-bb07-4bd8-8c95-f0293fe43542	33ba105b-d0a6-4667-b6e9-927859eb4481	598bcaca-dbe2-495c-9a83-0a5551d475e1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ff81430e-ab00-417b-b5de-3a4cf611d60a	33ba105b-d0a6-4667-b6e9-927859eb4481	531a543f-77f0-4b07-9f69-500c04f6da30	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5aecd1cd-386f-44e5-a433-6d7e5b13b9e6	33ba105b-d0a6-4667-b6e9-927859eb4481	84012120-00e5-42b9-8fc8-12541cda050f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0e455e47-f68a-4897-98b0-c456161e4eb5	33ba105b-d0a6-4667-b6e9-927859eb4481	536a7bad-ec25-4edd-9105-98c3446de139	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1ca5feda-7b77-409f-afff-62d34108b164	33ba105b-d0a6-4667-b6e9-927859eb4481	40dc3eae-9e1c-454a-bb51-44f197d5134b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
eb1940e4-407d-4572-bbdb-1a688e7c2a7a	33ba105b-d0a6-4667-b6e9-927859eb4481	2b4f1a89-f719-42ca-a334-5529cf2c7ce6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
325d185c-8847-4514-860c-edb7221a9323	33ba105b-d0a6-4667-b6e9-927859eb4481	205a9fe5-b317-4c05-8803-1c7d98cc6728	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
376ec4e6-2b44-4d66-905c-3f5f34d0ac14	33ba105b-d0a6-4667-b6e9-927859eb4481	10c56e6a-d65e-4219-b25c-fb624f36a9f8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8bd5453a-742a-4396-bd9a-7553685ebb7d	33ba105b-d0a6-4667-b6e9-927859eb4481	e1f29232-3703-4517-87da-65791a162ce3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
76b38d14-b6fd-48d2-a6dd-a62d77f4dc94	33ba105b-d0a6-4667-b6e9-927859eb4481	28d9a28e-7ece-4ad3-925e-1b976941fa52	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
58c23f8e-7224-4d6c-91c0-470921e21de6	33ba105b-d0a6-4667-b6e9-927859eb4481	8a01b626-ae72-465a-8ba1-5acf0209963d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
65863252-7768-4450-aaa4-a1f05c2fcf9e	33ba105b-d0a6-4667-b6e9-927859eb4481	9fd4903a-b359-4b5c-9e5d-d93e2658fc24	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e1cd25e7-ae95-45a0-9bb5-c7afd6f62ed6	33ba105b-d0a6-4667-b6e9-927859eb4481	d887e66d-5595-458a-a9f4-bf98386d8f53	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6dbf0db7-54f1-4398-b69b-25c3a684f7d5	33ba105b-d0a6-4667-b6e9-927859eb4481	48ba79eb-951a-4707-9e23-490d8b0b418f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4729a323-1651-4710-9e25-1c2924a61c61	33ba105b-d0a6-4667-b6e9-927859eb4481	0833fc29-cdeb-4cbc-84a4-0dca5f35edfb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ec57c1e2-ec52-4b3c-a595-310c4626d6de	33ba105b-d0a6-4667-b6e9-927859eb4481	8c2fba7d-1d6f-424f-a644-28d7e38d9f9d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
018610d0-f5b2-40ca-b5a5-71c50066e764	33ba105b-d0a6-4667-b6e9-927859eb4481	0eaeeb04-a26a-4b46-8b2a-9070ee200a4f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
22421dc9-8c91-484c-91ee-0b4820c9b2b5	33ba105b-d0a6-4667-b6e9-927859eb4481	4365e77c-0942-43a1-8f31-782a88bfa265	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7bd6bec9-dd37-4e66-be9e-6ebccc5d0dea	33ba105b-d0a6-4667-b6e9-927859eb4481	729ba811-064c-4357-8225-b3c6f7030db8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
adfa95b5-abd4-440c-9ec8-67d7ac027322	33ba105b-d0a6-4667-b6e9-927859eb4481	7ec93d74-6bfb-4924-b6a3-ac894e5c05e7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5514a496-c61a-4c6e-9bdc-d8f14535c5f8	33ba105b-d0a6-4667-b6e9-927859eb4481	c3f1ab59-6be3-41e2-a68c-6cf4e714bfd5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f0b47cb0-34f3-4b72-8f39-4c9314eac507	33ba105b-d0a6-4667-b6e9-927859eb4481	16cf6405-f1c7-44eb-94ab-928300c777fb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
47e5692d-a093-4f2e-bab6-17e61617f821	33ba105b-d0a6-4667-b6e9-927859eb4481	dddc0c93-7015-4dbe-b810-bc750fdb8081	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
79c8ba27-47a3-41ee-bd26-e453c8bcf53f	33ba105b-d0a6-4667-b6e9-927859eb4481	d203898d-4125-4c0b-83a0-67d7b0524773	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fcf95c53-9391-4754-a02a-5d03a517b5bc	33ba105b-d0a6-4667-b6e9-927859eb4481	12a807dc-7d5c-4e37-98c8-b07a28f98f1f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d3866c1f-f737-4cc0-bc7f-e6c3af81a1b4	33ba105b-d0a6-4667-b6e9-927859eb4481	50771793-e857-4b72-a9e9-de879aa12ed9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2cc3406b-a7c5-4023-bd99-fb1f3d2ed64f	33ba105b-d0a6-4667-b6e9-927859eb4481	f0e37aef-c08c-4f09-8df6-9067a8d97297	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f475bd7f-ab54-4e80-96c5-f272da66da9d	33ba105b-d0a6-4667-b6e9-927859eb4481	47cf9f8f-8c8a-4ea2-870a-39f5e7c0ea63	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
466639c2-4338-4099-aaf5-7c9af9888b37	33ba105b-d0a6-4667-b6e9-927859eb4481	5b444f2d-dbf7-4ffb-a977-815ed4401b60	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
90182a15-c211-49d0-b214-8a88bae64954	33ba105b-d0a6-4667-b6e9-927859eb4481	c33b9bde-3627-44f0-920f-5f625d66c7a8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
322586f1-2947-4d48-8b15-cc9f1155cb71	33ba105b-d0a6-4667-b6e9-927859eb4481	53a404fc-6ac5-4648-b0b9-eb402c5af60a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2435901a-410a-4491-8cc7-49731a4ba887	33ba105b-d0a6-4667-b6e9-927859eb4481	1391ee7c-4070-4701-a19b-83ac9bc570e3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8282f04b-61ac-41d5-9bfc-5f2abd8907b2	33ba105b-d0a6-4667-b6e9-927859eb4481	56b49b61-640c-4a0c-af50-34c4d57ff002	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1f749e7c-a7af-4533-881b-0a289f33d895	33ba105b-d0a6-4667-b6e9-927859eb4481	c089d975-1478-4949-9a4c-7ea5b89061c3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
24761994-5807-4443-85cf-366e48b42a57	33ba105b-d0a6-4667-b6e9-927859eb4481	9fae4973-bf8d-4639-a8d8-42dd1d8a86d6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
328b5845-a7de-467b-a159-25fb112ac8a6	33ba105b-d0a6-4667-b6e9-927859eb4481	c4886f97-4057-4283-8941-90955ca6b136	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bab90813-5183-4f37-9549-35fe52267bec	33ba105b-d0a6-4667-b6e9-927859eb4481	6dc9160e-efc5-476d-b7c8-cf23aa67617b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d877428f-a380-4130-8541-1712f6da842d	33ba105b-d0a6-4667-b6e9-927859eb4481	538e80b2-97b3-49e5-8f4b-c8c6cffae1d1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
157cc32e-5126-4298-8408-aa4a7c520abc	33ba105b-d0a6-4667-b6e9-927859eb4481	f7fbaa70-2085-4992-830f-9e62bcfdcae6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
15725920-56a9-42a1-a6af-c652e80909ef	33ba105b-d0a6-4667-b6e9-927859eb4481	66d63a0e-4ded-4fe6-8027-df0e5f58883d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c24688cc-9762-4657-b0a4-03d1b0d14e09	33ba105b-d0a6-4667-b6e9-927859eb4481	61d4a736-de0a-46ba-b13e-b1b9bc458354	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7a6e99c8-e2c0-40ca-86d2-04d4b48dcfb1	33ba105b-d0a6-4667-b6e9-927859eb4481	afc9aa8d-45bd-4f93-a36f-a1cab277977b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7485dc63-9fc2-413e-b63d-9dc0f5449ba3	33ba105b-d0a6-4667-b6e9-927859eb4481	8c0befb0-b6df-4e35-89fa-2830f348aac2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
39dfb91d-68ba-4c9f-92d5-743113d4ea63	33ba105b-d0a6-4667-b6e9-927859eb4481	6647e799-322d-4d68-9671-9ee75b221763	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0601278d-123c-49ae-bea9-c7624245f610	33ba105b-d0a6-4667-b6e9-927859eb4481	41b2fefe-fb02-465a-88f1-70d3f4f0035c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9e94898e-e69f-4e57-b28a-7b8d60cc6767	33ba105b-d0a6-4667-b6e9-927859eb4481	9f01b9b9-ff84-4dc4-bdca-bffbc706a4e0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5bd81de8-7f41-4876-923d-6ef9a549cda2	33ba105b-d0a6-4667-b6e9-927859eb4481	499e5da1-163e-4a5b-a7d2-4c18ecbd25df	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0c7e64a2-716f-4343-9bc0-9e5ec365e791	33ba105b-d0a6-4667-b6e9-927859eb4481	5b13adac-657f-45ac-8a63-738966d2211a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e16ab70d-f21a-4339-ade4-8af90e5beb36	33ba105b-d0a6-4667-b6e9-927859eb4481	f78ac58f-8207-4be5-ab66-2f6633a85d31	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bced08b5-87c0-44d8-ad9e-6a94d4117834	33ba105b-d0a6-4667-b6e9-927859eb4481	9e7558b0-fdf3-4975-8d43-2aeacf9d81c1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8bdcd3dd-9e8d-47c1-8a80-a61f669385f8	33ba105b-d0a6-4667-b6e9-927859eb4481	0a132e5e-f8e6-4d23-8003-30c349d2e9bc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
53d82b6a-885f-47bc-8138-7f40850e3fc5	33ba105b-d0a6-4667-b6e9-927859eb4481	4c135345-c7fe-45d2-acab-3882fdf834fa	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b2313fb0-dbcc-4237-b961-fb719460a5ec	33ba105b-d0a6-4667-b6e9-927859eb4481	fe5a045d-c3ed-4aa8-a426-e9e6166cfd9e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5e3dd396-ec51-4d0f-bfa0-7b04ce8a6a04	33ba105b-d0a6-4667-b6e9-927859eb4481	40104ccc-87fe-4b55-995a-a00743d035cc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
349a422f-0727-4548-9745-1869251ef5cf	33ba105b-d0a6-4667-b6e9-927859eb4481	059bc02f-d224-44e3-8553-258d81dd7993	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
37c87d6c-3a5e-4f0b-8eb5-5240fbc884ae	33ba105b-d0a6-4667-b6e9-927859eb4481	2fc748cd-dbbb-488b-8aa0-4f6ddba22f7a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ced25abe-d742-41df-bdcb-d1bbc330efe7	33ba105b-d0a6-4667-b6e9-927859eb4481	742e478d-aaf0-42ba-8fa9-8267808b64c3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
881726aa-ae1f-40ab-99a3-3a5f7e7d2633	33ba105b-d0a6-4667-b6e9-927859eb4481	25315b4a-2e27-43af-9256-47ba33a1178a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
94d81304-14cf-435f-a895-97b3b79f1302	33ba105b-d0a6-4667-b6e9-927859eb4481	81b62720-ffca-43c8-9e58-5c7a53176400	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0481fb32-63ea-4242-8e39-356254f3aed8	33ba105b-d0a6-4667-b6e9-927859eb4481	895cc18e-a7f6-4589-ae67-1360384f09b5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b2f11c65-6d96-4ccf-8cd2-259110250737	33ba105b-d0a6-4667-b6e9-927859eb4481	0e4f9b52-d222-4f74-b710-b4a324153034	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
04fa7470-3db9-40e1-9225-e4b7a9302868	33ba105b-d0a6-4667-b6e9-927859eb4481	c9d037ea-a00d-449a-96e5-d89b605ba3e6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
110ad1dc-3af5-4637-99e2-923c3b0e191f	33ba105b-d0a6-4667-b6e9-927859eb4481	46459ef6-baf6-4729-8232-2a51fc6491a6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
75bb2827-907a-46c5-b156-624ce9d98ab9	33ba105b-d0a6-4667-b6e9-927859eb4481	cdf9a600-84ef-4ea6-99ed-6acd5df192bb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2a1b5256-fced-4634-95e8-21ca8387a8ff	33ba105b-d0a6-4667-b6e9-927859eb4481	63b14f7a-e198-4551-925e-1f9c5d07fb16	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
012b4929-6bdc-4b69-a6fc-a0a0232fef8e	33ba105b-d0a6-4667-b6e9-927859eb4481	a1f30561-736f-4915-92de-9adbb25f699d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
905e718a-97ca-4919-bbfd-619ccebc8681	33ba105b-d0a6-4667-b6e9-927859eb4481	a866e0cb-98f3-4d96-985c-0dc4677efedf	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
051352ef-d212-46b6-93b3-19c96a939d67	33ba105b-d0a6-4667-b6e9-927859eb4481	61098814-7560-4818-a607-9981f1941e2e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
28623367-de78-42f6-8400-80dd3c5707bd	33ba105b-d0a6-4667-b6e9-927859eb4481	2a6c8842-25ec-4eb6-a97a-5fdfa19bbcde	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
82b0c881-3b74-4f80-ac8e-0ad2718f13da	33ba105b-d0a6-4667-b6e9-927859eb4481	8db07b1f-725c-41bf-85f2-1c296043dd9d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
870476f5-e121-4851-8c97-071491bfd997	33ba105b-d0a6-4667-b6e9-927859eb4481	db4436b6-95e1-4705-875e-43be52ed6487	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
db67b1b9-463e-4a47-ae95-98a2b633847e	33ba105b-d0a6-4667-b6e9-927859eb4481	f6540e59-0d52-4780-a526-60f9841eed98	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ef89dff2-f989-4580-98d4-a7e818d393c1	33ba105b-d0a6-4667-b6e9-927859eb4481	57f17ad0-6463-4a12-8b3b-e6cbeb8909bf	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d0edf69a-3700-4594-8985-b2140a3ef8b8	33ba105b-d0a6-4667-b6e9-927859eb4481	511b07e2-02ca-4bf2-83ea-5811dd5cdf9d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0a4bb6a1-313e-4ab8-82a2-b5ef2172c7b3	33ba105b-d0a6-4667-b6e9-927859eb4481	6974d20f-96de-427a-b03d-9b0d9ac53f02	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9ba26948-dbb9-4c1a-9e9d-46853256efa3	33ba105b-d0a6-4667-b6e9-927859eb4481	1e6b46de-fef6-4e73-bea8-1131c9da0faf	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
185d54f1-f332-4b4d-b302-50966014fd2d	33ba105b-d0a6-4667-b6e9-927859eb4481	e8ada8df-d99c-42cb-9d07-95078a422753	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
656e337a-ea21-4ecc-91c1-c7e2da3d822a	33ba105b-d0a6-4667-b6e9-927859eb4481	b04c8eef-dd06-491f-a009-d3ad1d932f8c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
88a5751c-0a4a-4a07-96ce-75af1bd69b6d	33ba105b-d0a6-4667-b6e9-927859eb4481	8283c783-6023-4122-8213-70c33cbf129c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9d4ba5a7-103a-43a1-87f2-7b2a31b70413	33ba105b-d0a6-4667-b6e9-927859eb4481	1aaadbd1-4a0b-4dc9-b559-0cf1c764f18e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
74a85df2-dce1-4ac6-a87d-8482b1db0981	33ba105b-d0a6-4667-b6e9-927859eb4481	6c1a87f2-c162-4064-922f-74c78b11de16	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c020199b-31e8-4f2e-9705-44f22fe93d9a	33ba105b-d0a6-4667-b6e9-927859eb4481	4c73a2b0-f6d6-4e40-b20a-3c6ec7225dd1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c725e145-f51a-4e9c-b32c-22dd96c7bde5	33ba105b-d0a6-4667-b6e9-927859eb4481	3e72bd22-b876-4baf-bfde-85028574fbf6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
20567633-679a-4ff4-8c3e-e1a3f28e18d3	33ba105b-d0a6-4667-b6e9-927859eb4481	fb1e82e3-ae3f-4854-abbf-b279a661cfd8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dd7241d6-c3a7-41e1-97b4-becedb7105a1	33ba105b-d0a6-4667-b6e9-927859eb4481	6fe3e0b2-7449-4185-995c-72b93d510215	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
76b44245-594e-4c9e-8acc-a208c8890646	33ba105b-d0a6-4667-b6e9-927859eb4481	dd2c65de-a5b2-4b58-aa90-32c12ccf2330	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
86edd7cf-2ea3-41ce-b69f-598b1cd1fa21	33ba105b-d0a6-4667-b6e9-927859eb4481	f1d069d8-8c7f-41e6-8ee9-291314a4b685	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
157a3bf9-7b09-4515-8378-420f384f5010	33ba105b-d0a6-4667-b6e9-927859eb4481	8d8efd4c-fa83-43d0-94f1-11e62628c902	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2ea87e20-58d5-4efe-9e82-d65a868d1528	33ba105b-d0a6-4667-b6e9-927859eb4481	3797615d-07a8-4908-8cba-7cccab96e045	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1544fb14-8fed-46d3-bcf1-c24f2037ab30	33ba105b-d0a6-4667-b6e9-927859eb4481	3fd4eb3b-297a-4f8c-bd5e-b4196dcff5e3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0b17ff0b-ce0e-488c-acfd-8f08c4011a12	33ba105b-d0a6-4667-b6e9-927859eb4481	2be467bb-d12f-4e98-bd8b-6f4758ced2b0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2cb41668-99e8-4fda-a2ed-1792842dd61b	33ba105b-d0a6-4667-b6e9-927859eb4481	545ed5fa-bcaf-4fee-8808-dcbe9d23b1da	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
adb840f8-7659-4ce1-982a-456c2ca2b432	33ba105b-d0a6-4667-b6e9-927859eb4481	38bade80-dbd6-41f2-b0b0-1974688afd52	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
cde107d7-c24a-4c05-83c8-1c03bb45ffa7	33ba105b-d0a6-4667-b6e9-927859eb4481	c38ab09a-a847-4650-bda4-47d2e50b8056	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
19d61059-f255-4eae-b214-a5e54558ed6c	33ba105b-d0a6-4667-b6e9-927859eb4481	1f8dc229-e77a-47e9-aaa8-fc3da2d1f49f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
68c3b520-91be-4fbd-b0f8-5be21269e3fc	33ba105b-d0a6-4667-b6e9-927859eb4481	781ddc71-2043-4803-ae4b-64a7721540a7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b7518140-eae7-42e1-a380-81a123dbc748	33ba105b-d0a6-4667-b6e9-927859eb4481	f209020c-301e-4e87-9540-ed64fc9e8649	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4661e1ff-d0a9-4252-b54e-6c24e80ee9c3	33ba105b-d0a6-4667-b6e9-927859eb4481	3521ea4a-ee23-4a5b-88e8-3b3ade993b78	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9fbaff06-7592-45b6-aa9a-7f13d8eec329	33ba105b-d0a6-4667-b6e9-927859eb4481	9f46890b-c706-40f9-918c-dd3089fa0e2c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4a52764b-645e-4ed4-9487-ef97e23c807a	33ba105b-d0a6-4667-b6e9-927859eb4481	67b1c83a-f169-43e5-bcc6-368742ea501e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ee23d419-ba16-4c32-9f30-88a5970ab656	33ba105b-d0a6-4667-b6e9-927859eb4481	a7d10d60-2391-4b6d-a40e-ecc3d0d3c465	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
61348625-fd9d-447c-a7fc-01ec9f443386	33ba105b-d0a6-4667-b6e9-927859eb4481	cf72ce66-04be-42dd-ad3f-91540f939fbc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a3d8c7fb-c843-475b-b83a-2a3a998dae05	33ba105b-d0a6-4667-b6e9-927859eb4481	30356105-2abd-43e1-8238-53d90f9c41ae	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
efde1d88-8930-454d-84b1-f6f7bd284eab	33ba105b-d0a6-4667-b6e9-927859eb4481	017f6ae5-a216-4127-8e79-dae82f965089	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2c34f70d-d402-47ca-8dc0-7b5959dda7cb	33ba105b-d0a6-4667-b6e9-927859eb4481	bea5204d-3497-482e-8e3b-71493cec4054	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d8e60fad-831a-4a11-bd26-7c6b60002e90	33ba105b-d0a6-4667-b6e9-927859eb4481	d4b50761-d7e3-40a3-85de-0cb0d97b4daa	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
061e1106-501e-4b23-910b-bb3b12130a7c	33ba105b-d0a6-4667-b6e9-927859eb4481	0d1c3c4b-be80-4802-961c-6d5468239bb7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
193eaa73-2c91-4e26-9a09-9b2f548be2b3	33ba105b-d0a6-4667-b6e9-927859eb4481	5c22a73a-e94a-4bcb-8a50-187c981e2336	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c5ad5705-0bee-4300-bcb3-e0870f9bcd0c	33ba105b-d0a6-4667-b6e9-927859eb4481	01314dd5-13d2-44de-b703-8ceacbd79df7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0ef1d5a2-75ac-424a-a025-25cdb919ac6a	33ba105b-d0a6-4667-b6e9-927859eb4481	8a9c7a66-b27b-4619-bf0d-787bcd8ef0fa	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
90ca59e9-eeb8-4ae8-85fb-213a47f4dbd2	33ba105b-d0a6-4667-b6e9-927859eb4481	eed94fb6-6fac-46df-9ef5-70c5f99ed297	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9e61eb1a-2468-4e17-be34-1d41391732a7	33ba105b-d0a6-4667-b6e9-927859eb4481	8e585878-b6f4-4d2c-b2e9-c9e1f7cf50e9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c8174f56-abdb-41de-b0ad-1eebb7c29918	33ba105b-d0a6-4667-b6e9-927859eb4481	179f878d-f262-484b-9e99-2f9b9fd8ac88	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
986feb53-204d-4894-9832-94bf3e82466f	33ba105b-d0a6-4667-b6e9-927859eb4481	e466907c-b69b-4f4a-9b28-644b090e2325	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6039da42-4c72-41aa-a394-a99c7d6cfc62	33ba105b-d0a6-4667-b6e9-927859eb4481	179bb60a-ae3b-4e11-ba9d-28f53ed1812f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
27c464bf-2876-4f1f-b225-e6e149fa89a4	33ba105b-d0a6-4667-b6e9-927859eb4481	ac41272c-0a4d-4ba5-b740-2fb9847104fd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b6013faf-dca5-457e-9134-4fb2be8f8d64	33ba105b-d0a6-4667-b6e9-927859eb4481	ec452ceb-2f97-4fbf-bacf-d447ed7a4c1f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5ad996c9-8231-46a0-8728-45947881be94	33ba105b-d0a6-4667-b6e9-927859eb4481	2a623867-95a1-428b-b8a1-40fb7b8273e9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
69c6287c-4bcb-4ebd-ae1f-c08f9c07612b	33ba105b-d0a6-4667-b6e9-927859eb4481	db798725-9768-4608-9bdd-34cec117e875	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
06b02ae8-0195-4560-b5bb-e8fee65b50f5	33ba105b-d0a6-4667-b6e9-927859eb4481	d655db93-b004-461e-888f-384f31dd7b29	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3461d4c9-e590-4a43-a51a-cdb6f9e43041	33ba105b-d0a6-4667-b6e9-927859eb4481	81d0d03d-737a-4a93-92c4-b57c4a21f779	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
057210fb-71cc-4bc3-acfc-8f4945a97b2c	33ba105b-d0a6-4667-b6e9-927859eb4481	791e44b7-9ee0-46e2-9a18-40e0b42dd23b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
45cede6e-c281-4646-a156-2697482022e0	33ba105b-d0a6-4667-b6e9-927859eb4481	c923c6a6-2cc8-4469-946e-3b6971dbf060	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
47d4670d-b776-4032-af84-752965f8f862	33ba105b-d0a6-4667-b6e9-927859eb4481	2657705a-9ada-490e-b519-528ccf60fb97	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9346bba3-2fbb-4006-8477-48e8c382693b	33ba105b-d0a6-4667-b6e9-927859eb4481	7467a7ab-8c99-4c65-a227-190291a159b1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
70a6b9d3-68ec-4214-9190-a2d5adb8914e	33ba105b-d0a6-4667-b6e9-927859eb4481	e2a2c57e-d46a-4105-9357-f2e75087645f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c5c7a964-8312-4a14-b309-56b33af63762	33ba105b-d0a6-4667-b6e9-927859eb4481	f285714b-68b7-4147-9724-86f059dbe6f4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
395018bd-4526-4df6-8dfe-0244a5ebdfab	33ba105b-d0a6-4667-b6e9-927859eb4481	1a10896b-8cff-410c-b71b-90ab9dcc91ef	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
619f1ded-946f-43fa-9b2f-4790b657cf15	33ba105b-d0a6-4667-b6e9-927859eb4481	55fddcad-8c3a-4d8a-8ecb-d068c244d942	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b88bde53-9c95-46a0-a30a-4452cff432ff	33ba105b-d0a6-4667-b6e9-927859eb4481	3ca6aa15-539e-4ba6-aeb6-a0e1a4af12e6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f49c49fc-2be3-481e-886a-0303158fe8a2	33ba105b-d0a6-4667-b6e9-927859eb4481	f25a391c-375a-4752-9d61-7d278001ed59	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
44daec94-9560-431a-b201-97fe2f8e87c5	33ba105b-d0a6-4667-b6e9-927859eb4481	11e21752-5717-47b1-8b96-f092dff10b39	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1f8901f0-4446-414b-821e-d6fc6647f932	33ba105b-d0a6-4667-b6e9-927859eb4481	3ccbd001-7efb-4a38-aa4b-01b130232e69	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2e909eac-c529-4360-924c-8ca08c4c597f	33ba105b-d0a6-4667-b6e9-927859eb4481	2164853b-b028-460c-8cbb-f38e127d12fa	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4da99177-6a30-4759-a680-b70b96d4edca	33ba105b-d0a6-4667-b6e9-927859eb4481	ee7fc232-90fe-418a-a120-5bdf4277dd6d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3e72dff1-3382-4806-b2e4-680ad6724b64	33ba105b-d0a6-4667-b6e9-927859eb4481	339bf2dd-5330-46cd-a893-6c81233bf761	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3822035d-51ab-4f7b-be27-ebeeb4ae92fe	33ba105b-d0a6-4667-b6e9-927859eb4481	b9c33ecb-37a2-47ba-8d9c-9e0ae3980f4a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
22f47e5a-3d50-419d-b2ad-a76531301a76	33ba105b-d0a6-4667-b6e9-927859eb4481	820e292a-cb17-4727-aabc-4d9b6f7fa9be	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2cfcb4fd-afee-43b3-9606-5337b5e2ed06	33ba105b-d0a6-4667-b6e9-927859eb4481	9f40b8e0-7bf5-4a87-8341-0d4e5f294fa7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fda5ea1e-c6a3-42fa-af30-878747422236	33ba105b-d0a6-4667-b6e9-927859eb4481	7a3764ce-ed85-470c-8bb6-b9de2fbdb95f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
35597970-4c9f-4baf-9173-ca3190bf2628	33ba105b-d0a6-4667-b6e9-927859eb4481	ca9877ee-7d6f-472b-9e97-ea942f28bdc7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
87df22c6-c3f3-423c-9291-8017e675ed9f	33ba105b-d0a6-4667-b6e9-927859eb4481	c6f235c2-afd2-4d7a-a99e-535a9ebe588c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d7995f2a-d721-4fa6-9dec-ed4237dd1e76	33ba105b-d0a6-4667-b6e9-927859eb4481	ada2db34-cea6-471c-93de-f42de5ff3d66	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0b6bb694-f20d-4298-b6cf-f5494f2c9e74	33ba105b-d0a6-4667-b6e9-927859eb4481	a8ed83e9-940d-4cd2-bb60-b43940d20a0c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5ab3598c-6559-4719-bca5-914dbc2555a9	33ba105b-d0a6-4667-b6e9-927859eb4481	f67ca84e-9da8-4aa3-a075-5d1119802f9b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d31d334a-1cce-4c6a-80ec-a96dedb64cae	33ba105b-d0a6-4667-b6e9-927859eb4481	0ffa64f2-ab01-40ce-a404-f02d08aacda3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a17d61e8-00c1-4c4d-bd6b-339345268cdc	33ba105b-d0a6-4667-b6e9-927859eb4481	3e3f77b4-4ff2-481d-907d-0e0506f225bf	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
903e91ac-bdcc-4d09-9c49-767d6286c919	33ba105b-d0a6-4667-b6e9-927859eb4481	ec657423-2bfd-416d-b911-1cd5f5a747da	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4f5cdd94-84eb-4492-986d-ad1f06269b0e	33ba105b-d0a6-4667-b6e9-927859eb4481	95069c11-8df1-4295-a5ff-eca483de3063	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0a51c021-416c-4696-b428-945cdae713df	33ba105b-d0a6-4667-b6e9-927859eb4481	95aaf308-5f38-4161-87db-833a6f2f6ea3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b8cc08a1-4981-4505-99f8-eb5062b1b8b7	33ba105b-d0a6-4667-b6e9-927859eb4481	aeb6148d-78b2-42a4-aab2-8e2413536702	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f40f9c2d-e830-493b-8604-597263f0daac	33ba105b-d0a6-4667-b6e9-927859eb4481	80d1c48c-b87f-4017-a75b-50b5f363857d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2ed8f34c-8fce-4cfc-8ea2-cd8a258a0c37	33ba105b-d0a6-4667-b6e9-927859eb4481	38fa1334-0907-4b38-aaf6-65aa99ef83dc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
04719075-578b-48a3-ae74-ed955eb79f25	33ba105b-d0a6-4667-b6e9-927859eb4481	152fd163-e248-4062-8a75-6dd5aa945840	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d3cdb774-3c75-4161-9d9a-623e24f79efa	33ba105b-d0a6-4667-b6e9-927859eb4481	e89d3bec-39a3-486c-bf99-43c4f1846dce	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b25eddfe-972b-4891-b8ba-eda4a6947e87	33ba105b-d0a6-4667-b6e9-927859eb4481	89fed694-8cfd-4818-ae01-505934ec2f8c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
af260b64-a498-4eb0-8be7-815dca34cf45	33ba105b-d0a6-4667-b6e9-927859eb4481	8d2b0e69-dfe0-4c1a-bbe2-359d28446b6e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
13c0659f-722d-4fc4-8f29-8a20bbf4a4cf	33ba105b-d0a6-4667-b6e9-927859eb4481	53393c97-98e4-40f4-9a54-010fe4295dd0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5a7d6a4d-3eb9-4af9-af36-343572274e5d	33ba105b-d0a6-4667-b6e9-927859eb4481	a9b502fc-20fb-46d3-83da-9df724b3a099	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9485ae1e-6823-4ac5-9ebe-dc1c155568b1	33ba105b-d0a6-4667-b6e9-927859eb4481	2915914e-f69b-4cfd-ad01-111dfa753770	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
49852d55-5df4-49a8-ba4b-b58f99faff78	33ba105b-d0a6-4667-b6e9-927859eb4481	06a2b0e0-cbb2-49ad-9184-f27371a0171e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6a16ac35-fdd7-43b1-985e-0daae0e4a39a	33ba105b-d0a6-4667-b6e9-927859eb4481	106c01d9-57ca-4434-9986-1ebec31ceff1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b0119e44-9a2f-4842-b621-19851716f3b7	33ba105b-d0a6-4667-b6e9-927859eb4481	d5a41768-aecb-4878-96dc-e54fd9392aba	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1383c936-47be-4345-bea9-c87ee2d776f3	33ba105b-d0a6-4667-b6e9-927859eb4481	ac3c530c-fac5-4b4b-b3b3-e75fc8a35fa6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
673c42a9-7f4e-45f0-9cb3-51f2ca377b72	33ba105b-d0a6-4667-b6e9-927859eb4481	3cf0a06e-ad71-4347-b0a4-6f6aed6baf23	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1aff2797-483b-4916-8b56-829bddc6b44f	33ba105b-d0a6-4667-b6e9-927859eb4481	901264cf-8113-4bf9-8da6-018424e03196	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2e184969-ccff-4812-b314-57bc4f70bc52	33ba105b-d0a6-4667-b6e9-927859eb4481	331f2b6f-bfd1-425d-8874-19c3f1eaa5e9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
91b49d08-bb5c-44db-822c-4ee29e7f46d3	33ba105b-d0a6-4667-b6e9-927859eb4481	aa35fda4-f6b3-4212-ae86-2410b168841a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a4c3b11a-de21-4a70-9894-6db7e4f0922c	33ba105b-d0a6-4667-b6e9-927859eb4481	5aed1819-fdf8-4a20-8211-2cbcef8cb2ab	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5fbd850b-b2d0-4fe9-8305-546addab25e3	33ba105b-d0a6-4667-b6e9-927859eb4481	e4160613-c418-4b30-93c2-3b35964ba568	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0aac4649-6da2-42ec-8860-64dd67808456	33ba105b-d0a6-4667-b6e9-927859eb4481	f087e915-83b1-46d8-9c8f-a1d1b2e57eb1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1f049b43-2c08-431a-8de8-a3e7c25ee761	33ba105b-d0a6-4667-b6e9-927859eb4481	20e0e3dd-4f94-48f7-83b6-4eb88f9c86b8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
096ab781-54c5-4ca9-81eb-ae8e9fc3f794	33ba105b-d0a6-4667-b6e9-927859eb4481	c6021acf-f869-4c5b-89e7-af209997b0e3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
66f70029-07c1-40ec-8e2f-49e04046f469	33ba105b-d0a6-4667-b6e9-927859eb4481	eaac721f-eeee-4f0c-9976-57cdc5c1da8a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
22944b07-cacd-4932-887e-b0ef7f5d27d7	33ba105b-d0a6-4667-b6e9-927859eb4481	cab79f25-9629-477a-81bb-7e00da7a13a4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fbd1656e-a231-490b-86d4-69f7f244479b	33ba105b-d0a6-4667-b6e9-927859eb4481	a12d4e91-d5b7-440f-a3f2-2bfeee78a54d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a908b524-6ab9-4f05-be7b-e55a15075e89	33ba105b-d0a6-4667-b6e9-927859eb4481	f88b35ea-f95e-419c-8173-af39e9fc801c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
baaa1fa1-632d-4aec-a149-77957171f0f7	33ba105b-d0a6-4667-b6e9-927859eb4481	6cb63dfc-41a4-457a-a201-8dde951d3915	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
081a9752-024b-4730-a041-ebc2b1032d3f	33ba105b-d0a6-4667-b6e9-927859eb4481	c4919058-d2ea-444c-b75d-3cd53d7ae5ec	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8a62a304-4eb4-4a5e-83e7-c99a7cd2796b	33ba105b-d0a6-4667-b6e9-927859eb4481	612f91ab-09d3-436b-a92f-c5d2ef53267a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dd376cb7-66eb-49fb-847c-479ca76c2552	33ba105b-d0a6-4667-b6e9-927859eb4481	046d9d4e-5416-4f1f-b548-f9c117fcc2a5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a4b4da87-97bc-4316-8f74-0e095d3a01eb	33ba105b-d0a6-4667-b6e9-927859eb4481	61c60468-4b7a-4b50-9e9e-f22ef0db9d5b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
43ab209f-f4f8-4d43-8a86-e3d46b35fae5	33ba105b-d0a6-4667-b6e9-927859eb4481	e5817e5b-dd37-4327-8d64-ce51cd97298d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
04602fd3-a445-4dfa-b29d-e4bf6f559d12	33ba105b-d0a6-4667-b6e9-927859eb4481	a5c5325e-d4d6-4d51-b1ec-ffe8d889410d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c76a7ca0-1d0e-4efd-b533-e1340a20a211	33ba105b-d0a6-4667-b6e9-927859eb4481	ee20fec2-5cec-48f3-9682-7d3a031013a1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a587365e-1bd9-4551-b5fb-20f1aeccb968	33ba105b-d0a6-4667-b6e9-927859eb4481	dfbe5ffa-8c3a-4431-8633-16a91c4c8e7a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
060e6332-7dd9-49e0-ae1c-a073a1506ea6	33ba105b-d0a6-4667-b6e9-927859eb4481	71440925-2e06-4ca1-b961-10571536c0de	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a1a2c7ee-1d86-4ca8-b303-6e7a6a6b3b78	33ba105b-d0a6-4667-b6e9-927859eb4481	ced86a58-1356-421c-9299-4e9101476764	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5a78160b-2950-4b77-b54b-4a1400cf6548	33ba105b-d0a6-4667-b6e9-927859eb4481	312a38b3-b8d2-407d-8194-3ac102a25feb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2853008d-feaf-44f2-8825-c29904a4b102	33ba105b-d0a6-4667-b6e9-927859eb4481	b53f16d5-53c9-48f2-9365-b99075ef9d4a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fa2a9675-5944-4d3c-a166-3903c84c436f	33ba105b-d0a6-4667-b6e9-927859eb4481	c8a7ace8-a004-4b25-a544-95cdb1f8fa24	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
231a2ff7-348c-4f35-ba38-88e133933133	33ba105b-d0a6-4667-b6e9-927859eb4481	1135a2d2-1263-4fc8-a24e-5ae4a3056341	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0ec1643f-8c57-46e2-bf4e-45001250b550	33ba105b-d0a6-4667-b6e9-927859eb4481	8761727b-6676-4df3-b494-11578e16a4f5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8a4d8305-7e77-4922-85c5-72eced5e726a	33ba105b-d0a6-4667-b6e9-927859eb4481	436bd090-b753-4806-bd98-1f8affac5d9c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
771754da-2367-4eeb-9f40-818428e535b6	33ba105b-d0a6-4667-b6e9-927859eb4481	03e00c6d-d796-4098-aa58-0be80ac18bf7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7bddcefe-cb9c-444c-8a1e-4dcc7016edfd	33ba105b-d0a6-4667-b6e9-927859eb4481	9d9fd90c-4512-47d7-82bc-d63082d752dd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e04669d8-5ba7-4608-ad85-f0875c4e6b96	33ba105b-d0a6-4667-b6e9-927859eb4481	46538421-9341-4d9d-bae6-05b9a40d28b4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ee3efc30-1a70-4c47-9355-fd00e99d715b	33ba105b-d0a6-4667-b6e9-927859eb4481	e8dcb1f1-8d31-4723-9b38-18dc2d6a7ecc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0a2d5109-5641-48d6-b35b-b751e0aa09e8	33ba105b-d0a6-4667-b6e9-927859eb4481	4ee55aa6-4afc-414c-a234-ef10db07284c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8c103653-8500-422d-ae9d-a8cd999f146d	33ba105b-d0a6-4667-b6e9-927859eb4481	d018434a-0d3f-4ab6-8284-d62db75dc61f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
70ba0622-1352-4e2f-bea8-d726a9f5700a	33ba105b-d0a6-4667-b6e9-927859eb4481	4d72a954-8a3a-4ab3-bbde-88f12cb8717d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ecf16789-cbc3-4059-8843-37766a9faaff	33ba105b-d0a6-4667-b6e9-927859eb4481	2d1f4466-cdb5-45c3-baa7-214372c06081	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
61184c12-8bb3-4f7f-988a-8209160d0215	33ba105b-d0a6-4667-b6e9-927859eb4481	9765fb91-5321-4271-8ad5-312e4f4a5209	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1f980a27-708d-4f4b-aa28-c7f7b9c7302f	33ba105b-d0a6-4667-b6e9-927859eb4481	93f07369-806f-48f9-8563-5a9a733789e2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8f5aede5-1772-453c-afe9-11013e801917	33ba105b-d0a6-4667-b6e9-927859eb4481	3f3fac3c-5ddc-4858-9049-0bd1d8078c98	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0c9d1836-1861-403f-af05-c9cfc4f701f6	33ba105b-d0a6-4667-b6e9-927859eb4481	b6c428a9-1989-4f40-9663-728a19e94c3d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
285cf813-e228-491c-8369-88003b47c64c	33ba105b-d0a6-4667-b6e9-927859eb4481	c38b3bd2-d37c-404f-a6e5-2c988a872fd8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
184d0c17-ed83-48f6-bcc7-0f515614c9d8	33ba105b-d0a6-4667-b6e9-927859eb4481	ee0ba439-f04e-4e69-b66e-081e84b7a563	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
410bde84-b555-4d00-bf99-e8bb55e9caa9	33ba105b-d0a6-4667-b6e9-927859eb4481	244b6a83-a17e-42b9-bc6f-4a8a8e99f31b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2f52c53e-28df-4702-884b-7135f0d233ec	33ba105b-d0a6-4667-b6e9-927859eb4481	313d1c60-d5cc-4288-b42f-6aeb1aa0315d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4ba783ab-fd93-4a18-914d-5791b4085f0b	33ba105b-d0a6-4667-b6e9-927859eb4481	487b6c10-98de-4894-82b0-a0a6dd2a7f8b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5a190528-2634-4f0d-9783-af896205be9f	33ba105b-d0a6-4667-b6e9-927859eb4481	0d203413-b7cb-43bd-b3cf-be3d2267d19d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
988292e7-7d3d-4d74-b7f4-58f0a8c8a109	33ba105b-d0a6-4667-b6e9-927859eb4481	33b3289f-2079-4c5a-be64-de420cfc7060	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
90b32fe5-b7b5-415a-9662-a1bc55c4d51d	33ba105b-d0a6-4667-b6e9-927859eb4481	22d62f74-8bf3-4dd9-9202-020bd743bfc0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
551fa47d-50e8-497e-bc7c-0cf33621fbc1	33ba105b-d0a6-4667-b6e9-927859eb4481	9fbb0636-93c2-4163-9a6b-c63ccf54122c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a426a58c-321c-451c-a83d-ba60f0beab28	33ba105b-d0a6-4667-b6e9-927859eb4481	e9dc3d55-7e98-4995-9a71-7075d98e795b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0c797ed4-363e-4ddd-ab87-c81afec389b9	33ba105b-d0a6-4667-b6e9-927859eb4481	efd8793b-dfbe-417a-aa2e-716dffc38f8b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1a1fcc01-d02a-4162-83fe-077021d0ebbf	33ba105b-d0a6-4667-b6e9-927859eb4481	61c4342f-1a18-4720-bedb-566268cd56ba	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
491b8df5-be21-46ea-8fe2-39dcf6394fdc	33ba105b-d0a6-4667-b6e9-927859eb4481	d01d74f7-08ab-4685-9a7d-1509e25ae1b6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b273dc59-61b5-4f43-80b8-17fa80be7338	33ba105b-d0a6-4667-b6e9-927859eb4481	a02e39be-fa91-40a2-8450-3779cf175047	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
aa31c4d7-8d04-4b12-b170-76bb23a82f34	33ba105b-d0a6-4667-b6e9-927859eb4481	cf1fcdea-8ca0-4ffe-93bb-aaeebbf8c6a5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
caffedf1-1111-46fa-b59c-3c03360430cf	33ba105b-d0a6-4667-b6e9-927859eb4481	6925e912-9431-436a-b4a4-17450fab7ec0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b29e29ea-c710-45a9-8a00-46f6ab898656	33ba105b-d0a6-4667-b6e9-927859eb4481	19e11347-c03a-42a8-8713-1d04deccc0c9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
157db6d0-9880-4939-a899-aadf9ee94490	33ba105b-d0a6-4667-b6e9-927859eb4481	bc3bac42-753e-48e5-adc6-f969ac366645	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3b32c69d-2bf2-48f6-bc62-f3d02841a3ad	33ba105b-d0a6-4667-b6e9-927859eb4481	a8efaa16-6511-424c-816c-e171ebfb0aca	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d7ff2f70-929d-4122-b7f6-d171f5167c45	33ba105b-d0a6-4667-b6e9-927859eb4481	a90c8987-c7b3-4f1c-bede-0cd4af926f11	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
11bf972c-c5b4-4943-9adf-b6c042ed66b1	33ba105b-d0a6-4667-b6e9-927859eb4481	f471fd43-e84a-4e68-8e16-cb799b43116d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d27355be-1496-4e39-9101-636b704520f7	33ba105b-d0a6-4667-b6e9-927859eb4481	62c94eec-08fb-4946-8d6e-fc91e9e1e3b3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7e394f95-1beb-463c-83c0-18e394a37692	33ba105b-d0a6-4667-b6e9-927859eb4481	63eef403-d624-4098-8339-72d14df4caa3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c0b0fef2-8150-4141-a0e1-1558a78f2e18	33ba105b-d0a6-4667-b6e9-927859eb4481	8431b50d-5783-4016-b519-9ca0e3156205	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
856fb53d-2240-4a95-9f95-f91116adf430	33ba105b-d0a6-4667-b6e9-927859eb4481	890dd3d6-3af0-4be4-97ca-eafeb8573c09	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c4b887d8-039f-4103-b9c7-c8636784c543	33ba105b-d0a6-4667-b6e9-927859eb4481	448065cd-fe23-4b2e-8e12-fbbd33829233	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
646097cd-d13f-45c1-a2ae-9d63bd1804da	33ba105b-d0a6-4667-b6e9-927859eb4481	2f83844c-9384-4458-8a87-73cc742c435c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
154cca3a-564b-490d-ac5a-f89d33af71bf	33ba105b-d0a6-4667-b6e9-927859eb4481	712dc761-2981-408d-b616-36e76f628864	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8ae8ca73-a6fa-4dfe-8579-7515968c0661	33ba105b-d0a6-4667-b6e9-927859eb4481	54556387-fd94-43ea-9ef2-7f1c0054b976	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
790a62d6-d6f5-4692-b054-e524d0e8a365	33ba105b-d0a6-4667-b6e9-927859eb4481	949af886-60f4-4fc2-ae20-8dfee15f4523	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
98e38f10-863e-457e-8c89-9a23be96066c	33ba105b-d0a6-4667-b6e9-927859eb4481	da3e26cd-9d4c-4e75-bf3b-28b8e4f1a2b7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
29b04209-2883-4faf-ae79-cd49389a44dc	33ba105b-d0a6-4667-b6e9-927859eb4481	b0c14d48-72a8-4989-af5b-b8dd8c298e49	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ced1e813-f30c-40d2-9c17-694dcd4b1534	33ba105b-d0a6-4667-b6e9-927859eb4481	8ae12903-b894-4b8a-9bf6-96a3c0409581	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
352d7e71-3dce-4d1b-beab-c6d6f58455ad	33ba105b-d0a6-4667-b6e9-927859eb4481	bbff580f-6974-4a42-bc8e-f7053dc0bdb5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6ca269fc-ee3a-4a7d-b623-a1895168acf5	33ba105b-d0a6-4667-b6e9-927859eb4481	91053158-b4f4-456c-9ba0-f5f933222e5a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
51e1b661-a898-497f-89eb-d4fcf293f21b	33ba105b-d0a6-4667-b6e9-927859eb4481	326cb7bf-998a-4499-8dfa-9ed5af4fe8e2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5e7f1699-b011-46bd-a452-158072f0f0fc	33ba105b-d0a6-4667-b6e9-927859eb4481	5d2d76ae-b03e-46b9-9868-403471183594	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
87a6bbad-5401-414a-8b89-75e2bf059dab	33ba105b-d0a6-4667-b6e9-927859eb4481	0ad836d4-e9a4-4c1b-ba2d-36a9a7a1f172	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6393cbec-992b-4077-9a6c-c9c349a1f82d	33ba105b-d0a6-4667-b6e9-927859eb4481	209fb6f9-e81d-4a9e-a8a2-2d91138ee2e7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5da848fa-7f0a-4182-be78-cd63e453c3ed	33ba105b-d0a6-4667-b6e9-927859eb4481	a53728d0-b13b-42b6-a1cd-9ee0c6813691	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7a03d7f2-c919-4665-8a4e-35e61f0aa60b	33ba105b-d0a6-4667-b6e9-927859eb4481	05bf30c8-b9ba-442e-adc6-e75cd0c13eba	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1c95468a-8f3d-4dad-8c18-2a1b81ec2b6f	33ba105b-d0a6-4667-b6e9-927859eb4481	d3ab9f6c-2eb7-4dcf-8164-6d697dbe401c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
08761e89-1279-4724-8b00-aa1919ea158e	33ba105b-d0a6-4667-b6e9-927859eb4481	6ed2ca88-75ee-46b2-a6c4-f3c039427c47	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1a3fe08f-d652-4d43-9dc0-88a82eb9d6c6	33ba105b-d0a6-4667-b6e9-927859eb4481	5e892c09-3743-4225-9698-99f2edb38147	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
17b013f1-a48b-4008-8692-fbe94d6ef40f	33ba105b-d0a6-4667-b6e9-927859eb4481	9a7018d0-4760-44e3-a28e-58cc3fa92ee4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f43d9acd-4e5e-4b10-a5f5-d7f57aeddb53	33ba105b-d0a6-4667-b6e9-927859eb4481	91c38df7-9df0-4e04-bda6-40394116f661	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
51b1d7ca-616f-4098-923a-f7cb423f3397	33ba105b-d0a6-4667-b6e9-927859eb4481	f35656cb-c73e-423d-b415-151045d39041	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
73c42cac-0437-432f-9ab5-e5a50a7888a7	33ba105b-d0a6-4667-b6e9-927859eb4481	fb634a4a-2bd5-49ab-84ce-4c5db408d1ad	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
217770c9-3f9d-480a-bfb1-6455565a7999	33ba105b-d0a6-4667-b6e9-927859eb4481	50cbec59-9a2b-42a9-a453-c1c54d6f4b12	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
31f39711-7126-44ca-a85c-bde908b46bc9	33ba105b-d0a6-4667-b6e9-927859eb4481	44a7d6a5-b261-4ba6-9346-7b6009bfabf3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5c714c63-0ef1-49b1-b0de-1ec8ecc68d3e	33ba105b-d0a6-4667-b6e9-927859eb4481	c3c170ab-99dc-4370-9116-b635db7bac67	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bf4f344c-dddd-4014-83c2-383e168bd6d5	33ba105b-d0a6-4667-b6e9-927859eb4481	9af83db6-a91e-423c-b2ef-bf3fba38b6ef	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8c1630ff-7dff-430e-8360-80ee337f3c9f	33ba105b-d0a6-4667-b6e9-927859eb4481	3e37dc98-958f-4283-906c-fac29b4ce27a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7490403d-ee0f-43e9-9722-8f3e259fc1ba	33ba105b-d0a6-4667-b6e9-927859eb4481	c7432204-89f9-4271-90c7-0ae0f2e3f0d0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1847e237-7f37-40bc-958e-9fe756b179ed	33ba105b-d0a6-4667-b6e9-927859eb4481	0dc1abc0-9ce7-4c2f-8c97-e03a987e8a21	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ef71c613-ec56-40ef-8e17-aefc09b65094	33ba105b-d0a6-4667-b6e9-927859eb4481	e456e281-1ee2-45e1-8203-238bee1c3e80	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
66c779d1-526b-465a-9409-6ff80389fded	33ba105b-d0a6-4667-b6e9-927859eb4481	ae1aaa83-1643-4ba5-b768-eb73d5c1de49	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
398ba1a5-f5ee-4e18-95a1-2071ff109f98	33ba105b-d0a6-4667-b6e9-927859eb4481	2d702569-4e78-4d1a-bbe7-ee6a81b4dbcb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9767510f-d40c-4d1e-b9fd-f23ec73f0d3b	33ba105b-d0a6-4667-b6e9-927859eb4481	da74c625-7125-4e81-9db9-c203e9d6818f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7f983300-ce43-4eb3-9eef-92f18f78214e	33ba105b-d0a6-4667-b6e9-927859eb4481	219fe38d-1f54-455d-be5c-9a91a03b5d66	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
76285bc7-332f-4b6c-836c-4b4c74171f7e	33ba105b-d0a6-4667-b6e9-927859eb4481	94fbdc33-6f5c-40bb-ad15-8c82b52a96ab	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b23915a6-e602-4eb8-b1f6-ae7d2af5f237	33ba105b-d0a6-4667-b6e9-927859eb4481	0978d229-956d-4331-b5d2-01e7b8c8c9d8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
88780da2-d866-46fe-83e2-74f87aab4d73	33ba105b-d0a6-4667-b6e9-927859eb4481	fd22b8c8-c356-451f-afbb-27c2e3f52240	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
539767c5-d133-4440-8185-9f2c2d20ae69	33ba105b-d0a6-4667-b6e9-927859eb4481	001f1f6c-61eb-4319-9ef8-d9ebaf9cb701	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9b97636d-ab77-4821-bab5-d4beebe8dcc0	33ba105b-d0a6-4667-b6e9-927859eb4481	94f63765-e9dc-42d9-a46a-0c8756a95984	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
579bbaba-7840-4086-8045-21e48d6a8dae	33ba105b-d0a6-4667-b6e9-927859eb4481	c4ce1d94-5574-49d6-8583-4cd754c7d4d6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
eb01a03b-e89b-4d27-874d-230aba4ed6f4	33ba105b-d0a6-4667-b6e9-927859eb4481	d6c7ef74-720d-49e8-af44-164271bd6f96	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6da25a3d-5df6-41ab-8da8-e78cb8d261e6	33ba105b-d0a6-4667-b6e9-927859eb4481	cd1607b6-6b70-45eb-ae3b-91eca7e843f0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b7731821-59c4-4cd9-9c9c-d46f44ea2e7e	33ba105b-d0a6-4667-b6e9-927859eb4481	a4b3cbd0-39fe-4b3e-b395-f4bd5f025c94	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2072bb2f-642e-49f7-ad5f-52ed5c8c8245	33ba105b-d0a6-4667-b6e9-927859eb4481	eb8da0e6-e6a3-418b-9b6b-2fcd2a09ccea	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
51492a4b-74bd-4787-b1a2-e753b9847f9a	33ba105b-d0a6-4667-b6e9-927859eb4481	da332d3d-e43f-41bf-bb51-17f7a79a6f1c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3a6b5aa8-9c94-4642-8efe-ebe29dff8243	33ba105b-d0a6-4667-b6e9-927859eb4481	bd8487f3-d855-4d04-b38d-de59be5ff422	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ffc4da80-3c8e-4021-85e9-7d76c442362d	33ba105b-d0a6-4667-b6e9-927859eb4481	8b8e9742-7065-4026-b027-2270f7f73413	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
69e4edd8-5bf7-4422-9f16-693f1db2d373	33ba105b-d0a6-4667-b6e9-927859eb4481	008bae1b-e8ea-46d2-8b92-4144def10086	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
63d3eb6e-0d0e-4f3e-945e-178783ea74c3	33ba105b-d0a6-4667-b6e9-927859eb4481	6cb0d03c-63dc-4161-93ad-096797488c3a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a1f8e6b4-0cc6-4db4-a4af-ccf2abb7225d	33ba105b-d0a6-4667-b6e9-927859eb4481	a960a468-63a8-4fca-80e4-b199017bb514	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
26995f04-6415-4503-ba6f-11168e87237f	33ba105b-d0a6-4667-b6e9-927859eb4481	159a6e4e-a06c-49fb-bb18-3b221f15c3ba	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5dd42ab0-3d2f-4dea-a637-6d11949322b2	33ba105b-d0a6-4667-b6e9-927859eb4481	0cd2664b-2bc4-495f-aaaf-6fd7f4cef2dd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7d40ebfb-4696-4f70-ab2b-f45779489442	33ba105b-d0a6-4667-b6e9-927859eb4481	8c5b5a59-b6b2-40a5-afae-0609b70c5290	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
35acf6d1-4e54-490e-8b9c-19008ed44163	33ba105b-d0a6-4667-b6e9-927859eb4481	9485b506-3ee7-47e4-952f-4d1c017c1147	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
12e4e5c3-4d79-4944-b4e0-96278e48c9ce	33ba105b-d0a6-4667-b6e9-927859eb4481	7cea84da-0c8d-4351-bc16-45a7448b237c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2a4ef900-619a-49be-ae94-249ea3770e61	33ba105b-d0a6-4667-b6e9-927859eb4481	42dbbeda-ecf8-40c4-8e2a-c4fa100c1964	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ecef3470-b391-4ce3-ab43-9bdb40cfc707	33ba105b-d0a6-4667-b6e9-927859eb4481	9bdc2221-0b46-421c-9dda-b61693c31ec5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2b1d9ac3-4f8f-4a19-890c-850bccc9252b	33ba105b-d0a6-4667-b6e9-927859eb4481	72fa3f0b-a4c2-44a4-8c50-08a07afdb951	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1449a425-731b-46f6-bd35-5beb2bcbb44f	33ba105b-d0a6-4667-b6e9-927859eb4481	57e3cac5-5f91-4945-a32c-8e1fd68e7018	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ddbc73c7-08c2-4bd4-a7da-a60544845eb4	33ba105b-d0a6-4667-b6e9-927859eb4481	664b28a6-6308-4db4-851e-ca19679b174b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dbcac02f-26e1-4499-bc41-edd1a39b15f7	33ba105b-d0a6-4667-b6e9-927859eb4481	b3c3e95b-c711-4bfe-8c9a-28b34c89a235	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8da3d508-3cc4-4fd3-8505-baec6b1a5f9a	33ba105b-d0a6-4667-b6e9-927859eb4481	2a499471-176d-4243-ba71-0bb4816dc54c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
62683788-d876-4197-95af-d44bb2e37fd4	33ba105b-d0a6-4667-b6e9-927859eb4481	2e5d1445-6ae4-4e72-a21d-508ac3f52e6d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
617c632d-3d46-4695-b3da-85873e0fe754	33ba105b-d0a6-4667-b6e9-927859eb4481	3ceba21f-c32a-4b08-b628-221f62dff14d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
154ee947-d28d-40b0-807b-64f98be1e20a	33ba105b-d0a6-4667-b6e9-927859eb4481	4ad71a0f-ba54-4a3b-a07a-1c4049dd0ab3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f35c1db3-85ec-47ad-8941-bc14419a75ac	33ba105b-d0a6-4667-b6e9-927859eb4481	3a9d50fa-0d37-45eb-82cc-f20333d79f8d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7b455504-924d-40d2-8443-72c66ea8ccd7	33ba105b-d0a6-4667-b6e9-927859eb4481	7595dd00-7a39-404d-97ad-ccaba60678a7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
72912bab-c5bb-4193-8f06-a9fd0fd9045f	33ba105b-d0a6-4667-b6e9-927859eb4481	38a8e704-e0e5-4c94-9ee0-677956bf126a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f7bdf720-de09-4685-96b7-4766bfd72a8f	33ba105b-d0a6-4667-b6e9-927859eb4481	c3883637-d0a9-47e0-aeeb-b2312b9214bd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
122935f1-4698-4fd8-8b3c-2e5d66934796	33ba105b-d0a6-4667-b6e9-927859eb4481	d0a65563-5711-494c-b3d7-29d9093b644c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d786e3be-aebc-4922-80dc-888fff702406	33ba105b-d0a6-4667-b6e9-927859eb4481	69d240f6-e46f-47a7-ba08-953beffe59d9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
85737ff1-5165-4e9a-8b6a-99c769ccbb11	33ba105b-d0a6-4667-b6e9-927859eb4481	75c94438-0508-4144-b6a2-f2c808f1dc77	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
cd75f124-9a2c-4f3f-a207-c2a73907f4c9	33ba105b-d0a6-4667-b6e9-927859eb4481	40f2ef16-f7b3-40d9-8d90-b78ab68d610e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3896554a-86c6-46b3-b129-7dc3430b4942	33ba105b-d0a6-4667-b6e9-927859eb4481	cf31d9ad-fcc8-41f1-bd1e-bd0d292a2e5d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bb7fd52b-9fc6-48b5-8cb8-815e5332ba31	33ba105b-d0a6-4667-b6e9-927859eb4481	02dce982-e875-4a12-8729-f3be5de4c3f0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8e7c7e60-4055-4587-872d-3979649332a3	33ba105b-d0a6-4667-b6e9-927859eb4481	37c3d86e-82c1-4c44-a129-6c0d69b478a5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
19ae7ce1-6587-4583-bf83-98060bbbd869	33ba105b-d0a6-4667-b6e9-927859eb4481	960109a1-18dc-4dfd-b58c-57a3e4f9a2bc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0feb7a17-84b4-4a1d-87d6-ae4b61b02f13	33ba105b-d0a6-4667-b6e9-927859eb4481	bf76e1e5-1299-4692-89ef-7324e7c5397a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
005365b0-beb6-46cb-ae59-840678484043	33ba105b-d0a6-4667-b6e9-927859eb4481	4e0ca41d-205e-4cef-afba-d744417d3dc5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
93800659-28f9-4933-b629-9583f432e305	33ba105b-d0a6-4667-b6e9-927859eb4481	1f32f97f-bc51-49c5-8e45-27fa3116248b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
436c0b46-dc6e-406a-b758-887f68231f6a	33ba105b-d0a6-4667-b6e9-927859eb4481	b1c21740-2daa-4728-816e-da885b41c8a6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dc9548ae-3a43-460f-9d68-4b540265ce4e	33ba105b-d0a6-4667-b6e9-927859eb4481	e2f99b3f-753c-4286-87f2-e4b7640537da	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ea2ca459-58d0-4152-90bd-3658a1b10e68	33ba105b-d0a6-4667-b6e9-927859eb4481	30a8a1a9-4b95-4e29-bef2-4be4b072108b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
66e327b7-781a-4e49-863a-c8b3ffbc1d74	33ba105b-d0a6-4667-b6e9-927859eb4481	b704be90-df98-4d90-8e3c-b1bb83e7dfda	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
827870d2-b432-46ad-a77d-fc3ff19e4dd6	33ba105b-d0a6-4667-b6e9-927859eb4481	a71aa043-e695-40b9-b3e4-802815738815	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6ca5d45b-e580-4ea7-b9b6-f215f391dd08	33ba105b-d0a6-4667-b6e9-927859eb4481	c41b06cf-c114-4b78-9e0d-007822fed668	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7a9e261e-0a5e-4803-8fc9-a90c19a5a425	33ba105b-d0a6-4667-b6e9-927859eb4481	42cfed9c-0ca7-45a6-b865-fcd50c2b98b1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0cfb9e44-2a33-49b3-8f6c-fdfbc76b5517	33ba105b-d0a6-4667-b6e9-927859eb4481	47b65c87-8d48-47d8-8f5d-679066b826ef	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1f3608b6-1d1b-4379-b531-cc0e9e8083c0	33ba105b-d0a6-4667-b6e9-927859eb4481	e53d949c-5d2d-424b-b4d3-9663ecb3a63c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f1adea07-808f-486e-88e9-0d682ac63b46	33ba105b-d0a6-4667-b6e9-927859eb4481	71c1e0c6-2a75-4f7e-b15a-9f40991965a1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
317fd94f-c842-4771-9493-26b862bade10	33ba105b-d0a6-4667-b6e9-927859eb4481	1e8842ac-3edd-44a9-b7cd-b745f2c73d52	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
efec60da-0adb-4625-8ed9-37005e85a912	33ba105b-d0a6-4667-b6e9-927859eb4481	907cbdb7-8ad8-4a26-9ff6-8cf664762487	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0ba78074-4284-4b75-a684-894159b50204	33ba105b-d0a6-4667-b6e9-927859eb4481	368db12d-3e0d-4d84-bf54-9e9adab15b80	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ff3cc9b3-fdeb-4ba5-bd81-bd06ccea606b	33ba105b-d0a6-4667-b6e9-927859eb4481	d871940c-e5ba-4eb9-bf2e-d640b9227fb2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
046c29be-d2c1-40a2-bb96-9d032b35595a	33ba105b-d0a6-4667-b6e9-927859eb4481	afbc8441-e6da-496c-a859-f572c0f24c87	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e7703bd1-bd8a-4819-b71e-c5883b40265a	33ba105b-d0a6-4667-b6e9-927859eb4481	3a57da7c-3899-4cf6-a5ca-ec5d5fe6266d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
29cb8ef0-aea2-4b00-8475-3a10884c0f0f	33ba105b-d0a6-4667-b6e9-927859eb4481	7e687aff-c2f7-487f-84dc-e35e89c77b3f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0741733b-4db9-4e45-9cd5-019e25c0e050	33ba105b-d0a6-4667-b6e9-927859eb4481	598b197c-c3d4-4f5c-a80f-99aee838476b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
62a484a3-7e82-48b4-a215-5d649c7c88ca	33ba105b-d0a6-4667-b6e9-927859eb4481	0e3755b8-0455-4602-a94a-68baa6f15f36	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e4068ad2-ef7d-4454-915b-9ff76b3f5a8a	33ba105b-d0a6-4667-b6e9-927859eb4481	a68076d9-b0f9-413f-82c8-e8d38e300beb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
54e03853-ca11-4c83-a1db-21afa6fba3cc	33ba105b-d0a6-4667-b6e9-927859eb4481	f79acf6e-685f-4e61-9752-b66fc79264bf	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d80d9510-c2b3-4bab-b372-1a8934551277	33ba105b-d0a6-4667-b6e9-927859eb4481	d1787421-8fab-475b-a59b-afbe7c83cf17	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3ddb672a-ef6e-41a5-8b0a-a2ab8937bf0c	33ba105b-d0a6-4667-b6e9-927859eb4481	e0b53d97-a919-4be1-90c0-fd9e904c426f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4cbbdc48-268e-4e2d-9c2e-1419d4962cd4	33ba105b-d0a6-4667-b6e9-927859eb4481	6b2f2b9f-0085-4606-a483-c1b824cdcf65	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d733d860-2364-4579-b224-787c730702f4	33ba105b-d0a6-4667-b6e9-927859eb4481	065fa74f-cf8f-4741-9135-1b11f08adb76	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9785e406-3c14-4900-9cc0-68ca1ce641d6	33ba105b-d0a6-4667-b6e9-927859eb4481	80844d0d-83f5-4cea-8291-01a7be3e7642	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3dc3fbb6-1d84-41c0-80e9-8915edd426f0	33ba105b-d0a6-4667-b6e9-927859eb4481	a3c7e0f9-f240-4c26-b733-dfbdefee93cd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a1d93672-8e72-4105-a9c4-5e8626e96fb4	33ba105b-d0a6-4667-b6e9-927859eb4481	6a0f53d4-dd83-4f1d-94af-b4057980b1c1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5cde8164-6c8a-42b2-870d-3e34de356809	33ba105b-d0a6-4667-b6e9-927859eb4481	7b6b0af0-3152-4195-b0e8-9c4b0c9aab1c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
41bc62d5-afbb-45ae-86b1-7aec68bd3f0d	33ba105b-d0a6-4667-b6e9-927859eb4481	66b52fb0-d809-4f6f-88a4-655cb4108adb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
cf2e31b8-980d-42b5-97d0-43f00fbea671	33ba105b-d0a6-4667-b6e9-927859eb4481	0f816d16-a338-4dc2-8471-5384150a0b3e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
580a1064-43aa-4355-8a1d-cf8bbfb7e2e0	33ba105b-d0a6-4667-b6e9-927859eb4481	20186d21-beb4-4d82-acd5-b16b9568dbdb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7bc44163-8672-4ef7-978f-f8a9758ceccc	33ba105b-d0a6-4667-b6e9-927859eb4481	84024871-ec04-4469-bd0d-b8afac1912b0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
088ebe75-db10-4a8f-ae29-2d8ef285abbd	33ba105b-d0a6-4667-b6e9-927859eb4481	670993b0-cbb0-4293-9c29-1ab1a9466ed3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
738c7050-7765-495b-8b3b-c1b6f7e3579d	33ba105b-d0a6-4667-b6e9-927859eb4481	0873fe58-1bff-436e-89d4-6353b5467a70	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0bec09ef-bf6c-4d02-9e37-e9765b1cbcb4	33ba105b-d0a6-4667-b6e9-927859eb4481	c8b8dc3d-1b43-482c-91fc-5b7970343b97	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e2741d34-77ed-4cee-a68f-60e0ad343421	33ba105b-d0a6-4667-b6e9-927859eb4481	89f3927d-ab29-4a1f-bb5f-11895f94abb1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6e7221a0-6631-4233-9940-9e04a7e253b1	33ba105b-d0a6-4667-b6e9-927859eb4481	5498c9ce-31f9-43ad-9d8d-6a2c2fed6bfa	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a4de65cb-fbc7-43af-9620-2aac26ac2a92	33ba105b-d0a6-4667-b6e9-927859eb4481	2608e064-867a-4fd3-9923-028b4bbeca52	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
23532020-35c2-4c4e-aedd-97fb0734c6a2	33ba105b-d0a6-4667-b6e9-927859eb4481	57a944d8-51c9-4246-80a4-51348abb4a40	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
342009da-0e51-48cd-a9bb-a6f7beae1181	33ba105b-d0a6-4667-b6e9-927859eb4481	e4bb949c-487c-4198-a3c2-3a1cb3200e0e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d11a76ce-71b0-4fcf-b3a8-08b01f716e9b	33ba105b-d0a6-4667-b6e9-927859eb4481	848b05f2-a664-477c-abcd-dfcf4cef355a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
98d1adb1-768f-4002-974f-9ecda70552e5	33ba105b-d0a6-4667-b6e9-927859eb4481	a430761f-d4c1-40ba-a0a9-cb6b8ac68eec	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
373760f5-dec9-4be6-a922-be4be60bb1c2	33ba105b-d0a6-4667-b6e9-927859eb4481	45e07a88-cfc0-48f6-b9d2-cab1b7f0b381	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
108147ff-f8b7-4a65-8a22-7acbd632cd7c	33ba105b-d0a6-4667-b6e9-927859eb4481	29031217-35da-4283-9304-306dba5aa4a8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7e1851f6-e538-444e-87ce-754450d82175	33ba105b-d0a6-4667-b6e9-927859eb4481	b630df0f-3f70-4473-a18f-da0a038feef0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5aa33f14-798d-489f-9425-c99c6289692f	33ba105b-d0a6-4667-b6e9-927859eb4481	416968a6-8555-4898-9e27-749ad4590b14	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4a2cc3c5-5a64-4cac-b653-582e9b35fda4	33ba105b-d0a6-4667-b6e9-927859eb4481	8a6f4a10-f491-46e3-a644-e9de1bc10f0d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
13926f87-8637-4c72-8a75-d897b7f48a45	33ba105b-d0a6-4667-b6e9-927859eb4481	9c4e0713-911b-47a2-9455-f5fa809727e4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
824a5f73-351b-482f-9da5-197821262812	33ba105b-d0a6-4667-b6e9-927859eb4481	7ea80c70-a01f-432f-a97a-e3d27a45f040	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
454eb409-a38f-4ae2-8ecf-aca21063acad	33ba105b-d0a6-4667-b6e9-927859eb4481	a949e31c-1a90-4e4d-b64f-abb8961b7503	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b42df961-985b-4d9b-8e92-783f5d78ae78	33ba105b-d0a6-4667-b6e9-927859eb4481	a31e98a4-fbc8-47a8-9eb0-ab0cea691825	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6362a7b9-fe00-47e5-8d91-60750f61298d	33ba105b-d0a6-4667-b6e9-927859eb4481	fd3362a3-cb2c-41c6-936c-070fd526e4db	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7aa1b2ba-9086-4251-8fea-30588ba938b2	33ba105b-d0a6-4667-b6e9-927859eb4481	4e47687e-dd88-47ba-b779-8a31560bad7b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c7cf22d6-354f-4363-a220-648c3941b19d	33ba105b-d0a6-4667-b6e9-927859eb4481	f57535ff-a57d-40a4-a42e-bbf1c9bbb8ff	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4f999317-708d-4439-9725-6507bbf4aea5	33ba105b-d0a6-4667-b6e9-927859eb4481	f70bbfb9-2af8-4cfa-90eb-b94c4d5e186d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
473eccb2-2bcd-4788-8511-2da74827e282	33ba105b-d0a6-4667-b6e9-927859eb4481	7c170301-7eef-4433-942e-27307dfe0cd6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9ffd8a20-78ea-4f12-a672-b7112a6423ab	33ba105b-d0a6-4667-b6e9-927859eb4481	cf05fd28-ee79-48e2-9966-0a40a1ac8c2f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d7c2df32-4abd-495b-8a14-1a759c83d9cb	33ba105b-d0a6-4667-b6e9-927859eb4481	2cef2d1d-f12d-41e4-ad62-311bc103e8e0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8169f1d0-f5c5-4e1b-ac2e-e448ca828c9e	33ba105b-d0a6-4667-b6e9-927859eb4481	f530fa98-9cc0-4d57-b029-26b1342271e2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ae6e2d44-06f7-41e9-8719-34659209edba	33ba105b-d0a6-4667-b6e9-927859eb4481	d8d868e3-bced-4696-be25-b786faf42f4b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3be56129-c1b9-4001-8c24-e553516f4b52	33ba105b-d0a6-4667-b6e9-927859eb4481	6e870847-537d-436b-9de1-ad964e35496c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ffcb0128-34da-41b4-8c8f-639ed01b1480	33ba105b-d0a6-4667-b6e9-927859eb4481	d2dac919-c4e6-4b1c-a514-ef498cb5f8ff	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a4000b14-0452-4073-96a4-74abe5257de4	33ba105b-d0a6-4667-b6e9-927859eb4481	eb1da70f-7417-42ec-b300-ab7f113ab4fc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
aedcd7e5-bc51-4d2b-8a72-a939368f87a1	33ba105b-d0a6-4667-b6e9-927859eb4481	25a09bbe-e244-4f48-8ad0-4ab93c8e60c3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
eb0cdf10-3c5f-429b-b0c6-40d2bb275717	33ba105b-d0a6-4667-b6e9-927859eb4481	04464365-8e0d-4032-a713-2b7f6f995e4d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ac7f8102-6517-41b7-97fe-1289f5ac997d	33ba105b-d0a6-4667-b6e9-927859eb4481	436cf968-febd-47f4-ad16-8d15a38c0b19	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3e36e2dd-2947-48b4-9041-4b070861e430	33ba105b-d0a6-4667-b6e9-927859eb4481	a6fab1a6-6167-45c0-b133-a6a13058009f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b6069ddb-8ae3-499a-bf46-b8c6d6ab78ca	33ba105b-d0a6-4667-b6e9-927859eb4481	c9b99c92-6f3c-48a3-b461-e53a77e5089e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ca669843-f4ee-4a97-b45e-77867930368f	33ba105b-d0a6-4667-b6e9-927859eb4481	c4fe7b95-219a-4f3f-b292-9ef2bd9d0be9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c62be0f5-625b-44be-93ed-f2d9e1efe7a7	33ba105b-d0a6-4667-b6e9-927859eb4481	23aedea7-888b-4842-ac00-ea22ad8cdfc0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7bbe2e5f-69d8-4066-b1fc-74740ef56d3e	33ba105b-d0a6-4667-b6e9-927859eb4481	0a78b3c5-32c7-4e39-a7f7-3b7539fd1ac7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c9d4cf5d-7f96-4ee0-8cf4-2a9b6e769890	33ba105b-d0a6-4667-b6e9-927859eb4481	593b2dc0-fc81-4c4e-99f0-f205a64645c1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8b1f3c80-31f7-46f9-bc07-affda2a249cd	33ba105b-d0a6-4667-b6e9-927859eb4481	208afe7d-23fc-4041-a42f-27addd6468f2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c3b4250b-be60-4b78-b1f5-c7371392df17	33ba105b-d0a6-4667-b6e9-927859eb4481	06506681-6c43-44f3-8e1d-c405813477bf	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3da355bd-71d7-4e97-adcb-a913a595a759	33ba105b-d0a6-4667-b6e9-927859eb4481	2158eccb-597a-4ae1-bd15-1574170db46e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dd899773-5ddc-4858-8c3c-e0a6cf0296a3	33ba105b-d0a6-4667-b6e9-927859eb4481	4893928f-8614-4820-a175-456cc65a0775	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dd87e1fe-cf24-4022-a561-44b0b5c63d85	33ba105b-d0a6-4667-b6e9-927859eb4481	a0f5e4c7-bdd9-4be1-abe5-167048539bef	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b83deaf6-4ee5-4cf0-940e-e329ac02651a	33ba105b-d0a6-4667-b6e9-927859eb4481	9d97449f-6cda-4f37-87a7-18c376816bad	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
68263094-783c-4216-9c44-651618143bf9	33ba105b-d0a6-4667-b6e9-927859eb4481	73e5fa1e-681e-4166-b550-9b208c24e3c0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d30be915-aec2-4198-be00-0b52e4edfe33	33ba105b-d0a6-4667-b6e9-927859eb4481	1ab89282-75d4-459c-8eea-032407a2742f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fa4f0fb7-f096-4152-9326-2bc600766aee	33ba105b-d0a6-4667-b6e9-927859eb4481	b9f56f93-10e1-40f6-ae9e-6667d6c33f86	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f56a6e97-e376-48ef-bae7-f39e558f0aea	33ba105b-d0a6-4667-b6e9-927859eb4481	f0c83e41-ae55-45ec-91cc-ff243bb9fc49	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
042d1d1d-c4de-4bd5-a117-33e3d6649339	33ba105b-d0a6-4667-b6e9-927859eb4481	ee52d85b-5bfb-4ca4-8979-5acb5fd6aaab	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
cb00bf00-025e-4e59-b2f2-9915c4eeab6b	33ba105b-d0a6-4667-b6e9-927859eb4481	2540be8f-2a5d-4121-9514-7d547be6eef0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c0093198-4333-4963-96cd-604bf71b06b1	33ba105b-d0a6-4667-b6e9-927859eb4481	517f2e8e-edc9-463d-baa3-bc3064f67e11	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3ccad2a5-94d1-4e73-8841-4668ee7a8356	33ba105b-d0a6-4667-b6e9-927859eb4481	24b93eee-c881-43d9-90b8-4f98fcf733fd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0b1c2826-7d35-4763-a0c2-b79c0192979c	33ba105b-d0a6-4667-b6e9-927859eb4481	a9287274-3195-4c95-bf47-a04481ddf04e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
32df5706-f80f-4ecc-bccb-f8b1fb942b08	33ba105b-d0a6-4667-b6e9-927859eb4481	5f44ae08-08c7-4d94-997e-b20c26a3d3d2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
79c1cdf7-aaa4-4d70-aa97-722e9911bc9f	33ba105b-d0a6-4667-b6e9-927859eb4481	068f197e-5bd0-49dd-9599-af0f7061a844	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9504a137-5357-4a73-bc94-01ec06699d03	33ba105b-d0a6-4667-b6e9-927859eb4481	06a0b35f-3146-4b72-b224-df6264161bfd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
13e94d6d-f9ba-4ca4-bbed-1bb6b39b0bf5	33ba105b-d0a6-4667-b6e9-927859eb4481	8410c20f-f925-416c-925c-ce2365b9ffb2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
504d65ad-6b22-4451-b2d0-d4a3cc9692fb	33ba105b-d0a6-4667-b6e9-927859eb4481	99c4170d-f79b-4b8d-8217-c744dc2a060f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7ccbd07a-85a0-4e9e-b81c-b7daf23bcba6	33ba105b-d0a6-4667-b6e9-927859eb4481	46c22828-0861-4e49-91e4-91bfea02a02f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f77efdd3-66cf-46c0-bca7-5e55b8fd514c	33ba105b-d0a6-4667-b6e9-927859eb4481	89453004-e027-4e98-8ff5-64f3fbdf698b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c4c20366-b03a-472a-b437-37730a3d86f9	33ba105b-d0a6-4667-b6e9-927859eb4481	b36eb4eb-bf6e-49e6-aedf-48ae1cb8d005	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a056059d-da8d-4175-9aa0-33c91006e974	33ba105b-d0a6-4667-b6e9-927859eb4481	82aad02b-aa9c-4c64-88d7-b98df17dbb2c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3d260a93-6d37-44e7-bbd1-6227cdc7d724	33ba105b-d0a6-4667-b6e9-927859eb4481	3a5b507a-96d7-49eb-85ae-fcba48c2dc7c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5f9f5f67-19a8-44aa-afa8-e87f2ca32990	33ba105b-d0a6-4667-b6e9-927859eb4481	ed6ed4cd-c259-4f7c-a04f-44bd558104fe	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
965f03b6-9e8e-4cc0-b02b-c853fb5e08c5	33ba105b-d0a6-4667-b6e9-927859eb4481	b52be0ae-2e8a-442e-abba-001c4757ff4c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c5c4de34-32db-43d2-a3c8-0af61d1435dc	33ba105b-d0a6-4667-b6e9-927859eb4481	02292b54-6e0c-49a9-abd6-137d37d05fb9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
29015d13-0db3-46b6-8d43-5b292168dee1	33ba105b-d0a6-4667-b6e9-927859eb4481	1af26070-fbe3-4ca4-a831-8f3a71f8ddf7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
605b8916-26df-4913-a9f1-05302faff6a4	33ba105b-d0a6-4667-b6e9-927859eb4481	b13c50e8-fac8-4820-ad35-6f9c21a76fe2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
682f7c69-ce09-4ab8-8e0a-9f9187f28522	33ba105b-d0a6-4667-b6e9-927859eb4481	ba18a28e-ec17-477f-b172-69d82698b00d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
12d5fff2-cb7e-4de0-97b9-20c1eba2b21a	33ba105b-d0a6-4667-b6e9-927859eb4481	83f3ffbb-4c99-4725-a5e0-e85f8d9ff1eb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6bafa797-3a78-4a58-b6d0-9c3b25e1c686	33ba105b-d0a6-4667-b6e9-927859eb4481	35e4296d-3256-4876-8f03-5c7d8cee2479	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
adbded81-e214-44a9-9969-09f7ba2bab12	33ba105b-d0a6-4667-b6e9-927859eb4481	3b4c4e31-331e-4679-83c4-28bdf09b0496	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
349bdbbc-653a-4b5f-8bbe-71184a9f13ce	33ba105b-d0a6-4667-b6e9-927859eb4481	15aab06f-f875-4279-afc8-aeb3f9b460d0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
50a84711-a233-4f32-ac31-c751ba35d350	33ba105b-d0a6-4667-b6e9-927859eb4481	c05f727f-3ff4-48df-9e0f-d8467541c7ce	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a7fd0cf5-1d08-40d1-a37e-758f7e7a61c3	33ba105b-d0a6-4667-b6e9-927859eb4481	406528a5-ea1f-4a4d-bdb2-e86febe02208	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
78d24173-a398-4817-b4d0-4c3170caeaf7	33ba105b-d0a6-4667-b6e9-927859eb4481	2f645122-e172-4e06-ba4c-edc192dacc7a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
baabba2c-1546-406d-8bab-c12f9e51e0fb	33ba105b-d0a6-4667-b6e9-927859eb4481	59d737da-ddc3-432a-a9f7-7bae7c80f110	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2dfc215d-54d6-4a6f-add9-8a051d20d62b	33ba105b-d0a6-4667-b6e9-927859eb4481	c7789c03-1712-4859-9961-9644654a60a9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a08fa7ed-ec90-4c3c-9927-9545aeb09143	33ba105b-d0a6-4667-b6e9-927859eb4481	69fe0f7e-4d2c-460c-9a63-bd1c895e83b1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
019f4ed2-56ef-4d11-86ea-87347daec33e	33ba105b-d0a6-4667-b6e9-927859eb4481	448ccc1e-7cc0-43f7-9514-ce384c26dcbb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d3c6360b-5482-4813-b8ef-d44c9125253a	33ba105b-d0a6-4667-b6e9-927859eb4481	72343ed1-d562-42be-92b1-8e6fe9bccba6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d94d5d6a-1b9f-41ff-8784-bfc6941884cc	33ba105b-d0a6-4667-b6e9-927859eb4481	daa6f6ae-7c26-4dce-bafd-59eb0c2a9292	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
207a7395-cbef-4082-90c1-57f2abca55fb	33ba105b-d0a6-4667-b6e9-927859eb4481	a78a9d1b-f8a1-4084-a933-a7f3b0f9b35a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e98109c0-b4f4-4d59-a716-b3f8f30be9d3	33ba105b-d0a6-4667-b6e9-927859eb4481	f1cc4ee1-b19c-4a8c-bf7e-290fba38d659	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
592a4491-d32d-466b-af4c-5ec15a9b64e4	33ba105b-d0a6-4667-b6e9-927859eb4481	a38152f0-3250-42db-a86f-535983de5b41	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e5fda364-472f-43d9-aab5-833f68bbc083	33ba105b-d0a6-4667-b6e9-927859eb4481	4cc1d2da-0011-4393-bc32-4925c66b5dd0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
13188b27-40ff-41d0-abcc-5b5898b6c19f	33ba105b-d0a6-4667-b6e9-927859eb4481	3c2f8219-1cbe-4623-aef3-1ab472c7f5ee	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
00776b74-1d06-46bf-aa53-9269804ec4b9	33ba105b-d0a6-4667-b6e9-927859eb4481	d5f83d64-38fc-4463-88e2-9dae7aa83e9d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1282c74a-51ea-4d37-af89-3fd71c85dea6	33ba105b-d0a6-4667-b6e9-927859eb4481	b56f2302-aa58-4b21-874d-718c318d0285	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
333a92c4-5d00-4815-98fa-1fef848d1226	33ba105b-d0a6-4667-b6e9-927859eb4481	b0c1b34a-150a-4e8c-aa52-693c63fcd50e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8984d63b-0cc8-47a9-bc3e-41b9e9df2216	33ba105b-d0a6-4667-b6e9-927859eb4481	c1911d14-a326-4e6c-841f-095f713230a9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
63498cfe-a6de-430f-b399-5ae6939972b8	33ba105b-d0a6-4667-b6e9-927859eb4481	26833a3d-b940-4730-bdb6-771b8de5d6bb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
915cd6bd-7e3d-4b15-b273-1ac6b6230e33	33ba105b-d0a6-4667-b6e9-927859eb4481	a28ac42f-6e91-48db-8de2-cb446b788506	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
690f26b1-07ab-4200-bc23-e098af71d9f0	33ba105b-d0a6-4667-b6e9-927859eb4481	aacd58b9-7cd5-415d-a590-95539fa55722	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
82c52aef-12b0-4e5e-92b0-32c0390cdf79	33ba105b-d0a6-4667-b6e9-927859eb4481	0db7301e-cabc-4125-9753-d1baa2c44135	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1d8f9f23-950b-42ab-8110-c863d55d5151	33ba105b-d0a6-4667-b6e9-927859eb4481	38473a9a-ba04-4113-8ecd-fd86d62c9861	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f1142816-2568-4fa8-b30a-f6e2ae6012ac	33ba105b-d0a6-4667-b6e9-927859eb4481	49d74075-b2ad-4def-90eb-2a7ae764230d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
105a04ab-4b65-4801-b1fa-9be5b4e81f1e	33ba105b-d0a6-4667-b6e9-927859eb4481	902fd70b-064b-43bf-a2bc-fdacb7b3be69	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
72667d62-57b9-4271-9ab7-8f64f615f8e3	33ba105b-d0a6-4667-b6e9-927859eb4481	b232af8b-30f0-46dc-b691-e6e75fa357e7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8923bf8e-d89f-4e22-8841-95c54644b5bb	33ba105b-d0a6-4667-b6e9-927859eb4481	d73d50b0-1c32-4220-933f-0a71afcaa9d3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
26a77290-c4d3-415f-a284-1d4ef1212663	33ba105b-d0a6-4667-b6e9-927859eb4481	92099359-d41b-417b-acca-3aa178b313d7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b2d29f27-8577-4d2b-ba26-44304a5c7633	33ba105b-d0a6-4667-b6e9-927859eb4481	f52a7ac4-59f4-4a23-9fbd-544cd7a62687	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fd2e3e96-a747-47ad-a713-4386755caf6f	33ba105b-d0a6-4667-b6e9-927859eb4481	e939b98a-b455-415e-b937-b7e0b7b45397	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3c65730e-73dd-431d-94c3-ebfb0b780743	33ba105b-d0a6-4667-b6e9-927859eb4481	6d01ada6-6047-4856-96f7-51abb0b3ef03	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
da13c4c5-8811-420e-94f7-7ba5f518c11d	33ba105b-d0a6-4667-b6e9-927859eb4481	6f1e06ec-4bfa-4fbb-bfde-7b50b7dcb7b8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
22550fb2-8c09-4a05-870a-fd5aae193d70	33ba105b-d0a6-4667-b6e9-927859eb4481	b0fb7fe3-abe5-449d-b539-e3ec0443fc47	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e6deae0c-495c-4d3c-b886-bd033f918ca9	33ba105b-d0a6-4667-b6e9-927859eb4481	d03bf414-6c6c-4b16-a1b4-3c546a8a7fd1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2a2867f1-20ba-47e0-9284-79c26770576d	33ba105b-d0a6-4667-b6e9-927859eb4481	dbf6cd6d-402a-4f39-8f26-7ef9480b6c3b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c72b905b-ad7b-4696-bd25-e7fdacce6f6a	33ba105b-d0a6-4667-b6e9-927859eb4481	e4894564-51d5-4d0c-84bb-33e72708447d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
85673a41-bd7d-4610-8747-296b5d41d4ed	33ba105b-d0a6-4667-b6e9-927859eb4481	4a81eb90-d3f5-47bd-a87b-4403a611caa8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a0007eaa-0191-4ec8-905a-c752c594f3c8	33ba105b-d0a6-4667-b6e9-927859eb4481	c0f8cd81-ec14-4a0c-b792-afa5aa50ec6e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
aaa57456-115f-40e8-ae9e-ae0ddc7a8690	33ba105b-d0a6-4667-b6e9-927859eb4481	1d057682-ba7f-4818-8bb9-62768de6c8d3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b90dfca5-4180-4701-a903-5cd6b93aeaaf	33ba105b-d0a6-4667-b6e9-927859eb4481	4c76a6a1-c667-4b15-86dc-a2cf45920bec	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0285c20f-d0e5-46ef-b9a7-49fdcf18bfaf	33ba105b-d0a6-4667-b6e9-927859eb4481	f9100cc8-a2e2-4d2b-8c52-ae60b0795e76	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8bbe1160-87a9-4d4c-9b18-f0b61f55fa35	33ba105b-d0a6-4667-b6e9-927859eb4481	3051482a-c212-4398-9a8c-22bde46b7a24	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3413925b-5f39-4d1e-b43b-1bb5fa15ffac	33ba105b-d0a6-4667-b6e9-927859eb4481	b334eed7-c4b2-4748-9f6e-448e29203a4a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
25c81df3-ed6c-477d-803c-cfd5575b0405	33ba105b-d0a6-4667-b6e9-927859eb4481	44640921-5287-4001-afa2-d9892e9fd492	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fad6695b-dd31-4b0e-be76-8bdb460b8f3a	33ba105b-d0a6-4667-b6e9-927859eb4481	7bbcf2c3-6b90-4f3b-ba5f-ad6cd89f1fe7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fe738764-9930-48e6-a46b-f0b1ff91a485	33ba105b-d0a6-4667-b6e9-927859eb4481	e7bdf9f3-95b8-4c5d-9518-ba50b6a96401	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6cce9023-cfdb-45dd-9c61-dd7c0ee44035	33ba105b-d0a6-4667-b6e9-927859eb4481	54ebee77-6acf-42b4-95d9-7fb0fa2baeb7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1701633b-65c6-4d2b-92b5-c3505468af95	33ba105b-d0a6-4667-b6e9-927859eb4481	0adbe8c9-1db4-4ac0-8f99-c93fc58d13a6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a5472d4b-678c-4b55-8be9-3fc9f7c7af78	33ba105b-d0a6-4667-b6e9-927859eb4481	34f0cf48-f9e2-4c8f-9ae0-3af955beae05	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
42ed5e12-5a37-4a8e-b9d0-dac0ba3c9e4c	33ba105b-d0a6-4667-b6e9-927859eb4481	20d0c2ee-a22e-4809-b788-2ef9fef37577	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fcb2e3a2-ebd7-4d77-8bd1-dff379b5b5dd	33ba105b-d0a6-4667-b6e9-927859eb4481	10853ff8-7f2b-4b0b-a6bf-222261507521	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6bd6f643-5849-413c-a6b6-8c6bd40d2891	33ba105b-d0a6-4667-b6e9-927859eb4481	149dd0ad-9e4f-4618-ac18-c8ee94ff0132	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8f63e479-ef92-4f9e-8084-0955e197e746	33ba105b-d0a6-4667-b6e9-927859eb4481	fcfb0a94-e078-4015-9e5b-ee4397f781eb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7a3d57d1-4b33-427f-ae90-b1ddda54c54f	33ba105b-d0a6-4667-b6e9-927859eb4481	9cc22c49-1373-4181-be01-977f31108acb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c57400da-5704-42a7-8791-87de1c1a047c	33ba105b-d0a6-4667-b6e9-927859eb4481	03c1bd46-23f7-4c52-8192-14a9ba8cf60c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
75497473-89b5-48d5-a7cb-e4a181b0935a	33ba105b-d0a6-4667-b6e9-927859eb4481	965cc39c-99a4-477f-9b6f-d3205c8bc09e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4a178abc-71e7-4d61-8285-d68a2b70d25d	33ba105b-d0a6-4667-b6e9-927859eb4481	f3738d5d-e775-4a3a-9ec1-2d877494cda8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bd8f4303-7c61-4163-8a73-817e420acd29	33ba105b-d0a6-4667-b6e9-927859eb4481	cc3325b4-daf6-4866-81e2-70ad41ac137c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
355414b6-51c3-4fc0-ae1f-b6256891221a	33ba105b-d0a6-4667-b6e9-927859eb4481	6c132ca3-e2ea-4936-b866-5a5e1e4d036e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
387fab9f-1137-408b-9775-17406676e936	33ba105b-d0a6-4667-b6e9-927859eb4481	1d913d6e-6ff5-4b5b-8b7d-1a0cffa931da	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
694d18db-c552-45d9-b7b3-8f98b6c80c19	33ba105b-d0a6-4667-b6e9-927859eb4481	4a01ad83-6e0a-40a2-b85b-cf5d60cfd330	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8aaa5d5d-ca80-40d4-8da4-dd4ff1d98bcb	33ba105b-d0a6-4667-b6e9-927859eb4481	6d4ba333-b115-4be4-9c37-e0ae7729e8d9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
75edae0c-ddb2-4b9f-8f53-6c261cd3b12b	33ba105b-d0a6-4667-b6e9-927859eb4481	ac0c6eef-ffdc-4eaa-8245-e1489668f35a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8bd4cb1d-ec6d-4ed2-bf80-d8ef111200ed	33ba105b-d0a6-4667-b6e9-927859eb4481	b46e0b58-9c99-4ec2-8943-3dd1ae98c753	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9c49a4fd-090c-4232-a77c-394573b90134	33ba105b-d0a6-4667-b6e9-927859eb4481	80b0a098-d72a-44e7-92ce-e73bdc7c30b6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e4da6b3a-5d5f-41ce-83de-6bb375e016d9	33ba105b-d0a6-4667-b6e9-927859eb4481	ccc9ee14-4c17-4f79-923b-453d26108f33	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5ef983c8-153b-41d1-acf5-454fb4b42bb7	33ba105b-d0a6-4667-b6e9-927859eb4481	2ef8f6d0-8dbd-4c97-9aeb-87fa1cf68bd6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
09a976bb-109e-498a-9f2c-891827fabb83	33ba105b-d0a6-4667-b6e9-927859eb4481	846d718e-7d96-40dd-99dc-53df7da1b893	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3476640a-1165-4018-aef7-de9a44d872ee	33ba105b-d0a6-4667-b6e9-927859eb4481	c836bca2-5364-4503-916f-d99e57df4e0c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
eb5be3fc-eaa8-406d-8834-1efff26962cf	33ba105b-d0a6-4667-b6e9-927859eb4481	d4a8f643-3d09-48ba-93a5-130e4a701fc3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3dd23347-1ef4-44ff-9f15-79ff2d444e37	33ba105b-d0a6-4667-b6e9-927859eb4481	e396c7f9-6f57-4ed3-8a17-5d7e2a33e98d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3c81b247-89dd-4762-ba74-a6779639d41a	33ba105b-d0a6-4667-b6e9-927859eb4481	8165476d-62fd-4f4d-9336-2113d2e21338	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5b3a57b6-e68a-454b-a04d-5644208d4927	33ba105b-d0a6-4667-b6e9-927859eb4481	d3cd4b2d-382b-43b8-a7f6-6542fb59fa45	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4dbb0c96-2fa6-4fd2-87ae-a6bff23ac3f7	33ba105b-d0a6-4667-b6e9-927859eb4481	8990165e-8c4d-4fa9-9076-e545a6eb271a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f2dde0b8-1ded-4a1b-a4b3-faea5f2a3cad	33ba105b-d0a6-4667-b6e9-927859eb4481	73b7742d-5e43-4115-beed-8bd04010ad2b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
605cff4a-1cfd-4e5e-ab74-cd7805482c54	33ba105b-d0a6-4667-b6e9-927859eb4481	11594ef9-e4bb-4741-8e7d-3f0d8ff075ac	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0abe7860-62d6-4f36-8904-a5becf3f9543	33ba105b-d0a6-4667-b6e9-927859eb4481	b6835ffd-e222-4784-94ec-7293d0f2a034	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e3802fee-a6a9-496b-bf40-206a3ec5f4b5	33ba105b-d0a6-4667-b6e9-927859eb4481	4765ccb4-c263-4d70-b409-e0c7dc9152e4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4ee33bf5-351b-4b53-8134-15cd406e6e3b	33ba105b-d0a6-4667-b6e9-927859eb4481	f4102737-995e-4a47-97df-963713abf9fe	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
33c78f3c-9f66-4bdf-8fc8-f887e7a8d5e2	33ba105b-d0a6-4667-b6e9-927859eb4481	4cc91b8e-9072-4f2f-b21f-a331a1746569	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
94cffb31-c293-4cb1-83e5-3d39349f089f	33ba105b-d0a6-4667-b6e9-927859eb4481	cf22b938-6fbe-4ea0-b2f0-742cf9623324	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fd49ea87-f539-4fb8-8ecd-db7113cd84d0	33ba105b-d0a6-4667-b6e9-927859eb4481	a5b42d8a-15df-4d5f-9f22-3bd90958ec57	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c11323ee-b09f-4a3b-b5d0-b118df4816b7	33ba105b-d0a6-4667-b6e9-927859eb4481	e39a3898-4d7a-4d77-bf4b-82441326c7a7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
31aa0a53-9334-47e4-a39d-63f44de4d136	33ba105b-d0a6-4667-b6e9-927859eb4481	eb996983-3b0e-41a2-8948-d6f9df98a7cd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5d0158ad-a6f6-4296-afae-465afa9c90b3	33ba105b-d0a6-4667-b6e9-927859eb4481	4ed9c81f-25c7-450c-bfdf-bffbdfaaf8d1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
279cd291-a27b-4f07-9448-755223fed9c0	33ba105b-d0a6-4667-b6e9-927859eb4481	92def23a-e6b1-4ac7-85de-27d5cbacfbce	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2fbc5801-c506-4c15-903e-a1526c1e593d	33ba105b-d0a6-4667-b6e9-927859eb4481	f53ad995-a44e-4ace-8541-8fa19935705e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4b793568-0d21-4df4-8bdf-5fb38f474c75	33ba105b-d0a6-4667-b6e9-927859eb4481	d83f2786-950d-4627-b53d-85bd96988f7b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
cc2bd33c-8e28-40a9-b7a3-006adc32ab76	33ba105b-d0a6-4667-b6e9-927859eb4481	6bd9a1d5-067a-48b5-8ed5-7a5a1c67d8a8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
30252830-aff1-47b1-bf03-d864232b8163	33ba105b-d0a6-4667-b6e9-927859eb4481	f119568d-c086-4d3b-bed5-6326b855176f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
eb220d0d-ebf1-4280-b72e-5544ce4e7722	33ba105b-d0a6-4667-b6e9-927859eb4481	28348cbe-d2c3-4f96-a047-2e241886012a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f19e2367-adc9-4d0e-9bed-d4f8274c19c2	33ba105b-d0a6-4667-b6e9-927859eb4481	8f1492f2-81f8-42c9-ae49-5617b3a65aac	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ec0f20e4-aef3-4e13-971b-64c1bd0b4704	33ba105b-d0a6-4667-b6e9-927859eb4481	4bf9e22e-4307-4033-8fa9-1f49af895170	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0935a3df-b419-4dcf-b460-4e25d934f13d	33ba105b-d0a6-4667-b6e9-927859eb4481	99d30d49-b799-41a9-b2d0-0b627d9c9e9f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bd2a48b7-a185-45e3-9c2d-78df4b1a7ec6	33ba105b-d0a6-4667-b6e9-927859eb4481	08847c02-aecd-4110-9b90-e696659d27ab	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a55edea8-13d3-43f9-a8bf-22f0d27e6e5a	33ba105b-d0a6-4667-b6e9-927859eb4481	00ca20cc-d92c-4708-bc23-e7fad854d6d2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7dab8c63-06c4-4ce5-8670-b2edf0bf1c44	33ba105b-d0a6-4667-b6e9-927859eb4481	129257fc-04f1-435b-9de2-a9956504496a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7398c582-216a-4a6e-b0a7-8ab36877d48f	33ba105b-d0a6-4667-b6e9-927859eb4481	6e891062-ab0e-490d-bb17-c51719f9bca9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a0ef9f4d-39e1-47cb-8a67-741d74efafbc	33ba105b-d0a6-4667-b6e9-927859eb4481	62ee02ce-049f-4a3f-a735-4ed4f7e4107a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d5d67a13-829f-4ddc-800b-b8ca0e30373f	33ba105b-d0a6-4667-b6e9-927859eb4481	64630fdc-75e4-4f45-97df-2b73a0eee21b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
aa783bdd-87ca-4633-afcf-ba5eebf6be69	33ba105b-d0a6-4667-b6e9-927859eb4481	d087b0e3-ee4e-4704-9dbd-f57f4af23c59	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
92dfc0a9-290e-4582-8420-ed97ca44ddcf	33ba105b-d0a6-4667-b6e9-927859eb4481	de3d8bc9-187b-4610-866c-d98bfd124697	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6f45a250-4f1a-4198-b5c0-80f30b7d04ee	33ba105b-d0a6-4667-b6e9-927859eb4481	33956074-3708-4d03-b8a2-23a524002d46	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
15ebb356-5c44-4f09-b4a9-284b30662475	33ba105b-d0a6-4667-b6e9-927859eb4481	97bf6485-a9e8-403f-82a6-1595d547e6c7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1c2bc328-c7a8-45d4-b9ee-473de7ed8e17	33ba105b-d0a6-4667-b6e9-927859eb4481	e8a32a29-373a-46c2-bdd0-2bcf2067cfaa	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ee164902-1fac-4c41-a91f-8e12e6f316f2	33ba105b-d0a6-4667-b6e9-927859eb4481	46c6947d-d3c1-4d87-a20d-f80c640815ba	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2b64fdd7-09d4-47cf-8536-a21461de9202	33ba105b-d0a6-4667-b6e9-927859eb4481	c23ca553-a768-4eef-b237-4f7a1963182f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
11f0352c-9146-4691-82b6-b6702678753e	33ba105b-d0a6-4667-b6e9-927859eb4481	30ea4649-210f-489d-8b25-eb7752952a58	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
aae1ec58-f4a6-4d52-98b4-b98275711db8	33ba105b-d0a6-4667-b6e9-927859eb4481	2753d745-4fde-44ad-a817-a926e2416c26	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c231ee7e-9f7b-4e93-b6d5-f013f0b1c3f2	33ba105b-d0a6-4667-b6e9-927859eb4481	a52d2763-eaaa-4283-823e-698e31304ac7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3331125e-6f19-4ced-8f0a-e4adaf086f27	33ba105b-d0a6-4667-b6e9-927859eb4481	3cdce22c-e760-49b5-bb60-d1577acb2750	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5a71d221-f04e-42f1-80dd-3804b627db2f	33ba105b-d0a6-4667-b6e9-927859eb4481	b98504a2-18f3-4d87-a127-101372b44237	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
535f8234-3f3d-4e66-b827-0f65d844e1fc	33ba105b-d0a6-4667-b6e9-927859eb4481	3373dbf4-1675-4263-84a5-5cce2c8835c5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8635210c-e2db-4efa-be9d-c6aab9f2ea8b	33ba105b-d0a6-4667-b6e9-927859eb4481	143bd3ec-ef82-49ae-9ef6-c32eb8c481ec	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
23097c39-c155-43f2-97ef-ec25105126fd	33ba105b-d0a6-4667-b6e9-927859eb4481	c0724f6b-1a47-441b-ada7-11a0b12cb944	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
43ec81b8-7b50-446c-90b7-f71e96c8cfad	33ba105b-d0a6-4667-b6e9-927859eb4481	52dee135-9501-426c-a3db-231ea6521fee	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e67aa118-261c-4f66-8f26-2d6107f149ce	33ba105b-d0a6-4667-b6e9-927859eb4481	bcd2d343-b857-4fc5-a3a0-5c81ce009acf	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c5bdaf05-a1ba-43d6-b2a7-fbd08a00a61f	33ba105b-d0a6-4667-b6e9-927859eb4481	fcfc351f-a70e-4fe5-a31b-41d222f912a7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
db8603f2-3514-4cd2-b0dc-fd890599ba64	33ba105b-d0a6-4667-b6e9-927859eb4481	a0df12b1-415d-40d0-8bc1-03acd83f9918	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9761f2ef-2164-47e0-a647-35b4993c6ce8	33ba105b-d0a6-4667-b6e9-927859eb4481	469870c6-7f05-4396-a9bf-71600605852f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5738d0ed-961b-4c35-94c8-58926124b9de	33ba105b-d0a6-4667-b6e9-927859eb4481	a9ac42a0-a727-4add-a3bb-5deddf2cadc1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d3c9fde7-f80e-49ec-b371-30650c75d1c2	33ba105b-d0a6-4667-b6e9-927859eb4481	4975269a-144e-49f1-ad97-16f120d1cbd3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0fe731dd-afcf-415e-ba19-1a4883ba4904	33ba105b-d0a6-4667-b6e9-927859eb4481	743681fe-8f16-4ea4-94c1-1c7719d567ec	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a6d216c7-50eb-4ba5-8f48-ebdfde7e8144	33ba105b-d0a6-4667-b6e9-927859eb4481	7a9151c4-2be6-4f64-9ee7-f158ca3471e1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c86a8a48-e92e-4319-85c7-38c1e5767bbc	33ba105b-d0a6-4667-b6e9-927859eb4481	708e26f3-fa66-4a29-a38c-5f544dd31662	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
96e921a7-c661-46c9-9732-7dc3e6a83203	33ba105b-d0a6-4667-b6e9-927859eb4481	00ee0df7-f531-4d7d-92e4-b9db178dbc30	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3b140c95-97dc-4d33-bd1e-5e5eb891ae65	33ba105b-d0a6-4667-b6e9-927859eb4481	2525a59c-0f76-4b6f-8802-c552221c2c8b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
69cd3925-f620-4550-9b58-1cf99b383988	33ba105b-d0a6-4667-b6e9-927859eb4481	fcbba7b9-fd30-47f8-931a-705573f4e87e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
17154fb6-4add-4356-b1c2-96137af956a0	33ba105b-d0a6-4667-b6e9-927859eb4481	9196af56-2465-49c7-9d81-ec5191deb357	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b22cab7a-bd97-4239-97a7-8f5a533ed7de	33ba105b-d0a6-4667-b6e9-927859eb4481	4924cd3e-87c7-4838-bd40-de0f29768239	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b7cf0137-7ba2-4bec-a0d1-b0eba75ef3f7	33ba105b-d0a6-4667-b6e9-927859eb4481	6f2d7423-305a-41e1-b471-ad6bbce92983	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
12fffad8-7ec3-419a-9b84-17f66d10ba78	33ba105b-d0a6-4667-b6e9-927859eb4481	762c6869-1df4-41e7-a12e-5fde1ec2d3e1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8f0610ab-45ab-4903-8f86-9c24b610dac3	33ba105b-d0a6-4667-b6e9-927859eb4481	36afdfac-e2ce-4bd3-9eaa-698000f13c57	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4981c88f-a7b9-45ef-952b-3cec59885b48	33ba105b-d0a6-4667-b6e9-927859eb4481	989205c4-5925-4dce-ae16-a6a0f27c431f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ee3fe9c9-6d57-4316-ae6f-1dc4a46e4ad4	33ba105b-d0a6-4667-b6e9-927859eb4481	3f3f8960-2894-4c63-b3d1-68045b53c92a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5dc3b340-8435-4a63-8d85-2f0972872f11	33ba105b-d0a6-4667-b6e9-927859eb4481	5c68ca9a-48b5-4a77-87a7-b80a3699dbc5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9826840c-4ecd-4a28-8df9-5981ffc812b9	33ba105b-d0a6-4667-b6e9-927859eb4481	36e77366-636b-4e0d-81a0-209ec3226fc5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bf3a9a59-883a-4e9e-b926-57e807ae5668	33ba105b-d0a6-4667-b6e9-927859eb4481	3a1e4c0d-e0e9-4704-8238-9f1f02c8a307	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6763bc0a-42ae-4aa5-9185-e5e06ca3ae46	33ba105b-d0a6-4667-b6e9-927859eb4481	4ccd6559-e071-4372-bbe2-e2a971cc6768	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1bf6e013-1004-47b4-b478-1ce32706700a	33ba105b-d0a6-4667-b6e9-927859eb4481	20f11418-baba-4b62-aa82-9d137f19396e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a9332f18-9162-444d-a2df-033586f74a2b	33ba105b-d0a6-4667-b6e9-927859eb4481	8e4d7117-aac5-4564-b497-4d6ec589b631	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c4a39e61-e925-4428-b7bf-b7482c251372	33ba105b-d0a6-4667-b6e9-927859eb4481	e2d34508-d906-4139-96ac-845f5ac22b58	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1ac64082-c9bd-47b0-9641-4326ae55c0b4	33ba105b-d0a6-4667-b6e9-927859eb4481	6bd34503-6140-4c80-859b-baaa14ada3bb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
75e91b24-0e3a-40ea-99d9-2b2f28d15c1f	33ba105b-d0a6-4667-b6e9-927859eb4481	90d7d88b-fbcb-4a96-9e4b-51150e6187c4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3113ebd2-ad9b-4528-aaae-0ccf5da472ec	33ba105b-d0a6-4667-b6e9-927859eb4481	1fdb69e0-4372-424a-9f27-8f1be8b782db	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6127026c-b8ab-4e62-9d32-d838de83dd9d	33ba105b-d0a6-4667-b6e9-927859eb4481	83cb1b24-e748-4fc0-945d-364f9f1dfe9e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ded05de5-e691-474c-abcf-9227e9ec6fc0	33ba105b-d0a6-4667-b6e9-927859eb4481	ca593b9c-ea6a-49e3-afb4-a36c38e6022c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ecd0a04a-63ab-42a6-9aac-24d1e74d7e55	33ba105b-d0a6-4667-b6e9-927859eb4481	48f4cf7a-891a-4289-9d09-a04ee52d2467	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
58b5602f-10ed-4aa6-9e68-e32ce7cdc0ed	33ba105b-d0a6-4667-b6e9-927859eb4481	5f74ed26-98c9-456f-95a2-54ffe311b19a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
490467b1-8420-495a-8988-7d339fadacc9	33ba105b-d0a6-4667-b6e9-927859eb4481	bf90d1be-4d92-4e8a-b25c-ff5ae900dd6c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
562460aa-dbf6-4925-9fc3-11c1db90dedf	33ba105b-d0a6-4667-b6e9-927859eb4481	91ec904c-c1cf-414c-a046-2ed695539265	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
65f4a14f-a6ee-44a3-b9ac-a0b1ef95307a	33ba105b-d0a6-4667-b6e9-927859eb4481	cd578b3a-2398-4268-882a-5df025decb87	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d8240977-0b94-4d1f-960c-85dd93472efa	33ba105b-d0a6-4667-b6e9-927859eb4481	2a59340f-976f-4f1a-9471-eeff102efe40	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ed4854d6-166f-493f-ba7d-21c45ddae091	33ba105b-d0a6-4667-b6e9-927859eb4481	9b5eebe1-3e82-4f10-9fa7-a97c553e6bc0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
26221896-563f-4ce1-991d-5e6c4362ba35	33ba105b-d0a6-4667-b6e9-927859eb4481	be966f62-f172-4c93-9bcb-d3ac1a34cdcd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
06eebd2c-43b4-4545-bf05-b335ddc3480d	33ba105b-d0a6-4667-b6e9-927859eb4481	4b51a8f8-4863-485f-ba7e-45aa5c056582	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f9e2ff15-a086-4fe1-b543-6cc28d975a14	33ba105b-d0a6-4667-b6e9-927859eb4481	8207054d-016b-4566-aa6c-4a33f946b368	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
02df1111-d1c9-471c-974f-365f18a58ca6	33ba105b-d0a6-4667-b6e9-927859eb4481	3f1bfec5-a2e1-4463-af4e-15f19632f398	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bdf550ed-d54a-43be-8117-590d363d267b	33ba105b-d0a6-4667-b6e9-927859eb4481	c0cf6a76-07af-49ef-b2dd-8cc63c914c55	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
57ccf9c4-ebc8-49f1-a719-b0fbd769ce48	33ba105b-d0a6-4667-b6e9-927859eb4481	bc9e9813-f31f-4ae8-8367-4a5e7e75ea4d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4cd7d0ed-950f-4d7d-8c3d-9512e6286163	33ba105b-d0a6-4667-b6e9-927859eb4481	298a2ce5-03e8-4bc3-90c2-f100bc798067	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2897b8bf-8e5a-4884-a0e6-9dadac244c02	33ba105b-d0a6-4667-b6e9-927859eb4481	80a3d0d6-4fee-4d16-b0e4-da9b5b5f7e9a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
10d906ea-0af7-48c1-bd55-d0a90cd00766	33ba105b-d0a6-4667-b6e9-927859eb4481	6a0804e8-8d14-413c-b77f-b8d925240ca6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ab34664d-352a-48e9-b386-cb3452bfa21c	33ba105b-d0a6-4667-b6e9-927859eb4481	88e8d64f-4ffe-45af-a5c2-bf41e05f5daa	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d5c98e2d-5af1-4c15-bb8a-e2250cd1f0ba	33ba105b-d0a6-4667-b6e9-927859eb4481	19e74b3a-e81d-4046-8e2f-155e3c44ea3c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6d3f38ea-30c3-46e1-80f6-ff90ec980772	33ba105b-d0a6-4667-b6e9-927859eb4481	b0b55a81-cc70-4670-8381-fed9b85d4795	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ffe943aa-2d74-4a99-b6f3-25639b399ef6	33ba105b-d0a6-4667-b6e9-927859eb4481	4cf7ced8-df93-4ae9-a25d-1630d6df5afd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9e6aa14b-a116-4f00-99b3-daf3d83ab2d7	33ba105b-d0a6-4667-b6e9-927859eb4481	d87d39c4-b0c8-4785-a105-8474a8c48bad	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
62420531-b1de-437f-b393-063e0bd18db8	33ba105b-d0a6-4667-b6e9-927859eb4481	5b2821a5-e35e-44c4-8c13-d63d6345ba5a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
826fa79f-7866-4693-afc5-1cf1b67577cb	33ba105b-d0a6-4667-b6e9-927859eb4481	4ecc2531-c07c-4c78-8754-7bc14aeed18c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1321c79a-b852-40e0-a5c5-25e522db1e83	33ba105b-d0a6-4667-b6e9-927859eb4481	ba096883-f4e9-4f53-84f9-1b14226e2593	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b43160d7-b9c9-47fd-95b3-66635ce011fa	33ba105b-d0a6-4667-b6e9-927859eb4481	f6fa5712-a021-457c-bdbc-1d25071ac028	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
afa2e2fd-152b-491c-ac08-5b28c5073e84	33ba105b-d0a6-4667-b6e9-927859eb4481	4baf01a8-d3df-461f-bd31-e3283aaec78e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3b44b2d1-c729-4131-804a-f6fc6daf8d6f	33ba105b-d0a6-4667-b6e9-927859eb4481	b803db15-e821-45f7-b77c-16b9409fc423	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f2232704-329a-403b-83a3-233c2b1fb513	33ba105b-d0a6-4667-b6e9-927859eb4481	6079583e-d988-4f99-91aa-99e0c0bb20f4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
be30daa0-e02c-4eee-9b98-7dc870d82a43	33ba105b-d0a6-4667-b6e9-927859eb4481	ca91806e-64bb-4580-a882-d715e1c22f4c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
398410ff-6831-4de5-9fcc-ba796416e8eb	33ba105b-d0a6-4667-b6e9-927859eb4481	cfb318fd-1e1e-4fd8-bcdb-bde939c66b76	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
18d92d25-b5b6-4d91-ab15-58290f2b716e	33ba105b-d0a6-4667-b6e9-927859eb4481	2f782948-8df8-4550-923a-9d582b413d9d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
99e8ed59-cc93-4020-99e9-ea00a85b527d	33ba105b-d0a6-4667-b6e9-927859eb4481	df0f8567-fc9b-426c-aba7-632bf3a2f69e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9791c7cc-cfc0-47c3-b2e0-4bb2b8f7bb4e	33ba105b-d0a6-4667-b6e9-927859eb4481	58a60da9-bb63-4882-b28d-a899d6e00f52	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
12684e64-14b6-44c1-a2b3-df8ee5804868	33ba105b-d0a6-4667-b6e9-927859eb4481	7fd76e58-6082-4eb2-809b-5bce5cf8cd32	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2a9ee12c-79e5-43a7-988b-d5eaf5956443	33ba105b-d0a6-4667-b6e9-927859eb4481	0a8d7236-b26f-404d-94a4-08189f56d6d3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bc8dfbba-f4f7-4ac7-a2f9-00a794c99b7d	33ba105b-d0a6-4667-b6e9-927859eb4481	f644f4d4-07d4-4a68-9ebb-2d867faf1a9a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6147bd63-7e49-44ba-8b4e-ceb8e6301811	33ba105b-d0a6-4667-b6e9-927859eb4481	a9123596-3d31-4156-9c2f-5c24dae4b8ff	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d4617e3c-667f-4241-92a7-ee09a58f8e88	33ba105b-d0a6-4667-b6e9-927859eb4481	b7f0d91b-f540-4dbb-a1d6-67945f3de9fe	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9238c134-7665-41b0-afb6-6ffe7e902a3e	33ba105b-d0a6-4667-b6e9-927859eb4481	88feafc5-50e7-49cc-94ca-19ac20a62381	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
732f2483-3492-4b84-9f57-e30b2d3a8440	33ba105b-d0a6-4667-b6e9-927859eb4481	c83b313a-6377-48f6-b423-61bcbd1befac	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
89ad4ded-e99b-4f59-ba97-d4da510cd6c2	33ba105b-d0a6-4667-b6e9-927859eb4481	3d76ee07-337e-4e71-925b-5a4ad34a6217	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
10cdf015-0fbe-41af-849f-8d17028bd10f	33ba105b-d0a6-4667-b6e9-927859eb4481	7278d8a2-1afa-47ea-8f45-aca80363e7fd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
50a36582-b4bb-4b15-a6bc-3b0d423645cb	33ba105b-d0a6-4667-b6e9-927859eb4481	eb4ca459-a7c5-418b-b663-72482539d188	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f49b354b-d407-4025-b8dc-f2bf19fc3f80	33ba105b-d0a6-4667-b6e9-927859eb4481	97beb27d-91c6-4d5a-bde8-ce522ae7cf3f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c859b168-3cf8-43ee-9048-867408cc8b3d	33ba105b-d0a6-4667-b6e9-927859eb4481	e8397cbe-b0c5-4e24-a1b7-c4b70b096289	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d3760070-f4bb-44f4-ae63-e43fa459c176	33ba105b-d0a6-4667-b6e9-927859eb4481	df2e1002-2afb-4016-90b8-e042eb0397a3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fe5c5f27-13b4-491b-b872-7eac8dcb851d	33ba105b-d0a6-4667-b6e9-927859eb4481	c12b01cc-f893-4719-acb3-93037b400058	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
26fa373d-4783-4636-89ba-84322e59fc71	33ba105b-d0a6-4667-b6e9-927859eb4481	721735a9-8a80-4464-8384-aa2969f9bed9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
862b21df-e6bf-4bd7-a959-f4a83ae36948	33ba105b-d0a6-4667-b6e9-927859eb4481	4606b7b7-7fe5-4409-937f-2bea04577896	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3350d7c2-3dae-4c4a-a1a3-9945e2f1cae1	33ba105b-d0a6-4667-b6e9-927859eb4481	9c851f5b-3b22-4bdd-b23f-bfd4bedc71c3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
90c5953b-16cc-4050-bc80-06ce09b587e4	33ba105b-d0a6-4667-b6e9-927859eb4481	043573ca-8b01-4937-880c-363faa091589	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b7a60ff7-6240-437f-a121-406af94c6f6e	33ba105b-d0a6-4667-b6e9-927859eb4481	d6a7f0c5-56a8-40ab-8eae-7c5747555fe8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
92eb69e6-d189-45f3-8a7a-b6b352a87095	33ba105b-d0a6-4667-b6e9-927859eb4481	62f0715d-c698-419a-a5d0-fc9fda75bfb4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2bbf80fc-d4cc-4f71-924b-48e88d61d895	33ba105b-d0a6-4667-b6e9-927859eb4481	fba6af6e-fe6b-41ad-a222-4467da95e989	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4878427f-f99a-4de3-b83c-6f8390275dff	33ba105b-d0a6-4667-b6e9-927859eb4481	9ddc5858-cec8-4a12-abb9-de920843f065	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e9538ef9-a409-4541-a765-45c0bccebd96	33ba105b-d0a6-4667-b6e9-927859eb4481	adf94e1e-154d-461e-97bf-23d2a7f41b5f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9fba5b39-0d63-4c71-a47b-27b5826aabd8	33ba105b-d0a6-4667-b6e9-927859eb4481	cb0fcdda-d13d-4b13-b383-7233c3a91968	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4fa1064f-2446-4e89-8b13-de9e80ec76a3	33ba105b-d0a6-4667-b6e9-927859eb4481	0e2317c5-78bc-4fd9-8c1a-e0bc352c701d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e8d1d50f-79f4-4590-94f7-65337124a1a4	33ba105b-d0a6-4667-b6e9-927859eb4481	4c833ed7-ac64-43bf-b08e-7a0b66810842	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ce834b52-90f4-4c41-a4f7-0b2c0caf1025	33ba105b-d0a6-4667-b6e9-927859eb4481	2a841cca-0a94-4173-a2e3-94064c295dba	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
eadb7937-5f2c-4235-a8cc-30a30fc16b32	33ba105b-d0a6-4667-b6e9-927859eb4481	8ec38741-d1f6-4cfb-bde3-56bcefe7f9b0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a6b996dc-6c4d-43d5-8521-d985ff9a993b	33ba105b-d0a6-4667-b6e9-927859eb4481	aa063d12-8ac0-423b-be80-1ea10ce165e3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
169deff1-5231-4df4-ba34-150f7a6bc003	33ba105b-d0a6-4667-b6e9-927859eb4481	c6a21385-ae1b-48fb-a6a2-090dd3563729	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
076718a4-56f7-4d9f-96bc-1a9fcec9cbd8	33ba105b-d0a6-4667-b6e9-927859eb4481	33b53ed0-62bb-4617-bec2-90d8bba22d3d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
16252deb-186b-49a6-b231-6539164de4d4	33ba105b-d0a6-4667-b6e9-927859eb4481	83ac9581-1559-427e-ac19-3aca64177e50	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5c4a9d9c-adf4-442c-ad7d-dcb81084beb5	33ba105b-d0a6-4667-b6e9-927859eb4481	df69d456-0455-4f98-af86-c2c83a75c8a2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
106a56b3-7c4b-4371-af98-3a027e932d0d	33ba105b-d0a6-4667-b6e9-927859eb4481	518ec9ad-7df7-4d4b-8eff-04a6c3c36653	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fa71d810-dc5a-464a-9e69-a3d1139d5466	33ba105b-d0a6-4667-b6e9-927859eb4481	2d059afd-e97c-42b7-a1b3-a2e9cdbef966	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fe357dae-0573-401e-8e61-78d5af12d942	33ba105b-d0a6-4667-b6e9-927859eb4481	5c1a91f9-a5f9-48aa-b130-3b611255c7ea	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
47323122-fa51-4b00-94c7-bcfcc8413e38	33ba105b-d0a6-4667-b6e9-927859eb4481	358f7ed5-56c9-4d88-abe7-39ecbc3864b8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
51f1c03c-41a5-414d-95d6-59a6eae7ecc9	33ba105b-d0a6-4667-b6e9-927859eb4481	d1c725e2-edf7-41db-b67b-e6b07a9124dd	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f5369bc7-e3f7-4657-9203-e7838b542d30	33ba105b-d0a6-4667-b6e9-927859eb4481	2cfdda52-727c-4980-9b51-f6cb8d569a36	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
551cac24-8969-4c83-9295-e91b94efd0a6	33ba105b-d0a6-4667-b6e9-927859eb4481	f3621ac9-9731-4356-adcf-f5cc7fbc5652	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
242047bd-f644-42f8-8d13-135995a3123f	33ba105b-d0a6-4667-b6e9-927859eb4481	290ed9b7-ebfd-4fdc-ac2d-310f72f83df1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
94bc94b7-26f1-4f3b-9183-927a4b8f4918	33ba105b-d0a6-4667-b6e9-927859eb4481	111623ca-05ec-4e32-9c32-384496708f96	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
293da75a-0811-454c-9902-b65d4209644f	33ba105b-d0a6-4667-b6e9-927859eb4481	f15ee116-4252-45f1-944b-8a0325a927e5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ec701253-85d5-4826-9a90-4732ce021f4b	33ba105b-d0a6-4667-b6e9-927859eb4481	1cfdd92a-7159-4181-8417-0ef11efffb3c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4a27291b-d629-4145-8526-9ef4a0a5fd54	33ba105b-d0a6-4667-b6e9-927859eb4481	89660c46-97e8-416f-ae27-ac04c6e740f5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7eedd767-7e4c-43d8-86d6-0c37f040d26e	33ba105b-d0a6-4667-b6e9-927859eb4481	3ad518c1-cba5-4b49-a75c-000da86b1655	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1d4094fb-c5c5-4069-809f-678b20e019b4	33ba105b-d0a6-4667-b6e9-927859eb4481	e167a583-fb30-4951-9340-ba25f3500b66	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
93c90eaf-893d-47ea-ac2c-1722214578cc	33ba105b-d0a6-4667-b6e9-927859eb4481	82fa6a07-a523-4391-bd0c-f3d1b90e5ba8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6eaf9a7b-0268-4f2b-92e2-556a6083a5c3	33ba105b-d0a6-4667-b6e9-927859eb4481	3c340a19-7f91-432e-a3f2-1ef9c34f9c78	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e8986813-c5b4-472f-a695-de6e42324c9a	33ba105b-d0a6-4667-b6e9-927859eb4481	d024e83f-2ffd-4ca3-a4ed-e8115c78c09d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0fed1171-f706-420a-b7c1-bf775f9ef607	33ba105b-d0a6-4667-b6e9-927859eb4481	02192424-8888-4564-9c78-96b4268ac20a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
df469978-b645-4563-951e-81fdaf31969b	33ba105b-d0a6-4667-b6e9-927859eb4481	56e47716-ac53-4d03-b072-67f621dc18eb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9b62789b-0ee3-43a7-acf4-b70433347c1f	33ba105b-d0a6-4667-b6e9-927859eb4481	d9d656a9-c247-41fc-9014-e7a6e02221d0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ed4a00a4-05a0-499a-a24d-6a7465dc7119	33ba105b-d0a6-4667-b6e9-927859eb4481	d7d58ee0-f368-4cd2-b434-79bb1d42d84a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
04937cb9-18e9-4708-8640-a0fb4bea501f	33ba105b-d0a6-4667-b6e9-927859eb4481	cc0a2281-81fa-4f0b-ad41-755b93e7d4c8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2fe870a8-d187-43b6-9846-11f907eac480	33ba105b-d0a6-4667-b6e9-927859eb4481	05698e9f-9315-452d-bff6-3a9c117e3236	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a0285345-5405-4bf3-83fc-e9fe0734dbd9	33ba105b-d0a6-4667-b6e9-927859eb4481	3c31632e-fc0e-4eda-b4ec-99fe922ac61d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9a037cce-0e2e-4dd7-8807-da6c46f58048	33ba105b-d0a6-4667-b6e9-927859eb4481	83bd502d-c6cd-4b40-91c6-5d243069fb36	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7dfa5491-8f91-4831-97d3-d864c187fd2a	33ba105b-d0a6-4667-b6e9-927859eb4481	e1ca767e-3a70-442c-b1d5-d92fb895b9c7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dc8a8ee5-1df5-4286-b1a0-5c5346458f30	33ba105b-d0a6-4667-b6e9-927859eb4481	a26f2142-d8f3-40bf-9327-ce73cd8e17bb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9e22b827-4adc-428d-9d8c-d906dca2c0c6	33ba105b-d0a6-4667-b6e9-927859eb4481	21d5d841-5807-4931-baeb-3de36b2dc53c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dd2e6c1a-ab88-442d-b3b4-8e147b87a1e1	33ba105b-d0a6-4667-b6e9-927859eb4481	1ea9e3a4-13d8-4c2d-8e87-bded3021d6bf	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a467d8b9-69ac-4255-acbb-a95460b64ae0	33ba105b-d0a6-4667-b6e9-927859eb4481	f1371e95-3952-4515-b169-d487e8fa006f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1e4b5fdd-af21-4070-981e-ed624590dcff	33ba105b-d0a6-4667-b6e9-927859eb4481	e6c38cb8-b3ef-47c1-a621-df282c4f5d03	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e22b43a3-65e7-4fd4-a4ed-6d2aa8d76579	33ba105b-d0a6-4667-b6e9-927859eb4481	743943b8-a53c-41fa-ae92-ca5ca48cb031	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
90b6ae87-8836-4f62-9653-dc60c8589fb5	33ba105b-d0a6-4667-b6e9-927859eb4481	5b77c20d-5298-49a8-8237-4f70a2bbb166	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
514d0b2d-92a3-433f-845c-52fd9ae9ccb3	33ba105b-d0a6-4667-b6e9-927859eb4481	5479dc5f-ae7c-43a3-9697-59c25ff67102	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
453e324d-850d-4fb9-bcda-40db2ad792f7	33ba105b-d0a6-4667-b6e9-927859eb4481	62f6956f-c724-4cf2-afc8-023d642e0f41	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
325e64c9-1fe3-4ba0-bae3-cbd5d5cf4edb	33ba105b-d0a6-4667-b6e9-927859eb4481	543068a9-8fc4-46f7-bdef-05cc09172a48	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
379202ba-56c7-4297-af59-c42eb94fb1ca	33ba105b-d0a6-4667-b6e9-927859eb4481	71073869-267d-404b-88bc-3716117c9877	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b4cc8a5e-f3e6-4a03-ade8-91d77a623c33	33ba105b-d0a6-4667-b6e9-927859eb4481	ff7e817a-b706-4f69-b6cc-19f06a9c75e4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9b1885b5-be57-4848-84cb-d99ab8b48ef5	33ba105b-d0a6-4667-b6e9-927859eb4481	86aaf5d3-990d-4211-b717-60da64f6fca4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
caa465b8-2fcf-4775-a6d7-85647e77886c	33ba105b-d0a6-4667-b6e9-927859eb4481	6c39d722-fa9e-4fe7-98d1-4cff6a5d4b2b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
26cda365-1c10-49cd-8db7-d44e8157f89a	33ba105b-d0a6-4667-b6e9-927859eb4481	5a380c5b-1642-4f36-b9ad-8c533b2208fc	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
856ecf64-4cfd-47c2-be10-fe262a73f60c	33ba105b-d0a6-4667-b6e9-927859eb4481	ad130cf0-dd4f-4f2c-9a78-8c76bc7a794d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ad84affa-d546-40c3-8657-4a66de1ddab8	33ba105b-d0a6-4667-b6e9-927859eb4481	ece32bda-232d-4f38-88da-6224fef8a93a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4cbd3c1a-d87e-488a-9bca-b6fdd75cb925	33ba105b-d0a6-4667-b6e9-927859eb4481	30cdb8dc-6b03-4d0d-a20a-3336c9f0a537	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f22d2155-8421-4a46-a87c-122df192fbc5	33ba105b-d0a6-4667-b6e9-927859eb4481	3218a59e-15fe-491a-ad1f-8f5b77766324	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
845655ce-5dab-4c37-baee-84253c6ba768	33ba105b-d0a6-4667-b6e9-927859eb4481	bf499975-6f8c-4098-a10b-de971c75af31	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
25498535-b53a-42f4-9064-900863c7cab6	33ba105b-d0a6-4667-b6e9-927859eb4481	b71efee2-b438-4423-99ab-f84530927a58	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
81ddbba9-d459-4b09-bedb-51d15a3ad544	33ba105b-d0a6-4667-b6e9-927859eb4481	e8eaa061-7cca-4172-b9a1-43fb0951dad1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
20f96012-6e03-4937-a8a0-e939da0755cb	33ba105b-d0a6-4667-b6e9-927859eb4481	7e3ad6a3-cff0-4f76-af75-248dc9aa1faa	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6698c208-e477-42a4-b6d6-b92fa3f68413	33ba105b-d0a6-4667-b6e9-927859eb4481	41373a30-bdf3-4bc6-b65b-1ebc08500900	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e53370b6-a3f9-458a-ae46-af4a977ece36	33ba105b-d0a6-4667-b6e9-927859eb4481	e4b92bea-a98d-4112-b971-5434d3e2c46d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
8701dd06-4037-435d-9177-a76cb2d399de	33ba105b-d0a6-4667-b6e9-927859eb4481	ece454a6-dfd7-45be-857a-7ee7e21a8985	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0c2ab507-9adc-438b-9419-aa5e3e4a5b2f	33ba105b-d0a6-4667-b6e9-927859eb4481	ccd752a3-b8be-4a14-8945-1a67d9d196a2	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
634d26e0-9c5e-4462-81d9-38ef903f189a	33ba105b-d0a6-4667-b6e9-927859eb4481	6689f4bd-b72f-4121-9f3f-114353160c14	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a1c8a1ee-cb38-46db-a606-fdbaac9df0ed	33ba105b-d0a6-4667-b6e9-927859eb4481	93277032-c93f-461a-a51d-e5b78b31548a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b0b134fe-8c44-4de5-9552-9fd1e58933fc	33ba105b-d0a6-4667-b6e9-927859eb4481	3fa77826-f8ca-4c21-9bf6-b34f43019217	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c63957e8-ec90-489a-9a3e-0fca6a467319	33ba105b-d0a6-4667-b6e9-927859eb4481	6b65e501-10b2-4acd-a0f0-f92713627a0f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0e736d66-0638-4418-bb57-6acaa5d3814b	33ba105b-d0a6-4667-b6e9-927859eb4481	d036913a-b726-43e6-acc0-be191148c57d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
51c8af8f-c248-4b7c-bfc5-f84d00357fbe	33ba105b-d0a6-4667-b6e9-927859eb4481	1914df22-66fe-47e4-8d8f-4109beb88612	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9055ba06-07a4-4959-8847-1297086a6555	33ba105b-d0a6-4667-b6e9-927859eb4481	bdd99634-653b-4c38-8844-c7fa410af743	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f9344ff5-fcd3-466a-8b9f-3c52b849f4be	33ba105b-d0a6-4667-b6e9-927859eb4481	f12d1632-feb5-45b1-b72d-665cace4816d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7a98d103-818d-4d67-bdaa-5ab8c42bca66	33ba105b-d0a6-4667-b6e9-927859eb4481	697b7bf9-8478-4465-b15a-4e7800a95cb3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
020765b4-b1b6-4c51-9d2b-ee23320928fb	33ba105b-d0a6-4667-b6e9-927859eb4481	cfb30a4f-a146-46b8-bb35-6111fa82ef6b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c1b1f5d1-9ad1-4010-81ec-5889ac88248c	33ba105b-d0a6-4667-b6e9-927859eb4481	c2b4fa64-c2c1-4672-bfd8-4e7b5d8d43f6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
783dbba8-0354-4e7c-8572-296992430808	33ba105b-d0a6-4667-b6e9-927859eb4481	a228493f-b29b-4acb-aee3-8e53a0b3b25d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b106f58f-6bcd-4730-aa70-5ccb8d752f99	33ba105b-d0a6-4667-b6e9-927859eb4481	e1162b96-7ad5-40bd-9594-490b56fd4d3c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f1fae87f-b0cf-4297-b222-5ab69448d279	33ba105b-d0a6-4667-b6e9-927859eb4481	a7c8e6dd-ba40-4c26-a44f-6f5d27b62698	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c2ff0232-fd73-4843-be88-20508fc397a5	33ba105b-d0a6-4667-b6e9-927859eb4481	0c7612e3-7c10-4ca1-8a9d-f350ee74117b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
096c38f5-e7c7-4501-87d2-a3bc5ec58eab	33ba105b-d0a6-4667-b6e9-927859eb4481	06ecd909-ab38-4c7f-a0a8-16d6420a3308	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
35974c1b-7c85-4f2a-a69c-3f9654909b7c	33ba105b-d0a6-4667-b6e9-927859eb4481	552f0633-1c38-47db-b88b-b426253df114	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fc17a552-1e02-49a5-8e17-ae5c5f12b1df	33ba105b-d0a6-4667-b6e9-927859eb4481	fcc9066a-29ee-40e8-a4cc-39e7d0ff5883	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f6d699a6-f296-4218-b2d1-cb65e0c5375e	33ba105b-d0a6-4667-b6e9-927859eb4481	0a633284-cac8-4b8b-93db-6726538764c9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
213a8149-a5cd-4634-9d64-12d054cb400c	33ba105b-d0a6-4667-b6e9-927859eb4481	1e0f2164-5a78-4069-a1a5-a4fdaf48dd05	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9e610644-a432-4fbc-9599-2996f97e7f36	33ba105b-d0a6-4667-b6e9-927859eb4481	abe1af21-8a38-4881-a466-76cea6c3a3f4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4a7e27f1-c527-433d-b164-5f667247ded3	33ba105b-d0a6-4667-b6e9-927859eb4481	a887fc48-4cf9-436c-84da-c4778757bf7b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
66a2f4ce-1872-45db-ac40-7ae1755c6dbc	33ba105b-d0a6-4667-b6e9-927859eb4481	b975fd8d-8663-47ab-987d-56847a3e797a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1f4dd2b8-c5a8-44b3-b0e2-ed9ce3f1b7c5	33ba105b-d0a6-4667-b6e9-927859eb4481	141ada26-3715-4066-8294-25b29b0dcc96	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
91a8f8cf-4d25-4939-a8d5-93d6dcf9516d	33ba105b-d0a6-4667-b6e9-927859eb4481	102dc420-b7fd-4662-bad8-ba7f7cd724e3	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
596d4580-2b20-4f47-8cbd-aaca8c641a9e	33ba105b-d0a6-4667-b6e9-927859eb4481	8adc5622-f3c5-40a5-861d-805e0639cadf	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b0699b56-b1cc-41cd-a741-97b7f9f4dc3b	33ba105b-d0a6-4667-b6e9-927859eb4481	4aab688b-d98d-4470-8886-09e2e48d999e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4b903705-aecb-4dbc-baef-1f21e6de247b	33ba105b-d0a6-4667-b6e9-927859eb4481	dd7c949b-bf77-4f9e-80a2-c454b47d8d62	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
204b1b8b-dd6f-424f-969d-ec3a1b2c377d	33ba105b-d0a6-4667-b6e9-927859eb4481	39028101-e53c-4b15-ba72-26da2dc7e756	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
62d3e323-99c5-45ae-a387-4d25f0563a6d	33ba105b-d0a6-4667-b6e9-927859eb4481	cba9b16e-5cfd-4ee0-a182-f6af4d626517	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6f647e10-a3f8-4599-aea1-cc91d6babb43	33ba105b-d0a6-4667-b6e9-927859eb4481	ef143131-ceb0-4822-8f7f-b32e53f8cdb1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
37e88b96-419b-4b0a-aa62-e4828d8011ae	33ba105b-d0a6-4667-b6e9-927859eb4481	50b7ab86-eb0d-4c7b-875d-6e448d2e0a70	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c4a15fa4-f37a-4d90-91f6-4473fa34f7af	33ba105b-d0a6-4667-b6e9-927859eb4481	bfc30775-59cd-4f86-831d-996eb2c5fa5a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ad07001f-df88-42cc-9594-eea3c23ef7d4	33ba105b-d0a6-4667-b6e9-927859eb4481	ba1dd5db-9ee0-4da4-8752-eb43e9c8a295	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d315ea56-8182-4ed9-9cf7-75d1a9245502	33ba105b-d0a6-4667-b6e9-927859eb4481	954a704a-4da5-4dc6-bf41-6daf029a96e4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3a0c321a-064c-4a9e-9d81-e06016a962a6	33ba105b-d0a6-4667-b6e9-927859eb4481	69d168d9-7240-4a60-82a2-92144d2356e8	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3f1e2f60-eb9b-4d63-a444-3ecfe4d9d82a	33ba105b-d0a6-4667-b6e9-927859eb4481	526db99b-3ca1-410d-998e-817c9d4625eb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
19967da1-0f63-4230-bb82-e18b5efb3be3	33ba105b-d0a6-4667-b6e9-927859eb4481	8cac2333-470a-4711-92f4-7bede9c83f84	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
dfe7363c-68ff-4b17-ad93-2c7e11ef1e33	33ba105b-d0a6-4667-b6e9-927859eb4481	4e6d87e7-e15f-4b0c-9c5f-9d13c0c734eb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c792a512-c409-4c87-a5b1-772da55057e9	33ba105b-d0a6-4667-b6e9-927859eb4481	92b08548-b122-4559-afc4-910e3450d7ce	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
809428b2-b2e8-44ca-9060-571a1220fa38	33ba105b-d0a6-4667-b6e9-927859eb4481	f907e0e8-bb2d-4907-b6a2-a786210b9e87	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4c18713d-5267-4475-a900-80ebb33d5478	33ba105b-d0a6-4667-b6e9-927859eb4481	833a8dfb-88c7-49d4-8350-5e5921f37953	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3c7b5150-0037-4ad7-9b2d-4f2796d3d92a	33ba105b-d0a6-4667-b6e9-927859eb4481	1e7fc55c-c6bc-41e7-aadc-8d88752f9803	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
881d53f2-c979-40e5-960b-99c167a4d36d	33ba105b-d0a6-4667-b6e9-927859eb4481	a34bda89-e2a5-4c20-9188-95ba124d5ace	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b0a84302-448c-464b-b1c5-1090b88f251d	33ba105b-d0a6-4667-b6e9-927859eb4481	bb38aceb-1705-41ce-9c24-80775da5c812	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f1d0abb2-3486-4583-89cf-d6c860a70b26	33ba105b-d0a6-4667-b6e9-927859eb4481	cd321fa9-3214-4694-b6f2-db79ec682fd7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
be6c9362-6872-4910-8502-c33f1b0287c0	33ba105b-d0a6-4667-b6e9-927859eb4481	ad7384e8-902a-487a-82d3-55b33b122a3e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
45536921-a4c7-4f31-9df6-ddc67a3ef7fb	33ba105b-d0a6-4667-b6e9-927859eb4481	b5ed27f5-d452-4b07-84d9-539fe869388e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
54f28731-b755-4c77-a98e-6b9d22206093	33ba105b-d0a6-4667-b6e9-927859eb4481	a0454995-d917-4e91-8ec5-e5991daddaa4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
ec4faf7b-393e-4d1b-8b63-b43159ecbf92	33ba105b-d0a6-4667-b6e9-927859eb4481	5227a011-383d-4c9b-a42a-06598a5c8547	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5a2afc48-acde-4759-9ce8-229e2156d755	33ba105b-d0a6-4667-b6e9-927859eb4481	9309fd3c-e584-4a76-a31c-3cd5e8f9b194	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5179d076-b091-4dce-8a1f-397803fbbd90	33ba105b-d0a6-4667-b6e9-927859eb4481	e0e8a240-ea37-4400-90d2-9a59f6c2e68d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
59274029-d658-405b-a353-dca2fd740674	33ba105b-d0a6-4667-b6e9-927859eb4481	8fa410bc-c485-4f90-931f-391e0fd81983	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
46b7a81e-4edd-4b2a-8073-4a89fb6bbf12	33ba105b-d0a6-4667-b6e9-927859eb4481	45d036cb-d08a-4f41-b3a3-0bc36f3e1ab6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9745670b-10ef-4f2c-a073-4ade42dcaaa1	33ba105b-d0a6-4667-b6e9-927859eb4481	6e5d11d0-a5fa-423b-8399-a722d91872a1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2d2ba055-adfa-4103-989b-b492ab99cb21	33ba105b-d0a6-4667-b6e9-927859eb4481	71606ef3-5fd7-4621-9cea-0b919bae8f57	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e2469b17-8aa4-4bbf-81e4-7cec2e6dbf1d	33ba105b-d0a6-4667-b6e9-927859eb4481	92df571d-a4d9-4d3a-9aee-f736ee9f4aee	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
127193d6-d9bf-4809-a07d-1cf692fcea87	33ba105b-d0a6-4667-b6e9-927859eb4481	d222bc28-f243-40af-b848-1f6cc875ccc9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
70c6a22f-acd7-46fe-846b-ea344094f5bf	33ba105b-d0a6-4667-b6e9-927859eb4481	246d7ca9-0b2a-4492-9870-94795b61ddc7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d8a6dfc3-e36c-4533-aa06-7d5705bd4104	33ba105b-d0a6-4667-b6e9-927859eb4481	20877256-7129-435b-b16b-b433aa1d3e1e	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
cc1818e3-f695-4330-9edd-44db1d9dea55	33ba105b-d0a6-4667-b6e9-927859eb4481	990a9f68-8d21-4898-a48e-ea450b94268a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f921accd-cd1f-4959-9a90-55aba3386056	33ba105b-d0a6-4667-b6e9-927859eb4481	f890a885-6d44-43e0-be9d-c92a404aa074	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6e6274a8-e857-4417-ab24-e3c331ac025e	33ba105b-d0a6-4667-b6e9-927859eb4481	a2940828-84a6-4e6e-b6fd-9dad55f96b7a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c4f87b80-3c49-4ffa-98c4-cc83f87aa8e2	33ba105b-d0a6-4667-b6e9-927859eb4481	417a7e81-4a0b-47cf-95e7-712a55328d1a	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d85ce74c-9f1e-4d6a-be86-72e8f50f75a6	33ba105b-d0a6-4667-b6e9-927859eb4481	7a06a82e-2dd8-464c-a310-dc3b80d3759c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c0633437-ccde-4b6f-8b0f-0d1dd885b089	33ba105b-d0a6-4667-b6e9-927859eb4481	9223809b-3b12-4c9d-b3ea-b5f26c2848b7	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6abce516-12df-4bb2-819e-5d96bd0e4254	33ba105b-d0a6-4667-b6e9-927859eb4481	bf714bac-d921-40e1-bddf-4c16fccd8868	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
79f87eef-a088-451e-bd02-2665ef904505	33ba105b-d0a6-4667-b6e9-927859eb4481	b80b1a76-e57c-4685-bec8-30a0dee24331	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
99e9f09e-dd34-423b-97c0-62b3ff61e012	33ba105b-d0a6-4667-b6e9-927859eb4481	0df7591d-dc8d-4627-bb2b-351d7cd5f1f0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a0157d2c-1d74-4b01-926e-743cd0a0a2ab	33ba105b-d0a6-4667-b6e9-927859eb4481	bcc7949d-2326-4a0d-8428-64050ac20671	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
23703464-5ef9-461f-989e-e9c9d13c59a2	33ba105b-d0a6-4667-b6e9-927859eb4481	c94e7434-bc82-4bac-8bd1-7aa09be3be73	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6ca9075a-122f-41a7-998f-5011001e3e11	33ba105b-d0a6-4667-b6e9-927859eb4481	778e07b2-3b2d-47c0-ad46-48dcf9215ae6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
77702fff-56f5-4f72-97a6-5530b8245dbd	33ba105b-d0a6-4667-b6e9-927859eb4481	363d0bad-f2d6-4623-8ae3-e23875e04b94	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5c89bb7f-0fe2-4fbd-b530-870f05fed5be	33ba105b-d0a6-4667-b6e9-927859eb4481	c02279fe-75f5-4486-b5f4-9eaf84e0e8de	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
649dd958-c24b-4c1a-b2c3-ed2ec86e0be7	33ba105b-d0a6-4667-b6e9-927859eb4481	259bdeb5-e418-4538-8906-324ead26d15b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
2a1fa20c-96ed-47fa-9c55-f10c60c06179	33ba105b-d0a6-4667-b6e9-927859eb4481	72241839-cab9-4dcc-ba30-89f3194061d4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1aef02b3-8d26-4566-9e52-9bbdb05af7e7	33ba105b-d0a6-4667-b6e9-927859eb4481	5c192358-ce0e-45ad-b403-932aa9f8e416	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
5fdd936a-5199-470a-a46b-388a1802eb79	33ba105b-d0a6-4667-b6e9-927859eb4481	ed07bfac-5fc8-4f2b-9305-f99bfae90985	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1695e541-a65a-4e84-90c1-e91d48ef2c33	33ba105b-d0a6-4667-b6e9-927859eb4481	eee14ba1-80ab-4aaa-87c3-86b3e54bf004	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
aaf06ba3-0dfb-4387-b7fb-83186be2ce21	33ba105b-d0a6-4667-b6e9-927859eb4481	4054a070-5b5e-49af-a0f9-aaaac843c3c5	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d50252e6-9694-451d-8411-814bfd469159	33ba105b-d0a6-4667-b6e9-927859eb4481	10239fd8-886d-4e6d-8848-aab5b176dff4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a56beb69-287f-405e-89e3-e640ad43a957	33ba105b-d0a6-4667-b6e9-927859eb4481	f24aa9a1-5921-41dd-a47d-35f63a437ccb	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7f5f69b1-db37-4a12-96f6-e11e48aea024	33ba105b-d0a6-4667-b6e9-927859eb4481	6205b20b-6bff-47be-b060-0dcf156c84ed	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a1f33edd-aa96-4761-ab9a-2c792e9db413	33ba105b-d0a6-4667-b6e9-927859eb4481	d7155d1b-e011-4e81-9c5f-6fb6b1b4cc22	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6ff1bf7a-7d88-4883-81da-d4f666c09d32	33ba105b-d0a6-4667-b6e9-927859eb4481	68d15dcc-2d84-4b66-ae05-7e08a115aea4	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e63d686e-f81a-4960-88f4-87f46d43e93e	33ba105b-d0a6-4667-b6e9-927859eb4481	ae39b796-add7-4fe2-b732-adb177cace7f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1227c2aa-ff2a-4373-9e98-f01fdb449f8d	33ba105b-d0a6-4667-b6e9-927859eb4481	0cf96b99-ac98-428f-8534-d9d7a25b1f65	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a7288d4e-6fc8-4fe0-8094-24df94f90c88	33ba105b-d0a6-4667-b6e9-927859eb4481	b7c5e060-b564-4d1d-b7f6-83212c978a9b	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
45b6d336-53e6-4f64-8ed7-89211827d54e	33ba105b-d0a6-4667-b6e9-927859eb4481	8eaa9edb-3669-40dd-bfb9-9a2e33735487	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
82cc7964-03e9-4dbe-adbe-dd9ad9a7a5e3	33ba105b-d0a6-4667-b6e9-927859eb4481	e1f43c98-4625-4dd4-adc1-a84c1f94eee0	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
1eb3f8a0-aef9-4213-9d44-2b56fa0a8d25	33ba105b-d0a6-4667-b6e9-927859eb4481	76745f14-37c9-4317-b741-c1ebcf6a46b1	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0e3d9ff5-38bc-483a-8f3e-454f88d4083a	33ba105b-d0a6-4667-b6e9-927859eb4481	d548ac3e-54bf-406e-9384-98da6ef9a8b6	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7894e344-b7f3-404a-b2d5-79bb30737d21	33ba105b-d0a6-4667-b6e9-927859eb4481	efa2f5ad-3b4c-4bbe-89e8-6cf227db799c	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a651bdc3-3da5-4914-9aa2-30b5a2e23e51	33ba105b-d0a6-4667-b6e9-927859eb4481	5461966f-82bb-428a-95f8-de2117b7b7c9	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b5fe79b5-4274-454f-a7f8-9fc8f9fcd17d	33ba105b-d0a6-4667-b6e9-927859eb4481	b58c50c5-5a88-4ca5-b151-539231aa0e4f	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4c0701d4-9655-4aad-84c2-1d36044ee9de	33ba105b-d0a6-4667-b6e9-927859eb4481	4e0efc01-e1d7-48e6-9f37-82846dc00f9d	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
\.


--
-- Data for Name: overrides; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.overrides (id, order_id, result_id, result, overridden_by, active, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: patients_archive; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.patients_archive (id, mrn, first_name, last_name, middle_name, dob, gender, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: predefined_comments; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.predefined_comments (id, comment, category_id, active, created_at, updated_at) FROM stdin;
1	Canned comment for corrected report	1	t	2024-05-23 21:17:25.386352+00	2024-05-23 21:17:25.386352+00
2	Canned commend for Ammended report	2	t	2024-05-23 21:17:25.386352+00	2024-05-23 21:17:25.386352+00
3	Canoed Additional comment for result	3	t	2024-05-23 21:17:25.386352+00	2024-05-23 21:17:25.386352+00
4	Canned General comment for result	4	t	2024-05-23 21:17:25.386352+00	2024-05-23 21:17:25.386352+00
\.


--
-- Data for Name: procedure_details; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.procedure_details (id, procedure_id, gene_id, positions, alleles, created_at, updated_at) FROM stdin;
7ca57f9c-2249-42a6-8982-327bd7044ca2	3979e189-aa25-4087-8c21-df777bb264bd	32638f99-ec66-41e9-87db-40b5f6c8d7d6	{rs12769205,rs4244285,rs12248560,rs28399504,rs41291556,rs72552267,rs17884712,rs140278421,rs4986893,rs6413438,rs375781227,rs72558186,rs118203757,rs56337013,rs192154563,rs118203759}	{*1,*2,*3,*4,*5,*6,*7,*8,*9,*10,*16,*17,*22,*24,*25,*26,*35}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
8871d9ef-2d3d-4a46-819f-3e37ca640d58	a6000906-9b4a-4670-91c6-50a8e828a293	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	{rs1801268,rs67376798,rs3918290,rs72549303,rs55886062,rs56038477,rs78060119,rs75017182,rs1801266,rs115232898,rs72549309}	{"No Variants Detected",c.295_298del,"c.557A>G (p.Y186C)","c.703C>T (p.R235W)","c.1129-5923C>G, c.1236G>A","c.1156G>T (p.E386X)","c.1679T>G (p.I560S)","c.1898del (p.P633Qfs)",c.1905+1G>A,"c.2846A>T (p.D949V)","c.2983G>T (p.V995F)"}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
7ca7abe1-153a-47d1-b806-3e399eb3012d	4aed92f8-9c4f-45e2-ac49-47b8790fcb19	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	{rs41303343,rs776746,rs10264272}	{*1,*3,*6,*7}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
3789fd1c-3ff6-48c1-94d0-928ac8f81760	7091e051-8cfe-46e8-967e-b734ea9d5230	e8d718e4-4831-496c-8448-16ad044c2e9d	{rs72558187,rs1799853,rs7900194,rs72558190,rs9332131,rs72558192,rs28371685,rs1057910,rs56165452,rs28371686,rs9332239}	{*1,*2,*3,*4,*5,*6,*8,*11,*12,*13,*15,*16}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
0b22af3c-0c18-49bf-835c-67936597de40	6eefc3e8-f2f6-4037-a074-2bf293ca7e90	daa86f03-86c6-4a8d-abab-476fcd043c9c	{rs746071566,rs116855232,rs147390019,rs186364861,rs746071566,rs766023281,g.48611985A>G}	{*1,*2,*3,*4,*5,*6,*7,*8,*9}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
bbaa8055-0085-4365-b1bd-31e3c01feee2	6eefc3e8-f2f6-4037-a074-2bf293ca7e90	9ca2999f-1b56-4ee8-a254-2da4415cbb72	{rs1142345,rs1800584,rs74423290,rs9333570,rs1800460,rs72552738,rs1800462,rs267607275,rs9333569}	{*1,*2,*3A,*3B,*3C,*4,*11,*14,*15,*23,*29,*41}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
8edb9611-5cb5-414b-8a4f-ac3cfd324da3	ed2db461-efa1-4da5-90e0-9988d07222c5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	{rs12769205,rs4244285,rs12248560,rs28399504,rs41291556,rs72552267,rs17884712,rs140278421,rs4986893,rs6413438,rs375781227,rs72558186,rs118203757,rs56337013,rs192154563,rs118203759}	{*1,*2,*3,*4,*5,*6,*7,*8,*9,*10,*16,*17,*22,*24,*25,*26,*35}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
f012d8dc-4217-4be4-abe1-1fb9319f05ba	ed2db461-efa1-4da5-90e0-9988d07222c5	e8d718e4-4831-496c-8448-16ad044c2e9d	{rs72558187,rs1799853,rs7900194,rs72558190,rs9332131,rs72558192,rs28371685,rs1057910,rs56165452,rs28371686,rs9332239}	{*1,*2,*3,*4,*5,*6,*8,*11,*12,*13,*15,*16}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
547f0f0c-5bdd-4d11-8dab-03d228562dc9	ed2db461-efa1-4da5-90e0-9988d07222c5	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	{rs1801268,rs67376798,rs3918290,rs72549303,rs55886062,rs56038477,rs78060119,rs75017182,rs1801266,rs115232898,rs72549309}	{"No Variants Detected",c.295_298del,"c.557A>G (p.Y186C)","c.703C>T (p.R235W)","c.1129-5923C>G, c.1236G>A","c.1156G>T (p.E386X)","c.1679T>G (p.I560S)","c.1898del (p.P633Qfs)",c.1905+1G>A,"c.2846A>T (p.D949V)","c.2983G>T (p.V995F)"}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
5f8a8fa7-8600-49fb-a220-24c64403b877	ed2db461-efa1-4da5-90e0-9988d07222c5	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	{rs1135840,rs16947,rs28371706,rs72549346,rs72549347,rs59421388,rs28371725,rs79292917,rs5030867,rs5030656,rs72549352,rs35742686,rs3892097,rs5030865,rs5030655,rs61736512,rs1135822,rs774671100,rs5030862,rs1065852}	{*1,*2,*3,*4,*5,*6,*7,*8,*9,*10,*12,*14,*15,*17,*21,*29,*39,*41,*42,*49,*56,*59,*114}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
ef6a2647-9080-4864-9d47-de52dac9396b	ed2db461-efa1-4da5-90e0-9988d07222c5	c0f1136b-6463-4304-a473-cae1f384fc8e	{rs9923231}	{}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
4bc03862-a6a2-459b-a056-9f59ff8bf540	ed2db461-efa1-4da5-90e0-9988d07222c5	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	{rs41303343,rs776746,rs10264272}	{*1,*3,*6,*7}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
bc7d415c-33c7-4f97-80a9-e85155f15546	ed2db461-efa1-4da5-90e0-9988d07222c5	22fb682a-e57d-4ad2-8dc5-8159f28a9862	{rs2306283,rs11045819,rs4149056}	{*1,*5,*14,*15,*37}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
1f355f5f-90a6-4acd-bf51-4907a6c0a874	ed2db461-efa1-4da5-90e0-9988d07222c5	9ca2999f-1b56-4ee8-a254-2da4415cbb72	{rs1142345,rs1800584,rs74423290,rs9333570,rs1800460,rs72552738,rs1800462,rs267607275,rs9333569}	{*1,*2,*3A,*3B,*3C,*4,*11,*14,*15,*23,*29,*41}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
e6a89e09-3c4c-4086-83cb-be95604554be	ed2db461-efa1-4da5-90e0-9988d07222c5	93d511ec-e5fc-4832-9581-813842b25860	{rs2108622}	{*1,*3}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
d6ff7f8d-e6ea-434f-8b73-71fda3cf8109	ed2db461-efa1-4da5-90e0-9988d07222c5	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	{rs12777823}	{}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
b4edf04c-b43d-4b7f-a828-eb2fab9d29aa	ed2db461-efa1-4da5-90e0-9988d07222c5	39f5387b-4a50-4696-99ae-6c9062e70c52	{rs2231142}	{}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
102b9894-1f97-43af-9eff-65cd87186e6e	ed2db461-efa1-4da5-90e0-9988d07222c5	01b74a5e-f95b-4086-a5b7-899a8de1f228	{rs3745274,rs34223104,rs28399499,rs3211371}	{*1,*5,*6,*7,*18,*22}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
25b1f4a9-5301-417a-8002-3ea63204a98c	ed2db461-efa1-4da5-90e0-9988d07222c5	daa86f03-86c6-4a8d-abab-476fcd043c9c	{rs746071566,rs116855232,rs147390019,rs186364861,rs746071566,rs766023281,g.48611985A>G}	{*1,*2,*3,*4,*5,*6,*7,*8,*9}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
3b9f9a41-60ff-4c23-b872-a895494d1675	ed2db461-efa1-4da5-90e0-9988d07222c5	58f41405-4198-4822-b10e-eb43cd77bc27	{rs3064744,rs4148323,rs35350960}	{*1,*6,*27,*28,*36,*37}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
16294f3b-e86c-4546-b43a-4a4978e3cc96	ed2db461-efa1-4da5-90e0-9988d07222c5	9be7b66e-d066-4d98-bc30-ec1511489398	{rs1050829,rs1050828,rs72554664,rs72554665,rs5030869,rs76723693,rs137852330,rs5030868,rs267606836,rs267606835}	{B,A,Asahi,Canton,Chatham,Cosenza,Mediterranean,"Coimbra Shunde",Vancouver,Kaiping,"A- 202A_376G","A- 968C_376G"}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
5c827aa0-817f-42f5-b9b6-08585cb793bf	ed2db461-efa1-4da5-90e0-9988d07222c5	b31967bd-f6da-49d9-ba4e-cafdd7786116	{rs2395029}	{}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
070bfff2-ab71-42fd-beac-a6e2cea3a44b	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	32638f99-ec66-41e9-87db-40b5f6c8d7d6	{rs12769205,rs4244285,rs12248560,rs28399504,rs41291556,rs72552267,rs17884712,rs140278421,rs4986893,rs6413438,rs375781227,rs72558186,rs118203757,rs56337013,rs192154563,rs118203759}	{*1,*2,*3,*4,*5,*6,*7,*8,*9,*10,*16,*17,*22,*24,*25,*26,*35}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
1b09807b-5b88-4fc9-b8a3-0da72e061a9f	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	e8d718e4-4831-496c-8448-16ad044c2e9d	{rs72558187,rs1799853,rs7900194,rs72558190,rs9332131,rs72558192,rs28371685,rs1057910,rs56165452,rs28371686,rs9332239}	{*1,*2,*3,*4,*5,*6,*8,*11,*12,*13,*15,*16}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
959a348b-cd82-46ba-a273-511b52dc5f0c	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	{rs1801268,rs67376798,rs3918290,rs72549303,rs55886062,rs56038477,rs78060119,rs75017182,rs1801266,rs115232898,rs72549309}	{"No Variants Detected",c.295_298del,"c.557A>G (p.Y186C)","c.703C>T (p.R235W)","c.1129-5923C>G, c.1236G>A","c.1156G>T (p.E386X)","c.1679T>G (p.I560S)","c.1898del (p.P633Qfs)",c.1905+1G>A,"c.2846A>T (p.D949V)","c.2983G>T (p.V995F)"}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
e0f59b1c-aa8e-468c-bfe6-c9ec48a46153	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	{rs1135840,rs16947,rs28371706,rs72549346,rs72549347,rs59421388,rs28371725,rs79292917,rs5030867,rs5030656,rs72549352,rs35742686,rs3892097,rs5030865,rs5030655,rs61736512,rs1135822,rs774671100,rs5030862,rs1065852}	{*1,*2,*3,*4,*5,*6,*7,*8,*9,*10,*12,*14,*15,*17,*21,*29,*39,*41,*42,*49,*56,*59,*114}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
c5ec496a-f348-4ca8-86a9-37b7892a0cde	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	c0f1136b-6463-4304-a473-cae1f384fc8e	{rs9923231}	{}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
057749be-41ee-46fd-a18e-e71cc137f060	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	{rs41303343,rs776746,rs10264272}	{*1,*3,*6,*7}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
02931bf5-580f-4ce5-a270-ee854a3d46c4	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	22fb682a-e57d-4ad2-8dc5-8159f28a9862	{rs2306283,rs11045819,rs4149056}	{*1,*5,*14,*15,*37}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
0df70b2f-41cb-4fa3-9856-7e81679e3987	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	9ca2999f-1b56-4ee8-a254-2da4415cbb72	{rs1142345,rs1800584,rs74423290,rs9333570,rs1800460,rs72552738,rs1800462,rs267607275,rs9333569}	{*1,*2,*3A,*3B,*3C,*4,*11,*14,*15,*23,*29,*41}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
b7f5e0ea-6a39-4175-9771-1d629cdbf6d2	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	93d511ec-e5fc-4832-9581-813842b25860	{rs2108622}	{*1,*3}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
ecf9731e-4fca-4e52-bde1-5aadd8734b92	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	{rs12777823}	{}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
c1233e75-a860-4991-aa35-253eafbc82d5	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	39f5387b-4a50-4696-99ae-6c9062e70c52	{rs2231142}	{}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
37a5dc57-5444-4774-b005-1109f7a68204	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	01b74a5e-f95b-4086-a5b7-899a8de1f228	{rs3745274,rs34223104,rs28399499,rs3211371}	{*1,*5,*6,*7,*18,*22}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
9ada2f0e-d802-44b4-af0e-f4b9dfbe7ee3	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	daa86f03-86c6-4a8d-abab-476fcd043c9c	{rs116855232,rs147390019,rs186364861,rs746071566,rs766023281,g.48611985A>G}	{*1,*2,*3,*4,*5,*6,*7,*8,*9}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
2ea1975a-5479-40c4-8968-ff9a150725f7	8fe0a9d5-7bda-4cbb-bbda-aa918b34c501	b31967bd-f6da-49d9-ba4e-cafdd7786116	{rs2395029}	{}	2024-05-23 21:17:24.741442+00	2024-05-23 21:17:24.741442+00
\.


--
-- Data for Name: recommendation_details; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.recommendation_details (id, recommendation_id, gene_id, gene_property_id, value, status, active, created_at, updated_at) FROM stdin;
001bacfa-e497-481d-884a-90f311a6df26	4990a392-3b4c-4892-9e6c-76e6cecc9280	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
46d7b2ab-5383-4bad-8bab-45a4fec5f597	f503feb9-7558-4ff5-bd66-16fad0cd8a5a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
76250cce-abc0-45a4-8562-b8acddf2f204	691a50fb-a2af-4bd5-a85f-1ad3ab57af73	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5d2121b4-89a6-459b-b452-64e856184ded	3c64be84-c28a-424c-a87e-e06458e58587	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2ca2d454-f5e1-49a1-9567-b4726db04766	7949de13-fe43-4946-bfa4-65b756b42e50	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
abd4138d-ae9c-4e09-b7c5-ec486770f995	793158bd-aacb-4a8c-9d27-31879e222317	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
74375d1f-62f8-4751-bf46-29e1f260e5a7	19251ea9-c41b-4207-88bb-373d1b618a92	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f088b9b2-6c00-49fc-8946-75e8287e5176	3a504cc4-966c-440a-9a63-26ec0e9564f1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cc8fb70a-050c-458d-a6e4-98b453d16409	b5a9ac55-68d4-4e2a-8eeb-ddb909d8db78	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c24b71ad-c738-4535-b27e-f4974a6b84d0	6058eb73-6738-467c-8b91-9c84eaa70f2b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c792c172-818c-4386-8833-ea1173ddac9f	7b46531a-93f6-491d-8aee-57b3b17204ad	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
25a76ff9-ddb4-4184-8c62-79501c781228	9618fc26-e1b3-493b-a61a-232a7ab79955	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
713423e4-8d38-476e-96c3-7baea63b5404	02ec260b-4589-406a-b044-b1983e374c69	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9ae24126-705b-4e31-96b3-35f1b04e70e6	598bcaca-dbe2-495c-9a83-0a5551d475e1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a24958e6-f5da-4478-934a-bca20f1c9c35	531a543f-77f0-4b07-9f69-500c04f6da30	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f78355a4-676e-4317-8ded-d13321d5a59b	84012120-00e5-42b9-8fc8-12541cda050f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1e3d3da6-0994-41b2-bc4b-dc69ad48095e	536a7bad-ec25-4edd-9105-98c3446de139	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d03f42b1-f2bd-4ee1-beda-cb7fa1307ea8	40dc3eae-9e1c-454a-bb51-44f197d5134b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6f1a11c5-f7e8-4457-b7fa-fa653188383a	205a9fe5-b317-4c05-8803-1c7d98cc6728	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5d3e489f-c981-4841-9be9-3320085b37e3	10c56e6a-d65e-4219-b25c-fb624f36a9f8	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f6cf6277-1236-47ba-b9e5-208a3940669f	e1f29232-3703-4517-87da-65791a162ce3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6991b607-09da-4271-8103-22d74cf1114c	28d9a28e-7ece-4ad3-925e-1b976941fa52	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
78d97be6-da51-4350-b915-79c5d533edca	8a01b626-ae72-465a-8ba1-5acf0209963d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
42a5f5ef-ff34-461a-8a63-6fa030713f54	9fd4903a-b359-4b5c-9e5d-d93e2658fc24	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0c6d4244-fcf5-4a1c-a976-9942f9523a89	d887e66d-5595-458a-a9f4-bf98386d8f53	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
22b765b9-2ef0-4ec6-8f1f-f14194982da7	48ba79eb-951a-4707-9e23-490d8b0b418f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b4cf6868-07b8-4c9c-9ca7-442b8df0f681	8c2fba7d-1d6f-424f-a644-28d7e38d9f9d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f1eefdcb-e16b-4332-8134-aa91d9569fb2	0eaeeb04-a26a-4b46-8b2a-9070ee200a4f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2050eb19-1220-4972-9e4c-c2f5d770e07b	4365e77c-0942-43a1-8f31-782a88bfa265	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ab99ce3f-c7fb-4e31-9afb-c181f73314aa	729ba811-064c-4357-8225-b3c6f7030db8	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0946132a-8ee4-4d91-b3bd-01b6fac40051	7ec93d74-6bfb-4924-b6a3-ac894e5c05e7	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
439a38b6-409b-4ab7-9a38-3f060e52fe40	c3f1ab59-6be3-41e2-a68c-6cf4e714bfd5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
26dc5883-a915-4a76-b8ac-de99877bf916	16cf6405-f1c7-44eb-94ab-928300c777fb	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
365e19ef-b1fe-49b1-9636-b4eb7867a23a	dddc0c93-7015-4dbe-b810-bc750fdb8081	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fd547d6e-f47f-4cf2-be06-6438ef50984d	d203898d-4125-4c0b-83a0-67d7b0524773	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
71cb9aff-26f3-41c2-bbc5-d7d3aa6a7b22	12a807dc-7d5c-4e37-98c8-b07a28f98f1f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b25c9528-7f39-4150-a331-a32fe6855920	50771793-e857-4b72-a9e9-de879aa12ed9	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8564f49b-8ad3-4a23-9504-0e763967e2ad	f0e37aef-c08c-4f09-8df6-9067a8d97297	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
df0933e6-99e4-4bed-9c83-63aa002aaa57	47cf9f8f-8c8a-4ea2-870a-39f5e7c0ea63	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8e580028-1d39-44f0-a52b-6b6392f303a5	5b444f2d-dbf7-4ffb-a977-815ed4401b60	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ff427ea1-66d3-4c05-9317-7fdff9f8ad24	c33b9bde-3627-44f0-920f-5f625d66c7a8	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
673fd69e-b78b-44a0-8fdd-98c95df24ffd	53a404fc-6ac5-4648-b0b9-eb402c5af60a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
50e7aea4-aaf6-496d-abf0-fba574642ff3	1391ee7c-4070-4701-a19b-83ac9bc570e3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9aa5467d-3d53-4ca6-aa50-e7a953db96ba	56b49b61-640c-4a0c-af50-34c4d57ff002	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4e3fdbc0-cf32-489d-a5a5-8b8b514ce8a9	c089d975-1478-4949-9a4c-7ea5b89061c3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
789c0260-7b32-4a8f-995a-782ea5d9c668	6dc9160e-efc5-476d-b7c8-cf23aa67617b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0abffa2e-a37a-4751-a82e-df9c2cbe52c3	538e80b2-97b3-49e5-8f4b-c8c6cffae1d1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6e2120ee-33bb-41ad-853a-20f2d77ec411	f7fbaa70-2085-4992-830f-9e62bcfdcae6	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f70d376d-33d8-481d-b31f-163f0df26e54	66d63a0e-4ded-4fe6-8027-df0e5f58883d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c379a138-fcd3-4cb3-af84-cdfbe150682a	61d4a736-de0a-46ba-b13e-b1b9bc458354	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5bafcb78-1bfa-4ce3-ab15-085a1442018c	afc9aa8d-45bd-4f93-a36f-a1cab277977b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4709969b-885c-44b9-b6db-ecfecc7d92de	8c0befb0-b6df-4e35-89fa-2830f348aac2	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
279f3ce5-2b3d-4155-8c0b-991f03263b25	2b4f1a89-f719-42ca-a334-5529cf2c7ce6	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bb0bd222-dd71-46e4-ab49-b102e49ba6b1	6647e799-322d-4d68-9671-9ee75b221763	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f87c8dd9-b8a1-4558-b867-272b3841af02	41b2fefe-fb02-465a-88f1-70d3f4f0035c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
65b0bc98-6aba-48ac-abc9-e5ecf1db7128	9f01b9b9-ff84-4dc4-bdca-bffbc706a4e0	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7f8377bf-9adb-4cbd-a6d8-43b35b934b7e	499e5da1-163e-4a5b-a7d2-4c18ecbd25df	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
20c2d725-299c-4627-8406-f6a29536f8f0	9af83db6-a91e-423c-b2ef-bf3fba38b6ef	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ceaafc8d-ec59-48b5-9917-e152b4c0fefe	5b13adac-657f-45ac-8a63-738966d2211a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c780b7b4-0ece-4775-9c46-d078fc502e89	f78ac58f-8207-4be5-ab66-2f6633a85d31	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
47894530-fd2e-4a63-8ce6-e9fc31942ee3	9e7558b0-fdf3-4975-8d43-2aeacf9d81c1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
643744b7-5c2b-4eb6-b842-3fc57f6779c6	0833fc29-cdeb-4cbc-84a4-0dca5f35edfb	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3c6f1d8e-c62f-4f31-8c01-efd6baeea20c	0a132e5e-f8e6-4d23-8003-30c349d2e9bc	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3951f415-9d2a-4a27-90ab-29002830e678	4c135345-c7fe-45d2-acab-3882fdf834fa	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f0d610d9-c8d3-45d8-9789-2ee0dbbd2e25	fe5a045d-c3ed-4aa8-a426-e9e6166cfd9e	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
54e3b126-d9ef-4b07-8387-e9bbefac17a7	40104ccc-87fe-4b55-995a-a00743d035cc	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1f32ee66-ae2e-49cd-b34e-ccc8dffdbafb	059bc02f-d224-44e3-8553-258d81dd7993	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6bbf1c36-4f7e-4390-ab94-83c77c2288f9	2fc748cd-dbbb-488b-8aa0-4f6ddba22f7a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f2183a74-6cfb-40cf-9808-30c3b0c13fd8	742e478d-aaf0-42ba-8fa9-8267808b64c3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6bfa0f65-9169-41ca-8add-3f6286180a0d	9fae4973-bf8d-4639-a8d8-42dd1d8a86d6	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2243a9fa-14d9-43f4-9fb2-730dff38d1db	25315b4a-2e27-43af-9256-47ba33a1178a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
79d14549-c1cf-43cf-8b49-1bb93ac84fb9	81b62720-ffca-43c8-9e58-5c7a53176400	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
34a2a5b6-5d84-4115-b5a7-d67bb9a0ef9d	895cc18e-a7f6-4589-ae67-1360384f09b5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bc4efa78-2187-46d1-9c9b-1d65bff2abfb	0e4f9b52-d222-4f74-b710-b4a324153034	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ebb538e6-1997-43da-8e69-7a06a86b3214	c9d037ea-a00d-449a-96e5-d89b605ba3e6	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8336d1d6-eb31-4cd0-bd32-3b5f6d4f9594	46459ef6-baf6-4729-8232-2a51fc6491a6	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9c113e76-6ba5-4aff-a82a-9371c2cb5839	cdf9a600-84ef-4ea6-99ed-6acd5df192bb	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4893a81a-60b4-4590-986c-cdf475637396	c4886f97-4057-4283-8941-90955ca6b136	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6a977a3b-e1a6-4c95-a141-90928869dc04	63b14f7a-e198-4551-925e-1f9c5d07fb16	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
68b9ed83-84a9-4e55-9638-9f3a072242d4	a1f30561-736f-4915-92de-9adbb25f699d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6a8c7e76-877f-4665-b5dd-a63ca064c183	a866e0cb-98f3-4d96-985c-0dc4677efedf	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c4ecda18-947d-42f9-81a8-9eaacd5121ca	61098814-7560-4818-a607-9981f1941e2e	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3ee25ac6-7b4e-479e-9a56-dcd028898734	61098814-7560-4818-a607-9981f1941e2e	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3eb1857a-36f9-4073-8732-2af69aa560da	2a6c8842-25ec-4eb6-a97a-5fdfa19bbcde	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
64e98b6c-5ad3-4bd4-beaa-ea4a4cdfce0d	2a6c8842-25ec-4eb6-a97a-5fdfa19bbcde	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ceeb5396-794f-4a17-be99-03459ba0fae4	8db07b1f-725c-41bf-85f2-1c296043dd9d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5b8d2f98-3cd2-4d74-bc61-d4aaa083c499	8db07b1f-725c-41bf-85f2-1c296043dd9d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
609bbb71-4935-4be5-813a-63aa3bd806fc	db4436b6-95e1-4705-875e-43be52ed6487	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4254817e-877c-434f-876b-8ea440e14adc	db4436b6-95e1-4705-875e-43be52ed6487	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
48dddf38-3110-4c22-a2ee-5f390d0efd72	f6540e59-0d52-4780-a526-60f9841eed98	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3c6c9a80-a9f5-4c1b-9e52-27ff123b8e3c	f6540e59-0d52-4780-a526-60f9841eed98	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0919c15e-446b-47dd-bc77-be99b6a238c9	511b07e2-02ca-4bf2-83ea-5811dd5cdf9d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
87dbe9f4-1747-4dc4-917c-25701506ebe3	511b07e2-02ca-4bf2-83ea-5811dd5cdf9d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
76666bf0-a6eb-4d32-a118-d07c5ba41e4b	6974d20f-96de-427a-b03d-9b0d9ac53f02	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
725e70b1-21e8-4fcd-b278-8d1c781926ba	6974d20f-96de-427a-b03d-9b0d9ac53f02	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d5fa040e-ed35-472d-894d-229be95f4e73	1e6b46de-fef6-4e73-bea8-1131c9da0faf	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
75b6cd3c-92d0-4ef8-b32a-b0ef0da01f58	1e6b46de-fef6-4e73-bea8-1131c9da0faf	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
765b36bd-a97b-46dc-b467-f47577a0338a	e8ada8df-d99c-42cb-9d07-95078a422753	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
38894c52-fdbe-4eb2-a368-5d3ccf0a04dc	e8ada8df-d99c-42cb-9d07-95078a422753	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c75b97fc-035c-4d64-a38b-18ffd60cb162	b04c8eef-dd06-491f-a009-d3ad1d932f8c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e18d07d3-9208-4d6d-bd2c-78e37df372b7	b04c8eef-dd06-491f-a009-d3ad1d932f8c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9c21cf2c-8bd5-433b-bca5-97f473416754	8283c783-6023-4122-8213-70c33cbf129c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7e6ecbba-1d84-4d06-99b7-13d0969d7d3e	8283c783-6023-4122-8213-70c33cbf129c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dc0c3dfd-6688-4eee-bcd3-a9cee6687e62	1aaadbd1-4a0b-4dc9-b559-0cf1c764f18e	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2c235f3b-2fd2-4c90-878b-0c8f0440250a	1aaadbd1-4a0b-4dc9-b559-0cf1c764f18e	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5a90e5e2-8696-47f0-8d49-12bf82866aa4	4c73a2b0-f6d6-4e40-b20a-3c6ec7225dd1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
16883307-152b-4deb-b7ee-73bf9e27a4c9	4c73a2b0-f6d6-4e40-b20a-3c6ec7225dd1	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
65cc51d2-a84b-4dee-adbe-74d95158f232	3e72bd22-b876-4baf-bfde-85028574fbf6	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1d625cae-ef95-40d5-8cc1-6d2f02bf74b5	3e72bd22-b876-4baf-bfde-85028574fbf6	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dda15907-7bd4-455b-ac04-ef49a0fbf2e8	fb1e82e3-ae3f-4854-abbf-b279a661cfd8	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
334fbf7b-007c-4b0a-bf3e-fbc3e1150100	fb1e82e3-ae3f-4854-abbf-b279a661cfd8	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ef8f5585-e305-4646-81cd-e36d348c4814	6fe3e0b2-7449-4185-995c-72b93d510215	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7f810970-be55-4d1f-a136-21b823cd746a	6fe3e0b2-7449-4185-995c-72b93d510215	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c942b5d2-d19f-402a-9225-7fb0c6d8acb0	dd2c65de-a5b2-4b58-aa90-32c12ccf2330	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7c25e33f-aec5-43f5-9972-ad269de1fc3c	dd2c65de-a5b2-4b58-aa90-32c12ccf2330	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8595cd6f-c95d-47da-92e9-957cf05268b0	f1d069d8-8c7f-41e6-8ee9-291314a4b685	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
69b0348f-6610-4c92-a0a5-682b3c5597a4	f1d069d8-8c7f-41e6-8ee9-291314a4b685	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ea615cbb-3a97-469d-b179-7971af012f4c	6c1a87f2-c162-4064-922f-74c78b11de16	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f44cbf3d-abf9-421d-858f-0dd85389c985	6c1a87f2-c162-4064-922f-74c78b11de16	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
441f36d1-4c01-466b-a03b-977e29c950f5	57f17ad0-6463-4a12-8b3b-e6cbeb8909bf	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c874b0de-389b-4043-850b-82862613a335	57f17ad0-6463-4a12-8b3b-e6cbeb8909bf	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2fa0290f-ff01-4347-b455-5b973aeaab2a	8d8efd4c-fa83-43d0-94f1-11e62628c902	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c73207bc-0458-4b7d-a5e3-e8e182593843	8d8efd4c-fa83-43d0-94f1-11e62628c902	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0dd6da64-2ffc-4518-a4e1-3d65daa2571f	3797615d-07a8-4908-8cba-7cccab96e045	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
76e103c8-2d87-4486-91be-ca97ee61ecee	3797615d-07a8-4908-8cba-7cccab96e045	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
685e33c4-0cde-42f6-8322-2e6574fb3574	3fd4eb3b-297a-4f8c-bd5e-b4196dcff5e3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b59e53c7-e405-4224-beb0-34a46b2152ff	3fd4eb3b-297a-4f8c-bd5e-b4196dcff5e3	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
243fff61-e896-4388-99ae-b4b8d863e8f5	2be467bb-d12f-4e98-bd8b-6f4758ced2b0	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
15b48ba5-e025-4db0-adcf-bf62b933339b	2be467bb-d12f-4e98-bd8b-6f4758ced2b0	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5d885352-629c-41cb-9439-25e3fec2f328	545ed5fa-bcaf-4fee-8808-dcbe9d23b1da	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
514b8e34-6aac-41cb-a104-7f39c48954a3	545ed5fa-bcaf-4fee-8808-dcbe9d23b1da	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b4a5ce1f-26d9-40a3-81c8-314bd26f55aa	38bade80-dbd6-41f2-b0b0-1974688afd52	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8e3aece2-8af3-4569-83c6-b4e12021461a	38bade80-dbd6-41f2-b0b0-1974688afd52	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2bd7b584-d318-4a03-8c9c-7cb38e398cbe	c38ab09a-a847-4650-bda4-47d2e50b8056	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
25c22386-1050-46c8-a202-ce319a76a6da	c38ab09a-a847-4650-bda4-47d2e50b8056	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7f5368d6-9c11-4301-a710-920e63f04a07	1f8dc229-e77a-47e9-aaa8-fc3da2d1f49f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
40a45f53-ea87-4e15-81ca-cfac3964d56e	1f8dc229-e77a-47e9-aaa8-fc3da2d1f49f	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8e83865d-c336-46a0-b598-37fd90c568d3	781ddc71-2043-4803-ae4b-64a7721540a7	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e8e54f1d-65ff-47c3-8232-25a77338a8a7	781ddc71-2043-4803-ae4b-64a7721540a7	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
49a737cb-eae6-44db-a596-320156091882	f209020c-301e-4e87-9540-ed64fc9e8649	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9d3708b7-fce7-498f-bc6e-de62752de3ef	f209020c-301e-4e87-9540-ed64fc9e8649	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
19cd3aa8-21c9-4b5b-8919-e486287e4cf8	3521ea4a-ee23-4a5b-88e8-3b3ade993b78	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ee856bdb-4a85-460c-9ed6-316fbe5de8d7	3521ea4a-ee23-4a5b-88e8-3b3ade993b78	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0b9b8574-20dd-49f6-9c31-e69f0b1e740b	9f46890b-c706-40f9-918c-dd3089fa0e2c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a6c66866-ce12-4238-81d1-f84005b7b9fd	9f46890b-c706-40f9-918c-dd3089fa0e2c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6f8607db-6f3e-44de-b1ad-7ed76f07867f	67b1c83a-f169-43e5-bcc6-368742ea501e	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8c8cd60d-398b-4209-a49a-f2eab774918b	67b1c83a-f169-43e5-bcc6-368742ea501e	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dadabb82-85de-4644-8e6d-09ec8e6278d3	a7d10d60-2391-4b6d-a40e-ecc3d0d3c465	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
426fad53-7c44-4be6-85fc-1c64b900f15c	a7d10d60-2391-4b6d-a40e-ecc3d0d3c465	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
63aa4eef-38ea-4cff-bf5c-0fd2ab967ea7	cf72ce66-04be-42dd-ad3f-91540f939fbc	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
afeeb113-9fca-4c8e-8e21-2952592a7d59	cf72ce66-04be-42dd-ad3f-91540f939fbc	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
44d0f97d-36a0-470a-8d61-119e91a67399	30356105-2abd-43e1-8238-53d90f9c41ae	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7166e70e-0f97-46d5-b59f-74f6573b9f4c	30356105-2abd-43e1-8238-53d90f9c41ae	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
be52f419-baed-427d-b0b4-7a66864ccc97	017f6ae5-a216-4127-8e79-dae82f965089	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
eafdb63e-6be2-4299-baa8-4f6511da49e7	017f6ae5-a216-4127-8e79-dae82f965089	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
921aec5b-61f0-49b3-8f6d-45462dfa352b	bea5204d-3497-482e-8e3b-71493cec4054	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fc92170d-e995-4727-a06b-68848747ca55	bea5204d-3497-482e-8e3b-71493cec4054	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
325b1197-88f3-4b21-bf24-1d5896cf8588	d4b50761-d7e3-40a3-85de-0cb0d97b4daa	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a3cef18-1868-4f2a-8459-0548c0255e50	d4b50761-d7e3-40a3-85de-0cb0d97b4daa	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
76f4aa4b-4e11-4240-ae71-9c16ad829fae	01314dd5-13d2-44de-b703-8ceacbd79df7	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c278fb0e-f082-4565-8932-1321f4849954	01314dd5-13d2-44de-b703-8ceacbd79df7	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5b83cea6-c2ca-47cc-badf-ecefb198ad70	8a9c7a66-b27b-4619-bf0d-787bcd8ef0fa	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6e7274a1-dd1d-4a4b-b3e7-59edb49e2c97	8a9c7a66-b27b-4619-bf0d-787bcd8ef0fa	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2ce69cab-45d2-4899-92fa-9a4214a35e47	eed94fb6-6fac-46df-9ef5-70c5f99ed297	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a5845b13-d5a2-44c3-8d2a-02a4fe624639	eed94fb6-6fac-46df-9ef5-70c5f99ed297	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
01e40749-74a4-4eac-ae88-8c223c7f7445	8e585878-b6f4-4d2c-b2e9-c9e1f7cf50e9	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6a472036-06b3-4099-806c-f350b8f76a8e	8e585878-b6f4-4d2c-b2e9-c9e1f7cf50e9	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9080c51e-d314-40ef-b49d-833fa187c06a	179bb60a-ae3b-4e11-ba9d-28f53ed1812f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
50d62478-2854-4b00-9607-7d4208490a8f	179bb60a-ae3b-4e11-ba9d-28f53ed1812f	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
06d2bf61-1f7f-4372-a84c-13ce68a220fa	ac41272c-0a4d-4ba5-b740-2fb9847104fd	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a44d059-781a-444b-a1c3-82116b1ce7a2	ac41272c-0a4d-4ba5-b740-2fb9847104fd	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c239ab18-41ae-452c-b787-17856f15b65d	ec452ceb-2f97-4fbf-bacf-d447ed7a4c1f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f4d516a8-6e29-4ca8-b058-c91c6cf3d78e	ec452ceb-2f97-4fbf-bacf-d447ed7a4c1f	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cdc31d2d-6f75-4c8b-a8b4-93ee1476735a	2a623867-95a1-428b-b8a1-40fb7b8273e9	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8429c72a-8f0e-4cfa-a212-f0c487470c5b	2a623867-95a1-428b-b8a1-40fb7b8273e9	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1a8496da-d741-44a4-8df6-b9d9f775df8a	81d0d03d-737a-4a93-92c4-b57c4a21f779	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a7dbe628-a807-4951-84ef-6131162a4d29	81d0d03d-737a-4a93-92c4-b57c4a21f779	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
63a3e7a2-6095-45dc-9cb2-fb1e33cc68e5	791e44b7-9ee0-46e2-9a18-40e0b42dd23b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d706a50c-659a-435d-b74b-368b17f39cd5	791e44b7-9ee0-46e2-9a18-40e0b42dd23b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a394fabf-86d8-4874-812d-5494efb67273	c923c6a6-2cc8-4469-946e-3b6971dbf060	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ca144679-025e-4294-9431-f0a134b96fae	c923c6a6-2cc8-4469-946e-3b6971dbf060	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c17bdc71-c4de-498d-a51c-7236fbb36be5	2657705a-9ada-490e-b519-528ccf60fb97	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2783dc70-0ff4-44c6-b1b9-ca0da6d75cfc	2657705a-9ada-490e-b519-528ccf60fb97	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c4835962-04ef-4309-a2c0-a49f43fb1f90	7467a7ab-8c99-4c65-a227-190291a159b1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d41add60-37bb-456d-80cf-b3f7baaca857	7467a7ab-8c99-4c65-a227-190291a159b1	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
81f43c21-f4e5-46d7-b362-7fdc2f4ca595	e2a2c57e-d46a-4105-9357-f2e75087645f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3f9886ea-3b91-49b9-8cb2-6e11bc569c87	e2a2c57e-d46a-4105-9357-f2e75087645f	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
338b5e26-be5e-4a80-bf79-a18892b5e30c	f285714b-68b7-4147-9724-86f059dbe6f4	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3409c20d-24dd-496f-9cbc-cc8f66bb4737	f285714b-68b7-4147-9724-86f059dbe6f4	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c8bc4cd9-890d-413e-90bb-4ee02d16ce47	1a10896b-8cff-410c-b71b-90ab9dcc91ef	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cd6a303a-a906-4451-9b54-befbbe85e7f0	1a10896b-8cff-410c-b71b-90ab9dcc91ef	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c0ed4452-3d84-40d2-80e3-9dbc928effbb	55fddcad-8c3a-4d8a-8ecb-d068c244d942	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4158ad87-1107-4805-8a28-ddda98cf72c2	55fddcad-8c3a-4d8a-8ecb-d068c244d942	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
db3d323f-dd76-45ce-b64a-ccd3ed815ca2	11e21752-5717-47b1-8b96-f092dff10b39	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8d01fb77-ca55-4a5f-96cd-9ddd9708107a	11e21752-5717-47b1-8b96-f092dff10b39	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dfa5c815-3690-4ca7-ae15-13e241e9d6d3	3ccbd001-7efb-4a38-aa4b-01b130232e69	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
87e704e0-b2ac-4662-bc4a-73639fa1ed28	3ccbd001-7efb-4a38-aa4b-01b130232e69	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6b9b2944-a9df-4c01-8131-aed273481030	2164853b-b028-460c-8cbb-f38e127d12fa	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c6c76a73-ce46-4bbb-9013-c441be7f3a2a	2164853b-b028-460c-8cbb-f38e127d12fa	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a93aa1d-073d-4be7-a776-fcbb30f80de7	ee7fc232-90fe-418a-a120-5bdf4277dd6d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7cbfc280-d6bc-458e-97b3-66b340a02551	ee7fc232-90fe-418a-a120-5bdf4277dd6d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
418e63b9-dcea-45c7-9369-a4150d749445	339bf2dd-5330-46cd-a893-6c81233bf761	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c731d00f-5641-4110-9e58-5b07e9d61180	339bf2dd-5330-46cd-a893-6c81233bf761	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a153127c-4a39-4c3a-b9e8-5b380dc64820	b9c33ecb-37a2-47ba-8d9c-9e0ae3980f4a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d6e75fae-fb47-4541-a8cc-5177b076fec3	b9c33ecb-37a2-47ba-8d9c-9e0ae3980f4a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5ca0b3e8-bebb-412c-aff2-7e220f31a4df	820e292a-cb17-4727-aabc-4d9b6f7fa9be	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2cc05bc9-084d-468c-abe2-2db959686347	820e292a-cb17-4727-aabc-4d9b6f7fa9be	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
66829b5c-5e0f-40cb-acab-c5ccf6bcb961	9f40b8e0-7bf5-4a87-8341-0d4e5f294fa7	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
871b826a-7bdb-44b1-9dbd-590cc6c93208	9f40b8e0-7bf5-4a87-8341-0d4e5f294fa7	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c630db40-7139-42f1-bb82-c560ee4f287b	7a3764ce-ed85-470c-8bb6-b9de2fbdb95f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
03338926-21e9-436d-a07d-b7f03bc7349e	7a3764ce-ed85-470c-8bb6-b9de2fbdb95f	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fe242306-f9bd-4f4d-8462-a18ae627c8b2	c6f235c2-afd2-4d7a-a99e-535a9ebe588c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4e9d21b3-055d-452c-a5ef-097543761ab1	c6f235c2-afd2-4d7a-a99e-535a9ebe588c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
773d37de-6954-48fd-bad3-5fb097848609	ada2db34-cea6-471c-93de-f42de5ff3d66	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
74e20d52-a375-4871-b104-01cf7e38d7ff	ada2db34-cea6-471c-93de-f42de5ff3d66	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d844cedd-44c8-4132-8e6d-8e8ffd44f23e	a8ed83e9-940d-4cd2-bb60-b43940d20a0c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dc63aa85-b865-44f1-8a1f-0205e6009c50	a8ed83e9-940d-4cd2-bb60-b43940d20a0c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4b431ea2-5dd7-4c58-935e-6736b662e760	f67ca84e-9da8-4aa3-a075-5d1119802f9b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b04d3181-8208-4026-b4e1-170217e65f0d	f67ca84e-9da8-4aa3-a075-5d1119802f9b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f1db5308-17a1-4237-b219-387a19104584	3e3f77b4-4ff2-481d-907d-0e0506f225bf	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5989f3ab-9262-4248-8aef-962b75e18375	3e3f77b4-4ff2-481d-907d-0e0506f225bf	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2641d9c1-72fe-427f-b093-04366139d086	ec657423-2bfd-416d-b911-1cd5f5a747da	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b566f973-e055-4792-ab69-8fca2a4bd8ad	ec657423-2bfd-416d-b911-1cd5f5a747da	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
98a72278-5492-4620-98cf-0f66e6e68242	95069c11-8df1-4295-a5ff-eca483de3063	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a3d8a6cd-4023-4e7a-83d4-ddbe1cfc2d08	95069c11-8df1-4295-a5ff-eca483de3063	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
560d2a2b-0abc-4ff1-be5c-01965f320b0f	95aaf308-5f38-4161-87db-833a6f2f6ea3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3e1bf4e9-9dda-443f-bb10-a5b18c5dac97	95aaf308-5f38-4161-87db-833a6f2f6ea3	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8f679d1e-e00f-4dae-a028-ae50dd0c3fd2	0ffa64f2-ab01-40ce-a404-f02d08aacda3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f8d9544d-7f67-469f-83f6-bbd0f00635eb	0ffa64f2-ab01-40ce-a404-f02d08aacda3	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e8b5346a-3b49-4e46-afda-fe15a2e837fa	80d1c48c-b87f-4017-a75b-50b5f363857d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
804b58a4-c0fa-4b78-9104-95f5878a0ea4	80d1c48c-b87f-4017-a75b-50b5f363857d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
694932e3-7618-4deb-b744-be1a19eefd42	38fa1334-0907-4b38-aaf6-65aa99ef83dc	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5ddb6d4e-634b-4763-b778-d96f7241fcf2	38fa1334-0907-4b38-aaf6-65aa99ef83dc	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a52b0f7f-e6b4-4798-aa4c-5d64fd24db40	152fd163-e248-4062-8a75-6dd5aa945840	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cdb785d3-9f7f-4253-8187-385f0e3b82c6	152fd163-e248-4062-8a75-6dd5aa945840	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
38843a14-146f-431a-9c85-40a6f40fe798	e89d3bec-39a3-486c-bf99-43c4f1846dce	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6a678d22-c603-4a31-840c-54a0d91a5df3	e89d3bec-39a3-486c-bf99-43c4f1846dce	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b248e65d-82b8-47e2-ac2f-39672dfdcbe9	8d2b0e69-dfe0-4c1a-bbe2-359d28446b6e	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f2a05b6e-2c95-4ad1-b640-6c65a605a69a	8d2b0e69-dfe0-4c1a-bbe2-359d28446b6e	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
97e8b80f-cd29-450f-8957-e8b9e60f6c6c	53393c97-98e4-40f4-9a54-010fe4295dd0	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
82c1a216-6c96-4da6-8ee5-42b7b021ba93	53393c97-98e4-40f4-9a54-010fe4295dd0	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5017ccad-1636-4cf6-819e-71e421a1d454	a9b502fc-20fb-46d3-83da-9df724b3a099	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fec1f8a9-14a2-44e3-95a7-fcce7b468deb	a9b502fc-20fb-46d3-83da-9df724b3a099	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ca8fbf80-db1e-42f4-b28b-a98b9f4c313e	2915914e-f69b-4cfd-ad01-111dfa753770	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
84b6a8ff-9134-475e-9b4a-b811d03349e5	2915914e-f69b-4cfd-ad01-111dfa753770	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b652f0c8-52b4-4372-9bc9-fa21fc59c5fb	d5a41768-aecb-4878-96dc-e54fd9392aba	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f6ccba24-8c15-4946-b3b7-09f08e05d94a	d5a41768-aecb-4878-96dc-e54fd9392aba	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
02fc0b11-5749-4a0c-ab26-120c12c430db	ac3c530c-fac5-4b4b-b3b3-e75fc8a35fa6	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c106ef42-0053-4fea-81a8-0f602d1b68e1	ac3c530c-fac5-4b4b-b3b3-e75fc8a35fa6	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
34cbb3b7-df2f-45e9-97e9-afbbecb99914	3cf0a06e-ad71-4347-b0a4-6f6aed6baf23	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f52dc8b2-deeb-4be6-ba25-b1026f9d8941	3cf0a06e-ad71-4347-b0a4-6f6aed6baf23	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f7769375-68d8-4d3b-9db1-c6ca21451217	901264cf-8113-4bf9-8da6-018424e03196	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5a817f8e-b0df-4990-9f8b-9fcaf79a9d9e	901264cf-8113-4bf9-8da6-018424e03196	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d31767cc-45f7-4238-a4fb-b2e8ea655ede	aa35fda4-f6b3-4212-ae86-2410b168841a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
127dfd77-6746-46cf-a0c2-979ed1a29fd4	aa35fda4-f6b3-4212-ae86-2410b168841a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4bd377f1-6352-4e19-a128-d3d2ccec037f	5aed1819-fdf8-4a20-8211-2cbcef8cb2ab	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7210c236-aea9-40f4-b5f6-0970cb96412d	5aed1819-fdf8-4a20-8211-2cbcef8cb2ab	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c58e0e6b-7d90-4613-9af3-7fa6d940706a	e4160613-c418-4b30-93c2-3b35964ba568	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6458af78-3a91-4ba5-bbe6-89bfde6d50e5	e4160613-c418-4b30-93c2-3b35964ba568	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1cb524a0-092e-4115-a052-cdfd2dc07eeb	f087e915-83b1-46d8-9c8f-a1d1b2e57eb1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
aa2f0d9d-59c6-4deb-90c2-373c95709a41	f087e915-83b1-46d8-9c8f-a1d1b2e57eb1	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5b2b3376-2f70-41fe-ae6c-f0d217650f1c	331f2b6f-bfd1-425d-8874-19c3f1eaa5e9	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
93579cfb-d20b-49d8-b3c8-7371765fc8ef	331f2b6f-bfd1-425d-8874-19c3f1eaa5e9	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c3b273c0-df77-444a-8277-f6afcdc93921	89fed694-8cfd-4818-ae01-505934ec2f8c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
11602297-7f8a-41fc-beea-efdad4340bcc	89fed694-8cfd-4818-ae01-505934ec2f8c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bd8d6117-08f7-4f17-b5e5-af01eabfa27d	c6021acf-f869-4c5b-89e7-af209997b0e3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
50bb0431-d509-4b1a-9635-bd6f3b4f36a0	c6021acf-f869-4c5b-89e7-af209997b0e3	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4fd751ef-339d-4770-a678-ef1ff63e1bf3	eaac721f-eeee-4f0c-9976-57cdc5c1da8a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b672b614-e7bb-46d3-be7b-fdfc686100bd	eaac721f-eeee-4f0c-9976-57cdc5c1da8a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
34257e5e-df61-4863-98fd-77d3cff6991b	cab79f25-9629-477a-81bb-7e00da7a13a4	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4db2fd95-190a-46b5-86ba-f5bce50a4884	cab79f25-9629-477a-81bb-7e00da7a13a4	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
87416ee6-549c-452f-8837-171753b4b836	a12d4e91-d5b7-440f-a3f2-2bfeee78a54d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
54b5ddc2-16ef-432c-9457-c542e8638a18	a12d4e91-d5b7-440f-a3f2-2bfeee78a54d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
68b68521-56be-4718-b51c-a724a18c03be	6cb63dfc-41a4-457a-a201-8dde951d3915	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a5e6db46-477a-456d-adc6-74aedddeaec2	6cb63dfc-41a4-457a-a201-8dde951d3915	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e5b63c86-e334-4688-878c-89c486490603	c4919058-d2ea-444c-b75d-3cd53d7ae5ec	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c5d04f15-d6d5-4a56-b22a-0c23f0e5c946	c4919058-d2ea-444c-b75d-3cd53d7ae5ec	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3feba4be-4cd1-442c-9a32-b39240b77720	612f91ab-09d3-436b-a92f-c5d2ef53267a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4038b763-afd8-4fe7-bb3d-8b3c8125fb0a	612f91ab-09d3-436b-a92f-c5d2ef53267a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
27ad782e-5b42-4b19-ac94-355c2f39f72d	046d9d4e-5416-4f1f-b548-f9c117fcc2a5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
401679b1-9d95-4e06-90c7-75fe5bdc1976	046d9d4e-5416-4f1f-b548-f9c117fcc2a5	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
39f27f7f-e646-4bd8-a56a-d185b3c9e085	61c60468-4b7a-4b50-9e9e-f22ef0db9d5b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
10cb3b99-2273-4913-a050-22fb6bfcf025	61c60468-4b7a-4b50-9e9e-f22ef0db9d5b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b8bbf47e-54b5-4d66-a549-34d9120e952d	a5c5325e-d4d6-4d51-b1ec-ffe8d889410d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4a385a20-f3c0-4617-83bf-40dca9c7602a	a5c5325e-d4d6-4d51-b1ec-ffe8d889410d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4def2466-606b-434b-96f0-9bf58b439dfe	ee20fec2-5cec-48f3-9682-7d3a031013a1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
893fe752-d2ed-4cbc-ab2e-c72d1a3ea827	ee20fec2-5cec-48f3-9682-7d3a031013a1	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
28b68928-460c-4d65-9622-17b5d328d55f	dfbe5ffa-8c3a-4431-8633-16a91c4c8e7a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7cd880b6-c4d2-42d8-a1bb-a7108e9f6ca2	dfbe5ffa-8c3a-4431-8633-16a91c4c8e7a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dadfaba5-ea48-45a7-a134-16e4c6cba8b3	71440925-2e06-4ca1-b961-10571536c0de	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
82eefc79-1a68-4a73-9469-c578cdf6bc78	71440925-2e06-4ca1-b961-10571536c0de	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9c20cb01-73d6-420a-b516-af581cefae2f	312a38b3-b8d2-407d-8194-3ac102a25feb	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
650949c5-226a-4a19-972f-5600434cc7b3	312a38b3-b8d2-407d-8194-3ac102a25feb	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
32b9ff27-3410-4fa5-baa2-f889e0bb075d	b53f16d5-53c9-48f2-9365-b99075ef9d4a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
65a37431-be7c-4a1d-8fda-d492e9357a28	b53f16d5-53c9-48f2-9365-b99075ef9d4a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4ba02a13-c133-4dc4-ac78-64fa41327ddb	c8a7ace8-a004-4b25-a544-95cdb1f8fa24	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
382282c8-a5b0-43cc-a6d0-df0cb8809740	c8a7ace8-a004-4b25-a544-95cdb1f8fa24	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3946677f-db57-492b-9dba-268ac70515b2	1135a2d2-1263-4fc8-a24e-5ae4a3056341	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ea2663e7-b538-4b8f-8318-7e5c555f7dc9	1135a2d2-1263-4fc8-a24e-5ae4a3056341	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4e83a64b-09f5-4a7b-9008-e2a08aea497d	8761727b-6676-4df3-b494-11578e16a4f5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
645bec45-6825-45bb-ac26-966e9be53476	8761727b-6676-4df3-b494-11578e16a4f5	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
28215d71-502e-4efa-9274-17be29e2a355	436bd090-b753-4806-bd98-1f8affac5d9c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
70cd4a8d-1218-42f6-b50d-b4217d9309ba	436bd090-b753-4806-bd98-1f8affac5d9c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
60346e8e-5671-400f-9662-e00d46925281	03e00c6d-d796-4098-aa58-0be80ac18bf7	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1339fb7f-ace6-4210-a08d-c4095afccd97	03e00c6d-d796-4098-aa58-0be80ac18bf7	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a8804d0-af90-44ab-91d7-fd0c03df69e6	9d9fd90c-4512-47d7-82bc-d63082d752dd	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4be2c206-faae-4a40-86f1-5a4d34a43be2	9d9fd90c-4512-47d7-82bc-d63082d752dd	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
66a1011f-d06a-488d-b804-d340b586b2b7	46538421-9341-4d9d-bae6-05b9a40d28b4	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
41a74f3c-fb84-44d9-94b2-25d37c8412df	46538421-9341-4d9d-bae6-05b9a40d28b4	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3e820638-c818-4c2b-996e-47f919ea15af	4ee55aa6-4afc-414c-a234-ef10db07284c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3d0bc29b-3054-49eb-9542-e9017048848c	4ee55aa6-4afc-414c-a234-ef10db07284c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
336a5656-14e1-465e-9b6d-0adbd28611a9	d018434a-0d3f-4ab6-8284-d62db75dc61f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b8300a23-a5a7-4631-91fb-12137a4b9096	d018434a-0d3f-4ab6-8284-d62db75dc61f	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1e2d6f3b-72a6-485a-bff8-d6bc29a11aca	4d72a954-8a3a-4ab3-bbde-88f12cb8717d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8d6007f0-d45a-4c5e-b83e-223b7a6e5305	4d72a954-8a3a-4ab3-bbde-88f12cb8717d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
79bbb540-53a1-46fc-a8d3-2965c1e8b793	2d1f4466-cdb5-45c3-baa7-214372c06081	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5e70f077-e221-45e5-83a2-6b675e11d9d7	2d1f4466-cdb5-45c3-baa7-214372c06081	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e55fb9d9-7baf-4502-ad23-d7c43aa1e6c8	93f07369-806f-48f9-8563-5a9a733789e2	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4f7605a3-67d7-4573-b756-2151425fa01c	93f07369-806f-48f9-8563-5a9a733789e2	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3a0dc34c-6eeb-4170-b213-7b2d36fde4f9	3f3fac3c-5ddc-4858-9049-0bd1d8078c98	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e2991abc-afe2-4413-8465-31b03c3da694	3f3fac3c-5ddc-4858-9049-0bd1d8078c98	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
425e29b3-cf78-4c0f-bbd1-35d434a2d0f9	b6c428a9-1989-4f40-9663-728a19e94c3d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3de4ebb0-b2fe-40cc-90b9-cf47c90ce924	b6c428a9-1989-4f40-9663-728a19e94c3d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
034a9e0d-62bb-4546-b6bd-e60fbdf161ed	c38b3bd2-d37c-404f-a6e5-2c988a872fd8	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
68b1fa2f-15e1-4817-a5c9-d2f1f9b48f59	c38b3bd2-d37c-404f-a6e5-2c988a872fd8	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6c5b1894-b1ef-4990-9a4b-aae2449518c4	9765fb91-5321-4271-8ad5-312e4f4a5209	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c03cf49b-f13e-4eaf-b3f9-4a795e0ff6fb	9765fb91-5321-4271-8ad5-312e4f4a5209	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9e0d11d0-5160-4a1f-8c62-5165904e69f2	313d1c60-d5cc-4288-b42f-6aeb1aa0315d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c53429b3-3b23-498a-8d4c-ae328358179a	313d1c60-d5cc-4288-b42f-6aeb1aa0315d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
91645cf1-c916-43b1-a127-3248166b5274	487b6c10-98de-4894-82b0-a0a6dd2a7f8b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
00c49184-0059-4a42-a07f-3b8ebcba6c85	487b6c10-98de-4894-82b0-a0a6dd2a7f8b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
aac0a4d2-32fb-4221-b035-4b832fbb4f63	0d203413-b7cb-43bd-b3cf-be3d2267d19d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c5c220d2-4c98-4c0a-811e-b09e2a5c9c3a	0d203413-b7cb-43bd-b3cf-be3d2267d19d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fc46c127-f6f8-44d0-b9ba-5fd5b229d18f	33b3289f-2079-4c5a-be64-de420cfc7060	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
63933cfe-7cbd-408d-94be-4774ea869ad6	33b3289f-2079-4c5a-be64-de420cfc7060	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b598cb03-4680-4dd7-bed8-cc2e5980579a	e9dc3d55-7e98-4995-9a71-7075d98e795b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
029a54a9-54c2-4463-a99a-9b763004e85c	e9dc3d55-7e98-4995-9a71-7075d98e795b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6f01b2cc-10a5-41ae-9ffd-a27097052677	efd8793b-dfbe-417a-aa2e-716dffc38f8b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1d152bf6-9af2-452f-9c85-51bc67fe78bd	efd8793b-dfbe-417a-aa2e-716dffc38f8b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cae98257-a264-437f-8c39-23258ebc28f8	61c4342f-1a18-4720-bedb-566268cd56ba	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ac90639e-405a-42cb-a90c-252bf9099952	61c4342f-1a18-4720-bedb-566268cd56ba	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
624b8a66-35f4-44de-9b5a-0a3e8e6673a9	d01d74f7-08ab-4685-9a7d-1509e25ae1b6	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8a0eb2d9-21f2-46f4-8b04-7fdb05af10fa	d01d74f7-08ab-4685-9a7d-1509e25ae1b6	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bfd718ea-249a-416d-aa2a-d425d616d428	a02e39be-fa91-40a2-8450-3779cf175047	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b1dbfcca-cab1-473b-b452-6afc3a6119c4	a02e39be-fa91-40a2-8450-3779cf175047	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
778733a8-7a4a-4671-b9ab-37874e68f159	cf1fcdea-8ca0-4ffe-93bb-aaeebbf8c6a5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
51b7ccd7-88cd-41cf-838d-26c4b31409d5	cf1fcdea-8ca0-4ffe-93bb-aaeebbf8c6a5	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1e8aee38-e68c-4baf-a1a9-f2dafc7df115	6925e912-9431-436a-b4a4-17450fab7ec0	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fcd5b827-b636-4eef-8a38-c0a695f594c5	6925e912-9431-436a-b4a4-17450fab7ec0	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
192a2ca2-35b7-4e43-ba37-5f07da1aa009	19e11347-c03a-42a8-8713-1d04deccc0c9	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cbc655d7-2927-4320-ada3-87ab35f16788	19e11347-c03a-42a8-8713-1d04deccc0c9	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4982644f-a69c-48a9-9e14-a9df8915b7d5	bc3bac42-753e-48e5-adc6-f969ac366645	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
07df818d-94c9-4e84-a621-a35ff41ce80a	bc3bac42-753e-48e5-adc6-f969ac366645	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b95feecd-5991-4ec8-8b7a-690f4ddfc823	f471fd43-e84a-4e68-8e16-cb799b43116d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
59a43ffd-9d75-431f-9419-957726f04b2c	f471fd43-e84a-4e68-8e16-cb799b43116d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1e4647e4-918e-42b5-ae48-c216fef3822e	62c94eec-08fb-4946-8d6e-fc91e9e1e3b3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f07d2db5-6a3a-4272-b52b-b8a720829558	62c94eec-08fb-4946-8d6e-fc91e9e1e3b3	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5d052bff-766e-428e-922a-619e94edb0a1	63eef403-d624-4098-8339-72d14df4caa3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2cb435c8-1ee9-4a01-93d5-b9518efcb6e2	63eef403-d624-4098-8339-72d14df4caa3	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e35a781d-83d2-42eb-87dc-6e986173cdfc	8431b50d-5783-4016-b519-9ca0e3156205	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c47be95a-c3ce-49dd-bc22-4c7e70aad42a	8431b50d-5783-4016-b519-9ca0e3156205	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bee6f286-f35b-42ea-8bd5-ac25a4df1bfc	890dd3d6-3af0-4be4-97ca-eafeb8573c09	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
536c7c36-9781-42ab-b253-47deb6504d4f	890dd3d6-3af0-4be4-97ca-eafeb8573c09	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ac310595-ed65-422c-8da9-41081b87485e	448065cd-fe23-4b2e-8e12-fbbd33829233	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5b674680-d22c-43dd-8cd8-96919822aeaf	448065cd-fe23-4b2e-8e12-fbbd33829233	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
116664ec-3da3-4f33-a4e2-1c66070736fd	2f83844c-9384-4458-8a87-73cc742c435c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
29807744-432c-47e8-94f4-43140519eaa3	2f83844c-9384-4458-8a87-73cc742c435c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
80f7ed25-709f-429e-b663-e93bec5b6c56	712dc761-2981-408d-b616-36e76f628864	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3d72bb25-9698-488a-a3d4-dc42af5a8dde	712dc761-2981-408d-b616-36e76f628864	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e890d7ff-4648-43de-b7d9-e6ea64bd0ba5	54556387-fd94-43ea-9ef2-7f1c0054b976	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
af683ab5-a3c0-4359-b714-84066c988eea	54556387-fd94-43ea-9ef2-7f1c0054b976	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5e794385-87ef-4217-98ff-3a6be7dac789	b0c14d48-72a8-4989-af5b-b8dd8c298e49	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7c609c6a-db2f-4369-9ea1-c53e647b21b7	b0c14d48-72a8-4989-af5b-b8dd8c298e49	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
85931dda-1409-4db0-b21b-a23accc7b079	8ae12903-b894-4b8a-9bf6-96a3c0409581	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
441e2d27-42c8-4558-b6b8-7e5ebbb28a1c	8ae12903-b894-4b8a-9bf6-96a3c0409581	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
acab2c23-1836-4409-9500-c81f07130f49	bbff580f-6974-4a42-bc8e-f7053dc0bdb5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f79e0f08-f0c1-4056-8bc9-746b884ab18b	bbff580f-6974-4a42-bc8e-f7053dc0bdb5	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5acc9590-d4d7-49b5-9433-91bf5de9e476	91053158-b4f4-456c-9ba0-f5f933222e5a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8712f4e3-c5d8-4ffd-9485-659a0499e49d	91053158-b4f4-456c-9ba0-f5f933222e5a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
72d01e30-14bc-4aee-9248-eae506be510e	326cb7bf-998a-4499-8dfa-9ed5af4fe8e2	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ef19022b-30f2-48b4-8fd2-aef9323fa5d6	326cb7bf-998a-4499-8dfa-9ed5af4fe8e2	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f0bd9d83-f155-4a04-976a-f7639d69796e	5d2d76ae-b03e-46b9-9868-403471183594	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
67ba8a04-42c6-45c2-b5f0-5d4dd9a40f8d	5d2d76ae-b03e-46b9-9868-403471183594	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
23a8a618-f775-4508-b490-ea891c67a724	0ad836d4-e9a4-4c1b-ba2d-36a9a7a1f172	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4f11fecf-7ee2-4304-91fd-99f27a1876c5	0ad836d4-e9a4-4c1b-ba2d-36a9a7a1f172	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
36da2d4e-f70c-4f01-940c-56bd0fbf7c47	209fb6f9-e81d-4a9e-a8a2-2d91138ee2e7	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
92dbb0ee-54ae-4410-9dd6-d86c4d8c8207	209fb6f9-e81d-4a9e-a8a2-2d91138ee2e7	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6f56ea9c-41e7-4134-bb46-64647a20ebe0	a53728d0-b13b-42b6-a1cd-9ee0c6813691	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
409cfaa5-cd91-41d9-aec6-3704579a1f28	a53728d0-b13b-42b6-a1cd-9ee0c6813691	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e22487f4-39e2-4cd4-a262-d869ca01d6d7	6ed2ca88-75ee-46b2-a6c4-f3c039427c47	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
72b66346-8b77-4870-9cda-25c7a902d651	6ed2ca88-75ee-46b2-a6c4-f3c039427c47	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5ed82088-008e-48ed-bd83-bb01be6cc64c	5e892c09-3743-4225-9698-99f2edb38147	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
56169e15-bbca-4d51-b597-f0d18a022074	5e892c09-3743-4225-9698-99f2edb38147	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f6c87e35-83b8-49fd-8d36-c41a2555fc7e	9a7018d0-4760-44e3-a28e-58cc3fa92ee4	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b44bc469-147d-4977-b59c-60a2a13cbb64	9a7018d0-4760-44e3-a28e-58cc3fa92ee4	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2b0e5a51-19e4-452c-bb81-1e4075a810c1	91c38df7-9df0-4e04-bda6-40394116f661	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0feea7c2-8b87-4dc6-a500-78c4a6dff488	91c38df7-9df0-4e04-bda6-40394116f661	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e781129c-39f0-4d22-99cd-497ad7412aa2	fb634a4a-2bd5-49ab-84ce-4c5db408d1ad	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4632dd4c-1679-48cf-9d68-34014036f83e	fb634a4a-2bd5-49ab-84ce-4c5db408d1ad	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c5193d82-cab6-4238-bc87-93a10f51256a	50cbec59-9a2b-42a9-a453-c1c54d6f4b12	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e1cc40e5-6b5d-4eef-97a4-eb178a2a762e	50cbec59-9a2b-42a9-a453-c1c54d6f4b12	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1307e0c8-5197-4a89-bea1-a55de5828207	44a7d6a5-b261-4ba6-9346-7b6009bfabf3	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f74981a8-b2cc-4a71-936e-b0aeb3627caf	c3c170ab-99dc-4370-9116-b635db7bac67	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6590e94e-9f34-48e9-85ed-fe7ca380e4f4	3e37dc98-958f-4283-906c-fac29b4ce27a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7b71fbf9-b3fa-4f50-a5be-4a65e919c7c8	f35656cb-c73e-423d-b415-151045d39041	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1997927e-3f90-4edc-b273-ecadc47e779a	0dc1abc0-9ce7-4c2f-8c97-e03a987e8a21	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
57280f13-8237-4384-a670-cfa75d638486	e456e281-1ee2-45e1-8203-238bee1c3e80	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0c9547cf-7e42-4387-87a9-5bb1462722a2	ae1aaa83-1643-4ba5-b768-eb73d5c1de49	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
047caf09-e85d-40b9-9f1a-a8e2f0149a28	2d702569-4e78-4d1a-bbe7-ee6a81b4dbcb	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d1d1abba-cfa4-4306-80c8-1ea8b2f36741	da74c625-7125-4e81-9db9-c203e9d6818f	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a9f7d538-4a7f-4c6d-a287-867f8e5b2393	219fe38d-1f54-455d-be5c-9a91a03b5d66	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
57d0af6a-f853-405e-9b38-56c2222854c5	219fe38d-1f54-455d-be5c-9a91a03b5d66	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
44156fab-d643-47b3-91ef-7f27d5740fac	fd22b8c8-c356-451f-afbb-27c2e3f52240	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
220eb40c-464a-48be-9af0-f63f479a91d4	fd22b8c8-c356-451f-afbb-27c2e3f52240	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a6b850f6-57b7-4285-af41-ee39a240b69d	001f1f6c-61eb-4319-9ef8-d9ebaf9cb701	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9843d8c9-d445-4d5c-a2b4-89dc72c62625	001f1f6c-61eb-4319-9ef8-d9ebaf9cb701	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
43fe0c2d-50ca-4f1d-8350-7d8ced4e61c2	94f63765-e9dc-42d9-a46a-0c8756a95984	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b862a728-0e8e-47f4-b890-80479fd258e3	94f63765-e9dc-42d9-a46a-0c8756a95984	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
06f8b50e-a9e9-4d91-b3e7-6417e7c5b5f0	c4ce1d94-5574-49d6-8583-4cd754c7d4d6	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3d3c8d68-a416-458a-8f61-7292b254982e	c4ce1d94-5574-49d6-8583-4cd754c7d4d6	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6cf51fc4-3976-451c-9138-df123c20360b	d6c7ef74-720d-49e8-af44-164271bd6f96	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6ab4e615-94a8-4873-aefc-8e54d0b96ab4	d6c7ef74-720d-49e8-af44-164271bd6f96	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
52b42559-9a25-45b3-9fb1-3a6485f09e9b	cd1607b6-6b70-45eb-ae3b-91eca7e843f0	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
99fda389-6e4c-443b-a3bb-3af0d8282f91	cd1607b6-6b70-45eb-ae3b-91eca7e843f0	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5737353b-f2e2-4372-84c5-637839287147	a4b3cbd0-39fe-4b3e-b395-f4bd5f025c94	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
76af9350-8c81-4499-9f12-7d8ffb4de1ad	a4b3cbd0-39fe-4b3e-b395-f4bd5f025c94	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
86f23f00-7cde-4d06-aed2-8fa3ba3270a3	bd8487f3-d855-4d04-b38d-de59be5ff422	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1444495f-919b-44a1-ae86-f9f0109bcd51	bd8487f3-d855-4d04-b38d-de59be5ff422	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9e1c76a7-ad77-45c2-a4cc-411497d0c611	8b8e9742-7065-4026-b027-2270f7f73413	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1125a913-391b-4a01-9fbe-deea8b58a560	8b8e9742-7065-4026-b027-2270f7f73413	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fe066151-2200-4a11-866d-eff695e0f5ff	008bae1b-e8ea-46d2-8b92-4144def10086	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
015bfdd2-3f87-4d6c-a94e-cad8148b9709	008bae1b-e8ea-46d2-8b92-4144def10086	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b377a86a-351b-4256-bae7-9e55f8b6c8fe	6cb0d03c-63dc-4161-93ad-096797488c3a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bcc69442-04e5-4a1c-93c2-6adcb07f4737	6cb0d03c-63dc-4161-93ad-096797488c3a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ff91a471-03d0-4ccc-b2e8-2687ea80872f	a960a468-63a8-4fca-80e4-b199017bb514	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ef57a20a-cbc6-407f-8e09-a71df96c0fa6	a960a468-63a8-4fca-80e4-b199017bb514	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e84a69de-b46c-4aa4-a5ea-2656d851b44f	159a6e4e-a06c-49fb-bb18-3b221f15c3ba	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5f5935b7-6617-49d7-bfa4-e562d3436f05	159a6e4e-a06c-49fb-bb18-3b221f15c3ba	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
108a55a6-1c7d-48de-bfa1-08436848d9a4	9485b506-3ee7-47e4-952f-4d1c017c1147	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7f35b8e5-8b44-40b0-9af8-2dfebce9b86b	9485b506-3ee7-47e4-952f-4d1c017c1147	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c97f728e-5997-4eb1-b664-ad3c2b55869e	7cea84da-0c8d-4351-bc16-45a7448b237c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a8c0ec1-28d8-4066-92ab-7b676cf26df0	7cea84da-0c8d-4351-bc16-45a7448b237c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6b59cdfb-51d8-482e-ade5-5f0b9d72804a	42dbbeda-ecf8-40c4-8e2a-c4fa100c1964	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2db6a2d5-6161-4b32-abda-d8843c9813d4	42dbbeda-ecf8-40c4-8e2a-c4fa100c1964	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
af8983a6-1d45-4c85-8037-f4745eebd34a	9bdc2221-0b46-421c-9dda-b61693c31ec5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6cf2e81e-c0ca-4073-b77e-40754195336d	9bdc2221-0b46-421c-9dda-b61693c31ec5	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
384f1a4e-4d7c-4aed-a802-0070eaace8aa	72fa3f0b-a4c2-44a4-8c50-08a07afdb951	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a61eb694-be66-4b93-8b4c-52b6227ec480	72fa3f0b-a4c2-44a4-8c50-08a07afdb951	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
08820cfd-345b-41c1-be81-f6c6859c395e	57e3cac5-5f91-4945-a32c-8e1fd68e7018	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2b2a0343-796f-459c-8312-4afc56c572fc	57e3cac5-5f91-4945-a32c-8e1fd68e7018	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1dd9a895-e3da-4db9-927c-1452cd974f41	664b28a6-6308-4db4-851e-ca19679b174b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6285f99b-d033-4461-b75c-23efe51645cf	664b28a6-6308-4db4-851e-ca19679b174b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4d63601d-d360-4b36-a070-1d8f6bc518e9	2e5d1445-6ae4-4e72-a21d-508ac3f52e6d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e403b092-618e-43b9-b114-337b704a0423	2e5d1445-6ae4-4e72-a21d-508ac3f52e6d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
50555cb4-8f76-4ff5-aa44-274e4199e55e	3ceba21f-c32a-4b08-b628-221f62dff14d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e9abcbd5-76b7-4f34-860f-e508dc35f371	3ceba21f-c32a-4b08-b628-221f62dff14d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e125c22b-a194-4e43-817f-2835f418836c	4ad71a0f-ba54-4a3b-a07a-1c4049dd0ab3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
259c529a-b177-446c-9884-06f2a8bdc00e	4ad71a0f-ba54-4a3b-a07a-1c4049dd0ab3	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ab7c4e5e-6ea2-4700-a282-8b054f6bc9da	3a9d50fa-0d37-45eb-82cc-f20333d79f8d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2ca2a5f3-dbfd-4b95-9bf7-60a8b5d3a07c	3a9d50fa-0d37-45eb-82cc-f20333d79f8d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b2c5ba54-8e24-4635-ac06-a9ec1dd583e7	7595dd00-7a39-404d-97ad-ccaba60678a7	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
faca1e86-1335-4094-9357-76c655e56d7f	7595dd00-7a39-404d-97ad-ccaba60678a7	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ab850107-3cdb-4e7e-8ee8-0f403df1d3c8	38a8e704-e0e5-4c94-9ee0-677956bf126a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
45db0a7f-7ee9-450f-b7c2-cce45e9021cb	38a8e704-e0e5-4c94-9ee0-677956bf126a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b3325653-168e-4599-88ad-2882da960743	c7432204-89f9-4271-90c7-0ae0f2e3f0d0	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5dc875c5-8b6a-4356-925d-a45da08c1257	c7432204-89f9-4271-90c7-0ae0f2e3f0d0	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
28fe6de3-2ff2-477f-afbd-26aee2e06071	94fbdc33-6f5c-40bb-ad15-8c82b52a96ab	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2f2f5dda-47cc-42ba-acd1-603c1e45c59f	94fbdc33-6f5c-40bb-ad15-8c82b52a96ab	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9cf0209c-e54c-436b-a6d1-86d97de0ce62	c3883637-d0a9-47e0-aeeb-b2312b9214bd	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
453ef3c4-1560-4965-b08e-c51a5f9043cb	c3883637-d0a9-47e0-aeeb-b2312b9214bd	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f67bfda2-43a9-4acd-b6bd-fd61c02df0f8	d0a65563-5711-494c-b3d7-29d9093b644c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
57a9621b-e9f3-4887-9263-cd35b9e49578	d0a65563-5711-494c-b3d7-29d9093b644c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
929df923-99da-4666-b368-81a6068d15bb	69d240f6-e46f-47a7-ba08-953beffe59d9	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cf95f7a1-d73f-4d29-bd75-051209ee0116	69d240f6-e46f-47a7-ba08-953beffe59d9	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
67bb8563-2766-42da-8b16-c01a14671275	75c94438-0508-4144-b6a2-f2c808f1dc77	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ae4a9abb-7318-4251-93de-75dc6322ea7e	75c94438-0508-4144-b6a2-f2c808f1dc77	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1581e925-e504-44a5-9c90-ec3e95cd08fe	40f2ef16-f7b3-40d9-8d90-b78ab68d610e	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7363dbe1-ada9-45ed-ae04-bcc62ae50a81	40f2ef16-f7b3-40d9-8d90-b78ab68d610e	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
392aceac-23fc-4b33-9a09-7cafce40579f	cf31d9ad-fcc8-41f1-bd1e-bd0d292a2e5d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b6201d0c-dbd0-4f91-bfb9-bf94faeef742	cf31d9ad-fcc8-41f1-bd1e-bd0d292a2e5d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
af7d276d-60fc-4768-a58a-1a1108249b48	eb8da0e6-e6a3-418b-9b6b-2fcd2a09ccea	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c662b53a-a11a-4750-94de-b4e5711ec8f7	eb8da0e6-e6a3-418b-9b6b-2fcd2a09ccea	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2e0cfc6e-24d3-4fa4-b233-68c43079e7af	0cd2664b-2bc4-495f-aaaf-6fd7f4cef2dd	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0e5282ed-dd08-4173-9c0b-cc15ae9348c7	0cd2664b-2bc4-495f-aaaf-6fd7f4cef2dd	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b2719294-9235-4ad9-b40e-4e10baacad7f	02dce982-e875-4a12-8729-f3be5de4c3f0	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
97222495-c0fb-4a76-b964-69af59a340ca	02dce982-e875-4a12-8729-f3be5de4c3f0	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
94815939-d5ee-4160-a359-b74c2aa182f2	37c3d86e-82c1-4c44-a129-6c0d69b478a5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e8b5f791-d3ce-4ff3-8c33-7567271919f0	37c3d86e-82c1-4c44-a129-6c0d69b478a5	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2910de00-b1f0-4fd1-bd0d-e342c01593a7	960109a1-18dc-4dfd-b58c-57a3e4f9a2bc	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d58c63ae-5773-4901-ae45-55f2c67f1ece	960109a1-18dc-4dfd-b58c-57a3e4f9a2bc	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7ff56159-b0c0-4c56-b4ca-61aef7d390a0	bf76e1e5-1299-4692-89ef-7324e7c5397a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7ae18c04-8968-41c8-970d-970de5e81935	4e0ca41d-205e-4cef-afba-d744417d3dc5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cfc10915-a4ea-4a3b-ac27-a69a8065f14b	1f32f97f-bc51-49c5-8e45-27fa3116248b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c8bf63d2-3c9b-4ab7-bb53-b1b33dba7178	b1c21740-2daa-4728-816e-da885b41c8a6	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4cee6a6c-6790-4028-9ac1-3b1cd1923061	e2f99b3f-753c-4286-87f2-e4b7640537da	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7f6674cf-4b4a-404c-b781-5918b4d07f4e	b3c3e95b-c711-4bfe-8c9a-28b34c89a235	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
427c56cf-e304-4334-bb63-2864005f87c8	0d1c3c4b-be80-4802-961c-6d5468239bb7	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
93a6f275-3baf-452e-8339-2d9efc1d13a0	179f878d-f262-484b-9e99-2f9b9fd8ac88	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
044344c1-0866-461e-953e-49b4e961a977	db798725-9768-4608-9bdd-34cec117e875	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
60ad2e3d-1509-40b6-bf3c-6c9f2458585a	3ca6aa15-539e-4ba6-aeb6-a0e1a4af12e6	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
182a0567-b192-458b-8f19-ddd1beeb8d8a	f88b35ea-f95e-419c-8173-af39e9fc801c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
323e4ab7-16a9-4ab7-8b8c-3da3dfd0789e	ced86a58-1356-421c-9299-4e9101476764	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
80eb42cc-86ec-4e8e-ab10-2969d072f71f	30a8a1a9-4b95-4e29-bef2-4be4b072108b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
86e4cbbf-b6ae-4d06-b264-d7303bbd1036	b704be90-df98-4d90-8e3c-b1bb83e7dfda	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9b1b40d8-ce8f-4089-a4bd-8316af5a9385	a71aa043-e695-40b9-b3e4-802815738815	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
71ea5f33-3c1a-4dba-acc8-87c834f1a927	c41b06cf-c114-4b78-9e0d-007822fed668	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e70cb2e1-a175-4e44-8cb6-8fb7a8862ac1	42cfed9c-0ca7-45a6-b865-fcd50c2b98b1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
70d9fa04-f1e7-42e6-bb33-8d8e5ea017a4	47b65c87-8d48-47d8-8f5d-679066b826ef	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
81430038-9340-45d5-ae2a-7d033c780d99	e53d949c-5d2d-424b-b4d3-9663ecb3a63c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e5c168a0-fcc5-4b28-a42b-df4f71068437	71c1e0c6-2a75-4f7e-b15a-9f40991965a1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cb87f760-4afb-46dc-911f-0049e26a17d0	1e8842ac-3edd-44a9-b7cd-b745f2c73d52	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2dec7d5a-5c99-48fe-be41-e5dac4f238a7	907cbdb7-8ad8-4a26-9ff6-8cf664762487	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c83dfce5-fe00-46c2-8441-5debdf82c790	e8dcb1f1-8d31-4723-9b38-18dc2d6a7ecc	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e33c4444-991f-48d5-88bc-5c4d1df45f68	ee0ba439-f04e-4e69-b66e-081e84b7a563	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
70539197-8878-4cf0-96f1-564900ad81c0	244b6a83-a17e-42b9-bc6f-4a8a8e99f31b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fe881165-2456-4888-951e-04a87c8bcf63	244b6a83-a17e-42b9-bc6f-4a8a8e99f31b	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f85e1241-00d4-475f-b460-15112dd9320d	22d62f74-8bf3-4dd9-9202-020bd743bfc0	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6c5fc684-0cf0-4364-8cc5-2c07b2c0fe15	22d62f74-8bf3-4dd9-9202-020bd743bfc0	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c4e76f98-75ce-44b1-825a-950309d4402a	9fbb0636-93c2-4163-9a6b-c63ccf54122c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d314cb42-0991-4907-afa0-c03822288f9e	9fbb0636-93c2-4163-9a6b-c63ccf54122c	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6815884e-8538-4c9d-aefc-8f74b66ffe68	a8efaa16-6511-424c-816c-e171ebfb0aca	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
25b8deae-f77d-49b5-bf9b-fb1ca9d3b3db	a8efaa16-6511-424c-816c-e171ebfb0aca	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
73a23805-c463-45df-af74-79f9f87b238b	a90c8987-c7b3-4f1c-bede-0cd4af926f11	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a11991b5-ea05-45f0-bf08-42a614f58dc8	a90c8987-c7b3-4f1c-bede-0cd4af926f11	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0e2aea1c-7f56-47c2-ada6-75fb5bb27e05	949af886-60f4-4fc2-ae20-8dfee15f4523	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
951743a1-ecc3-46fd-bee2-f9b5f6a2ae60	949af886-60f4-4fc2-ae20-8dfee15f4523	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
198c3e3b-0b5d-438c-8d11-fd51d84996bf	da3e26cd-9d4c-4e75-bf3b-28b8e4f1a2b7	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2df18113-a665-4ab3-a6e4-dfe5c106741f	da3e26cd-9d4c-4e75-bf3b-28b8e4f1a2b7	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f917e93e-4009-41e6-8fcc-146843e5c1c7	05bf30c8-b9ba-442e-adc6-e75cd0c13eba	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
666a9819-4f0e-436b-88e6-aa27941ca94d	05bf30c8-b9ba-442e-adc6-e75cd0c13eba	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
679dcda4-235a-4f94-808c-296b70efded5	d3ab9f6c-2eb7-4dcf-8164-6d697dbe401c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bd02eed9-ce61-46d2-a11c-51532bb2e849	d3ab9f6c-2eb7-4dcf-8164-6d697dbe401c	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5b3ea460-dbe0-4d44-b45c-e498aae6f1fa	0978d229-956d-4331-b5d2-01e7b8c8c9d8	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
479f8fa1-f4cf-4391-98fb-14845d8ac8ad	0978d229-956d-4331-b5d2-01e7b8c8c9d8	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
934a4b1c-8776-45d3-b0da-92c51ae1ac30	ca9877ee-7d6f-472b-9e97-ea942f28bdc7	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0ef75e11-5530-43ac-9060-06d5685a842b	ca9877ee-7d6f-472b-9e97-ea942f28bdc7	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d9677457-ec1c-49e8-9b6e-53cecfda63f4	aeb6148d-78b2-42a4-aab2-8e2413536702	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f470f26f-fd3b-4b28-9e13-c18819563e07	aeb6148d-78b2-42a4-aab2-8e2413536702	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6fe639f3-6dc6-45f1-a768-157af311b0c2	d871940c-e5ba-4eb9-bf2e-d640b9227fb2	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5d5942a5-a61f-4438-abd5-6a0041b4df53	d871940c-e5ba-4eb9-bf2e-d640b9227fb2	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7d79d9ff-c67d-48ba-b9a9-227b98203d0d	afbc8441-e6da-496c-a859-f572c0f24c87	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b7dee956-c646-459d-aae3-91e18acdc67f	afbc8441-e6da-496c-a859-f572c0f24c87	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5d5eab58-9d64-4d2a-bc3e-3f5bcad5f78a	3a57da7c-3899-4cf6-a5ca-ec5d5fe6266d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
75f12050-e30f-4088-90f3-12c26748dca4	3a57da7c-3899-4cf6-a5ca-ec5d5fe6266d	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0def119f-4b42-4471-aff8-ca36cee85af8	7e687aff-c2f7-487f-84dc-e35e89c77b3f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6f232e6d-ed70-4633-b534-3734805ba07b	7e687aff-c2f7-487f-84dc-e35e89c77b3f	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e103a963-381b-445a-a12d-bdad52388d5e	598b197c-c3d4-4f5c-a80f-99aee838476b	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e46038ad-9a4b-4642-8603-6a45af773b33	598b197c-c3d4-4f5c-a80f-99aee838476b	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
88fb76c0-7dc6-4d16-8a6b-78f9fbaefcee	0e3755b8-0455-4602-a94a-68baa6f15f36	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
961f69d6-0b8d-4ff0-b2d8-9048500010d9	0e3755b8-0455-4602-a94a-68baa6f15f36	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e6c906b9-45d3-4778-b470-5228f99c365f	a68076d9-b0f9-413f-82c8-e8d38e300beb	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
69687c50-83e9-4b0f-b743-79376eff1c4f	a68076d9-b0f9-413f-82c8-e8d38e300beb	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
88ec16a7-48cf-431a-a663-5b2065c04960	f79acf6e-685f-4e61-9752-b66fc79264bf	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
516bff80-3b2d-408e-af49-a44ec4a00e43	f79acf6e-685f-4e61-9752-b66fc79264bf	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
67efc3bd-1a8b-430f-86c7-8d7ac108fbc9	d1787421-8fab-475b-a59b-afbe7c83cf17	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a93cc034-2abb-47e8-b62a-3a58195452a9	d1787421-8fab-475b-a59b-afbe7c83cf17	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5ed7107d-59a5-4010-8947-a7967e32b2a8	e0b53d97-a919-4be1-90c0-fd9e904c426f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ad810fee-7bbb-4842-8517-99b93c71d56c	e0b53d97-a919-4be1-90c0-fd9e904c426f	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
933c4929-0160-449d-b0d7-70d8ad7a0795	20e0e3dd-4f94-48f7-83b6-4eb88f9c86b8	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c21c2129-52fd-4e46-8946-7c5a93ebb7ad	20e0e3dd-4f94-48f7-83b6-4eb88f9c86b8	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
967a2119-cb26-41b3-9a95-7880ff972bfa	8c5b5a59-b6b2-40a5-afae-0609b70c5290	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7c1e2829-9cf2-4c80-b02c-2dcaede1db06	8c5b5a59-b6b2-40a5-afae-0609b70c5290	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a6d243ef-8963-4b88-b952-ce4d4580be2b	2a499471-176d-4243-ba71-0bb4816dc54c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dff5395f-d3d8-48a2-a9a1-2b297af2623b	2a499471-176d-4243-ba71-0bb4816dc54c	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
638e270d-ad9b-46bd-b850-7395717fd953	5c22a73a-e94a-4bcb-8a50-187c981e2336	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c8c62aa0-186c-45a6-b804-8eac4bbf95ca	5c22a73a-e94a-4bcb-8a50-187c981e2336	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
726eb376-7c9b-4ba8-a2d8-50309f10bcca	e466907c-b69b-4f4a-9b28-644b090e2325	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
85b959b5-9f11-4fc2-829a-83a308f529a2	e466907c-b69b-4f4a-9b28-644b090e2325	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
384d78f2-30a9-414e-98e9-5c7eba2d4de9	d655db93-b004-461e-888f-384f31dd7b29	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7e05c9c7-8ca2-4de0-a386-e91a85bf7b9d	d655db93-b004-461e-888f-384f31dd7b29	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
69bd9e05-c87a-4ea4-b040-29b96b7a6beb	06a2b0e0-cbb2-49ad-9184-f27371a0171e	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
537fc625-c2f2-49ff-91e4-ab681b5124b7	06a2b0e0-cbb2-49ad-9184-f27371a0171e	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4ae2f8ae-058d-4976-bdf0-0dbcbb1f4806	065fa74f-cf8f-4741-9135-1b11f08adb76	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
790bb3f1-5cf9-4ae3-a135-e758d9163269	065fa74f-cf8f-4741-9135-1b11f08adb76	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8ad6ce27-e66c-4d1a-891e-0c71548fec65	80844d0d-83f5-4cea-8291-01a7be3e7642	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a971ac76-3a9c-462e-ae0a-b27bb857617c	80844d0d-83f5-4cea-8291-01a7be3e7642	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
661a3e7f-538d-44f6-997d-86fcb1ab9739	a3c7e0f9-f240-4c26-b733-dfbdefee93cd	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1372d8ed-4dc9-4891-8574-c5061bca026c	a3c7e0f9-f240-4c26-b733-dfbdefee93cd	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5796cbfa-f6ba-47b1-9a8c-bd16de73bde0	6a0f53d4-dd83-4f1d-94af-b4057980b1c1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8af3b8e6-0095-49ae-a66f-fc3dc67f4f40	6a0f53d4-dd83-4f1d-94af-b4057980b1c1	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
eac19ea0-7747-43ca-b93d-68d26844d01e	7b6b0af0-3152-4195-b0e8-9c4b0c9aab1c	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8b0cf9cd-54a4-4ded-b489-9226bb74d224	7b6b0af0-3152-4195-b0e8-9c4b0c9aab1c	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
81c98023-f250-4c1c-966c-8171f50b7d09	66b52fb0-d809-4f6f-88a4-655cb4108adb	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f0b19b4f-1f26-4b8f-9e13-9fab27974dec	66b52fb0-d809-4f6f-88a4-655cb4108adb	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d9eb6603-35cd-48bc-b9ee-b2d793614daa	0f816d16-a338-4dc2-8471-5384150a0b3e	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ca292233-0cc2-408c-ae40-2886d5280758	0f816d16-a338-4dc2-8471-5384150a0b3e	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
60fa7628-3eae-44eb-9767-1ff628adc098	20186d21-beb4-4d82-acd5-b16b9568dbdb	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
80aa6b71-8230-42b5-b986-84b985a4c5f5	20186d21-beb4-4d82-acd5-b16b9568dbdb	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0dc2a125-b815-4200-b325-ce30b7c1c89c	670993b0-cbb0-4293-9c29-1ab1a9466ed3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
33f2bce2-7fa5-4909-adec-fb494d2e04c7	670993b0-cbb0-4293-9c29-1ab1a9466ed3	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
755f5a29-da80-4f2b-ac30-4eb22fdc9c94	0873fe58-1bff-436e-89d4-6353b5467a70	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7926a78a-6bea-4d9c-a97d-196846de276d	0873fe58-1bff-436e-89d4-6353b5467a70	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6ef19968-4af2-48d3-ad78-8197f448d921	c8b8dc3d-1b43-482c-91fc-5b7970343b97	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
60963629-c3e1-48cf-b958-a53a03d2e4d6	c8b8dc3d-1b43-482c-91fc-5b7970343b97	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1ecb00ef-0a5c-43d1-8170-90d840d27158	89f3927d-ab29-4a1f-bb5f-11895f94abb1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a43fe568-9666-496f-80e8-61fe75476203	89f3927d-ab29-4a1f-bb5f-11895f94abb1	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1712d86e-b92f-4ed8-8a02-d14e1e70c886	5498c9ce-31f9-43ad-9d8d-6a2c2fed6bfa	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e95542ea-ba8b-4a3d-be2b-6cfceb2ad161	5498c9ce-31f9-43ad-9d8d-6a2c2fed6bfa	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8160745b-49a7-4ea5-bafa-336ccbdf0958	2608e064-867a-4fd3-9923-028b4bbeca52	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0d04e54f-9d56-4ad1-b0f7-48465d1bb44d	2608e064-867a-4fd3-9923-028b4bbeca52	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
22d1e197-50ad-4739-8b19-67c196a2bd51	57a944d8-51c9-4246-80a4-51348abb4a40	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fdeb8fd0-795a-4561-96d1-6a189edbc926	57a944d8-51c9-4246-80a4-51348abb4a40	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c994fdd2-caf5-4229-9e30-29511a8f8ac7	e4bb949c-487c-4198-a3c2-3a1cb3200e0e	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7268ccac-a76a-47e6-8ca0-a81b5d4c344d	e4bb949c-487c-4198-a3c2-3a1cb3200e0e	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6bb149b3-3c02-4744-a21d-3db1ada02bd2	848b05f2-a664-477c-abcd-dfcf4cef355a	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d0f3f618-bf32-4943-8247-094a50b64619	848b05f2-a664-477c-abcd-dfcf4cef355a	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
605ec657-80b8-4ca4-8e1a-5b06c22097ea	a430761f-d4c1-40ba-a0a9-cb6b8ac68eec	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4cd88bb8-fca2-4537-80b5-54613bed3426	a430761f-d4c1-40ba-a0a9-cb6b8ac68eec	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ab293359-1f0a-490f-ada6-cf8c6b0a146f	84024871-ec04-4469-bd0d-b8afac1912b0	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e78ed34c-5bab-44f0-9ca5-0c075043a64b	84024871-ec04-4469-bd0d-b8afac1912b0	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
de5f6ac9-4dfc-415c-8b75-6def00019a18	45e07a88-cfc0-48f6-b9d2-cab1b7f0b381	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
53b35f43-6949-4e8a-b373-cacc49ae15e8	29031217-35da-4283-9304-306dba5aa4a8	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e90d38bd-4ea5-49c4-99a0-9ad32c118258	b630df0f-3f70-4473-a18f-da0a038feef0	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2d8c3f5a-7ca8-4505-b0a0-e307c551f024	416968a6-8555-4898-9e27-749ad4590b14	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2670035d-db51-4cbe-ba7e-0ecfb2493650	8a6f4a10-f491-46e3-a644-e9de1bc10f0d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6dd92c46-2c97-420d-b338-95f2b6ab782a	9c4e0713-911b-47a2-9455-f5fa809727e4	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1024b70f-2c60-4ff5-a723-bb03ab39da13	7ea80c70-a01f-432f-a97a-e3d27a45f040	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c3e3b242-81af-4451-8e5e-208237c77311	a949e31c-1a90-4e4d-b64f-abb8961b7503	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ea6fd07b-abb9-4584-897c-68c370b93a3d	a31e98a4-fbc8-47a8-9eb0-ab0cea691825	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b4b97759-fbec-4c29-8a3d-f925746f72be	fd3362a3-cb2c-41c6-936c-070fd526e4db	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8ee225c9-dbe7-464a-9f1e-3f97734212f3	4e47687e-dd88-47ba-b779-8a31560bad7b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4b000a47-a7ab-48eb-9079-a702eb784f21	106c01d9-57ca-4434-9986-1ebec31ceff1	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7af29ae8-5180-4538-b4ea-bfd4f23aa959	f57535ff-a57d-40a4-a42e-bbf1c9bbb8ff	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
96c73474-17a6-4926-b197-5668aefcf885	f70bbfb9-2af8-4cfa-90eb-b94c4d5e186d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
355e855b-a497-44cc-8b9c-34578e07942d	7c170301-7eef-4433-942e-27307dfe0cd6	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b835c0d9-e359-40fa-9739-4970f3443981	cf05fd28-ee79-48e2-9966-0a40a1ac8c2f	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3c6f02a5-58a7-498c-b87d-f6e8c11797cb	2cef2d1d-f12d-41e4-ad62-311bc103e8e0	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b19e24d8-e1de-47cc-adc1-e9913eb6f145	f530fa98-9cc0-4d57-b029-26b1342271e2	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ba591198-bead-4684-a8ed-30f2280efa8f	d8d868e3-bced-4696-be25-b786faf42f4b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
780c3e3b-595e-4271-ba54-2b96fd30d379	6e870847-537d-436b-9de1-ad964e35496c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
414d9f01-903c-4e9b-b4eb-7e18381b7e41	d2dac919-c4e6-4b1c-a514-ef498cb5f8ff	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5a001f7a-780f-4d5d-b6b9-c7275e59b0ba	eb1da70f-7417-42ec-b300-ab7f113ab4fc	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b1489dd9-7c5b-4150-ab32-4174a19768c7	25a09bbe-e244-4f48-8ad0-4ab93c8e60c3	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4433c6e6-1e2d-4fb0-a58b-490b9d0036d4	6b2f2b9f-0085-4606-a483-c1b824cdcf65	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e8df6120-8118-411e-b469-9d04968e57e3	04464365-8e0d-4032-a713-2b7f6f995e4d	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2f8fb2ba-4520-44bf-949f-5647625c9a84	436cf968-febd-47f4-ad16-8d15a38c0b19	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c3609e8a-c3a6-416a-971b-4faf79fd8c5f	a6fab1a6-6167-45c0-b133-a6a13058009f	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4af340ca-7b80-41d9-adf9-46bc3e6fbbf5	c9b99c92-6f3c-48a3-b461-e53a77e5089e	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6b0a6ab6-5cfa-43aa-9dcf-7ce1a88ddeee	c4fe7b95-219a-4f3f-b292-9ef2bd9d0be9	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3b8ca08a-5401-4276-b213-ca13958ffc5b	23aedea7-888b-4842-ac00-ea22ad8cdfc0	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
68bbc200-573c-4ed6-b1fd-e001abc3a48a	0a78b3c5-32c7-4e39-a7f7-3b7539fd1ac7	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cc97df96-9496-4d52-b536-15219625654c	593b2dc0-fc81-4c4e-99f0-f205a64645c1	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
25dd67e7-91e0-4a5f-9d86-227fe7ece8d1	208afe7d-23fc-4041-a42f-27addd6468f2	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7a0b2989-de27-4c8c-96cd-4a6d60c39d87	06506681-6c43-44f3-8e1d-c405813477bf	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
30403757-da2c-445d-8b64-3a65c8c75bc2	2158eccb-597a-4ae1-bd15-1574170db46e	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
50c727a2-945f-4ca1-90ec-f18f8b74c893	4893928f-8614-4820-a175-456cc65a0775	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7278ce80-926c-4a81-b523-6cd6ca7fd8a3	a0f5e4c7-bdd9-4be1-abe5-167048539bef	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3415fe80-0105-4a37-aedb-27fc456e335f	9d97449f-6cda-4f37-87a7-18c376816bad	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9b14ea70-f3a6-430c-b6b5-c475cd4abf95	73e5fa1e-681e-4166-b550-9b208c24e3c0	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
23fb2507-6650-4d61-9479-61c5e2d563ad	b9f56f93-10e1-40f6-ae9e-6667d6c33f86	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
107fe62c-bbce-407d-9ce5-748ae73ee3d9	f0c83e41-ae55-45ec-91cc-ff243bb9fc49	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5d875296-06e6-48f9-b4f2-e3fa04d82c5b	ee52d85b-5bfb-4ca4-8979-5acb5fd6aaab	01b74a5e-f95b-4086-a5b7-899a8de1f228	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0ed4d182-96f4-4c6b-b599-3a09f60663f4	2540be8f-2a5d-4121-9514-7d547be6eef0	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d9ebfd68-6072-4967-aaf1-a5bdd4deb536	517f2e8e-edc9-463d-baa3-bc3064f67e11	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
abb7f31f-6213-4e77-8af7-e9bbba0a1660	1ab89282-75d4-459c-8eea-032407a2742f	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c869cf0d-6aa5-48b6-b95d-a14bcd3ca87c	f25a391c-375a-4752-9d61-7d278001ed59	cd3bc960-aea4-40fb-a1ad-f54c10b7228b	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e15cd8ee-5f12-471e-9cfa-7213e59f4df3	e5817e5b-dd37-4327-8d64-ce51cd97298d	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3f95026d-e066-453c-96fa-3437c649aa82	da332d3d-e43f-41bf-bb51-17f7a79a6f1c	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
828f52e5-c441-428d-b939-37c24a47b055	24b93eee-c881-43d9-90b8-4f98fcf733fd	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8f9e15c1-8dd0-4c22-ab7f-1119e2d0004d	a9287274-3195-4c95-bf47-a04481ddf04e	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5c053a66-cc9d-4198-8d3f-cfaa24c48384	5f44ae08-08c7-4d94-997e-b20c26a3d3d2	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3f8a8478-47be-460d-b973-ab5e53191749	068f197e-5bd0-49dd-9599-af0f7061a844	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ae1f0e7d-d248-450f-a8e9-f4c009522eb5	06a0b35f-3146-4b72-b224-df6264161bfd	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
90bdf16d-ba92-4898-b08a-5f108986af3a	8410c20f-f925-416c-925c-ce2365b9ffb2	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0b8261ec-1e46-482e-9ed7-81cd6d9d0575	99c4170d-f79b-4b8d-8217-c744dc2a060f	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f64603f8-5260-4acd-9ac2-cd8c055e4b31	46c22828-0861-4e49-91e4-91bfea02a02f	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
96568a43-b535-4e19-b79e-401bb4aa2ec0	89453004-e027-4e98-8ff5-64f3fbdf698b	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d6dcb767-8b2d-448b-bd9e-bdab25fbb4bf	b36eb4eb-bf6e-49e6-aedf-48ae1cb8d005	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ba6f8437-4d87-4f9b-9f29-1929f55a42be	82aad02b-aa9c-4c64-88d7-b98df17dbb2c	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e54b1c92-9697-4cd5-80b4-112ad0c07da4	3a5b507a-96d7-49eb-85ae-fcba48c2dc7c	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a372d9b2-c638-43d0-b752-2decba5caec7	ed6ed4cd-c259-4f7c-a04f-44bd558104fe	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
81b17386-1e67-449e-83ae-95ec5c277719	b52be0ae-2e8a-442e-abba-001c4757ff4c	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
aefc9a87-5cdf-494c-acc0-7cd70ab16a88	02292b54-6e0c-49a9-abd6-137d37d05fb9	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0cad8608-eb62-4c8a-aaab-c9a2d2e06c54	1af26070-fbe3-4ca4-a831-8f3a71f8ddf7	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8ec07cde-6d8f-44da-90eb-c7358f45499b	b13c50e8-fac8-4820-ad35-6f9c21a76fe2	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8a0b2060-00f5-4c18-9f6f-92ba1ba7e041	368db12d-3e0d-4d84-bf54-9e9adab15b80	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
594a7972-b1c9-4dc5-a653-19440ef83458	ba18a28e-ec17-477f-b172-69d82698b00d	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3c726fd8-6bfd-411b-a4c7-621aa0fb483e	83f3ffbb-4c99-4725-a5e0-e85f8d9ff1eb	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8965aad4-6863-47fc-82a7-03764e0f6ed0	35e4296d-3256-4876-8f03-5c7d8cee2479	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7b8a3d27-d153-4100-b145-863f009f776f	3b4c4e31-331e-4679-83c4-28bdf09b0496	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f55bedc4-5f2a-43bc-92e3-4f29224fe051	15aab06f-f875-4279-afc8-aeb3f9b460d0	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
efece527-0c32-4b7b-af3a-7260337c3d21	c05f727f-3ff4-48df-9e0f-d8467541c7ce	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6289e2ea-b4c8-4d84-8800-aff6cad9e089	406528a5-ea1f-4a4d-bdb2-e86febe02208	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d55e67fe-399f-421d-aa6b-06394fd96a67	2f645122-e172-4e06-ba4c-edc192dacc7a	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8b062c75-ae90-4c51-83e4-4988a33a7e6e	c7789c03-1712-4859-9961-9644654a60a9	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5a3a31b1-ac43-456f-b98a-a05dc71e9e32	69fe0f7e-4d2c-460c-9a63-bd1c895e83b1	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
112f2461-e3ae-4db9-aaf0-257d1f832837	448ccc1e-7cc0-43f7-9514-ce384c26dcbb	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0b3e7886-de83-4eb5-916f-96c09c70290a	72343ed1-d562-42be-92b1-8e6fe9bccba6	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
327f9505-e004-43d9-a352-9018f8832757	daa6f6ae-7c26-4dce-bafd-59eb0c2a9292	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
52e8ded0-fe11-4107-8f77-a5243d39240a	a78a9d1b-f8a1-4084-a933-a7f3b0f9b35a	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7147050c-e965-4af3-ac78-096f61db1809	f1cc4ee1-b19c-4a8c-bf7e-290fba38d659	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8694d84c-7e96-4ff0-a12e-02008e27e6ea	a38152f0-3250-42db-a86f-535983de5b41	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
837458ef-803d-402f-a26e-eadd7fe924df	4cc1d2da-0011-4393-bc32-4925c66b5dd0	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f1686f49-bf3d-4fa2-9410-d9a8045f7786	3c2f8219-1cbe-4623-aef3-1ab472c7f5ee	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b41eee47-2ffc-444e-a767-273603ead01a	d5f83d64-38fc-4463-88e2-9dae7aa83e9d	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
82a50696-ac3f-4790-8cca-25774662fb95	b56f2302-aa58-4b21-874d-718c318d0285	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
67dae1cb-b34f-4c6c-a26a-9ff7532db753	b0c1b34a-150a-4e8c-aa52-693c63fcd50e	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4af9f1ab-7928-4d9a-bccc-d1eec0f552bf	c1911d14-a326-4e6c-841f-095f713230a9	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
175411e2-ebe6-47e7-a919-c0c2461a707f	26833a3d-b940-4730-bdb6-771b8de5d6bb	e8d718e4-4831-496c-8448-16ad044c2e9d	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	*3/*3	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
422e4a61-fdc5-4bde-845d-625b152cb4b8	a28ac42f-6e91-48db-8de2-cb446b788506	e8d718e4-4831-496c-8448-16ad044c2e9d	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	*1/*3	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0ef93b00-ddbe-465f-80d8-6caf5d27e2ff	aacd58b9-7cd5-415d-a590-95539fa55722	e8d718e4-4831-496c-8448-16ad044c2e9d	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	*2/*3	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c444ddd2-f8a4-4411-8602-f292e53109a2	0db7301e-cabc-4125-9753-d1baa2c44135	e8d718e4-4831-496c-8448-16ad044c2e9d	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3d5d26c7-46dc-470d-9d5d-481c5996bbd6	38473a9a-ba04-4113-8ecd-fd86d62c9861	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9af2cd22-6e1c-4786-8634-ffc7a110537e	49d74075-b2ad-4def-90eb-2a7ae764230d	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
565f1b3b-d6d8-4621-8864-8ddcab7e3bfd	902fd70b-064b-43bf-a2bc-fdacb7b3be69	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
49ba3a9e-aa40-4da8-87f5-aee0ddb5b88d	b232af8b-30f0-46dc-b691-e6e75fa357e7	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ffbb2c73-b67a-46f1-8c68-faf41a6db8c3	92099359-d41b-417b-acca-3aa178b313d7	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8ceafe6a-3a3d-4f8f-ac15-9d5b2fbcd16e	f52a7ac4-59f4-4a23-9fbd-544cd7a62687	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dcbd356c-97da-4d44-b64b-acfd857dc09b	e939b98a-b455-415e-b937-b7e0b7b45397	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0ad96dca-f31f-4ae2-a2d4-288b167c2449	6d01ada6-6047-4856-96f7-51abb0b3ef03	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
afc158b0-ec9e-4083-ac51-8cc0386e8bf0	6f1e06ec-4bfa-4fbb-bfde-7b50b7dcb7b8	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
edab43c1-189b-4254-a8a6-4438c155be0b	b0fb7fe3-abe5-449d-b539-e3ec0443fc47	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d94eee4c-4d61-4eb6-87c9-c24a3ae0b7f2	d03bf414-6c6c-4b16-a1b4-3c546a8a7fd1	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e22d3797-1268-4189-a803-20d747bf9178	dbf6cd6d-402a-4f39-8f26-7ef9480b6c3b	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
03371ac5-7131-49cf-8603-779c64a85e7b	e4894564-51d5-4d0c-84bb-33e72708447d	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7c9c8df7-609b-464b-a5e9-6902f4592453	4a81eb90-d3f5-47bd-a87b-4403a611caa8	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
89440155-f235-478c-a1d2-80f1e90c9130	c0f8cd81-ec14-4a0c-b792-afa5aa50ec6e	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ef75b88d-d74d-4c76-aa03-4d0ecb7e6ddf	1d057682-ba7f-4818-8bb9-62768de6c8d3	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c213bd14-0848-4608-9275-79493cdd4b1a	4c76a6a1-c667-4b15-86dc-a2cf45920bec	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8ac2f1ac-3f90-4f3a-80b9-4465dff1ce80	f9100cc8-a2e2-4d2b-8c52-ae60b0795e76	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fdabda29-a417-4ffc-82b6-92e99be973e7	3051482a-c212-4398-9a8c-22bde46b7a24	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d27ea87f-4278-4995-94e0-b3cf2e1f7a3c	b334eed7-c4b2-4748-9f6e-448e29203a4a	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cd1da558-9fa6-4354-a42c-641e77bf3836	44640921-5287-4001-afa2-d9892e9fd492	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e241cd8e-4979-47d0-a464-7801416e8b84	7bbcf2c3-6b90-4f3b-ba5f-ad6cd89f1fe7	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
13e9c9c6-77df-484d-99c0-604390753b9a	e7bdf9f3-95b8-4c5d-9518-ba50b6a96401	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e7328a24-b9e1-479a-ac6b-47c2fb8572ae	54ebee77-6acf-42b4-95d9-7fb0fa2baeb7	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
59daf7c4-4bfc-4d71-aa89-a4f104e9999a	0adbe8c9-1db4-4ac0-8f99-c93fc58d13a6	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
87df1b4b-f85a-419d-9944-1f00ba3c370c	59d737da-ddc3-432a-a9f7-7bae7c80f110	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0b967b0f-a4c7-4cb0-b11c-df4ceb14e6c3	34f0cf48-f9e2-4c8f-9ae0-3af955beae05	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
932c5274-cda5-46f4-8252-c19982283882	20d0c2ee-a22e-4809-b788-2ef9fef37577	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
827f57a1-42c3-4bcc-ad4a-9234cf1d4933	10853ff8-7f2b-4b0b-a6bf-222261507521	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
05910f4b-8642-4075-b8ad-516600e0b6b2	149dd0ad-9e4f-4618-ac18-c8ee94ff0132	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
77fb4776-eed8-46e0-9b04-c64a1f9204c4	fcfb0a94-e078-4015-9e5b-ee4397f781eb	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fa1f3397-604c-436f-8f1f-edf245129acb	9cc22c49-1373-4181-be01-977f31108acb	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b5ac3bca-4a58-44f1-939e-227a507f2917	03c1bd46-23f7-4c52-8192-14a9ba8cf60c	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f738a5ec-e64b-446b-93ef-604ed3bd0050	965cc39c-99a4-477f-9b6f-d3205c8bc09e	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
85163969-987c-441a-b4c6-b053507ed2f8	f3738d5d-e775-4a3a-9ec1-2d877494cda8	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8d79a9f3-68d6-425f-8d16-614857c66d22	f3738d5d-e775-4a3a-9ec1-2d877494cda8	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f1b5fff0-52a3-462e-8341-d878b9688f25	cc3325b4-daf6-4866-81e2-70ad41ac137c	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
834336dd-b92e-4628-804c-ce88598ad6db	cc3325b4-daf6-4866-81e2-70ad41ac137c	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
796b5dc9-4713-4bc0-b99e-01dcd484462b	1d913d6e-6ff5-4b5b-8b7d-1a0cffa931da	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ef1580d6-5f5f-4001-bcd9-6580ac912253	1d913d6e-6ff5-4b5b-8b7d-1a0cffa931da	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ff0cc278-cf10-4b6a-b093-3f8851aefe1e	4a01ad83-6e0a-40a2-b85b-cf5d60cfd330	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6f842caf-a1b3-45ae-a3fe-07d98af3c538	4a01ad83-6e0a-40a2-b85b-cf5d60cfd330	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8183bbc4-8760-4f32-99a7-4111b697a68c	bdd99634-653b-4c38-8844-c7fa410af743	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2262321d-ce24-4380-a54b-ce5bac21db9a	6d4ba333-b115-4be4-9c37-e0ae7729e8d9	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
21cf60e7-f3de-42e6-85ba-d8f1c1ed291b	6d4ba333-b115-4be4-9c37-e0ae7729e8d9	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f8af608d-8fd6-42b7-a76d-57ebca123a01	ac0c6eef-ffdc-4eaa-8245-e1489668f35a	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
65f4574f-ad46-427b-9881-80113aee9a1a	ac0c6eef-ffdc-4eaa-8245-e1489668f35a	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9833df80-cd8b-41ea-9655-6a6b9f0a9239	b46e0b58-9c99-4ec2-8943-3dd1ae98c753	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4cae9d9c-726d-4190-9fab-c38ee69bd973	b46e0b58-9c99-4ec2-8943-3dd1ae98c753	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
08f9ac75-3bba-42e4-bdcf-bf807855ed7d	80b0a098-d72a-44e7-92ce-e73bdc7c30b6	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0a35fed2-96b2-414e-afed-773ad8e46883	80b0a098-d72a-44e7-92ce-e73bdc7c30b6	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
003a9819-0bea-4409-87e5-34f4d1782de4	ccc9ee14-4c17-4f79-923b-453d26108f33	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d0316adc-738e-4a3c-bf4e-9cc8d4a812bb	ccc9ee14-4c17-4f79-923b-453d26108f33	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ba193a1d-9331-4c5a-87db-4090dae35572	2ef8f6d0-8dbd-4c97-9aeb-87fa1cf68bd6	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
00494aa6-ebb7-4799-ae00-08b48e8d1df6	2ef8f6d0-8dbd-4c97-9aeb-87fa1cf68bd6	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c9e886ae-1644-4bb4-82a3-9ea3239f809e	c836bca2-5364-4503-916f-d99e57df4e0c	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1909fee1-7ced-400a-a646-5a397cf4b42d	c836bca2-5364-4503-916f-d99e57df4e0c	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d3d16376-568c-4dd8-bc28-99f378b5bfef	d4a8f643-3d09-48ba-93a5-130e4a701fc3	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b0cf4fd0-5810-44a1-82ec-e5d63689f6a0	d4a8f643-3d09-48ba-93a5-130e4a701fc3	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a06c6abe-54ad-4a20-8d19-6757219baf14	e396c7f9-6f57-4ed3-8a17-5d7e2a33e98d	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e428454a-0ef7-4dac-a5b1-e84771bfc293	e396c7f9-6f57-4ed3-8a17-5d7e2a33e98d	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
43e54bb2-52e3-460f-8379-29c83c6dd1b2	8165476d-62fd-4f4d-9336-2113d2e21338	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e0d40b3a-ec0d-413f-b4e3-47e094f120da	8165476d-62fd-4f4d-9336-2113d2e21338	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
def0e863-3698-4846-a5fe-96cc4d41f0dc	d3cd4b2d-382b-43b8-a7f6-6542fb59fa45	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
94cf284f-100f-4ee4-bcb9-6d4f7a6e40fe	d3cd4b2d-382b-43b8-a7f6-6542fb59fa45	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
15e70114-e9ae-4f1d-a235-c75eebc6563e	8990165e-8c4d-4fa9-9076-e545a6eb271a	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b42b6301-9409-4ac7-a69c-393279863de4	8990165e-8c4d-4fa9-9076-e545a6eb271a	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c9992969-cc74-4c8b-9177-f522ce2fb733	73b7742d-5e43-4115-beed-8bd04010ad2b	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
60e8080a-7b8e-4d01-bd4f-4bb1e7d523c9	73b7742d-5e43-4115-beed-8bd04010ad2b	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
057d949c-a7c4-46cc-bf6d-4e8448ba5c2d	b6835ffd-e222-4784-94ec-7293d0f2a034	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
164d0ab6-1711-434d-a7b3-27ff9b43997a	b6835ffd-e222-4784-94ec-7293d0f2a034	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bffcac8b-d8e6-4f58-b8cc-207b677ba2e0	4765ccb4-c263-4d70-b409-e0c7dc9152e4	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3c2eec98-8029-409e-bf10-fa2598ead2a5	4765ccb4-c263-4d70-b409-e0c7dc9152e4	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5953b5cd-5c7c-4a2a-a846-93454bb3f0a9	f4102737-995e-4a47-97df-963713abf9fe	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c7a4cfaf-ca90-4672-b3b9-e219a084c789	f4102737-995e-4a47-97df-963713abf9fe	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6f66941f-e702-4d70-9edf-5041c5fca6fd	4cc91b8e-9072-4f2f-b21f-a331a1746569	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4e83164c-da8c-423d-93ac-86797ad390b5	4cc91b8e-9072-4f2f-b21f-a331a1746569	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
53cab533-508f-446d-a19f-85f304cdd525	cf22b938-6fbe-4ea0-b2f0-742cf9623324	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f72c9e7b-f498-47b9-aeb1-069d6a4a2e02	cf22b938-6fbe-4ea0-b2f0-742cf9623324	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
10b1abd2-615e-41ac-864b-7565dd165dbb	a5b42d8a-15df-4d5f-9f22-3bd90958ec57	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
829a652b-b1c8-4ece-adae-6ffcc6ff0f66	a5b42d8a-15df-4d5f-9f22-3bd90958ec57	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
befe274d-7d28-4cd5-af85-69d4d2fb62e4	e39a3898-4d7a-4d77-bf4b-82441326c7a7	e8d718e4-4831-496c-8448-16ad044c2e9d	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0610e798-5fd6-4438-9fd5-528192884bd7	e39a3898-4d7a-4d77-bf4b-82441326c7a7	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
727f2243-a4dc-4b41-a7c4-5787c70f5135	d73d50b0-1c32-4220-933f-0a71afcaa9d3	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d8ebd217-99a0-4274-a064-5a2e36752cf4	d73d50b0-1c32-4220-933f-0a71afcaa9d3	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
04360bbc-9d90-42d6-a2ec-aeddbf6b4a46	6c132ca3-e2ea-4936-b866-5a5e1e4d036e	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a81380b3-5fd5-4a5a-8879-dbbcbdcabfd4	6c132ca3-e2ea-4936-b866-5a5e1e4d036e	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e11108e2-71ff-4ce6-bfdb-fde3e4c674d5	846d718e-7d96-40dd-99dc-53df7da1b893	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cd57363f-cccd-4404-a499-86bb3f904384	846d718e-7d96-40dd-99dc-53df7da1b893	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0a381e54-0ff7-4595-864d-da3e09b2d79f	eb996983-3b0e-41a2-8948-d6f9df98a7cd	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
14af33fc-fdc7-4def-9635-4fce43ca9a0a	eb996983-3b0e-41a2-8948-d6f9df98a7cd	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
75535fb8-7c83-474e-9291-0ed215d9ef36	4ed9c81f-25c7-450c-bfdf-bffbdfaaf8d1	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
25e6d857-d8c6-42f7-8902-f1fef7ec3af2	4ed9c81f-25c7-450c-bfdf-bffbdfaaf8d1	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
10e00c2d-b077-4d62-929b-b0d8b5e588c9	92def23a-e6b1-4ac7-85de-27d5cbacfbce	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a34d914b-1e8f-4811-93fa-be7e15fe99f1	92def23a-e6b1-4ac7-85de-27d5cbacfbce	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d1b55179-3c30-44fa-b54d-cd8cc836eafe	f53ad995-a44e-4ace-8541-8fa19935705e	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
537ead92-0745-480a-a157-9934ada75d87	f53ad995-a44e-4ace-8541-8fa19935705e	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8987d069-813a-4394-8489-3c578fb6a0ed	d83f2786-950d-4627-b53d-85bd96988f7b	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
772ac217-9d07-48b5-b46b-60cbc9598f6a	d83f2786-950d-4627-b53d-85bd96988f7b	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3520ee93-81b6-42bc-8583-a0b86c4c6597	6bd9a1d5-067a-48b5-8ed5-7a5a1c67d8a8	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d68d5cde-74d0-4f40-9fc6-5a958db3b6bb	6bd9a1d5-067a-48b5-8ed5-7a5a1c67d8a8	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1c7396f1-7ca1-47f1-a197-6d531e120383	f119568d-c086-4d3b-bed5-6326b855176f	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
39f227f9-e137-4156-9723-9488f98d60b4	f119568d-c086-4d3b-bed5-6326b855176f	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2c3cc92c-5f63-4aed-8a77-355214f2959c	28348cbe-d2c3-4f96-a047-2e241886012a	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a61011c5-2e0f-467d-b60b-79b5461388d5	28348cbe-d2c3-4f96-a047-2e241886012a	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e9c2e5d0-9385-47b0-adfa-e2a454fffee0	4bf9e22e-4307-4033-8fa9-1f49af895170	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4fe43ae1-97d9-40a4-92e3-de3d96c5c3d6	4bf9e22e-4307-4033-8fa9-1f49af895170	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bb51637e-43be-4f93-8aff-db4a0498eda6	99d30d49-b799-41a9-b2d0-0b627d9c9e9f	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1bd36d24-783d-455f-85bd-7b062e015a32	99d30d49-b799-41a9-b2d0-0b627d9c9e9f	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
91476593-8920-4d75-af24-72fc505a1b61	08847c02-aecd-4110-9b90-e696659d27ab	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
79cb57ac-2110-4256-95d1-eafcf0a792dc	08847c02-aecd-4110-9b90-e696659d27ab	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
158576ec-2f24-496a-bf45-de9151490d86	00ca20cc-d92c-4708-bc23-e7fad854d6d2	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
db1a7e1b-a381-4b33-afd3-0374910e2476	00ca20cc-d92c-4708-bc23-e7fad854d6d2	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9ef8fd90-c62f-4afa-a464-ad9b7a497af5	129257fc-04f1-435b-9de2-a9956504496a	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1d9f79ad-eb15-4584-a5b3-b8b85c99bbca	129257fc-04f1-435b-9de2-a9956504496a	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6876bbb9-d78c-4d1c-9daa-1160a2fd03ef	6e891062-ab0e-490d-bb17-c51719f9bca9	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0dbaf293-d9c5-47ed-bdbe-0cd82cf33110	6e891062-ab0e-490d-bb17-c51719f9bca9	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bd147247-b64f-4177-bd68-57913a95579f	62ee02ce-049f-4a3f-a735-4ed4f7e4107a	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
627737fb-ce05-454a-9ca5-2184c6b69483	62ee02ce-049f-4a3f-a735-4ed4f7e4107a	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
de65d6c3-bce8-4b10-b8cf-343440e914be	64630fdc-75e4-4f45-97df-2b73a0eee21b	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c4a2d9fc-6cb9-43b2-a456-9401c0431c62	64630fdc-75e4-4f45-97df-2b73a0eee21b	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Increased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
26801c75-cdba-455e-8220-74f6c30d94b3	de3d8bc9-187b-4610-866c-d98bfd124697	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
eae112db-9ed7-4fc8-adf6-b030c0d1562c	de3d8bc9-187b-4610-866c-d98bfd124697	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a152df5f-58e1-4347-a0ba-e7a73068613a	33956074-3708-4d03-b8a2-23a524002d46	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b9e7d9ac-2fdb-4667-b0fb-f56dc88bb27a	33956074-3708-4d03-b8a2-23a524002d46	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c96a4943-88bf-4b36-9c6b-f5f8eed1a84d	97bf6485-a9e8-403f-82a6-1595d547e6c7	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c658b11c-cde3-4c2a-99c4-49eae8a5259b	97bf6485-a9e8-403f-82a6-1595d547e6c7	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0462c88e-311a-48ca-b00c-259fa3c6b23a	e8a32a29-373a-46c2-bdd0-2bcf2067cfaa	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d5087dcf-e26a-4be3-a1dd-19f02d6ca438	e8a32a29-373a-46c2-bdd0-2bcf2067cfaa	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Possible Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f98279b2-b111-46d6-83fc-9786e9627248	46c6947d-d3c1-4d87-a20d-f80c640815ba	39f5387b-4a50-4696-99ae-6c9062e70c52	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f0150175-cae6-4fb5-9722-80c697a52013	46c6947d-d3c1-4d87-a20d-f80c640815ba	22fb682a-e57d-4ad2-8dc5-8159f28a9862	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ee055ed2-a3da-49ea-95e3-77624e525783	c23ca553-a768-4eef-b237-4f7a1963182f	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c0c05eec-4311-48b4-b118-566b5135e50c	30ea4649-210f-489d-8b25-eb7752952a58	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
716878d6-6f8a-4725-9359-387d3bc08f2b	2753d745-4fde-44ad-a817-a926e2416c26	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	*28/*28	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dbfcfc88-3316-453e-8b3d-d583f0312026	a52d2763-eaaa-4283-823e-698e31304ac7	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
11f676dc-b1d8-48a8-bbce-23572563a637	3cdce22c-e760-49b5-bb60-d1577acb2750	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d3717f1b-a63f-4bac-96f8-e7b97965ee31	11594ef9-e4bb-4741-8e7d-3f0d8ff075ac	58f41405-4198-4822-b10e-eb43cd77bc27	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ad9faafa-53ac-4546-b376-230dbfb5e812	8f1492f2-81f8-42c9-ae49-5617b3a65aac	58f41405-4198-4822-b10e-eb43cd77bc27	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d3aeced8-7dd2-44bd-bfa6-9052e326ab2c	b98504a2-18f3-4d87-a127-101372b44237	58f41405-4198-4822-b10e-eb43cd77bc27	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
65c23884-89b9-451f-a28b-1eda815abfd2	3373dbf4-1675-4263-84a5-5cce2c8835c5	58f41405-4198-4822-b10e-eb43cd77bc27	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
527874c8-9afb-4b64-b4c0-f4bfd1db1a05	143bd3ec-ef82-49ae-9ef6-c32eb8c481ec	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
05fe74f4-21d2-4b94-aeda-ca1a39edaecb	c0724f6b-1a47-441b-ada7-11a0b12cb944	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ee8faff9-281a-4adc-9df2-5ccaac087e0f	52dee135-9501-426c-a3db-231ea6521fee	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
93125fe3-ddc9-4341-96f0-3a9f010abc53	bcd2d343-b857-4fc5-a3a0-5c81ce009acf	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
10862026-e059-42d2-a826-07c1210749c9	fcfc351f-a70e-4fe5-a31b-41d222f912a7	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased or Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
891d0416-520b-4a37-a260-54589f441af3	a0df12b1-415d-40d0-8bc1-03acd83f9918	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3c454311-6b64-427c-ae31-6e48dd63debb	469870c6-7f05-4396-a9bf-71600605852f	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e8012399-2bda-431e-bb29-c397cc7837fc	a9ac42a0-a727-4add-a3bb-5deddf2cadc1	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1dcb0b9c-87a0-4c7b-baf5-6ddaa0f7a82b	4975269a-144e-49f1-ad97-16f120d1cbd3	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
035f7272-54ae-4dc3-96c6-ff04a361d527	743681fe-8f16-4ea4-94c1-1c7719d567ec	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased or Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ad0d119c-b727-4887-afb4-88a40282245d	7a9151c4-2be6-4f64-9ee7-f158ca3471e1	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
66577f6f-1b4d-4a36-94ef-04c26950417d	708e26f3-fa66-4a29-a38c-5f544dd31662	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dc77de4b-3193-4347-834c-88df1db1518d	d087b0e3-ee4e-4704-9dbd-f57f4af23c59	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e8a5a5f7-ac24-4ea3-a253-d11e14971fe2	00ee0df7-f531-4d7d-92e4-b9db178dbc30	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
54ff00b5-1895-4d64-b27c-a1dd9528449d	2525a59c-0f76-4b6f-8802-c552221c2c8b	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased or Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
00666d1e-6b8b-4ef1-9045-cc3402c8a962	fcbba7b9-fd30-47f8-931a-705573f4e87e	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7845eb8f-ff05-4d40-b786-6ac5950e75fd	9196af56-2465-49c7-9d81-ec5191deb357	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ecbf126b-0c4a-4c7f-a4d0-02e60491b712	4924cd3e-87c7-4838-bd40-de0f29768239	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d0e7cac4-c609-49db-9255-f60af7ed4103	6f2d7423-305a-41e1-b471-ad6bbce92983	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7cdbb4fd-d7f7-478c-939f-82ab674cc4d3	762c6869-1df4-41e7-a12e-5fde1ec2d3e1	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased or Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e445b5d2-369d-4234-9045-dad369eee3a1	36afdfac-e2ce-4bd3-9eaa-698000f13c57	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d57c364c-dd93-43c7-ad05-e425c47bb915	989205c4-5925-4dce-ae16-a6a0f27c431f	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
377ac68a-14cb-497a-824d-002665968f44	3f3f8960-2894-4c63-b3d1-68045b53c92a	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b7adcf7e-d386-41e2-8e54-d06ed1d70d4d	5c68ca9a-48b5-4a77-87a7-b80a3699dbc5	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
310295db-bad9-4640-9a69-070ece314856	36e77366-636b-4e0d-81a0-209ec3226fc5	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased or Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6863ec0e-b041-4a16-95ee-02b04701aeb8	3a1e4c0d-e0e9-4704-8238-9f1f02c8a307	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f4d9d87d-941c-4a77-8952-beb64a68fbb8	20f11418-baba-4b62-aa82-9d137f19396e	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
83ca03db-caee-4515-aa70-dbacee685c8a	8e4d7117-aac5-4564-b497-4d6ec589b631	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5a211d8e-c870-44e9-9f57-c7cb9d37f093	e2d34508-d906-4139-96ac-845f5ac22b58	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
82116549-2876-452d-a6ab-1009839cf42a	6bd34503-6140-4c80-859b-baaa14ada3bb	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased or Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a8f3f98-b0ab-4e0a-9dc4-215c2a09a99b	90d7d88b-fbcb-4a96-9e4b-51150e6187c4	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
33b95672-b220-41d6-8c98-1533b82afbb5	1fdb69e0-4372-424a-9f27-8f1be8b782db	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cec371d5-150d-46e1-a186-25df2b5f77b5	83cb1b24-e748-4fc0-945d-364f9f1dfe9e	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f32b2cb1-5d89-46e6-b461-1c240970c1c0	ca593b9c-ea6a-49e3-afb4-a36c38e6022c	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
912cb937-8a73-468e-8d95-3c1e3ff91d70	48f4cf7a-891a-4289-9d09-a04ee52d2467	9be7b66e-d066-4d98-bc30-ec1511489398	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Decreased or Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b64ff584-799b-4d35-94c4-515da57574ff	5f74ed26-98c9-456f-95a2-54ffe311b19a	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2d0d3915-db6e-4d31-b305-a50bf4efa186	5f74ed26-98c9-456f-95a2-54ffe311b19a	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
63ffc1d0-c11d-46a7-ba2e-d316abc2f332	bf90d1be-4d92-4e8a-b25c-ff5ae900dd6c	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1c87e8ec-7ca2-49ef-add5-cd04995fdbe9	bf90d1be-4d92-4e8a-b25c-ff5ae900dd6c	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0e4edd17-504e-4401-aa22-47473811fd7b	91ec904c-c1cf-414c-a046-2ed695539265	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7850b46e-7aaa-418d-91a8-4f3f41c5ada0	91ec904c-c1cf-414c-a046-2ed695539265	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8f6cd39c-0fb1-4fca-850a-dee8c3cb63da	cd578b3a-2398-4268-882a-5df025decb87	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3f1609ae-80db-4cbb-a21a-db79440ed79e	cd578b3a-2398-4268-882a-5df025decb87	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a923750-e815-45bd-befb-5bcedba38de7	2a59340f-976f-4f1a-9471-eeff102efe40	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4b4de153-adb3-4aa8-860a-7dd3fe547548	2a59340f-976f-4f1a-9471-eeff102efe40	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c4ac3d34-5006-4e37-87f5-f0813c8f3942	9b5eebe1-3e82-4f10-9fa7-a97c553e6bc0	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8e87768b-d109-4c6d-bdf0-94e915650d5c	9b5eebe1-3e82-4f10-9fa7-a97c553e6bc0	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cf42f413-7d39-4eaf-a495-0ba33dc652ac	be966f62-f172-4c93-9bcb-d3ac1a34cdcd	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f57694ea-8d90-43ff-b02e-b0892a6ef042	be966f62-f172-4c93-9bcb-d3ac1a34cdcd	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8278e728-2842-4017-a9d0-e12b8acef781	4b51a8f8-4863-485f-ba7e-45aa5c056582	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8b71ed48-298f-4dba-98c7-80bfa74f2bf0	4b51a8f8-4863-485f-ba7e-45aa5c056582	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5e22b8c6-cb39-4056-a64a-6cc3599eebe9	8207054d-016b-4566-aa6c-4a33f946b368	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cbb03bd4-d3a3-4fc5-92cb-aba0af1e1b67	8207054d-016b-4566-aa6c-4a33f946b368	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c06ece1d-ffd6-4419-a54c-0d1a3f2c266b	3f1bfec5-a2e1-4463-af4e-15f19632f398	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0a1b2f00-a820-4bd2-9d7d-4d535deab9e1	3f1bfec5-a2e1-4463-af4e-15f19632f398	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
44d341c9-5b81-4624-9401-86f7b1291792	c0cf6a76-07af-49ef-b2dd-8cc63c914c55	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2e775092-cfe7-454f-84f6-998b9e681aac	c0cf6a76-07af-49ef-b2dd-8cc63c914c55	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
623ed5ca-4583-4a99-b5b1-843fb5497575	bc9e9813-f31f-4ae8-8367-4a5e7e75ea4d	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3819bb26-c973-4e1d-819c-71edd6c05aee	bc9e9813-f31f-4ae8-8367-4a5e7e75ea4d	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
93b54414-bda9-417d-a55f-9d37780f9af4	298a2ce5-03e8-4bc3-90c2-f100bc798067	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ea77dbe2-7570-4043-b752-35d491ee97fb	298a2ce5-03e8-4bc3-90c2-f100bc798067	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d026459a-2923-4cdd-85bd-afaa37c46839	80a3d0d6-4fee-4d16-b0e4-da9b5b5f7e9a	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f7a82f5b-6fec-43a3-815e-8555076d0047	80a3d0d6-4fee-4d16-b0e4-da9b5b5f7e9a	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
24fd3440-e6c6-4f5d-9d6a-58365e3240d6	6a0804e8-8d14-413c-b77f-b8d925240ca6	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a802e9ee-c182-4693-bd75-6b6139f6edc2	6a0804e8-8d14-413c-b77f-b8d925240ca6	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
18ad88f2-eca0-418a-bc0c-ee63161aaf63	88e8d64f-4ffe-45af-a5c2-bf41e05f5daa	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4a3dda59-7a59-412f-9cd6-b222c8ee2d4e	88e8d64f-4ffe-45af-a5c2-bf41e05f5daa	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
38ce0d63-f49b-49bb-b577-b277c42c5d02	19e74b3a-e81d-4046-8e2f-155e3c44ea3c	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3bfdeb09-bade-489e-a28d-0dc31007a13f	19e74b3a-e81d-4046-8e2f-155e3c44ea3c	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d346bc5a-d3a8-494f-b32c-60ba34be52b1	b0b55a81-cc70-4670-8381-fed9b85d4795	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7edfdb09-4597-40f0-8daa-0cf66e4bdea7	b0b55a81-cc70-4670-8381-fed9b85d4795	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b684c517-1011-491e-8e4f-d885abe8dfba	4cf7ced8-df93-4ae9-a25d-1630d6df5afd	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
01c1d5ba-8f33-441c-af41-5539c08984a4	4cf7ced8-df93-4ae9-a25d-1630d6df5afd	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3ec76480-d86e-49fb-aef1-7c41f730ab01	d87d39c4-b0c8-4785-a105-8474a8c48bad	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1555deb9-c781-49a7-bc77-d88cf8a347fd	d87d39c4-b0c8-4785-a105-8474a8c48bad	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
88013611-6c75-438f-9354-046d1f1552e1	5b2821a5-e35e-44c4-8c13-d63d6345ba5a	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
559118a1-bfbb-4d9d-a24e-5f471777c82e	5b2821a5-e35e-44c4-8c13-d63d6345ba5a	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4b6a6682-087a-4e63-b53e-2a77b8383623	f6fa5712-a021-457c-bdbc-1d25071ac028	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
edf7f8c2-3044-4354-a435-a3141172dc45	f6fa5712-a021-457c-bdbc-1d25071ac028	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6289c098-37f7-4494-8cfb-b9ff7a4788a3	4baf01a8-d3df-461f-bd31-e3283aaec78e	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
084deed6-fbec-4277-ad4c-5ef91c4b8231	4baf01a8-d3df-461f-bd31-e3283aaec78e	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4727492d-0d00-4d48-be08-96b0c97fb77d	b803db15-e821-45f7-b77c-16b9409fc423	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7d31236d-0bbd-4feb-988e-31f1e740406b	b803db15-e821-45f7-b77c-16b9409fc423	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
900106eb-5815-4664-bd58-dd38dfa10cdc	6079583e-d988-4f99-91aa-99e0c0bb20f4	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
eba3a208-e2b5-46da-857c-d3d9265c312d	6079583e-d988-4f99-91aa-99e0c0bb20f4	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fed6b736-65e7-4223-8231-b5cb11377ef9	ca91806e-64bb-4580-a882-d715e1c22f4c	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9fcf29c5-9679-452d-b852-abd86e9b3227	ca91806e-64bb-4580-a882-d715e1c22f4c	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b793c0df-e058-4104-a3a5-6f06d32f2532	58a60da9-bb63-4882-b28d-a899d6e00f52	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
481b915c-34ca-4d70-b2f3-dda4c4a3789a	58a60da9-bb63-4882-b28d-a899d6e00f52	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e35f962f-9fe8-4900-b407-60a9111e9a01	7fd76e58-6082-4eb2-809b-5bce5cf8cd32	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c857b97f-880e-4685-8b3b-7760e2159adb	7fd76e58-6082-4eb2-809b-5bce5cf8cd32	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2f5d05ee-e2fa-49be-b9e6-54bb4100631d	0a8d7236-b26f-404d-94a4-08189f56d6d3	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5033b366-9e78-462a-8a34-db7c75f27a3a	0a8d7236-b26f-404d-94a4-08189f56d6d3	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
eff8bb98-e17b-4298-a7cf-cb1fddcd504e	f644f4d4-07d4-4a68-9ebb-2d867faf1a9a	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e9f63a70-4b55-46f0-9cb8-6ad26451f2f8	f644f4d4-07d4-4a68-9ebb-2d867faf1a9a	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ed1ef616-3467-4007-8e69-e87afa12163f	a9123596-3d31-4156-9c2f-5c24dae4b8ff	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
47409e9e-aee8-4591-8a5f-33e5059d4fbc	a9123596-3d31-4156-9c2f-5c24dae4b8ff	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6e9ec718-95c2-4663-b719-ff8d581b89a5	b7f0d91b-f540-4dbb-a1d6-67945f3de9fe	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1048e836-4565-434f-9fc6-bad3d9ce9071	b7f0d91b-f540-4dbb-a1d6-67945f3de9fe	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a0a685a-113b-4dac-8847-81f2020f6360	4ccd6559-e071-4372-bbe2-e2a971cc6768	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8bd3c39a-701d-4493-a98c-ffabd01cff10	4ccd6559-e071-4372-bbe2-e2a971cc6768	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
48e068b9-0e0c-46bc-8b58-475009d9d52d	c83b313a-6377-48f6-b423-61bcbd1befac	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d87c83e6-d776-4253-ba5d-b3f63b39c88d	c83b313a-6377-48f6-b423-61bcbd1befac	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
27ab529a-a89a-4d1c-bb52-6d5741760278	3d76ee07-337e-4e71-925b-5a4ad34a6217	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d0d2652a-23e8-490e-a9c5-ddc466adcf51	3d76ee07-337e-4e71-925b-5a4ad34a6217	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
be5b079f-e3c3-4e87-9069-b7286a27ee56	7278d8a2-1afa-47ea-8f45-aca80363e7fd	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
945e2905-db93-4539-bc8d-9a422140833c	7278d8a2-1afa-47ea-8f45-aca80363e7fd	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2cf27037-17f7-4d49-92b4-4d4beef58deb	eb4ca459-a7c5-418b-b663-72482539d188	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a0bd3661-af4c-4e33-ac22-e0ab7cbdba74	eb4ca459-a7c5-418b-b663-72482539d188	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
04c4023f-585d-4add-a0cb-1550d60472db	97beb27d-91c6-4d5a-bde8-ce522ae7cf3f	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4fc43cbd-18a4-4a6f-97cf-c8d5d901445e	97beb27d-91c6-4d5a-bde8-ce522ae7cf3f	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
64b905fd-2bb2-46eb-8c9d-8d084e5dafe5	e8397cbe-b0c5-4e24-a1b7-c4b70b096289	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5290a717-8664-448f-8a72-5057b02bb461	e8397cbe-b0c5-4e24-a1b7-c4b70b096289	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2b6e1bd0-65e4-4a22-a85b-7da7d5b0fff4	c12b01cc-f893-4719-acb3-93037b400058	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1fa09369-bea5-4b79-b62e-285e896056ca	c12b01cc-f893-4719-acb3-93037b400058	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
97dbe5c4-7c47-4499-ba24-ad7f59656c2f	721735a9-8a80-4464-8384-aa2969f9bed9	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a573503f-9f34-422f-a012-b093a18fd63b	721735a9-8a80-4464-8384-aa2969f9bed9	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
02c46dd4-730f-460d-b612-c515aeb1371a	4606b7b7-7fe5-4409-937f-2bea04577896	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d6259edf-73f2-4e20-b829-76ae83706292	4606b7b7-7fe5-4409-937f-2bea04577896	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
511ca17c-e9fe-4c75-b688-34c1bd827ac8	9c851f5b-3b22-4bdd-b23f-bfd4bedc71c3	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6ea3feb0-ec77-408d-818a-734c6f47ebaf	9c851f5b-3b22-4bdd-b23f-bfd4bedc71c3	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
84b09ea9-0147-48b2-bcd9-3d690a985c97	043573ca-8b01-4937-880c-363faa091589	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
523ae1c2-d575-41df-8fa9-a64536a85f85	043573ca-8b01-4937-880c-363faa091589	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a06ffc3e-67b1-4054-987c-76018f126898	d6a7f0c5-56a8-40ab-8eae-7c5747555fe8	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
974608c4-947c-4247-80fa-5300c723533a	d6a7f0c5-56a8-40ab-8eae-7c5747555fe8	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6b30df89-34e0-489c-9159-4ca24b744dff	adf94e1e-154d-461e-97bf-23d2a7f41b5f	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7f1762e8-496a-4a89-ad5f-34daf3f4c600	adf94e1e-154d-461e-97bf-23d2a7f41b5f	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d26e1bcb-bf18-4152-ab94-93b0ea126c5f	cb0fcdda-d13d-4b13-b383-7233c3a91968	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c6680b66-6dea-41a8-95c9-0473d75f729f	cb0fcdda-d13d-4b13-b383-7233c3a91968	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
46ea1857-4151-4f3f-8733-e51268586ca5	0e2317c5-78bc-4fd9-8c1a-e0bc352c701d	9ca2999f-1b56-4ee8-a254-2da4415cbb72	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c0e56b28-5b72-4701-8a26-98ac4a33c677	0e2317c5-78bc-4fd9-8c1a-e0bc352c701d	daa86f03-86c6-4a8d-abab-476fcd043c9c	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
164ae685-4a6e-4ba3-b0bd-d05de30eb8a5	4c833ed7-ac64-43bf-b08e-7a0b66810842	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e34520ef-4bb4-4c5a-a749-a783a65c1cba	2a841cca-0a94-4173-a2e3-94064c295dba	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ace72fa8-0176-4d01-a892-e0a66f0c67ba	8ec38741-d1f6-4cfb-bde3-56bcefe7f9b0	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a47b76d0-a4b8-407e-a041-cf521ff2de81	aa063d12-8ac0-423b-be80-1ea10ce165e3	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
415995c5-5b09-4641-b91e-477d0129ec15	c6a21385-ae1b-48fb-a6a2-090dd3563729	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
87d42f0a-d4a6-452a-ae77-f41ab072abe5	33b53ed0-62bb-4617-bec2-90d8bba22d3d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1527675c-d790-4994-b013-e5731faa74ef	83ac9581-1559-427e-ac19-3aca64177e50	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
da854eee-c24b-4f62-b5db-5e3b127cae98	df69d456-0455-4f98-af86-c2c83a75c8a2	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8147c219-d042-408e-b1cc-8fbc1fe94c28	518ec9ad-7df7-4d4b-8eff-04a6c3c36653	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3086791c-bf02-449b-88df-d90e240b4520	2d059afd-e97c-42b7-a1b3-a2e9cdbef966	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4cbf47e0-b8f1-489c-b394-f36edf06b01d	5c1a91f9-a5f9-48aa-b130-3b611255c7ea	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ac3e65dd-ae62-40d8-917f-e69149ecc06d	358f7ed5-56c9-4d88-abe7-39ecbc3864b8	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a6ce63b4-c2fd-49b1-92a9-1dcfaa87abb6	4ecc2531-c07c-4c78-8754-7bc14aeed18c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
80eec433-eed8-4e87-b7cf-af551ea4b10f	ba096883-f4e9-4f53-84f9-1b14226e2593	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d33adde8-4b5d-43e0-9081-6d45acf23966	cfb318fd-1e1e-4fd8-bcdb-bde939c66b76	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
da199037-b12f-43f5-8c74-39123bce9d77	2f782948-8df8-4550-923a-9d582b413d9d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
64087301-b319-4d7f-b4e9-867a126733ad	df0f8567-fc9b-426c-aba7-632bf3a2f69e	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
86131ad5-c98b-4ada-a5f6-11abe3f98cff	88feafc5-50e7-49cc-94ca-19ac20a62381	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
397ee694-6f8b-4b2b-bed7-38c90933d818	df2e1002-2afb-4016-90b8-e042eb0397a3	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1e375f81-57cb-4e25-a4ef-975bed2356d2	62f0715d-c698-419a-a5d0-fc9fda75bfb4	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4a99c21e-f1e2-4857-bd7a-134e6dfcfba2	fba6af6e-fe6b-41ad-a222-4467da95e989	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
06022170-6c3f-426c-8d54-4c725f7d953a	d1c725e2-edf7-41db-b67b-e6b07a9124dd	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0135f33e-9cdd-4855-a6d6-57706aa53b93	2cfdda52-727c-4980-9b51-f6cb8d569a36	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
45ae38f6-b27d-42b9-8a74-a5720eb4195a	f3621ac9-9731-4356-adcf-f5cc7fbc5652	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ef30afb1-c1f1-4c29-8d92-6646967498e0	290ed9b7-ebfd-4fdc-ac2d-310f72f83df1	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6143a0b8-64b7-4a6c-843c-523ed02f2894	111623ca-05ec-4e32-9c32-384496708f96	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
200227b6-b501-42e3-b2bc-32a69b3a0f43	f15ee116-4252-45f1-944b-8a0325a927e5	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
921fcc5d-9e93-428c-992e-4f7d7c10cad3	1cfdd92a-7159-4181-8417-0ef11efffb3c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
84d5b133-6f84-4d74-b42e-8ae4e3c2d263	89660c46-97e8-416f-ae27-ac04c6e740f5	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
20d001ba-f83c-4baf-bf1f-399e308a28a9	3ad518c1-cba5-4b49-a75c-000da86b1655	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f3a4d78f-9921-4042-9d4a-7068cc7433db	e167a583-fb30-4951-9340-ba25f3500b66	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c463b929-c77c-4097-a4fa-c39f46d9821d	82fa6a07-a523-4391-bd0c-f3d1b90e5ba8	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
78b5dfd3-65e0-42c2-a423-9ef10af1ff2d	3c340a19-7f91-432e-a3f2-1ef9c34f9c78	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8779b51d-4bb0-4079-a569-2e54e8a790a6	d024e83f-2ffd-4ca3-a4ed-e8115c78c09d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
33e72aec-0b14-4349-9a9e-912f8c16cda4	02192424-8888-4564-9c78-96b4268ac20a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7ed47f7d-15ad-4a63-8aae-a1422e5b8492	56e47716-ac53-4d03-b072-67f621dc18eb	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
39c2ca11-1f35-4870-ac73-70eb422d06d1	d9d656a9-c247-41fc-9014-e7a6e02221d0	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7c17b597-3d19-48f6-9d3c-46b7bc617892	d7d58ee0-f368-4cd2-b434-79bb1d42d84a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5c64efe5-afdf-42cf-9ebf-cc9267dd94af	cc0a2281-81fa-4f0b-ad41-755b93e7d4c8	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ce16af29-3fad-44ae-8e27-081030451069	05698e9f-9315-452d-bff6-3a9c117e3236	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f1c567d7-02af-4e75-ab71-dd869de400e8	3c31632e-fc0e-4eda-b4ec-99fe922ac61d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d722e717-fd7d-4b8f-b534-8a14ce1cda35	83bd502d-c6cd-4b40-91c6-5d243069fb36	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d2af3782-66f1-4d50-9404-4666e6efa014	e1ca767e-3a70-442c-b1d5-d92fb895b9c7	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0bc1facb-08a1-411a-8077-2cb5902abd52	a26f2142-d8f3-40bf-9327-ce73cd8e17bb	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d72b1822-b339-4a8a-8b23-1b26d4100af5	21d5d841-5807-4931-baeb-3de36b2dc53c	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d434705d-9a08-4713-a6e1-40a7109a8d3f	1ea9e3a4-13d8-4c2d-8e87-bded3021d6bf	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8eabcc93-30b3-4da6-9170-c346e878065e	f1371e95-3952-4515-b169-d487e8fa006f	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ef5928bb-ea8b-44a7-8c27-9e00020cc68e	e6c38cb8-b3ef-47c1-a621-df282c4f5d03	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
39e752bb-7b2f-4337-bcca-f7cc6f4c6e3b	743943b8-a53c-41fa-ae92-ca5ca48cb031	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a480f31a-940d-4d9c-935b-6e466f2801f4	5b77c20d-5298-49a8-8237-4f70a2bbb166	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
07ad68b7-4f6a-4ed2-aaec-c30a95d55fa1	5479dc5f-ae7c-43a3-9697-59c25ff67102	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
044bafba-d344-4042-806a-1091a998a4cc	62f6956f-c724-4cf2-afc8-023d642e0f41	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
410eac99-0456-41f8-80f9-583ff25da8d2	543068a9-8fc4-46f7-bdef-05cc09172a48	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
13fffa06-66d4-44a2-9d51-6ba905c117f7	71073869-267d-404b-88bc-3716117c9877	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
07efa16e-9dd4-44d3-b366-7833d4a56375	ff7e817a-b706-4f69-b6cc-19f06a9c75e4	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
443157da-487d-4145-ab50-d75a44c74d6a	86aaf5d3-990d-4211-b717-60da64f6fca4	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
db5bf944-ce92-4687-95ea-27fe44ebb4dc	6c39d722-fa9e-4fe7-98d1-4cff6a5d4b2b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fed694de-7879-4833-8408-5c17575791f1	5a380c5b-1642-4f36-b9ad-8c533b2208fc	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
da7c6431-8a18-4421-9813-f7a10328e54b	ad130cf0-dd4f-4f2c-9a78-8c76bc7a794d	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c145fb23-0d65-4853-8168-50623dec430b	ece32bda-232d-4f38-88da-6224fef8a93a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f940f0f6-efda-4649-9e9b-0f64acf65aeb	9ddc5858-cec8-4a12-abb9-de920843f065	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e6cbcde9-d1bb-4ce2-86fa-cce18002a3f9	30cdb8dc-6b03-4d0d-a20a-3336c9f0a537	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
065e7e2a-f90d-4ef4-86e0-5dd280247773	3218a59e-15fe-491a-ad1f-8f5b77766324	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1d8754fa-7f71-434b-9c0c-0b6f31340465	bf499975-6f8c-4098-a10b-de971c75af31	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
543a2334-fbc5-44dd-9944-c080bc5bd053	b71efee2-b438-4423-99ab-f84530927a58	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
623fb5c2-3737-4bd2-aa81-5fdd0987ace8	e8eaa061-7cca-4172-b9a1-43fb0951dad1	b31967bd-f6da-49d9-ba4e-cafdd7786116	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Risk	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f9c0a285-0581-4988-b99c-f9eeee921cf1	7e3ad6a3-cff0-4f76-af75-248dc9aa1faa	b31967bd-f6da-49d9-ba4e-cafdd7786116	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Risk	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
188c4155-e1d5-4be6-a5b2-7f10475ce549	41373a30-bdf3-4bc6-b65b-1ebc08500900	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0321a826-ea55-4f71-9dc5-bc67c3dbb9d0	41373a30-bdf3-4bc6-b65b-1ebc08500900	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8cdfd7e4-0fec-475f-8aa1-d38561f8a5ab	41373a30-bdf3-4bc6-b65b-1ebc08500900	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
edfba373-efcf-43bb-9a0b-58f384b539be	41373a30-bdf3-4bc6-b65b-1ebc08500900	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0cf600c2-91e2-4915-8118-5b8209a7cd43	e4b92bea-a98d-4112-b971-5434d3e2c46d	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
52fc1d13-ceb8-4d5c-ab87-96dc59720abd	e4b92bea-a98d-4112-b971-5434d3e2c46d	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
408287b2-3ee0-4a8c-873d-3fe68bb84ada	e4b92bea-a98d-4112-b971-5434d3e2c46d	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
701efcc1-1220-447f-8978-d1432b6352dd	e4b92bea-a98d-4112-b971-5434d3e2c46d	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
646460df-8fcc-4864-90eb-9ac4c5adaf1a	ece454a6-dfd7-45be-857a-7ee7e21a8985	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4bbcc4c9-8d81-40b1-8773-1f5913b1a9e6	ece454a6-dfd7-45be-857a-7ee7e21a8985	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ba13e0a8-c99a-4b23-878e-f69d285fdb7b	ece454a6-dfd7-45be-857a-7ee7e21a8985	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
233d6e76-ddd8-4390-962a-0af4bee1f98a	ece454a6-dfd7-45be-857a-7ee7e21a8985	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6bfe54d6-b7a6-420c-b8f1-7d588aaf1915	ccd752a3-b8be-4a14-8945-1a67d9d196a2	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
00fa9224-a715-4fa4-9865-3585e5d12270	ccd752a3-b8be-4a14-8945-1a67d9d196a2	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3dc8216c-59c1-418e-9823-15b7ba9fde74	ccd752a3-b8be-4a14-8945-1a67d9d196a2	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
223fd136-bef4-4229-89d5-f2cce891dc3c	ccd752a3-b8be-4a14-8945-1a67d9d196a2	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d077593d-635e-44df-960b-b34417e10ec1	6689f4bd-b72f-4121-9f3f-114353160c14	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ef790b18-2fdd-461a-b4e4-04cb284e5c5f	6689f4bd-b72f-4121-9f3f-114353160c14	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7c0adfe1-59f7-4687-a309-9b2b1517df5a	6689f4bd-b72f-4121-9f3f-114353160c14	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ddf89369-ea6b-42e5-aaa2-8bfd343f77cb	6689f4bd-b72f-4121-9f3f-114353160c14	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1e1686bf-5509-449d-b8c4-fe909849b02b	93277032-c93f-461a-a51d-e5b78b31548a	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
72851381-5aaa-4ad7-b4b0-aa46136c1fb0	93277032-c93f-461a-a51d-e5b78b31548a	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
40938453-cd0d-4f80-a609-7852d77b4581	93277032-c93f-461a-a51d-e5b78b31548a	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3af8a0ca-66d0-4c3c-88e1-f0cd9073b130	93277032-c93f-461a-a51d-e5b78b31548a	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9340741f-79b4-4ea6-99d3-c53247cdba71	3fa77826-f8ca-4c21-9bf6-b34f43019217	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e38fa195-d2a0-48f6-94d8-0843f3c8cac7	3fa77826-f8ca-4c21-9bf6-b34f43019217	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d5b5bb96-8214-49d3-b34e-a73639cd71fc	3fa77826-f8ca-4c21-9bf6-b34f43019217	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1ae4bf99-fbff-458c-9315-c4359df09f27	3fa77826-f8ca-4c21-9bf6-b34f43019217	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
02b22cf5-5d51-4f22-a6bb-5de29f1af18e	6b65e501-10b2-4acd-a0f0-f92713627a0f	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c2bf9014-5656-4668-83ee-04f2599d564e	6b65e501-10b2-4acd-a0f0-f92713627a0f	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7765a289-c904-4a52-80df-79b708d58bc2	6b65e501-10b2-4acd-a0f0-f92713627a0f	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e950bbeb-c1b9-422d-b186-8bbce970f421	6b65e501-10b2-4acd-a0f0-f92713627a0f	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2c6d4cc4-20c3-4861-9dfe-cfd0548c569c	d036913a-b726-43e6-acc0-be191148c57d	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6819b81d-0ca4-4269-9c05-52e0d9ece8f3	d036913a-b726-43e6-acc0-be191148c57d	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1af807d9-7fd4-4978-9c5b-0d736b21c28b	d036913a-b726-43e6-acc0-be191148c57d	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4e41617c-e38e-4f6b-ac35-e586c4740c15	d036913a-b726-43e6-acc0-be191148c57d	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
77705e46-650d-4ee0-8497-82dcc64409ff	1914df22-66fe-47e4-8d8f-4109beb88612	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4569c8f7-b609-458d-84dc-b33fe0b3f834	1914df22-66fe-47e4-8d8f-4109beb88612	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6c15c2e8-dfc6-4848-90b9-e0e07ccb68fd	1914df22-66fe-47e4-8d8f-4109beb88612	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8c175194-c591-4bef-a6c9-7a600b0f785c	1914df22-66fe-47e4-8d8f-4109beb88612	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5ad0bb12-d8c4-46d8-9c47-c9f60830c5c4	bdd99634-653b-4c38-8844-c7fa410af743	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
536c9201-e305-4b76-b2dc-6752e62d6fcf	bdd99634-653b-4c38-8844-c7fa410af743	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8bc7a660-f8f8-4d0f-b349-a4908649f406	bdd99634-653b-4c38-8844-c7fa410af743	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e1a09057-dccb-4279-b74f-691fe4161551	f12d1632-feb5-45b1-b72d-665cace4816d	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
725b09a4-4ac7-4466-9932-ed8da80f05bb	f12d1632-feb5-45b1-b72d-665cace4816d	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
95acfd9b-8e6c-47c1-8c08-3d35da35b066	f12d1632-feb5-45b1-b72d-665cace4816d	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2e5fcbba-6833-4cc6-8365-1fe50783bd99	f12d1632-feb5-45b1-b72d-665cace4816d	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6fe538eb-4b05-43f2-8929-db3be81b5fd0	697b7bf9-8478-4465-b15a-4e7800a95cb3	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5461c7f9-05f0-463d-806a-f806f9ed52dc	697b7bf9-8478-4465-b15a-4e7800a95cb3	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fbf6ea69-747a-43c4-b88a-4b0d72746725	697b7bf9-8478-4465-b15a-4e7800a95cb3	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
70e02bba-da17-44ba-a0d9-5db4f6e21139	697b7bf9-8478-4465-b15a-4e7800a95cb3	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bb882789-fdd3-4821-b1c8-c82362fd239f	cfb30a4f-a146-46b8-bb35-6111fa82ef6b	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
66217ad4-0e56-477d-9ab5-da3d5b3060f9	cfb30a4f-a146-46b8-bb35-6111fa82ef6b	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6519b786-28c0-48bf-aa7e-ec2d00f28bdc	cfb30a4f-a146-46b8-bb35-6111fa82ef6b	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e0537ff1-5c7f-46d3-9b3b-0e1d26caf005	cfb30a4f-a146-46b8-bb35-6111fa82ef6b	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ee706114-b353-4bc5-ae6b-53ae79c1a73d	c2b4fa64-c2c1-4672-bfd8-4e7b5d8d43f6	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
11b1fc42-0f8b-4111-848f-3d3b95d66d04	c2b4fa64-c2c1-4672-bfd8-4e7b5d8d43f6	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8f5ea841-d60e-4bdd-b051-9072768ecbac	c2b4fa64-c2c1-4672-bfd8-4e7b5d8d43f6	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0f7308b0-e4dd-453d-850c-8a93d04a5be7	c2b4fa64-c2c1-4672-bfd8-4e7b5d8d43f6	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7d83b6bc-190f-46cf-b0a9-b53bbcad2164	a228493f-b29b-4acb-aee3-8e53a0b3b25d	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a2387a71-d80b-4321-b82b-cd8063201f8f	a228493f-b29b-4acb-aee3-8e53a0b3b25d	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7b37aeeb-5c4b-49c8-9d83-e0ec40514f9d	a228493f-b29b-4acb-aee3-8e53a0b3b25d	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e20e25ef-059f-4e0a-923a-6f771d082f50	a228493f-b29b-4acb-aee3-8e53a0b3b25d	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
50fc40d8-0d0b-4061-8adf-6f5d8dc67763	e1162b96-7ad5-40bd-9594-490b56fd4d3c	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
43aee157-2472-4416-9fbb-f073fd741bd4	e1162b96-7ad5-40bd-9594-490b56fd4d3c	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
102f3664-74ed-4338-bdf5-466b8a136c2a	e1162b96-7ad5-40bd-9594-490b56fd4d3c	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d3201b71-5474-4260-9356-6da591eeac98	e1162b96-7ad5-40bd-9594-490b56fd4d3c	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
367c2b63-013c-4e80-a4a0-2d8569ce248e	a7c8e6dd-ba40-4c26-a44f-6f5d27b62698	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
98236b24-87ad-44fa-97d7-d2427ba0b0b0	a7c8e6dd-ba40-4c26-a44f-6f5d27b62698	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
395bd639-c47f-4a2f-8543-e54614320d1b	a7c8e6dd-ba40-4c26-a44f-6f5d27b62698	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3296b6e9-91ed-4024-9f45-bd2a66d4d902	a7c8e6dd-ba40-4c26-a44f-6f5d27b62698	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e4c38d3c-192a-4031-bc94-eb324a27bf24	0c7612e3-7c10-4ca1-8a9d-f350ee74117b	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
382a37d5-93e2-408e-9dea-3758416bade5	0c7612e3-7c10-4ca1-8a9d-f350ee74117b	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0985598f-d3c2-4be3-b767-01b982898074	0c7612e3-7c10-4ca1-8a9d-f350ee74117b	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0e8a5807-8d91-4054-8bea-32f3536d561b	0c7612e3-7c10-4ca1-8a9d-f350ee74117b	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
97d202ae-ddc6-4d5a-90d2-3e96a88ae456	06ecd909-ab38-4c7f-a0a8-16d6420a3308	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
12c621d4-98bc-4399-b9ce-26b4a11e204e	06ecd909-ab38-4c7f-a0a8-16d6420a3308	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
86d961c1-b8d4-49e5-81a5-2d59650eb92b	06ecd909-ab38-4c7f-a0a8-16d6420a3308	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
83bc9561-d376-4e03-9e8a-cb77e204da20	06ecd909-ab38-4c7f-a0a8-16d6420a3308	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9012b48f-72e6-4cd7-9565-02852480d54f	552f0633-1c38-47db-b88b-b426253df114	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4fe1324f-fc7b-426f-b97a-e09b885662fb	552f0633-1c38-47db-b88b-b426253df114	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f6229f1f-5c55-41b6-9851-1b1ccfad9ccb	552f0633-1c38-47db-b88b-b426253df114	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fd83d7ca-2c6a-4295-a0d8-72f8524c11b8	552f0633-1c38-47db-b88b-b426253df114	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
054987e9-07db-408f-b4cb-8f12c90f9617	fcc9066a-29ee-40e8-a4cc-39e7d0ff5883	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
77cec980-33d0-4f12-af66-f49f47e1bfd7	fcc9066a-29ee-40e8-a4cc-39e7d0ff5883	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
08e73039-cbc3-4023-b554-68cc1f8051b3	fcc9066a-29ee-40e8-a4cc-39e7d0ff5883	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bfa686fa-4999-40ce-af52-71a56f2df0d1	fcc9066a-29ee-40e8-a4cc-39e7d0ff5883	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e734fec7-db36-432f-b933-027585d4e8a7	0a633284-cac8-4b8b-93db-6726538764c9	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bcc4c4e3-8fa2-4753-b170-ae206d6a841f	0a633284-cac8-4b8b-93db-6726538764c9	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a39c36ee-9b4d-4a2e-bbfc-0e624f08031f	0a633284-cac8-4b8b-93db-6726538764c9	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9cb9ece0-15cd-4ee2-a3c1-8c87b30a7adb	0a633284-cac8-4b8b-93db-6726538764c9	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8b481c75-c292-41ec-b1a6-2b370a2a8d33	1e0f2164-5a78-4069-a1a5-a4fdaf48dd05	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f3b428b7-bda9-42b7-9d8d-b50b39a2e628	1e0f2164-5a78-4069-a1a5-a4fdaf48dd05	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1983fe4f-9193-4a4a-a287-328d5a42c7d7	1e0f2164-5a78-4069-a1a5-a4fdaf48dd05	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
42d7b7f6-9872-4ed1-817f-0140601d0607	1e0f2164-5a78-4069-a1a5-a4fdaf48dd05	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
aeaffc4f-8fdf-4fd5-a4a7-0fa2d3d78257	abe1af21-8a38-4881-a466-76cea6c3a3f4	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2abfd801-8453-48db-9c90-b69298164e4a	abe1af21-8a38-4881-a466-76cea6c3a3f4	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f4e183a9-2cbd-4f26-a557-4917b6289262	abe1af21-8a38-4881-a466-76cea6c3a3f4	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6f14e51a-0ad3-4dae-b47a-3e93ddc68c0c	abe1af21-8a38-4881-a466-76cea6c3a3f4	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4dd78d61-6cff-4fa2-96aa-8b554c6180b1	a887fc48-4cf9-436c-84da-c4778757bf7b	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3d63f4c8-15c3-4ffd-9e5b-7c454484c6fa	a887fc48-4cf9-436c-84da-c4778757bf7b	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2dfa9886-8469-4ec6-97b3-5a36ad19b847	a887fc48-4cf9-436c-84da-c4778757bf7b	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2da3978d-9375-45f5-b8d1-ee22eb61eb89	a887fc48-4cf9-436c-84da-c4778757bf7b	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
05bc0aa5-4130-4b35-b92e-de25b9cd9330	b975fd8d-8663-47ab-987d-56847a3e797a	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
857d0232-e78f-4826-a944-0ec5f7eec057	b975fd8d-8663-47ab-987d-56847a3e797a	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4a2a91e3-4d91-4067-afad-5fad267e9e34	b975fd8d-8663-47ab-987d-56847a3e797a	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a218f434-5d7a-4e97-914f-c8f1361dfdad	b975fd8d-8663-47ab-987d-56847a3e797a	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
244921fd-7bbe-44de-93da-8225cb294f94	141ada26-3715-4066-8294-25b29b0dcc96	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
df96456e-41f0-46bb-b433-bb0dc903c33e	141ada26-3715-4066-8294-25b29b0dcc96	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9f28708e-aa17-46fc-8cab-eceda1d3205b	141ada26-3715-4066-8294-25b29b0dcc96	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
32792a36-06c7-4a3f-92ce-cd97dc108d61	141ada26-3715-4066-8294-25b29b0dcc96	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
899a09f0-fe0f-4604-935f-6d8ee845844d	102dc420-b7fd-4662-bad8-ba7f7cd724e3	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ff1a93ba-5275-4125-bbb1-fccd90d12dda	102dc420-b7fd-4662-bad8-ba7f7cd724e3	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
af118778-d7ec-465d-b72f-4a21e100cd7d	102dc420-b7fd-4662-bad8-ba7f7cd724e3	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
888a366a-25ac-468c-b6d4-42fcea41e566	102dc420-b7fd-4662-bad8-ba7f7cd724e3	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
add280e8-f9f3-4f56-9b65-266bb2f14446	8adc5622-f3c5-40a5-861d-805e0639cadf	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
835d205e-674c-4860-8c29-dd873a6f71c7	8adc5622-f3c5-40a5-861d-805e0639cadf	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
707fb808-a1da-47c9-95dd-07b61f2776a9	8adc5622-f3c5-40a5-861d-805e0639cadf	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
32b9691f-153c-4291-923e-42477449032d	8adc5622-f3c5-40a5-861d-805e0639cadf	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dc95eb61-cad6-4d9d-80b0-946dddb044b8	4aab688b-d98d-4470-8886-09e2e48d999e	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
76aaec34-f6a2-4468-9f36-6eae70b4ac42	4aab688b-d98d-4470-8886-09e2e48d999e	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b45b9f15-2e72-46c0-9d3b-9ce028432ebd	4aab688b-d98d-4470-8886-09e2e48d999e	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
63d4764d-5507-4924-9721-fe3e09f01b12	4aab688b-d98d-4470-8886-09e2e48d999e	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
52e56e31-3cc9-4983-8c65-2d0b0d309d8b	dd7c949b-bf77-4f9e-80a2-c454b47d8d62	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
98f3250d-fcce-442e-80af-9433b25881f8	dd7c949b-bf77-4f9e-80a2-c454b47d8d62	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fc60c283-69ae-4df2-8713-f209fedf06c0	dd7c949b-bf77-4f9e-80a2-c454b47d8d62	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7eab974b-3726-4737-8497-0e96d3444db5	dd7c949b-bf77-4f9e-80a2-c454b47d8d62	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2a5a6fae-6e53-40b2-9233-dfdc4b993ced	39028101-e53c-4b15-ba72-26da2dc7e756	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	1	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
87dede7c-043d-4536-a784-eb89f8b57d7c	39028101-e53c-4b15-ba72-26da2dc7e756	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f4e6d206-29c4-49b9-bc05-392975556c16	39028101-e53c-4b15-ba72-26da2dc7e756	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8c411088-765c-4cad-9631-55921f01a0aa	39028101-e53c-4b15-ba72-26da2dc7e756	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5db22c89-5845-4f46-bf4d-036de40417ac	cba9b16e-5cfd-4ee0-a182-f6af4d626517	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6effd51f-3da4-403a-9b38-f06c47afc8e5	cba9b16e-5cfd-4ee0-a182-f6af4d626517	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1e528f1d-fcfb-46ae-b8e9-784324406ab9	cba9b16e-5cfd-4ee0-a182-f6af4d626517	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7d320c8e-98dc-4de4-b060-a943a0647fb6	cba9b16e-5cfd-4ee0-a182-f6af4d626517	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bbf286eb-1314-4d6d-b73b-1057ecfd3f73	ef143131-ceb0-4822-8f7f-b32e53f8cdb1	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d51ff3be-ea05-4096-bbc7-fbe43e991ffc	ef143131-ceb0-4822-8f7f-b32e53f8cdb1	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
788cb556-7473-41d8-ada0-829d824a2a60	ef143131-ceb0-4822-8f7f-b32e53f8cdb1	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
afd954c2-a06c-455b-876c-8c30822ed7e5	ef143131-ceb0-4822-8f7f-b32e53f8cdb1	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
76b8ef56-a64c-41e0-a6f9-2cec38d8057e	50b7ab86-eb0d-4c7b-875d-6e448d2e0a70	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cd07e385-e095-4e63-92d5-7b37df8c4063	50b7ab86-eb0d-4c7b-875d-6e448d2e0a70	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
588dfec0-3259-434b-8138-2cae1dff529d	50b7ab86-eb0d-4c7b-875d-6e448d2e0a70	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9f67c5e5-064d-441e-969c-c300b79392cb	50b7ab86-eb0d-4c7b-875d-6e448d2e0a70	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0092f23b-8b15-4bb5-9555-539275745ce4	bfc30775-59cd-4f86-831d-996eb2c5fa5a	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
786269d1-3c59-422c-9ea8-c6a551e8a00b	bfc30775-59cd-4f86-831d-996eb2c5fa5a	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b2d02fb7-a508-4bf1-8b5d-ad50550d4d2d	bfc30775-59cd-4f86-831d-996eb2c5fa5a	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ef46079d-3933-42ec-9de1-a2eb1ecff8ed	bfc30775-59cd-4f86-831d-996eb2c5fa5a	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6596849b-13a3-4b12-a94e-9a268fe08b3a	ba1dd5db-9ee0-4da4-8752-eb43e9c8a295	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
eb056b68-537f-47b4-bb85-7f856f6ff513	ba1dd5db-9ee0-4da4-8752-eb43e9c8a295	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fb6fb548-8366-4330-9031-dac49618123f	ba1dd5db-9ee0-4da4-8752-eb43e9c8a295	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5c12a5f1-3f3f-4725-b7cb-52676646f548	ba1dd5db-9ee0-4da4-8752-eb43e9c8a295	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0f26bb9e-b9fc-479f-bf49-e2d82c25e2eb	954a704a-4da5-4dc6-bf41-6daf029a96e4	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
faf7f3b3-aaf1-48e2-881c-07544f5be649	954a704a-4da5-4dc6-bf41-6daf029a96e4	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
43c19e34-5372-460e-beba-4b9cc5509c39	954a704a-4da5-4dc6-bf41-6daf029a96e4	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a16ae22b-2bd6-4392-9c51-6651a70246cb	954a704a-4da5-4dc6-bf41-6daf029a96e4	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b817c893-13eb-4fca-a019-fdf173130b45	69d168d9-7240-4a60-82a2-92144d2356e8	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c91a167d-3087-4fab-aec0-398470cbc52f	69d168d9-7240-4a60-82a2-92144d2356e8	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d0ef9953-72e6-4023-8a5b-09668ef34193	69d168d9-7240-4a60-82a2-92144d2356e8	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b9b96a5d-8650-475b-a2ba-39b5aa1df059	69d168d9-7240-4a60-82a2-92144d2356e8	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3ac5b4c5-7371-4142-90e7-b5a246664209	526db99b-3ca1-410d-998e-817c9d4625eb	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
925036aa-8a3d-4e8c-8f30-78744ed1cf3e	526db99b-3ca1-410d-998e-817c9d4625eb	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
cfc83609-6c67-4e22-b0f6-06f59b7c8f8f	526db99b-3ca1-410d-998e-817c9d4625eb	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
423ee935-0899-439c-80d7-e85ecd094f6a	526db99b-3ca1-410d-998e-817c9d4625eb	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4018a8cf-7ac0-459d-b477-83dea206abfe	8cac2333-470a-4711-92f4-7bede9c83f84	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
8ccd2b53-16da-4f15-b6f5-e8b87f644847	8cac2333-470a-4711-92f4-7bede9c83f84	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
40b2628c-a7ce-4232-8517-abc86104c25b	8cac2333-470a-4711-92f4-7bede9c83f84	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e625e042-726c-4056-9ddb-1f2de65302fa	8cac2333-470a-4711-92f4-7bede9c83f84	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
49b040fb-e812-4ade-a599-a9321472e8b3	4e6d87e7-e15f-4b0c-9c5f-9d13c0c734eb	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e0e14193-f80e-415c-9ca1-b9c25697ea50	4e6d87e7-e15f-4b0c-9c5f-9d13c0c734eb	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
03a6939c-0f5e-4456-a21d-ead6d218d530	4e6d87e7-e15f-4b0c-9c5f-9d13c0c734eb	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0a4df41d-19ae-4819-99a2-2f63388203aa	4e6d87e7-e15f-4b0c-9c5f-9d13c0c734eb	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c4a2d8c2-be5e-4d12-95bd-e9ebdee5e93f	92b08548-b122-4559-afc4-910e3450d7ce	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
93a341a0-feb9-4574-bc24-e069e21b5d96	92b08548-b122-4559-afc4-910e3450d7ce	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
59532b7b-c4c1-447d-930f-7c3fa671cdfa	92b08548-b122-4559-afc4-910e3450d7ce	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
5576941f-680e-49c1-b092-54a47ded27f4	92b08548-b122-4559-afc4-910e3450d7ce	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9065c526-1aa3-43fd-933f-47a45418b03a	f907e0e8-bb2d-4907-b6a2-a786210b9e87	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0.5	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c80b4f2d-935b-4529-adb5-55bf2e2fe142	f907e0e8-bb2d-4907-b6a2-a786210b9e87	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ee7db38b-db82-44ab-834c-92f16b7f25f2	f907e0e8-bb2d-4907-b6a2-a786210b9e87	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
32a69f55-6b90-4ddb-b9cf-2242a1a2ae37	f907e0e8-bb2d-4907-b6a2-a786210b9e87	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
e3f02b26-e355-4837-a181-67045d024154	833a8dfb-88c7-49d4-8350-5e5921f37953	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
f0817a1e-1c09-4d3a-9cf3-e059b5ae38de	833a8dfb-88c7-49d4-8350-5e5921f37953	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c94f8da2-4d73-4949-845f-6890128f6497	833a8dfb-88c7-49d4-8350-5e5921f37953	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
0eae63e1-593d-4dea-9be3-b435135c39b3	833a8dfb-88c7-49d4-8350-5e5921f37953	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b970bce7-e984-4d39-9a5e-3dfa93dd394e	1e7fc55c-c6bc-41e7-aadc-8d88752f9803	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
be84bc0f-748a-4632-8b9e-c656a6617d56	1e7fc55c-c6bc-41e7-aadc-8d88752f9803	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
326a4550-2c28-468b-b90c-baa8d129466c	1e7fc55c-c6bc-41e7-aadc-8d88752f9803	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d4398369-551f-4f95-a1db-3f52c2dac076	1e7fc55c-c6bc-41e7-aadc-8d88752f9803	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
1fec7a73-b149-49d2-a997-74affa6ab275	a34bda89-e2a5-4c20-9188-95ba124d5ace	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9505265a-75b7-49fd-8715-3daf54dd283d	a34bda89-e2a5-4c20-9188-95ba124d5ace	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
40484208-c3a0-4777-9eff-dcb10114b06f	a34bda89-e2a5-4c20-9188-95ba124d5ace	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6bd69a18-5530-4fba-84d1-6b5742d9becf	a34bda89-e2a5-4c20-9188-95ba124d5ace	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d88793bd-5f2c-44d3-acd1-754c1527bd02	bb38aceb-1705-41ce-9c24-80775da5c812	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
c8b86f06-ffb1-43d8-8546-85e605319c93	bb38aceb-1705-41ce-9c24-80775da5c812	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a9d88d40-a3ea-45ad-a176-2a1c5fe50926	bb38aceb-1705-41ce-9c24-80775da5c812	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
115e6fe7-f570-4dd7-943e-e349c1db4735	bb38aceb-1705-41ce-9c24-80775da5c812	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
12e211fd-51aa-4257-8005-fedc0c272484	cd321fa9-3214-4694-b6f2-db79ec682fd7	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fcb7b515-5c8a-422e-89dd-dd7b97bb1a3b	cd321fa9-3214-4694-b6f2-db79ec682fd7	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
a8612ad2-ba60-4051-94dd-8ebc607045f5	cd321fa9-3214-4694-b6f2-db79ec682fd7	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
6a6966ec-ac1e-434d-bddb-1bdac29814fe	cd321fa9-3214-4694-b6f2-db79ec682fd7	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7fc275f2-c698-4674-9f7e-ef621055c0f0	ad7384e8-902a-487a-82d3-55b33b122a3e	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
699fd8bc-9ca7-455e-b078-2bc363a8829b	ad7384e8-902a-487a-82d3-55b33b122a3e	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
fc716fda-5015-4dd0-98d7-e8022e6e05a4	ad7384e8-902a-487a-82d3-55b33b122a3e	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
12ec726f-8190-4bee-8de6-48e4c08594df	ad7384e8-902a-487a-82d3-55b33b122a3e	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
dd8ca86c-e8fa-4287-b60c-89dbf54a1637	b5ed27f5-d452-4b07-84d9-539fe869388e	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
b4507067-ebfa-4916-a9bb-429d0c9c756f	b5ed27f5-d452-4b07-84d9-539fe869388e	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4630ce9f-2ae2-4da8-bd8f-191708960b76	b5ed27f5-d452-4b07-84d9-539fe869388e	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
99681dc8-8dad-45eb-8c68-51c641a45534	b5ed27f5-d452-4b07-84d9-539fe869388e	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
37fb5be9-9f84-4eb2-8736-0502a1d90ab7	a0454995-d917-4e91-8ec5-e5991daddaa4	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
079add86-d578-4ca4-be66-33278db669c3	a0454995-d917-4e91-8ec5-e5991daddaa4	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
bdb53e8e-9d87-4b9f-b40a-36d5ed17146f	a0454995-d917-4e91-8ec5-e5991daddaa4	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4592ebb7-67c0-425c-ab97-289bb699ad50	a0454995-d917-4e91-8ec5-e5991daddaa4	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
d3b67a29-fc80-40e4-a0de-8660c928c211	5227a011-383d-4c9b-a42a-06598a5c8547	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ea0d65c6-b350-4857-9816-bc46e71dd939	5227a011-383d-4c9b-a42a-06598a5c8547	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
073a8bad-7810-41be-a1b1-3b1269602317	5227a011-383d-4c9b-a42a-06598a5c8547	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3e246247-feb5-4022-99ad-f102bb547d5d	5227a011-383d-4c9b-a42a-06598a5c8547	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3345c134-c91a-4540-9da6-3859047c1cec	9309fd3c-e584-4a76-a31c-3cd5e8f9b194	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
4c9c02fe-26a8-4166-859d-644c53a8cb82	9309fd3c-e584-4a76-a31c-3cd5e8f9b194	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
442e3f91-9cf0-4688-8680-3c0b9c044232	9309fd3c-e584-4a76-a31c-3cd5e8f9b194	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
233b6577-b6eb-4c60-bd92-2a7107797691	9309fd3c-e584-4a76-a31c-3cd5e8f9b194	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
ea045a19-d847-485e-a707-31a310cb4b98	e0e8a240-ea37-4400-90d2-9a59f6c2e68d	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
9d29d6b4-78f8-41b2-8a37-95d9381e2251	e0e8a240-ea37-4400-90d2-9a59f6c2e68d	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
88473dcd-a4a1-4e11-a8ce-a61b6f9b95a5	e0e8a240-ea37-4400-90d2-9a59f6c2e68d	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
71d17770-b5f4-4860-9157-6507a0f126d2	e0e8a240-ea37-4400-90d2-9a59f6c2e68d	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
86d5adef-02d2-4fe9-897b-4bfdc9a02e90	8fa410bc-c485-4f90-931f-391e0fd81983	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	0	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
90a9a6f1-3a1a-48c0-92bf-e3f274c18630	8fa410bc-c485-4f90-931f-391e0fd81983	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
7c047142-53bd-46b0-9df4-e96779dac458	8fa410bc-c485-4f90-931f-391e0fd81983	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
2b6c3816-9e53-48f9-875f-7552dfcb39d1	8fa410bc-c485-4f90-931f-391e0fd81983	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Sensitivity	5	t	2024-05-23 21:17:24.925327+00	2024-05-23 21:17:24.925327+00
3ca54f0d-ade7-4518-b3d1-8bb0c9c415e8	b12f0012-a731-47aa-a3a9-54d460c2b37e	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
39d6a819-caee-44e1-8661-e4486f1b0ef8	6a026526-9603-4b87-8f16-701883f5a339	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
30394883-12d6-4290-8b5f-ab3df38714be	28fd5f1a-fe9c-496d-8dd4-a1b10cd4e9ca	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
e791c51c-3e65-4690-b5b7-815bf77a6fca	1add5f41-2f7e-4730-a4b4-d327f2903039	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
e0be6839-84a2-425d-90b8-679c5501ac63	81d42f9d-b621-4589-bf2d-1e15e1823e31	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
c501b9d5-b3a7-4ab0-ac70-2abb9bbe388a	34baeb95-7a29-428a-8ec7-0c147b929dae	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
f8dd99bf-98e9-4088-bbaa-0176d2f550a4	b74a236e-a9ca-434d-a608-1f7f10b995e7	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
39c927b6-b19c-4620-b3b5-627f64461057	943f33e0-a76d-4f3c-806e-207882e10c4a	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
1daff280-a3a7-4dcd-81e4-66a25c1375b8	97ff38cf-d4ab-4c53-a0bd-4032d39f19c8	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
18e67d68-180f-47da-8a35-142e31d70792	9d2f270e-3ae6-41bc-8429-ae6a0e6165f8	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
b04acf7e-946f-44a1-9272-bedb56c5dfed	242ce7e9-218c-43fe-9fe7-8ed55161f181	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
63b8a0f3-3d57-48f6-aba7-2092d569da9f	d6580c21-3f56-4ce3-91a4-df9fdc3258ce	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
8cc7cf4f-e997-4e65-9201-6bfc6def6823	75f0bc43-e2c5-44e3-a23a-a1328ac03bd4	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
b1e1a0f8-f5be-436f-a5b0-f1de2aeccbeb	70d6fbbd-00aa-44d6-9770-8b12962a5086	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
d004e152-7776-49c2-9e6f-e41c6ca16ff7	8ab9e061-13ff-4f95-b3a6-3a54d6267fa1	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
7e1616ba-a6c8-48be-9a41-cfcc1bc6b365	89f53ee0-88ab-4bf6-ac36-5167d91cbc3a	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
782cfcca-a0f0-4799-aa30-dccd5da89b09	432791e2-d04c-4f1a-a44c-c3f5ed0a04c4	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
9489985a-77ad-449d-a28e-c2f471e122d6	014d2ddd-7bd7-46ab-b299-bd12f574b2e0	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
f7bf9af4-4cb8-4f59-83d2-990bcd3dc7af	014d2ddd-7bd7-46ab-b299-bd12f574b2e0	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Warfarin Sensitivity	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
c6d3a8d4-ec96-474b-b033-344cdc64ef7b	014d2ddd-7bd7-46ab-b299-bd12f574b2e0	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
5f306f43-d374-4882-a71d-ac5a057d7553	014d2ddd-7bd7-46ab-b299-bd12f574b2e0	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
7f599b14-1ae7-4508-8577-7a0594a7fce4	4de01839-1ba3-49df-908d-440528adee29	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
fa920115-9f4f-4fca-a71d-52255b21e879	4de01839-1ba3-49df-908d-440528adee29	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Warfarin Sensitivity	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
fda663bc-5770-453b-9867-dc4bfc281350	4de01839-1ba3-49df-908d-440528adee29	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
a0f7f268-e240-4f7b-a927-8bd449433473	4de01839-1ba3-49df-908d-440528adee29	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
1427acb5-f4eb-44ca-83a8-dd0cb45b2a08	58246eac-11a3-422e-abb9-a550ef6b5b01	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
523bd501-9eee-45c4-a4ef-4f6350adcda3	58246eac-11a3-422e-abb9-a550ef6b5b01	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
7766a769-3b33-4cce-bff4-77077e34cd75	58246eac-11a3-422e-abb9-a550ef6b5b01	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
378cf8d4-0d2a-4bc5-8f99-2d473075b031	58246eac-11a3-422e-abb9-a550ef6b5b01	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	f	2024-05-23 21:17:24.925327+00	2024-05-23 21:19:49.674629+00
2995cc83-fef1-4e2a-87ed-51888c5558ea	45d036cb-d08a-4f41-b3a3-0bc36f3e1ab6	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
05d4cd68-8527-4401-a4fe-3b74d976299b	6e5d11d0-a5fa-423b-8399-a722d91872a1	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4e9976e8-ebfa-4fac-a8d8-34635d41ca6c	71606ef3-5fd7-4621-9cea-0b919bae8f57	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e0c08520-1e5a-4697-a643-ef8d54cf5c63	92df571d-a4d9-4d3a-9aee-f736ee9f4aee	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
356b3722-0d83-49ea-9c13-9da743478406	d222bc28-f243-40af-b848-1f6cc875ccc9	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
898aa803-d137-49cb-bc08-9d904da76663	246d7ca9-0b2a-4492-9870-94795b61ddc7	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
047d82aa-235b-4f7e-b5b6-0d4f132ce9ee	20877256-7129-435b-b16b-b433aa1d3e1e	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b23de8a1-cb99-4090-9e2f-3cec110f1479	990a9f68-8d21-4898-a48e-ea450b94268a	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f65ef962-57e5-4508-b710-a0ffae74598d	f890a885-6d44-43e0-be9d-c92a404aa074	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
47c30ca3-b8b2-4328-8212-4d646bc0a4cc	a2940828-84a6-4e6e-b6fd-9dad55f96b7a	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
508659b8-38da-4667-94dd-093b088a6f0f	417a7e81-4a0b-47cf-95e7-712a55328d1a	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
133c50c6-6b4c-44ad-8e13-1fcab8d0b47e	7a06a82e-2dd8-464c-a310-dc3b80d3759c	0f0237e6-0568-4790-ae5b-03b0cd6e6d20	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c8915e24-ba45-4f8c-bd94-5c19fad075ca	9223809b-3b12-4c9d-b3ea-b5f26c2848b7	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0fb2b0da-0f36-4631-affa-5fba57be3104	bf714bac-d921-40e1-bddf-4c16fccd8868	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7924786a-bb82-4e79-b97c-3f3a669db372	b80b1a76-e57c-4685-bec8-30a0dee24331	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
fb08a3b7-e0d4-4c5a-a1f5-377456f64601	0df7591d-dc8d-4627-bb2b-351d7cd5f1f0	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
24a77afa-d287-4c37-9419-382065da8360	bcc7949d-2326-4a0d-8428-64050ac20671	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
eb8b3645-6213-4edf-b564-6993aa1fa73e	c94e7434-bc82-4bac-8bd1-7aa09be3be73	e8d718e4-4831-496c-8448-16ad044c2e9d	ae88964e-da53-4fcc-9c4e-171828f2445b	2	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
6cc86426-c921-4121-bb91-74beb0eabbed	c94e7434-bc82-4bac-8bd1-7aa09be3be73	c0f1136b-6463-4304-a473-cae1f384fc8e	e42a990d-eaa3-4b4b-8c95-55d0854cb290	High Warfarin Sensitivity	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
e759cbf6-caca-4e0e-a7cd-791071124c81	c94e7434-bc82-4bac-8bd1-7aa09be3be73	93d511ec-e5fc-4832-9581-813842b25860	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Reduced Function	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
3f99da55-8e44-48e5-975c-992cbc5a0669	c94e7434-bc82-4bac-8bd1-7aa09be3be73	59d8aa6e-b29c-4449-8e24-b6fdf9e6fa35	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Low Sensitivity	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
d4e6c679-3cae-4d9c-a933-c3f1949fa766	778e07b2-3b2d-47c0-ad46-48dcf9215ae6	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c355db97-c5ca-408c-83dd-331f6a9089d5	363d0bad-f2d6-4623-8ae3-e23875e04b94	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
926f3385-8f6a-43e8-bbd0-640edd0a19d8	c02279fe-75f5-4486-b5f4-9eaf84e0e8de	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
58f4ab67-bfe2-4529-ae08-db5e8e13ac16	259bdeb5-e418-4538-8906-324ead26d15b	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
c58a7d63-5624-420e-8df1-7461a0f41e4c	72241839-cab9-4dcc-ba30-89f3194061d4	aba94ef2-e507-4963-84dd-24dc2d4f7ffc	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a93f6474-8e8d-4945-a0f5-ecdc08fe228f	5c192358-ce0e-45ad-b403-932aa9f8e416	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Ultra-rapid Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
043caf0c-567e-4bf6-be56-ae0f6d38b4b3	ed07bfac-5fc8-4f2b-9305-f99bfae90985	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Rapid Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
b9e9355b-725f-42dd-83cb-35588191e2e5	eee14ba1-80ab-4aaa-87c3-86b3e54bf004	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Normal Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
76c182c4-af51-4cdd-a791-68b5b8187440	4054a070-5b5e-49af-a0f9-aaaac843c3c5	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Intermediate Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
0b4fca0e-94ff-48db-aa87-9c2613de616a	10239fd8-886d-4e6d-8848-aab5b176dff4	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Intermediate Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
4afbc2cb-0f87-4722-986f-4ce3f0775141	f24aa9a1-5921-41dd-a47d-35f63a437ccb	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Poor Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a4b6f260-ec90-4121-8b58-91397ba6035d	6205b20b-6bff-47be-b060-0dcf156c84ed	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Likely Poor Metabolizer	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a6303fd2-939a-48e6-97a9-09fc385b7420	d7155d1b-e011-4e81-9c5f-6fb6b1b4cc22	32638f99-ec66-41e9-87db-40b5f6c8d7d6	e42a990d-eaa3-4b4b-8c95-55d0854cb290	Indeterminate	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
33b69d19-9dcc-45eb-a2e4-fa40a7f43e30	68d15dcc-2d84-4b66-ae05-7e08a115aea4	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
13cd14b9-f822-4c9f-8ef0-4ce2ff3315d8	ae39b796-add7-4fe2-b732-adb177cace7f	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
bd32a737-74bd-4f99-a1ac-c41f92b99fe7	0cf96b99-ac98-428f-8534-d9d7a25b1f65	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
719807f8-a001-4ec0-8706-36d2b835c9cf	b7c5e060-b564-4d1d-b7f6-83212c978a9b	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	*28/*28	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
f3061e0c-bb54-4276-81ff-b98d0ef44ca9	8eaa9edb-3669-40dd-bfb9-9a2e33735487	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	*6/*28	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
56f3be0e-40bd-4ea2-9507-238d0511d67d	e1f43c98-4625-4dd4-adc1-a84c1f94eee0	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	*6/*6	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a635e663-68fb-4836-b180-bbb4bd52b2e2	76745f14-37c9-4317-b741-c1ebcf6a46b1	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
7d6a0403-126d-4ca2-9596-2928ba8a275d	d548ac3e-54bf-406e-9384-98da6ef9a8b6	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
577e38c6-2acf-44fe-9f65-1656e83d265b	efa2f5ad-3b4c-4bbe-89e8-6cf227db799c	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
cbbd8f20-461f-449b-8592-d93acc4987bb	5461966f-82bb-428a-95f8-de2117b7b7c9	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
a6ff906f-3c62-40e4-b4d4-7c249893ef10	b58c50c5-5a88-4ca5-b151-539231aa0e4f	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	*28/*28	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
9f0836d8-3b49-4659-89ca-2fca73741a07	4e0efc01-e1d7-48e6-9f37-82846dc00f9d	58f41405-4198-4822-b10e-eb43cd77bc27	aaea2f54-350c-4b2b-bbe7-26b1ee754e11	\N	5	t	2024-05-23 21:19:49.674629+00	2024-05-23 21:19:49.674629+00
\.


--
-- Data for Name: repeat_order_messages; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.repeat_order_messages (id, incoming_message, active, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: result_drug_recommendations; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.result_drug_recommendations (id, result_id, recommendations, active, created_by, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: tracker; Type: TABLE DATA; Schema: backend; Owner: postgres
--

COPY backend.tracker (id, user_id, order_id, status, created_at, updated_at, active) FROM stdin;
\.


--
-- Data for Name: sample_table; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY public.sample_table (id, name, age, email) FROM stdin;
1	John Doe	30	john.doe@example.com
2	Jane Smith	25	jane.smith@example.com
3	Alice Johnson	28	alice.johnson@example.com
4	Bob Brown	35	bob.brown@example.com
\.


--
-- Name: comment_categories_id_seq; Type: SEQUENCE SET; Schema: backend; Owner: postgres
--

SELECT pg_catalog.setval('backend.comment_categories_id_seq', 6, true);


--
-- Name: mapping_status_id_seq; Type: SEQUENCE SET; Schema: backend; Owner: postgres
--

SELECT pg_catalog.setval('backend.mapping_status_id_seq', 1, false);


--
-- Name: predefined_comments_id_seq; Type: SEQUENCE SET; Schema: backend; Owner: postgres
--

SELECT pg_catalog.setval('backend.predefined_comments_id_seq', 4, true);


--
-- Name: status_id_seq; Type: SEQUENCE SET; Schema: backend; Owner: postgres
--

SELECT pg_catalog.setval('backend.status_id_seq', 1, false);


--
-- Name: sample_table_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('public.sample_table_id_seq', 4, true);


--
-- PostgreSQL database dump complete
--

